6 O
ADVERSE O
REACTIONS O
The O
following O
important O
adverse O
reactions O
are O
described O
below O
and O
elsewhere O
in O
labeling O
: O
* O
Serotonin B-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
or O
NMS B-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Valvular B-OSE_Labeled_AE
Heart I-OSE_Labeled_AE
Disease I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Cognitive B-OSE_Labeled_AE
Impairment I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Psychiatric B-OSE_Labeled_AE
Disorders I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Hypoglycemia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Heart B-OSE_Labeled_AE
Rate I-OSE_Labeled_AE
Decreases I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Hematological B-OSE_Labeled_AE
Changes I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
* O
Prolactin B-OSE_Labeled_AE
Elevation I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
greater O
than O
5 O
% O
) O
in O
non-diabetic O
patients O
are O
headache O
, O
dizziness O
, O
fatigue O
, O
nausea O
, O
dry O
mouth O
, O
and O
constipation O
, O
and O
in O
diabetic O
patients O
are O
hypoglycemia O
, O
headache O
, O
back O
pain O
, O
cough O
, O
and O
fatigue O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Eisai O
Inc O
. O
at O
1-888-274-2378 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
at O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
In O
the O
BELVIQ O
placebo-controlled O
clinical O
database O
of O
trials O
of O
at O
least O
one O
year O
in O
duration O
, O
of O
6888 O
patients O
( O
3451 O
BELVIQ O
vs O
. O
3437 O
placebo O
; O
age O
range O
18-66 O
years O
, O
79.3 O
% O
women O
, O
66.6 O
% O
Caucasians O
, O
19.2 O
% O
Blacks O
, O
11.8 O
% O
Hispanics O
, O
2.4 O
% O
other O
, O
7.4 O
% O
type O
2 O
diabetics B-Not_AE_Candidate
) O
, O
a O
total O
of O
1969 O
patients O
were O
exposed O
to O
BELVIQ O
10 O
mg O
twice O
daily O
for O
1 O
year O
and O
426 O
patients O
were O
exposed O
for O
2 O
years O
. O

In O
clinical O
trials O
of O
at O
least O
one O
year O
in O
duration O
, O
8.6 O
% O
of O
patients O
treated O
with O
BELVIQ O
prematurely O
discontinued O
treatment O
due O
to O
adverse O
reactions O
, O
compared O
with O
6.7 O
% O
of O
placebo-treated O
patients O
. O

The O
most O
common O
adverse O
reactions O
leading O
to O
discontinuation O
more O
often O
among O
BELVIQ O
treated O
patients O
than O
placebo O
were O
headache B-OSE_Labeled_AE
( O
1.3 O
% O
vs O
. O
0.8 O
% O
) O
, O
depression B-OSE_Labeled_AE
( O
0.9 O
% O
vs O
. O
0.5 O
% O
) O
and O
dizziness B-OSE_Labeled_AE
( O
0.7 O
% O
vs O
. O
0.2 O
% O
) O
. O

Most O
Common O
Adverse O
Reactions O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

The O
most O
common O
adverse O
reactions O
for O
non-diabetic O
patients O
( O
greater O
than O
5 O
% O
and O
more O
commonly O
than O
placebo O
) O
treated O
with O
BELVIQ O
compared O
to O
placebo O
were O
headache B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
and O
constipation B-OSE_Labeled_AE
. O

The O
most O
common O
adverse O
reactions O
for O
diabetic O
patients O
were O
hypoglycemia B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
cough B-OSE_Labeled_AE
, O
and O
fatigue B-OSE_Labeled_AE
. O

Adverse O
reactions O
that O
were O
reported O
by O
greater O
than O
or O
equal O
to O
2 O
% O
of O
patients O
and O
were O
more O
frequently O
reported O
by O
patients O
taking O
BELVIQ O
compared O
to O
placebo O
are O
summarized O
in O
Table O
2 O
( O
non-diabetic O
subjects O
) O
and O
Table O
3 O
( O
subjects O
with O
type O
2 O
diabetes O
mellitus O
) O
. O

Table O
2 O
. O

Adverse O
Reactions O
Reported O
by O
Greater O
Than O
or O
Equal O
to O
2 O
% O
of O
BELVIQ O
Patients O
and O
More O
Commonly O
than O
with O
Placebo O
in O
Patients O
without O
Diabetes O
Mellitus O
Adverse O
Reaction O
Number O
of O
patients O
( O
% O
) O
BELVIQ O
10 O
mg O
BID O
N=3195 O
Placebo O
N=3185 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Nausea B-OSE_Labeled_AE
264 O
( O
8.3 O
) O
170 O
( O
5.3 O
) O
Diarrhea B-OSE_Labeled_AE
207 O
( O
6.5 O
) O
179 O
( O
5.6 O
) O
Constipation B-OSE_Labeled_AE
186 O
( O
5.8 O
) O
125 O
( O
3.9 O
) O
Dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
169 O
( O
5.3 O
) O
74 O
( O
2.3 O
) O
Vomiting B-OSE_Labeled_AE
122 O
( O
3.8 O
) O
83 O
( O
2.6 O
) O
General B-NonOSE_AE
Disorders I-NonOSE_AE
And I-NonOSE_AE
Administration I-NonOSE_AE
Site I-NonOSE_AE
Conditions I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
229 O
( O
7.2 O
) O
114 O
( O
3.6 O
) O
Infections B-NonOSE_AE
And O
Infestations O
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
439 O
( O
13.7 O
) O
391 O
( O
12.3 O
) O
Nasopharyngitis B-OSE_Labeled_AE
414 O
( O
13.0 O
) O
381 O
( O
12.0 O
) O
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
207 O
( O
6.5 O
) O
171 O
( O
5.4 O
) O
Musculoskeletal B-NonOSE_AE
And O
Connective O
Tissue O
Disorders I-NonOSE_AE
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
201 O
( O
6.3 O
) O
178 O
( O
5.6 O
) O
Musculoskeletal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
65 O
( O
2.0 O
) O
43 O
( O
1.4 O
) O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Headache B-OSE_Labeled_AE
537 O
( O
16.8 O
) O
321 O
( O
10.1 O
) O
Dizziness B-OSE_Labeled_AE
270 O
( O
8.5 O
) O
122 O
( O
3.8 O
) O
Respiratory B-NonOSE_AE
, O
Thoracic O
And O
Mediastinal O
Disorders I-NonOSE_AE
Cough B-OSE_Labeled_AE
136 O
( O
4.3 O
) O
109 O
( O
3.4 O
) O
Oropharyngeal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
111 O
( O
3.5 O
) O
80 O
( O
2.5 O
) O
Sinus B-OSE_Labeled_AE
congestion I-OSE_Labeled_AE
93 O
( O
2.9 O
) O
78 O
( O
2.4 O
) O
Skin B-NonOSE_AE
And I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Rash B-OSE_Labeled_AE
67 O
( O
2.1 O
) O
58 O
( O
1.8 O
) O
Table O
3 O
. O

Adverse O
Reactions O
Reported O
by O
Greater O
Than O
or O
Equal O
to O
2 O
% O
of O
BELVIQ O
Patients O
and O
More O
Commonly O
than O
with O
Placebo O
in O
Patients O
with O
Type O
2 O
Diabetes O
Mellitus O
Number O
of O
patients O
( O
% O
) O
Adverse O
Reaction O
BELVIQ O
10 O
mg O
BID O
N=256 O
Placebo O
N=252 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Nausea B-OSE_Labeled_AE
24 O
( O
9.4 O
) O
20 O
( O
7.9 O
) O
Toothache B-OSE_Labeled_AE
7 O
( O
2.7 O
) O
0 O
General B-NonOSE_AE
Disorders I-NonOSE_AE
And I-NonOSE_AE
Administration I-NonOSE_AE
Site I-NonOSE_AE
Conditions I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
19 O
( O
7.4 O
) O
10 O
( O
4.0 O
) O
Peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
12 O
( O
4.7 O
) O
6 O
( O
2.4 O
) O
Immune B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Seasonal B-OSE_Labeled_AE
allergy I-OSE_Labeled_AE
8 O
( O
3.1 O
) O
2 O
( O
0.8 O
) O
Infections B-NonOSE_AE
And O
Infestations O
Nasopharyngitis B-OSE_Labeled_AE
29 O
( O
11.3 O
) O
25 O
( O
9.9 O
) O
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
23 O
( O
9.0 O
) O
15 O
( O
6.0 O
) O
Gastroenteritis B-OSE_Labeled_AE
8 O
( O
3.1 O
) O
5 O
( O
2.0 O
) O
Metabolism B-NonOSE_AE
And I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
Hypoglycemia B-OSE_Labeled_AE
75 O
( O
29.3 O
) O
53 O
( O
21.0 O
) O
Worsening B-OSE_Labeled_AE
of I-OSE_Labeled_AE
diabetes I-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
7 O
( O
2.7 O
) O
2 O
( O
0.8 O
) O
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
6 O
( O
2.3 O
) O
1 O
( O
0.4 O
) O
Musculoskeletal B-NonOSE_AE
And O
Connective O
Tissue O
Disorders I-NonOSE_AE
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
30 O
( O
11.7 O
) O
20 O
( O
7.9 O
) O
Muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
12 O
( O
4.7 O
) O
9 O
( O
3.6 O
) O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Headache B-OSE_Labeled_AE
37 O
( O
14.5 O
) O
18 O
( O
7.1 O
) O
Dizziness B-OSE_Labeled_AE
18 O
( O
7.0 O
) O
16 O
( O
6.3 O
) O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
Anxiety B-OSE_Labeled_AE
9 O
( O
3.5 O
) O
8 O
( O
3.2 O
) O
Insomnia B-OSE_Labeled_AE
9 O
( O
3.5 O
) O
6 O
( O
2.4 O
) O
Stress B-OSE_Labeled_AE
7 O
( O
2.7 O
) O
3 O
( O
1.2 O
) O
Depression B-OSE_Labeled_AE
6 O
( O
2.3 O
) O
5 O
( O
2.0 O
) O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
Thoracic I-NonOSE_AE
And I-NonOSE_AE
Mediastinal I-NonOSE_AE
Disorders I-NonOSE_AE
Cough B-OSE_Labeled_AE
21 O
( O
8.2 O
) O
11 O
( O
4.4 O
) O
Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
13 O
( O
5.1 O
) O
8 O
( O
3.2 O
) O
Other O
Adverse O
Reactions O
Serotonin-associated O
Adverse O
Reactions O
SSRIs O
, O
SNRIs O
, O
bupropion O
, O
tricyclic O
antidepressants O
, O
and O
MAOIs O
were O
excluded O
from O
the O
BELVIQ O
trials O
. O

Triptans O
and O
dextromethorphan O
were O
permitted O
: O
2 O
% O
and O
15 O
% O
, O
respectively O
, O
of O
patients O
without O
diabetes O
and O
1 O
% O
and O
12 O
% O
, O
respectively O
, O
of O
patients O
with O
type O
2 O
diabetes O
experienced O
concomitant O
use O
at O
some O
point O
during O
the O
trials O
. O

Two O
patients O
treated O
with O
BELVIQ O
in O
the O
clinical O
program O
experienced O
a O
constellation O
of O
symptoms O
and O
signs O
consistent O
with O
serotonergic B-OSE_Labeled_AE
excess I-OSE_Labeled_AE
, O
including O
one O
patient O
on O
concomitant O
dextromethorphan O
who O
reported O
an O
event O
of O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
. O

Some O
symptoms O
of O
possible O
serotonergic O
etiology O
that O
are O
included O
in O
the O
criteria O
for O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
were O
reported O
by O
patients O
treated O
with O
BELVIQ O
and O
placebo O
during O
clinical O
trials O
of O
at O
least O
1 O
year O
in O
duration O
. O

In O
both O
groups O
, O
chills B-OSE_Labeled_AE
were O
the O
most O
frequent O
of O
these O
events O
( O
1.0 O
% O
vs O
. O
0.2 O
% O
, O
respectively O
) O
, O
followed O
by O
tremor B-OSE_Labeled_AE
( O
0.3 O
% O
vs O
. O
0.2 O
% O
) O
, O
confusional B-OSE_Labeled_AE
state I-OSE_Labeled_AE
( O
0.2 O
% O
vs O
. O
less O
than O
0.1 O
% O
) O
, O
disorientation B-OSE_Labeled_AE
( O
0.1 O
% O
vs O
. O
0.1 O
% O
) O
and O
hyperhidrosis B-OSE_Labeled_AE
( O
0.1 O
% O
vs O
. O
0.2 O
% O
) O
. O

Because O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
has O
a O
very O
low O
incidence O
, O
an O
association O
between O
BELVIQ O
and O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
can O
not O
be O
excluded O
on O
the O
basis O
of O
clinical O
trial O
results O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

Hypoglycemia O
in O
Patients O
with O
Type O
2 O
Diabetes O
In O
a O
clinical O
trial O
of O
patients O
with O
type B-Not_AE_Candidate
2 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
mellitus I-Not_AE_Candidate
, O
hypoglycemia B-OSE_Labeled_AE
requiring O
the O
assistance O
of O
another O
person O
occurred O
in O
4 O
( O
1.6 O
% O
) O
of O
BELVIQ-treated O
patients O
and O
in O
1 O
( O
0.4 O
% O
) O
placebo-treated O
patient O
. O

Of O
these O
4 O
BELVIQ-treated O
patients O
, O
all O
were O
concomitantly O
using O
a O
sulfonylurea O
( O
with O
or O
without O
metformin O
) O
. O

BELVIQ O
has O
not O
been O
studied O
in O
patients O
taking O
insulin O
. O

Hypoglycemia B-OSE_Labeled_AE
defined O
as O
blood B-NonOSE_AE
sugar I-NonOSE_AE
less I-NonOSE_AE
than I-NonOSE_AE
or I-NonOSE_AE
equal I-NonOSE_AE
to I-NonOSE_AE
6 I-NonOSE_AE
5 I-NonOSE_AE
mg I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
and I-NonOSE_AE
with I-NonOSE_AE
symptoms I-NonOSE_AE
occurred O
in O
19 O
( O
7.4 O
% O
) O
BELVIQ-treated O
patients O
and O
16 O
( O
6.3 O
% O
) O
placebo-treated O
patients O
. O

Cognitive O
Impairment O
In O
clinical O
trials O
of O
at O
least O
1-year O
duration O
, O
adverse O
reactions O
related O
to O
cognitive B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
( O
e.g. O
, O
difficulty B-OSE_Labeled_AE
with I-OSE_Labeled_AE
concentration I-OSE_Labeled_AE
/attention O
, O
difficulty B-OSE_Labeled_AE
with I-OSE_Labeled_AE
memory I-OSE_Labeled_AE
, O
and O
confusion B-OSE_Labeled_AE
) O
occurred O
in O
2.3 O
% O
of O
patients O
taking O
BELVIQ O
and O
0.7 O
% O
of O
patients O
taking O
placebo O
. O

Psychiatric O
Disorders O
Psychiatric B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
leading O
to O
hospitalization O
or O
drug O
withdrawal O
occurred O
more O
frequently O
in O
patients O
treated O
with O
BELVIQ O
( O
2.2 O
% O
) O
as O
compared O
to O
placebo O
( O
1.1 O
% O
) O
in O
non-diabetic O
patients O
. O

Euphoria B-OSE_Labeled_AE
. O

In O
short-term O
studies O
with O
healthy O
individuals O
, O
the O
incidence O
of O
euphoric B-NonOSE_AE
mood I-NonOSE_AE
following O
supratherapeutic O
doses O
of O
BELVIQ O
( O
40 O
and O
60 O
mg O
) O
was O
increased O
as O
compared O
to O
placebo O
[ O
see O
Drug O
Abuse O
and O
Dependence O
( O
9.2 O
) O
] O
. O

In O
clinical O
trials O
of O
at O
least O
1-year O
duration O
in O
obese B-Not_AE_Candidate
patients O
, O
euphoria B-OSE_Labeled_AE
was O
observed O
in O
0.17 O
% O
of O
patients O
taking O
BELVIQ O
and O
0.03 O
% O
taking O
placebo O
. O

Depression B-OSE_Labeled_AE
and O
Suicidality B-OSE_Labeled_AE
. O

In O
trials O
of O
at O
least O
one O
year O
in O
duration O
, O
reports O
of O
depression B-OSE_Labeled_AE
/ O
mood B-OSE_Labeled_AE
problems I-OSE_Labeled_AE
occurred O
in O
2.6 O
% O
BELVIQ-treated O
vs O
. O
2.4 O
% O
placebo-treated O
and O
suicidal B-OSE_Labeled_AE
ideation I-OSE_Labeled_AE
occurred O
in O
0.6 O
% O
BELVIQ-treated O
vs O
. O
0.4 O
% O
placebo-treated O
patients O
. O

1.3 O
% O
of O
BELVIQ O
patients O
vs O
. O
0.6 O
% O
of O
placebo O
patients O
discontinued O
drug O
due O
to O
depression B-OSE_Labeled_AE
- O
, O
mood B-OSE_Labeled_AE
- I-OSE_Labeled_AE
, O
or O
suicidal O
ideation- O
related I-OSE_Label
ed B-OSE_Labeled_AE
_ I-OSE_Labeled_AE
AE I-OSE_Labeled_AE
events I-OSE_Labeled_AE
  I-OSE_Labeled_AE
I I-OSE_Labeled_AE
- I-OSE_Labeled_AE
OSE_Labeled_AE O
. O

Laboratory O
Abnormalities O
Lymphocyte O
and O
Neutrophil O
Counts O
. O

In O
clinical O
trials O
of O
at O
least O
1-year O
duration O
, O
lymphocyte B-OSE_Labeled_AE
counts I-OSE_Labeled_AE
were O
below I-OSE_Labeled_AE
the I-OSE_Labeled_AE
lower I-OSE_Labeled_AE
limit I-OSE_Labeled_AE
of I-OSE_Labeled_AE
normal I-OSE_Labeled_AE
in O
12.2 O
% O
of O
patients O
taking O
BELVIQ O
and O
9.0 O
% O
taking O
placebo O
, O
and O
neutrophil B-OSE_Labeled_AE
counts I-OSE_Labeled_AE
were I-OSE_Labeled_AE
low I-OSE_Labeled_AE
in O
5.6 O
% O
and O
4.3 O
% O
, O
respectively O
. O

Hemoglobin O
. O

In O
clinical O
trials O
of O
at O
least O
1-year O
duration O
, O
10.4 O
% O
of O
patients O
taking O
BELVIQ O
and O
9.3 O
% O
taking O
placebo O
had O
hemoglobin B-OSE_Labeled_AE
below I-OSE_Labeled_AE
the I-OSE_Labeled_AE
lower I-OSE_Labeled_AE
limit I-OSE_Labeled_AE
of I-OSE_Labeled_AE
normal I-OSE_Labeled_AE
at O
some O
point O
during O
the O
trials O
. O

Prolactin O
. O

In O
clinical O
trials O
, O
elevations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
prolactin I-OSE_Labeled_AE
greater O
than O
the O
upper O
limit O
of O
normal O
, O
two O
times O
the O
upper O
limit O
of O
normal O
, O
and O
five O
times O
the O
upper O
limit O
of O
normal O
, O
occurred O
in O
6.7 O
% O
, O
1.7 O
% O
, O
and O
0.1 O
% O
of O
BELVIQ-treated O
patients O
and O
4.8 O
% O
, O
0.8 O
% O
, O
and O
0.0 O
% O
of O
placebo-treated O
patients O
, O
respectively O
. O

Eye O
disorders O
. O

More O
patients O
on O
BELVIQ O
reported O
an O
eye B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
than O
patients O
on O
placebo O
in O
clinical O
trials O
of O
patients O
without O
diabetes B-Not_AE_Candidate
( O
4.5 O
% O
vs O
. O
3.0 O
% O
) O
and O
with O
type B-Not_AE_Candidate
2 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
( O
6.3 O
% O
vs O
. O
1.6 O
% O
) O
. O

In O
the O
population O
without O
diabetes B-Not_AE_Candidate
, O
events O
of O
blurred B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
eye I-OSE_Labeled_AE
, O
and O
visual B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
occurred O
in O
BELVIQ-treated O
patients O
at O
an O
incidence O
greater O
than O
that O
of O
placebo O
. O

In O
the O
population O
with O
type B-Not_AE_Candidate
2 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
, O
visual B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
, O
conjunctival B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
irritations O
, O
and O
inflammations O
, O
ocular B-OSE_Labeled_AE
sensation I-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
, O
and O
cataract B-OSE_Labeled_AE
conditions I-OSE_Labeled_AE
occurred O
in O
BELVIQ-treated O
patients O
at O
an O
incidence O
greater O
than O
placebo O
. O

Echocardiographic O
Safety O
Assessments O
The O
possible O
occurrence O
of O
regurgitant B-NonOSE_AE
cardiac I-NonOSE_AE
valve I-NonOSE_AE
disease I-NonOSE_AE
was O
prospectively O
evaluated O
in O
7794 O
patients O
in O
three O
clinical O
trials O
of O
at O
least O
one O
year O
in O
duration O
, O
3451 O
of O
whom O
took O
BELVIQ O
10 O
mg O
twice O
daily O
. O

The O
primary O
echocardiographic O
safety O
parameter O
was O
the O
proportion O
of O
patients O
who O
developed O
echocardiographic O
criteria O
of O
mild O
or O
greater O
aortic B-NonOSE_AE
insufficiency I-NonOSE_AE
and/or O
moderate O
or O
greater O
mitral B-NonOSE_AE
insufficiency I-NonOSE_AE
from O
baseline O
to O
1 O
year O
. O

At O
1 O
year O
, O
2.4 O
% O
of O
patients O
who O
received O
BELVIQ O
and O
2.0 O
% O
of O
patients O
who O
received O
placebo O
developed O
valvular B-OSE_Labeled_AE
regurgitation I-OSE_Labeled_AE
. O

The O
relative O
risk O
for O
valvulopathy B-OSE_Labeled_AE
with O
BELVIQ O
is O
summarized O
in O
Table O
4 O
. O

BELVIQ O
was O
not O
studied O
in O
patients O
with O
congestive B-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
or O
hemodynamically-significant O
valvular B-Not_AE_Candidate
heart I-Not_AE_Candidate
disease I-Not_AE_Candidate
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

Table O
4 O
. O

Incidence O
of O
FDA-Defined O
Valvulopathy O
at O
Week O
52 O
by O
Treatment O
Group1 O
1 O
Patients O
without O
valvulopathy O
at O
baseline O
who O
received O
study O
medication O
and O
had O
a O
post-baseline O
echocardiogram O
; O
ITT-intention-to-treat O
; O
LOCF-last O
observation O
carried O
forward O
Study O
1 O
Study O
2 O
Study O
3 O
BELVIQ O
N=1278 O
Placebo O
N=1191 O
BELVIQ O
N=1208 O
Placebo O
N=1153 O
BELVIQ O
N=210 O
Placebo O
N=209 O
FDA-defined O
Valvulopathy B-OSE_Labeled_AE
, O
n O
( O
% O
) O
34 O
( O
2.7 O
) O
28 O
( O
2.4 O
) O
24 O
( O
2.0 O
) O
23 O
( O
2.0 O
) O
6 O
( O
2.9 O
) O
1 O
( O
0.5 O
) O
Relative O
Risk O
( O
95 O
% O
CI O
) O
1.13 O
( O
0.69 O
, O
1.85 O
) O
1.00 O
( O
0.57 O
, O
1.75 O
) O
5.97 O
( O
0.73 O
, O
49.17 O
) O
Pooled O
RR O
( O
95 O
% O
CI O
) O
1.16 O
( O
0.81 O
, O
1.67 O
) O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Serotonin O
Syndrome O
or O
Neuroleptic O
Malignant O
Syndrome O
( O
NMS O
) O
-like O
Reactions O
: O
The O
safety O
of O
coadministration O
with O
other O
serotonergic O
or O
antidopaminergic O
agents O
has O
not O
been O
established O
. O

Manage O
with O
immediate O
BELVIQ O
discontinuation O
and O
provide O
supportive O
treatment O
. O

( O
5.1 O
) O
* O
Valvular O
heart O
disease O
: O
If O
signs O
or O
symptoms O
develop O
consider O
BELVIQ O
discontinuation O
and O
evaluate O
the O
patient O
for O
possible O
valvulopathy O
. O

( O
5.2 O
) O
* O
Cognitive O
Impairment O
: O
May O
cause O
disturbances O
in O
attention O
or O
memory O
. O

Caution O
with O
use O
of O
hazardous O
machinery O
when O
starting O
BELVIQ O
treatment O
. O

( O
5.3 O
) O
* O
Psychiatric O
Disorders O
, O
including O
euphoria O
and O
dissociation O
: O
Do O
not O
exceed O
recommended O
dose O
of O
10 O
mg O
twice O
daily O
. O

( O
5.4 O
) O
* O
Monitor O
for O
depression O
or O
suicidal O
thoughts O
. O

Discontinue O
if O
symptoms O
develop O
. O

( O
5.4 O
) O
* O
Use O
of O
Antidiabetic O
Medications O
: O
weight O
loss O
may O
cause O
hypoglycemia O
. O

Monitor O
blood O
glucose O
. O

BELVIQ O
has O
not O
been O
studied O
in O
patients O
taking O
insulin O
. O

( O
5.5 O
) O
* O
Priapism O
: O
Patients O
should O
seek O
emergency O
treatment O
if O
an O
erection O
lasts O
> O
4 O
hours O
. O

Use O
BELVIQ O
with O
caution O
in O
patients O
predisposed O
to O
priapism O
. O

( O
5.6 O
) O
5.1 O
Serotonin O
Syndrome O
or O
Neuroleptic O
Malignant O
Syndrome O
( O
NMS O
) O
-like O
Reactions O
BELVIQ O
is O
a O
serotonergic O
drug O
. O

The O
development O
of O
a O
potentially O
life-threatening O
serotonin B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
or O
Neuroleptic B-OSE_Labeled_AE
Malignant I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( O
NMS O
) O
-like O
reactions O
have O
been O
reported O
during O
use O
of O
serotonergic O
drugs O
, O
including O
, O
but O
not O
limited O
to O
, O
selective O
serotonin-norepinephrine O
reuptake O
inhibitors O
( O
SNRIs O
) O
and O
selective O
serotonin O
reuptake O
inhibitors O
( O
SSRIs O
) O
, O
tricyclic O
antidepressants O
( O
TCAs O
) O
, O
bupropion O
, O
triptans O
, O
dietary O
supplements O
such O
as O
St O
. O
John O
's O
Wort O
and O
tryptophan O
, O
drugs O
that O
impair O
metabolism O
of O
serotonin O
( O
including O
monoamine O
oxidase O
inhibitors O
[ O
MAOIs O
] O
) O
, O
dextromethorphan O
, O
lithium O
, O
tramadol O
, O
antipsychotics O
or O
other O
dopamine O
antagonists O
, O
particularly O
when O
used O
in O
combination O
[ O
see O
Drug O
Interactions O
( O
7.1 O
) O
] O
. O

Serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
symptoms O
may O
include O
mental B-NonOSE_AE
status I-NonOSE_AE
changes I-NonOSE_AE
( O
e.g. O
, O
agitation B-NonOSE_AE
, O
hallucinations B-NonOSE_AE
, O
coma B-NonOSE_AE
) O
, O
autonomic B-NonOSE_AE
instability I-NonOSE_AE
( O
e.g. O
, O
tachycardia B-NonOSE_AE
, O
labile B-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
, O
hyperthermia B-NonOSE_AE
) O
, O
neuromuscular B-NonOSE_AE
aberrations I-NonOSE_AE
( O
e.g. O
, O
hyperreflexia B-NonOSE_AE
, O
incoordination B-NonOSE_AE
) O
and/or O
gastrointestinal B-NonOSE_AE
symptoms I-NonOSE_AE
( O
e.g. O
, O
nausea B-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
diarrhea B-NonOSE_AE
) O
. O

Serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
, O
in O
its O
most O
severe O
form O
, O
can O
resemble O
neuroleptic B-NonOSE_AE
malignant I-NonOSE_AE
syndrome I-NonOSE_AE
, O
which O
includes O
hyperthermia B-NonOSE_AE
, O
muscle B-NonOSE_AE
rigidity I-NonOSE_AE
, O
autonomic B-NonOSE_AE
instability I-NonOSE_AE
with O
possible O
rapid B-NonOSE_AE
fluctuation I-NonOSE_AE
of I-NonOSE_AE
vital I-NonOSE_AE
signs I-NonOSE_AE
, O
and O
mental B-NonOSE_AE
status I-NonOSE_AE
changes I-NonOSE_AE
. O

Patients O
should O
be O
monitored O
for O
the O
emergence O
of O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
or O
NMS B-NonOSE_AE
- I-NonOSE_AE
like I-NonOSE_AE
signs O
and O
symptoms O
. O

The O
safety O
of O
BELVIQ O
when O
coadministered O
with O
other O
serotonergic O
or O
antidopaminergic O
agents O
, O
including O
antipsychotics O
, O
or O
drugs O
that O
impair O
metabolism O
of O
serotonin O
, O
including O
MAOIs O
, O
has O
not O
been O
systematically O
evaluated O
and O
has O
not O
been O
established O
. O

If O
concomitant O
administration O
of O
BELVIQ O
with O
an O
agent O
that O
affects O
the O
serotonergic O
neurotransmitter O
system O
is O
clinically O
warranted O
, O
extreme O
caution O
and O
careful O
observation O
of O
the O
patient O
is O
advised O
, O
particularly O
during O
treatment O
initiation O
and O
dose O
increases O
. O

Treatment O
with O
BELVIQ O
and O
any O
concomitant O
serotonergic O
or O
antidopaminergic O
agents O
, O
including O
antipsychotics O
, O
should O
be O
discontinued O
immediately O
if O
the O
above O
events O
occur O
and O
supportive O
symptomatic O
treatment O
should O
be O
initiated O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
and O
Drug O
Interactions O
( O
7.1 O
) O
] O
. O

5.2 O
Valvular O
Heart O
Disease O
Regurgitant B-OSE_Labeled_AE
cardiac I-OSE_Labeled_AE
valvular I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
, O
primarily O
affecting O
the O
mitral O
and/or O
aortic O
valves O
, O
has O
been O
reported O
in O
patients O
who O
took O
serotonergic O
drugs O
with O
5-HT2Breceptor O
agonist O
activity O
. O

The O
etiology O
of O
the O
regurgitant B-NonOSE_AE
valvular I-NonOSE_AE
disease I-NonOSE_AE
is O
thought O
to O
be O
activation O
of O
5-HT2Breceptors O
on O
cardiac O
interstitial O
cells O
. O

At O
therapeutic O
concentrations O
, O
BELVIQ O
is O
selective O
for O
5-HT2Creceptors O
as O
compared O
to O
5-HT2Breceptors O
. O

In O
clinical O
trials O
of O
1-year O
duration O
, O
2.4 O
% O
of O
patients O
receiving O
BELVIQ O
and O
2.0 O
% O
of O
patients O
receiving O
placebo O
developed O
echocardiographic O
criteria O
for O
valvular B-OSE_Labeled_AE
regurgitation I-OSE_Labeled_AE
at O
one O
year O
( O
mild O
or O
greater O
aortic B-OSE_Labeled_AE
regurgitation I-OSE_Labeled_AE
and/or O
moderate O
or O
greater O
mitral B-OSE_Labeled_AE
regurgitation I-OSE_Labeled_AE
) O
: O
none O
of O
these O
patients O
was O
symptomatic O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
see O
Clinical O
Pharmacology O
( O
12.1 O
) O
] O
. O

BELVIQ O
has O
not O
been O
studied O
in O
patients O
with O
congestive B-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
or O
hemodynamically-significant O
valvular B-Not_AE_Candidate
heart I-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

Preliminary O
data O
suggest O
that O
5HT2Breceptors O
may O
be O
overexpressed O
in O
congestive B-NonOSE_AE
heart I-NonOSE_AE
failure I-NonOSE_AE
, O
Therefore O
, O
BELVIQ O
should O
be O
used O
with O
caution O
in O
patients O
with O
congestive B-NonOSE_AE
heart I-NonOSE_AE
failure I-NonOSE_AE
. O

BELVIQ O
should O
not O
be O
used O
in O
combination O
with O
serotonergic O
and O
dopaminergic O
drugs O
that O
are O
potent O
5-HT2Breceptor O
agonists O
and O
are O
known O
to O
increase O
the O
risk O
for O
cardiac B-NonOSE_AE
valvulopathy I-NonOSE_AE
( O
e.g. O
, O
cabergoline O
) O
. O

Patients O
who O
develop O
signs O
or O
symptoms O
of O
valvular B-NonOSE_AE
heart I-NonOSE_AE
disease I-NonOSE_AE
, O
including O
dyspnea B-NonOSE_AE
, O
dependent B-NonOSE_AE
edema I-NonOSE_AE
, O
congestive B-NonOSE_AE
heart I-NonOSE_AE
failure I-NonOSE_AE
, O
or O
a O
new O
cardiac B-NonOSE_AE
murmur I-NonOSE_AE
while O
being O
treated O
with O
BELVIQ O
should O
be O
evaluated O
and O
discontinuation O
of O
BELVIQ O
should O
be O
considered O
. O

5.3 O
Cognitive O
Impairment O
In O
clinical O
trials O
of O
at O
least O
one O
year O
in O
duration O
, O
impairments B-OSE_Labeled_AE
in I-OSE_Labeled_AE
attention I-OSE_Labeled_AE
and O
memory O
were O
reported O
adverse O
reactions O
associated O
with O
1.9 O
% O
of O
patients O
treated O
with O
BELVIQ O
and O
0.5 O
% O
of O
patients O
treated O
with O
placebo O
, O
and O
led O
to O
discontinuation O
in O
0.3 O
% O
and O
0.1 O
% O
of O
these O
patients O
, O
respectively O
. O

Other O
reported O
adverse O
reactions O
associated O
with O
BELVIQ O
in O
clinical O
trials O
included O
confusion B-OSE_Labeled_AE
, O
somnolence B-OSE_Labeled_AE
, O
and O
fatigue B-OSE_Labeled_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Since O
BELVIQ O
has O
the O
potential O
to O
impair B-OSE_Labeled_AE
cognitive I-OSE_Labeled_AE
function I-OSE_Labeled_AE
, O
patients O
should O
be O
cautioned O
about O
operating O
hazardous O
machinery O
, O
including O
automobiles O
, O
until O
they O
are O
reasonably O
certain O
that O
BELVIQ O
therapy O
does O
not O
affect O
them O
adversely O
[ O
see O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
. O

5.4 O
Psychiatric B-OSE_Labeled_AE
Disorders I-OSE_Labeled_AE
Events O
of O
euphoria B-NonOSE_AE
, O
hallucination B-NonOSE_AE
, O
and O
dissociation B-NonOSE_AE
were O
seen O
with O
BELVIQ O
at O
supratherapeutic O
doses O
in O
short-term O
studies O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
, O
Drug O
Abuse O
and O
Dependence O
( O
9.2 O
) O
, O
and O
Overdosage O
( O
10 O
) O
] O
. O

In O
clinical O
trials O
of O
at O
least O
1-year O
in O
duration O
, O
6 O
patients O
( O
0.2 O
% O
) O
treated O
with O
BELVIQ O
developed O
euphoria B-OSE_Labeled_AE
, O
as O
compared O
with O
1 O
patient O
( O
< O
0.1 O
% O
) O
treated O
with O
placebo O
. O

Doses O
of O
BELVIQ O
should O
not O
exceed O
10 O
mg O
twice O
a O
day O
. O

Some O
drugs O
that O
target O
the O
central O
nervous O
system O
have O
been O
associated O
with O
depression B-NonOSE_AE
or O
suicidal B-NonOSE_AE
ideation I-NonOSE_AE
. O

Patients O
treated O
with O
BELVIQ O
should O
be O
monitored O
for O
the O
emergence O
or O
worsening B-NonOSE_AE
of I-NonOSE_AE
depression I-NonOSE_AE
, O
suicidal B-NonOSE_AE
thoughts I-NonOSE_AE
or O
behavior O
, O
and/or O
any O
unusual O
changes B-NonOSE_AE
in I-NonOSE_AE
mood I-NonOSE_AE
or O
behavior O
. O

Discontinue O
BELVIQ O
in O
patients O
who O
experience O
suicidal B-NonOSE_AE
thoughts I-NonOSE_AE
or O
behaviors O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.5 O
Potential O
Risk O
of O
Hypoglycemia O
in O
Patients O
with O
Type O
2 O
Diabetes O
Mellitus O
on O
Anti-diabetic O
Therapy O
Weight B-NonOSE_AE
loss I-NonOSE_AE
may O
increase O
the O
risk O
of O
hypoglycemia B-NonOSE_AE
in O
patients O
with O
type B-Not_AE_Candidate
2 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
mellitus I-Not_AE_Candidate
treated O
with O
insulin O
and/or O
insulin O
secretagogues O
( O
e.g. O
, O
sulfonylureas O
) O
; O
hypoglycemia B-OSE_Labeled_AE
was O
observed O
in O
clinical O
trials O
with O
BELVIQ O
. O

BELVIQ O
has O
not O
been O
studied O
in O
combination O
with O
insulin O
. O

Measurement O
of O
blood O
glucose O
levels O
prior O
to O
starting O
BELVIQ O
and O
during O
BELVIQ O
treatment O
is O
recommended O
in O
patients O
with O
type B-Not_AE_Candidate
2 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
. O

Decreases O
in O
medication O
doses O
for O
anti-diabetic O
medications O
which O
are O
non-glucose-dependent O
should O
be O
considered O
to O
mitigate O
the O
risk O
of O
hypoglycemia B-NonOSE_AE
. O

If O
a O
patient O
develops O
hypoglycemia B-NonOSE_AE
after O
starting O
BELVIQ O
, O
appropriate O
changes O
should O
be O
made O
to O
the O
anti-diabetic O
drug O
regimen O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.6 O
Priapism O
Priapism B-OSE_Labeled_AE
( O
painful B-OSE_Labeled_AE
erections I-OSE_Labeled_AE
greater O
than O
6 O
hours O
in O
duration O
) O
is O
a O
potential O
effect O
of O
5-HT2Creceptor O
agonism O
. O

If O
not O
treated O
promptly O
, O
priapism B-NonOSE_AE
can O
result O
in O
irreversible O
damage B-NonOSE_AE
to I-NonOSE_AE
the I-NonOSE_AE
erectile I-NonOSE_AE
tissue I-NonOSE_AE
. O

Men O
who O
have O
an O
erection B-NonOSE_AE
lasting I-NonOSE_AE
greater I-NonOSE_AE
than I-NonOSE_AE
4 I-NonOSE_AE
hours I-NonOSE_AE
, O
whether O
painful O
or O
not O
, O
should O
immediately O
discontinue O
the O
drug O
and O
seek O
emergency O
medical O
attention O
. O

BELVIQ O
should O
be O
used O
with O
caution O
in O
men O
who O
have O
conditions O
that O
might O
predispose O
them O
to O
priapism B-NonOSE_AE
( O
e.g. O
, O
sickle B-NonOSE_AE
cell I-NonOSE_AE
anemia I-NonOSE_AE
, O
multiple B-NonOSE_AE
myeloma I-NonOSE_AE
, O
or O
leukemia B-NonOSE_AE
) O
, O
or O
in O
men O
with O
anatomical O
deformation O
of O
the O
penis B-NonOSE_AE
( O
e.g. O
, O
angulation I-NonOSE_AE
, O
cavernosal B-NonOSE_AE
fibrosis I-NonOSE_AE
, O
or O
Peyronie B-NonOSE_AE
' I-NonOSE_AE
s I-NonOSE_AE
disease I-NonOSE_AE
) O
. O

There O
is O
limited O
experience O
with O
the O
combination O
of O
BELVIQ O
and O
medication O
indicated O
for O
erectile B-NonOSE_AE
dysfunction I-NonOSE_AE
( O
e.g. O
, O
phosphodiesterase O
type O
5 O
inhibitors O
) O
. O

Therefore O
, O
the O
combination O
of O
BELVIQ O
and O
these O
medications O
should O
be O
used O
with O
caution O
. O

5.7 O
Heart O
Rate O
Decreases O
In O
clinical O
trials O
of O
at O
least O
1-year O
in O
duration O
, O
the O
mean B-NonOSE_AE
change I-NonOSE_AE
in I-NonOSE_AE
heart I-NonOSE_AE
rate I-NonOSE_AE
( O
HR O
) O
was O
- I-NonOSE_AE
1 O
. O

2 I-NonOSE_AE
beats O
per O
minute O
( O
bpm O
) O
in O
BELVIQ O
and O
-0 O
. I-NonOSE_AE
4 O
bpm O
in O
placebo-treated O
patients O
without O
diabetes O
and O
-2 O
. O

0 I-NonOSE_AE
beats I-NonOSE_AE
per I-NonOSE_AE
minute I-NonOSE_AE
( I-NonOSE_AE
bpm I-NonOSE_AE
) O
in O
BELVIQ O
and O
-0.4 O
bpm O
in O
placebo-treated O
patients O
with O
type B-Not_AE_Candidate
2 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
. O

The O
incidence O
of O
HR B-OSE_Labeled_AE
less I-OSE_Labeled_AE
than I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
bpm I-OSE_Labeled_AE
was O
5.3 O
% O
in O
BELVIQ O
and O
3.2 O
% O
in O
placebo-treated O
patients O
without O
diabetes O
and O
3.6 O
% O
in O
BELVIQ O
and O
2.0 O
% O
in O
placebo-treated O
patients O
with O
type O
2 O
diabetes O
. O

In O
the O
combined O
population O
, O
adverse O
reactions O
of O
bradycardia B-OSE_Labeled_AE
occurred O
in O
0.3 O
% O
of O
BELVIQ O
and O
0.1 O
% O
of O
placebo-treated O
patients O
. O

Use O
with O
caution O
in O
patients O
with O
bradycardia B-NonOSE_AE
or O
a O
history O
of O
heart B-NonOSE_AE
block I-NonOSE_AE
greater I-NonOSE_AE
than I-NonOSE_AE
first I-NonOSE_AE
degree I-NonOSE_AE
. O

5.8 O
Hematological B-OSE_Labeled_AE
Changes I-OSE_Labeled_AE
In O
clinical O
trials O
of O
at O
least O
one O
year O
in O
duration O
, O
adverse O
reactions O
of O
decreases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
white I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
count I-OSE_Labeled_AE
( O
including O
leukopenia B-OSE_Labeled_AE
, O
lymphopenia B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
and O
decreased B-OSE_Labeled_AE
white I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
count I-OSE_Labeled_AE
) O
were O
reported O
in O
0.4 O
% O
of O
patients O
treated O
with O
BELVIQ O
as O
compared O
to O
0.2 O
% O
of O
patients O
treated O
with O
placebo O
. O

Adverse O
reactions O
of O
decreases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
red I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
count I-OSE_Labeled_AE
( O
including O
anemia B-OSE_Labeled_AE
and O
decreases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
and O
hematocrit O
) O
were O
reported O
by O
1.3 O
% O
of O
patients O
treated O
with O
BELVIQ O
as O
compared O
to O
1.2 O
% O
treated O
with O
placebo O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Consider O
periodic O
monitoring O
of O
complete O
blood O
count O
during O
treatment O
with O
BELVIQ O
. O

5.9 O
Prolactin O
Elevation O
Lorcaserin O
moderately O
elevates B-OSE_Labeled_AE
prolactin I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
. O

In O
a O
subset O
of O
placebo-controlled O
clinical O
trials O
of O
at O
least O
one O
year O
in O
duration O
, O
elevations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
prolactin I-OSE_Labeled_AE
greater O
than O
the O
upper O
limit O
of O
normal O
, O
two O
times O
the O
upper O
limit O
of O
normal O
, O
and O
five O
times O
the O
upper O
limit O
of O
normal O
, O
measured O
both O
before O
and O
2 O
hours O
after O
dosing O
, O
occurred O
in O
6.7 O
% O
, O
1.7 O
% O
, O
and O
0.1 O
% O
of O
BELVIQ-treated O
patients O
and O
4.8 O
% O
, O
0.8 O
% O
, O
and O
0.0 O
% O
of O
placebo-treated O
patients O
, O
respectively O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Prolactin O
should O
be O
measured O
when O
symptoms O
and O
signs O
of O
prolactin B-NonOSE_AE
excess I-NonOSE_AE
are O
suspected O
( O
e.g. O
, O
galactorrhea B-NonOSE_AE
, O
gynecomastia B-NonOSE_AE
) O
. O

There O
was O
one O
patient O
treated O
with O
BELVIQ O
who O
developed O
a O
prolactinoma B-OSE_Labeled_AE
during O
the O
trial O
. O

The O
relationship O
of O
BELVIQ O
to O
the O
prolactinoma B-NonOSE_AE
in O
this O
patient O
is O
unknown O
. O

5.10 O
Pulmonary O
Hypertension O
Certain O
centrally-acting O
weight O
loss O
agents O
that O
act O
on O
the O
serotonin O
system O
have O
been O
associated O
with O
pulmonary B-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
, O
a O
rare O
but O
lethal O
disease O
. O

Because O
of O
the O
low O
incidence O
of O
this O
disease O
, O
the O
clinical O
trial O
experience O
with O
BELVIQ O
is O
inadequate O
to O
determine O
if O
BELVIQ O
increases O
the O
risk O
for O
pulmonary B-NonOSE_AE
hypertension I-NonOSE_AE
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
have O
been O
observed O
with O
BENLYSTA O
and O
are O
discussed O
in O
detail O
in O
the O
Warnings O
and O
Precautions O
section O
: O
* O
Mortality B-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Serious O
Infections B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Hypersensitivity B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
, O
including O
Anaphylaxis B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Infusion B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Depression B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Malignancy B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
with O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

EXCERPT O
: O
* O
Common O
adverse O
reactions O
( O
> O
=5 O
% O
) O
: O
nausea O
, O
diarrhea O
, O
pyrexia O
, O
nasopharyngitis O
, O
bronchitis O
, O
insomnia O
, O
pain O
in O
extremity O
, O
depression O
, O
migraine O
, O
pharyngitis O
, O
and O
injection O
site O
reactions O
( O
subcutaneous O
administration O
) O
. O

( O
6.1 O
, O
6.2 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
GlaxoSmithKline O
at O
1-877-423-6597 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
with O
Intravenous O
Administration O
The O
data O
described O
below O
reflect O
exposure O
to O
BENLYSTA O
administered O
intravenously O
plus O
standard O
therapy O
compared O
with O
placebo O
plus O
standard O
therapy O
in O
2,133 O
patients O
in O
3 O
controlled O
trials O
. O

Patients O
received O
BENLYSTA O
plus O
standard O
therapy O
at O
doses O
of O
1 O
mg/kg O
( O
n O
= O
673 O
) O
, O
4 O
mg/kg O
( O
n O
= O
111 O
; O
Trial O
1 O
only O
) O
, O
or O
10 O
mg/kg O
( O
n O
= O
674 O
) O
, O
or O
placebo O
plus O
standard O
therapy O
( O
n O
= O
675 O
) O
intravenously O
over O
a O
1-hour O
period O
on O
Days O
0 O
, O
14 O
, O
28 O
, O
and O
then O
every O
28 O
days O
. O

In O
2 O
of O
the O
trials O
( O
Trial O
1 O
and O
Trial O
3 O
) O
, O
treatment O
was O
given O
for O
48 O
weeks O
, O
while O
in O
the O
other O
trial O
( O
Trial O
2 O
) O
treatment O
was O
given O
for O
72 O
weeks O
[ O
see O
Clinical O
Studies O
( O
14.1 O
) O
] O
. O

Because O
there O
was O
no O
apparent O
dose-related O
increase O
in O
the O
majority O
of O
adverse O
events O
observed O
with O
BENLYSTA O
, O
the O
safety O
data O
summarized O
below O
are O
presented O
for O
the O
3 O
intravenous O
doses O
pooled O
, O
unless O
otherwise O
indicated O
; O
the O
adverse O
reaction O
table O
displays O
the O
results O
for O
the O
recommended O
intravenous O
dose O
of O
10 O
mg/kg O
compared O
with O
placebo O
. O

The O
population O
had O
a O
mean O
age O
of O
39 O
years O
( O
range O
: O
18 O
to O
75 O
) O
, O
94 O
% O
were O
female O
, O
and O
52 O
% O
were O
white O
. O

In O
these O
trials O
, O
93 O
% O
of O
patients O
treated O
with O
BENLYSTA O
plus O
standard O
therapy O
reported O
an O
adverse O
event O
compared O
with O
92 O
% O
treated O
with O
placebo O
plus O
standard O
therapy O
. O

The O
most O
common O
serious O
adverse O
events O
were O
serious O
infections B-OSE_Labeled_AE
( O
6.0 O
% O
and O
5.2 O
% O
in O
the O
groups O
receiving O
BENLYSTA O
and O
placebo O
plus O
standard O
therapy O
, O
respectively O
) O
, O
some O
of O
which O
were O
fatal B-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

The O
most O
commonly O
reported O
adverse O
events O
, O
occurring O
in O
> O
=5 O
% O
of O
patients O
in O
clinical O
trials O
were O
nausea B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
pyrexia B-OSE_Labeled_AE
, O
nasopharyngitis B-OSE_Labeled_AE
, O
bronchitis B-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
, O
migraine B-OSE_Labeled_AE
, O
and O
pharyngitis B-OSE_Labeled_AE
. O

The O
proportion O
of O
patients O
who O
discontinued O
treatment O
due O
to O
any O
adverse O
reaction O
during O
the O
controlled O
clinical O
trials O
was O
6.2 O
% O
for O
patients O
receiving O
BENLYSTA O
plus O
standard O
therapy O
and O
7.1 O
% O
for O
patients O
receiving O
placebo O
plus O
standard O
therapy O
. O

The O
most O
common O
adverse O
reactions O
resulting O
in O
discontinuation O
of O
treatment O
( O
> O
=1 O
% O
of O
patients O
receiving O
BENLYSTA O
or O
placebo O
) O
were O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
1.6 O
% O
BENLYSTA O
and O
0.9 O
% O
placebo O
) O
, O
lupus B-NonOSE_AE
nephritis I-NonOSE_AE
( O
0.7 O
% O
BENLYSTA O
and O
1.2 O
% O
placebo O
) O
, O
and O
infections B-NonOSE_AE
( O
0.7 O
% O
BENLYSTA O
and O
1.0 O
% O
placebo O
) O
. O

Table O
1 O
lists O
adverse O
reactions O
, O
regardless O
of O
causality O
, O
occurring O
in O
at O
least O
3 O
% O
of O
patients O
with O
SLE B-Not_AE_Candidate
who O
received O
BENLYSTA O
10 O
mg/kg O
plus O
standard O
therapy O
and O
at O
an O
incidence O
at O
least O
1 O
% O
greater O
than O
that O
observed O
with O
placebo O
plus O
standard O
therapy O
in O
the O
3 O
controlled O
studies O
. O

Table O
1 O
. O

Incidence O
of O
Adverse O
Reactions O
Occurring O
in O
at O
Least O
3 O
% O
of O
Patients O
Treated O
with O
BENLYSTA O
10 O
mg/kg O
plus O
Standard O
Therapy O
and O
at O
Least O
1 O
% O
More O
Frequently O
than O
in O
Patients O
Receiving O
Placebo O
plus O
Standard O
Therapy O
Preferred O
Term O
BENLYSTA O
10 O
mg/kg O
+ O
Standard O
Therapy O
( O
n O
= O
674 O
) O
% O
Placebo O
+ O
Standard O
Therapy O
( O
n O
= O
675 O
) O
% O
Nausea B-OSE_Labeled_AE
15 O
12 O
Diarrhea B-OSE_Labeled_AE
12 O
9 O
Pyrexia B-OSE_Labeled_AE
10 O
8 O
Nasopharyngitis B-OSE_Labeled_AE
9 O
7 O
Bronchitis B-OSE_Labeled_AE
9 O
5 O
Insomnia B-OSE_Labeled_AE
7 O
5 O
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
6 O
4 O
Depression B-OSE_Labeled_AE
5 O
4 O
Migraine B-OSE_Labeled_AE
5 O
4 O
Pharyngitis B-OSE_Labeled_AE
5 O
3 O
Cystitis B-OSE_Labeled_AE
4 O
3 O
Leukopenia B-OSE_Labeled_AE
4 O
2 O
Gastroenteritis B-OSE_Labeled_AE
viral I-OSE_Labeled_AE
3 O
1 O
6.2 O
Clinical O
Trials O
Experience O
with O
Subcutaneous O
Administration O
The O
data O
described O
below O
reflect O
exposure O
to O
BENLYSTA O
administered O
subcutaneously O
plus O
standard O
therapy O
compared O
with O
placebo O
plus O
standard O
therapy O
in O
836 O
patients O
in O
a O
controlled O
trial O
( O
Trial O
4 O
) O
. O

In O
addition O
to O
standard O
therapy O
, O
patients O
received O
BENLYSTA O
200 O
mg O
( O
n O
= O
556 O
) O
or O
placebo O
( O
n O
= O
280 O
) O
( O
2:1 O
randomization O
) O
once O
weekly O
for O
up O
to O
52 O
weeks O
[ O
see O
Clinical O
Studies O
( O
14.2 O
) O
] O
. O

The O
overall O
population O
had O
a O
mean O
age O
of O
39 O
years O
( O
range O
: O
18 O
to O
77 O
) O
, O
94 O
% O
were O
female O
, O
and O
60 O
% O
were O
white O
. O

In O
the O
trial O
, O
81 O
% O
of O
patients O
treated O
with O
BENLYSTA O
plus O
standard O
therapy O
reported O
an O
adverse O
event O
compared O
with O
84 O
% O
treated O
with O
placebo O
plus O
standard O
therapy O
. O

The O
proportion O
of O
patients O
who O
discontinued O
treatment O
due O
to O
any O
adverse O
reaction O
during O
the O
controlled O
clinical O
trial O
was O
7.2 O
% O
of O
patients O
receiving O
BENLYSTA O
plus O
standard O
therapy O
and O
8.9 O
% O
of O
patients O
receiving O
placebo O
plus O
standard O
therapy O
. O

The O
safety O
profile O
observed O
for O
BENLYSTA O
administered O
subcutaneously O
plus O
standard O
therapy O
was O
consistent O
with O
the O
known O
safety O
profile O
of O
BENLYSTA O
administered O
intravenously O
plus O
standard O
therapy O
, O
with O
the O
exception O
of O
local O
injection B-NonOSE_AE
site I-NonOSE_AE
reactions I-NonOSE_AE
. O

Injection O
Site O
Reactions O
In O
the O
clinical O
study O
for O
BENLYSTA O
administered O
subcutaneously O
, O
the O
frequency O
of O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
was O
6.1 O
% O
( O
34/556 O
) O
for O
patients O
receiving O
BENLYSTA O
plus O
standard O
therapy O
and O
2.5 O
% O
( O
7/280 O
) O
for O
patients O
receiving O
placebo O
plus O
standard O
therapy O
. O

These O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
most O
commonly O
pain O
, O
erythema O
, O
hematoma O
, O
pruritus O
, O
and O
induration O
) O
were O
mild O
to O
moderate O
in O
severity O
. O

The O
majority O
( O
94 O
% O
) O
did O
not O
necessitate O
discontinuation O
of O
treatment O
. O

6.3 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
postapproval O
use O
of O
BENLYSTA O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

* O
Fatal B-NonOSE_AE
anaphylaxis B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

6.4 O
Immunogenicity O
As O
with O
all O
therapeutic O
proteins O
, O
there O
is O
potential O
for O
immunogenicity B-OSE_Labeled_AE
. O

The O
detection O
of O
antibody B-NonOSE_AE
formation I-NonOSE_AE
is O
highly O
dependent O
on O
the O
sensitivity O
and O
specificity O
of O
the O
assay O
. O

Additionally O
, O
the O
observed O
incidence O
of O
antibody B-NonOSE_AE
( O
including O
neutralizing O
a O
ntibody B-NonOSE_AE
) I-NonOSE_AE
positivity I-NonOSE_AE
  I-NonOSE_AE
I-NonOSE_AE O
in O
an O
assay O
may O
be O
influenced O
by O
several O
factors O
including O
assay O
methodology O
, O
sample O
handling O
, O
timing O
of O
sample O
collection O
, O
concomitant O
medications O
, O
and O
underlying O
disease O
. O

For O
these O
reasons O
, O
comparison O
of O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
belimumab I-NonOSE_AE
with O
the O
incidence O
of O
antibodies B-NonOSE_AE
in O
other O
studies O
or O
to O
other O
products O
may O
be O
misleading O
. O

In O
Trials O
2 O
and O
3 O
( O
intravenous O
dosing O
) O
, O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
belimumab I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
were O
detected O
in O
4 O
of O
563 O
( O
0.7 O
% O
) O
patients O
receiving O
BENLYSTA O
10 O
mg/kg O
and O
in O
27 O
of O
559 O
( O
4.8 O
% O
) O
patients O
receiving O
BENLYSTA O
1 O
mg/kg O
. O

The O
reported O
frequency O
for O
the O
group O
receiving O
10 O
mg/kg O
may O
underestimate O
the O
actual O
frequency O
due O
to O
lower O
assay O
sensitivity O
in O
the O
presence O
of O
high O
drug O
concentrations O
. O

Neutralizing B-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
were O
detected I-OSE_Labeled_AE
in O
3 O
patients O
receiving O
BENLYSTA O
1 O
mg/kg O
. O

Three O
patients O
with O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
belimumab I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
experienced O
mild O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
of O
nausea B-OSE_Labeled_AE
, O
erythematous B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
eyelid B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
and O
dyspnea B-OSE_Labeled_AE
; O
none O
of O
the O
reactions O
was O
life-threatening O
. O

In O
Trial O
4 O
( O
subcutaneous O
dosing O
) O
, O
there O
was O
no O
formation O
of O
anti B-NonOSE_AE
- I-NonOSE_AE
belimumab I-NonOSE_AE
antibodies I-NonOSE_AE
in O
556 O
patients O
receiving O
BENLYSTA O
200 O
mg O
during O
the O
52-week O
placebo-controlled O
period O
. O

The O
clinical O
relevance O
of O
the O
presence O
of O
anti B-NonOSE_AE
- I-NonOSE_AE
belimumab I-NonOSE_AE
antibodies I-NonOSE_AE
is O
not O
known O
. O

The O
data O
reflect O
the O
percentage O
of O
patients O
whose O
test O
results O
were O
positive B-NonOSE_AE
for I-NonOSE_AE
antibodies I-NonOSE_AE
to I-NonOSE_AE
belimumab I-NonOSE_AE
in O
specific O
assays O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Mortality O
: O
There O
were O
more O
deaths O
reported O
with O
BENLYSTA O
than O
with O
placebo O
during O
the O
controlled O
period O
of O
clinical O
trials O
. O

( O
5.1 O
) O
* O
Serious O
Infections O
: O
Serious O
and O
sometimes O
fatal O
infections O
have O
been O
reported O
in O
patients O
receiving O
immunosuppressive O
agents O
, O
including O
BENLYSTA O
. O

Use O
with O
caution O
in O
patients O
with O
severe O
or O
chronic O
infections O
. O

Consider O
interrupting O
therapy O
with O
BENLYSTA O
if O
patients O
develop O
a O
new O
infection O
during O
treatment O
with O
BENLYSTA O
. O

( O
5.2 O
) O
* O
Progressive O
Multifocal O
Leukoencephalopathy O
( O
PML O
) O
: O
Patients O
presenting O
with O
new-onset O
or O
deteriorating O
neurological O
signs O
and O
symptoms O
should O
be O
evaluated O
for O
PML O
by O
an O
appropriate O
specialist O
. O

If O
PML O
is O
confirmed O
, O
consider O
discontinuation O
of O
immunosuppressant O
therapy O
, O
including O
BENLYSTA O
. O

( O
5.2 O
) O
* O
Hypersensitivity O
Reactions O
, O
including O
Anaphylaxis O
: O
Serious O
and O
fatal O
reactions O
have O
been O
reported O
. O

BENLYSTA O
for O
intravenous O
use O
should O
be O
administered O
by O
healthcare O
providers O
prepared O
to O
manage O
anaphylaxis O
. O

Monitor O
patients O
during O
and O
for O
an O
appropriate O
period O
of O
time O
after O
intravenous O
administration O
of O
BENLYSTA O
. O

( O
2.1 O
, O
5.3 O
) O
* O
Depression O
: O
Depression O
and O
suicidality O
have O
been O
reported O
in O
trials O
with O
BENLYSTA O
. O

Patients O
should O
be O
instructed O
to O
contact O
their O
healthcare O
provider O
if O
they O
experience O
new O
or O
worsening O
depression O
, O
suicidal O
thoughts O
, O
or O
other O
mood O
changes O
. O

( O
5.5 O
) O
* O
Immunization O
: O
Live O
vaccines O
should O
not O
be O
given O
concurrently O
with O
BENLYSTA O
. O

( O
5.7 O
) O
5.1 O
Mortality O
There O
were O
more O
deaths B-NonOSE_AE
reported O
with O
BENLYSTA O
than O
with O
placebo O
during O
the O
controlled O
period O
of O
the O
intravenous O
clinical O
trials O
. O

Out O
of O
2,133 O
patients O
in O
3 O
clinical O
trials O
, O
a O
total O
of O
14 O
deaths B-NonOSE_AE
occurred O
during O
the O
placebo-controlled O
, O
double-blind O
treatment O
periods O
: O
3/675 O
( O
0.4 O
% O
) O
, O
5/673 O
( O
0.7 O
% O
) O
, O
0/111 O
( O
0 O
% O
) O
, O
and O
6/674 O
( O
0.9 O
% O
) O
deaths B-NonOSE_AE
in O
the O
groups O
receiving O
placebo O
, O
BENLYSTA O
1 O
mg/kg O
, O
BENLYSTA O
4 O
mg/kg O
, O
and O
BENLYSTA O
10 O
mg/kg O
, O
respectively O
. O

No O
single O
cause O
of O
death B-NonOSE_AE
predominated O
. O

Etiologies O
included O
infection B-NonOSE_AE
, O
cardiovascular B-NonOSE_AE
disease I-NonOSE_AE
, O
and O
suicide B-NonOSE_AE
. O

In O
the O
controlled O
trial O
of O
BENLYSTA O
administered O
subcutaneously O
( O
N O
= O
836 O
) O
, O
a O
total O
of O
5 O
deaths B-NonOSE_AE
occurred O
during O
the O
placebo-controlled O
, O
double-blind O
treatment O
period O
( O
0.7 O
% O
[ O
2/280 O
] O
of O
patients O
receiving O
placebo O
and O
0.5 O
% O
[ O
3/556 O
] O
of O
patients O
receiving O
BENLYSTA O
) O
. O

Infection B-NonOSE_AE
was O
the O
most O
common O
cause O
of O
death B-NonOSE_AE
. O

5.2 O
Serious O
Infections O
Serious O
and O
sometimes O
fatal B-NonOSE_AE
infections B-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
receiving O
immunosuppressive B-NonOSE_AE
agents I-NonOSE_AE
, O
including O
BENLYSTA O
. O

Physicians O
should O
exercise O
caution O
when O
considering O
the O
use O
of O
BENLYSTA O
in O
patients O
with O
severe O
or O
chronic O
infections B-Not_AE_Candidate
. O

Consider O
interrupting O
therapy O
with O
BENLYSTA O
in O
patients O
who O
develop O
a O
new O
infection B-NonOSE_AE
while O
undergoing O
treatment O
with O
BENLYSTA O
and O
monitor O
these O
patients O
closely O
. O

In O
the O
controlled O
clinical O
trials O
of O
BENLYSTA O
administered O
intravenously O
, O
the O
overall O
incidence O
of O
infections B-OSE_Labeled_AE
was O
71 O
% O
in O
patients O
treated O
with O
BENLYSTA O
compared O
with O
67 O
% O
in O
patients O
who O
received O
placebo O
. O

The O
most O
frequent O
infections B-OSE_Labeled_AE
( O
> O
5 O
% O
of O
patients O
receiving O
BENLYSTA O
) O
were O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
nasopharyngitis B-OSE_Labeled_AE
, O
sinusitis B-OSE_Labeled_AE
, O
bronchitis B-OSE_Labeled_AE
, O
and O
influenza B-OSE_Labeled_AE
. O

Serious O
infections B-OSE_Labeled_AE
occurred O
in O
6.0 O
% O
of O
patients O
treated O
with O
BENLYSTA O
and O
in O
5.2 O
% O
of O
patients O
who O
received O
placebo O
. O

The O
most O
frequent O
serious O
infections B-OSE_Labeled_AE
included O
pneumonia B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
cellulitis B-OSE_Labeled_AE
, O
and O
bronchitis B-OSE_Labeled_AE
. O

Infections B-NonOSE_AE
leading O
to O
discontinuation O
of O
treatment O
occurred O
in O
0.7 O
% O
of O
patients O
receiving O
BENLYSTA O
and O
1.0 O
% O
of O
patients O
receiving O
placebo O
. O

Infections B-OSE_Labeled_AE
resulting O
in O
death B-NonOSE_AE
occurred O
in O
0.3 O
% O
( O
4/1,458 O
) O
of O
patients O
treated O
with O
BENLYSTA O
and O
in O
0.1 O
% O
( O
1/675 O
) O
of O
patients O
receiving O
placebo O
. O

In O
the O
controlled O
trial O
of O
BENLYSTA O
administered O
subcutaneously O
( O
N O
= O
836 O
) O
, O
the O
overall O
incidence O
of O
infections B-NonOSE_AE
was O
55 O
% O
in O
patients O
treated O
with O
BENLYSTA O
compared O
with O
57 O
% O
in O
patients O
who O
received O
placebo O
( O
serious O
infections B-NonOSE_AE
: O
4.1 O
% O
with O
BENLYSTA O
and O
5.4 O
% O
with O
placebo O
) O
. O

The O
most O
commonly O
reported O
infections B-NonOSE_AE
with O
BENLYSTA O
administered O
subcutaneously O
were O
similar O
to O
those O
reported O
with O
BENLYSTA O
administered O
intravenously O
. O

Progressive B-OSE_Labeled_AE
Multifocal I-OSE_Labeled_AE
Leukoencephalopathy I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PML I-OSE_Labeled_AE
) O
Cases O
of O
JC B-OSE_Labeled_AE
virus I-OSE_Labeled_AE
- I-OSE_Labeled_AE
associated I-OSE_Labeled_AE
PML B-OSE_Labeled_AE
resulting O
in O
neurological B-NonOSE_AE
deficits I-NonOSE_AE
, O
including O
fatal B-NonOSE_AE
cases O
, O
have O
been O
reported O
in O
patients O
with O
SLE B-Not_AE_Candidate
receiving O
immunosuppressants B-NonOSE_AE
, O
including O
BENLYSTA O
. O

Risk O
factors O
for O
PML B-NonOSE_AE
include O
treatment O
with O
immunosuppressant B-NonOSE_AE
therapies I-NonOSE_AE
and O
impairment B-NonOSE_AE
of I-NonOSE_AE
immune I-NonOSE_AE
function I-NonOSE_AE
. O

Consider O
the O
diagnosis O
of O
PML B-NonOSE_AE
in O
any O
patient O
presenting O
with O
new-onset O
or O
deteriorating O
neurological B-NonOSE_AE
signs I-NonOSE_AE
and O
symptoms O
and O
consult O
with O
a O
neurologist O
or O
other O
appropriate O
specialist O
as O
clinically O
indicated O
. O

In O
patients O
with O
confirmed O
PML B-NonOSE_AE
, O
consider O
stopping O
immunosuppressant B-NonOSE_AE
therapy I-NonOSE_AE
, O
including O
BENLYSTA O
. O

5.3 O
Hypersensitivity O
Reactions O
, O
including O
Anaphylaxis O
Acute O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
including O
anaphylaxis B-OSE_Labeled_AE
and O
death B-NonOSE_AE
, O
have O
been O
reported O
in O
association O
with O
BENLYSTA O
. O

These O
events O
generally O
occurred O
within O
hours O
of O
the O
infusion O
; O
however O
, O
they O
may O
occur O
later O
. O

Non-acute O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
including O
rash B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
myalgia B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
and O
facial B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
have O
been O
reported O
and O
typically O
occurred O
up O
to O
a O
week O
following O
the O
most O
recent O
infusion O
. O

Hypersensitivity B-OSE_Labeled_AE
, O
including O
serious O
reactions O
, O
has O
occurred O
in O
patients O
who O
have O
previously O
tolerated O
infusions O
of O
BENLYSTA O
. O

Limited O
data O
suggest O
that O
patients O
with O
a O
history O
of O
multiple O
drug B-Not_AE_Candidate
allergies I-Not_AE_Candidate
or O
significant O
hypersensitivity B-Not_AE_Candidate
may O
be O
at O
increased O
risk O
. O

In O
the O
controlled O
clinical O
trials O
of O
BENLYSTA O
administered O
intravenously O
, O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
occurring O
on O
the O
same O
day O
of O
infusion O
) O
were O
reported O
in O
13 O
% O
( O
191/1,458 O
) O
of O
patients O
receiving O
BENLYSTA O
and O
11 O
% O
( O
76/675 O
) O
of O
patients O
receiving O
placebo O
. O

Anaphylaxis B-OSE_Labeled_AE
was O
observed O
in O
0.6 O
% O
( O
9/1,458 O
) O
of O
patients O
receiving O
BENLYSTA O
and O
0.4 O
% O
( O
3/675 O
) O
of O
patients O
receiving O
placebo O
. O

Manifestations O
included O
hypotension B-NonOSE_AE
, O
angioedema B-NonOSE_AE
, O
urticaria B-NonOSE_AE
or O
other O
rash B-NonOSE_AE
, O
pruritus B-NonOSE_AE
, O
and O
dyspnea B-NonOSE_AE
. O

Due O
to O
overlap O
in O
signs O
and O
symptoms O
, O
it O
was O
not O
possible O
to O
distinguish O
between O
hypersensitivity B-NonOSE_AE
reactions I-NonOSE_AE
and O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
in O
all O
cases O
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
. O

Some O
patients O
( O
13 O
% O
) O
received O
premedication O
, O
which O
may O
have O
mitigated O
or O
masked O
a O
hypersensitivity B-NonOSE_AE
response O
; O
however O
, O
there O
is O
insufficient O
evidence O
to O
determine O
whether O
premedication O
diminishes O
the O
frequency O
or O
severity O
of O
hypersensitivity B-NonOSE_AE
reactions I-NonOSE_AE
. O

BENLYSTA O
for O
intravenous O
use O
should O
be O
administered O
by O
healthcare O
providers O
prepared O
to O
manage O
anaphylaxis B-NonOSE_AE
. O

In O
the O
event O
of O
a O
serious O
reaction O
, O
administration O
of O
BENLYSTA O
must O
be O
discontinued O
immediately O
and O
appropriate O
medical O
therapy O
administered O
. O

Patients O
should O
be O
monitored O
during O
and O
for O
an O
appropriate O
period O
of O
time O
after O
intravenous O
administration O
of O
BENLYSTA O
. O

In O
the O
controlled O
trial O
of O
BENLYSTA O
administered O
subcutaneously O
( O
N O
= O
836 O
) O
, O
systemic O
hypersensitivity B-NonOSE_AE
reactions I-NonOSE_AE
were O
similar O
to O
those O
observed O
in O
the O
intravenous O
clinical O
trials O
. O

Patients O
receiving O
BENLYSTA O
should O
be O
informed O
of O
the O
signs O
and O
symptoms O
of O
hypersensitivity B-NonOSE_AE
reactions I-NonOSE_AE
and O
be O
instructed O
to O
seek O
immediate O
medical O
care O
should O
a O
reaction O
occur O
. O

5.4 O
Infusion O
Reactions O
In O
the O
controlled O
clinical O
trials O
of O
BENLYSTA O
administered O
intravenously O
, O
adverse B-OSE_Labeled_AE
events I-OSE_Labeled_AE
associated I-OSE_Labeled_AE
with I-OSE_Labeled_AE
the I-OSE_Labeled_AE
infusion I-OSE_Labeled_AE
( O
occurring O
on O
the O
same O
day O
of O
the O
infusion O
) O
were O
reported O
in O
17 O
% O
( O
251/1,458 O
) O
of O
patients O
receiving O
BENLYSTA O
and O
15 O
% O
( O
99/675 O
) O
of O
patients O
receiving O
placebo O
. O

Serious O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
excluding O
hypersensitivity B-NonOSE_AE
reactions I-NonOSE_AE
) O
were O
reported O
in O
0.5 O
% O
of O
patients O
receiving O
BENLYSTA O
and O
0.4 O
% O
of O
patients O
receiving O
placebo O
and O
included O
bradycardia B-OSE_Labeled_AE
, O
myalgia B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
and O
hypotension B-OSE_Labeled_AE
. O

The O
most O
common O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
> O
=3 O
% O
of O
patients O
receiving O
BENLYSTA O
) O
were O
headache B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
and O
skin B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

Due O
to O
overlap O
in O
signs O
and O
symptoms O
, O
it O
was O
not O
possible O
to O
distinguish O
between O
hypersensitivity B-NonOSE_AE
reactions I-NonOSE_AE
and O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
in O
all O
cases O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

Some O
patients O
( O
13 O
% O
) O
received O
premedication O
, O
which O
may O
have O
mitigated O
or O
masked O
an O
infusion B-NonOSE_AE
reaction I-NonOSE_AE
; O
however O
, O
there O
is O
insufficient O
evidence O
to O
determine O
whether O
premedication O
diminishes O
the O
frequency O
or O
severity O
of O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

BENLYSTA O
for O
intravenous O
use O
should O
be O
administered O
by O
healthcare O
providers O
prepared O
to O
manage O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
. O

The O
infusion O
rate O
may O
be O
slowed O
or O
interrupted O
if O
the O
patient O
develops O
an O
infusion B-NonOSE_AE
reaction I-NonOSE_AE
. O

Healthcare O
providers O
should O
be O
aware O
of O
the O
risk O
of O
hypersensitivity B-NonOSE_AE
reactions I-NonOSE_AE
, O
which O
may O
present O
as O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
, O
and O
monitor O
patients O
closely O
. O

5.5 O
Depression O
In O
the O
controlled O
clinical O
trials O
of O
BENLYSTA O
administered O
intravenously O
, O
psychiatric B-OSE_Labeled_AE
events I-OSE_Labeled_AE
were O
reported O
more O
frequently O
with O
BENLYSTA O
( O
16 O
% O
) O
than O
with O
placebo O
( O
12 O
% O
) O
, O
related O
primarily O
to O
depression B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
events I-OSE_Labeled_AE
( O
6.3 O
% O
BENLYSTA O
and O
4.7 O
% O
placebo O
) O
, O
insomnia B-OSE_Labeled_AE
( O
6.0 O
% O
BENLYSTA O
and O
5.3 O
% O
placebo O
) O
, O
and O
anxiety B-OSE_Labeled_AE
( O
3.9 O
% O
BENLYSTA O
and O
2.8 O
% O
placebo O
) O
. O

Serious O
psychiatric B-OSE_Labeled_AE
events I-OSE_Labeled_AE
were O
reported O
in O
0.8 O
% O
of O
patients O
receiving O
BENLYSTA O
( O
0.6 O
% O
and O
1.2 O
% O
with O
1 O
and O
10 O
mg/kg O
, O
respectively O
) O
and O
0.4 O
% O
of O
patients O
receiving O
placebo O
. O

Serious O
depression B-OSE_Labeled_AE
was O
reported O
in O
0.4 O
% O
( O
6/1,458 O
) O
of O
patients O
receiving O
BENLYSTA O
and O
0.1 O
% O
( O
1/675 O
) O
of O
patients O
receiving O
placebo O
. O

Two O
suicides B-OSE_Labeled_AE
( O
0.1 O
% O
) O
were O
reported O
in O
patients O
receiving O
BENLYSTA O
. O

In O
the O
controlled O
trial O
of O
BENLYSTA O
administered O
subcutaneously O
( O
N O
= O
836 O
) O
, O
psychiatric B-NonOSE_AE
events I-NonOSE_AE
were O
reported O
in O
6 O
% O
of O
patients O
treated O
with O
BENLYSTA O
and O
in O
11 O
% O
of O
patients O
who O
received O
placebo O
. O

Depression B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
events I-NonOSE_AE
were O
reported O
in O
2.7 O
% O
of O
patients O
receiving O
BENLYSTA O
and O
3.6 O
% O
of O
patients O
receiving O
placebo O
. O

Serious O
psychiatric B-OSE_Labeled_AE
events I-OSE_Labeled_AE
were O
reported O
in O
0.2 O
% O
of O
patients O
receiving O
BENLYSTA O
and O
in O
no O
patients O
receiving O
placebo O
. O

There O
were O
no O
serious O
depression B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
events I-NonOSE_AE
or O
suicides B-NonOSE_AE
reported O
in O
either O
group O
. O

The O
majority O
of O
patients O
who O
reported O
serious O
depression B-NonOSE_AE
or O
suicidal B-NonOSE_AE
behavior I-NonOSE_AE
had O
a O
history O
of O
depression B-Not_AE_Candidate
or O
other O
serious O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
and O
most O
were O
receiving O
psychoactive O
medications O
. O

It O
is O
unknown O
if O
treatment O
with O
BENLYSTA O
is O
associated O
with O
increased O
risk O
for O
these O
events O
. O

Patients O
receiving O
BENLYSTA O
should O
be O
instructed O
to O
contact O
their O
healthcare O
provider O
if O
they O
experience O
new O
or O
worsening O
depression B-NonOSE_AE
, O
suicidal B-NonOSE_AE
thoughts I-NonOSE_AE
, O
or O
other O
mood B-NonOSE_AE
changes I-NonOSE_AE
. O

5.6 O
Malignancy O
The O
impact O
of O
treatment O
with O
BENLYSTA O
on O
the O
development O
of O
malignancies B-NonOSE_AE
is O
not O
known O
. O

In O
the O
controlled O
clinical O
trials O
of O
BENLYSTA O
administered O
intravenously O
, O
malignancies B-NonOSE_AE
( O
including O
non B-NonOSE_AE
- I-NonOSE_AE
melanoma I-NonOSE_AE
skin I-NonOSE_AE
cancers I-NonOSE_AE
) O
were O
reported O
in O
0.4 O
% O
of O
patients O
receiving O
BENLYSTA O
and O
0.4 O
% O
of O
patients O
receiving O
placebo O
. O

In O
the O
intravenous O
controlled O
clinical O
trials O
, O
malignancies B-NonOSE_AE
, O
excluding O
non B-NonOSE_AE
- I-NonOSE_AE
melanoma I-NonOSE_AE
skin I-NonOSE_AE
cancers I-NonOSE_AE
, O
were O
observed O
in O
0.2 O
% O
( O
3/1,458 O
) O
and O
0.3 O
% O
( O
2/675 O
) O
of O
patients O
receiving O
BENLYSTA O
and O
placebo O
, O
respectively O
. O

In O
the O
controlled O
clinical O
trial O
of O
BENLYSTA O
administered O
subcutaneously O
( O
N O
= O
836 O
) O
, O
the O
data O
were O
similar O
. O

The O
mechanism O
of O
action O
of O
BENLYSTA O
could O
increase O
the O
risk O
for O
the O
development O
of O
malignancies B-OSE_Labeled_AE
. O

5.7 O
Immunization O
Live O
vaccines O
should O
not O
be O
given O
for O
30 O
days O
before O
or O
concurrently O
with O
BENLYSTA O
as O
clinical O
safety O
has O
not O
been O
established O
. O

No O
data O
are O
available O
on O
the O
secondary B-NonOSE_AE
transmission I-NonOSE_AE
of I-NonOSE_AE
infection I-NonOSE_AE
from O
persons O
receiving O
live O
vaccines O
to O
patients O
receiving O
BENLYSTA O
or O
the O
effect O
of O
BENLYSTA O
on O
new O
immunizations O
. O

Because O
of O
its O
mechanism O
of O
action O
, O
BENLYSTA O
may O
interfere B-OSE_Labeled_AE
with I-OSE_Labeled_AE
the I-OSE_Labeled_AE
response I-OSE_Labeled_AE
to I-OSE_Labeled_AE
immunizations I-OSE_Labeled_AE
. O

5.8 O
Concomitant O
Use O
with O
Other O
Biologic O
Therapies O
or O
Intravenous O
Cyclophosphamide O
BENLYSTA O
has O
not O
been O
studied O
in O
combination O
with O
other O
biologic O
therapies O
, O
including O
B-cell O
targeted O
therapies O
, O
or O
intravenous O
cyclophosphamide O
. O

Therefore O
, O
use O
of O
BENLYSTA O
is O
not O
recommended O
in O
combination O
with O
biologic O
therapies O
or O
intravenous O
cyclophosphamide O
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
also O
discussed O
elsewhere O
in O
the O
labeling O
: O
* O
Bleeding B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Dyspnea B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
EXCERPT O
: O
Most O
common O
adverse O
reactions O
are O
bleeding O
12 O
% O
and O
dyspnea O
14 O
% O
. O

( O
5.1 O
, O
5.3 O
, O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
AstraZeneca O
at O
1-800-236-9933 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

BRILINTA O
has O
been O
evaluated O
for O
safety O
in O
more O
than O
27000 O
patients O
, O
including O
more O
than O
13000 O
patients O
treated O
for O
at O
least O
1 O
year O
. O

Bleeding O
in O
PLATO O
( O
Reduction O
in O
risk O
of O
thrombotic O
events O
in O
ACS O
) O
Figure O
1 O
is O
a O
plot O
of O
time O
to O
the O
first O
non-CABG O
major O
bleeding B-NonOSE_AE
event O
. O

Figure O
1 O
- O
Kaplan-Meier O
estimate O
of O
time O
to O
first O
non-CABG O
PLATO-defined O
major O
bleeding O
event O
( O
PLATO O
) O
Frequency O
of O
bleeding B-NonOSE_AE
in O
PLATO O
is O
summarized O
in O
Tables O
1 O
and O
2 O
. O

About O
half O
of O
the O
Non-CABG O
major O
bleeding B-OSE_Labeled_AE
events O
were O
in O
the O
first O
30 O
days O
. O

Table O
1 O
- O
Non-CABG O
related O
bleeds B-OSE_Labeled_AE
( O
PLATO O
) O
BRILINTA O
N=9235 O
Clopidogrel O
N=9186 O
n O
( O
% O
) O
patients O
with O
event O
n O
( O
% O
) O
patients O
with O
event O
PLATO O
Major O
+ O
Minor O
713 O
( O
7.7 O
) O
567 O
( O
6.2 O
) O
Major O
362 O
( O
3.9 O
) O
306 O
( O
3.3 O
) O
Fatal B-NonOSE_AE
/Life-threatening O
171 O
( O
1.9 O
) O
151 O
( O
1.6 O
) O
Fatal B-NonOSE_AE
15 O
( O
0.2 O
) O
16 O
( O
0.2 O
) O
Intracranial B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
( O
Fatal B-NonOSE_AE
/Life-threatening O
) O
26 O
( O
0.3 O
) O
15 O
( O
0.2 O
) O
PLATO O
Minor O
bleed B-OSE_Labeled_AE
: O
requires O
medical O
intervention O
to O
stop O
or O
treat O
bleeding B-NonOSE_AE
. O

PLATO O
Major O
bleed B-OSE_Labeled_AE
: O
any O
one O
of O
the O
following O
: O
fatal O
; O
intracrania O
l B-NonOSE_AE
  I-NonOSE_AE
I I-NonOSE_AE
- I-NonOSE_AE
O I-NonOSE_AE
SE_Labeled_AE O
; O
intrapericardial O
with O
cardiac B-NonOSE_AE
tamponade I-NonOSE_AE
; O
hypovolemic B-NonOSE_AE
shock I-NonOSE_AE
or O
severe B-NonOSE_AE
hypotension I-NonOSE_AE
requiring O
intervention O
; O
significantly O
disabling O
( O
e.g. O
, O
intraocular O
with O
permanent O
vision B-NonOSE_AE
loss I-NonOSE_AE
) O
; O
associated O
with O
a O
decrease B-NonOSE_AE
in I-NonOSE_AE
Hb I-NonOSE_AE
of O
at O
least O
3 O
g/dL O
( O
or O
a O
fall B-NonOSE_AE
in I-NonOSE_AE
hematocrit I-NonOSE_AE
( O
Hct O
) O
of O
at O
least O
9 O
% O
) O
; O
transfusion O
of O
2 O
or O
more O
units O
. O

PLATO O
Major O
bleed B-OSE_Labeled_AE
, O
fatal B-NonOSE_AE
/life-threatening O
: O
any O
major O
bleed B-OSE_Labeled_AE
as O
described O
above O
and O
associated O
with O
a O
decrease B-NonOSE_AE
in I-NonOSE_AE
Hb I-NonOSE_AE
of O
more O
than O
5 O
g/dL O
( O
or O
a O
fall B-NonOSE_AE
in I-NonOSE_AE
hematocrit I-NonOSE_AE
( O
Hct O
) O
of O
at O
least O
15 O
% O
) O
; O
transfusion O
of O
4 O
or O
more O
units O
. O

Fatal B-NonOSE_AE
: O
A O
bleeding B-OSE_Labeled_AE
event O
that O
directly O
led O
to O
death B-NonOSE_AE
within O
7 O
days O
. O

No O
baseline O
demographic O
factor O
altered O
the O
relative O
risk O
of O
bleeding B-NonOSE_AE
with O
BRILINTA O
compared O
to O
clopidogrel O
. O

In O
PLATO O
, O
1584 O
patients O
underwent O
CABG O
surgery O
. O

The O
percentages O
of O
those O
patients O
who O
bled B-NonOSE_AE
are O
shown O
in O
Figure O
2 O
and O
Table O
2 O
. O

Figure O
2 O
- O
'Major O
fatal/life-threatening O
' O
CABG-related O
bleeding O
by O
days O
from O
last O
dose O
of O
study O
drug O
to O
CABG O
procedure O
( O
PLATO O
) O
X-axis O
is O
days O
from O
last O
dose O
of O
study O
drug O
prior O
to O
CABG O
. O

The O
PLATO O
protocol O
recommended O
a O
procedure O
for O
withholding O
study O
drug O
prior O
to O
CABG O
or O
other O
major O
surgery O
without O
unblinding O
. O

If O
surgery O
was O
elective O
or O
non-urgent O
, O
study O
drug O
was O
interrupted O
temporarily O
, O
as O
follows O
: O
If O
local O
practice O
was O
to O
allow O
antiplatelet O
effects O
to O
dissipate O
before O
surgery O
, O
capsules O
( O
blinded O
clopidogrel O
) O
were O
withheld O
5 O
days O
before O
surgery O
and O
tablets O
( O
blinded O
ticagrelor O
) O
were O
withheld O
for O
a O
minimum O
of O
24 O
hours O
and O
a O
maximum O
of O
72 O
hours O
before O
surgery O
. O

If O
local O
practice O
was O
to O
perform O
surgery O
without O
waiting O
for O
dissipation O
of O
antiplatelet O
effects O
capsules O
and O
tablets O
were O
withheld O
24 O
hours O
prior O
to O
surgery O
and O
use O
of O
aprotinin O
or O
other O
haemostatic O
agents O
was O
allowed O
. O

If O
local O
practice O
was O
to O
use O
IPA O
monitoring O
to O
determine O
when O
surgery O
could O
be O
performed O
both O
the O
capsules O
and O
tablets O
were O
withheld O
at O
the O
same O
time O
and O
the O
usual O
monitoring O
procedures O
followed O
. O

T O
Ticagrelor O
; O
C O
Clopidogrel O
Table O
2 O
- O
CABG-related O
bleeding B-OSE_Labeled_AE
( O
PLATO O
) O
BRILINTA90 O
mg O
BID O
N=770 O
Clopidogrel O
N=814 O
PLATO O
Total O
Major O
626 O
( O
81.3 O
) O
666 O
( O
81.8 O
) O
Fatal B-NonOSE_AE
/Life-threatening O
337 O
( O
43.8 O
) O
350 O
( O
43.0 O
) O
Fatal B-NonOSE_AE
6 O
( O
0.8 O
) O
7 O
( O
0.9 O
) O
PLATO O
Major O
bleed B-OSE_Labeled_AE
: O
any O
one O
of O
the O
following O
: O
fatal O
; O
intracrania O
l B-NonOSE_AE
  I-NonOSE_AE
I I-NonOSE_AE
- I-NonOSE_AE
O I-NonOSE_AE
SE_Labeled_AE O
; O
intrapericardial O
with O
cardiac B-NonOSE_AE
tamponade I-NonOSE_AE
; O
hypovolemic B-NonOSE_AE
shock I-NonOSE_AE
or O
severe B-NonOSE_AE
hypotension I-NonOSE_AE
requiring O
intervention O
; O
significantly O
disabling O
( O
e.g. O
, O
intraocular O
with O
permanent O
vision B-NonOSE_AE
loss I-NonOSE_AE
) O
; O
associated O
with O
a O
decrease B-NonOSE_AE
in I-NonOSE_AE
Hb I-NonOSE_AE
of O
at O
least O
3 O
g/dL O
( O
or O
a O
fall B-NonOSE_AE
in I-NonOSE_AE
hematocrit I-NonOSE_AE
( O
Hct O
) O
of O
at O
least O
9 O
% O
) O
; O
transfusion O
of O
2 O
or O
more O
units O
. O

PLATO O
Major O
bleed B-OSE_Labeled_AE
, O
fatal B-NonOSE_AE
/life-threatening O
: O
any O
major O
bleed B-OSE_Labeled_AE
as O
described O
above O
and O
associated O
with O
a O
decrease B-NonOSE_AE
in I-NonOSE_AE
Hb I-NonOSE_AE
of O
more O
than O
5 O
g/dL O
( O
or O
a O
fall B-NonOSE_AE
in I-NonOSE_AE
hematocrit I-NonOSE_AE
( O
Hct O
) O
of O
at O
least O
15 O
% O
) O
; O
transfusion O
of O
4 O
or O
more O
units O
. O

When O
antiplatelet O
therapy O
was O
stopped O
5 O
days O
before O
CABG O
, O
major O
bleeding B-OSE_Labeled_AE
occurred O
in O
75 O
% O
of O
BRILINTA O
treated O
patients O
and O
79 O
% O
on O
clopidogrel O
. O

Other O
Adverse O
Reactions O
in O
PLATO O
Adverse O
reactions O
that O
occurred O
at O
a O
rate O
of O
4 O
% O
or O
more O
in O
PLATO O
are O
shown O
in O
Table O
3 O
. O

Table O
3 O
- O
Percentage O
of O
patients O
reporting O
non-hemorrhagic O
adverse O
reactions O
at O
least O
4 O
% O
or O
more O
in O
either O
group O
and O
more O
frequently O
on O
BRILINTA O
( O
PLATO O
) O
BRILINTAN=9235 O
ClopidogrelN=9186 O
Dyspnea B-OSE_Labeled_AE
13.8 O
7.8 O
Dizziness B-OSE_Labeled_AE
4.5 O
3.9 O
Nausea B-OSE_Labeled_AE
4.3 O
3.8 O
Bleeding O
in O
PEGASUS O
( O
Secondary O
Prevention O
in O
Patients O
with O
a O
History O
of O
Myocardial O
Infarction O
) O
Overall O
outcome O
of O
bleeding B-NonOSE_AE
events O
in O
the O
PEGASUS O
study O
are O
shown O
in O
Table O
4 O
. O

Table O
4 O
- O
Bleeding B-OSE_Labeled_AE
events O
( O
PEGASUS O
) O
BRILINTA60 O
mg O
BID O
+ O
Aspirin O
N=6958 O
Aspirin O
Alone O
N=6996 O
n O
( O
% O
) O
patients O
with O
event O
Events O
/100 O
pt O
yrs O
n O
patients O
with O
event O
Events O
/100 O
pt O
yrs O
TIMI O
Major O
115 O
( O
1.7 O
) O
0.78 O
54 O
( O
0.8 O
) O
0.34 O
Fatal B-NonOSE_AE
11 O
( O
0.2 O
) O
0.08 O
12 O
( O
0.2 O
) O
0.08 O
Intracranial B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
28 O
( O
0.4 O
) O
0.19 O
23 O
( O
0.3 O
) O
0.14 O
TIMI O
Major O
or O
Minor O
168 O
( O
2.4 O
) O
1.15 O
72 O
( O
1.0 O
) O
0.45 O
TIMI O
Major O
: O
Fatal B-NonOSE_AE
bleeding B-OSE_Labeled_AE
, O
OR O
any O
intracranial B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
, O
OR O
clinically O
overt O
signs O
of O
hemorrhage B-OSE_Labeled_AE
associated O
with O
a O
drop B-NonOSE_AE
in I-NonOSE_AE
hemoglobin I-NonOSE_AE
( I-NonOSE_AE
Hgb I-NonOSE_AE
) O
of O
> O
=5 O
g/dL O
, O
or O
a O
fall B-NonOSE_AE
in I-NonOSE_AE
hematocrit I-NonOSE_AE
( O
Hct O
) O
of O
15 O
% O
. O

Fatal B-NonOSE_AE
: O
A O
bleeding B-OSE_Labeled_AE
event O
that O
directly O
led O
to O
death B-NonOSE_AE
within O
7 O
days O
. O

TIMI O
Minor O
: O
Clinically O
apparent O
with O
3-5 O
g/dL O
decrease B-NonOSE_AE
in I-NonOSE_AE
hemoglobin I-NonOSE_AE
. O

The O
bleeding B-NonOSE_AE
profile O
of O
BRILINTA O
60 O
mg O
compared O
to O
aspirin O
alone O
was O
consistent O
across O
multiple O
pre-defined O
subgroups O
( O
e.g. O
, O
by O
age O
, O
gender O
, O
weight O
, O
race O
, O
geographic O
region O
, O
concurrent O
conditions O
, O
concomitant O
therapy O
, O
stent O
, O
and O
medical O
history O
) O
for O
TIMI O
Major O
and O
TIMI O
Major O
or O
Minor O
bleeding B-NonOSE_AE
events O
. O

Other O
Adverse O
Reactions O
in O
PEGASUS O
Adverse O
reactions O
that O
occurred O
in O
PEGASUS O
at O
rates O
of O
3 O
% O
or O
more O
are O
shown O
in O
Table O
5 O
. O

Table O
5 O
- O
Non-hemorrhagic O
adverse O
reactions O
reported O
in O
> O
3.0 O
% O
of O
patients O
in O
the O
ticagrelor O
60 O
mg O
treatment O
group O
( O
PEGASUS O
) O
BRILINTA O
N=6958 O
ClopidogrelN=6996 O
Dyspnea B-OSE_Labeled_AE
14.2 O
5.5 O
Dizziness B-OSE_Labeled_AE
4.5 O
4.1 O
Diarrhea B-OSE_Labeled_AE
3.3 O
2.5 O
Bradycardia O
In O
a O
Holter O
substudy O
of O
about O
3000 O
patients O
in O
PLATO O
, O
more O
patients O
had O
ventricular B-OSE_Labeled_AE
pauses I-OSE_Labeled_AE
with O
BRILINTA O
( O
6.0 O
% O
) O
than O
with O
clopidogrel O
( O
3.5 O
% O
) O
in O
the O
acute O
phase O
; O
rates O
were O
2.2 O
% O
and O
1.6 O
% O
respectively O
after O
1 O
month O
. O

PLATO O
and O
PEGASUS O
excluded O
patients O
at O
increased O
risk O
of O
bradycardic B-Not_AE_Candidate
events O
( O
e.g. O
, O
patients O
who O
have O
sick B-Not_AE_Candidate
sinus I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
, O
2 O
nd O
or O
3 O
rd O
degree O
AV B-Not_AE_Candidate
block I-Not_AE_Candidate
, O
or O
bradycardic B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
syncope I-Not_AE_Candidate
and O
not O
protected O
with O
a O
pacemaker O
) O
. O

In O
PLATO O
, O
syncope B-OSE_Labeled_AE
, O
pre B-OSE_Labeled_AE
- I-OSE_Labeled_AE
syncope I-OSE_Labeled_AE
and O
loss B-OSE_Labeled_AE
of I-OSE_Labeled_AE
consciousness I-OSE_Labeled_AE
were O
reported O
by O
1.7 O
% O
and O
1.5 O
% O
of O
BRILINTA O
90 O
mg O
and O
clopidogrel O
patients O
, O
respectively O
. O

In O
PEGASUS O
, O
syncope B-OSE_Labeled_AE
was O
reported O
by O
1.2 O
% O
and O
0.9 O
% O
of O
patients O
on O
BRILINTA O
60 O
mg O
and O
aspirin O
alone O
, O
respectively O
. O

Lab O
abnormalities O
Serum O
Uric O
Acid O
: O
In O
PLATO O
, O
serum B-OSE_Labeled_AE
uric I-OSE_Labeled_AE
acid I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
approximately O
0.6 O
mg/dL O
from O
baseline O
on O
BRILINTA O
90 O
mg O
and O
approximately O
0.2 O
mg/dL O
on O
clopidogrel O
. O

The O
difference O
disappeared O
within O
30 O
days O
of O
discontinuing O
treatment O
. O

Reports O
of O
gout B-OSE_Labeled_AE
did O
not O
differ O
between O
treatment O
groups O
in O
PLATO O
( O
0.6 O
% O
in O
each O
group O
) O
. O

In O
PEGASUS O
, O
serum B-OSE_Labeled_AE
uric I-OSE_Labeled_AE
acid I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
approximately O
0.2 O
mg/dL O
from O
baseline O
on O
BRILINTA O
60 O
mg O
and O
no O
elevation O
was O
observed O
on O
aspirin O
alone O
. O

Gout B-OSE_Labeled_AE
occurred O
more O
commonly O
in O
patients O
on O
BRILINTA O
than O
in O
patients O
on O
aspirin O
alone O
( O
1.5 O
% O
,1.1 O
% O
) O
. O

Mean O
serum B-NonOSE_AE
uric I-NonOSE_AE
acid I-NonOSE_AE
concentrations O
decrease I-NonOSE_AE
d O
after O
treatment O
was O
stopped O
. O

Serum O
Creatinine O
: O
In O
PLATO O
, O
a O
> O
50 O
% O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
was O
observed O
in O
7.4 O
% O
of O
patients O
receiving O
BRILINTA O
90 O
mg O
compared O
to O
5.9 O
% O
of O
patients O
receiving O
clopidogrel O
. O

The O
increases O
typically O
did O
not O
progress O
with O
ongoing O
treatment O
and O
often O
decreased O
with O
continued O
therapy O
. O

Evidence O
of O
reversibility O
upon O
discontinuation O
was O
observed O
even O
in O
those O
with O
the O
greatest O
on O
treatment O
increases O
. O

Treatment O
groups O
in O
PLATO O
did O
not O
differ O
for O
renal B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
serious I-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
events I-OSE_Labeled_AE
such O
as O
acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
chronic B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
toxic B-OSE_Labeled_AE
nephropathy I-OSE_Labeled_AE
, O
or O
oliguria B-OSE_Labeled_AE
. O

In O
PEGASUS O
, O
serum B-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
concentration O
increased O
by O
> O
50 O
% O
in O
approximately O
4 O
% O
of O
patients O
receiving O
BRILINTA O
60 O
mg O
, O
similar O
to O
aspirin O
alone O
. O

The O
frequency O
of O
renal B-OSE_Labeled_AE
related I-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
events I-OSE_Labeled_AE
was O
similar O
for O
ticagrelor O
and O
aspirin O
alone O
regardless O
of O
age O
and O
baseline O
renal O
function O
. O

Figure O
1 O
- O
Kaplan-Meier O
Graph O
Figure O
2 O
- O
Bar O
Graph O

BOXED O
WARNING O
: O
WARNING O
: O
( O
A O
) O
BLEEDING O
RISK O
, O
( O
B O
) O
ASPIRIN O
DOSE O
AND O
BRILINTA O
EFFECTIVENESS O
WARNING O
: O
( O
A O
) O
BLEEDING O
RISK O
, O
( O
B O
) O
ASPIRIN O
DOSE O
AND O
BRILINTA O
EFFECTIVENESS O
A O
. O

BLEEDING O
RISK O
* O
BRILINTA O
, O
like O
other O
antiplatelet O
agents O
, O
can O
cause O
significant O
, O
sometimes O
fatal B-NonOSE_AE
bleeding B-OSE_Labeled_AE
( O
5.1 O
, O
6.1 O
) O
. O

* O
Do O
not O
use O
BRILINTA O
in O
patients O
with O
active O
pathological O
bleeding B-Not_AE_Candidate
or O
a O
history O
of O
intracranial B-Not_AE_Candidate
hemorrhage I-Not_AE_Candidate
( O
4.1 O
, O
4.2 O
) O
. O

* O
Do O
not O
start O
BRILINTA O
in O
patients O
undergoing O
urgent O
coronary O
artery O
bypass O
graft O
surgery O
( O
CABG O
) O
( O
5.1 O
, O
6.1 O
) O
. O

* O
If O
possible O
, O
manage O
bleeding B-NonOSE_AE
without O
discontinuing O
BRILINTA O
. O

Stopping O
BRILINTA O
increases O
the O
risk O
of O
subsequent O
cardiovascular B-NonOSE_AE
events I-NonOSE_AE
( O
5.4 O
) O
. O

B O
. O
ASPIRIN O
DOSE O
AND O
BRILINTA O
EFFECTIVENESS O
* O
Maintenance O
doses O
of O
aspirin O
above O
100 O
mg O
reduce O
the O
effectiveness O
of O
BRILINTA O
and O
should O
be O
avoided O
( O
2.1 O
, O
5.2 O
, O
14.1 O
) O
. O

EXCERPT O
: O
WARNING O
: O
( O
A O
) O
BLEEDING O
RISK O
, O
and O
( O
B O
) O
ASPIRIN O
DOSE O
AND O
BRILINTA O
EFFECTIVENESS O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

BLEEDING O
RISK O
* O
BRILINTA O
, O
like O
other O
antiplatelet O
agents O
, O
can O
cause O
significant O
, O
sometimes O
fatal O
bleeding O
( O
5.1 O
, O
6.1 O
) O
. O

* O
Do O
not O
use O
BRILINTA O
in O
patients O
with O
active O
pathological O
bleeding O
or O
a O
history O
of O
intracranial O
hemorrhage O
( O
4.1 O
, O
4.2 O
) O
. O

* O
Do O
not O
start O
BRILINTA O
in O
patients O
undergoing O
urgent O
coronary O
artery O
bypass O
graft O
surgery O
( O
CABG O
) O
( O
5.1 O
, O
6.1 O
) O
. O

* O
If O
possible O
, O
manage O
bleeding O
without O
discontinuing O
BRILINTA O
. O

Stopping O
BRILINTA O
increases O
the O
risk O
of O
subsequent O
cardiovascular O
events O
( O
5.4 O
) O
. O

ASPIRIN O
DOSE O
AND O
BRILINTA O
EFFECTIVENESS O
* O
Maintenance O
doses O
of O
aspirin O
above O
100 O
mg O
reduce O
the O
effectiveness O
of O
BRILINTA O
and O
should O
be O
avoided O
. O

( O
2.1 O
, O
5.2 O
, O
14.1 O
) O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Dyspnea O
was O
reported O
more O
frequently O
with O
BRILINTA O
than O
with O
control O
agents O
in O
clinical O
trials O
. O

Dyspnea O
resulting O
from O
BRILINTA O
is O
self-limiting O
. O

( O
5.3 O
) O
* O
Severe O
Hepatic O
Impairment O
: O
Likely O
increase O
in O
exposure O
to O
ticagrelor O
. O

( O
5.5 O
) O
5.1 O
General O
Risk O
of O
Bleeding O
Drugs O
that O
inhibit O
platelet O
function O
including O
BRILINTA O
increase O
the O
risk O
of O
bleeding B-OSE_Labeled_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

If O
possible O
, O
manage O
bleeding B-NonOSE_AE
without O
discontinuing O
BRILINTA O
. O

Stopping O
BRILINTA O
increases O
the O
risk O
of O
subsequent O
cardiovascular B-NonOSE_AE
events I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
and O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.2 O
Concomitant O
Aspirin O
Maintenance O
Dose O
In O
PLATO O
the O
use O
of O
BRILINTA O
with O
maintenance O
doses O
of O
aspirin O
above O
100 O
mg O
decreased O
the O
effectiveness O
of O
BRILINTA O
. O

Therefore O
, O
after O
the O
initial O
loading O
dose O
of O
aspirin O
, O
use O
BRILINTA O
with O
a O
maintenance O
dose O
of O
aspirin O
of O
75-100 O
mg O
[ O
see O
Dosage O
and O
Administration O
( O
2.1 O
) O
and O
Clinical O
Studies O
( O
14.1 O
) O
] O
. O

5.3 O
Dyspnea O
In O
clinical O
trials O
, O
about O
14 O
% O
of O
patients O
treated O
with O
BRILINTA O
developed O
dyspnea B-OSE_Labeled_AE
. O

Dyspnea B-OSE_Labeled_AE
was O
usually O
mild O
to O
moderate O
in O
intensity O
and O
often O
resolved O
during O
continued O
treatment O
, O
but O
led O
to O
study O
drug O
discontinuation O
in O
0.9 O
% O
of O
BRILINTA O
and O
0.1 O
% O
of O
clopidogrel O
patients O
in O
PLATO O
and O
4.3 O
% O
of O
BRILINTA O
60 O
mg O
and O
0.7 O
% O
on O
aspirin O
alone O
patients O
in O
PEGASUS O
. O

In O
a O
substudy O
of O
PLATO O
, O
199 O
subjects O
underwent O
pulmonary O
function O
testing O
irrespective O
of O
whether O
they O
reported O
dyspnea B-NonOSE_AE
. O

There O
was O
no O
indication O
of O
an O
adverse B-NonOSE_AE
effect I-NonOSE_AE
on I-NonOSE_AE
pulmonary I-NonOSE_AE
function O
assessed O
after O
one O
month O
or O
after O
at O
least O
6 O
months O
of O
chronic O
treatment O
. O

If O
a O
patient O
develops O
new O
, O
prolonged O
, O
or O
worsened O
dyspnea B-NonOSE_AE
that O
is O
determined O
to O
be O
related O
to O
BRILINTA O
, O
no O
specific O
treatment O
is O
required O
; O
continue O
BRILINTA O
without O
interruption O
if O
possible O
. O

In O
the O
case O
of O
intolerable O
dyspnea B-NonOSE_AE
requiring O
discontinuation O
of O
BRILINTA O
, O
consider O
prescribing O
another O
antiplatelet O
agent O
. O

5.4 O
Discontinuation O
of O
BRILINTA O
Discontinuation O
of O
BRILINTA O
will O
increase O
the O
risk O
of O
myocardial B-NonOSE_AE
infarction I-NonOSE_AE
, O
stroke B-NonOSE_AE
, O
and O
death B-NonOSE_AE
. O

If O
BRILINTA O
must O
be O
temporarily O
discontinued O
( O
e.g. O
, O
to O
treat O
bleeding B-NonOSE_AE
or O
for O
significant O
surgery O
) O
, O
restart O
it O
as O
soon O
as O
possible O
. O

When O
possible O
, O
interrupt O
therapy O
with O
BRILINTA O
for O
five O
days O
prior O
to O
surgery O
that O
has O
a O
major O
risk O
of O
bleeding B-NonOSE_AE
. O

Resume O
BRILINTA O
as O
soon O
as O
hemostasis O
is O
achieved O
. O

5.5 O
Severe O
Hepatic O
Impairment O
Avoid O
use O
of O
BRILINTA O
in O
patients O
with O
severe O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
. O

Severe O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
is O
likely O
to O
increase O
serum O
concentration O
of O
ticagrelor O
. O

There O
are O
no O
studies O
of O
BRILINTA O
patients O
with O
severe O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
[ O
see O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

6 O
. O

ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
the O
labeling O
: O
* O
Cardiovascular B-OSE_Labeled_AE
Thrombotic I-OSE_Labeled_AE
Events I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
GI B-OSE_Labeled_AE
Bleeding I-OSE_Labeled_AE
, O
Ulceration O
and O
Perforation O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Hepatotoxicity B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Hypertension B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Heart B-OSE_Labeled_AE
Failure I-OSE_Labeled_AE
and O
Edema B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Renal B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
and O
Hyperkalemia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Anaphylactic B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Serious B-OSE_Labeled_AE
Skin I-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
* O
Hematologic B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.11 O
) O
] O
EXCERPT O
: O
Most O
common O
adverse O
reactions O
in O
arthritis O
trials O
( O
> O
2 O
% O
and O
> O
placebo O
) O
are O
: O
abdominal O
pain O
, O
diarrhea O
, O
dyspepsia O
, O
flatulence O
, O
peripheral O
edema O
, O
accidental O
injury O
, O
dizziness O
, O
pharyngitis O
, O
rhinitis O
, O
sinusitis O
, O
upper O
respiratory O
tract O
infection O
, O
rash O
( O
6.1 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Pfizer O
at O
1-800-438-1985 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

The O
adverse O
reaction O
information O
from O
clinical O
trials O
does O
, O
however O
, O
provide O
a O
basis O
for O
identifying O
the O
adverse O
events O
that O
appear O
to O
be O
related O
to O
drug O
use O
and O
for O
approximating O
rates O
. O

Of O
the O
CELEBREX-treated O
patients O
in O
the O
pre-marketing O
controlled O
clinical O
trials O
, O
approximately O
4,250 O
were O
patients O
with O
OA B-Not_AE_Candidate
, O
approximately O
2,100 O
were O
patients O
with O
RA B-Not_AE_Candidate
, O
and O
approximately O
1,050 O
were O
patients O
with O
post B-Not_AE_Candidate
- I-Not_AE_Candidate
surgical I-Not_AE_Candidate
pain I-Not_AE_Candidate
. O

More O
than O
8,500 O
patients O
received O
a O
total O
daily O
dose O
of O
CELEBREX O
of O
200 O
mg O
( O
100 O
mg O
twice O
daily O
or O
200 O
mg O
once O
daily O
) O
or O
more O
, O
including O
more O
than O
400 O
treated O
at O
800 O
mg O
( O
400 O
mg O
twice O
daily O
) O
. O

Approximately O
3,900 O
patients O
received O
CELEBREX O
at O
these O
doses O
for O
6 O
months O
or O
more O
; O
approximately O
2,300 O
of O
these O
have O
received O
it O
for O
1 O
year O
or O
more O
and O
124 O
of O
these O
have O
received O
it O
for O
2 O
years O
or O
more O
. O

Pre-marketing O
Controlled O
Arthritis O
Trials O
Table O
1 O
lists O
all O
adverse O
events O
, O
regardless O
of O
causality O
, O
occurring O
in O
> O
=2 O
% O
of O
patients O
receiving O
CELEBREX O
from O
12 O
controlled O
studies O
conducted O
in O
patients O
with O
OA B-Not_AE_Candidate
or O
RA B-Not_AE_Candidate
that O
included O
a O
placebo O
and/or O
a O
positive O
control O
group O
. O

Since O
these O
12 O
trials O
were O
of O
different O
durations O
, O
and O
patients O
in O
the O
trials O
may O
not O
have O
been O
exposed O
for O
the O
same O
duration O
of O
time O
, O
these O
percentages O
do O
not O
capture O
cumulative O
rates O
of O
occurrence O
. O

Table O
1 O
: O
Adverse O
Events O
Occurring O
in O
> O
=2 O
% O
of O
CELEBREX O
Patients O
from O
Pre-marketing O
Controlled O
Arthritis O
Trials O
CBXN=4146 O
PlaceboN=1864 O
NAPN=1366 O
DCFN=387 O
IBUN=345 O
CBX O
= O
CELEBREX O
100 O
- O
200 O
mg O
twice O
daily O
or O
200 O
mg O
once O
daily O
; O
NAP O
= O
Naproxen O
500 O
mg O
twice O
daily O
; O
DCF O
= O
Diclofenac O
75 O
mg O
twice O
daily O
; O
IBU O
= O
Ibuprofen O
800 O
mg O
three O
times O
daily O
. O

Gastrointestinal B-NonOSE_AE
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
4.1 O
% O
2.8 O
% O
7.7 O
% O
9.0 O
% O
9.0 O
% O
Diarrhea B-OSE_Labeled_AE
5.6 O
% O
3.8 O
% O
5.3 O
% O
9.3 O
% O
5.8 O
% O
Dyspepsia B-OSE_Labeled_AE
8.8 O
% O
6.2 O
% O
12.2 O
% O
10.9 O
% O
12.8 O
% O
Flatulence B-OSE_Labeled_AE
2.2 O
% O
1.0 O
% O
3.6 O
% O
4.1 O
% O
3.5 O
% O
Nausea B-OSE_Labeled_AE
3.5 O
% O
4.2 O
% O
6.0 O
% O
3.4 O
% O
6.7 O
% O
Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
whole I-NonOSE_AE
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
2.8 O
% O
3.6 O
% O
2.2 O
% O
2.6 O
% O
0.9 O
% O
Peripheral B-OSE_Labeled_AE
Edema I-OSE_Labeled_AE
2.1 O
% O
1.1 O
% O
2.1 O
% O
1.0 O
% O
3.5 O
% O
Injury B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Accidental I-OSE_Labeled_AE
2.9 O
% O
2.3 O
% O
3.0 O
% O
2.6 O
% O
3.2 O
% O
Central B-NonOSE_AE
, I-NonOSE_AE
Peripheral I-NonOSE_AE
Nervous I-NonOSE_AE
system I-NonOSE_AE
Dizziness B-OSE_Labeled_AE
2.0 O
% O
1.7 O
% O
2.6 O
% O
1.3 O
% O
2.3 O
% O
Headache B-OSE_Labeled_AE
15.8 O
% O
20.2 O
% O
14.5 O
% O
15.5 O
% O
15.4 O
% O
Psychiatric B-NonOSE_AE
Insomnia B-OSE_Labeled_AE
2.3 O
% O
2.3 O
% O
2.9 O
% O
1.3 O
% O
1.4 O
% O
Respiratory B-NonOSE_AE
Pharyngitis B-OSE_Labeled_AE
2.3 O
% O
1.1 O
% O
1.7 O
% O
1.6 O
% O
2.6 O
% O
Rhinitis B-OSE_Labeled_AE
2.0 O
% O
1.3 O
% O
2.4 O
% O
2.3 O
% O
0.6 O
% O
Sinusitis B-OSE_Labeled_AE
5.0 O
% O
4.3 O
% O
4.0 O
% O
5.4 O
% O
5.8 O
% O
Upper B-OSE_Labeled_AE
Respiratory I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
8.1 O
% O
6.7 O
% O
9.9 O
% O
9.8 O
% O
9.9 O
% O
Skin B-NonOSE_AE
Rash B-OSE_Labeled_AE
2.2 O
% O
2.1 O
% O
2.1 O
% O
1.3 O
% O
1.2 O
% O
In O
placebo- O
or O
active-controlled O
clinical O
trials O
, O
the O
discontinuation O
rate O
due O
to O
adverse O
events O
was O
7.1 O
% O
for O
patients O
receiving O
CELEBREX O
and O
6.1 O
% O
for O
patients O
receiving O
placebo O
. O

Among O
the O
most O
common O
reasons O
for O
discontinuation O
due O
to O
adverse O
events O
in O
the O
CELEBREX O
treatment O
groups O
were O
dyspepsia B-OSE_Labeled_AE
and O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
cited O
as O
reasons O
for O
discontinuation O
in O
0.8 O
% O
and O
0.7 O
% O
of O
CELEBREX O
patients O
, O
respectively O
) O
. O

Among O
patients O
receiving O
placebo O
, O
0.6 O
% O
discontinued O
due O
to O
dyspepsia B-NonOSE_AE
and O
0.6 O
% O
withdrew O
due O
to O
abdominal B-NonOSE_AE
pain I-NonOSE_AE
. O

The O
following O
adverse O
reactions O
occurred O
in O
0.1 O
- O
1.9 O
% O
of O
patients O
treated O
with O
CELEBREX O
( O
100 O
- O
200 O
mg O
twice O
daily O
or O
200 O
mg O
once O
daily O
) O
: O
Gastrointestinal B-NonOSE_AE
: O
Constipation B-OSE_Labeled_AE
, O
diverticulitis B-OSE_Labeled_AE
, O
dysphagia B-OSE_Labeled_AE
, O
eructation B-OSE_Labeled_AE
, O
esophagitis B-OSE_Labeled_AE
, O
gastritis B-OSE_Labeled_AE
, O
gastroenteritis B-OSE_Labeled_AE
, O
gastroesophageal B-OSE_Labeled_AE
reflux I-OSE_Labeled_AE
, O
hemorrhoids B-OSE_Labeled_AE
, O
hiatal B-OSE_Labeled_AE
hernia I-OSE_Labeled_AE
, O
melena B-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
stomatitis B-OSE_Labeled_AE
, O
tenesmus B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
Cardiovascular B-NonOSE_AE
: O
Aggravated B-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
, O
angina B-OSE_Labeled_AE
pectoris I-OSE_Labeled_AE
, O
coronary B-OSE_Labeled_AE
artery I-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
General B-NonOSE_AE
: O
Hypersensitivity B-OSE_Labeled_AE
, O
allergic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
cyst B-OSE_Labeled_AE
NOS I-OSE_Labeled_AE
, O
edema B-OSE_Labeled_AE
generalized I-OSE_Labeled_AE
, O
face B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
fever B-OSE_Labeled_AE
, O
hot B-OSE_Labeled_AE
flushes I-OSE_Labeled_AE
, O
influenza B-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
, O
pain B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
Central B-NonOSE_AE
, I-NonOSE_AE
peripheral I-NonOSE_AE
nervous I-NonOSE_AE
system I-NonOSE_AE
: O
Leg B-OSE_Labeled_AE
cramps I-OSE_Labeled_AE
, O
hypertonia B-OSE_Labeled_AE
, O
hypoesthesia B-OSE_Labeled_AE
, O
migraine B-OSE_Labeled_AE
, O
paresthesia B-OSE_Labeled_AE
, O
vertigo B-OSE_Labeled_AE
Hearing B-NonOSE_AE
and I-NonOSE_AE
vestibular I-NonOSE_AE
: O
Deafness B-OSE_Labeled_AE
, O
tinnitus B-OSE_Labeled_AE
Heart B-NonOSE_AE
rate I-NonOSE_AE
and I-NonOSE_AE
rhythm I-NonOSE_AE
: O
Palpitation B-OSE_Labeled_AE
, O
tachycardia B-OSE_Labeled_AE
Liver B-NonOSE_AE
and I-NonOSE_AE
biliary I-NonOSE_AE
: O
Hepatic B-OSE_Labeled_AE
enzyme I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
( O
including O
SGOT B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
SGPT B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
) O
Metabolic B-NonOSE_AE
and I-NonOSE_AE
nutritional I-NonOSE_AE
: O
BUN B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
CPK B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
hypercholesterolemia B-OSE_Labeled_AE
, O
hyperglycemia B-OSE_Labeled_AE
, O
hypokalemia B-OSE_Labeled_AE
, O
NPN B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
creatinine B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
alkaline B-OSE_Labeled_AE
phosphatase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
Musculoskeletal B-NonOSE_AE
: O
Arthralgia B-OSE_Labeled_AE
, O
arthrosis B-OSE_Labeled_AE
, O
myalgia B-OSE_Labeled_AE
, O
synovitis B-OSE_Labeled_AE
, O
tendinitis B-OSE_Labeled_AE
Platelets B-NonOSE_AE
( I-NonOSE_AE
bleeding I-NonOSE_AE
or I-NonOSE_AE
clotting I-NonOSE_AE
) O
: O
Ecchymosis B-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
thrombocythemia B-OSE_Labeled_AE
, O
Psychiatric B-NonOSE_AE
: O
Anorexia B-OSE_Labeled_AE
, O
anxiety B-OSE_Labeled_AE
, O
appetite B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
, O
nervousness B-OSE_Labeled_AE
, O
somnolence B-OSE_Labeled_AE
Hemic B-NonOSE_AE
: O
Anemia B-OSE_Labeled_AE
Respiratory B-NonOSE_AE
: O
Bronchitis B-OSE_Labeled_AE
, O
bronchospasm B-OSE_Labeled_AE
, O
bronchospasm B-OSE_Labeled_AE
aggravated I-OSE_Labeled_AE
, O
cough B-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
laryngitis B-OSE_Labeled_AE
, O
pneumonia B-OSE_Labeled_AE
Skin B-NonOSE_AE
and I-NonOSE_AE
appendages I-NonOSE_AE
: O
Alopecia B-OSE_Labeled_AE
, O
dermatitis B-OSE_Labeled_AE
, O
photosensitivity B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
erythematous I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
maculopapular I-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
dry I-OSE_Labeled_AE
, O
sweating B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
Application B-NonOSE_AE
site I-NonOSE_AE
disorders I-NonOSE_AE
: O
Cellulitis B-OSE_Labeled_AE
, O
dermatitis B-OSE_Labeled_AE
contact I-OSE_Labeled_AE
Urinary B-NonOSE_AE
: O
Albuminuria B-OSE_Labeled_AE
, O
cystitis B-OSE_Labeled_AE
, O
dysuria B-OSE_Labeled_AE
, O
hematuria B-OSE_Labeled_AE
, O
micturition B-OSE_Labeled_AE
frequency I-OSE_Labeled_AE
, O
renal B-OSE_Labeled_AE
calculus I-OSE_Labeled_AE
The O
following O
serious O
adverse O
events O
( O
causality O
not O
evaluated O
) O
occurred O
in O
< O
0.1 O
% O
of O
patients O
: O
Cardiovascular B-NonOSE_AE
: O
Syncope B-OSE_Labeled_AE
, O
congestive B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
ventricular B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
, O
cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
gangrene I-OSE_Labeled_AE
, O
thrombophlebitis B-OSE_Labeled_AE
Gastrointestinal B-NonOSE_AE
: O
Intestinal B-OSE_Labeled_AE
obstruction I-OSE_Labeled_AE
, O
intestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
, O
gastrointestinal B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
, O
colitis B-OSE_Labeled_AE
with I-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
, O
esophageal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
, O
pancreatitis B-OSE_Labeled_AE
, O
ileus B-OSE_Labeled_AE
General B-NonOSE_AE
: O
Sepsis B-OSE_Labeled_AE
, O
sudden B-OSE_Labeled_AE
death I-OSE_Labeled_AE
Liver B-NonOSE_AE
and I-NonOSE_AE
biliary I-NonOSE_AE
: O
Cholelithiasis B-OSE_Labeled_AE
Hemic B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
: O
Thrombocytopenia B-OSE_Labeled_AE
Nervous B-NonOSE_AE
: O
Ataxia B-OSE_Labeled_AE
, O
suicide B-OSE_Labeled_AE
[ O
see O
Drug O
Interactions O
( O
7.1 O
) O
] O
Renal B-NonOSE_AE
: O
Acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
The O
Celecoxib O
Long-Term O
Arthritis B-Not_AE_Candidate
Safety O
Study O
[ O
see O
Special O
Studies O
( O
14.6 O
) O
] O
Hematological B-NonOSE_AE
Events I-NonOSE_AE
: O
The O
incidence O
of O
clinically O
significant O
decreases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
( O
> O
2 O
g/dL O
) O
was O
lower O
in O
patients O
on O
CELEBREX O
400 O
mg O
twice O
daily O
( O
0.5 O
% O
) O
compared O
to O
patients O
on O
either O
diclofenac O
75 O
mg O
twice O
daily O
( O
1.3 O
% O
) O
or O
ibuprofen O
800 O
mg O
three O
times O
daily O
1.9 O
% O
. O

The O
lower O
incidence O
of O
events O
with O
CELEBREX O
was O
maintained O
with O
or O
without O
aspirin O
use O
[ O
see O
Clinical O
Pharmacology O
( O
12.2 O
) O
] O
. O

Withdrawals B-NonOSE_AE
/ O
Serious B-NonOSE_AE
Adverse I-NonOSE_AE
Events I-NonOSE_AE
: O
Kaplan-Meier O
cumulative O
rates O
at O
9 O
months O
for O
withdrawals O
due O
to O
adverse O
events O
for O
CELEBREX O
, O
diclofenac O
and O
ibuprofen O
were O
24 O
% O
, O
29 O
% O
, O
and O
26 O
% O
, O
respectively O
. O

Rates O
for O
serious O
adverse O
events O
( O
i.e. O
, O
causing O
hospitalization O
or O
felt O
to O
be O
life-threatening O
or O
otherwise O
medically O
significant O
) O
, O
regardless O
of O
causality O
, O
were O
not O
different O
across O
treatment O
groups O
( O
8 O
% O
, O
7 O
% O
, O
and O
8 O
% O
, O
respectively O
) O
. O

Juvenile O
Rheumatoid O
Arthritis O
Study O
In O
a O
12-week O
, O
double-blind O
, O
active-controlled O
study O
, O
242 O
JRA B-Not_AE_Candidate
patients O
2 O
years O
to O
17 O
years O
of O
age O
were O
treated O
with O
celecoxib O
or O
naproxen O
; O
77 O
JRA B-Not_AE_Candidate
patients O
were O
treated O
with O
celecoxib O
3 O
mg/kg O
twice O
daily O
, O
82 O
patients O
were O
treated O
with O
celecoxib O
6 O
mg/kg O
twice O
daily O
, O
and O
83 O
patients O
were O
treated O
with O
naproxen O
7.5 O
mg/kg O
twice O
daily O
. O

The O
most O
commonly O
occurring O
( O
> O
=5 O
% O
) O
adverse O
events O
in O
celecoxib O
treated O
patients O
were O
headache B-OSE_Labeled_AE
, O
fever B-OSE_Labeled_AE
( O
pyrexia B-OSE_Labeled_AE
) O
, O
upper B-OSE_Labeled_AE
abdominal I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
cough B-OSE_Labeled_AE
, O
nasopharyngitis B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
arthralgia B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
and O
vomiting B-OSE_Labeled_AE
. O

The O
most O
commonly O
occurring O
( O
> O
=5 O
% O
) O
adverse O
experiences O
for O
naproxen-treated O
patients O
were O
headache B-NonOSE_AE
, O
nausea B-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
fever B-NonOSE_AE
, O
upper B-NonOSE_AE
abdominal I-NonOSE_AE
pain I-NonOSE_AE
, O
diarrhea B-NonOSE_AE
, O
cough B-NonOSE_AE
, O
abdominal B-NonOSE_AE
pain I-NonOSE_AE
, O
and O
dizziness B-NonOSE_AE
( O
Table O
2 O
) O
. O

Compared O
with O
naproxen O
, O
celecoxib O
at O
doses O
of O
3 O
and O
6 O
mg/kg O
twice O
daily O
had O
no O
observable O
deleterious B-NonOSE_AE
effect I-NonOSE_AE
on I-NonOSE_AE
growth O
and O
development I-NonOSE_AE
during O
the O
course O
of O
the O
12-week O
double-blind O
study O
. O

There O
was O
no O
substantial O
difference O
in O
the O
number O
of O
clinical O
exacerbations B-NonOSE_AE
of I-NonOSE_AE
uveitis I-NonOSE_AE
or O
systemic O
features O
of O
JRA B-Not_AE_Candidate
among O
treatment O
groups O
. O

In O
a O
12-week O
, O
open-label O
extension O
of O
the O
double-blind O
study O
described O
above O
, O
202 O
JRA B-Not_AE_Candidate
patients O
were O
treated O
with O
celecoxib O
6 O
mg/kg O
twice O
daily O
. O

The O
incidence O
of O
adverse O
events O
was O
similar O
to O
that O
observed O
during O
the O
double-blind O
study O
; O
no O
unexpected O
adverse O
events O
of O
clinical O
importance O
emerged O
. O

Table O
2 O
: O
Adverse O
Events O
Occurring O
in O
> O
=5 O
% O
of O
JRA O
Patients O
in O
Any O
Treatment O
Group O
, O
by O
System O
Organ O
Class O
( O
% O
of O
patients O
with O
events O
) O
All O
Doses O
Twice O
Daily O
System O
Organ O
Class O
Preferred O
Term O
Celecoxib3 O
mg/kgN=77 O
Celecoxib6 O
mg/kgN=82 O
Naproxen7.5 O
mg/kgN=83 O
Any O
Event O
64 O
70 O
72 O
Eye B-OSE_Labeled_AE
Disorders I-OSE_Labeled_AE
5 O
5 O
5 O
Gastrointestinal B-NonOSE_AE
26 O
24 O
36 O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
NOS O
4 O
7 O
7 O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
8 O
6 O
10 O
Vomiting B-OSE_Labeled_AE
NOS O
3 O
6 O
11 O
Diarrhea B-OSE_Labeled_AE
NOS O
5 O
4 O
8 O
Nausea B-OSE_Labeled_AE
7 O
4 O
11 O
General B-NonOSE_AE
13 O
11 O
18 O
Pyrexia B-OSE_Labeled_AE
8 O
9 O
11 O
Infections B-OSE_Labeled_AE
25 O
20 O
27 O
Nasopharyngitis B-OSE_Labeled_AE
5 O
6 O
5 O
Injury B-NonOSE_AE
and I-NonOSE_AE
Poisoning I-NonOSE_AE
4 O
6 O
5 O
Investigations B-NonOSE_AE
[ O
note O
: O
Abnormal B-NonOSE_AE
laboratory I-NonOSE_AE
tests I-NonOSE_AE
, O
which O
include O
: O
Prolonged B-OSE_Labeled_AE
activated I-OSE_Labeled_AE
partial I-OSE_Labeled_AE
thromboplastin I-OSE_Labeled_AE
time I-OSE_Labeled_AE
, O
Bacteriuria B-OSE_Labeled_AE
NOS O
present O
, O
Blood B-OSE_Labeled_AE
creatine I-OSE_Labeled_AE
phosphokinase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
Blood B-OSE_Labeled_AE
culture I-OSE_Labeled_AE
positive I-OSE_Labeled_AE
, O
Blood B-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
Blood B-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
Blood B-OSE_Labeled_AE
uric I-OSE_Labeled_AE
acid I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
Hematocrit B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
Hematuria B-OSE_Labeled_AE
present I-OSE_Labeled_AE
, O
Hemoglobin B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
Liver B-OSE_Labeled_AE
function I-OSE_Labeled_AE
tests I-OSE_Labeled_AE
NOS O
abnormal I-OSE_Labeled_AE
, O
Proteinuria B-OSE_Labeled_AE
present O
, O
Transaminase B-OSE_Labeled_AE
NOS O
increased I-OSE_Labeled_AE
, O
Urine B-OSE_Labeled_AE
analysis I-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
NOS O
] O
3 O
11 O
7 O
Musculoskeletal B-NonOSE_AE
8 O
10 O
17 O
Arthralgia B-OSE_Labeled_AE
3 O
7 O
4 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
17 O
11 O
21 O
Headache B-OSE_Labeled_AE
NOS O
13 O
10 O
16 O
Dizziness B-OSE_Labeled_AE
( O
excl O
vertigo B-NonOSE_AE
) O
1 O
1 O
7 O
Respiratory B-NonOSE_AE
8 O
15 O
15 O
Cough B-OSE_Labeled_AE
7 O
7 O
8 O
Skin B-NonOSE_AE
& I-NonOSE_AE
Subcutaneous I-NonOSE_AE
10 O
7 O
18 O
Other O
Pre-Approval O
Studies O
Adverse O
Events O
from O
Ankylosing B-Not_AE_Candidate
Spondylitis I-Not_AE_Candidate
Studies O
: O
A O
total O
of O
378 O
patients O
were O
treated O
with O
CELEBREX O
in O
placebo- O
and O
active-controlled O
AS B-Not_AE_Candidate
studies O
. O

Doses O
up O
to O
400 O
mg O
once O
daily O
were O
studied O
. O

The O
types O
of O
adverse O
events O
reported O
in O
the O
AS B-Not_AE_Candidate
studies O
were O
similar O
to O
those O
reported O
in O
the O
OA B-Not_AE_Candidate
/ O
RA B-Not_AE_Candidate
studies O
. O

Adverse O
Events O
from O
Analgesia B-Not_AE_Candidate
and O
Dysmenorrhea B-Not_AE_Candidate
Studies O
: O
Approximately O
1,700 O
patients O
were O
treated O
with O
CELEBREX O
in O
analgesia B-Not_AE_Candidate
and O
dysmenorrhea B-Not_AE_Candidate
studies O
. O

All O
patients O
in O
post B-Not_AE_Candidate
- I-Not_AE_Candidate
oral I-Not_AE_Candidate
surgery I-Not_AE_Candidate
pain I-Not_AE_Candidate
studies O
received O
a O
single O
dose O
of O
study O
medication O
. O

Doses O
up O
to O
600 O
mg/day O
of O
CELEBREX O
were O
studied O
in O
primary O
dysmenorrhea B-Not_AE_Candidate
and O
post B-Not_AE_Candidate
- I-Not_AE_Candidate
orthopedic I-Not_AE_Candidate
surgery I-Not_AE_Candidate
pain I-Not_AE_Candidate
studies O
. O

The O
types O
of O
adverse O
events O
in O
the O
analgesia B-Not_AE_Candidate
and O
dysmenorrhea B-Not_AE_Candidate
studies O
were O
similar O
to O
those O
reported O
in O
arthritis B-Not_AE_Candidate
studies O
. O

The O
only O
additional O
adverse O
event O
reported O
was O
post B-OSE_Labeled_AE
- I-OSE_Labeled_AE
dental I-OSE_Labeled_AE
extraction I-OSE_Labeled_AE
alveolar I-OSE_Labeled_AE
osteitis I-OSE_Labeled_AE
( O
dry B-OSE_Labeled_AE
socket I-OSE_Labeled_AE
) O
in O
the O
post B-Not_AE_Candidate
- I-Not_AE_Candidate
oral I-Not_AE_Candidate
surgery I-Not_AE_Candidate
pain I-Not_AE_Candidate
studies O
. O

The O
APC O
and O
PreSAP O
Trials O
Adverse O
reactions O
from O
long-term O
, O
placebo-controlled O
polyp B-Not_AE_Candidate
prevention O
studies O
: O
Exposure O
to O
CELEBREX O
in O
the O
APC O
and O
PreSAP O
trials O
was O
400 O
to O
800 O
mg O
daily O
for O
up O
to O
3 O
years O
[ O
see O
Special O
Studies O
Adenomatous B-Not_AE_Candidate
Polyp I-Not_AE_Candidate
Prevention O
Studies O
( O
14.6 O
) O
] O
. O

Some O
adverse O
reactions O
occurred O
in O
higher O
percentages O
of O
patients O
than O
in O
the O
arthritis B-Not_AE_Candidate
pre-marketing O
trials O
( O
treatment O
durations O
up O
to O
12 O
weeks O
; O
see O
Adverse O
events O
from O
CELEBREX O
pre-marketing O
controlled O
arthritis B-Not_AE_Candidate
trials O
, O
above O
) O
. O

The O
adverse O
reactions O
for O
which O
these O
differences O
in O
patients O
treated O
with O
CELEBREX O
were O
greater O
as O
compared O
to O
the O
arthritis B-Not_AE_Candidate
pre-marketing O
trials O
were O
as O
follows O
: O
CELEBREX O
( O
400 O
to O
800 O
mg O
daily O
) O
N O
= O
2285 O
PlaceboN=1303 O
Diarrhea B-OSE_Labeled_AE
10.5 O
% O
7.0 O
% O
Gastroesophageal B-OSE_Labeled_AE
reflux I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
4.7 O
% O
3.1 O
% O
Nausea B-OSE_Labeled_AE
6.8 O
% O
5.3 O
% O
Vomiting B-OSE_Labeled_AE
3.2 O
% O
2.1 O
% O
Dyspnea B-OSE_Labeled_AE
2.8 O
% O
1.6 O
% O
Hypertension B-OSE_Labeled_AE
12.5 O
% O
9.8 O
% O
Nephrolithiasis B-OSE_Labeled_AE
2.1 O
% O
0.8 O
% O
The O
following O
additional O
adverse O
reactions O
occurred O
in O
> O
=0.1 O
% O
and O
< O
1 O
% O
of O
patients O
taking O
CELEBREX O
, O
at O
an O
incidence O
greater O
than O
placebo O
in O
the O
long-term O
polyp B-Not_AE_Candidate
prevention O
studies O
, O
and O
were O
either O
not O
reported O
during O
the O
controlled O
arthritis B-Not_AE_Candidate
pre-marketing O
trials O
or O
occurred O
with O
greater O
frequency O
in O
the O
long-term O
, O
placebo-controlled O
polyp B-Not_AE_Candidate
prevention O
studies O
: O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
Cerebral B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
Eye B-NonOSE_AE
disorders I-NonOSE_AE
: O
Vitreous B-OSE_Labeled_AE
floaters I-OSE_Labeled_AE
, O
conjunctival B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
Ear B-NonOSE_AE
and I-NonOSE_AE
labyrinth I-NonOSE_AE
: O
Labyrinthitis B-OSE_Labeled_AE
Cardiac B-NonOSE_AE
disorders I-NonOSE_AE
: O
Angina B-OSE_Labeled_AE
unstable I-OSE_Labeled_AE
, O
aortic B-OSE_Labeled_AE
valve I-OSE_Labeled_AE
incompetence I-OSE_Labeled_AE
, O
coronary B-OSE_Labeled_AE
artery I-OSE_Labeled_AE
atherosclerosis I-OSE_Labeled_AE
, O
sinus B-OSE_Labeled_AE
bradycardia I-OSE_Labeled_AE
, O
ventricular B-OSE_Labeled_AE
hypertrophy I-OSE_Labeled_AE
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
: O
Deep B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
Reproductive B-NonOSE_AE
system I-NonOSE_AE
and I-NonOSE_AE
breast I-NonOSE_AE
disorders I-NonOSE_AE
: O
Ovarian B-OSE_Labeled_AE
cyst I-OSE_Labeled_AE
Investigations B-NonOSE_AE
: O
Blood B-OSE_Labeled_AE
potassium I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
blood B-OSE_Labeled_AE
sodium I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
blood B-OSE_Labeled_AE
testosterone I-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
Injury B-NonOSE_AE
, I-NonOSE_AE
poisoning I-NonOSE_AE
and I-NonOSE_AE
procedural I-NonOSE_AE
complications I-NonOSE_AE
: O
Epicondylitis B-OSE_Labeled_AE
, O
tendon B-OSE_Labeled_AE
rupture I-OSE_Labeled_AE
6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
post O
approval O
use O
of O
CELEBREX O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
Cardiovascular B-NonOSE_AE
: O
Vasculitis B-OSE_Labeled_AE
, O
deep B-OSE_Labeled_AE
venous I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
General B-NonOSE_AE
: O
Anaphylactoid B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
Liver B-NonOSE_AE
and I-NonOSE_AE
biliary I-NonOSE_AE
: O
Liver B-OSE_Labeled_AE
necrosis I-OSE_Labeled_AE
, O
hepatitis B-OSE_Labeled_AE
, O
jaundice B-OSE_Labeled_AE
, O
hepatic B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
Hemic B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
: O
Agranulocytosis B-OSE_Labeled_AE
, O
aplastic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
, O
pancytopenia B-OSE_Labeled_AE
, O
leucopenia B-OSE_Labeled_AE
Metabolic B-NonOSE_AE
: O
Hypoglycemia B-OSE_Labeled_AE
, O
hyponatremia B-OSE_Labeled_AE
Nervous B-NonOSE_AE
: O
Aseptic B-OSE_Labeled_AE
meningitis I-OSE_Labeled_AE
, O
ageusia B-OSE_Labeled_AE
, O
anosmia B-OSE_Labeled_AE
, O
fatal B-NonOSE_AE
intracranial B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
Renal B-NonOSE_AE
: O
Interstitial B-OSE_Labeled_AE
nephritis I-OSE_Labeled_AE

BOXED O
WARNING O
: O
WARNING O
: O
RISK O
OF O
SERIOUS O
CARDIOVASCULAR O
AND O
GASTROINTESTINAL O
EVENTS O
WARNING O
: O
RISK O
OF O
SERIOUS O
CARDIOVASCULAR O
AND O
GASTROINTESTINAL O
EVENTS O
EXCERPT O
: O
WARNING O
: O
RISK O
OF O
SERIOUS O
CARDIOVASCULAR O
AND O
GASTROINTESTINAL O
EVENTS O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
Nonsteroidal O
anti-inflammatory O
drugs O
( O
NSAIDs O
) O
cause O
an O
increased O
risk O
of O
serious O
cardiovascular O
thrombotic O
events O
, O
including O
myocardial O
infarction O
and O
stroke O
, O
which O
can O
be O
fatal O
. O

This O
risk O
may O
occur O
early O
in O
the O
treatment O
and O
may O
increase O
with O
duration O
of O
use O
. O

( O
5.1 O
) O
* O
CELEBREX O
is O
contraindicated O
in O
the O
setting O
of O
coronary O
artery O
bypass O
graft O
( O
CABG O
) O
surgery O
. O

( O
4 O
, O
5.1 O
) O
* O
NSAIDs O
cause O
an O
increased O
risk O
of O
serious O
gastrointestinal O
( O
GI O
) O
adverse O
events O
including O
bleeding O
, O
ulceration O
, O
and O
perforation O
of O
the O
stomach O
or O
intestines O
, O
which O
can O
be O
fatal O
. O

These O
events O
can O
occur O
at O
any O
time O
during O
use O
and O
without O
warning O
symptoms O
. O

Elderly O
patients O
and O
patients O
with O
a O
prior O
history O
of O
peptic O
ulcer O
disease O
and/or O
GI O
bleeding O
are O
at O
greater O
risk O
for O
serious O
GI O
events O
. O

( O
5.2 O
) O
Cardiovascular O
Thrombotic O
Events O
* O
Nonsteroidal O
anti-inflammatory O
drugs O
( O
NSAIDs O
) O
cause O
an O
increased O
risk O
of O
serious O
cardiovascular B-OSE_Labeled_AE
thrombotic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
, O
including O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
, O
and O
stroke B-OSE_Labeled_AE
, O
which O
can O
be O
fatal B-NonOSE_AE
. O

This O
risk O
may O
occur O
early O
in O
the O
treatment O
and O
may O
increase O
with O
duration O
of O
use O
. O

[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
CELEBREX O
is O
contraindicated O
in O
the O
setting O
of O
coronary O
artery O
bypass O
graft O
( O
CABG O
) O
surgery O
. O

[ O
see O
Contraindications O
( O
4 O
) O
and O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
Gastrointestinal O
Bleeding O
, O
Ulceration O
, O
and O
Perforation O
* O
NSAIDs O
cause O
an O
increased O
risk O
of O
serious O
gastrointestinal B-OSE_Labeled_AE
( I-OSE_Labeled_AE
GI I-OSE_Labeled_AE
) I-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
events I-OSE_Labeled_AE
including O
bleeding O
, O
ulceration O
, O
and O
perforation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
stomach I-OSE_Labeled_AE
or O
intestines O
, O
which O
can O
be O
fatal B-NonOSE_AE
. O

These O
events O
can O
occur O
at O
any O
time O
during O
use O
and O
without O
warning O
symptoms O
. O

Elderly O
patients O
and O
patients O
with O
a O
prior O
history O
of O
peptic B-Not_AE_Candidate
ulcer I-Not_AE_Candidate
disease I-Not_AE_Candidate
and/or O
GI B-Not_AE_Candidate
bleeding I-Not_AE_Candidate
are O
at O
greater O
risk O
for O
serious O
( O
GI B-NonOSE_AE
) I-NonOSE_AE
events I-NonOSE_AE
. O

[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O

5 O
. O

WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Hepatotoxicity O
: O
Inform O
patients O
of O
warning O
signs O
and O
symptoms O
of O
hepatotoxicity O
. O

Discontinue O
if O
abnormal O
liver O
tests O
persist O
or O
worsen O
or O
if O
clinical O
signs O
and O
symptoms O
of O
liver O
disease O
develop O
( O
5.3 O
) O
* O
Hypertension O
: O
Patients O
taking O
some O
antihypertensive O
medications O
may O
have O
impaired O
response O
to O
these O
therapies O
when O
taking O
NSAIDs O
. O

Monitor O
blood O
pressure O
( O
5.4 O
, O
7 O
) O
* O
Heart O
Failure O
and O
Edema O
: O
Avoid O
use O
of O
CELEBREX O
in O
patients O
with O
severe O
heart O
failure O
unless O
benefits O
are O
expected O
to O
outweigh O
risk O
of O
worsening O
heart O
failure O
( O
5.5 O
) O
* O
Renal O
Toxicity O
: O
Monitor O
renal O
function O
in O
patients O
with O
renal O
or O
hepatic O
impairment O
, O
heart O
failure O
, O
dehydration O
, O
or O
hypovolemia O
. O

Avoid O
use O
of O
CELEBREX O
in O
patients O
with O
advanced O
renal O
disease O
unless O
benefits O
are O
expected O
to O
outweigh O
risk O
of O
worsening O
renal O
function O
( O
5.6 O
) O
* O
Anaphylactic O
Reactions O
: O
Seek O
emergency O
help O
if O
an O
anaphylactic O
reaction O
occurs O
( O
5.7 O
) O
* O
Exacerbation O
of O
Asthma O
Related O
to O
Aspirin O
Sensitivity O
: O
CELEBREX O
is O
contraindicated O
in O
patients O
with O
aspirin-sensitive O
asthma O
. O

Monitor O
patients O
with O
preexisting O
asthma O
( O
without O
aspirin O
sensitivity O
) O
( O
5.8 O
) O
* O
Serious O
Skin O
Reactions O
: O
Discontinue O
CELEBREX O
at O
first O
appearance O
of O
skin O
rash O
or O
other O
signs O
of O
hypersensitivity O
( O
5.9 O
) O
* O
Premature O
Closure O
of O
Fetal O
Ductus O
Arteriosus O
: O
Avoid O
use O
in O
pregnant O
women O
starting O
at O
30 O
weeks O
of O
gestation O
( O
5.10 O
, O
8.1 O
) O
* O
Hematologic O
Toxicity O
: O
Monitor O
hemoglobin O
or O
hematocrit O
in O
patients O
with O
any O
signs O
or O
symptoms O
of O
anemia O
( O
5.11 O
, O
7 O
) O
5.1 O
Cardiovascular O
Thrombotic O
Events O
Clinical O
trials O
of O
several O
COX-2 O
selective O
and O
nonselective O
NSAIDs O
of O
up O
to O
three O
years O
duration O
have O
shown O
an O
increased O
risk O
of O
serious O
cardiovascular B-OSE_Labeled_AE
( I-OSE_Labeled_AE
CV I-OSE_Labeled_AE
) I-OSE_Labeled_AE
thrombotic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
, O
including O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
( I-OSE_Labeled_AE
MI I-OSE_Labeled_AE
) O
and O
stroke B-OSE_Labeled_AE
, O
which O
can O
be O
fatal B-NonOSE_AE
. O

Based O
on O
available O
data O
, O
it O
is O
unclear O
that O
the O
risk O
for O
CV B-NonOSE_AE
thrombotic I-NonOSE_AE
events I-NonOSE_AE
is O
similar O
for O
all O
NSAIDs O
. O

The O
relative O
increase O
in O
serious O
CV B-NonOSE_AE
thrombotic I-NonOSE_AE
events I-NonOSE_AE
over O
baseline O
conferred O
by O
NSAID O
use O
appears O
to O
be O
similar O
in O
those O
with O
and O
without O
known O
CV B-Not_AE_Candidate
disease I-Not_AE_Candidate
or O
risk O
factors O
for O
CV B-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

However O
, O
patients O
with O
known O
CV B-Not_AE_Candidate
disease I-Not_AE_Candidate
or O
risk O
factors O
had O
a O
higher O
absolute O
incidence O
of O
excess O
serious O
CV B-NonOSE_AE
thrombotic I-NonOSE_AE
events I-NonOSE_AE
, O
due O
to O
their O
increased O
baseline O
rate O
. O

Some O
observational O
studies O
found O
that O
this O
increased O
risk O
of O
serious O
CV B-OSE_Labeled_AE
thrombotic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
began O
as O
early O
as O
the O
first O
weeks O
of O
treatment O
. O

The O
increase O
in O
CV B-NonOSE_AE
thrombotic I-NonOSE_AE
risk I-NonOSE_AE
has O
been O
observed O
most O
consistently O
at O
higher O
doses O
. O

In O
the O
APC O
( O
Adenoma B-Not_AE_Candidate
Prevention O
with O
Celecoxib O
) O
trial O
, O
the O
hazard O
ratio O
for O
the O
composite O
endpoint O
of O
cardiovascular B-OSE_Labeled_AE
death I-OSE_Labeled_AE
, O
MI B-OSE_Labeled_AE
, O
or O
stroke B-OSE_Labeled_AE
was O
3.4 O
( O
95 O
% O
CI O
1.4 O
- O
8.5 O
) O
for O
CELEBREX O
400 O
mg O
twice O
daily O
and O
2.8 O
( O
95 O
% O
CI O
1.1 O
- O
7.2 O
) O
with O
CELEBREX O
200 O
mg O
twice O
daily O
compared O
to O
placebo O
. O

Cumulative O
rates O
for O
this O
composite O
endpoint O
over O
3 O
years O
were O
3.0 O
% O
( O
20/671 O
subjects O
) O
and O
2.5 O
% O
( O
17/685 O
subjects O
) O
, O
respectively O
, O
compared O
to O
0.9 O
% O
( O
6/679 O
subjects O
) O
with O
placebo O
treatment O
. O

The O
increases O
in O
both O
celecoxib O
dose O
groups O
versus O
placebo-treated O
patients O
were O
mainly O
due O
to O
an O
increased O
incidence O
of O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
[ O
see O
Clinical O
Studies O
( O
14.6 O
) O
] O
. O

To O
minimize O
the O
potential O
risk O
for O
an O
adverse B-NonOSE_AE
CV I-NonOSE_AE
event I-NonOSE_AE
in O
NSAID-treated O
patients O
, O
use O
the O
lowest O
effective O
dose O
for O
the O
shortest O
duration O
possible O
. O

Physicians O
and O
patients O
should O
remain O
alert O
for O
the O
development O
of O
such O
events O
, O
throughout O
the O
entire O
treatment O
course O
, O
even O
in O
the O
absence O
of O
previous O
CV B-NonOSE_AE
symptoms I-NonOSE_AE
. O

Patients O
should O
be O
informed O
about O
the O
symptoms O
of O
serious O
CV B-NonOSE_AE
events I-NonOSE_AE
and O
the O
steps O
to O
take O
if O
they O
occur O
. O

There O
is O
no O
consistent O
evidence O
that O
concurrent O
use O
of O
aspirin O
mitigates O
the O
increased O
risk O
of O
serious O
CV B-NonOSE_AE
thrombotic I-NonOSE_AE
events I-NonOSE_AE
associated O
with O
NSAID O
use O
. O

The O
concurrent O
use O
of O
aspirin O
and O
an O
NSAID O
, O
such O
as O
celecoxib O
, O
increases O
the O
risk O
of O
serious O
gastrointestinal B-NonOSE_AE
( I-NonOSE_AE
GI I-NonOSE_AE
) I-NonOSE_AE
events I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

Status O
Post O
Coronary O
Artery O
Bypass O
Graft O
( O
CABG O
) O
Surgery O
Two O
large O
, O
controlled O
clinical O
trials O
of O
a O
COX-2 O
selective O
NSAID O
for O
the O
treatment O
of O
pain B-Not_AE_Candidate
in O
the O
first O
10-14 O
days O
following O
CABG O
surgery O
found O
an O
increased O
incidence O
of O
myocardial B-NonOSE_AE
infarction I-NonOSE_AE
and O
stroke B-NonOSE_AE
. O

NSAIDs O
are O
contraindicated O
in O
the O
setting O
of O
CABG O
[ O
see O
Contraindications O
( O
4 O
) O
] O
. O

Post-MI O
Patients O
Observational O
studies O
conducted O
in O
the O
Danish O
National O
Registry O
have O
demonstrated O
that O
patients O
treated O
with O
NSAIDs O
in O
the O
post- O
MI B-Not_AE_Candidate
period O
were O
at O
increased O
risk O
of O
reinfarction B-OSE_Labeled_AE
, O
CV B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
death I-OSE_Labeled_AE
, O
and O
all-cause O
mortality B-NonOSE_AE
beginning O
in O
the O
first O
week O
of O
treatment O
. O

In O
this O
same O
cohort O
, O
the O
incidence O
of O
death B-NonOSE_AE
in O
the O
first O
year O
post- O
MI B-Not_AE_Candidate
was O
20 O
per O
100 O
person O
years O
in O
NSAID-treated O
patients O
compared O
to O
12 O
per O
100 O
person O
years O
in O
non-NSAID O
exposed O
patients O
. O

Although O
the O
absolute O
rate O
of O
death B-NonOSE_AE
declined O
somewhat O
after O
the O
first O
year O
post- O
MI B-Not_AE_Candidate
, O
the O
increased O
relative O
risk O
of O
death B-NonOSE_AE
in O
NSAID O
users O
persisted O
over O
at O
least O
the O
next O
four O
years O
of O
follow-up O
. O

Avoid O
the O
use O
of O
Celebrex O
in O
patients O
with O
a O
recent O
MI B-Not_AE_Candidate
unless O
the O
benefits O
are O
expected O
to O
outweigh O
the O
risk O
of O
recurrent O
CV B-NonOSE_AE
thrombotic I-NonOSE_AE
events I-NonOSE_AE
. O

If O
Celebrex O
is O
used O
in O
patients O
with O
a O
recent O
MI B-Not_AE_Candidate
, O
monitor O
patients O
for O
signs O
of O
cardiac B-NonOSE_AE
ischemia I-NonOSE_AE
. O

5.2 O
Gastrointestinal O
Bleeding O
, O
Ulceration O
, O
and O
Perforation O
NSAIDs O
, O
including O
celecoxib O
cause O
serious O
gastrointestinal B-OSE_Labeled_AE
( I-OSE_Labeled_AE
GI I-OSE_Labeled_AE
) I-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
events I-OSE_Labeled_AE
including O
inflammation B-OSE_Labeled_AE
, O
bleeding B-OSE_Labeled_AE
, O
ulceration B-OSE_Labeled_AE
, O
and O
perforation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
esophagus O
, O
stomach O
, O
small I-OSE_Labeled_AE
intestine I-OSE_Labeled_AE
, O
or O
large O
intestine O
, O
which O
can O
be O
fatal B-NonOSE_AE
. O

These O
serious O
adverse O
events O
can O
occur O
at O
any O
time O
, O
with O
or O
without O
warning O
symptoms O
, O
in O
patients O
treated O
with O
CELEBREX O
. O

Only O
one O
in O
five O
patients O
who O
develop O
a O
serious O
upper B-NonOSE_AE
GI I-NonOSE_AE
adverse I-NonOSE_AE
event I-NonOSE_AE
on O
NSAID O
therapy O
is O
symptomatic O
. O

Upper B-OSE_Labeled_AE
GI I-OSE_Labeled_AE
ulcers I-OSE_Labeled_AE
, O
gross O
bleeding O
, O
or O
perforation O
caused O
by O
NSAIDs O
occurred O
in O
approximately O
1 O
% O
of O
patients O
treated O
for O
3-6 O
months O
, O
and O
in O
about O
2 O
% O
-4 O
% O
of O
patients O
treated O
for O
one O
year O
. O

However O
, O
even O
short-term O
NSAID O
therapy O
is O
not O
without O
risk O
. O

Risk O
Factors O
for O
GI O
Bleeding O
, O
Ulceration O
, O
and O
Perforation O
Patients O
with O
a O
prior O
history O
of O
peptic B-Not_AE_Candidate
ulcer I-Not_AE_Candidate
disease I-Not_AE_Candidate
and/or O
GI B-Not_AE_Candidate
bleeding I-Not_AE_Candidate
who O
used O
NSAIDs O
had O
a O
greater O
than O
10-fold O
increased O
risk O
for O
developing O
a O
GI B-OSE_Labeled_AE
bleed I-OSE_Labeled_AE
compared O
to O
patients O
without O
these O
risk O
factors O
. O

Other O
factors O
that O
increase O
the O
risk O
of O
GI B-NonOSE_AE
bleeding I-NonOSE_AE
in O
patients O
treated O
with O
NSAIDs O
include O
longer O
duration O
of O
NSAID O
therapy O
; O
concomitant O
use O
of O
oral O
corticosteroids O
, O
aspirin O
, O
anticoagulants O
; O
or O
selective O
serotonin O
reuptake O
inhibitors O
( O
SSRIs O
) O
; O
smoking O
; O
use O
of O
alcohol O
; O
older O
age O
; O
and O
poor O
general O
health O
status O
. O

Most O
postmarketing O
reports O
of O
fatal B-NonOSE_AE
GI B-OSE_Labeled_AE
events I-OSE_Labeled_AE
occurred O
in O
elderly O
or O
debilitated O
patients O
. O

Additionally O
, O
patients O
with O
advanced O
liver B-Not_AE_Candidate
disease I-Not_AE_Candidate
and/or O
coagulopathy B-Not_AE_Candidate
are O
at O
increased O
risk O
for O
GI B-NonOSE_AE
bleeding I-NonOSE_AE
. O

Complicated O
and O
symptomatic O
ulcer B-OSE_Labeled_AE
rates O
were O
0.78 O
% O
at O
nine O
months O
for O
all O
patients O
in O
the O
CLASS O
trial O
, O
and O
2.19 O
% O
for O
the O
subgroup O
on O
low-dose O
ASA O
. O

Patients O
65 O
years O
of O
age O
and O
older O
had O
an O
incidence O
of O
1.40 O
% O
at O
nine O
months O
, O
3.06 O
% O
when O
also O
taking O
ASA O
[ O
see O
Clinical O
Studies O
( O
14.6 O
) O
] O
. O

Strategies O
to O
Minimize O
the O
GI O
Risks O
in O
NSAID-treated O
patients O
: O
* O
Use O
the O
lowest O
effective O
dosage O
for O
the O
shortest O
possible O
duration O
. O

* O
Avoid O
administration O
of O
more O
than O
one O
NSAID O
at O
a O
time O
. O

* O
Avoid O
use O
in O
patients O
at O
higher O
risk O
unless O
benefits O
are O
expected O
to O
outweigh O
the O
increased O
risk O
of O
bleeding B-NonOSE_AE
. O

For O
such O
patients O
, O
as O
well O
as O
those O
with O
active O
GI B-Not_AE_Candidate
bleeding I-Not_AE_Candidate
, O
consider O
alternate O
therapies O
other O
than O
NSAIDs O
. O

* O
Remain O
alert O
for O
signs O
and O
symptoms O
of O
GI B-NonOSE_AE
ulceration I-NonOSE_AE
and O
bleeding O
during O
NSAID O
therapy O
. O

* O
If O
a O
serious O
GI B-NonOSE_AE
adverse I-NonOSE_AE
event I-NonOSE_AE
is O
suspected O
, O
promptly O
initiate O
evaluation O
and O
treatment O
, O
and O
discontinue O
CELEBREX O
until O
a O
serious O
GI B-NonOSE_AE
adverse I-NonOSE_AE
event I-NonOSE_AE
is O
ruled O
out O
. O

* O
In O
the O
setting O
of O
concomitant O
use O
of O
low-dose O
aspirin O
for O
cardiac O
prophylaxis O
, O
monitor O
patients O
more O
closely O
for O
evidence O
of O
GI B-NonOSE_AE
bleeding I-NonOSE_AE
[ O
see O
Drug O
Interactions O
( O
7 O
) O
] O
. O

5.3 O
Hepatotoxicity B-OSE_Labeled_AE
Elevations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
ALT O
or O
AST I-OSE_Labeled_AE
( O
three O
or O
more O
times O
the O
upper O
limit O
of O
normal O
[ O
ULN O
] O
) O
have O
been O
reported O
in O
approximately O
1 O
% O
of O
NSAID-treated O
patients O
in O
clinical O
trials O
. O

In O
addition O
, O
rare O
, O
sometimes O
fatal B-NonOSE_AE
, O
cases O
of O
severe O
hepatic B-OSE_Labeled_AE
injury I-OSE_Labeled_AE
, O
including O
fulminant B-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
, O
liver B-OSE_Labeled_AE
necrosis I-OSE_Labeled_AE
, O
and O
hepatic B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
have O
been O
reported O
. O

Elevations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
or O
AST O
( O
less O
than O
three O
times O
ULN O
) O
may O
occur O
in O
up O
to O
15 O
% O
of O
patients O
treated O
with O
NSAIDs O
including O
celecoxib O
. O

In O
controlled O
clinical O
trials O
of O
CELEBREX O
, O
the O
incidence O
of O
borderline O
elevations B-OSE_Labeled_AE
( O
greater O
than O
or O
equal O
to O
1.2 O
times O
and O
less O
than O
3 O
times O
the O
upper O
limit O
of I-OSE_Labeled_AE
normal O
) O
of O
liver I-OSE_Labeled_AE
associated I-OSE_Labeled_AE
enzymes I-OSE_Labeled_AE
was O
6 O
% O
for O
CELEBREX O
and O
5 O
% O
for O
placebo O
, O
and O
approximately O
0.2 O
% O
of O
patients O
taking O
CELEBREX O
and O
0.3 O
% O
of O
patients O
taking O
placebo O
had O
notable O
elevations B-NonOSE_AE
of O
ALT O
and O
AST I-NonOSE_AE
. O

Inform O
patients O
of O
the O
warning O
signs O
and O
symptoms O
of O
hepatotoxicity B-NonOSE_AE
( O
e.g. O
, O
nausea B-NonOSE_AE
, O
fatigue B-NonOSE_AE
, O
lethargy B-NonOSE_AE
, O
diarrhea B-NonOSE_AE
, O
pruritus B-NonOSE_AE
, O
jaundice B-NonOSE_AE
, O
right B-NonOSE_AE
upper I-NonOSE_AE
quadrant I-NonOSE_AE
tenderness I-NonOSE_AE
, O
and O
" B-NonOSE_AE
flu I-NonOSE_AE
- I-NonOSE_AE
like I-NonOSE_AE
" I-NonOSE_AE
symptoms I-NonOSE_AE
) O
. O

If O
clinical O
signs O
and O
symptoms O
consistent O
with O
liver B-NonOSE_AE
disease I-NonOSE_AE
develop O
, O
or O
if O
systemic O
manifestations O
occur O
( O
e.g. O
, O
eosinophilia B-NonOSE_AE
, O
rash B-NonOSE_AE
, O
etc O
. O

) O
, O
discontinue O
CELEBREX O
immediately O
, O
and O
perform O
a O
clinical O
evaluation O
of O
the O
patient O
. O

5.4 O
Hypertension O
NSAIDs O
, O
including O
CELEBREX O
can O
lead O
to O
new O
onset O
of O
hypertension B-OSE_Labeled_AE
or O
worsening B-OSE_Labeled_AE
of I-OSE_Labeled_AE
preexisting I-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
, O
either O
of O
which O
may O
contribute O
to O
the O
increased O
incidence O
of O
CV B-NonOSE_AE
events I-NonOSE_AE
. O

Patients O
taking O
angiotensin O
converting O
enzyme O
( O
ACE O
) O
inhibitors O
, O
thiazide O
diuretics O
or O
loop O
diuretics O
may O
have O
impaired O
response O
to O
these O
therapies O
when O
taking O
NSAIDs O
[ O
see O
Drug O
Interactions O
( O
7 O
) O
] O
. O

The O
rates O
of O
hypertension B-OSE_Labeled_AE
from O
the O
CLASS O
trial O
in O
the O
CELEBREX O
, O
ibuprofen O
and O
diclofenac-treated O
patients O
were O
2.4 O
% O
, O
4.2 O
% O
and O
2.5 O
% O
, O
respectively O
[ O
see O
Clinical O
Studies O
( O
14.6 O
) O
] O
. O

Monitor O
blood O
pressure O
( O
BP O
) O
during O
the O
initiation O
of O
NSAID O
treatment O
and O
throughout O
the O
course O
of O
therapy O
. O

5.5 O
Heart O
Failure O
and O
Edema O
The O
Coxib O
and O
traditional O
NSAID O
Trialists O
' O
Collaboration O
meta-analysis O
of O
randomized O
controlled O
trials O
demonstrated O
an O
approximately O
two-fold O
increase O
in O
hospitalizations O
for O
heart B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
in O
COX-2 O
selective-treated O
patients O
and O
nonselective O
NSAID-treated O
patients O
compared O
to O
placebo-treated O
patients O
. O

In O
a O
Danish O
National O
Registry O
study O
of O
patients O
with O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
NSAID O
use O
increased O
the O
risk O
of O
MI B-OSE_Labeled_AE
, O
hospitalization O
for O
heart B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
and O
death B-NonOSE_AE
. O

Additionally O
, O
fluid B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
and O
edema B-OSE_Labeled_AE
have O
been O
observed O
in O
some O
patients O
treated O
with O
NSAIDs O
. O

Use O
of O
celecoxib O
may O
blunt O
the O
CV B-NonOSE_AE
effects I-NonOSE_AE
of O
several O
therapeutic O
agents O
used O
to O
treat O
these O
medical O
conditions O
( O
e.g. O
, O
diuretics O
, O
ACE O
inhibitors O
, O
or O
angiotensin O
receptor O
blockers O
[ O
ARBs O
] O
) O
[ O
see O
Drug O
Interactions O
( O
7 O
) O
] O
. O

In O
the O
CLASS O
study O
[ O
see O
Clinical O
Studies O
( O
14.6 O
) O
] O
, O
the O
Kaplan-Meier O
cumulative O
rates O
at O
9 O
months O
of O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
in O
patients O
on O
CELEBREX O
400 O
mg O
twice O
daily O
( O
4-fold O
and O
2-fold O
the O
recommended O
OA B-Not_AE_Candidate
and O
RA B-Not_AE_Candidate
doses O
, O
respectively O
) O
, O
ibuprofen O
800 O
mg O
three O
times O
daily O
and O
diclofenac O
75 O
mg O
twice O
daily O
were O
4.5 O
% O
, O
6.9 O
% O
and O
4.7 O
% O
, O
respectively O
. O

Avoid O
the O
use O
of O
CELEBREX O
in O
patients O
with O
severe O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
unless O
the O
benefits O
are O
expected O
to O
outweigh O
the O
risk O
of O
worsening B-NonOSE_AE
heart I-NonOSE_AE
failure I-NonOSE_AE
. O

If O
CELEBREX O
is O
used O
in O
patients O
with O
severe O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
monitor O
patients O
for O
signs O
of O
worsening B-NonOSE_AE
heart I-NonOSE_AE
failure I-NonOSE_AE
. O

5.6 O
Renal O
Toxicity O
and O
Hyperkalemia O
Renal O
Toxicity O
Long-term O
administration O
of O
NSAIDs O
has O
resulted O
in O
renal B-OSE_Labeled_AE
papillary I-OSE_Labeled_AE
necrosis I-OSE_Labeled_AE
and O
other O
renal B-OSE_Labeled_AE
injury I-OSE_Labeled_AE
. O

Renal B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
has O
also O
been O
seen O
in O
patients O
in O
whom O
renal O
prostaglandins O
have O
a O
compensatory O
role O
in O
the O
maintenance O
of O
renal O
perfusion O
. O

In O
these O
patients O
, O
administration O
of O
an O
NSAID O
may O
cause O
a O
dose-dependent O
reduction B-NonOSE_AE
in I-NonOSE_AE
prostaglandin O
formation O
and O
, O
secondarily O
, O
in O
renal I-NonOSE_AE
blood I-NonOSE_AE
flow I-NonOSE_AE
, O
which O
may O
precipitate O
overt O
renal B-NonOSE_AE
decompensation I-NonOSE_AE
. O

Patients O
at O
greatest O
risk O
of O
this O
reaction O
are O
those O
with O
impaired B-Not_AE_Candidate
renal I-Not_AE_Candidate
function I-Not_AE_Candidate
, O
dehydration B-Not_AE_Candidate
, O
hypovolemia B-Not_AE_Candidate
, O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
liver B-Not_AE_Candidate
dysfunction I-Not_AE_Candidate
, O
those O
taking O
diuretics O
, O
ACE-inhibitors O
or O
the O
ARBs O
, O
and O
the O
elderly O
. O

Discontinuation O
of O
NSAID O
therapy O
is O
usually O
followed O
by O
recovery O
to O
the O
pretreatment O
state O
. O

No O
information O
is O
available O
from O
controlled O
clinical O
studies O
regarding O
the O
use O
of O
CELEBREX O
in O
patients O
with O
advanced O
renal B-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

The O
renal B-NonOSE_AE
effects I-NonOSE_AE
of O
CELEBREX O
may O
hasten O
the O
progression B-OSE_Labeled_AE
of I-OSE_Labeled_AE
renal I-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
in O
patients O
with O
preexisting O
renal B-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

Correct O
volume O
status O
in O
dehydrated B-Not_AE_Candidate
or O
hypovolemic B-Not_AE_Candidate
patients O
prior O
to O
initiating O
CELEBREX O
. O

Monitor O
renal O
function O
in O
patients O
with O
renal B-Not_AE_Candidate
or O
hepatic O
impairment I-Not_AE_Candidate
, O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
dehydration B-Not_AE_Candidate
, O
or O
hypovolemia B-Not_AE_Candidate
during O
use O
of O
CELEBREX O
[ O
see O
Drug O
Interactions O
( O
7 O
) O
] O
. O

Avoid O
the O
use O
of O
CELEBREX O
in O
patients O
with O
advanced O
renal B-Not_AE_Candidate
disease I-Not_AE_Candidate
unless O
the O
benefits O
are O
expected O
to O
outweigh O
the O
risk O
of O
worsening B-NonOSE_AE
renal I-NonOSE_AE
function I-NonOSE_AE
. O

If O
CELEBREX O
is O
used O
in O
patients O
with O
advanced O
renal B-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
monitor O
patients O
for O
signs O
of O
worsening B-NonOSE_AE
renal I-NonOSE_AE
function I-NonOSE_AE
. O

Hyperkalemia O
Increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
potassium I-OSE_Labeled_AE
concentration I-OSE_Labeled_AE
, O
including O
hyperkalemia B-OSE_Labeled_AE
, O
have O
been O
reported O
with O
use O
of O
NSAIDs O
, O
even O
in O
some O
patients O
without O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
. O

In O
patients O
with O
normal O
renal O
function O
, O
these O
effects O
have O
been O
attributed O
to O
a O
hyporeninemic B-Not_AE_Candidate
- I-Not_AE_Candidate
hypoadosteronism I-Not_AE_Candidate
state I-Not_AE_Candidate
. O

5.7 O
Anaphylactic O
Reactions O
Celecoxib O
has O
been O
associated O
with O
anaphylactic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
in O
patients O
with O
and O
without O
known O
hypersensitivity B-Not_AE_Candidate
to I-Not_AE_Candidate
celecoxib I-Not_AE_Candidate
and O
in O
patients O
with O
aspirin B-Not_AE_Candidate
sensitive I-Not_AE_Candidate
asthma I-Not_AE_Candidate
. O

Celebrex O
is O
a O
sulfonamide O
and O
both O
NSAIDs O
and O
sulfonamides O
may O
cause O
allergic B-OSE_Labeled_AE
type I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
including O
anaphylactic B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
and O
life-threatening O
or O
less O
severe O
asthmatic B-OSE_Labeled_AE
episodes I-OSE_Labeled_AE
in O
certain O
susceptible O
people O
[ O
see O
Contraindications O
( O
4 O
) O
and O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
. O

Seek O
emergency O
help O
if O
any O
anaphylactic B-NonOSE_AE
reaction I-NonOSE_AE
occurs O
. O

5.8 O
Exacerbation O
of O
Asthma O
Related O
to O
Aspirin O
Sensitivity O
A O
subpopulation O
of O
patients O
with O
asthma B-Not_AE_Candidate
may O
have O
aspirin B-Not_AE_Candidate
- I-Not_AE_Candidate
sensitive I-Not_AE_Candidate
asthma I-Not_AE_Candidate
which O
may O
include O
chronic O
rhinosinusitis B-Not_AE_Candidate
complicated O
by O
nasal B-Not_AE_Candidate
polyps I-Not_AE_Candidate
; O
severe O
, O
potentially O
fatal B-NonOSE_AE
bronchospasm B-Not_AE_Candidate
; O
and/or O
intolerance B-Not_AE_Candidate
to I-Not_AE_Candidate
aspirin I-Not_AE_Candidate
and O
other O
NSAIDs O
. O

Because O
cross B-Not_AE_Candidate
- I-Not_AE_Candidate
reactivity I-Not_AE_Candidate
between O
aspirin O
and O
other O
NSAIDs O
has O
been O
reported O
in O
such O
aspirin-sensitive O
patients O
, O
CELEBREX O
is O
contraindicated O
in O
patients O
with O
this O
form O
of O
aspirin O
sensitivity O
[ O
see O
Contraindications O
( O
4 O
) O
] O
. O

When O
CELEBREX O
is O
used O
in O
patients O
with O
preexisting O
asthma B-Not_AE_Candidate
( O
without O
known O
aspirin B-NonOSE_AE
sensitivity I-NonOSE_AE
) O
, O
monitor O
patients O
for O
changes O
in O
the O
signs O
and O
symptoms O
of O
asthma B-NonOSE_AE
. O

5.9 O
Serious O
Skin O
Reactions O
Serious O
skin B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
have O
occurred O
following O
treatment O
with O
Celebrex O
, O
including O
erythema B-OSE_Labeled_AE
multiforme I-OSE_Labeled_AE
, O
exfoliative B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
SJS I-OSE_Labeled_AE
) O
, O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
( I-OSE_Labeled_AE
TEN I-OSE_Labeled_AE
) O
, O
drug B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
with I-OSE_Labeled_AE
eosinophilia I-OSE_Labeled_AE
and I-OSE_Labeled_AE
systemic I-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
( I-OSE_Labeled_AE
DRESS I-OSE_Labeled_AE
) O
, O
and O
acute B-OSE_Labeled_AE
generalized I-OSE_Labeled_AE
exanthematous I-OSE_Labeled_AE
pustulosis I-OSE_Labeled_AE
( I-OSE_Labeled_AE
AGEP I-OSE_Labeled_AE
) O
. O

These O
serious O
events O
may O
occur O
without O
warning O
and O
can O
be O
fatal B-NonOSE_AE
. O

Inform O
patients O
about O
the O
signs O
and O
symptoms O
of O
serious O
skin B-NonOSE_AE
reactions I-NonOSE_AE
, O
and O
to O
discontinue O
the O
use O
of O
CELEBREX O
at O
the O
first O
appearance O
of O
skin B-NonOSE_AE
rash I-NonOSE_AE
or O
any O
other O
sign O
of O
hypersensitivity B-NonOSE_AE
. O

CELEBREX O
is O
contraindicated O
in O
patients O
with O
previous O
serious O
skin B-Not_AE_Candidate
reactions I-Not_AE_Candidate
to I-Not_AE_Candidate
NSAIDs I-Not_AE_Candidate
[ O
see O
Contraindications O
( O
4 O
) O
] O
. O

5.10 O
Premature O
Closure O
of O
Fetal O
Ductus O
Arteriosus O
Celecoxib O
may O
cause O
premature B-OSE_Labeled_AE
closure I-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
ductus I-OSE_Labeled_AE
arteriosus I-OSE_Labeled_AE
. O

Avoid O
use O
of O
NSAIDs O
, O
including O
CELEBREX O
, O
in O
pregnant B-Not_AE_Candidate
women O
starting O
at O
30 O
weeks O
of O
gestation O
( O
third O
trimester O
) O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.1 O
) O
] O
. O

5.11 O
Hematological B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
Anemia B-OSE_Labeled_AE
has O
occurred O
in O
NSAID-treated O
patients O
. O

This O
may O
be O
due O
to O
occult O
or O
gross O
blood B-Not_AE_Candidate
loss I-Not_AE_Candidate
, O
fluid B-Not_AE_Candidate
retention I-Not_AE_Candidate
, O
or O
an O
incompletely O
described O
effect B-Not_AE_Candidate
on I-Not_AE_Candidate
erythropoiesis I-Not_AE_Candidate
. O

If O
a O
patient O
treated O
with O
CELEBREX O
has O
any O
signs O
or O
symptoms O
of O
anemia B-NonOSE_AE
, O
monitor O
hemoglobin O
or O
hematocrit O
. O

In O
controlled O
clinical O
trials O
the O
incidence O
of O
anemia B-OSE_Labeled_AE
was O
0.6 O
% O
with O
CELEBREX O
and O
0.4 O
% O
with O
placebo O
. O

Patients O
on O
long-term O
treatment O
with O
CELEBREX O
should O
have O
their O
hemoglobin O
or O
hematocrit O
checked O
if O
they O
exhibit O
any O
signs O
or O
symptoms O
of O
anemia B-NonOSE_AE
or O
blood B-NonOSE_AE
loss I-NonOSE_AE
. O

NSAIDs O
, O
including O
CELEBREX O
, O
may O
increase O
the O
risk O
of O
bleeding B-OSE_Labeled_AE
events O
. O

Co-morbid O
conditions O
such O
as O
coagulation B-Not_AE_Candidate
disorders I-Not_AE_Candidate
or O
concomitant O
use O
of O
warfarin O
, O
other O
anticoagulants O
, O
antiplatelet O
agents O
( O
e.g. O
, O
aspirin O
) O
, O
serotonin O
reuptake O
inhibitors O
( O
SSRIs O
) O
and O
serotonin O
norepinephrine O
reuptake O
inhibitors O
( O
SNRIs O
) O
may O
increase O
this O
risk O
. O

Monitor O
these O
patients O
for O
signs O
of O
bleeding B-NonOSE_AE
[ O
see O
Drug O
Interactions O
( O
7 O
) O
] O
. O

5.12 O
Masking O
of O
Inflammation O
and O
Fever O
The O
pharmacological O
activity O
of O
CELEBREX O
in O
reducing B-NonOSE_AE
inflammation I-NonOSE_AE
, O
and O
possibly O
fever O
, O
may O
diminish O
the O
utility O
of O
diagnostic O
signs O
in O
detecting O
infections B-NonOSE_AE
. O

5.13 O
Laboratory O
Monitoring O
Because O
serious O
GI B-NonOSE_AE
bleeding I-NonOSE_AE
, O
hepatotoxicity B-NonOSE_AE
, O
and O
renal B-NonOSE_AE
injury I-NonOSE_AE
can O
occur O
without O
warning O
symptoms O
or O
signs O
, O
consider O
monitoring O
patients O
on O
long-term O
NSAID O
treatment O
with O
a O
CBC O
and O
a O
chemistry O
profile O
periodically O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
, O
5.3 O
, O
5.6 O
) O
] O
. O

In O
controlled O
clinical O
trials O
, O
elevated B-OSE_Labeled_AE
BUN I-OSE_Labeled_AE
occurred O
more O
frequently O
in O
patients O
receiving O
CELEBREX O
compared O
with O
patients O
on O
placebo O
. O

This O
laboratory B-NonOSE_AE
abnormality I-NonOSE_AE
was O
also O
seen O
in O
patients O
who O
received O
comparator O
NSAIDs O
in O
these O
studies O
. O

The O
clinical O
significance O
of O
this O
abnormality O
has O
not O
been O
established O
. O

5.14 O
Disseminated O
Intravascular O
Coagulation O
( O
DIC O
) O
Because O
of O
the O
risk O
of O
disseminated B-OSE_Labeled_AE
intravascular I-OSE_Labeled_AE
coagulation I-OSE_Labeled_AE
with O
use O
of O
CELEBREX O
in O
pediatric O
patients O
with O
systemic O
onset O
JRA B-Not_AE_Candidate
, O
monitor O
patients O
for O
signs O
and O
symptoms O
of O
abnormal B-NonOSE_AE
clotting I-NonOSE_AE
or O
bleeding B-NonOSE_AE
, O
and O
inform O
patients O
and O
their O
caregivers O
to O
report O
symptoms O
as O
soon O
as O
possible O
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
drug O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
the O
label O
: O
* O
Hemorrhage B-OSE_Labeled_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
and O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

* O
Arterial B-OSE_Labeled_AE
Thromboembolic I-OSE_Labeled_AE
Events I-OSE_Labeled_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
and O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

* O
Hypertension B-OSE_Labeled_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
and O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

* O
Infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Related I-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
and O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
. O

* O
Gastrointestinal B-OSE_Labeled_AE
Perforation I-OSE_Labeled_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
and O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
. O

* O
Impaired B-OSE_Labeled_AE
Wound I-OSE_Labeled_AE
Healing I-OSE_Labeled_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
and O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
. O

* O
Patients O
with O
Child B-Not_AE_Candidate
- I-Not_AE_Candidate
Pugh I-Not_AE_Candidate
B I-Not_AE_Candidate
or O
C O
Cirrhosis I-Not_AE_Candidate
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
. O

* O
Reversible B-OSE_Labeled_AE
Posterior I-OSE_Labeled_AE
Leukoencephalopathy I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
. O

* O
Proteinuria B-OSE_Labeled_AE
Including O
Nephrotic B-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
. O

* O
Thyroid B-OSE_Labeled_AE
Dysfunction I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
. O

* O
The O
most O
common O
adverse O
reactions O
observed O
in O
single-agent O
CYRAMZA-treated O
patients O
at O
a O
rate O
of O
> O
=10 O
% O
and O
> O
=2 O
% O
higher O
than O
placebo O
were O
hypertension B-OSE_Labeled_AE
and O
diarrhea B-OSE_Labeled_AE
. O

( O
6.1 O
) O
* O
The O
most O
common O
adverse O
reactions O
observed O
in O
patients O
treated O
with O
CYRAMZA O
plus O
paclitaxel O
at O
a O
rate O
of O
> O
=30 O
% O
and O
> O
=2 O
% O
higher O
than O
placebo O
plus O
paclitaxel O
were O
fatigue B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
and O
epistaxis B-OSE_Labeled_AE
. O

( O
6.1 O
) O
* O
The O
most O
common O
adverse O
reactions O
observed O
in O
patients O
treated O
with O
CYRAMZA O
plus O
docetaxel O
at O
a O
rate O
of O
> O
=30 O
% O
and O
> O
=2 O
% O
higher O
than O
placebo O
plus O
docetaxel O
were O
neutropenia B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
/ O
asthenia B-OSE_Labeled_AE
, O
and O
stomatitis B-OSE_Labeled_AE
/ O
mucosal B-OSE_Labeled_AE
inflammation I-OSE_Labeled_AE
. O

( O
6.1 O
) O
* O
The O
most O
common O
adverse O
reactions O
observed O
in O
patients O
treated O
with O
CYRAMZA O
plus O
FOLFIRI O
at O
a O
rate O
of O
> O
=30 O
% O
and O
> O
=2 O
% O
higher O
than O
placebo O
plus O
FOLFIRI O
were O
diarrhea B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
and O
stomatitis B-OSE_Labeled_AE
. O

( O
6.1 O
) O
EXCERPT O
: O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Eli O
Lilly O
and O
Company O
at O
1-800-LillyRx O
( O
1-800-545-5979 O
) O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Gastric O
Cancer O
Safety O
data O
are O
presented O
from O
two O
randomized O
, O
placebo O
controlled O
clinical O
trials O
in O
which O
patients O
received O
CYRAMZA O
: O
Study O
1 O
, O
a O
randomized O
( O
2:1 O
) O
, O
double-blind O
, O
clinical O
trial O
in O
which O
351 O
patients O
received O
either O
CYRAMZA O
8 O
mg/kg O
intravenously O
every O
two O
weeks O
or O
placebo O
every O
two O
weeks O
and O
Study O
2 O
, O
a O
double-blind O
, O
randomized O
( O
1:1 O
) O
clinical O
trial O
in O
which O
656 O
patients O
received O
paclitaxel O
80 O
mg/m O
2 O
on O
days O
1 O
, O
8 O
, O
and O
15 O
of O
each O
28-day O
cycle O
plus O
either O
CYRAMZA O
8 O
mg/kg O
intravenously O
every O
two O
weeks O
or O
placebo O
every O
two O
weeks O
. O

Both O
trials O
excluded O
patients O
with O
Eastern O
Cooperative O
Oncology O
Group O
( O
ECOG O
) O
performance O
status O
( O
PS O
) O
of O
2 O
or O
greater O
, O
uncontrolled O
hypertension B-Not_AE_Candidate
, O
major O
surgery O
within O
28 O
days O
, O
or O
patients O
receiving O
chronic O
anti-platelet O
therapy O
other O
than O
once O
daily O
aspirin O
. O

Study O
1 O
excluded O
patients O
with O
bilirubin O
> O
=1.5 O
mg/dL O
and O
Study O
2 O
excluded O
patients O
with O
bilirubin O
> O
1.5 O
times O
the O
upper O
limit O
of O
normal O
. O

CYRAMZA O
Administered O
as O
a O
Single O
Agent O
Among O
236 O
patients O
who O
received O
CYRAMZA O
( O
safety O
population O
) O
in O
Study O
1 O
, O
median O
age O
was O
60 O
years O
, O
28 O
% O
were O
women O
, O
76 O
% O
were O
White O
, O
and O
16 O
% O
were O
Asian O
. O

Patients O
in O
Study O
1 O
received O
a O
median O
of O
4 O
doses O
of O
CYRAMZA O
; O
the O
median O
duration O
of O
exposure O
was O
8 O
weeks O
, O
and O
32 O
( O
14 O
% O
of O
236 O
) O
patients O
received O
CYRAMZA O
for O
at O
least O
six O
months O
. O

In O
Study O
1 O
, O
the O
most O
common O
adverse O
reactions O
( O
all O
grades O
) O
observed O
in O
CYRAMZA-treated O
patients O
at O
a O
rate O
of O
> O
=10 O
% O
and O
> O
=2 O
% O
higher O
than O
placebo O
were O
hypertension B-OSE_Labeled_AE
and O
diarrhea B-OSE_Labeled_AE
. O

The O
most O
common O
serious O
adverse O
events O
with O
CYRAMZA O
were O
anemia B-OSE_Labeled_AE
( O
3.8 O
% O
) O
and O
intestinal B-OSE_Labeled_AE
obstruction I-OSE_Labeled_AE
( O
2.1 O
% O
) O
. O

Red O
blood O
cell O
transfusions O
were O
given O
to O
11 O
% O
of O
CYRAMZA-treated O
patients O
versus O
8.7 O
% O
of O
patients O
who O
received O
placebo O
. O

Table O
2 O
provides O
the O
frequency O
and O
severity O
of O
adverse O
reactions O
in O
Study O
1 O
. O

Table O
2 O
: O
Adverse O
Reactions O
Occurring O
at O
Incidence O
Rate O
> O
=5 O
% O
and O
a O
> O
=2 O
% O
Difference O
Between O
Arms O
in O
Patients O
Receiving O
CYRAMZA O
in O
Study O
1 O
Adverse O
Reactions O
( O
MedDRA O
) O
System O
Organ O
Class O
CYRAMZA O
( O
8 O
mg/kg O
) O
N=236 O
Placebo O
N=115 O
All O
Grades O
( O
Frequency O
% O
) O
Grade O
3-4 O
( O
Frequency O
% O
) O
All O
Grades O
( O
Frequency O
% O
) O
Grade O
3-4 O
( O
Frequency O
% O
) O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
14 O
1 O
9 O
2 O
Metabolism B-NonOSE_AE
and O
Nutrition O
Disorders I-NonOSE_AE
Hyponatremia B-OSE_Labeled_AE
6 O
3 O
2 O
1 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Headache B-OSE_Labeled_AE
9 O
0 O
3 O
0 O
Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
16 O
8 O
8 O
3 O
Clinically O
relevant O
adverse O
reactions O
reported O
in O
> O
=1 O
% O
and O
< O
5 O
% O
of O
CYRAMZA-treated O
patients O
in O
Study O
1 O
were O
: O
neutropenia B-OSE_Labeled_AE
( O
4.7 O
% O
CYRAMZA O
versus O
0.9 O
% O
placebo O
) O
, O
epistaxis B-OSE_Labeled_AE
( O
4.7 O
% O
CYRAMZA O
versus O
0.9 O
% O
placebo O
) O
, O
rash B-OSE_Labeled_AE
( O
4.2 O
% O
CYRAMZA O
versus O
1.7 O
% O
placebo O
) O
, O
intestinal B-OSE_Labeled_AE
obstruction I-OSE_Labeled_AE
( O
2.1 O
% O
CYRAMZA O
versus O
0 O
% O
placebo O
) O
, O
and O
arterial B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
( O
1.7 O
% O
CYRAMZA O
versus O
0 O
% O
placebo O
) O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
and O
Warnings O
and O
Precautions O
( O
5.1 O
, O
5.2 O
) O
] O
. O

Across O
clinical O
trials O
of O
CYRAMZA O
administered O
as O
a O
single O
agent O
, O
clinically O
relevant O
adverse O
reactions O
( O
including O
Grade O
> O
=3 O
) O
reported O
in O
CYRAMZA-treated O
patients O
included O
proteinuria B-OSE_Labeled_AE
, O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
, O
and O
infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

In O
Study O
1 O
, O
according O
to O
laboratory O
assessment O
, O
8 O
% O
of O
CYRAMZA-treated O
patients O
developed O
proteinuria B-OSE_Labeled_AE
versus O
3 O
% O
of O
placebo-treated O
patients O
. O

Two O
patients O
discontinued O
CYRAMZA O
due O
to O
proteinuria B-OSE_Labeled_AE
. O

The O
rate O
of O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
in O
Study O
1 O
was O
0.8 O
% O
and O
the O
rate O
of O
infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
was O
0.4 O
% O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
, O
2.3 O
) O
and O
Warnings O
and O
Precautions O
( O
5.4 O
, O
5.5 O
) O
] O
. O

CYRAMZA O
Administered O
in O
Combination O
with O
Paclitaxel O
Among O
327 O
patients O
who O
received O
CYRAMZA O
( O
safety O
population O
) O
in O
Study O
2 O
, O
median O
age O
was O
61 O
years O
, O
31 O
% O
were O
women O
, O
63 O
% O
were O
White O
, O
and O
33 O
% O
were O
Asian O
. O

Patients O
in O
Study O
2 O
received O
a O
median O
of O
9 O
doses O
of O
CYRAMZA O
; O
the O
median O
duration O
of O
exposure O
was O
18 O
weeks O
, O
and O
93 O
( O
28 O
% O
of O
327 O
) O
patients O
received O
CYRAMZA O
for O
at O
least O
six O
months O
. O

In O
Study O
2 O
, O
the O
most O
common O
adverse O
reactions O
( O
all O
grades O
) O
observed O
in O
patients O
treated O
with O
CYRAMZA O
plus O
paclitaxel O
at O
a O
rate O
of O
> O
=30 O
% O
and O
> O
=2 O
% O
higher O
than O
placebo O
plus O
paclitaxel O
were O
fatigue B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
and O
epistaxis B-OSE_Labeled_AE
. O

The O
most O
common O
serious O
adverse O
events O
with O
CYRAMZA O
plus O
paclitaxel O
were O
neutropenia B-OSE_Labeled_AE
( O
3.7 O
% O
) O
and O
febrile B-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
( O
2.4 O
% O
) O
; O
19 O
% O
of O
patients O
treated O
with O
CYRAMZA O
plus O
paclitaxel O
received O
granulocyte O
colony-stimulating O
factors O
. O

Adverse O
reactions O
resulting O
in O
discontinuation O
of O
any O
component O
of O
the O
CYRAMZA O
plus O
paclitaxel O
combination O
in O
2 O
% O
or O
more O
patients O
in O
Study O
2 O
were O
neutropenia B-OSE_Labeled_AE
( O
4 O
% O
) O
and O
thrombocytopenia B-OSE_Labeled_AE
( O
3 O
% O
) O
. O

Table O
3 O
provides O
the O
frequency O
and O
severity O
of O
adverse O
reactions O
in O
Study O
2 O
. O

Table O
3 O
: O
Adverse O
Reactions O
Occurring O
at O
Incidence O
Rate O
> O
=5 O
% O
and O
a O
> O
=2 O
% O
Difference O
Between O
Arms O
in O
Patients O
Receiving O
CYRAMZA O
plus O
Paclitaxel O
in O
Study O
2 O
Adverse O
Reactions O
( O
MedDRA O
) O
System O
Organ O
Class O
CYRAMZA O
plus O
Paclitaxel O
( O
N=327 O
) O
Placebo O
plus O
Paclitaxel O
( O
N=329 O
) O
All O
Grades O
( O
Frequency O
% O
) O
Grade O
> O
=3 O
( O
Frequency O
% O
) O
All O
Grades O
( O
Frequency O
% O
) O
Grade O
> O
=3 O
( O
Frequency O
% O
) O
Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Neutropenia B-OSE_Labeled_AE
54 O
41 O
31 O
19 O
Thrombocytopenia B-OSE_Labeled_AE
13 O
2 O
6 O
2 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
32 O
4 O
23 O
2 O
Gastrointestinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
events O
10 O
4 O
6 O
2 O
Stomatitis B-OSE_Labeled_AE
20 O
1 O
7 O
1 O
General O
Disorders O
and O
Administration B-NonOSE_AE
Site I-NonOSE_AE
Disorders I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
/ O
Asthenia B-OSE_Labeled_AE
57 O
12 O
44 O
6 O
Peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
25 O
2 O
14 O
1 O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
Hypoalbuminemia B-OSE_Labeled_AE
11 O
1 O
5 O
1 O
Renal B-NonOSE_AE
and O
Urinary O
Disorders I-NonOSE_AE
Proteinuria B-OSE_Labeled_AE
17 O
1 O
6 O
0 O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
Thoracic I-NonOSE_AE
, I-NonOSE_AE
and I-NonOSE_AE
Mediastinal I-NonOSE_AE
Disorders I-NonOSE_AE
Epistaxis B-OSE_Labeled_AE
31 O
0 O
7 O
0 O
Vascular B-NonOSE_AE
Disorder I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
25 O
15 O
6 O
3 O
Clinically O
relevant O
adverse O
reactions O
reported O
in O
> O
=1 O
% O
and O
< O
5 O
% O
of O
the O
CYRAMZA O
plus O
paclitaxel O
treated O
patients O
in O
Study O
2 O
were O
sepsis B-OSE_Labeled_AE
( O
3.1 O
% O
CYRAMZA O
plus O
paclitaxel O
versus O
1.8 O
% O
placebo O
plus O
paclitaxel O
) O
and O
gastrointestinal B-OSE_Labeled_AE
perforations I-OSE_Labeled_AE
( O
1.2 O
% O
CYRAMZA O
plus O
paclitaxel O
versus O
0.3 O
% O
for O
placebo O
plus O
paclitaxel O
) O
. O

Non-Small O
Cell O
Lung O
Cancer O
CYRAMZA O
Administered O
in O
Combination O
with O
Docetaxel O
Study O
3 O
was O
a O
multinational O
, O
randomized O
, O
double-blind O
study O
conducted O
in O
patients O
with O
NSCLC B-Not_AE_Candidate
with O
disease O
progression O
on O
or O
after O
one O
platinum-based O
therapy O
for O
locally O
advanced O
or O
metastatic B-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

Patients O
received O
either O
CYRAMZA O
10 O
mg/kg O
intravenously O
plus O
docetaxel O
75 O
mg/m O
2 O
intravenously O
every O
3 O
weeks O
or O
placebo O
plus O
docetaxel O
75 O
mg/m O
2 O
intravenously O
every O
3 O
weeks O
. O

Due O
to O
an O
increased O
incidence O
of O
neutropenia B-OSE_Labeled_AE
and O
febrile B-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
in O
patients O
enrolled O
in O
East O
Asian O
sites O
, O
Study O
3 O
was O
amended O
and O
24 O
patients O
( O
11 O
CYRAMZA O
plus O
docetaxel O
, O
13 O
placebo O
plus O
docetaxel O
) O
at O
East O
Asian O
sites O
received O
a O
starting O
dose O
of O
docetaxel O
at O
60 O
mg/m O
2 O
every O
3 O
weeks O
. O

Study O
3 O
excluded O
patients O
with O
an O
ECOG O
PS O
of O
2 O
or O
greater O
, O
bilirubin O
greater O
than O
the O
upper O
limit O
of O
normal O
( O
ULN O
) O
, O
uncontrolled O
hypertension B-Not_AE_Candidate
, O
major O
surgery O
within O
28 O
days O
, O
radiographic O
evidence O
of O
major O
airway B-Not_AE_Candidate
or O
blood O
vessel O
invasion I-Not_AE_Candidate
by O
cancer O
, O
radiographic O
evidence O
of O
intra B-Not_AE_Candidate
- I-Not_AE_Candidate
tumor I-Not_AE_Candidate
cavitation I-Not_AE_Candidate
, O
or O
gross O
hemoptysis B-Not_AE_Candidate
within O
the O
preceding O
2 O
months O
, O
and O
patients O
receiving O
therapeutic O
anticoagulation O
or O
chronic O
anti-platelet O
therapy O
other O
than O
once O
daily O
aspirin O
. O

The O
study O
also O
excluded O
patients O
whose O
only O
prior O
treatment O
for O
advanced O
NSCLC B-Not_AE_Candidate
was O
a O
tyrosine O
kinase O
( O
epidermal O
growth O
factor O
receptor O
[ O
EGFR O
] O
or O
anaplastic O
lymphoma O
kinase O
[ O
ALK O
] O
) O
inhibitor O
. O

The O
data O
described O
below O
reflect O
exposure O
to O
CYRAMZA O
plus O
docetaxel O
in O
627 O
patients O
in O
Study O
3 O
. O

Demographics O
and O
baseline O
characteristics O
were O
similar O
between O
treatment O
arms O
. O

Median O
age O
was O
62 O
years O
; O
67 O
% O
of O
patients O
were O
men O
; O
84 O
% O
were O
White O
and O
12 O
% O
were O
Asian O
; O
33 O
% O
had O
ECOG O
PS O
0 O
; O
74 O
% O
had O
non-squamous O
histology O
and O
25 O
% O
had O
squamous O
histology O
. O

Patients O
received O
a O
median O
of O
4.5 O
doses O
of O
CYRAMZA O
; O
the O
median O
duration O
of O
exposure O
was O
3.5 O
months O
, O
and O
195 O
( O
31 O
% O
of O
627 O
) O
patients O
received O
CYRAMZA O
for O
at O
least O
six O
months O
. O

In O
Study O
3 O
, O
the O
most O
common O
adverse O
reactions O
( O
all O
grades O
) O
observed O
in O
CYRAMZA O
plus O
docetaxel-treated O
patients O
at O
a O
rate O
of O
> O
=30 O
% O
and O
> O
=2 O
% O
higher O
than O
placebo O
plus O
docetaxel O
were O
neutropenia B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
/ O
asthenia B-OSE_Labeled_AE
, O
and O
stomatitis B-OSE_Labeled_AE
/ O
mucosal B-OSE_Labeled_AE
inflammation I-OSE_Labeled_AE
. O

Treatment O
discontinuation O
due O
to O
adverse O
reactions O
occurred O
more O
frequently O
in O
CYRAMZA O
plus O
docetaxel-treated O
patients O
( O
9 O
% O
) O
than O
in O
placebo O
plus O
docetaxel-treated O
patients O
( O
5 O
% O
) O
. O

The O
most O
common O
adverse O
events O
leading O
to O
treatment O
discontinuation O
of O
CYRAMZA O
were O
infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
( O
0.5 O
% O
) O
and O
epistaxis B-OSE_Labeled_AE
( O
0.3 O
% O
) O
. O

For O
patients O
with O
non-squamous O
histology O
, O
the O
overall O
incidence O
of O
pulmonary B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
was O
7 O
% O
and O
the O
incidence O
of O
> O
=Grade O
3 O
pulmonary B-NonOSE_AE
hemorrhage I-NonOSE_AE
was O
1 O
% O
for O
CYRAMZA O
plus O
docetaxel O
compared O
to O
6 O
% O
overall O
incidence O
and O
1 O
% O
for O
> O
=Grade O
3 O
pulmonary B-NonOSE_AE
hemorrhage I-NonOSE_AE
for O
placebo O
plus O
docetaxel O
. O

For O
patients O
with O
squamous O
histology O
, O
the O
overall O
incidence O
of O
pulmonary B-NonOSE_AE
hemorrhage I-NonOSE_AE
was O
10 O
% O
and O
the O
incidence O
of O
> O
=Grade O
3 O
pulmonary B-NonOSE_AE
hemorrhage I-NonOSE_AE
was O
2 O
% O
for O
CYRAMZA O
plus O
docetaxel O
compared O
to O
12 O
% O
overall O
incidence O
and O
2 O
% O
for O
> O
=Grade O
3 O
pulmonary B-NonOSE_AE
hemorrhage I-NonOSE_AE
for O
placebo O
plus O
docetaxel O
. O

The O
most O
common O
serious O
adverse O
events O
with O
CYRAMZA O
plus O
docetaxel O
were O
febrile B-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
( O
14 O
% O
) O
, O
pneumonia B-OSE_Labeled_AE
( O
6 O
% O
) O
, O
and O
neutropenia B-OSE_Labeled_AE
( O
5 O
% O
) O
. O

The O
use O
of O
granulocyte O
colony-stimulating O
factors O
was O
42 O
% O
in O
CYRAMZA O
plus O
docetaxel-treated O
patients O
versus O
37 O
% O
in O
patients O
who O
received O
placebo O
plus O
docetaxel O
. O

In O
patients O
> O
=65 O
years O
, O
there O
were O
18 O
( O
8 O
% O
) O
deaths B-NonOSE_AE
on O
treatment O
or O
within O
30 O
days O
of O
discontinuation O
for O
CYRAMZA O
plus O
docetaxel O
and O
9 O
( O
4 O
% O
) O
deaths B-NonOSE_AE
for O
placebo O
plus O
docetaxel O
. O

In O
patients O
< O
65 O
years O
, O
there O
were O
13 O
( O
3 O
% O
) O
deaths B-NonOSE_AE
on O
treatment O
or O
within O
30 O
days O
of O
discontinuation O
for O
CYRAMZA O
plus O
docetaxel O
and O
26 O
( O
6 O
% O
) O
deaths B-NonOSE_AE
for O
placebo O
plus O
docetaxel O
. O

Table O
4 O
provides O
the O
frequency O
and O
severity O
of O
adverse O
reactions O
in O
Study O
3 O
. O

Table O
4 O
: O
Adverse O
Reactions O
Occurring O
at O
Incidence O
Rate O
> O
=5 O
% O
and O
a O
> O
=2 O
% O
Difference O
Between O
Arms O
in O
Patients O
Receiving O
CYRAMZA O
in O
Study O
3 O
Adverse O
Reactions O
( O
MedDRA O
) O
System O
Organ O
Class O
CYRAMZA O
plus O
docetaxel O
( O
N=627 O
) O
Placebo O
plus O
docetaxel O
( O
N=618 O
) O
All O
Grades O
( O
Frequency O
% O
) O
Grade O
3-4 O
( O
Frequency O
% O
) O
All O
Grades O
( O
Frequency O
% O
) O
Grade O
3-4 O
( O
Frequency O
% O
) O
Blood B-NonOSE_AE
and O
Lymphatic O
System O
Disorders I-NonOSE_AE
Febrile B-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
16 O
16 O
10 O
10 O
Neutropenia B-OSE_Labeled_AE
55 O
49 O
46 O
40 O
Thrombocytopenia B-OSE_Labeled_AE
13 O
3 O
5 O
< O
1 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Stomatitis B-OSE_Labeled_AE
/ O
Mucosal B-OSE_Labeled_AE
inflammation I-OSE_Labeled_AE
37 O
7 O
19 O
2 O
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
Lacrimation B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
13 O
< O
1 O
5 O
0 O
General O
Disorders O
and O
Administration B-NonOSE_AE
Site I-NonOSE_AE
Disorders I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
/ O
Asthenia B-OSE_Labeled_AE
55 O
14 O
50 O
11 O
Peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
16 O
0 O
9 O
< O
1 O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
Thoracic I-NonOSE_AE
, I-NonOSE_AE
and I-NonOSE_AE
Mediastinal I-NonOSE_AE
Disorders I-NonOSE_AE
Epistaxis B-OSE_Labeled_AE
19 O
< O
1 O
7 O
< O
1 O
Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
11 O
6 O
5 O
2 O
Clinically O
relevant O
adverse O
drug O
reactions O
reported O
in O
> O
=1 O
% O
and O
< O
5 O
% O
of O
the O
CYRAMZA O
plus O
docetaxel-treated O
patients O
in O
Study O
3 O
were O
hyponatremia B-OSE_Labeled_AE
( O
4.8 O
% O
CYRAMZA O
plus O
docetaxel O
versus O
2.4 O
% O
for O
placebo O
plus O
docetaxel O
) O
and O
proteinuria B-OSE_Labeled_AE
( O
3.3 O
% O
CYRAMZA O
plus O
docetaxel O
versus O
0.8 O
% O
placebo O
plus O
docetaxel O
) O
. O

Colorectal O
Cancer O
CYRAMZA O
Administered O
in O
Combination O
with O
FOLFIRI O
Study O
4 O
was O
a O
multinational O
, O
randomized O
, O
double-blind O
study O
conducted O
in O
patients O
with O
metastatic B-Not_AE_Candidate
colorectal I-Not_AE_Candidate
cancer I-Not_AE_Candidate
with O
disease O
progression O
on O
or O
after O
therapy O
with O
bevacizumab O
, O
oxaliplatin O
, O
and O
a O
fluoropyrimidine O
. O

Patients O
received O
either O
CYRAMZA O
8 O
mg/kg O
intravenously O
plus O
FOLFIRI O
intravenously O
every O
2 O
weeks O
or O
placebo O
plus O
FOLFIRI O
intravenously O
every O
2 O
weeks O
. O

Study O
4 O
excluded O
patients O
with O
an O
ECOG O
PS O
of O
2 O
or O
greater O
, O
uncontrolled O
hypertension B-Not_AE_Candidate
, O
major O
surgery O
within O
28 O
days O
, O
and O
those O
who O
experienced O
any O
of O
the O
following O
during O
first-line O
therapy O
with O
a O
bevacizumab-containing O
regimen O
: O
an O
arterial B-Not_AE_Candidate
thrombotic I-Not_AE_Candidate
/thromboembolic O
event I-Not_AE_Candidate
; O
Grade O
4 O
hypertension B-Not_AE_Candidate
; O
Grade O
3 O
proteinuria B-Not_AE_Candidate
; O
a O
Grade O
3-4 O
bleeding B-Not_AE_Candidate
event O
; O
or O
bowel B-Not_AE_Candidate
perforation I-Not_AE_Candidate
. O

Demographics O
and O
baseline O
characteristics O
for O
the O
treated O
population O
were O
similar O
between O
treatment O
arms O
( O
n=1057 O
) O
. O

Median O
age O
was O
62 O
years O
; O
57 O
% O
of O
patients O
were O
men O
; O
76 O
% O
were O
White O
and O
20 O
% O
were O
Asian O
; O
48 O
% O
had O
ECOG O
PS O
0 O
. O

The O
data O
described O
in O
this O
section O
reflect O
exposure O
to O
CYRAMZA O
plus O
FOLFIRI O
in O
529 O
patients O
in O
Study O
4 O
. O

Patients O
received O
a O
median O
of O
8 O
doses O
( O
range O
1-68 O
) O
of O
CYRAMZA O
; O
the O
median O
duration O
of O
exposure O
was O
4.4 O
months O
, O
and O
169 O
( O
32 O
% O
of O
529 O
) O
patients O
received O
CYRAMZA O
for O
at O
least O
six O
months O
. O

The O
most O
common O
adverse O
reactions O
( O
all O
grades O
) O
observed O
in O
CYRAMZA O
plus O
FOLFIRI-treated O
patients O
at O
a O
rate O
of O
> O
=30 O
% O
and O
> O
=2 O
% O
higher O
than O
placebo O
plus O
FOLFIRI O
were O
diarrhea B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
and O
stomatitis B-OSE_Labeled_AE
. O

Twenty O
percent O
of O
patients O
treated O
with O
CYRAMZA O
plus O
FOLFIRI O
received O
granulocyte O
colony-stimulating O
factors O
. O

Treatment O
discontinuation O
of O
any O
study O
drug O
due O
to O
adverse O
reactions O
occurred O
more O
frequently O
in O
CYRAMZA O
plus O
FOLFIRI-treated O
patients O
( O
29 O
% O
) O
than O
in O
placebo O
plus O
FOLFIRI-treated O
patients O
( O
13 O
% O
) O
. O

The O
most O
common O
adverse O
reactions O
leading O
to O
discontinuation O
of O
any O
component O
of O
CYRAMZA O
plus O
FOLFIRI O
as O
compared O
to O
placebo O
plus O
FOLFIRI O
, O
were O
neutropenia B-OSE_Labeled_AE
( O
12.5 O
% O
versus O
5.3 O
% O
) O
and O
thrombocytopenia B-OSE_Labeled_AE
( O
4.2 O
% O
versus O
0.8 O
% O
) O
. O

The O
most O
common O
adverse O
reactions O
leading O
to O
treatment O
discontinuation O
of O
CYRAMZA O
were O
proteinuria B-OSE_Labeled_AE
( O
1.5 O
% O
) O
and O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
( O
1.7 O
% O
) O
. O

The O
most O
common O
serious O
adverse O
events O
with O
CYRAMZA O
plus O
FOLFIRI O
were O
diarrhea B-OSE_Labeled_AE
( O
3.6 O
% O
) O
, O
intestinal B-OSE_Labeled_AE
obstruction I-OSE_Labeled_AE
( O
3.0 O
% O
) O
, O
and O
febrile B-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
( O
2.8 O
% O
) O
. O

Table O
5 O
provides O
the O
frequency O
and O
severity O
of O
adverse O
reactions O
in O
Study O
4 O
. O

Table O
5 O
: O
Adverse O
Reactions O
Occurring O
at O
Incidence O
Rate O
> O
=5 O
% O
and O
a O
> O
=2 O
% O
Difference O
Between O
Arms O
in O
Patients O
Receiving O
CYRAMZA O
in O
Study O
4 O
a O
Includes O
3 O
patients O
with O
nephrotic B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
in O
the O
CYRAMZA O
plus O
FOLFIRI O
treatment O
group O
. O

Adverse O
Reactions O
( O
MedDRA O
) O
System O
Organ O
Class O
CYRAMZA O
plus O
FOLFIRI O
N=529 O
Placebo O
plus O
FOLFIRI O
N=528 O
All O
Grades O
( O
Frequency O
% O
) O
Grade O
> O
=3 O
( O
Frequency O
% O
) O
All O
Grades O
( O
Frequency O
% O
) O
Grade O
> O
=3 O
( O
Frequency O
% O
) O
Blood B-NonOSE_AE
and O
Lymphatic O
System O
Disorders I-NonOSE_AE
Neutropenia B-OSE_Labeled_AE
59 O
38 O
46 O
23 O
Thrombocytopenia B-OSE_Labeled_AE
28 O
3 O
14 O
< O
1 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
37 O
2 O
27 O
2 O
Diarrhea B-OSE_Labeled_AE
60 O
11 O
51 O
10 O
Gastrointestinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
events O
12 O
2 O
7 O
1 O
Stomatitis B-OSE_Labeled_AE
31 O
4 O
21 O
2 O
General O
Disorders O
and O
Administration B-NonOSE_AE
Site I-NonOSE_AE
Disorders I-NonOSE_AE
Peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
20 O
< O
1 O
9 O
0 O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
Hypoalbuminemia B-OSE_Labeled_AE
6 O
1 O
2 O
0 O
Renal B-NonOSE_AE
and O
Urinary O
Disorders I-NonOSE_AE
Proteinuria B-OSE_Labeled_AE
a O
17 O
3 O
5 O
< O
1 O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
Thoracic I-NonOSE_AE
, I-NonOSE_AE
and I-NonOSE_AE
Mediastinal I-NonOSE_AE
Disorders I-NonOSE_AE
Epistaxis B-OSE_Labeled_AE
33 O
0 O
15 O
0 O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Palmar B-OSE_Labeled_AE
- I-OSE_Labeled_AE
plantar I-OSE_Labeled_AE
erythrodysesthesia I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
13 O
1 O
5 O
< O
1 O
Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
26 O
11 O
9 O
3 O
Clinically O
relevant O
adverse O
reactions O
reported O
in O
> O
=1 O
% O
and O
< O
5 O
% O
of O
CYRAMZA O
plus O
FOLFIRI-treated O
patients O
in O
Study O
4 O
consisted O
of O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
( O
1.7 O
% O
CYRAMZA O
plus O
FOLFIRI O
versus O
0.6 O
% O
for O
placebo O
plus O
FOLFIRI O
) O
. O

Thyroid O
stimulating O
hormone O
( O
TSH O
) O
levels O
were O
evaluated O
in O
224 O
patients O
( O
115 O
CYRAMZA O
plus O
FOLFIRI-treated O
patients O
and O
109 O
placebo O
plus O
FOLFIRI-treated O
patients O
) O
with O
normal O
baseline O
TSH O
levels O
. O

Patients O
underwent O
periodic O
TSH O
laboratory O
assessments O
until O
30 O
days O
after O
the O
last O
dose O
of O
study O
treatment O
. O

Increased B-OSE_Labeled_AE
TSH I-OSE_Labeled_AE
levels O
were O
observed O
in O
53 O
( O
46 O
% O
) O
patients O
treated O
with O
CYRAMZA O
plus O
FOLFIRI O
compared O
with O
4 O
( O
4 O
% O
) O
patients O
treated O
with O
placebo O
plus O
FOLFIRI O
. O

6.2 O
Immunogenicity O
As O
with O
all O
therapeutic O
proteins O
, O
there O
is O
the O
potential O
for O
immunogenicity B-OSE_Labeled_AE
. O

In O
23 O
clinical O
trials O
, O
86/2890 O
( O
3.0 O
% O
) O
of O
CYRAMZA-treated O
patients O
tested O
positive B-OSE_Labeled_AE
for O
treatment-emergent O
anti I-OSE_Labeled_AE
- I-OSE_Labeled_AE
ramucirumab I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
by O
an O
enzyme-linked O
immunosorbent O
assay O
( O
ELISA O
) O
. O

Neutralizing B-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
were O
detected I-OSE_Labeled_AE
in O
14 O
of O
the O
86 O
patients O
who O
tested O
positive O
for O
treatment-emergent O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
ramucirumab I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
. O

The O
detection O
of O
antibody B-NonOSE_AE
formation I-NonOSE_AE
is O
highly O
dependent O
on O
the O
sensitivity O
and O
specificity O
of O
the O
assay O
. O

Additionally O
, O
the O
observed O
incidence O
of O
antibody B-NonOSE_AE
( O
including O
neutralizing O
antibody O
) O
positivity I-NonOSE_AE
in O
an O
assay O
may O
be O
influenced O
by O
several O
factors O
including O
assay O
methodology O
, O
sample O
handling O
, O
timing O
of O
sample O
collection O
, O
concomitant O
medications O
, O
and O
underlying O
disease O
. O

For O
these O
reasons O
, O
comparison O
of O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
CYRAMZA I-NonOSE_AE
with O
the O
incidences O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
other I-NonOSE_AE
products I-NonOSE_AE
may O
be O
misleading O
. O

BOXED O
WARNING O
: O
WARNING O
: O
HEMORRHAGE O
, O
GASTROINTESTINAL O
PERFORATION O
, O
AND O
IMPAIRED O
WOUND O
HEALING O
WARNING O
: O
HEMORRHAGE O
, O
GASTROINTESTINAL O
PERFORATION O
, O
AND O
IMPAIRED O
WOUND O
HEALING O
Hemorrhage B-NonOSE_AE
: O
CYRAMZA O
increased O
the O
risk O
of O
hemorrhage B-OSE_Labeled_AE
and O
gastrointestinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
including O
severe O
and O
sometimes O
fatal B-NonOSE_AE
hemorrhagic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
. O

Permanently O
discontinue O
CYRAMZA O
in O
patients O
who O
experience O
severe O
bleeding B-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
, O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

Gastrointestinal B-NonOSE_AE
Perforation I-NonOSE_AE
: O
CYRAMZA O
can O
increase O
the O
risk O
of O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
, O
a O
potentially O
fatal B-NonOSE_AE
event O
. O

Permanently O
discontinue O
CYRAMZA O
in O
patients O
who O
experience O
a O
gastrointestinal B-NonOSE_AE
perforation I-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
, O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
. O

Impaired B-NonOSE_AE
Wound I-NonOSE_AE
Healing I-NonOSE_AE
: O
Impaired B-OSE_Labeled_AE
wound I-OSE_Labeled_AE
healing I-OSE_Labeled_AE
can O
occur O
with O
antibodies O
inhibiting O
the O
VEGF O
pathway O
. O

Discontinue O
CYRAMZA O
therapy O
in O
patients O
with O
impaired B-NonOSE_AE
wound I-NonOSE_AE
healing I-NonOSE_AE
. O

Withhold O
CYRAMZA O
prior O
to O
surgery O
and O
discontinue O
CYRAMZA O
if O
a O
patient O
develops O
wound B-NonOSE_AE
healing I-NonOSE_AE
complications I-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
, O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
. O

EXCERPT O
: O
WARNING O
: O
HEMORRHAGE O
, O
GASTROINTESTINAL O
PERFORATION O
, O
AND O
IMPAIRED O
WOUND O
HEALING O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
Hemorrhage O
: O
CYRAMZA O
increased O
the O
risk O
of O
hemorrhage O
, O
and O
gastrointestinal O
hemorrhage O
, O
including O
severe O
and O
sometimes O
fatal O
hemorrhagic O
events O
. O

Permanently O
discontinue O
CYRAMZA O
in O
patients O
who O
experience O
severe O
bleeding O
. O

( O
2.3 O
, O
5.1 O
) O
* O
Gastrointestinal O
Perforation O
: O
Permanently O
discontinue O
CYRAMZA O
in O
patients O
who O
experience O
a O
gastrointestinal O
perforation O
. O

( O
2.3 O
, O
5.5 O
) O
* O
Impaired O
Wound O
Healing O
: O
Withhold O
CYRAMZA O
prior O
to O
surgery O
and O
discontinue O
CYRAMZA O
if O
a O
patient O
develops O
wound O
healing O
complications O
( O
2.3 O
, O
5.6 O
) O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Arterial O
Thromboembolic O
Events O
( O
ATEs O
) O
: O
Serious O
, O
sometimes O
fatal O
ATEs O
have O
been O
reported O
in O
clinical O
trials O
. O

Discontinue O
CYRAMZA O
for O
severe O
ATEs O
. O

( O
5.2 O
) O
* O
Hypertension O
: O
Monitor O
blood O
pressure O
and O
treat O
hypertension O
. O

Temporarily O
suspend O
CYRAMZA O
for O
severe O
hypertension O
. O

Discontinue O
CYRAMZA O
for O
hypertension O
that O
can O
not O
be O
medically O
controlled O
. O

( O
5.3 O
) O
* O
Infusion-Related O
Reactions O
: O
Monitor O
for O
signs O
and O
symptoms O
during O
infusion O
. O

( O
5.4 O
) O
* O
Impaired O
Wound O
Healing O
: O
Withhold O
CYRAMZA O
prior O
to O
surgery O
. O

( O
5.6 O
) O
* O
Clinical O
Deterioration O
in O
Patients O
with O
Cirrhosis O
: O
New O
onset O
or O
worsening O
encephalopathy O
, O
ascites O
, O
or O
hepatorenal O
syndrome O
can O
occur O
in O
patients O
with O
Child-Pugh O
B O
or O
C O
cirrhosis O
. O

( O
5.7 O
) O
* O
Reversible O
Posterior O
Leukoencephalopathy O
Syndrome O
: O
Discontinue O
CYRAMZA O
. O

( O
5.8 O
) O
* O
Proteinuria O
Including O
Nephrotic O
Syndrome O
: O
Monitor O
proteinuria O
. O

Interrupt O
CYRAMZA O
for O
urine O
protein O
levels O
> O
=2 O
g/24 O
hours O
. O

Permanently O
discontinue O
CYRAMZA O
for O
urine O
protein O
levels O
> O
3 O
g/24 O
hours O
or O
for O
nephrotic O
syndrome O
. O

( O
5.9 O
) O
* O
Thyroid O
Dysfunction O
: O
Monitor O
thyroid O
function O
during O
treatment O
with O
CYRAMZA O
. O

( O
5.10 O
) O
* O
Embryofetal O
Risk O
: O
Can O
cause O
fetal O
harm O
. O

( O
5.11 O
) O
5.1 O
Hemorrhage O
CYRAMZA O
increased O
the O
risk O
of O
hemorrhage B-OSE_Labeled_AE
and O
gastrointestinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
including O
severe O
and O
sometimes O
fatal B-NonOSE_AE
hemorrhagic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
. O

In O
Study O
1 O
, O
the O
incidence O
of O
severe O
bleeding B-OSE_Labeled_AE
was O
3.4 O
% O
for O
CYRAMZA O
and O
2.6 O
% O
for O
placebo O
. O

In O
Study O
2 O
, O
the O
incidence O
of O
severe O
bleeding B-OSE_Labeled_AE
was O
4.3 O
% O
for O
CYRAMZA O
plus O
paclitaxel O
and O
2.4 O
% O
for O
placebo O
plus O
paclitaxel O
. O

Patients O
with O
gastric B-Not_AE_Candidate
cancer I-Not_AE_Candidate
receiving O
nonsteroidal O
anti-inflammatory O
drugs O
( O
NSAIDs O
) O
were O
excluded O
from O
enrollment O
in O
Studies O
1 O
and O
2 O
; O
therefore O
, O
the O
risk O
of O
gastric B-NonOSE_AE
hemorrhage I-NonOSE_AE
in O
CYRAMZA-treated O
patients O
with O
gastric B-Not_AE_Candidate
tumors I-Not_AE_Candidate
receiving O
NSAIDs O
is O
unknown O
. O

In O
Study O
3 O
, O
the O
incidence O
of O
severe O
bleeding B-OSE_Labeled_AE
was O
2.4 O
% O
for O
CYRAMZA O
plus O
docetaxel O
and O
2.3 O
% O
for O
placebo O
plus O
docetaxel O
. O

Patients O
with O
NSCLC B-Not_AE_Candidate
receiving O
therapeutic O
anticoagulation O
or O
chronic O
therapy O
with O
NSAIDS O
or O
other O
anti-platelet O
therapy O
other O
than O
once O
daily O
aspirin O
or O
with O
radiographic O
evidence O
of O
major B-Not_AE_Candidate
airway I-Not_AE_Candidate
or O
blood O
vessel O
invasion I-Not_AE_Candidate
or O
intratumor B-Not_AE_Candidate
cavitation I-Not_AE_Candidate
were O
excluded O
from O
Study O
3 O
; O
therefore O
the O
risk O
of O
pulmonary B-NonOSE_AE
hemorrhage I-NonOSE_AE
in O
these O
groups O
of O
patients O
is O
unknown O
. O

In O
Study O
4 O
, O
the O
incidence O
of O
severe O
bleeding B-OSE_Labeled_AE
was O
2.5 O
% O
for O
CYRAMZA O
plus O
FOLFIRI O
and O
1.7 O
% O
for O
placebo O
plus O
FOLFIRI O
. O

Permanently O
discontinue O
CYRAMZA O
in O
patients O
who O
experience O
severe O
bleeding B-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

5.2 O
Arterial O
Thromboembolic O
Events O
Serious O
, O
sometimes O
fatal B-NonOSE_AE
, O
arterial B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ATEs I-OSE_Labeled_AE
) I-OSE_Labeled_AE
including O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
, O
cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
, O
and O
cerebral B-OSE_Labeled_AE
ischemia I-OSE_Labeled_AE
occurred O
in O
clinical O
trials O
including O
1.7 O
% O
of O
236 O
patients O
who O
received O
CYRAMZA O
as O
a O
single O
agent O
for O
gastric B-Not_AE_Candidate
cancer I-Not_AE_Candidate
in O
Study O
1 O
. O

Permanently O
discontinue O
CYRAMZA O
in O
patients O
who O
experience O
a O
severe O
ATE B-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

5.3 O
Hypertension O
An O
increased O
incidence O
of O
severe O
hypertension B-OSE_Labeled_AE
occurred O
in O
patients O
receiving O
CYRAMZA O
as O
a O
single O
agent O
( O
8 O
% O
) O
as O
compared O
to O
placebo O
( O
3 O
% O
) O
, O
in O
patients O
receiving O
CYRAMZA O
plus O
paclitaxel O
( O
15 O
% O
) O
as O
compared O
to O
placebo O
plus O
paclitaxel O
( O
3 O
% O
) O
, O
in O
patients O
receiving O
CYRAMZA O
plus O
docetaxel O
( O
6 O
% O
) O
as O
compared O
to O
placebo O
plus O
docetaxel O
( O
2 O
% O
) O
, O
and O
in O
patients O
receiving O
CYRAMZA O
plus O
FOLFIRI O
( O
11 O
% O
) O
as O
compared O
to O
placebo O
plus O
FOLFIRI O
( O
3 O
% O
) O
. O

Control O
hypertension B-Not_AE_Candidate
prior O
to O
initiating O
treatment O
with O
CYRAMZA O
. O

Monitor O
blood O
pressure O
every O
two O
weeks O
or O
more O
frequently O
as O
indicated O
during O
treatment O
. O

Temporarily O
suspend O
CYRAMZA O
for O
severe O
hypertension B-NonOSE_AE
until O
medically O
controlled O
. O

Permanently O
discontinue O
CYRAMZA O
if O
medically O
significant O
hypertension B-NonOSE_AE
can O
not O
be O
controlled O
with O
antihypertensive B-NonOSE_AE
therapy I-NonOSE_AE
or O
in O
patients O
with O
hypertensive B-NonOSE_AE
crisis I-NonOSE_AE
or O
hypertensive B-NonOSE_AE
encephalopathy I-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

5.4 O
Infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Related I-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
Prior O
to O
the O
institution O
of O
premedication O
recommendations O
across O
clinical O
trials O
of O
CYRAMZA O
, O
IRRs B-OSE_Labeled_AE
occurred O
in O
6 O
out O
of O
37 O
patients O
( O
16 O
% O
) O
, O
including O
two O
severe O
events O
. O

The O
majority O
of O
IRRs B-OSE_Labeled_AE
across O
trials O
occurred O
during O
or O
following O
a O
first O
or O
second O
CYRAMZA O
infusion O
. O

Symptoms O
of O
IRRs B-NonOSE_AE
included O
rigors B-NonOSE_AE
/ O
tremors B-NonOSE_AE
, O
back B-NonOSE_AE
pain I-NonOSE_AE
/spasms O
, O
chest B-NonOSE_AE
pain I-NonOSE_AE
and/or O
tightness O
, O
chills B-NonOSE_AE
, O
flushing B-NonOSE_AE
, O
dyspnea B-NonOSE_AE
, O
wheezing B-NonOSE_AE
, O
hypoxia B-NonOSE_AE
, O
and O
paresthesia B-NonOSE_AE
. O

In O
severe O
cases O
, O
symptoms O
included O
bronchospasm B-NonOSE_AE
, O
supraventricular B-NonOSE_AE
tachycardia I-NonOSE_AE
, O
and O
hypotension B-NonOSE_AE
. O

Monitor O
patients O
during O
the O
infusion O
for O
signs O
and O
symptoms O
of O
IRRs B-NonOSE_AE
in O
a O
setting O
with O
available O
resuscitation O
equipment O
. O

Immediately O
and O
permanently O
discontinue O
CYRAMZA O
for O
Grade O
3 O
or O
4 O
IRRs B-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

5.5 O
Gastrointestinal O
Perforations O
CYRAMZA O
is O
an O
antiangiogenic O
therapy O
that O
can O
increase O
the O
risk O
of O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
, O
a O
potentially O
fatal O
event O
. O

Four O
of O
570 O
patients O
( O
0.7 O
% O
) O
who O
received O
CYRAMZA O
as O
a O
single O
agent O
in O
clinical O
trials O
experienced O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
. O

In O
Study O
2 O
, O
the O
incidence O
of O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
was O
also O
increased O
in O
patients O
that O
received O
CYRAMZA O
plus O
paclitaxel O
( O
1.2 O
% O
) O
as O
compared O
to O
patients O
receiving O
placebo O
plus O
paclitaxel O
( O
0.3 O
% O
) O
. O

In O
Study O
3 O
, O
the O
incidence O
of O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
was O
1 O
% O
for O
CYRAMZA O
plus O
docetaxel O
and O
0.3 O
% O
for O
placebo O
plus O
docetaxel O
. O

In O
Study O
4 O
, O
the O
incidence O
of O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
was O
1.7 O
% O
for O
CYRAMZA O
plus O
FOLFIRI O
and O
0.6 O
% O
for O
placebo O
plus O
FOLFIRI O
. O

Permanently O
discontinue O
CYRAMZA O
in O
patients O
who O
experience O
a O
gastrointestinal B-NonOSE_AE
perforation I-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

5.6 O
Impaired O
Wound O
Healing O
Impaired B-OSE_Labeled_AE
wound I-OSE_Labeled_AE
healing I-OSE_Labeled_AE
can O
occur O
with O
antibodies O
inhibiting O
the O
VEGF O
pathway O
. O

CYRAMZA O
has O
not O
been O
studied O
in O
patients O
with O
serious O
or O
non-healing O
wounds O
. O

CYRAMZA O
, O
an O
antiangiogenic O
therapy O
, O
has O
the O
potential O
to O
adversely B-NonOSE_AE
affect I-NonOSE_AE
wound I-NonOSE_AE
healing I-NonOSE_AE
. O

Discontinue O
CYRAMZA O
therapy O
in O
patients O
with O
impaired B-NonOSE_AE
wound I-NonOSE_AE
healing I-NonOSE_AE
. O

Withhold O
CYRAMZA O
prior O
to O
surgery O
. O

Resume O
following O
the O
surgical O
intervention O
based O
on O
clinical O
judgment O
of O
adequate O
wound O
healing O
. O

If O
a O
patient O
develops O
wound B-NonOSE_AE
healing I-NonOSE_AE
complications I-NonOSE_AE
during O
therapy O
, O
discontinue O
CYRAMZA O
until O
the O
wound O
is O
fully O
healed O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

5.7 O
Clinical O
Deterioration O
in O
Patients O
with O
Child-Pugh O
B O
or O
C O
Cirrhosis O
Clinical O
deterioration B-OSE_Labeled_AE
, O
manifested O
by O
new O
onset O
or O
worsening O
encephalopathy O
, O
ascites O
, O
or O
hepatorenal O
syndrome O
was O
reported O
in O
patients O
with O
Child I-OSE_Lab
eled B-NonOSE_AE
_ I-NonOSE_AE
AE I-NonOSE_AE
- I-NonOSE_AE
  I-NonOSE_AE
I I-NonOSE_AE
- I-NonOSE_AE
O I-NonOSE_AE
SE O
_ B-NonOSE_AE
Labele I-NonOSE_AE
d_AE O
Pug B-NonOSE_AE
h I-NonOSE_AE
  I-NonOSE_AE
I I-NonOSE_AE
-OS I-NonOSE_AE
E I-NonOSE_AE
_Labele I-NonOSE_AE
d I-NonOSE_AE
_AE O
B I-OSE_Labeled_AE
or O
C O
cirrhosis I-OSE_Labeled_AE
who O
received O
single-agent O
CYRAMZA O
. O

Use O
CYRAMZA O
in O
patients O
with O
Child B-Not_AE_Candidate
- I-Not_AE_Candidate
Pugh I-Not_AE_Candidate
B I-Not_AE_Candidate
or O
C O
cirrhosis I-Not_AE_Candidate
only O
if O
the O
potential O
benefits O
of O
treatment O
are O
judged O
to O
outweigh O
the O
risks O
of O
clinical O
deterioration O
. O

5.8 O
Reversible O
Posterior O
Leukoencephalopathy O
Syndrome O
Reversible B-OSE_Labeled_AE
Posterior I-OSE_Labeled_AE
Leukoencephalopathy I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
RPLS I-OSE_Labeled_AE
) O
has O
been O
reported O
with O
a O
rate O
of O
< O
0.1 O
% O
in O
clinical O
studies O
with O
CYRAMZA O
. O

Confirm O
the O
diagnosis O
of O
RPLS B-NonOSE_AE
with O
MRI O
and O
discontinue O
CYRAMZA O
in O
patients O
who O
develop O
RPLS B-NonOSE_AE
. O

Symptoms O
may O
resolve O
or O
improve O
within O
days O
, O
although O
some O
patients O
with O
RPLS B-NonOSE_AE
can O
experience O
ongoing O
neurologic B-NonOSE_AE
sequelae I-NonOSE_AE
or O
death B-NonOSE_AE
. O

5.9 O
Proteinuria O
Including O
Nephrotic O
Syndrome O
In O
Study O
4 O
, O
severe O
proteinuria B-OSE_Labeled_AE
occurred O
more O
frequently O
in O
patients O
treated O
with O
CYRAMZA O
plus O
FOLFIRI O
compared O
to O
patients O
receiving O
placebo O
plus O
FOLFIRI O
. O

Severe O
proteinuria B-OSE_Labeled_AE
was O
reported O
in O
3 O
% O
of O
patients O
treated O
with O
CYRAMZA O
plus O
FOLFIRI O
( O
including O
3 O
cases O
[ O
0.6 O
% O
] O
of O
nephrotic B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
) O
compared O
to O
0.2 O
% O
of O
patients O
treated O
with O
placebo O
plus O
FOLFIRI O
. O

Monitor O
proteinuria B-NonOSE_AE
by O
urine O
dipstick O
and/or O
urinary O
protein O
creatinine O
ratio O
for O
the O
development O
of O
worsening O
of O
proteinuria B-NonOSE_AE
during O
CYRAMZA O
therapy O
. O

Withhold O
CYRAMZA O
for O
urine O
protein O
levels O
that O
are O
2 O
or O
more O
grams O
over O
24 O
hours O
. O

Reinitiate O
CYRAMZA O
at O
a O
reduced O
dose O
once O
the O
urine O
protein O
level O
returns O
to O
less O
than O
2 O
grams O
over O
24 O
hours O
. O

Permanently O
discontinue O
CYRAMZA O
for O
urine O
protein O
levels O
greater O
than O
3 O
grams O
over O
24 O
hours O
or O
in O
the O
setting O
of O
nephrotic B-NonOSE_AE
syndrome I-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

5.10 O
Thyroid O
Dysfunction O
Monitor O
thyroid O
function O
during O
treatment O
with O
CYRAMZA O
. O

In O
Study O
4 O
, O
the O
incidence O
of O
hypothyroidism B-OSE_Labeled_AE
reported O
as O
an O
adverse O
event O
was O
2.6 O
% O
in O
the O
CYRAMZA O
plus O
FOLFIRI O
treated O
patients O
and O
0.9 O
% O
in O
the O
placebo O
plus O
FOLFIRI O
treated O
patients O
. O

5.11 O
Embryofetal B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
Based O
on O
its O
mechanism O
of O
action O
, O
CYRAMZA O
can O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
when O
administered O
to O
pregnant B-Not_AE_Candidate
women O
. O

Animal O
models O
link O
angiogenesis O
, O
VEGF O
and O
VEGF O
Receptor O
2 O
( O
VEGFR2 O
) O
to O
critical O
aspects O
of O
female O
reproduction O
, O
embryofetal O
development O
, O
and O
postnatal O
development O
. O

Advise O
pregnant B-Not_AE_Candidate
women O
of O
the O
potential O
risk B-OSE_Labeled_AE
to I-OSE_Labeled_AE
a I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
. O

Advise O
females O
of O
reproductive O
potential O
to O
use O
effective O
contraception O
during O
treatment O
with O
CYRAMZA O
and O
for O
at O
3 O
least O
months O
after O
the O
last O
dose O
of O
CYRAMZA O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.1 O
, O
8.3 O
) O
] O
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
serious O
adverse O
reactions O
are O
described O
below O
and O
elsewhere O
in O
the O
labeling O
: O
* O
Bone B-OSE_Labeled_AE
Marrow I-OSE_Labeled_AE
Suppression I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Mucositis B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Dermatologic B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Tumor B-OSE_Labeled_AE
Lysis I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Hepatic B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
The O
most O
common O
adverse O
reactions O
observed O
in O
patients O
with O
peripheral B-Not_AE_Candidate
T I-Not_AE_Candidate
- I-Not_AE_Candidate
cell I-Not_AE_Candidate
lymphoma I-Not_AE_Candidate
( O
PTCL O
) O
treated O
with O
FOLOTYN O
were O
mucositis B-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
and O
fatigue B-OSE_Labeled_AE
. O

EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
> O
35 O
% O
) O
are O
mucositis O
, O
thrombocytopenia O
, O
nausea O
, O
and O
fatigue O
. O

Most O
common O
serious O
adverse O
reactions O
are O
pyrexia O
, O
mucositis O
, O
sepsis O
, O
febrile O
neutropenia O
, O
dehydration O
, O
dyspnea O
, O
and O
thrombocytopenia O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Allos O
Therapeutics O
, O
Inc O
at O
1-888-ALLOS88 O
( O
1-888-255-6788 O
) O
or O
www.FOLOTYN.com O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
studies O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
studies O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
studies O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

The O
safety O
of O
FOLOTYN O
was O
evaluated O
in O
111 O
PTCL B-Not_AE_Candidate
patients O
in O
a O
single-arm O
clinical O
study O
in O
which O
patients O
received O
a O
starting O
dose O
of O
30 O
mg/m O
2 O
once O
weekly O
for O
6 O
weeks O
in O
7-week O
cycles O
. O

The O
median O
duration O
of O
treatment O
was O
70 O
days O
( O
range O
1-540 O
days O
) O
. O

Most O
Frequent O
Adverse O
Reactions O
Table O
4 O
summarizes O
the O
most O
frequent O
adverse O
reactions O
, O
regardless O
of O
causality O
, O
using O
the O
National O
Cancer O
Institute-Common O
Terminology O
Criteria O
for O
Adverse O
Events O
( O
NCI O
CTCAE O
, O
version O
3.0 O
) O
. O

Table O
4 O
Adverse O
Reactions O
Occurring O
in O
PTCL O
Patients O
( O
Incidence O
> O
= O
10 O
% O
of O
patients O
) O
N=111 O
Total O
Grade O
3 O
Grade O
4 O
Preferred O
Term O
N O
% O
N O
% O
N O
% O
a O
Stomatitis B-OSE_Labeled_AE
or O
mucosal B-OSE_Labeled_AE
inflammation I-OSE_Labeled_AE
of I-OSE_Labeled_AE
the O
gastrointestinal I-OSE_Labeled_AE
and O
genitourinary O
tracts I-OSE_Labeled_AE
. O

bFive O
patients O
with O
platelets B-OSE_Labeled_AE
< I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
, I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
mcL I-OSE_Labeled_AE
c O
Alanine B-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
, O
aspartate O
aminotransferase O
, O
and O
transaminases O
increased I-OSE_Labeled_AE
Any O
Adverse O
Event O
111 O
100 O
48 O
43 O
34 O
31 O
Mucositis B-OSE_Labeled_AE
a O
78 O
70 O
19 O
17 O
4 O
4 O
Thrombocytopenia B-OSE_Labeled_AE
b O
45 O
41 O
15 O
14 O
21 O
19 O
b O
Nausea B-OSE_Labeled_AE
44 O
40 O
4 O
4 O
0 O
0 O
Fatigue B-OSE_Labeled_AE
40 O
36 O
5 O
5 O
2 O
2 O
Anemia B-OSE_Labeled_AE
38 O
34 O
17 O
15 O
2 O
2 O
Constipation B-OSE_Labeled_AE
37 O
33 O
0 O
0 O
0 O
0 O
Pyrexia B-OSE_Labeled_AE
36 O
32 O
1 O
1 O
1 O
1 O
Edema B-OSE_Labeled_AE
33 O
30 O
1 O
1 O
0 O
0 O
Cough B-OSE_Labeled_AE
31 O
28 O
1 O
1 O
0 O
0 O
Epistaxis B-OSE_Labeled_AE
29 O
26 O
0 O
0 O
0 O
0 O
Vomiting B-OSE_Labeled_AE
28 O
25 O
2 O
2 O
0 O
0 O
Neutropenia B-OSE_Labeled_AE
27 O
24 O
14 O
13 O
8 O
7 O
Diarrhea B-OSE_Labeled_AE
23 O
21 O
2 O
2 O
0 O
0 O
Dyspnea B-OSE_Labeled_AE
21 O
19 O
8 O
7 O
0 O
0 O
Anorexia B-OSE_Labeled_AE
17 O
15 O
3 O
3 O
0 O
0 O
Hypokalemia B-OSE_Labeled_AE
17 O
15 O
4 O
4 O
1 O
1 O
Rash B-OSE_Labeled_AE
17 O
15 O
0 O
0 O
0 O
0 O
Pruritus B-OSE_Labeled_AE
16 O
14 O
2 O
2 O
0 O
0 O
Pharyngolaryngeal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
15 O
14 O
1 O
1 O
0 O
0 O
Liver B-OSE_Labeled_AE
function I-OSE_Labeled_AE
test I-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
c O
14 O
13 O
6 O
5 O
0 O
0 O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
13 O
12 O
4 O
4 O
0 O
0 O
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
13 O
12 O
0 O
0 O
0 O
0 O
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
12 O
11 O
3 O
3 O
0 O
0 O
Leukopenia B-OSE_Labeled_AE
12 O
11 O
3 O
3 O
4 O
4 O
Night B-OSE_Labeled_AE
sweats I-OSE_Labeled_AE
12 O
11 O
0 O
0 O
0 O
0 O
Asthenia B-OSE_Labeled_AE
11 O
10 O
1 O
1 O
0 O
0 O
Tachycardia B-OSE_Labeled_AE
11 O
10 O
0 O
0 O
0 O
0 O
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
11 O
10 O
1 O
1 O
0 O
0 O
Serious O
Adverse O
Events O
Forty-four O
percent O
of O
patients O
( O
n O
= O
49 O
) O
experienced O
a O
serious O
adverse O
event O
while O
on O
study O
or O
within O
30 O
days O
after O
their O
last O
dose O
of O
FOLOTYN O
. O

The O
most O
common O
serious O
adverse O
events O
( O
> O
3 O
% O
) O
, O
regardless O
of O
causality O
, O
were O
pyrexia B-OSE_Labeled_AE
, O
mucositis B-OSE_Labeled_AE
, O
sepsis B-OSE_Labeled_AE
, O
febrile B-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
, O
dehydration B-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
and O
thrombocytopenia B-OSE_Labeled_AE
. O

One O
death B-NonOSE_AE
from O
cardiopulmonary B-NonOSE_AE
arrest I-NonOSE_AE
in O
a O
patient O
with O
mucositis B-NonOSE_AE
and O
febrile B-NonOSE_AE
neutropenia I-NonOSE_AE
was O
reported O
in O
this O
trial O
. O

Deaths B-NonOSE_AE
from O
mucositis B-NonOSE_AE
, O
febrile B-NonOSE_AE
neutropenia I-NonOSE_AE
, O
sepsis B-NonOSE_AE
, O
and O
pancytopenia B-NonOSE_AE
occurred O
in O
1.2 O
% O
of O
patients O
treated O
on O
all O
FOLOTYN O
trials O
at O
doses O
ranging O
from O
30 O
to O
325 O
mg/m O
2 O
. O

Discontinuations O
Twenty-three O
percent O
of O
patients O
( O
n O
= O
25 O
) O
discontinued O
treatment O
with O
FOLOTYN O
due O
to O
adverse O
reactions O
. O

The O
adverse O
reactions O
reported O
most O
frequently O
as O
the O
reason O
for O
discontinuation O
of O
treatment O
were O
mucositis B-OSE_Labeled_AE
( O
6 O
% O
, O
n O
= O
7 O
) O
and O
thrombocytopenia B-OSE_Labeled_AE
( O
5 O
% O
, O
n O
= O
5 O
) O
. O

Dose O
Modifications O
The O
target O
dose O
of O
FOLOTYN O
was O
30 O
mg/m O
2 O
once O
weekly O
for O
6 O
weeks O
in O
7-week O
cycles O
. O

The O
majority O
of O
patients O
( O
69 O
% O
, O
n O
= O
77 O
) O
remained O
at O
the O
target O
dose O
for O
the O
duration O
of O
treatment O
. O

Overall O
, O
85 O
% O
of O
scheduled O
doses O
were O
administered O
. O

6.2 O
Post O
Marketing O
Experience O
Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Dermatologic O
Reactions O
Toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
, O
sometimes O
fatal B-NonOSE_AE
, O
has O
been O
reported O
during O
post-marketing O
use O
of O
FOLOTYN O
. O

Fatal B-NonOSE_AE
cases O
have O
been O
reported O
following O
the O
first O
dose O
of O
FOLOTYN O
, O
including O
when O
a O
reduced O
dose O
is O
given O
, O
and O
have O
been O
reported O
in O
patients O
with O
end B-Not_AE_Candidate
- I-Not_AE_Candidate
stage I-Not_AE_Candidate
renal I-Not_AE_Candidate
disease I-Not_AE_Candidate
undergoing O
dialysis O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
, O
Use O
in O
Specific O
Populations O
( O
8.7 O
) O
, O
and O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Thrombocytopenia O
, O
neutropenia O
, O
and O
anemia O
: O
Monitor O
blood O
counts O
and O
omit O
and/or O
reduce O
dose O
for O
hematologic O
toxicities O
. O

( O
2.2 O
, O
5.1 O
) O
* O
Mucositis O
: O
Monitor O
at O
least O
weekly O
. O

If O
> O
= O
Grade O
2 O
mucositis O
is O
observed O
, O
omit O
and/or O
reduce O
dose O
. O

( O
2.2 O
, O
5.2 O
) O
* O
Dermatologic O
reactions O
: O
Reactions O
, O
including O
fatal O
reactions O
, O
have O
occurred O
and O
may O
be O
progressive O
and O
increase O
in O
severity O
with O
further O
treatment O
. O

Monitor O
closely O
, O
and O
omit O
and/or O
reduce O
dose O
or O
discontinue O
FOLOTYN O
. O

( O
2.2 O
, O
5.3 O
) O
* O
Tumor O
lysis O
syndrome O
: O
Anticipate O
, O
monitor O
, O
and O
treat O
promptly O
. O

( O
5.4 O
) O
* O
Hepatic O
toxicity O
: O
Monitor O
for O
toxicity O
. O

For O
liver O
function O
test O
abnormalities O
Grade O
3 O
or O
greater O
, O
omit O
until O
recovery O
then O
reduce O
dose O
or O
discontinue O
therapy O
as O
required O
. O

( O
2.2 O
, O
5.5 O
) O
* O
Risk O
of O
increased O
toxicity O
with O
renal O
impairment O
: O
Patients O
with O
moderate O
to O
severe O
renal O
function O
impairment O
may O
be O
at O
greater O
risk O
for O
increased O
exposure O
and O
toxicity O
. O

Monitor O
patients O
for O
renal O
function O
and O
systemic O
toxicity O
and O
adjust O
dosing O
accordingly O
. O

Avoid O
FOLOTYN O
use O
in O
patients O
with O
end O
stage O
renal O
disease O
including O
those O
undergoing O
dialysis O
unless O
the O
potential O
benefit O
justifies O
the O
potential O
risk O
. O

( O
2.2 O
, O
5.6 O
, O
6.2 O
) O
* O
Embryo-Fetal O
toxicity O
: O
Women O
should O
avoid O
becoming O
pregnant O
while O
being O
treated O
with O
FOLOTYN O
. O

Inform O
pregnant O
women O
of O
the O
potential O
harm O
to O
the O
fetus O
. O

( O
5.7 O
, O
8.1 O
) O
5.1 O
Bone O
Marrow O
Suppression O
FOLOTYN O
can O
cause O
bone B-OSE_Labeled_AE
marrow I-OSE_Labeled_AE
suppression I-OSE_Labeled_AE
, O
manifested O
by O
thrombocytopenia B-NonOSE_AE
, O
neutropenia B-NonOSE_AE
, O
and/or O
anemia B-NonOSE_AE
. O

Monitor O
complete O
blood O
counts O
and O
omit O
and/or O
reduce O
the O
dose O
based O
on O
ANC O
and O
platelet O
count O
prior O
to O
each O
dose O
as O
outlined O
in O
Section O
2.2 O
Table O
2 O
. O

Administer O
vitamin O
B12and O
instruct O
patients O
to O
take O
folic O
acid O
to O
reduce O
the O
risk O
of O
treatment-related O
hematological B-NonOSE_AE
toxicity I-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.1 O
) O
( O
2.2 O
) O
and O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.2 O
Mucositis O
FOLOTYN O
can O
cause O
mucositis B-OSE_Labeled_AE
. O

Monitor O
for O
mucositis B-NonOSE_AE
weekly O
and O
if O
> O
= O
Grade O
2 O
mucositis B-NonOSE_AE
is O
observed O
, O
omit O
and/or O
reduce O
the O
dose O
as O
outlined O
in O
Section O
2.2 O
Table O
1 O
. O

Administer O
vitamin O
B12and O
instruct O
patients O
to O
take O
folic O
acid O
to O
reduce O
the O
risk O
of O
mucositis B-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.1 O
) O
( O
2.2 O
) O
and O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.3 O
Dermatologic O
Reactions O
FOLOTYN O
can O
cause O
severe O
dermatologic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
which O
may O
result O
in O
death B-NonOSE_AE
. O

These O
dermatologic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
have O
been O
reported O
in O
clinical O
studies O
( O
14/663 O
patients O
[ O
2.1 O
% O
] O
) O
and O
post O
marketing O
experience O
, O
and O
have O
included O
skin B-OSE_Labeled_AE
exfoliation I-OSE_Labeled_AE
, O
ulceration O
, O
and O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
( O
TEN O
) O
. O

They O
may O
be O
progressive O
and O
increase O
in O
severity O
with O
further O
treatment O
, O
and O
may O
involve O
skin O
and O
subcutaneous O
sites O
of O
known O
lymphoma B-Not_AE_Candidate
. O

Monitor O
patients O
with O
dermatologic B-NonOSE_AE
reactions I-NonOSE_AE
closely O
, O
and O
if O
severe O
, O
withhold O
or O
discontinue O
FOLOTYN O
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
and O
Use O
in O
Specific O
Populations O
( O
8.7 O
) O
] O
. O

5.4 O
Tumor O
Lysis O
Syndrome O
FOLOTYN O
can O
cause O
tumor B-OSE_Labeled_AE
lysis I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( O
TLS O
) O
. O

Monitor O
patients O
who O
are O
at O
increased O
risk O
of O
TLS B-NonOSE_AE
and O
treat O
promptly O
. O

5.5 O
Hepatic O
Toxicity O
FOLOTYN O
can O
cause O
hepatic B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
and O
liver B-OSE_Labeled_AE
function I-OSE_Labeled_AE
test I-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
. O

Persistent O
liver B-NonOSE_AE
function I-NonOSE_AE
test I-NonOSE_AE
abnormalities I-NonOSE_AE
may O
be O
indicators O
of O
hepatic B-NonOSE_AE
toxicity I-NonOSE_AE
and O
require O
dose O
modification O
or O
discontinuation O
. O

Monitor O
liver O
function O
tests O
. O

Omit O
dose O
until O
recovery O
, O
adjust O
or O
discontinue O
therapy O
based O
on O
the O
severity O
of O
the O
hepatic B-NonOSE_AE
toxicity I-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
and O
Use O
in O
Specific O
Populations O
( O
8.6 O
) O
] O
. O

5.6 O
Risk O
of O
Increased O
Toxicity O
in O
the O
Presence O
of O
Impaired O
Renal O
Function O
Patients O
with O
moderate O
to O
severe O
renal B-Not_AE_Candidate
function I-Not_AE_Candidate
impairment I-Not_AE_Candidate
may O
be O
at O
greater O
risk O
for O
increased O
exposure O
and O
toxicity O
. O

Monitor O
patients O
for O
renal O
function O
and O
systemic O
toxicity O
and O
adjust O
dosing O
accordingly O
. O

Serious O
adverse O
drug O
reactions O
including O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
and O
mucositis B-OSE_Labeled_AE
were O
reported O
in O
patients O
with O
end B-Not_AE_Candidate
stage I-Not_AE_Candidate
renal I-Not_AE_Candidate
disease I-Not_AE_Candidate
( O
ESRD O
) O
undergoing O
dialysis O
who O
were O
administered O
FOLOTYN O
therapy O
. O

Avoid O
FOLOTYN O
use O
in O
patients O
with O
end B-Not_AE_Candidate
stage I-Not_AE_Candidate
renal I-Not_AE_Candidate
disease I-Not_AE_Candidate
including O
those O
undergoing O
dialysis O
unless O
the O
potential O
benefit O
justifies O
the O
potential O
risk O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
, O
Adverse O
Reactions O
( O
6.2 O
) O
, O
Use O
in O
Specific O
Populations O
( O
8.7 O
) O
, O
and O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

5.7 O
Embryo B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Fetal I-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
FOLOTYN O
can O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
when O
administered O
to O
a O
pregnant B-Not_AE_Candidate
woman O
. O

FOLOTYN O
was O
embryotoxic B-NonOSE_AE
and O
fetotoxic B-NonOSE_AE
in O
rats O
and O
rabbits O
. O

If O
this O
drug O
is O
used O
during O
pregnancy B-Not_AE_Candidate
, O
or O
if O
the O
patient O
becomes O
pregnant B-NonOSE_AE
while O
taking O
this O
drug O
, O
the O
patient O
should O
be O
apprised O
of O
the O
potential O
hazard B-OSE_Labeled_AE
to I-OSE_Labeled_AE
the I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.1 O
) O
] O
. O

ADVERSE O
REACTIONS O
Adverse O
reactions O
are O
categorized O
below O
by O
organ O
system O
and O
listed O
by O
decreasing O
severity O
. O

Gastrointestinal B-NonOSE_AE
System I-NonOSE_AE
Reactions I-NonOSE_AE
* O
1 O
. O
hepatic B-OSE_Labeled_AE
encephalopathy I-OSE_Labeled_AE
in O
patients O
with O
hepatocellular B-Not_AE_Candidate
insufficiency I-Not_AE_Candidate
* O
2 O
. O
pancreatitis B-OSE_Labeled_AE
* O
3 O
. O
jaundice B-OSE_Labeled_AE
( O
intrahepatic B-OSE_Labeled_AE
cholestatic I-OSE_Labeled_AE
jaundice I-OSE_Labeled_AE
) O
* O
4 O
. O
increased B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
enzymes I-OSE_Labeled_AE
* O
5 O
. O
anorexia B-OSE_Labeled_AE
* O
6 O
. O
oral B-OSE_Labeled_AE
and O
gastric O
irritation I-OSE_Labeled_AE
* O
7 O
. O
cramping B-OSE_Labeled_AE
* O
8 O
. O
diarrhea B-OSE_Labeled_AE
* O
9 O
. O
constipation B-OSE_Labeled_AE
* O
10 O
. O
nausea B-OSE_Labeled_AE
* O
11 O
. O
vomiting B-OSE_Labeled_AE
Systemic B-NonOSE_AE
Hypersensitivity I-NonOSE_AE
Reactions I-NonOSE_AE
* O
1 O
. O
severe O
anaphylactic B-OSE_Labeled_AE
or O
anaphylactoid B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
e.g O
. O

with O
shock B-OSE_Labeled_AE
) O
* O
2 O
. O
systemic B-OSE_Labeled_AE
vasculitis I-OSE_Labeled_AE
* O
3 O
. O
interstitial B-OSE_Labeled_AE
nephritis I-OSE_Labeled_AE
* O
4 O
. O
necrotizing B-OSE_Labeled_AE
angiitis I-OSE_Labeled_AE
Central B-NonOSE_AE
Nervous I-NonOSE_AE
System I-NonOSE_AE
Reactions I-NonOSE_AE
* O
1 O
. O
tinnitus B-OSE_Labeled_AE
and O
hearing B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
* O
2 O
. O
paresthesias B-OSE_Labeled_AE
* O
3 O
. O
vertigo B-OSE_Labeled_AE
* O
4 O
. O
dizziness B-OSE_Labeled_AE
* O
5 O
. O
headache B-OSE_Labeled_AE
* O
6 O
. O
blurred B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
* O
7 O
. O
xanthopsia B-OSE_Labeled_AE
Hematologic B-NonOSE_AE
Reactions I-NonOSE_AE
* O
1 O
. O
aplastic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
* O
2 O
. O
thrombocytopenia B-OSE_Labeled_AE
* O
3 O
. O
agranulocytosis B-OSE_Labeled_AE
* O
4 O
. O
hemolytic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
* O
5 O
. O
leukopenia B-OSE_Labeled_AE
* O
6 O
. O
anemia B-OSE_Labeled_AE
* O
7 O
. O
eosinophilia B-OSE_Labeled_AE
Dermatologic B-NonOSE_AE
- I-NonOSE_AE
Hypersensitivity I-NonOSE_AE
Reactions I-NonOSE_AE
* O
1 O
. O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
* O
2 O
. O

Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
* O
3 O
. O
erythema B-OSE_Labeled_AE
multiforme I-OSE_Labeled_AE
* O
4 O
. O
drug B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
with I-OSE_Labeled_AE
eosinophilia I-OSE_Labeled_AE
and I-OSE_Labeled_AE
systemic I-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
* O
5 O
. O
acute B-OSE_Labeled_AE
generalized I-OSE_Labeled_AE
exanthematous I-OSE_Labeled_AE
pustulosis I-OSE_Labeled_AE
* O
6 O
. O
exfoliative B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
* O
7 O
. O
bullous B-OSE_Labeled_AE
pemphigoid I-OSE_Labeled_AE
* O
8 O
. O
purpura B-OSE_Labeled_AE
* O
9 O
. O
photosensitivity B-OSE_Labeled_AE
* O
10 O
. O
rash B-OSE_Labeled_AE
* O
11 O
. O
pruritis B-OSE_Labeled_AE
* O
12 O
. O
urticaria B-OSE_Labeled_AE
Cardiovascular B-NonOSE_AE
Reaction I-NonOSE_AE
* O
1 O
. O

Orthostatic B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
may O
occur O
and O
be O
aggravated O
by O
alcohol O
, O
barbiturates O
or O
narcotics O
. O

* O
2 O
. O

Increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
and O
triglyceride O
serum O
levels O
. O

Other B-NonOSE_AE
Reactions I-NonOSE_AE
* O
1 O
. O
hyperglycemia B-OSE_Labeled_AE
* O
2 O
. O
glycosuria B-OSE_Labeled_AE
* O
3 O
. O
hyperuricemia B-OSE_Labeled_AE
* O
4 O
. O
muscle B-OSE_Labeled_AE
spasm I-OSE_Labeled_AE
* O
5 O
. O
weakness B-OSE_Labeled_AE
* O
6 O
. O
restlessness B-OSE_Labeled_AE
* O
7 O
. O
urinary B-OSE_Labeled_AE
bladder I-OSE_Labeled_AE
spasm I-OSE_Labeled_AE
* O
8 O
. O
thrombophlebitis B-OSE_Labeled_AE
* O
9 O
. O
fever B-OSE_Labeled_AE
Whenever O
adverse O
reactions O
are O
moderate O
or O
severe O
, O
furosemide O
dosage O
should O
be O
reduced O
or O
therapy O
withdrawn O
. O

PRECAUTIONS O
General O
Excessive O
diuresis B-NonOSE_AE
may O
cause O
dehydration B-OSE_Labeled_AE
and O
blood B-OSE_Labeled_AE
volume I-OSE_Labeled_AE
reduction I-OSE_Labeled_AE
with O
circulatory B-OSE_Labeled_AE
collapse I-OSE_Labeled_AE
and O
possibly O
vascular B-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
and O
embolism O
, O
particularly O
in O
elderly O
patients O
. O

As O
with O
any O
effective O
diuretic B-NonOSE_AE
, O
electrolyte B-OSE_Labeled_AE
depletion I-OSE_Labeled_AE
may O
occur O
during O
furosemide O
therapy O
, O
especially O
in O
patients O
receiving O
higher O
doses O
and O
a O
restricted O
salt O
intake O
. O

Hypokalemia B-OSE_Labeled_AE
may O
develop O
with O
furosemide O
, O
especially O
with O
brisk O
diuresis B-NonOSE_AE
, O
inadequate O
oral O
electrolyte O
intake O
, O
when O
cirrhosis B-Not_AE_Candidate
is O
present O
, O
or O
during O
concomitant O
use O
of O
corticosteroids O
, O
ACTH O
, O
licorice O
in O
large O
amounts O
, O
or O
prolonged O
use O
of O
laxatives O
. O

Digitalis O
therapy O
may O
exaggerate O
metabolic O
effects O
of O
hypokalemia B-NonOSE_AE
, O
especially O
myocardial B-NonOSE_AE
effects I-NonOSE_AE
. O

All O
patients O
receiving O
furosemide O
therapy O
should O
be O
observed O
for O
these O
signs O
or O
symptoms O
of O
fluid B-NonOSE_AE
or O
electrolyte O
imbalance I-NonOSE_AE
( O
hyponatremia B-NonOSE_AE
, O
hypochloremic B-NonOSE_AE
alkalosis I-NonOSE_AE
, O
hypokalemia B-NonOSE_AE
, O
hypomagnesemia B-NonOSE_AE
or O
hypocalcemia B-NonOSE_AE
) O
: O
dryness B-NonOSE_AE
of I-NonOSE_AE
mouth I-NonOSE_AE
, O
thirst B-NonOSE_AE
, O
weakness B-NonOSE_AE
, O
lethargy B-NonOSE_AE
, O
drowsiness B-NonOSE_AE
, O
restlessness B-NonOSE_AE
, O
muscle B-NonOSE_AE
pains I-NonOSE_AE
or O
cramps O
, O
muscular B-NonOSE_AE
fatigue I-NonOSE_AE
, O
hypotension B-NonOSE_AE
, O
oliguria B-NonOSE_AE
, O
tachycardia B-NonOSE_AE
, O
arrhythmia B-NonOSE_AE
, O
or O
gastrointestinal B-NonOSE_AE
disturbances I-NonOSE_AE
such O
as O
nausea B-NonOSE_AE
and O
vomiting B-NonOSE_AE
. O

Increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
and O
alterations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
tolerance I-OSE_Labeled_AE
tests I-OSE_Labeled_AE
( O
with O
abnormalities B-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
fasting I-OSE_Labeled_AE
and O
2-hour O
postprandial O
sugar I-OSE_Labeled_AE
) O
have O
been O
observed O
, O
and O
rarely O
, O
precipitation O
of O
diabetes B-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
has O
been O
reported O
. O

In O
patients O
with O
severe O
symptoms O
of O
urinary B-Not_AE_Candidate
retention I-Not_AE_Candidate
( O
because O
of O
bladder B-Not_AE_Candidate
emptying I-Not_AE_Candidate
disorders I-Not_AE_Candidate
, O
prostatic B-Not_AE_Candidate
hyperplasia I-Not_AE_Candidate
, O
urethral B-Not_AE_Candidate
narrowing I-Not_AE_Candidate
) O
, O
the O
administration O
of O
furosemide O
can O
cause O
acute B-OSE_Labeled_AE
urinary I-OSE_Labeled_AE
retention I-OSE_Labeled_AE
related O
to O
increased B-NonOSE_AE
production I-NonOSE_AE
and O
retention O
of I-NonOSE_AE
urine I-NonOSE_AE
. O

Thus O
, O
these O
patients O
require O
careful O
monitoring O
, O
especially O
during O
the O
initial O
stages O
of O
treatment O
. O

In O
patients O
at O
high O
risk O
for O
radiocontrast B-Not_AE_Candidate
nephropathy I-Not_AE_Candidate
furosemide O
can O
lead O
to O
a O
higher O
incidence O
of O
deterioration B-NonOSE_AE
in I-NonOSE_AE
renal I-NonOSE_AE
function I-NonOSE_AE
after O
receiving O
radiocontrast O
compared O
to O
high-risk O
patients O
who O
received O
only O
intravenous O
hydration O
prior O
to O
receiving O
radiocontrast O
. O

In O
patients O
with O
hypoproteinemia B-Not_AE_Candidate
( O
e.g. O
, O
associated O
with O
nephrotic B-Not_AE_Candidate
syndrome I-Not_AE_Candidate
) O
the O
effect O
of O
furosemide O
may O
be O
weakened O
and O
its O
ototoxicity B-OSE_Labeled_AE
potentiated O
. O

Asymptomatic O
hyperuricemia B-OSE_Labeled_AE
can O
occur O
and O
gout B-OSE_Labeled_AE
may O
rarely O
be O
precipitated O
. O

Patients O
allergic B-OSE_Labeled_AE
to I-OSE_Labeled_AE
sulfonamides I-OSE_Labeled_AE
may I-OSE_Labeled_AE
also I-OSE_Labeled_AE
be I-OSE_Labeled_AE
allergic I-OSE_Labeled_AE
to I-OSE_Labeled_AE
furosemide I-OSE_Labeled_AE
. O

The O
possibility O
exists O
of O
exacerbation O
or O
activation O
of O
systemic B-OSE_Labeled_AE
lupus I-OSE_Labeled_AE
erythematosus I-OSE_Labeled_AE
. O

As O
with O
many O
other O
drugs O
, O
patients O
should O
be O
observed O
regularly O
for O
the O
possible O
occurrence O
of O
blood B-NonOSE_AE
dyscrasias I-NonOSE_AE
, O
liver B-NonOSE_AE
or O
kidney O
damage I-NonOSE_AE
, O
or O
other O
idiosyncratic B-NonOSE_AE
reactions I-NonOSE_AE
. O

Information O
for O
Patients O
Patients O
receiving O
furosemide O
should O
be O
advised O
that O
they O
may O
experience O
symptoms O
from O
excessive O
fluid B-NonOSE_AE
and/or O
electrolyte O
losses I-NonOSE_AE
. O

The O
postural B-NonOSE_AE
hypotension I-NonOSE_AE
that O
sometimes O
occurs O
can O
usually O
be O
managed O
by O
getting O
up O
slowly O
. O

Potassium O
supplements O
and/or O
dietary O
measures O
may O
be O
needed O
to O
control O
or O
avoid O
hypokalemia B-NonOSE_AE
. O

Patients O
with O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
should O
be O
told O
that O
furosemide O
may O
increase B-NonOSE_AE
blood I-NonOSE_AE
glucose I-NonOSE_AE
levels I-NonOSE_AE
and O
thereby O
affect O
urine O
glucose O
tests O
. O

The O
skin B-NonOSE_AE
of I-NonOSE_AE
some I-NonOSE_AE
patients I-NonOSE_AE
may I-NonOSE_AE
be I-NonOSE_AE
more I-NonOSE_AE
sensitive I-NonOSE_AE
to I-NonOSE_AE
the I-NonOSE_AE
effects I-NonOSE_AE
of I-NonOSE_AE
sunlight I-NonOSE_AE
while O
taking O
furosemide O
. O

Hypertensive B-Not_AE_Candidate
patients O
should O
avoid O
medications O
that O
may O
increase B-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
, O
including O
over-the-counter O
products O
for O
appetite B-Not_AE_Candidate
suppression I-Not_AE_Candidate
and O
cold B-Not_AE_Candidate
symptoms I-Not_AE_Candidate
. O

Laboratory O
Tests O
Serum O
electrolytes O
( O
particularly O
potassium O
) O
, O
CO2 O
, O
creatinine O
and O
BUN O
should O
be O
determined O
frequently O
during O
the O
first O
few O
months O
of O
furosemide O
therapy O
and O
periodically O
thereafter O
. O

Serum O
and O
urine O
electrolyte O
determinations O
are O
particularly O
important O
when O
the O
patient O
is O
vomiting B-NonOSE_AE
profusely O
or O
receiving O
parenteral O
fluids O
. O

Abnormalities O
should O
be O
corrected O
or O
the O
drug O
temporarily O
withdrawn O
. O

Other O
medications O
may O
also O
influence O
serum O
electrolytes O
. O

Reversible O
elevations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
BUN I-OSE_Labeled_AE
may O
occur O
and O
are O
associated O
with O
dehydration B-OSE_Labeled_AE
, O
which O
should O
be O
avoided O
, O
particularly O
in O
patients O
with O
renal B-Not_AE_Candidate
insufficiency I-Not_AE_Candidate
. O

Urine O
and O
blood O
glucose O
should O
be O
checked O
periodically O
in O
diabetics B-Not_AE_Candidate
receiving O
furosemide O
, O
even O
in O
those O
suspected O
of O
latent O
diabetes B-Not_AE_Candidate
. O

Furosemide O
may O
lower B-OSE_Labeled_AE
serum I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
of I-OSE_Labeled_AE
calcium I-OSE_Labeled_AE
( O
rarely O
cases O
of O
tetany B-OSE_Labeled_AE
have O
been O
reported O
) O
and O
magnesium O
. O

Accordingly O
, O
serum O
levels O
of O
these O
electrolytes O
should O
be O
determined O
periodically O
. O

In O
premature B-Not_AE_Candidate
infants I-Not_AE_Candidate
furosemide O
may O
precipitate O
nephrocalcinosis B-OSE_Labeled_AE
/ O
nephrolithiasis B-OSE_Labeled_AE
, O
therefore O
renal O
function O
must O
be O
monitored O
and O
renal O
ultrasonography O
performed O
. O

( O
See O
PRECAUTIONS O
: O
Pediatric O
Use O
) O
Drug O
Interactions O
Furosemide O
may O
increase O
the O
ototoxic B-NonOSE_AE
potential O
of O
aminoglycoside O
antibiotics O
, O
especially O
in O
the O
presence O
of O
impaired B-Not_AE_Candidate
renal I-Not_AE_Candidate
function I-Not_AE_Candidate
. O

Except O
in O
life-threatening O
situations O
, O
avoid O
this O
combination O
. O

Furosemide O
should O
not O
be O
used O
concomitantly O
with O
ethacrynic O
acid O
because O
of O
the O
possibility O
of O
ototoxicity B-NonOSE_AE
. O

Patients O
receiving O
high O
doses O
of O
salicylates O
concomitantly O
with O
furosemide O
, O
as O
in O
rheumatic O
disease O
, O
may O
experience O
salicylate B-NonOSE_AE
toxicity I-NonOSE_AE
at O
lower O
doses O
because O
of O
competitive O
renal O
excretory O
sites O
. O

There O
is O
a O
risk O
of O
ototoxic B-NonOSE_AE
effects O
if O
cisplatin O
and O
furosemide O
are O
given O
concomitantly O
. O

In O
addition O
, O
nephrotoxicity B-NonOSE_AE
of O
nephrotoxic B-NonOSE_AE
drugs I-NonOSE_AE
such O
as O
cisplatin O
may O
be O
enhanced O
if O
furosemide O
is O
not O
given O
in O
lower O
doses O
and O
with O
positive B-NonOSE_AE
fluid I-NonOSE_AE
balance I-NonOSE_AE
when O
used O
to O
achieve O
forced O
diuresis B-NonOSE_AE
during O
cisplatin O
treatment O
. O

Furosemide O
has O
a O
tendency O
to O
antagonize O
the O
skeletal O
muscle O
relaxing O
effect O
of O
tubocurarine O
and O
may O
potentiate O
the O
action O
of O
succinylcholine O
. O

Lithium O
generally O
should O
not O
be O
given O
with O
diuretics B-NonOSE_AE
because O
they O
reduce O
lithium O
's O
renal O
clearance O
and O
add O
a O
high O
risk O
of O
lithium B-NonOSE_AE
toxicity I-NonOSE_AE
. O

Furosemide O
combined O
with O
angiotensin O
converting O
enzyme O
inhibitors O
or O
angiotensin O
II O
receptor O
blockers O
may O
lead O
to O
severe O
hypotension B-NonOSE_AE
and O
deterioration B-NonOSE_AE
in I-NonOSE_AE
renal I-NonOSE_AE
function I-NonOSE_AE
, O
including O
renal B-NonOSE_AE
failure I-NonOSE_AE
. O

An O
interruption O
or O
reduction O
in O
the O
dosage O
of O
furosemide O
, O
angiotensin O
converting O
enzyme O
inhibitors O
, O
or O
angiotensin O
receptor O
blockers O
may O
be O
necessary O
. O

Potentiation O
occurs O
with O
ganglionic O
or O
peripheral O
adrenergic O
blocking O
drugs O
. O

Furosemide O
may O
decrease B-NonOSE_AE
arterial I-NonOSE_AE
responsiveness I-NonOSE_AE
to O
norepinephrine O
. O

However O
, O
norepinephrine O
may O
still O
be O
used O
effectively O
. O

Simultaneous O
administration O
of O
sucralfate O
and O
furosemide O
tablets O
may O
reduce B-NonOSE_AE
the I-NonOSE_AE
natriuretic I-NonOSE_AE
and O
antihypertensive O
effects O
of O
furosemide O
. O

Patients O
receiving O
both O
drugs O
should O
be O
observed O
closely O
to O
determine O
if O
the O
desired O
diuretic B-NonOSE_AE
and/or O
antihypertensive B-NonOSE_AE
effect I-NonOSE_AE
of O
furosemide O
is O
achieved O
. O

The O
intake O
of O
furosemide O
and O
sucralfate O
should O
be O
separated O
by O
at O
least O
two O
hours O
. O

In O
isolated O
cases O
, O
intravenous O
administration O
of O
furosemide O
within O
24 O
hours O
of O
taking O
chloral O
hydrate O
may O
lead O
to O
flushing B-NonOSE_AE
, O
sweating B-NonOSE_AE
attacks I-NonOSE_AE
, O
restlessness B-NonOSE_AE
, O
nausea B-NonOSE_AE
, O
increase B-NonOSE_AE
in I-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
and O
tachycardia B-NonOSE_AE
. O

Use O
of O
furosemide O
concomitantly O
with O
chloral O
hydrate O
is O
, O
therefore O
, O
not O
recommended O
. O

Phenytoin O
interferes O
directly O
with O
renal O
action O
of O
furosemide O
. O

There O
is O
evidence O
that O
treatment O
with O
phenytoin O
leads O
to O
decrease O
intestinal O
absorption O
of O
furosemide O
, O
and O
consequently O
to O
lower O
peak O
serum O
furosemide O
concentrations O
. O

Methotrexate O
and O
other O
drugs O
that O
, O
like O
furosemide O
, O
undergo O
significant O
renal O
tubular O
secretion O
may O
reduce O
the O
effect O
of O
furosemide O
. O

Conversely O
, O
furosemide O
may O
decrease O
renal O
elimination O
of O
other O
drugs O
that O
undergo O
tubular O
secretion O
. O

High-dose O
treatment O
of O
both O
furosemide O
and O
these O
other O
drugs O
, O
may O
result O
in O
elevated O
serum O
levels O
of O
these O
drugs O
and O
may O
potentiate O
their O
toxicity O
as O
well O
as O
the O
toxicity B-NonOSE_AE
of I-NonOSE_AE
furosemide I-NonOSE_AE
. O

Furosemide O
can O
increase O
the O
risk O
of O
cephalosporin B-NonOSE_AE
- I-NonOSE_AE
induced I-NonOSE_AE
nephrotoxicity I-NonOSE_AE
even O
in O
the O
setting O
of O
minor O
or O
transient O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
. O

Concomitant O
use O
of O
cyclosporine O
and O
furosemide O
is O
associated O
with O
increased O
risk O
of O
gouty B-NonOSE_AE
arthritis I-NonOSE_AE
secondary O
to O
furosemide-induced O
hyperurecemia B-OSE_Labeled_AE
and O
cyclosporine O
impairment B-NonOSE_AE
of I-NonOSE_AE
renal I-NonOSE_AE
urate I-NonOSE_AE
excretion I-NonOSE_AE
. O

High O
doses O
( O
> O
80 O
mg O
) O
of O
furosemide O
may O
inhibit O
the O
binding O
of O
thyroid O
hormones O
to O
carrier O
proteins O
and O
result O
in O
transient O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
free I-OSE_Labeled_AE
thyroid I-OSE_Labeled_AE
hormones I-OSE_Labeled_AE
, O
followed O
by O
an O
overall O
decrease B-NonOSE_AE
in I-NonOSE_AE
total I-NonOSE_AE
thyroid I-NonOSE_AE
hormone I-NonOSE_AE
levels I-NonOSE_AE
. O

One O
study O
in O
six O
subjects O
demonstrated O
that O
the O
combination O
of O
furosemide O
and O
acetylsalicylic O
acid O
temporarily O
reduced B-NonOSE_AE
creatinine I-NonOSE_AE
clearance I-NonOSE_AE
in O
patients O
with O
chronic B-Not_AE_Candidate
renal I-Not_AE_Candidate
insufficiency I-Not_AE_Candidate
. O

There O
are O
case O
reports O
of O
patients O
who O
developed O
increased B-NonOSE_AE
BUN I-NonOSE_AE
, O
serum O
creatinine O
and O
serum O
potassium O
levels O
, O
and O
weight B-NonOSE_AE
gain I-NonOSE_AE
when O
furosemide O
was O
used O
in O
conjunction O
with O
NSAIDs O
. O

Literature O
reports O
indicate O
that O
coadministration O
of O
indomethacin O
may O
reduce B-NonOSE_AE
the I-NonOSE_AE
natriuretic I-NonOSE_AE
and O
antihypertensive O
effects I-NonOSE_AE
of O
furosemide O
in O
some O
patients O
by O
inhibiting O
prostaglandin O
synthesis O
. O

Indomethacin O
may O
also O
affect O
plasma O
renin O
levels O
, O
aldosterone O
excretion O
, O
and O
renin O
profile O
evaluation O
. O

Patients O
receiving O
both O
indomethacin O
and O
furosemide O
should O
be O
observed O
closely O
to O
determine O
if O
the O
desired O
diuretic B-NonOSE_AE
and/or O
antihypertensive B-NonOSE_AE
effect I-NonOSE_AE
of O
furosemide O
is O
achieved O
. O

Carcinogenesis O
, O
Mutagenesis O
, O
Impairment O
of O
Fertility O
Furosemide O
was O
tested O
for O
carcinogenicity B-NonOSE_AE
by O
oral O
administration O
in O
one O
strain O
of O
mice O
and O
one O
strain O
of O
rats O
. O

A O
small O
but O
significantly O
increased O
incidence O
of O
mammary B-NonOSE_AE
gland I-NonOSE_AE
carcinomas I-NonOSE_AE
occurred O
in O
female O
mice O
at O
a O
dose O
17.5 O
times O
the O
maximum O
human O
dose O
of O
600 O
mg O
. O

There O
were O
marginal O
increases O
in O
uncommon O
tumors B-NonOSE_AE
in O
male O
rats O
at O
a O
dose O
of O
15 O
mg/kg O
( O
slightly O
greater O
than O
the O
maximum O
human O
dose O
) O
but O
not O
at O
30 O
mg/kg O
. O

Furosemide O
was O
devoid O
of O
mutagenic B-NonOSE_AE
activity O
in O
various O
strains O
of O
Salmonella O
typhimurium O
when O
tested O
in O
the O
presence O
or O
absence O
of O
an O
in O
vitro O
metabolic O
activation O
system O
, O
and O
questionably O
positive B-NonOSE_AE
for I-NonOSE_AE
gene I-NonOSE_AE
mutation I-NonOSE_AE
in I-NonOSE_AE
mouse I-NonOSE_AE
lymphoma I-NonOSE_AE
cells I-NonOSE_AE
in I-NonOSE_AE
the I-NonOSE_AE
presence I-NonOSE_AE
of I-NonOSE_AE
rat I-NonOSE_AE
liver I-NonOSE_AE
S9 O
at O
the O
highest O
dose O
tested O
. O

Furosemide O
did O
not O
induce O
sister B-NonOSE_AE
chromatid I-NonOSE_AE
exchange I-NonOSE_AE
in O
human O
cells O
in O
vitro O
, O
but O
other O
studies O
on O
chromosomal B-NonOSE_AE
aberrations I-NonOSE_AE
in O
human O
cells O
in O
vitro O
gave O
conflicting O
results O
. O

In O
Chinese O
hamster O
cells O
it O
induced O
chromosomal B-NonOSE_AE
damage I-NonOSE_AE
but O
was O
questionably O
positive B-NonOSE_AE
for I-NonOSE_AE
sister I-NonOSE_AE
chromatid I-NonOSE_AE
exchange I-NonOSE_AE
. O

Studies O
on O
the O
induction O
by O
furosemide O
of O
chromosomal B-NonOSE_AE
aberrations I-NonOSE_AE
in O
mice O
were O
inconclusive O
. O

The O
urine O
of O
rats O
treated O
with O
this O
drug O
did O
not O
induce B-NonOSE_AE
gene I-NonOSE_AE
conversion I-NonOSE_AE
in I-NonOSE_AE
Saccharomyces I-NonOSE_AE
cerevisiae I-NonOSE_AE
. O

Furosemide O
produced O
no B-NonOSE_AE
impairment I-NonOSE_AE
of I-NonOSE_AE
fertility I-NonOSE_AE
in O
male O
or O
female O
rats O
, O
at O
100 O
mg/kg/day O
( O
the O
maximum O
effective O
diuretic B-NonOSE_AE
dose O
in O
the O
rat O
and O
8 O
times O
the O
maximal O
human O
dose O
of O
600 O
mg/day O
) O
. O

Pregnancy O
Pregnancy O
Category O
C O
Furosemide O
has O
been O
shown O
to O
cause O
unexplained O
maternal B-NonOSE_AE
deaths I-NonOSE_AE
and O
abortions B-NonOSE_AE
in O
rabbits O
at O
2 O
, O
4 O
and O
8 O
times O
the O
maximal O
recommended O
human O
dose O
. O

There O
are O
no O
adequate O
and O
well-controlled O
studies O
in O
pregnant B-Not_AE_Candidate
women O
. O

Furosemide O
should O
be O
used O
during O
pregnancy B-Not_AE_Candidate
only O
if O
the O
potential O
benefit O
justifies O
the O
potential O
risk B-NonOSE_AE
to I-NonOSE_AE
the I-NonOSE_AE
fetus I-NonOSE_AE
. O

Treatment O
during O
pregnancy B-Not_AE_Candidate
requires O
monitoring O
of O
fetal O
growth O
because O
of O
the O
potential O
for O
higher B-OSE_Labeled_AE
birth I-OSE_Labeled_AE
weights I-OSE_Labeled_AE
. O

The O
effects O
of O
furosemide O
on O
embryonic O
and O
fetal O
development O
and O
on O
pregnant B-NonOSE_AE
dams O
were O
studied O
in O
mice O
, O
rats O
and O
rabbits O
. O

Furosemide O
caused O
unexplained O
maternal B-NonOSE_AE
deaths I-NonOSE_AE
and O
abortions B-NonOSE_AE
in O
the O
rabbit O
at O
the O
lowest O
dose O
of O
25 O
mg/kg O
( O
2 O
times O
the O
maximal O
recommended O
human O
dose O
of O
600 O
mg/day O
) O
. O

In O
another O
study O
, O
a O
dose O
of O
50 O
mg/kg O
( O
4 O
times O
the O
maximal O
recommended O
human O
dose O
of O
600 O
mg/day O
) O
also O
caused O
maternal B-NonOSE_AE
deaths I-NonOSE_AE
and O
abortions B-NonOSE_AE
when O
administered O
to O
rabbits O
between O
Days O
12 O
and O
17 O
of O
gestation O
. O

In O
a O
third O
study O
, O
none O
of O
the O
pregnant B-NonOSE_AE
rabbits O
survived O
a O
dose O
of O
100 O
mg/kg O
. O

Data O
from O
the O
above O
studies O
indicate O
fetal B-NonOSE_AE
lethality I-NonOSE_AE
that O
can O
precede O
maternal B-NonOSE_AE
deaths I-NonOSE_AE
. O

The O
results O
of O
the O
mouse O
study O
and O
one O
of O
the O
three O
rabbit O
studies O
also O
showed O
an O
increased O
incidence O
and O
severity O
of O
hydronephrosis B-NonOSE_AE
( O
distention O
of O
the O
renal O
pelvis O
and O
, O
in I-NonOSE_AE
some O
cases O
, O
of O
the O
ureters O
) O
in O
fetuses I-NonOSE_AE
derived O
from O
the O
treated O
dams O
as O
compared O
with O
the O
incidence O
in O
fetuses O
from O
the O
control O
group O
. O

Nursing O
Mothers O
Because O
it O
appears O
in O
breast O
milk O
, O
caution O
should O
be O
exercised O
when O
furosemide O
is O
administered O
to O
a O
nursing O
mother O
. O

Furosemide O
may O
inhibit B-OSE_Labeled_AE
lactation I-OSE_Labeled_AE
. O

Pediatric O
Use O
In O
premature B-Not_AE_Candidate
infants I-Not_AE_Candidate
furosemide O
may O
precipitate O
nephrocalcinosis B-OSE_Labeled_AE
/ O
nephrolithiasis B-OSE_Labeled_AE
. O

Nephrocalcinosis B-OSE_Labeled_AE
/ O
nephrolithiasis B-OSE_Labeled_AE
has O
also O
been O
observed O
in O
children O
under O
4 O
years O
of O
age O
with O
no O
history O
of O
prematurity B-Not_AE_Candidate
who O
have O
been O
treated O
chronically O
with O
furosemide O
. O

Monitor O
renal O
function O
, O
and O
renal O
ultrasonography O
should O
be O
considered O
, O
in O
pediatric O
patients O
receiving O
furosemide O
. O

If O
furosemide O
is O
administered O
to O
premature B-Not_AE_Candidate
infants I-Not_AE_Candidate
during O
the O
first O
weeks O
of O
life O
, O
it O
may O
increase O
the O
risk O
of O
persistence O
of O
patent B-OSE_Labeled_AE
ductus I-OSE_Labeled_AE
arteriosus I-OSE_Labeled_AE
. O

Geriatric O
Use O
Controlled O
clinical O
studies O
of O
furosemide O
did O
not O
include O
sufficient O
numbers O
of O
subjects O
aged O
65 O
and O
over O
to O
determine O
whether O
they O
respond O
differently O
from O
younger O
subjects O
. O

Other O
reported O
clinical O
experience O
has O
not O
identified O
differences O
in O
responses O
between O
the O
elderly O
and O
younger O
patients O
. O

In O
general O
, O
dose O
selection O
for O
the O
elderly O
patient O
should O
be O
cautious O
, O
usually O
starting O
at O
the O
low O
end O
of O
the O
dosing O
range O
, O
reflecting O
the O
greater O
frequency O
of O
decreased B-Not_AE_Candidate
hepatic I-Not_AE_Candidate
, O
renal O
or O
cardiac O
function I-Not_AE_Candidate
, O
and O
of O
concomitant O
disease O
or O
other O
drug O
therapy O
. O

This O
drug O
is O
known O
to O
be O
substantially O
excreted O
by O
the O
kidney O
, O
and O
the O
risk O
of O
toxic B-NonOSE_AE
reactions I-NonOSE_AE
to O
this O
drug O
may O
be O
greater O
in O
patients O
with O
impaired B-Not_AE_Candidate
renal I-Not_AE_Candidate
function I-Not_AE_Candidate
. O

Because O
elderly O
patients O
are O
more O
likely O
to O
have O
decreased B-Not_AE_Candidate
renal I-Not_AE_Candidate
function I-Not_AE_Candidate
, O
care O
should O
be O
taken O
in O
dose O
selection O
and O
it O
may O
be O
useful O
to O
monitor O
renal O
function O
. O

( O
See O
PRECAUTIONS O
: O
General O
and O
DOSAGE O
AND O
ADMINISTRATION O
. O
) O

WARNINGS O
In O
patients O
with O
hepatic B-Not_AE_Candidate
cirrhosis I-Not_AE_Candidate
and O
ascites B-Not_AE_Candidate
, O
furosemide O
therapy O
is O
best O
initiated O
in O
the O
hospital O
. O

In O
hepatic B-Not_AE_Candidate
coma I-Not_AE_Candidate
and O
in O
states O
of O
electrolyte B-Not_AE_Candidate
depletion I-Not_AE_Candidate
, O
therapy O
should O
not O
be O
instituted O
until O
the O
basic O
condition O
is O
improved O
. O

Sudden O
alterations B-NonOSE_AE
of I-NonOSE_AE
fluid I-NonOSE_AE
and O
electrolyte O
balance I-NonOSE_AE
in O
patients O
with O
cirrhosis B-Not_AE_Candidate
may O
precipitate O
hepatic B-NonOSE_AE
coma I-NonOSE_AE
; O
therefore O
, O
strict O
observation O
is O
necessary O
during O
the O
period O
of O
diuresis B-NonOSE_AE
. O

Supplemental O
potassium O
chloride O
and O
, O
if O
required O
, O
an O
aldosterone O
antagonist O
are O
helpful O
in O
preventing O
hypokalemia B-NonOSE_AE
and O
metabolic B-NonOSE_AE
alkalosis I-NonOSE_AE
. O

If O
increasing O
azotemia B-NonOSE_AE
and O
oliguria B-NonOSE_AE
occur O
during O
treatment O
of O
severe O
progressive O
renal B-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
furosemide O
should O
be O
discontinued O
. O

Cases O
of O
tinnitus B-OSE_Labeled_AE
and O
reversible O
or O
irreversible B-OSE_Labeled_AE
hearing I-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
and O
deafness B-OSE_Labeled_AE
have O
been O
reported O
. O

Reports O
usually O
indicate O
that O
furosemide O
ototoxicity B-OSE_Labeled_AE
is O
associated O
with O
rapid O
injection O
, O
severe O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
, O
the O
use O
of O
higher O
than O
recommended O
doses O
, O
hypoproteinemia B-Not_AE_Candidate
, O
or O
concomitant O
therapy O
with O
aminoglycoside O
antibiotics O
, O
ethacrynic O
acid O
, O
or O
other O
ototoxic B-NonOSE_AE
drugs I-NonOSE_AE
. O

If O
the O
physician O
elects O
to O
use O
high O
dose O
parenteral O
therapy O
, O
controlled O
intravenous O
infusion O
is O
advisable O
( O
for O
adults O
, O
an O
infusion O
rate O
not O
exceeding O
4 O
mg O
furosemide O
per O
minute O
has O
been O
used O
) O
. O

( O
See O
PRECAUTIONS O
: O
Drug O
Interactions O
) O

6 O
. O

ADVERSE O
REACTIONS O
EXCERPT O
: O
The O
most O
common O
adverse O
reactions O
( O
incidence O
> O
5 O
% O
and O
at O
least O
twice O
as O
high O
on O
HETLIOZ O
than O
on O
placebo O
) O
were O
headache O
, O
increased O
alanine O
aminotransferase O
, O
nightmares O
or O
unusual O
dreams O
, O
and O
upper O
respiratory O
or O
urinary O
tract O
infection O
( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Vanda O
Pharmaceuticals O
Inc O
. O
at O
1-844-438-5469 O
or O
www.hetlioz.com O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

A O
total O
of O
1346 O
subjects O
were O
treated O
with O
at O
least O
one O
dose O
of O
HETLIOZ O
, O
of O
which O
139 O
were O
treated O
for O
> O
26 O
weeks O
and O
93 O
were O
treated O
for O
> O
1 O
year O
. O

A O
26-week O
, O
parallel-arm O
placebo-controlled O
study O
( O
Study O
1 O
) O
evaluated O
HETLIOZ O
( O
n=42 O
) O
compared O
to O
placebo O
( O
n=42 O
) O
in O
patients O
with O
Non-24 O
. O

A O
randomized-withdrawal O
, O
placebo- O
controlled O
study O
of O
8 O
weeks O
duration O
( O
Study O
2 O
) O
also O
evaluated O
HETLIOZ O
( O
n=10 O
) O
, O
compared O
to O
placebo O
( O
n=10 O
) O
, O
in O
patients O
with O
Non-24 O
. O

In O
placebo-controlled O
studies O
, O
6 O
% O
of O
patients O
exposed O
to O
HETLIOZ O
discontinued O
treatment O
due O
to O
an O
adverse O
event O
, O
compared O
with O
4 O
% O
of O
patients O
who O
received O
placebo O
. O

Table O
1 O
shows O
the O
incidence O
of O
adverse O
reactions O
from O
Study O
1 O
. O

*Adverse O
reactions O
with O
an O
incidence O
> O
5 O
% O
and O
at O
least O
twice O
as O
high O
on O
HETLIOZ O
than O
on O
placebo O
are O
displayed O
. O

Table O
1 O
: O
Adverse O
Reactions O
in O
Study O
1 O
HETLIOZN=42 O
PlaceboN=42 O
Headache B-OSE_Labeled_AE
17 O
% O
7 O
% O
Alanine B-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
10 O
% O
5 O
% O
Nightmare B-OSE_Labeled_AE
/ O
abnormal B-OSE_Labeled_AE
dreams I-OSE_Labeled_AE
10 O
% O
0 O
% O
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
7 O
% O
0 O
% O
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
7 O
% O
2 O
% O

5 O
. O

WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
May O
cause O
somnolence O
: O
After O
taking O
HETLIOZ O
, O
patients O
should O
limit O
their O
activity O
to O
preparing O
for O
going O
to O
bed O
, O
because O
HETLIOZ O
can O
impair O
the O
performance O
of O
activities O
requiring O
complete O
mental O
alertness O
( O
5.1 O
) O
5.1 O
Somnolence B-OSE_Labeled_AE
After O
taking O
HETLIOZ O
, O
patients O
should O
limit O
their O
activity O
to O
preparing O
for O
going O
to O
bed O
. O

HETLIOZ O
can O
potentially O
impair B-OSE_Labeled_AE
the I-OSE_Labeled_AE
performance I-OSE_Labeled_AE
of I-OSE_Labeled_AE
activities I-OSE_Labeled_AE
requiring I-OSE_Labeled_AE
complete I-OSE_Labeled_AE
mental I-OSE_Labeled_AE
alertness I-OSE_Labeled_AE
. O

6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
* O
The O
most O
common O
adverse O
reactions O
reported O
in O
> O
=5 O
% O
of O
patients O
simultaneously O
started O
on O
sitagliptin O
and O
metformin O
and O
more O
commonly O
than O
in O
patients O
treated O
with O
placebo O
were O
diarrhea O
, O
upper O
respiratory O
tract O
infection O
, O
and O
headache O
. O

( O
6.1 O
) O
* O
Adverse O
reactions O
reported O
in O
> O
=5 O
% O
of O
patients O
treated O
with O
sitagliptin O
in O
combination O
with O
sulfonylurea O
and O
metformin O
and O
more O
commonly O
than O
in O
patients O
treated O
with O
placebo O
in O
combination O
with O
sulfonylurea O
and O
metformin O
were O
hypoglycemia O
and O
headache O
. O

( O
6.1 O
) O
* O
Hypoglycemia O
was O
the O
only O
adverse O
reaction O
reported O
in O
> O
=5 O
% O
of O
patients O
treated O
with O
sitagliptin O
in O
combination O
with O
insulin O
and O
metformin O
and O
more O
commonly O
than O
in O
patients O
treated O
with O
placebo O
in O
combination O
with O
insulin O
and O
metformin O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Merck O
Sharp O
& O
Dohme O
Corp. O
, O
a O
subsidiary O
of O
Merck O
& O
Co. O
, O
Inc. O
, O
at O
1-877-888-4231 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Sitagliptin O
and O
Metformin O
Coadministration O
in O
Patients O
with O
Type O
2 O
Diabetes O
Inadequately O
Controlled O
on O
Diet O
and O
Exercise O
Table O
1 O
summarizes O
the O
most O
common O
( O
> O
=5 O
% O
of O
patients O
) O
adverse O
reactions O
reported O
( O
regardless O
of O
investigator O
assessment O
of O
causality O
) O
in O
a O
24-week O
placebo-controlled O
factorial O
study O
in O
which O
sitagliptin O
and O
metformin O
were O
coadministered O
to O
patients O
with O
type B-Not_AE_Candidate
2 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
inadequately O
controlled O
on O
diet O
and O
exercise O
. O

Table O
1 O
: O
Sitagliptin O
and O
Metformin O
Coadministered O
to O
Patients O
with O
Type O
2 O
Diabetes O
Inadequately O
Controlled O
on O
Diet O
and O
Exercise O
: O
Adverse O
Reactions O
Reported O
( O
Regardless O
of O
Investigator O
Assessment O
of O
Causality O
) O
in O
> O
=5 O
% O
of O
Patients O
Receiving O
Combination O
Therapy O
( O
and O
Greater O
than O
in O
Patients O
Receiving O
Placebo O
) O
Intent-to-treat O
population O
. O

Number O
of O
Patients O
( O
% O
) O
Placebo O
Sitagliptin O
100 O
mg O
once O
daily O
Metformin O
500 O
mg/ O
Metformin O
1000 O
mg O
twice O
daily O
[ O
note O
: O
Data O
pooled O
for O
the O
patients O
given O
the O
lower O
and O
higher O
doses O
of O
metformin O
. O
] O

Sitagliptin O
50 O
mg O
twice O
daily O
+ O
Metformin O
500 O
mg/ O
Metformin O
1000 O
mg O
twice O
daily O
N O
= O
176 O
N O
= O
179 O
N O
= O
364 O
N O
= O
372 O
Diarrhea B-OSE_Labeled_AE
7 O
( O
4.0 O
) O
5 O
( O
2.8 O
) O
28 O
( O
7.7 O
) O
28 O
( O
7.5 O
) O
Upper B-OSE_Labeled_AE
Respiratory I-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
9 O
( O
5.1 O
) O
8 O
( O
4.5 O
) O
19 O
( O
5.2 O
) O
23 O
( O
6.2 O
) O
Headache B-OSE_Labeled_AE
5 O
( O
2.8 O
) O
2 O
( O
1.1 O
) O
14 O
( O
3.8 O
) O
22 O
( O
5.9 O
) O
Sitagliptin O
Add-on O
Therapy O
in O
Patients O
with O
Type O
2 O
Diabetes O
Inadequately O
Controlled O
on O
Metformin O
Alone O
In O
a O
24-week O
placebo-controlled O
trial O
of O
sitagliptin O
100 O
mg O
administered O
once O
daily O
added O
to O
a O
twice O
daily O
metformin O
regimen O
, O
there O
were O
no O
adverse O
reactions O
reported O
regardless O
of O
investigator O
assessment O
of O
causality O
in O
> O
=5 O
% O
of O
patients O
and O
more O
commonly O
than O
in O
patients O
given O
placebo O
. O

Discontinuation O
of O
therapy O
due O
to O
clinical O
adverse O
reactions O
was O
similar O
to O
the O
placebo O
treatment O
group O
( O
sitagliptin O
and O
metformin O
, O
1.9 O
% O
; O
placebo O
and O
metformin O
, O
2.5 O
% O
) O
. O

Gastrointestinal O
Adverse O
Reactions O
The O
incidences O
of O
pre-selected O
gastrointestinal B-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
experiences I-OSE_Labeled_AE
in O
patients O
treated O
with O
sitagliptin O
and O
metformin O
were O
similar O
to O
those O
reported O
for O
patients O
treated O
with O
metformin O
alone O
. O

See O
Table O
2 O
. O

Table O
2 O
: O
Pre-selected O
Gastrointestinal O
Adverse O
Reactions O
( O
Regardless O
of O
Investigator O
Assessment O
of O
Causality O
) O
Reported O
in O
Patients O
with O
Type O
2 O
Diabetes O
Receiving O
Sitagliptin O
and O
Metformin O
Number O
of O
Patients O
( O
% O
) O
Study O
of O
Sitagliptin O
and O
Metformin O
in O
Patients O
Inadequately O
Controlled O
on O
Diet O
and O
Exercise O
Study O
of O
Sitagliptin O
Add-on O
in O
Patients O
Inadequately O
Controlled O
on O
Metformin O
Alone O
Placebo O
Sitagliptin O
100 O
mg O
once O
daily O
Metformin O
500 O
mg/ O
Metformin O
1000 O
mg O
twice O
daily O
[ O
note O
: O
Data O
pooled O
for O
the O
patients O
given O
the O
lower O
and O
higher O
doses O
of O
metformin O
. O
] O

Sitagliptin O
50 O
mg O
twice O
daily O
+ O
Metformin O
500 O
mg/ O
Metformin O
1000 O
mg O
twice O
daily O
Placebo O
and O
Metformin O
> O
=1500 O
mg O
daily O
Sitagliptin O
100 O
mg O
once O
daily O
and O
Metformin O
> O
=1500 O
mg O
daily O
N O
= O
176 O
N O
= O
179 O
N O
= O
364 O
N O
= O
372 O
N O
= O
237 O
N O
= O
464 O
Diarrhea B-OSE_Labeled_AE
7 O
( O
4.0 O
) O
5 O
( O
2.8 O
) O
28 O
( O
7.7 O
) O
28 O
( O
7.5 O
) O
6 O
( O
2.5 O
) O
11 O
( O
2.4 O
) O
Nausea B-OSE_Labeled_AE
2 O
( O
1.1 O
) O
2 O
( O
1.1 O
) O
20 O
( O
5.5 O
) O
18 O
( O
4.8 O
) O
2 O
( O
0.8 O
) O
6 O
( O
1.3 O
) O
Vomiting B-OSE_Labeled_AE
1 O
( O
0.6 O
) O
0 O
( O
0.0 O
) O
2 O
( O
0.5 O
) O
8 O
( O
2.2 O
) O
2 O
( O
0.8 O
) O
5 O
( O
1.1 O
) O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
[ O
note O
: O
Abdominal B-OSE_Labeled_AE
discomfort I-OSE_Labeled_AE
was O
included O
in O
the O
analysis O
of O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
in O
the O
study O
of O
initial O
therapy O
. O
] O

4 O
( O
2.3 O
) O
6 O
( O
3.4 O
) O
14 O
( O
3.8 O
) O
11 O
( O
3.0 O
) O
9 O
( O
3.8 O
) O
10 O
( O
2.2 O
) O
Sitagliptin O
in O
Combination O
with O
Metformin O
and O
Glimepiride O
In O
a O
24-week O
placebo-controlled O
study O
of O
sitagliptin O
100 O
mg O
as O
add-on O
therapy O
in O
patients O
with O
type B-Not_AE_Candidate
2 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
inadequately O
controlled O
on O
metformin O
and O
glimepiride O
( O
sitagliptin O
, O
N=116 O
; O
placebo O
, O
N=113 O
) O
, O
the O
adverse O
reactions O
reported O
regardless O
of O
investigator O
assessment O
of O
causality O
in O
> O
=5 O
% O
of O
patients O
treated O
with O
sitagliptin O
and O
more O
commonly O
than O
in O
patients O
treated O
with O
placebo O
were O
: O
hypoglycemia B-OSE_Labeled_AE
( O
Table O
3 O
) O
and O
headache B-OSE_Labeled_AE
( O
6.9 O
% O
, O
2.7 O
% O
) O
. O

Sitagliptin O
in O
Combination O
with O
Metformin O
and O
Rosiglitazone O
In O
a O
placebo-controlled O
study O
of O
sitagliptin O
100 O
mg O
as O
add-on O
therapy O
in O
patients O
with O
type B-Not_AE_Candidate
2 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
inadequately O
controlled O
on O
metformin O
and O
rosiglitazone O
( O
sitagliptin O
, O
N=181 O
; O
placebo O
, O
N=97 O
) O
, O
the O
adverse O
reactions O
reported O
regardless O
of O
investigator O
assessment O
of O
causality O
through O
Week O
18 O
in O
> O
=5 O
% O
of O
patients O
treated O
with O
sitagliptin O
and O
more O
commonly O
than O
in O
patients O
treated O
with O
placebo O
were O
: O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
sitagliptin O
, O
5.5 O
% O
; O
placebo O
, O
5.2 O
% O
) O
and O
nasopharyngitis B-OSE_Labeled_AE
( O
6.1 O
% O
, O
4.1 O
% O
) O
. O

Through O
Week O
54 O
, O
the O
adverse O
reactions O
reported O
regardless O
of O
investigator O
assessment O
of O
causality O
in O
> O
=5 O
% O
of O
patients O
treated O
with O
sitagliptin O
and O
more O
commonly O
than O
in O
patients O
treated O
with O
placebo O
were O
: O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
sitagliptin O
, O
15.5 O
% O
; O
placebo O
, O
6.2 O
% O
) O
, O
nasopharyngitis B-OSE_Labeled_AE
( O
11.0 O
% O
, O
9.3 O
% O
) O
, O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
( O
8.3 O
% O
, O
5.2 O
% O
) O
, O
and O
headache B-OSE_Labeled_AE
( O
5.5 O
% O
, O
4.1 O
% O
) O
. O

Sitagliptin O
in O
Combination O
with O
Metformin O
and O
Insulin O
In O
a O
24-week O
placebo-controlled O
study O
of O
sitagliptin O
100 O
mg O
as O
add-on O
therapy O
in O
patients O
with O
type B-Not_AE_Candidate
2 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
inadequately O
controlled O
on O
metformin O
and O
insulin O
( O
sitagliptin O
, O
N=229 O
; O
placebo O
, O
N=233 O
) O
, O
the O
only O
adverse O
reaction O
reported O
regardless O
of O
investigator O
assessment O
of O
causality O
in O
> O
=5 O
% O
of O
patients O
treated O
with O
sitagliptin O
and O
more O
commonly O
than O
in O
patients O
treated O
with O
placebo O
was O
hypoglycemia B-OSE_Labeled_AE
( O
Table O
3 O
) O
. O

Hypoglycemia O
In O
all O
( O
N=5 O
) O
studies O
, O
adverse O
reactions O
of O
hypoglycemia B-NonOSE_AE
were O
based O
on O
all O
reports O
of O
symptomatic O
hypoglycemia B-NonOSE_AE
; O
a O
concurrent O
glucose O
measurement O
was O
not O
required O
although O
most O
( O
77 O
% O
) O
reports O
of O
hypoglycemia B-OSE_Labeled_AE
were O
accompanied O
by O
a O
blood B-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
measurement I-OSE_Labeled_AE
< I-OSE_Labeled_AE
= I-OSE_Labeled_AE
7 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
. O

When O
the O
combination O
of O
sitagliptin O
and O
metformin O
was O
coadministered O
with O
a O
sulfonylurea O
or O
with O
insulin O
, O
the O
percentage O
of O
patients O
reporting O
at O
least O
one O
adverse O
reaction O
of O
hypoglycemia B-NonOSE_AE
was O
higher O
than O
that O
observed O
with O
placebo O
and O
metformin O
coadministered O
with O
a O
sulfonylurea O
or O
with O
insulin O
( O
Table O
3 O
) O
. O

Table O
3 O
: O
Incidence O
and O
Rate O
of O
Hypoglycemia B-OSE_Labeled_AE
Adverse O
reactions O
of O
hypoglycemia B-NonOSE_AE
were O
based O
on O
all O
reports O
of O
symptomatic O
hypoglycemia B-OSE_Labeled_AE
; O
a O
concurrent O
glucose O
measurement O
was O
not O
required O
: O
Intent-to-treat O
population O
. O

( O
Regardless O
of O
Investigator O
Assessment O
of O
Causality O
) O
in O
Placebo-Controlled O
Clinical O
Studies O
of O
Sitagliptin O
in O
Combination O
with O
Metformin O
Coadministered O
with O
Glimepiride O
or O
Insulin O
Add-On O
to O
Glimepiride O
+ O
Metformin O
( O
24 O
weeks O
) O
Sitagliptin O
100 O
mg O
+ O
Metformin O
+ O
Glimepiride O
Placebo O
+ O
Metformin O
+ O
Glimepiride O
N O
= O
116 O
N O
= O
113 O
Overall O
( O
% O
) O
19 O
( O
16.4 O
) O
1 O
( O
0.9 O
) O
Rate O
( O
episodes/patient-year O
) O
[ O
note O
: O
Based O
on O
total O
number O
of O
events O
( O
i.e. O
, O
a O
single O
patient O
may O
have O
had O
multiple O
events O
) O
. O
] O

0.82 O
0.02 O
Severe O
( O
% O
) O
[ O
note O
: O
Severe O
events O
of O
hypoglycemia B-NonOSE_AE
were O
defined O
as O
those O
events O
requiring O
medical O
assistance O
or O
exhibiting O
depressed B-OSE_Labeled_AE
level I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
loss I-OSE_Labeled_AE
of I-OSE_Labeled_AE
consciousness I-OSE_Labeled_AE
or O
seizure B-OSE_Labeled_AE
. O
] O

0 O
( O
0.0 O
) O
0 O
( O
0.0 O
) O
Add-On O
to O
Insulin O
+ O
Metformin O
( O
24 O
weeks O
) O
Sitagliptin O
100 O
mg O
+ O
Metformin O
+ O
Insulin O
Placebo O
+ O
Metformin O
+ O
Insulin O
N O
= O
229 O
N O
= O
233 O
Overall O
( O
% O
) O
35 O
( O
15.3 O
) O
19 O
( O
8.2 O
) O
Rate O
( O
episodes/patient-year O
) O
0.98 O
0.61 O
Severe O
( O
% O
) O
1 O
( O
0.4 O
) O
1 O
( O
0.4 O
) O
The O
overall O
incidence O
of O
reported O
adverse O
reactions O
of O
hypoglycemia B-OSE_Labeled_AE
in O
patients O
with O
type B-Not_AE_Candidate
2 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
inadequately O
controlled O
on O
diet O
and O
exercise O
was O
0.6 O
% O
in O
patients O
given O
placebo O
, O
0.6 O
% O
in O
patients O
given O
sitagliptin O
alone O
, O
0.8 O
% O
in O
patients O
given O
metformin O
alone O
, O
and O
1.6 O
% O
in O
patients O
given O
sitagliptin O
in O
combination O
with O
metformin O
. O

In O
patients O
with O
type B-Not_AE_Candidate
2 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
inadequately O
controlled O
on O
metformin O
alone O
, O
the O
overall O
incidence O
of O
adverse O
reactions O
of O
hypoglycemia B-NonOSE_AE
was O
1.3 O
% O
in O
patients O
given O
add-on O
sitagliptin O
and O
2.1 O
% O
in O
patients O
given O
add-on O
placebo O
. O

In O
the O
study O
of O
sitagliptin O
and O
add-on O
combination O
therapy O
with O
metformin O
and O
rosiglitazone O
, O
the O
overall O
incidence O
of O
hypoglycemia B-OSE_Labeled_AE
was O
2.2 O
% O
in O
patients O
given O
add-on O
sitagliptin O
and O
0.0 O
% O
in O
patients O
given O
add-on O
placebo O
through O
Week O
18 O
. O

Through O
Week O
54 O
, O
the O
overall O
incidence O
of O
hypoglycemia B-OSE_Labeled_AE
was O
3.9 O
% O
in O
patients O
given O
add-on O
sitagliptin O
and O
1.0 O
% O
in O
patients O
given O
add-on O
placebo O
. O

Vital O
Signs O
and O
Electrocardiograms O
With O
the O
combination O
of O
sitagliptin O
and O
metformin O
, O
no O
clinically O
meaningful O
changes B-NonOSE_AE
in I-NonOSE_AE
vital I-NonOSE_AE
signs I-NonOSE_AE
or O
in O
ECG O
( O
including O
in O
QTc O
interval O
) O
were O
observed O
. O

Pancreatitis O
In O
a O
pooled O
analysis O
of O
19 O
double-blind O
clinical O
trials O
that O
included O
data O
from O
10,246 O
patients O
randomized O
to O
receive O
sitagliptin O
100 O
mg/day O
( O
N=5429 O
) O
or O
corresponding O
( O
active O
or O
placebo O
) O
control O
( O
N=4817 O
) O
, O
the O
incidence O
of O
acute B-OSE_Labeled_AE
pancreatitis I-OSE_Labeled_AE
was O
0.1 O
per O
100 O
patient-years O
in O
each O
group O
( O
4 O
patients O
with O
an O
event O
in O
4708 O
patient-years O
for O
sitagliptin O
and O
4 O
patients O
with O
an O
event O
in O
3942 O
patient-years O
for O
control O
) O
. O

[ O
See O
Warnings O
and O
Precautions O
( O
5.2 O
) O
. O
] O

Sitagliptin O
The O
most O
common O
adverse O
experience O
in O
sitagliptin O
monotherapy O
reported O
regardless O
of O
investigator O
assessment O
of O
causality O
in O
> O
=5 O
% O
of O
patients O
and O
more O
commonly O
than O
in O
patients O
given O
placebo O
was O
nasopharyngitis B-OSE_Labeled_AE
. O

Metformin O
hydrochloride O
The O
most O
common O
( O
> O
5 O
% O
) O
established O
adverse O
reactions O
due O
to O
initiation O
of O
metformin O
therapy O
are O
diarrhea B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
/ O
vomiting B-OSE_Labeled_AE
, O
flatulence B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
discomfort I-OSE_Labeled_AE
, O
indigestion B-OSE_Labeled_AE
, O
asthenia B-OSE_Labeled_AE
, O
and O
headache B-OSE_Labeled_AE
. O

Laboratory O
Tests O
Sitagliptin O
The O
incidence O
of O
laboratory B-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
was O
similar O
in O
patients O
treated O
with O
sitagliptin O
and O
metformin O
( O
7.6 O
% O
) O
compared O
to O
patients O
treated O
with O
placebo O
and O
metformin O
( O
8.7 O
% O
) O
. O

In O
most O
but O
not O
all O
studies O
, O
a O
small O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
white I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
count I-OSE_Labeled_AE
( O
approximately O
200 O
cells/microL O
difference O
in O
WBC O
vs O
placebo O
; O
mean O
baseline O
WBC O
approximately O
6600 O
cells/microL O
) O
was O
observed O
due O
to O
a O
small O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
neutrophils I-OSE_Labeled_AE
. O

This O
change O
in O
laboratory O
parameters O
is O
not O
considered O
to O
be O
clinically O
relevant O
. O

Metformin O
hydrochloride O
In O
controlled O
clinical O
trials O
of O
metformin O
of O
29 O
weeks O
duration O
, O
a O
decrease B-OSE_Labeled_AE
to I-OSE_Labeled_AE
subnormal I-OSE_Labeled_AE
levels O
of O
previously O
normal O
serum O
Vitamin I-OSE_Labeled_AE
B I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
, O
without O
clinical O
manifestations O
, O
was O
observed O
in O
approximately O
7 O
% O
of O
patients O
. O

Such O
decrease O
, O
possibly O
due O
to O
interference B-NonOSE_AE
with I-NonOSE_AE
B I-NonOSE_AE
1 I-NonOSE_AE
2 I-NonOSE_AE
absorption I-NonOSE_AE
from O
the O
B12-intrinsic O
factor O
complex O
, O
is O
, O
however O
, O
very O
rarely O
associated O
with O
anemia B-NonOSE_AE
and O
appears O
to O
be O
rapidly O
reversible O
with O
discontinuation O
of O
metformin O
or O
Vitamin O
B12supplementation O
. O

[ O
See O
Warnings O
and O
Precautions O
( O
5.5 O
) O
. O
] O

6.2 O
Postmarketing O
Experience O
Additional O
adverse O
reactions O
have O
been O
identified O
during O
postapproval O
use O
of O
JANUMET O
, O
sitagliptin O
, O
or O
metformin O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
generally O
not O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
including O
anaphylaxis B-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
cutaneous B-OSE_Labeled_AE
vasculitis I-OSE_Labeled_AE
, O
and O
exfoliative B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
conditions I-OSE_Labeled_AE
including O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
; O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
; O
hepatic B-OSE_Labeled_AE
enzyme I-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
; O
acute B-OSE_Labeled_AE
pancreatitis I-OSE_Labeled_AE
, O
including O
fatal B-NonOSE_AE
and O
non-fatal O
hemorrhagic B-OSE_Labeled_AE
and O
necrotizing O
pancreatitis I-OSE_Labeled_AE
[ O
see O
Indications O
and O
Usage O
( O
1 O
) O
; O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
; O
worsening B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
function I-OSE_Labeled_AE
, O
including O
acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
( O
sometimes O
requiring O
dialysis O
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
; O
severe O
and O
disabling O
arthralgia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
; O
bullous B-OSE_Labeled_AE
pemphigoid I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.11 O
) O
] O
; O
constipation B-OSE_Labeled_AE
; O
vomiting B-OSE_Labeled_AE
; O
headache B-OSE_Labeled_AE
; O
myalgia B-OSE_Labeled_AE
; O
pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
; O
back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
; O
pruritus B-OSE_Labeled_AE
; O
cholestatic B-OSE_Labeled_AE
, O
hepatocellular O
, O
and O
mixed O
hepatocellular O
liver I-OSE_Labeled_AE
injury I-OSE_Labeled_AE
. O

BOXED O
WARNING O
: O
WARNING O
: O
LACTIC O
ACIDOSIS O
WARNING O
: O
LACTIC O
ACIDOSIS O
Postmarketing O
cases O
of O
metformin-associated O
lactic B-OSE_Labeled_AE
acidosis I-OSE_Labeled_AE
have O
resulted O
in O
death B-NonOSE_AE
, O
hypothermia B-NonOSE_AE
, O
hypotension B-NonOSE_AE
, O
and O
resistant O
bradyarrhythmias B-NonOSE_AE
. O

The O
onset O
of O
metformin-associated O
lactic B-NonOSE_AE
acidosis I-NonOSE_AE
is O
often O
subtle O
, O
accompanied O
only O
by O
nonspecific O
symptoms O
such O
as O
malaise B-NonOSE_AE
, O
myalgias B-NonOSE_AE
, O
respiratory B-NonOSE_AE
distress I-NonOSE_AE
, O
somnolence B-NonOSE_AE
, O
and O
abdominal B-NonOSE_AE
pain I-NonOSE_AE
. O

Metformin-associated O
lactic B-OSE_Labeled_AE
acidosis I-OSE_Labeled_AE
was O
characterized O
by O
elevated B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
lactate I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
( O
> O
5 O
mmol/Liter O
) O
, O
anion B-OSE_Labeled_AE
gap I-OSE_Labeled_AE
acidosis I-OSE_Labeled_AE
( O
without O
evidence O
of O
ketonuria B-NonOSE_AE
or O
ketonemia B-NonOSE_AE
) O
, O
an O
increased B-OSE_Labeled_AE
lactate I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
pyruvate I-OSE_Labeled_AE
ratio I-OSE_Labeled_AE
, O
and O
metformin O
plasma O
levels O
generally O
> O
5 O
mcg/mL O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

Risk O
factors O
for O
metformin-associated O
lactic B-NonOSE_AE
acidosis I-NonOSE_AE
include O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
, O
concomitant O
use O
of O
certain O
drugs O
( O
e.g. O
, O
carbonic O
anhydrase O
inhibitors O
such O
as O
topiramate O
) O
, O
age O
65 O
years O
old O
or O
greater O
, O
having O
a O
radiological O
study O
with O
contrast O
, O
surgery O
and O
other O
procedures O
, O
hypoxic B-Not_AE_Candidate
states I-Not_AE_Candidate
( O
e.g. O
, O
acute B-Not_AE_Candidate
congestive I-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
) O
, O
excessive O
alcohol O
intake O
, O
and O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
. O

Steps O
to O
reduce O
the O
risk O
of O
and O
manage O
metformin-associated O
lactic B-NonOSE_AE
acidosis I-NonOSE_AE
in O
these O
high O
risk O
groups O
are O
provided O
in O
the O
full O
prescribing O
information O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
, O
Contraindications O
( O
4 O
) O
, O
Warnings O
and O
Precautions O
( O
5.1 O
) O
, O
Drug O
Interactions O
( O
7 O
) O
, O
and O
Use O
in O
Specific O
Populations O
( O
8.6 O
, O
8.7 O
) O
] O
. O

If O
metformin-associated O
lactic B-NonOSE_AE
acidosis I-NonOSE_AE
is O
suspected O
, O
immediately O
discontinue O
JANUMET O
and O
institute O
general O
supportive O
measures O
in O
a O
hospital O
setting O
. O

Prompt O
hemodialysis O
is O
recommended O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

EXCERPT O
: O
WARNING O
: O
LACTIC O
ACIDOSIS O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
Postmarketing O
cases O
of O
metformin-associated O
lactic O
acidosis O
have O
resulted O
in O
death O
, O
hypothermia O
, O
hypotension O
, O
and O
resistant O
bradyarrhythmias O
. O

Symptoms O
included O
malaise O
, O
myalgias O
, O
respiratory O
distress O
, O
somnolence O
, O
and O
abdominal O
pain O
. O

Laboratory O
abnormalities O
included O
elevated O
blood O
lactate O
levels O
, O
anion O
gap O
acidosis O
, O
increased O
lactate/pyruvate O
ratio O
, O
and O
metformin O
plasma O
levels O
generally O
> O
5 O
mcg/mL O
. O

( O
5.1 O
) O
* O
Risk O
factors O
include O
renal O
impairment O
, O
concomitant O
use O
of O
certain O
drugs O
, O
age O
> O
=65 O
years O
old O
, O
radiological O
studies O
with O
contrast O
, O
surgery O
and O
other O
procedures O
, O
hypoxic O
states O
, O
excessive O
alcohol O
intake O
, O
and O
hepatic O
impairment O
. O

Steps O
to O
reduce O
the O
risk O
of O
and O
manage O
metformin-associated O
lactic O
acidosis O
in O
these O
high O
risk O
groups O
are O
provided O
in O
the O
Full O
Prescribing O
Information O
. O

( O
5.1 O
) O
* O
If O
lactic O
acidosis O
is O
suspected O
, O
discontinue O
JANUMET O
and O
institute O
general O
supportive O
measures O
in O
a O
hospital O
setting O
. O

Prompt O
hemodialysis O
is O
recommended O
. O

( O
5.1 O
) O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Lactic O
acidosis O
: O
See O
boxed O
warning O
. O

( O
5.1 O
) O
* O
There O
have O
been O
postmarketing O
reports O
of O
acute O
pancreatitis O
, O
including O
fatal O
and O
non-fatal O
hemorrhagic O
or O
necrotizing O
pancreatitis O
. O

If O
pancreatitis O
is O
suspected O
, O
promptly O
discontinue O
JANUMET O
. O

( O
5.2 O
) O
* O
Heart O
failure O
has O
been O
observed O
with O
two O
other O
members O
of O
the O
DPP-4 O
inhibitor O
class O
. O

Consider O
risks O
and O
benefits O
of O
JANUMET O
in O
patients O
who O
have O
known O
risk O
factors O
for O
heart O
failure O
. O

Monitor O
patients O
for O
signs O
and O
symptoms O
. O

( O
5.3 O
) O
* O
There O
have O
been O
postmarketing O
reports O
of O
acute O
renal O
failure O
, O
sometimes O
requiring O
dialysis O
. O

Before O
initiating O
JANUMET O
and O
at O
least O
annually O
thereafter O
, O
assess O
renal O
function O
. O

( O
5.4 O
) O
* O
Vitamin O
B12deficiency O
: O
Metformin O
may O
lower O
Vitamin O
B12levels O
. O

Measure O
hematologic O
parameters O
annually O
. O

( O
5.5 O
) O
* O
When O
used O
with O
an O
insulin O
secretagogue O
( O
e.g. O
, O
sulfonylurea O
) O
or O
with O
insulin O
, O
a O
lower O
dose O
of O
the O
insulin O
secretagogue O
or O
insulin O
may O
be O
required O
to O
reduce O
the O
risk O
of O
hypoglycemia O
. O

( O
5.7 O
) O
* O
There O
have O
been O
postmarketing O
reports O
of O
serious O
allergic O
and O
hypersensitivity O
reactions O
in O
patients O
treated O
with O
sitagliptin O
( O
one O
of O
the O
components O
of O
JANUMET O
) O
, O
such O
as O
anaphylaxis O
, O
angioedema O
, O
and O
exfoliative O
skin O
conditions O
including O
Stevens-Johnson O
syndrome O
. O

In O
such O
cases O
, O
promptly O
stop O
JANUMET O
, O
assess O
for O
other O
potential O
causes O
, O
institute O
appropriate O
monitoring O
and O
treatment O
, O
and O
initiate O
alternative O
treatment O
for O
diabetes O
. O

( O
5.9 O
) O
* O
Severe O
and O
disabling O
arthralgia O
has O
been O
reported O
in O
patients O
taking O
DPP-4 O
inhibitors O
. O

Consider O
as O
a O
possible O
cause O
for O
severe O
joint O
pain O
and O
discontinue O
drug O
if O
appropriate O
. O

( O
5.10 O
) O
* O
There O
have O
been O
postmarketing O
reports O
of O
bullous O
pemphigoid O
requiring O
hospitalization O
in O
patients O
taking O
DPP-4 O
inhibitors O
. O

Tell O
patients O
to O
report O
development O
of O
blisters O
or O
erosions O
. O

If O
bullous O
pemphigoid O
is O
suspected O
, O
discontinue O
JANUMET O
. O

( O
5.11 O
) O
* O
There O
have O
been O
no O
clinical O
studies O
establishing O
conclusive O
evidence O
of O
macrovascular O
risk O
reduction O
with O
JANUMET O
or O
any O
other O
anti-diabetic O
drug O
. O

( O
5.12 O
) O
5.1 O
Lactic O
Acidosis O
Metformin O
hydrochloride O
There O
have O
been O
postmarketing O
cases O
of O
metformin-associated O
lactic B-OSE_Labeled_AE
acidosis I-OSE_Labeled_AE
, O
including O
fatal B-NonOSE_AE
cases O
. O

These O
cases O
had O
a O
subtle O
onset O
and O
were O
accompanied O
by O
nonspecific O
symptoms O
such O
as O
malaise B-NonOSE_AE
, O
myalgias B-NonOSE_AE
, O
abdominal B-NonOSE_AE
pain I-NonOSE_AE
, O
respiratory B-NonOSE_AE
distress I-NonOSE_AE
, O
or O
increased B-NonOSE_AE
somnolence I-NonOSE_AE
; O
however O
, O
hypothermia B-NonOSE_AE
, O
hypotension B-NonOSE_AE
and O
resistant O
bradyarrhythmias B-NonOSE_AE
have O
occurred O
with O
severe O
acidosis B-NonOSE_AE
. O

Metformin-associated O
lactic B-OSE_Labeled_AE
acidosis I-OSE_Labeled_AE
was O
characterized O
by O
elevated B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
lactate I-OSE_Labeled_AE
concentrations I-OSE_Labeled_AE
( O
> O
5 O
mmol/Liter O
) O
, O
anion B-OSE_Labeled_AE
gap I-OSE_Labeled_AE
acidosis I-OSE_Labeled_AE
( O
without O
evidence O
of O
ketonuria B-NonOSE_AE
or O
ketonemia B-NonOSE_AE
) O
, O
and O
an O
increased B-OSE_Labeled_AE
lactate I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
pyruvate I-OSE_Labeled_AE
ratio I-OSE_Labeled_AE
; O
metformin O
plasma O
levels O
were O
generally O
> O
5 O
mcg/mL O
. O

Metformin O
decreases O
liver O
uptake O
of O
lactate O
increasing B-OSE_Labeled_AE
lactate I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
which O
may O
increase O
the O
risk O
of O
lactic B-OSE_Labeled_AE
acidosis I-OSE_Labeled_AE
, O
especially O
in O
patients O
at O
risk O
. O

If O
metformin-associated O
lactic B-NonOSE_AE
acidosis I-NonOSE_AE
is O
suspected O
, O
general O
supportive O
measures O
should O
be O
instituted O
promptly O
in O
a O
hospital O
setting O
, O
along O
with O
immediate O
discontinuation O
of O
JANUMET O
. O

In O
JANUMET-treated O
patients O
with O
a O
diagnosis O
or O
strong O
suspicion O
of O
lactic B-NonOSE_AE
acidosis I-NonOSE_AE
, O
prompt O
hemodialysis O
is O
recommended O
to O
correct O
the O
acidosis B-NonOSE_AE
and O
remove O
accumulated O
metformin O
( O
metformin O
hydrochloride O
is O
dialyzable O
, O
with O
a O
clearance O
of O
up O
to O
170 O
mL/min O
under O
good O
hemodynamic O
conditions O
) O
. O

Hemodialysis O
has O
often O
resulted O
in O
reversal O
of O
symptoms O
and O
recovery O
. O

Educate O
patients O
and O
their O
families O
about O
the O
symptoms O
of O
lactic B-NonOSE_AE
acidosis I-NonOSE_AE
and O
if O
these O
symptoms O
occur O
instruct O
them O
to O
discontinue O
JANUMET O
and O
report O
these O
symptoms O
to O
their O
health O
care O
provider O
. O

For O
each O
of O
the O
known O
and O
possible O
risk O
factors O
for O
metformin-associated O
lactic B-NonOSE_AE
acidosis I-NonOSE_AE
, O
recommendations O
to O
reduce O
the O
risk O
of O
and O
manage O
metformin-associated O
lactic B-NonOSE_AE
acidosis I-NonOSE_AE
are O
provided O
below O
: O
Renal O
Impairment O
The O
postmarketing O
metformin-associated O
lactic B-OSE_Labeled_AE
acidosis I-OSE_Labeled_AE
cases O
primarily O
occurred O
in O
patients O
with O
significant O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
. O

The O
risk O
of O
metformin O
accumulation O
and O
metformin-associated O
lactic B-NonOSE_AE
acidosis I-NonOSE_AE
increases O
with O
the O
severity O
of O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
because O
metformin O
is O
substantially O
excreted O
by O
the O
kidney O
. O

Clinical O
recommendations O
based O
upon O
the O
patient O
's O
renal O
function O
include O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
, O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
: O
* O
Before O
initiating O
JANUMET O
, O
obtain O
an O
estimated O
glomerular O
filtration O
rate O
( O
eGFR O
) O
. O

* O
JANUMET O
is O
contraindicated O
in O
patients O
with O
an O
eGFR B-Not_AE_Candidate
below I-Not_AE_Candidate
3 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
/ I-Not_AE_Candidate
1 I-Not_AE_Candidate
. I-Not_AE_Candidate
7 I-Not_AE_Candidate
3 I-Not_AE_Candidate
m I-Not_AE_Candidate
2 I-Not_AE_Candidate
[ O
see O
Contraindications O
( O
4 O
) O
] O
. O

* O
JANUMET O
is O
not O
recommended O
in O
patients O
with O
an O
eGFR B-Not_AE_Candidate
between I-Not_AE_Candidate
3 I-Not_AE_Candidate
0 I-Not_AE_Candidate
and I-Not_AE_Candidate
< I-Not_AE_Candidate
4 I-Not_AE_Candidate
5 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
/ I-Not_AE_Candidate
1 I-Not_AE_Candidate
. I-Not_AE_Candidate
7 I-Not_AE_Candidate
3 I-Not_AE_Candidate
m I-Not_AE_Candidate
2 I-Not_AE_Candidate
because O
these O
patients O
require O
a O
lower O
dosage O
of O
sitagliptin O
than O
what O
is O
available O
in O
the O
fixed O
combination O
JANUMET O
product O
. O

* O
Obtain O
an O
eGFR O
at O
least O
annually O
in O
all O
patients O
taking O
JANUMET O
. O

In O
patients O
at O
increased O
risk O
for O
the O
development O
of O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
( O
e.g. O
, O
the O
elderly O
) O
, O
renal O
function O
should O
be O
assessed O
more O
frequently O
. O

Drug O
Interactions O
The O
concomitant O
use O
of O
JANUMET O
with O
specific O
drugs O
may O
increase O
the O
risk O
of O
metformin-associated O
lactic B-NonOSE_AE
acidosis I-NonOSE_AE
: O
those O
that O
impair B-NonOSE_AE
renal I-NonOSE_AE
function I-NonOSE_AE
, O
result O
in O
significant O
hemodynamic B-NonOSE_AE
change I-NonOSE_AE
, O
interfere B-NonOSE_AE
with I-NonOSE_AE
acid I-NonOSE_AE
- I-NonOSE_AE
base I-NonOSE_AE
balance I-NonOSE_AE
or O
increase O
metformin O
accumulation O
[ O
see O
Drug O
Interactions O
( O
7 O
) O
] O
. O

Therefore O
, O
consider O
more O
frequent O
monitoring O
of O
patients O
. O

Age O
65 O
or O
Greater O
The O
risk O
of O
metformin-associated O
lactic B-OSE_Labeled_AE
acidosis I-OSE_Labeled_AE
increases O
with O
the O
patient O
's O
age O
because O
elderly O
patients O
have O
a O
greater O
likelihood O
of O
having O
hepatic B-Not_AE_Candidate
, O
renal O
, O
or O
cardiac O
impairment I-Not_AE_Candidate
than O
younger O
patients O
. O

Assess O
renal O
function O
more O
frequently O
in O
elderly O
patients O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.5 O
) O
] O
. O

Radiological O
Studies O
with O
Contrast O
Administration O
of O
intravascular O
iodinated O
contrast O
agents O
in O
metformin-treated O
patients O
has O
led O
to O
an O
acute O
decrease B-NonOSE_AE
in I-NonOSE_AE
renal I-NonOSE_AE
function I-NonOSE_AE
and O
the O
occurrence O
of O
lactic B-NonOSE_AE
acidosis I-NonOSE_AE
. O

Stop O
JANUMET O
at O
the O
time O
of O
, O
or O
prior O
to O
, O
an O
iodinated O
contrast O
imaging O
procedure O
in O
patients O
with O
an O
eGFR B-Not_AE_Candidate
between I-Not_AE_Candidate
3 I-Not_AE_Candidate
0 I-Not_AE_Candidate
and I-Not_AE_Candidate
6 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
/ I-Not_AE_Candidate
1 I-Not_AE_Candidate
. I-Not_AE_Candidate
7 I-Not_AE_Candidate
3 I-Not_AE_Candidate
m I-Not_AE_Candidate
2 I-Not_AE_Candidate
; O
in O
patients O
with O
a O
history O
of O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
, O
alcoholism O
, O
or O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
; O
or O
in O
patients O
who O
will O
be O
administered O
intra-arterial O
iodinated O
contrast O
. O

Re-evaluate O
eGFR O
48 O
hours O
after O
the O
imaging O
procedure O
, O
and O
restart O
JANUMET O
if O
renal O
function O
is O
stable O
. O

Surgery O
and O
Other O
Procedures O
Withholding O
of O
food O
and O
fluids O
during O
surgical O
or O
other O
procedures O
may O
increase O
the O
risk O
for O
volume B-NonOSE_AE
depletion I-NonOSE_AE
, O
hypotension B-NonOSE_AE
and O
renal B-NonOSE_AE
impairment I-NonOSE_AE
. O

JANUMET O
should O
be O
temporarily O
discontinued O
while O
patients O
have O
restricted O
food O
and O
fluid O
intake O
. O

Hypoxic O
States O
Several O
of O
the O
postmarketing O
cases O
of O
metformin-associated O
lactic B-OSE_Labeled_AE
acidosis I-OSE_Labeled_AE
occurred O
in O
the O
setting O
of O
acute B-Not_AE_Candidate
congestive I-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
( O
particularly O
when O
accompanied O
by O
hypoperfusion B-Not_AE_Candidate
and O
hypoxemia B-Not_AE_Candidate
) O
. O

Cardiovascular B-Not_AE_Candidate
collapse I-Not_AE_Candidate
( O
shock B-Not_AE_Candidate
) O
, O
acute B-Not_AE_Candidate
myocardial I-Not_AE_Candidate
infarction I-Not_AE_Candidate
, O
sepsis B-Not_AE_Candidate
, O
and O
other O
conditions O
associated O
with O
hypoxemia B-Not_AE_Candidate
have O
been O
associated O
with O
lactic B-NonOSE_AE
acidosis I-NonOSE_AE
and O
may O
also O
cause O
prerenal B-NonOSE_AE
azotemia I-NonOSE_AE
. O

When O
such O
events O
occur O
, O
discontinue O
JANUMET O
. O

Excessive O
Alcohol O
Intake O
Alcohol O
potentiates O
the O
effect O
of O
metformin O
on O
lactate O
metabolism O
and O
this O
may O
increase O
the O
risk O
of O
metformin-associated O
lactic B-NonOSE_AE
acidosis I-NonOSE_AE
. O

Warn O
patients O
against O
excessive O
alcohol O
intake O
while O
receiving O
JANUMET O
. O

Hepatic O
Impairment O
Patients O
with O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
have O
developed O
with O
cases O
of O
metformin-associated O
lactic B-OSE_Labeled_AE
acidosis I-OSE_Labeled_AE
. O

This O
may O
be O
due O
to O
impaired O
lactate O
clearance O
resulting O
in O
higher B-NonOSE_AE
lactate I-NonOSE_AE
blood I-NonOSE_AE
levels I-NonOSE_AE
. O

Therefore O
, O
avoid O
use O
of O
JANUMET O
in O
patients O
with O
clinical O
or O
laboratory O
evidence O
of O
hepatic B-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

5.2 O
Pancreatitis O
There O
have O
been O
postmarketing O
reports O
of O
acute B-OSE_Labeled_AE
pancreatitis I-OSE_Labeled_AE
, O
including O
fatal B-NonOSE_AE
and O
non-fatal O
hemorrhagic B-OSE_Labeled_AE
or O
necrotizing O
pancreatitis I-OSE_Labeled_AE
, O
in O
patients O
taking O
JANUMET O
. O

After O
initiation O
of O
JANUMET O
, O
patients O
should O
be O
observed O
carefully O
for O
signs O
and O
symptoms O
of O
pancreatitis B-NonOSE_AE
. O

If O
pancreatitis B-NonOSE_AE
is O
suspected O
, O
JANUMET O
should O
promptly O
be O
discontinued O
and O
appropriate O
management O
should O
be O
initiated O
. O

It O
is O
unknown O
whether O
patients O
with O
a O
history O
of O
pancreatitis B-Not_AE_Candidate
are O
at O
increased O
risk O
for O
the O
development O
of O
pancreatitis B-NonOSE_AE
while O
using O
JANUMET O
. O

5.3 O
Heart O
Failure O
An O
association O
between O
dipeptidyl O
peptidase-4 O
( O
DPP-4 O
) O
inhibitor O
treatment O
and O
heart B-NonOSE_AE
failure I-NonOSE_AE
has O
been O
observed O
in O
cardiovascular O
outcomes O
trials O
for O
two O
other O
members O
of O
the O
DPP-4 O
inhibitor O
class O
. O

These O
trials O
evaluated O
patients O
with O
type B-Not_AE_Candidate
2 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
mellitus I-Not_AE_Candidate
and O
atherosclerotic B-Not_AE_Candidate
cardiovascular I-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

Consider O
the O
risks O
and O
benefits O
of O
JANUMET O
prior O
to O
initiating O
treatment O
in O
patients O
at O
risk O
for O
heart B-NonOSE_AE
failure I-NonOSE_AE
, O
such O
as O
those O
with O
a O
prior O
history O
of O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
and O
a O
history O
of O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
, O
and O
observe O
these O
patients O
for O
signs O
and O
symptoms O
of O
heart B-NonOSE_AE
failure I-NonOSE_AE
during O
therapy O
. O

Advise O
patients O
of O
the O
characteristic O
symptoms O
of O
heart B-NonOSE_AE
failure I-NonOSE_AE
and O
to O
immediately O
report O
such O
symptoms O
. O

If O
heart B-NonOSE_AE
failure I-NonOSE_AE
develops O
, O
evaluate O
and O
manage O
according O
to O
current O
standards O
of O
care O
and O
consider O
discontinuation O
of O
JANUMET O
. O

5.4 O
Assessment O
of O
Renal O
Function O
Metformin O
and O
sitagliptin O
are O
known O
to O
be O
substantially O
excreted O
by O
the O
kidney O
. O

Metformin O
hydrochloride O
JANUMET O
is O
contraindicated O
in O
patients O
with O
severe O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
[ O
see O
Contraindications O
( O
4 O
) O
and O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

Sitagliptin O
There O
have O
been O
postmarketing O
reports O
of O
worsening B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
function I-OSE_Labeled_AE
, O
including O
acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
sometimes O
requiring O
dialysis O
. O

Before O
initiation O
of O
therapy O
with O
JANUMET O
and O
at O
least O
annually O
thereafter O
, O
renal O
function O
should O
be O
assessed O
. O

In O
patients O
in O
whom O
development O
of O
renal B-NonOSE_AE
dysfunction I-NonOSE_AE
is O
anticipated O
, O
particularly O
in O
elderly O
patients O
, O
renal O
function O
should O
be O
assessed O
more O
frequently O
and O
JANUMET O
discontinued O
if O
evidence O
of O
renal B-NonOSE_AE
impairment I-NonOSE_AE
is O
present O
. O

5.5 O
Vitamin O
B12Levels O
In O
controlled O
clinical O
trials O
of O
metformin O
of O
29 O
weeks O
duration O
, O
a O
decrease B-OSE_Labeled_AE
to I-OSE_Labeled_AE
subnormal I-OSE_Labeled_AE
levels O
of O
previously O
normal O
serum O
Vitamin I-OSE_Labeled_AE
B I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
, O
without O
clinical O
manifestations O
, O
was O
observed O
in O
approximately O
7 O
% O
of O
patients O
. O

Such O
decrease O
, O
possibly O
due O
to O
interference B-NonOSE_AE
with I-NonOSE_AE
B I-NonOSE_AE
1 I-NonOSE_AE
2 I-NonOSE_AE
absorption I-NonOSE_AE
from O
the O
B12-intrinsic O
factor O
complex O
, O
is O
, O
however O
, O
very O
rarely O
associated O
with O
anemia B-NonOSE_AE
and O
appears O
to O
be O
rapidly O
reversible O
with O
discontinuation O
of O
metformin O
or O
Vitamin O
B12supplementation O
. O

Measurement O
of O
hematologic O
parameters O
on O
an O
annual O
basis O
is O
advised O
in O
patients O
on O
JANUMET O
and O
any O
apparent O
abnormalities O
should O
be O
appropriately O
investigated O
and O
managed O
. O

[ O
See O
Adverse O
Reactions O
( O
6.1 O
) O
. O
] O

Certain O
individuals O
( O
those O
with O
inadequate B-Not_AE_Candidate
Vitamin I-Not_AE_Candidate
B I-Not_AE_Candidate
1 I-Not_AE_Candidate
2 I-Not_AE_Candidate
or O
calcium O
intake O
or O
absorption I-Not_AE_Candidate
) O
appear O
to O
be O
predisposed O
to O
developing O
subnormal B-NonOSE_AE
Vitamin I-NonOSE_AE
B I-NonOSE_AE
1 I-NonOSE_AE
2 I-NonOSE_AE
levels I-NonOSE_AE
. O

In O
these O
patients O
, O
routine O
serum O
Vitamin O
B12measurements O
at O
two- O
to O
three-year O
intervals O
may O
be O
useful O
. O

5.6 O
Change O
in O
Clinical O
Status O
of O
Patients O
with O
Previously O
Controlled O
Type O
2 O
Diabetes O
A O
patient O
with O
type B-Not_AE_Candidate
2 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
previously O
well O
controlled O
on O
JANUMET O
who O
develops O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
or O
clinical O
illness O
( O
especially O
vague O
and O
poorly O
defined O
illness O
) O
should O
be O
evaluated O
promptly O
for O
evidence O
of O
ketoacidosis B-NonOSE_AE
or O
lactic B-NonOSE_AE
acidosis I-NonOSE_AE
. O

Evaluation O
should O
include O
serum O
electrolytes O
and O
ketones O
, O
blood O
glucose O
and O
, O
if O
indicated O
, O
blood O
pH O
, O
lactate O
, O
pyruvate O
, O
and O
metformin O
levels O
. O

If O
acidosis B-NonOSE_AE
of O
either O
form O
occurs O
, O
JANUMET O
must O
be O
stopped O
immediately O
and O
other O
appropriate O
corrective O
measures O
initiated O
. O

5.7 O
Use O
with O
Medications O
Known O
to O
Cause O
Hypoglycemia O
Sitagliptin O
When O
sitagliptin O
was O
used O
in O
combination O
with O
a O
sulfonylurea O
or O
with O
insulin O
, O
medications O
known O
to O
cause O
hypoglycemia B-NonOSE_AE
, O
the O
incidence O
of O
hypoglycemia B-NonOSE_AE
was O
increased O
over O
that O
of O
placebo O
used O
in O
combination O
with O
a O
sulfonylurea O
or O
with O
insulin O
[ O
see O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

Therefore O
, O
patients O
also O
receiving O
an O
insulin O
secretagogue O
( O
e.g. O
, O
sulfonylurea O
) O
or O
insulin O
may O
require O
a O
lower O
dose O
of O
the O
insulin O
secretagogue O
or O
insulin O
to O
reduce O
the O
risk O
of O
hypoglycemia B-NonOSE_AE
[ O
see O
Drug O
Interactions O
( O
7.4 O
) O
] O
. O

Metformin O
hydrochloride O
Hypoglycemia B-NonOSE_AE
does O
not O
occur O
in O
patients O
receiving O
metformin O
alone O
under O
usual O
circumstances O
of O
use O
, O
but O
could O
occur O
when O
caloric O
intake O
is O
deficient O
, O
when O
strenuous O
exercise O
is O
not O
compensated O
by O
caloric O
supplementation O
, O
or O
during O
concomitant O
use O
with O
other O
glucose-lowering O
agents O
( O
such O
as O
sulfonylureas O
and O
insulin O
) O
or O
ethanol O
. O

Elderly O
, O
debilitated B-Not_AE_Candidate
, O
or O
malnourished O
patients O
, O
and O
those O
with O
adrenal B-Not_AE_Candidate
or O
pituitary O
insufficiency I-Not_AE_Candidate
or O
alcohol B-Not_AE_Candidate
intoxication I-Not_AE_Candidate
are O
particularly O
susceptible O
to O
hypoglycemic B-OSE_Labeled_AE
effects I-OSE_Labeled_AE
. O

Hypoglycemia B-NonOSE_AE
may O
be O
difficult O
to O
recognize O
in O
the O
elderly O
, O
and O
in O
people O
who O
are O
taking O
beta-adrenergic O
blocking O
drugs O
. O

5.8 O
Loss O
of O
Control O
of O
Blood O
Glucose O
When O
a O
patient O
stabilized O
on O
any O
diabetic O
regimen O
is O
exposed O
to O
stress O
such O
as O
fever B-Not_AE_Candidate
, O
trauma B-Not_AE_Candidate
, O
infection B-Not_AE_Candidate
, O
or O
surgery O
, O
a O
temporary O
loss B-NonOSE_AE
of I-NonOSE_AE
glycemic I-NonOSE_AE
control I-NonOSE_AE
may O
occur O
. O

At O
such O
times O
, O
it O
may O
be O
necessary O
to O
withhold O
JANUMET O
and O
temporarily O
administer O
insulin O
. O

JANUMET O
may O
be O
reinstituted O
after O
the O
acute O
episode O
is O
resolved O
. O

5.9 O
Hypersensitivity O
Reactions O
There O
have O
been O
postmarketing O
reports O
of O
serious O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
in O
patients O
treated O
with O
sitagliptin O
, O
one O
of O
the O
components O
of O
JANUMET O
. O

These O
reactions O
include O
anaphylaxis B-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
, O
and O
exfoliative B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
conditions I-OSE_Labeled_AE
including O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
. O

Onset O
of O
these O
reactions O
occurred O
within O
the O
first O
3 O
months O
after O
initiation O
of O
treatment O
with O
sitagliptin O
, O
with O
some O
reports O
occurring O
after O
the O
first O
dose O
. O

If O
a O
hypersensitivity B-NonOSE_AE
reaction I-NonOSE_AE
is O
suspected O
, O
discontinue O
JANUMET O
, O
assess O
for O
other O
potential O
causes O
for O
the O
event O
, O
and O
institute O
alternative O
treatment O
for O
diabetes B-Not_AE_Candidate
. O

[ O
See O
Adverse O
Reactions O
( O
6.2 O
) O
. O
] O

Angioedema B-NonOSE_AE
has O
also O
been O
reported O
with O
other O
DPP-4 O
inhibitors O
. O

Use O
caution O
in O
a O
patient O
with O
a O
history O
of O
angioedema B-Not_AE_Candidate
with O
another O
DPP-4 O
inhibitor O
because O
it O
is O
unknown O
whether O
such O
patients O
will O
be O
predisposed O
to O
angioedema B-NonOSE_AE
with O
JANUMET O
. O

5.10 O
Severe O
and O
Disabling O
Arthralgia O
There O
have O
been O
postmarketing O
reports O
of O
severe O
and O
disabling O
arthralgia B-OSE_Labeled_AE
in O
patients O
taking O
DPP-4 O
inhibitors O
. O

The O
time O
to O
onset O
of O
symptoms O
following O
initiation O
of O
drug O
therapy O
varied O
from O
one O
day O
to O
years O
. O

Patients O
experienced O
relief O
of O
symptoms O
upon O
discontinuation O
of O
the O
medication O
. O

A O
subset O
of O
patients O
experienced O
a O
recurrence O
of O
symptoms O
when O
restarting O
the O
same O
drug O
or O
a O
different O
DPP-4 O
inhibitor O
. O

Consider O
DPP-4 O
inhibitors O
as O
a O
possible O
cause O
for O
severe O
joint B-NonOSE_AE
pain I-NonOSE_AE
and O
discontinue O
drug O
if O
appropriate O
. O

5.11 O
Bullous O
Pemphigoid O
Postmarketing O
cases O
of O
bullous B-OSE_Labeled_AE
pemphigoid I-OSE_Labeled_AE
requiring O
hospitalization O
have O
been O
reported O
with O
DPP-4 O
inhibitor O
use O
. O

In O
reported O
cases O
, O
patients O
typically O
recovered O
with O
topical O
or O
systemic O
immunosuppressive B-NonOSE_AE
treatment I-NonOSE_AE
and O
discontinuation O
of O
the O
DPP-4 O
inhibitor O
. O

Tell O
patients O
to O
report O
development O
of O
blisters B-NonOSE_AE
or O
erosions B-NonOSE_AE
while O
receiving O
JANUMET O
. O

If O
bullous B-NonOSE_AE
pemphigoid I-NonOSE_AE
is O
suspected O
, O
JANUMET O
should O
be O
discontinued O
and O
referral O
to O
a O
dermatologist O
should O
be O
considered O
for O
diagnosis O
and O
appropriate O
treatment O
. O

5.12 O
Macrovascular O
Outcomes O
There O
have O
been O
no O
clinical O
studies O
establishing O
conclusive O
evidence O
of O
macrovascular B-NonOSE_AE
risk O
reduction O
with O
JANUMET O
or O
any O
other O
anti-diabetic O
drug O
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
serious O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
the O
label O
: O
* O
Rhabdomyolysis B-OSE_Labeled_AE
with O
myoglobinuria B-OSE_Labeled_AE
and O
acute B-NonOSE_AE
renal I-NonOSE_AE
failure I-NonOSE_AE
and O
myopathy B-OSE_Labeled_AE
( O
including O
myositis B-OSE_Labeled_AE
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

* O
Liver B-OSE_Labeled_AE
Enzyme I-OSE_Labeled_AE
Abnormalities I-OSE_Labeled_AE
[ O
see O
Warning O
and O
Precautions O
( O
5.2 O
) O
] O
. O

Of O
4,798 O
patients O
enrolled O
in O
10 O
controlled O
clinical O
studies O
and O
4 O
subsequent O
open-label O
extension O
studies O
, O
3,291 O
patients O
were O
administered O
pitavastatin O
1 O
mg O
to O
4 O
mg O
daily O
. O

The O
mean O
continuous O
exposure O
of O
pitavastatin O
( O
1 O
mg O
to O
4 O
mg O
) O
was O
36.7 O
weeks O
( O
median O
51.1 O
weeks O
) O
. O

The O
mean O
age O
of O
the O
patients O
was O
60.9 O
years O
( O
range O
; O
18 O
years O
- O
89 O
years O
) O
and O
the O
gender O
distribution O
was O
48 O
% O
males O
and O
52 O
% O
females O
. O

Approximately O
93 O
% O
of O
the O
patients O
were O
Caucasian O
, O
7 O
% O
were O
Asian/Indian O
, O
0.2 O
% O
were O
African O
American O
and O
0.3 O
% O
were O
Hispanic O
and O
other O
. O

EXCERPT O
: O
The O
most O
frequent O
adverse O
reactions O
( O
rate O
> O
=2.0 O
% O
in O
at O
least O
one O
marketed O
dose O
) O
were O
myalgia O
, O
back O
pain O
, O
diarrhea O
, O
constipation O
and O
pain O
in O
extremity O
. O

( O
6 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Kowa O
Pharmaceuticals O
America O
, O
Inc O
. O
at O
1-877-334-3464 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Studies O
Experience O
Because O
clinical O
studies O
on O
LIVALO O
are O
conducted O
in O
varying O
study O
populations O
and O
study O
designs O
, O
the O
frequency O
of O
adverse O
reactions O
observed O
in O
the O
clinical O
studies O
of O
LIVALO O
can O
not O
be O
directly O
compared O
with O
that O
in O
the O
clinical O
studies O
of O
other O
HMG-CoA O
reductase O
inhibitors O
and O
may O
not O
reflect O
the O
frequency O
of O
adverse O
reactions O
observed O
in O
clinical O
practice O
. O

Adverse O
reactions O
reported O
in O
> O
= O
2 O
% O
of O
patients O
in O
controlled O
clinical O
studies O
and O
at O
a O
rate O
greater O
than O
or O
equal O
to O
placebo O
are O
shown O
in O
Table O
1 O
. O

These O
studies O
had O
treatment O
duration O
of O
up O
to O
12 O
weeks O
. O

Table O
1 O
. O

Adverse O
Reactions* O
Reported O
by O
> O
=2.0 O
% O
of O
Patients O
Treated O
with O
LIVALO O
and O
> O
Placebo O
in O
Short-Term O
Controlled O
Studies O
* O
Adverse O
reactions O
by O
MedDRA O
preferred O
term O
. O

AdverseReactions* O
PlaceboN= O
208 O
LIVALO1 O
mgN=309 O
LIVALO2 O
mgN=951 O
LIVALO4 O
mgN=1540 O
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
2.9 O
% O
3.9 O
% O
1.8 O
% O
1.4 O
% O
Constipation B-OSE_Labeled_AE
1.9 O
% O
3.6 O
% O
1.5 O
% O
2.2 O
% O
Diarrhea B-OSE_Labeled_AE
1.9 O
% O
2.6 O
% O
1.5 O
% O
1.9 O
% O
Myalgia B-OSE_Labeled_AE
1.4 O
% O
1.9 O
% O
2.8 O
% O
3.1 O
% O
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
1.9 O
% O
2.3 O
% O
0.6 O
% O
0.9 O
% O
Other O
adverse O
reactions O
reported O
from O
clinical O
studies O
were O
arthralgia B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
influenza B-OSE_Labeled_AE
, O
and O
nasopharyngitis B-OSE_Labeled_AE
. O

The O
following O
laboratory O
abnormalities O
have O
also O
been O
reported O
: O
elevated B-OSE_Labeled_AE
creatine I-OSE_Labeled_AE
phosphokinase I-OSE_Labeled_AE
, O
transaminases O
, O
alkaline O
phosphatase O
, O
bilirubin O
, O
and O
glucose O
. O

In O
controlled O
clinical O
studies O
and O
their O
open-label O
extensions O
, O
3.9 O
% O
( O
1 O
mg O
) O
, O
3.3 O
% O
( O
2 O
mg O
) O
, O
and O
3.7 O
% O
( O
4 O
mg O
) O
of O
pitavastatin-treated O
patients O
were O
discontinued O
due O
to O
adverse O
reactions O
. O

The O
most O
common O
adverse O
reactions O
that O
led O
to O
treatment O
discontinuation O
were O
: O
elevated B-OSE_Labeled_AE
creatine I-OSE_Labeled_AE
phosphokinase I-OSE_Labeled_AE
( O
0.6 O
% O
on O
4 O
mg O
) O
and O
myalgia B-OSE_Labeled_AE
( O
0.5 O
% O
on O
4 O
mg O
) O
. O

Hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
including O
rash B-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
and O
urticaria B-OSE_Labeled_AE
have O
been O
reported O
with O
LIVALO O
. O

6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
postapproval O
use O
of O
LIVALO O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Adverse O
reactions O
associated O
with O
LIVALO O
therapy O
reported O
since O
market O
introduction O
, O
regardless O
of O
causality O
assessment O
, O
include O
the O
following O
: O
abdominal B-OSE_Labeled_AE
discomfort I-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
dyspepsia B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
asthenia B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
malaise B-OSE_Labeled_AE
, O
hepatitis B-OSE_Labeled_AE
, O
jaundice B-OSE_Labeled_AE
, O
fatal B-NonOSE_AE
and O
non-fatal O
hepatic B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
hypoesthesia B-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
, O
interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
, O
erectile B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
and O
muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
. O

There O
have O
been O
rare O
postmarketing O
reports O
of O
cognitive B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
( O
e.g. O
, O
memory B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
, O
forgetfulness B-OSE_Labeled_AE
, O
amnesia B-OSE_Labeled_AE
, O
memory B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
, O
confusion B-OSE_Labeled_AE
) O
associated O
with O
statin O
use O
. O

These O
cognitive B-OSE_Labeled_AE
issues I-OSE_Labeled_AE
have O
been O
reported O
for O
all O
statins O
. O

The O
reports O
are O
generally O
nonserious O
, O
and O
reversible O
upon O
statin O
discontinuation O
, O
with O
variable O
times O
to O
symptom O
onset O
( O
1 O
day O
to O
years O
) O
and O
symptom O
resolution O
( O
median O
of O
3 O
weeks O
) O
. O

There O
have O
been O
rare O
reports O
of O
immune B-OSE_Labeled_AE
- I-OSE_Labeled_AE
mediated I-OSE_Labeled_AE
necrotizing I-OSE_Labeled_AE
myopathy I-OSE_Labeled_AE
associated O
with O
statin O
use O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Skeletal O
muscle O
effects O
( O
e.g. O
, O
myopathy O
and O
rhabdomyolysis O
) O
: O
Risks O
increase O
in O
a O
dose-dependent O
manner O
, O
with O
advanced O
age O
( O
> O
=65 O
) O
, O
renal O
impairment O
, O
and O
inadequately O
treated O
hypothyroidism O
. O

Advise O
patients O
to O
promptly O
report O
unexplained O
and/or O
persistent O
muscle O
pain O
, O
tenderness O
, O
or O
weakness O
, O
and O
discontinue O
LIVALO O
( O
5.1 O
) O
* O
Liver O
enzyme O
abnormalities O
: O
Persistent O
elevations O
in O
hepatic O
transaminases O
can O
occur O
. O

Check O
liver O
enzyme O
tests O
before O
initiating O
therapy O
and O
as O
clinically O
indicated O
thereafter O
( O
5.2 O
) O
5.1 O
Skeletal O
Muscle O
Effects O
Cases O
of O
myopathy B-OSE_Labeled_AE
and O
rhabdomyolysis B-OSE_Labeled_AE
with O
acute B-NonOSE_AE
renal I-NonOSE_AE
failure I-NonOSE_AE
secondary O
to O
myoglobinuria B-OSE_Labeled_AE
have O
been O
reported O
with O
HMG-CoA O
reductase O
inhibitors O
, O
including O
LIVALO O
. O

These O
risks O
can O
occur O
at O
any O
dose O
level O
, O
but O
increase O
in O
a O
dose-dependent O
manner O
. O

LIVALO O
should O
be O
prescribed O
with O
caution O
in O
patients O
with O
predisposing O
factors O
for O
myopathy B-NonOSE_AE
. O

These O
factors O
include O
advanced O
age O
( O
> O
=65 O
years O
) O
, O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
, O
and O
inadequately O
treated O
hypothyroidism B-Not_AE_Candidate
. O

The O
risk O
of O
myopathy B-NonOSE_AE
may O
also O
be O
increased O
with O
concurrent O
administration O
of O
fibrates O
or O
lipid-modifying O
doses O
of O
niacin O
. O

LIVALO O
should O
be O
administered O
with O
caution O
in O
patients O
with O
impaired B-Not_AE_Candidate
renal I-Not_AE_Candidate
function I-Not_AE_Candidate
, O
in O
elderly O
patients O
, O
or O
when O
used O
concomitantly O
with O
fibrates O
or O
lipid-modifying O
doses O
of O
niacin O
[ O
see O
Drug O
Interactions O
( O
7.6 O
) O
, O
Use O
in O
Specific O
Populations O
( O
8.5 O
, O
8.6 O
) O
and O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

Cases O
of O
myopathy B-NonOSE_AE
, O
including O
rhabdomyolysis B-NonOSE_AE
, O
have O
been O
reported O
with O
HMG-CoA O
reductase O
inhibitors O
coadministered O
with O
colchicine O
, O
and O
caution O
should O
be O
exercised O
when O
prescribing O
LIVALO O
with O
colchicine O
[ O
see O
Drug O
Interactions O
( O
7.7 O
) O
] O
. O

There O
have O
been O
rare O
reports O
of O
immune B-OSE_Labeled_AE
- I-OSE_Labeled_AE
mediated I-OSE_Labeled_AE
necrotizing I-OSE_Labeled_AE
myopathy I-OSE_Labeled_AE
( I-OSE_Labeled_AE
IMNM I-OSE_Labeled_AE
) O
, O
an O
autoimmune B-OSE_Labeled_AE
myopathy I-OSE_Labeled_AE
, O
associated O
with O
statin O
use O
. O

IMNM B-NonOSE_AE
is O
characterized O
by O
: O
proximal B-NonOSE_AE
muscle I-NonOSE_AE
weakness I-NonOSE_AE
and O
elevated B-NonOSE_AE
serum I-NonOSE_AE
creatine I-NonOSE_AE
kinase I-NonOSE_AE
, O
which O
persist O
despite O
discontinuation O
of O
statin O
treatment O
; O
muscle O
biopsy O
showing O
necrotizing B-NonOSE_AE
myopathy I-NonOSE_AE
without O
significant O
inflammation B-NonOSE_AE
; O
improvement O
with O
immunosuppressive B-NonOSE_AE
agents I-NonOSE_AE
. O

LIVALO O
therapy O
should O
be O
discontinued O
if O
markedly O
elevated B-NonOSE_AE
creatine I-NonOSE_AE
kinase I-NonOSE_AE
( I-NonOSE_AE
CK I-NonOSE_AE
) O
levels O
occur O
or O
myopathy B-NonOSE_AE
is O
diagnosed O
or O
suspected O
. O

LIVALO O
therapy O
should O
also O
be O
temporarily O
withheld O
in O
any O
patient O
with O
an O
acute O
, O
serious O
condition O
suggestive O
of O
myopathy B-NonOSE_AE
or O
predisposing O
to O
the O
development O
of O
renal B-NonOSE_AE
failure I-NonOSE_AE
secondary O
to O
rhabdomyolysis B-NonOSE_AE
( O
e.g. O
, O
sepsis B-Not_AE_Candidate
, O
hypotension B-Not_AE_Candidate
, O
dehydration B-Not_AE_Candidate
, O
major O
surgery O
, O
trauma O
, O
severe B-Not_AE_Candidate
metabolic I-Not_AE_Candidate
, O
endocrine O
, O
and O
electrolyte O
disorders I-Not_AE_Candidate
, O
or O
uncontrolled O
seizures B-Not_AE_Candidate
) O
. O

All O
patients O
should O
be O
advised O
to O
promptly O
report O
unexplained O
muscle B-NonOSE_AE
pain I-NonOSE_AE
, O
tenderness B-NonOSE_AE
, O
or O
weakness B-NonOSE_AE
, O
particularly O
if O
accompanied O
by O
malaise B-NonOSE_AE
or O
fever B-NonOSE_AE
or O
if O
muscle B-NonOSE_AE
signs I-NonOSE_AE
and I-NonOSE_AE
symptoms I-NonOSE_AE
persist O
after O
discontinuing O
LIVALO O
. O

5.2 O
Liver O
Enzyme O
Abnormalities O
Increases B-OSE_Labeled_AE
in O
serum I-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
( O
aspartate O
aminotransferase O
[ O
AST O
] O
/serum O
glutamic-oxaloacetic O
transaminase O
, O
or O
alanine O
aminotransferase O
[ O
ALT O
] O
/serum O
glutamic-pyruvic O
transaminase O
) O
have O
been O
reported O
with O
HMG-CoA O
reductase O
inhibitors O
, O
including O
LIVALO O
. O

In O
most O
cases O
, O
the O
elevations O
were O
transient O
and O
resolved O
or O
improved O
on O
continued O
therapy O
or O
after O
a O
brief O
interruption O
in O
therapy O
. O

In O
placebo-controlled O
Phase O
2 O
studies O
, O
ALT B-NonOSE_AE
> I-NonOSE_AE
3 I-NonOSE_AE
times I-NonOSE_AE
the I-NonOSE_AE
upper I-NonOSE_AE
limit I-NonOSE_AE
of I-NonOSE_AE
normal I-NonOSE_AE
was O
not O
observed O
in O
the O
placebo O
, O
LIVALO O
1 O
mg O
, O
or O
LIVALO O
2 O
mg O
groups O
. O

One O
out O
of O
202 O
patients O
( O
0.5 O
% O
) O
administered O
LIVALO O
4 O
mg O
had O
ALT B-OSE_Labeled_AE
> I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
times I-OSE_Labeled_AE
the I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
limit I-OSE_Labeled_AE
of I-OSE_Labeled_AE
normal I-OSE_Labeled_AE
. O

It O
is O
recommended O
that O
liver O
enzyme O
tests O
be O
performed O
before O
the O
initiation O
of O
LIVALO O
and O
if O
signs O
or O
symptoms O
of O
liver B-NonOSE_AE
injury I-NonOSE_AE
occur O
. O

There O
have O
been O
rare O
postmarketing O
reports O
of O
fatal B-NonOSE_AE
and O
non-fatal O
hepatic B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
in O
patients O
taking O
statins O
, O
including O
pitavastatin O
. O

If O
serious O
liver B-NonOSE_AE
injury I-NonOSE_AE
with O
clinical O
symptoms O
and/or O
hyperbilirubinemia B-NonOSE_AE
or O
jaundice B-NonOSE_AE
occurs O
during O
treatment O
with O
LIVALO O
, O
promptly O
interrupt O
therapy O
. O

If O
an O
alternate O
etiology O
is O
not O
found O
do O
not O
restart O
LIVALO O
. O

As O
with O
other O
HMG-CoA O
reductase O
inhibitors O
, O
LIVALO O
should O
be O
used O
with O
caution O
in O
patients O
who O
consume O
substantial O
quantities O
of O
alcohol O
. O

Active O
liver B-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
which O
may O
include O
unexplained O
persistent O
transaminase B-Not_AE_Candidate
elevations I-Not_AE_Candidate
, O
is O
a O
contraindication O
to O
the O
use O
of O
LIVALO O
[ O
see O
Contraindications O
( O
4 O
) O
] O
. O

5.3 O
Endocrine O
Function O
Increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
HbA I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
c I-OSE_Labeled_AE
and O
fasting O
serum O
glucose O
levels O
have O
been O
reported O
with O
HMG-CoA O
reductase O
inhibitors O
, O
including O
LIVALO O
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
serious O
adverse O
reactions O
are O
discussed O
elsewhere O
in O
the O
labeling O
: O
* O
Severe O
cardiopulmonary B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
incidence O
> O
= O
0.5 O
% O
) O
are O
headache O
and O
nausea O
( O
6.1 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Bracco O
Diagnostics O
Inc O
at O
1-800-257-5181 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

In O
completed O
clinical O
trials O
, O
a O
total O
of O
6307 O
adult O
subjects O
( O
128 O
healthy O
volunteers O
and O
6179 O
patients O
) O
received O
Lumason O
at O
cumulative O
doses O
ranging O
from O
0.2 O
to O
161 O
mL O
( O
mean O
10.5 O
mL O
) O
. O

Lumason O
was O
administered O
mainly O
as O
single O
or O
multiple O
injections O
; O
however O
, O
some O
subjects O
received O
infusion O
dosing O
. O

The O
majority O
( O
73 O
% O
) O
of O
subjects O
received O
Lumason O
at O
cumulative O
doses O
of O
10 O
mL O
or O
less O
. O

There O
were O
65 O
% O
men O
and O
35 O
% O
women O
, O
with O
an O
average O
age O
of O
59 O
years O
( O
range O
17 O
to O
99 O
years O
) O
. O

A O
total O
of O
4993 O
( O
79 O
% O
) O
subjects O
were O
Caucasian O
; O
192 O
( O
3 O
% O
) O
were O
Black O
; O
1053 O
( O
17 O
% O
) O
were O
Asian O
; O
33 O
( O
< O
1 O
% O
) O
were O
Hispanic O
; O
and O
36 O
( O
< O
1 O
% O
) O
were O
in O
other O
racial O
groups O
or O
race O
was O
not O
reported O
. O

In O
the O
clinical O
trials O
, O
serious O
adverse O
reactions O
were O
observed O
in O
2 O
subjects O
; O
one O
who O
experienced O
a O
hypersensitivity B-OSE_Labeled_AE
- I-OSE_Labeled_AE
type I-OSE_Labeled_AE
rash I-OSE_Labeled_AE
and O
near B-OSE_Labeled_AE
syncope I-OSE_Labeled_AE
symptoms O
and O
another O
who O
experienced O
anaphylactic B-OSE_Labeled_AE
shock I-OSE_Labeled_AE
shortly O
following O
Lumason O
administration O
. O

The O
most O
commonly O
reported O
adverse O
reactions O
among O
patients O
( O
occurring O
among O
at O
least O
0.2 O
% O
of O
patients O
) O
are O
listed O
below O
( O
Table O
1 O
) O
. O

Most O
adverse O
reactions O
were O
mild O
to O
moderate O
in O
intensity O
and O
resolved O
spontaneously O
. O

* O
occurring O
in O
at O
least O
0.2 O
% O
of O
patients O
Table O
1 O
. O

Adverse O
Reactions O
in O
Patients*n O
= O
6179 O
Number O
( O
% O
) O
of O
Patients O
with O
Adverse O
Reactions O
302 O
( O
4.9 O
% O
) O
Headache B-OSE_Labeled_AE
56 O
( O
0.9 O
% O
) O
Nausea B-OSE_Labeled_AE
34 O
( O
0.6 O
% O
) O
Dysgeusia B-OSE_Labeled_AE
19 O
( O
0.3 O
% O
) O
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
18 O
( O
0.3 O
% O
) O
Chest B-OSE_Labeled_AE
discomfort I-OSE_Labeled_AE
16 O
( O
0.3 O
% O
) O
Feeling B-OSE_Labeled_AE
Hot I-OSE_Labeled_AE
16 O
( O
0.3 O
% O
) O
Chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
11 O
( O
0.2 O
% O
) O
Injection B-OSE_Labeled_AE
Site I-OSE_Labeled_AE
Warmth I-OSE_Labeled_AE
11 O
( O
0.2 O
% O
) O
6.2 O
Postmarketing O
Experience O
In O
the O
international O
postmarketing O
clinical O
experience O
and O
on-going O
clinical O
trials O
, O
serious O
adverse O
reactions O
have O
uncommonly O
been O
reported O
following O
administration O
of O
Lumason O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

The O
serious O
adverse O
reactions O
include O
fatalities O
, O
especially O
in O
a O
pattern O
of O
symptoms O
suggestive O
of O
anaphylactoid B-OSE_Labeled_AE
/hypersensitivity O
reactions I-OSE_Labeled_AE
. O

Other O
serious O
reactions O
included O
arrhythmias B-OSE_Labeled_AE
and O
hypertensive B-OSE_Labeled_AE
episodes I-OSE_Labeled_AE
. O

These O
reactions O
typically O
occurred O
within O
30 O
minutes O
of O
Lumason O
administration O
. O

The O
risk O
for O
serious O
cardiopulmonary B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
may O
be O
increased O
among O
patients O
with O
unstable O
cardiopulmonary B-Not_AE_Candidate
conditions I-Not_AE_Candidate
( O
acute B-Not_AE_Candidate
myocardial I-Not_AE_Candidate
infarction I-Not_AE_Candidate
, O
acute B-Not_AE_Candidate
coronary I-Not_AE_Candidate
artery O
syndromes I-Not_AE_Candidate
, O
worsening B-Not_AE_Candidate
or O
unstable O
congestive I-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
or O
serious O
ventricular B-Not_AE_Candidate
arrhythmias I-Not_AE_Candidate
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
] O
) O
. O

BOXED O
WARNING O
: O
WARNING O
: O
SERIOUS O
CARDIOPULMONARY O
REACTIONS O
WARNING O
: O
SERIOUS O
CARDIOPULMONARY O
REACTIONS O
Serious O
cardiopulmonary B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
including O
fatalities B-NonOSE_AE
, O
have O
occurred O
uncommonly O
during O
or O
following O
the O
injection O
of O
ultrasound O
contrast O
agents O
, O
including O
sulfur O
hexafluoride O
lipid O
microspheres O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

Most O
serious O
reactions O
occur O
within O
30 O
minutes O
of O
administration O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

* O
Assess O
all O
patients O
for O
the O
presence O
of O
any O
condition O
that O
precludes O
administration O
[ O
see O
Contraindications O
( O
4 O
) O
] O
. O

* O
Always O
have O
resuscitation O
equipment O
and O
trained O
personnel O
readily O
available O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

EXCERPT O
: O
WARNING O
: O
SERIOUS O
CARDIOPULMONARY O
REACTIONS O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

Serious O
cardiopulmonary O
reactions O
, O
including O
fatalities O
, O
have O
occurred O
uncommonly O
during O
or O
following O
the O
injection O
of O
ultrasound O
contrast O
agents O
, O
including O
sulfur O
hexafluoride O
lipid O
microspheres O
( O
5.1 O
) O
. O

Most O
serious O
reactions O
occur O
within O
30 O
minutes O
of O
administration O
( O
5.1 O
) O
. O

* O
Assess O
all O
patients O
for O
the O
presence O
of O
any O
condition O
that O
precludes O
administration O
( O
4 O
) O
. O

* O
Always O
have O
resuscitation O
equipment O
and O
trained O
personnel O
readily O
available O
( O
5.1 O
) O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Cardiopulmonary O
reactions O
, O
including O
fatalities O
. O

Always O
have O
resuscitation O
equipment O
and O
trained O
personnel O
readily O
available O
( O
5.1 O
) O
* O
Anaphylactoid O
reactions O
( O
5.2 O
) O
5.1 O
Cardiopulmonary O
Reactions O
Serious O
cardiopulmonary B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
including O
fatalities B-NonOSE_AE
have O
occurred O
uncommonly O
during O
or O
shortly O
following O
administration O
of O
ultrasound O
contrast O
agents O
, O
including O
Lumason O
. O

These O
reactions O
typically O
occurred O
within O
30 O
minutes O
of O
administration O
. O

The O
risk O
for O
these O
reactions O
may O
be O
increased O
among O
patients O
with O
unstable O
cardiopulmonary B-Not_AE_Candidate
conditions I-Not_AE_Candidate
( O
acute B-Not_AE_Candidate
myocardial I-Not_AE_Candidate
infarction I-Not_AE_Candidate
, O
acute B-Not_AE_Candidate
coronary I-Not_AE_Candidate
artery O
syndromes I-Not_AE_Candidate
, O
worsening B-Not_AE_Candidate
or O
unstable O
congestive I-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
or O
serious O
ventricular B-Not_AE_Candidate
arrhythmias I-Not_AE_Candidate
) O
. O

Always O
have O
cardiopulmonary O
resuscitation O
personnel O
and O
equipment O
readily O
available O
prior O
to O
Lumason O
administration O
and O
monitor O
all O
patients O
for O
acute O
reactions O
. O

The O
reported O
reactions O
that O
may O
follow O
the O
administration O
of O
ultrasound O
contrast O
agents O
include O
: O
fatal O
cardiac B-OSE_Labeled_AE
or O
respiratory O
arrest I-OSE_Labeled_AE
, O
shock B-OSE_Labeled_AE
, O
syncope B-OSE_Labeled_AE
, O
symptomatic B-OSE_Labeled_AE
arrhythmias I-OSE_Labeled_AE
( O
atrial B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
, O
tachycardia B-OSE_Labeled_AE
, O
bradycardia B-OSE_Labeled_AE
, O
supraventricular B-OSE_Labeled_AE
tachycardia I-OSE_Labeled_AE
, O
ventricular B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
, O
and O
ventricular B-OSE_Labeled_AE
tachycardia I-OSE_Labeled_AE
) O
, O
hypertension B-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
hypoxia B-OSE_Labeled_AE
, O
chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
respiratory B-OSE_Labeled_AE
distress I-OSE_Labeled_AE
, O
stridor B-OSE_Labeled_AE
, O
wheezing B-OSE_Labeled_AE
, O
loss B-OSE_Labeled_AE
of I-OSE_Labeled_AE
consciousness I-OSE_Labeled_AE
, O
and O
convulsions B-OSE_Labeled_AE
. O

5.2 O
Anaphylactoid O
Reactions O
Anaphylactoid B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
such O
as O
skin B-OSE_Labeled_AE
erythema I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
flushing B-OSE_Labeled_AE
, O
throat B-OSE_Labeled_AE
tightness I-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
or O
anaphylactic B-OSE_Labeled_AE
shock I-OSE_Labeled_AE
have O
uncommonly O
been O
observed O
following O
the O
injection O
of O
Lumason O
. O

These O
reactions O
may O
occur O
in O
patients O
with O
no O
history O
of O
prior O
exposure O
to O
sulfur O
hexafluoride O
lipid O
containing O
microspheres O
. O

5.3 O
Systemic B-OSE_Labeled_AE
Embolization I-OSE_Labeled_AE
In O
patients O
with O
right B-Not_AE_Candidate
- I-Not_AE_Candidate
to I-Not_AE_Candidate
- I-Not_AE_Candidate
left I-Not_AE_Candidate
, O
bi-directional O
, O
or O
transient O
right-to-left O
cardiac I-Not_AE_Candidate
shunts I-Not_AE_Candidate
, O
some O
intravenously O
injected O
sulfur O
hexafluoride O
lipid O
containing O
microspheres O
may O
bypass O
filtering O
by O
the O
lung O
and O
directly O
enter O
the O
arterial O
circulation O
. O

Occlusion B-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
microcirculation I-OSE_Labeled_AE
by O
these O
microspheres O
may O
result O
in O
tissue B-NonOSE_AE
ischemia I-NonOSE_AE
. O

Lumason O
is O
only O
for O
intravenous O
administration O
; O
do O
not O
administer O
Lumason O
by O
intra-arterial O
injection O
. O

5.4 O
High O
Mechanical O
Index O
High O
ultrasound B-NonOSE_AE
mechanical I-NonOSE_AE
index I-NonOSE_AE
values I-NonOSE_AE
may I-NonOSE_AE
cause I-NonOSE_AE
microsphere I-NonOSE_AE
cavitation I-NonOSE_AE
or I-NonOSE_AE
rupture I-NonOSE_AE
and O
lead O
to O
ventricular B-OSE_Labeled_AE
arrhythmias I-OSE_Labeled_AE
. O

Additionally O
, O
end-systolic O
triggering O
with O
high O
mechanical O
indices O
has O
been O
reported O
to O
cause O
ventricular B-NonOSE_AE
arrhythmias I-NonOSE_AE
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
discussed O
elsewhere O
in O
the O
labeling O
: O
* O
Myelodysplastic B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
/ O
Acute B-OSE_Labeled_AE
Myeloid I-OSE_Labeled_AE
Leukemia I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Pneumonitis B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Most O
common O
adverse O
reactions O
( O
> O
=20 O
% O
) O
in O
clinical O
trials O
were O
anemia B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
( O
including O
asthenia B-OSE_Labeled_AE
) O
, O
vomiting B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
dysgeusia B-OSE_Labeled_AE
, O
dyspepsia B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
nasopharyngitis B-OSE_Labeled_AE
/ O
pharyngitis B-OSE_Labeled_AE
/ O
URI B-OSE_Labeled_AE
, O
cough B-OSE_Labeled_AE
, O
arthralgia B-OSE_Labeled_AE
/ O
musculoskeletal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
myalgia B-OSE_Labeled_AE
, O
back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
dermatitis B-OSE_Labeled_AE
/ O
rash B-OSE_Labeled_AE
and O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
/discomfort O
. O

( O
6.1 O
) O
* O
Most O
common O
laboratory O
abnormalities O
( O
> O
=25 O
% O
) O
were O
increase B-OSE_Labeled_AE
in O
creatinine I-OSE_Labeled_AE
, O
mean B-OSE_Labeled_AE
corpuscular I-OSE_Labeled_AE
volume I-OSE_Labeled_AE
elevation I-OSE_Labeled_AE
, O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
, O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
lymphocytes I-OSE_Labeled_AE
, O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
absolute I-OSE_Labeled_AE
neutrophil I-OSE_Labeled_AE
count I-OSE_Labeled_AE
, O
and O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
platelets I-OSE_Labeled_AE
. O

( O
6.1 O
) O
EXCERPT O
: O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
AstraZeneca O
at O
1-800-236-9933 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trial O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Lynparza O
400 O
mg O
twice O
daily O
as O
monotherapy O
, O
has O
been O
studied O
in O
300 O
patients O
with O
g O
BRCA B-Not_AE_Candidate
- I-Not_AE_Candidate
mutated I-Not_AE_Candidate
advanced I-Not_AE_Candidate
ovarian I-Not_AE_Candidate
cancer I-Not_AE_Candidate
, O
and O
223 O
of O
these O
patients O
had O
received O
3 O
or O
more O
prior O
lines O
of O
chemotherapy O
. O

In O
the O
223 O
patients O
with O
g B-Not_AE_Candidate
BRCA I-Not_AE_Candidate
- I-Not_AE_Candidate
mutated I-Not_AE_Candidate
ovarian I-Not_AE_Candidate
cancer I-Not_AE_Candidate
who O
received O
3 O
or O
more O
prior O
lines O
of O
chemotherapy O
( O
including O
137 O
patients O
in O
Study O
1 O
with O
measureable O
disease O
) O
[ O
see O
Clinical O
Studies O
( O
14 O
) O
] O
, O
adverse O
reactions O
led O
to O
dose O
interruption O
in O
40 O
% O
of O
patients O
, O
dose O
reduction O
in O
4 O
% O
, O
and O
discontinuation O
in O
7 O
% O
. O

There O
were O
8 O
( O
4 O
% O
) O
patients O
with O
adverse O
reactions O
leading O
to O
death B-NonOSE_AE
, O
two O
were O
attributed O
to O
acute B-OSE_Labeled_AE
leukemia I-OSE_Labeled_AE
, O
and O
one O
each O
was O
attributed O
to O
COPD B-OSE_Labeled_AE
, O
cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
, O
intestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
, O
sepsis B-OSE_Labeled_AE
, O
and O
suture O
rupture O
. O

Table O
1 O
presents O
the O
frequency O
of O
adverse O
reactions O
reported O
in O
> O
=20 O
% O
of O
223 O
patients O
( O
in O
6 O
studies O
) O
with O
g B-Not_AE_Candidate
BRCA I-Not_AE_Candidate
- I-Not_AE_Candidate
mutated I-Not_AE_Candidate
advanced I-Not_AE_Candidate
ovarian I-Not_AE_Candidate
cancer I-Not_AE_Candidate
who O
had O
received O
3 O
or O
more O
prior O
lines O
of O
chemotherapy O
who O
were O
treated O
with O
Lynparza O
400 O
mg O
twice O
daily O
. O

The O
median O
exposure O
to O
Lynparza O
in O
these O
patients O
was O
158 O
days O
. O

Table O
1 O
Adverse O
Reactions O
Reported O
in O
> O
=20 O
% O
of O
Patients O
with O
gBRCA-Mutated O
Advanced O
Ovarian O
Cancer O
Receiving O
Lynparza O
3 O
or O
more O
lines O
of O
prior O
chemotherapy O
Adverse O
Reaction O
Grades O
1-4 O
N=223 O
% O
Grades O
3-4 O
N=223 O
% O
Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
disorders I-NonOSE_AE
Anemia B-OSE_Labeled_AE
34 O
18 O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
/discomfort O
43 O
8 O
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
22 O
1 O
Nausea B-OSE_Labeled_AE
64 O
3 O
Vomiting B-OSE_Labeled_AE
43 O
4 O
Diarrhea B-OSE_Labeled_AE
31 O
1 O
Dyspepsia B-OSE_Labeled_AE
25 O
0 O
General B-NonOSE_AE
disorders I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
/ O
asthenia B-OSE_Labeled_AE
66 O
8 O
Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
Nasopharyngitis B-OSE_Labeled_AE
/ O
URI B-OSE_Labeled_AE
26 O
0 O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
disorders I-NonOSE_AE
Arthralgia B-OSE_Labeled_AE
/ O
musculoskeletal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
21 O
0 O
Myalgia B-OSE_Labeled_AE
22 O
0 O
Table O
2 O
presents O
the O
frequency O
of O
abnormal B-NonOSE_AE
laboratory I-NonOSE_AE
findings I-NonOSE_AE
in O
the O
223 O
patients O
with O
g B-Not_AE_Candidate
BRCA I-Not_AE_Candidate
- I-Not_AE_Candidate
mutated I-Not_AE_Candidate
advanced I-Not_AE_Candidate
ovarian I-Not_AE_Candidate
cancer I-Not_AE_Candidate
who O
had O
received O
three O
or O
more O
prior O
lines O
of O
chemotherapy O
receiving O
Lynparza O
400 O
mg O
twice O
daily O
. O

Table O
2 O
Laboratory O
Abnormalities O
Reported O
in O
Patients O
with O
gBRCA-Mutated O
Advanced O
Ovarian O
Cancer O
Receiving O
Lynparza O
Laboratory O
Parameter1 O
3 O
or O
more O
lines O
of O
prior O
chemotherapy O
Grades O
1-4 O
N=223 O
% O
Grades O
3-4 O
N=223 O
% O
Decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
( O
anemia B-OSE_Labeled_AE
) O
90 O
15 O
Decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
absolute I-OSE_Labeled_AE
neutrophil I-OSE_Labeled_AE
count I-OSE_Labeled_AE
( O
neutropenia B-OSE_Labeled_AE
) O
25 O
7 O
Decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
platelets I-OSE_Labeled_AE
( O
thrombocytopenia B-OSE_Labeled_AE
) O
30 O
3 O
Decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
lymphocytes I-OSE_Labeled_AE
( O
lymphopenia B-OSE_Labeled_AE
) O
56 O
17 O
Mean B-OSE_Labeled_AE
corpuscular I-OSE_Labeled_AE
volume I-OSE_Labeled_AE
elevation I-OSE_Labeled_AE
57 O
- O
Increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
30 O
2 O
The O
following O
adverse O
reactions O
and O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
have O
been O
identified O
in O
> O
=10 O
to O
< O
20 O
% O
of O
the O
223 O
patients O
receiving O
Lynparza O
and O
not O
included O
in O
the O
table O
: O
cough B-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
dysgeusia B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
and O
rash B-OSE_Labeled_AE
. O

The O
following O
adverse O
reactions O
and O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
have O
been O
identified O
in O
> O
=1 O
to O
< O
10 O
% O
of O
the O
223 O
patients O
receiving O
Lynparza O
and O
not O
included O
in O
the O
table O
: O
leukopenia B-OSE_Labeled_AE
, O
stomatitis B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
, O
pyrexia B-OSE_Labeled_AE
, O
hypomagnesemia B-OSE_Labeled_AE
, O
hyperglycemia B-OSE_Labeled_AE
, O
anxiety B-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
dysuria B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
incontinence I-OSE_Labeled_AE
, O
vulvovaginal B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
/ O
eczema B-OSE_Labeled_AE
, O
pruritis B-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
venous B-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
( O
including O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
) O
, O
and O
hot B-OSE_Labeled_AE
flush I-OSE_Labeled_AE
. O

Table O
3 O
presents O
adverse O
reactions O
reported O
in O
> O
=20 O
% O
of O
patients O
from O
a O
randomized O
trial O
of O
Lynparza O
400 O
mg O
twice O
daily O
as O
maintenance O
monotherapy O
compared O
to O
placebo O
in O
patients O
with O
platinum O
sensitive O
, O
relapsed O
, O
high-grade O
serous O
ovarian B-Not_AE_Candidate
cancer I-Not_AE_Candidate
following O
treatment O
with O
2 O
or O
more O
platinum-containing O
regimens O
. O

Table O
4 O
presents O
the O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
in O
patients O
from O
this O
randomized O
trial O
. O

Of O
the O
96 O
patients O
with O
g B-Not_AE_Candidate
BRCA I-Not_AE_Candidate
- I-Not_AE_Candidate
mutation I-Not_AE_Candidate
, O
53 O
received O
Lynparza O
, O
and O
43 O
received O
placebo O
. O

The O
median O
duration O
on O
treatment O
with O
Lynparza O
was O
11.1 O
months O
for O
patients O
with O
a O
g B-Not_AE_Candidate
BRCA I-Not_AE_Candidate
mutation I-Not_AE_Candidate
compared O
to O
4.4 O
months O
for O
patients O
with O
g B-Not_AE_Candidate
BRCA I-Not_AE_Candidate
mutation I-Not_AE_Candidate
on O
placebo O
. O

Adverse O
reactions O
led O
to O
dose O
interruptions O
in O
26 O
% O
of O
those O
receiving O
Lynparza O
and O
7 O
% O
of O
those O
receiving O
placebo O
; O
dose O
reductions O
in O
15 O
% O
of O
Lynparza O
and O
5 O
% O
of O
placebo O
patients O
; O
and O
discontinuation O
in O
9 O
% O
of O
Lynparza O
and O
0 O
% O
in O
placebo O
patients O
. O

One O
( O
2 O
% O
) O
patient O
on O
Lynparza O
died B-NonOSE_AE
as O
a O
result O
of O
an O
adverse O
reaction O
. O

Table O
3 O
Adverse O
Reactions O
Reported O
in O
> O
=20 O
% O
of O
Patients O
with O
gBRCA-Mutated O
Ovarian O
Cancer O
in O
the O
Randomized O
Trial O
Adverse O
Reactions O
Lynparza O
N=53 O
Placebo O
N=43 O
Grades O
1-4 O
% O
Grades O
3-4 O
% O
Grades O
1-4 O
% O
Grades O
3-4 O
% O
Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
disorders I-NonOSE_AE
Anemia B-OSE_Labeled_AE
25 O
4 O
7 O
2 O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
/discomfort O
47 O
0 O
58 O
2 O
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
25 O
0 O
14 O
0 O
Nausea B-OSE_Labeled_AE
75 O
2 O
37 O
0 O
Vomiting B-OSE_Labeled_AE
32 O
4 O
9 O
0 O
Diarrhea B-OSE_Labeled_AE
28 O
4 O
21 O
2 O
Dyspepsia B-OSE_Labeled_AE
25 O
0 O
14 O
0 O
Dysgeusia B-OSE_Labeled_AE
21 O
0 O
9 O
0 O
General B-NonOSE_AE
disorders I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
( O
including O
asthenia B-OSE_Labeled_AE
, O
lethargy B-OSE_Labeled_AE
) O
68 O
6 O
53 O
2 O
Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
Nasopharyngitis B-OSE_Labeled_AE
/ O
Pharyngitis B-OSE_Labeled_AE
/ O
URI B-OSE_Labeled_AE
43 O
0 O
16 O
0 O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
Connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Arthralgia B-OSE_Labeled_AE
/ O
Musculoskeletal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
32 O
4 O
21 O
0 O
Myalgia B-OSE_Labeled_AE
25 O
2 O
12 O
0 O
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
25 O
6 O
21 O
0 O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorder I-NonOSE_AE
Headache B-OSE_Labeled_AE
25 O
0 O
19 O
2 O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
Thoracic I-NonOSE_AE
, I-NonOSE_AE
Mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
Cough B-OSE_Labeled_AE
21 O
0 O
14 O
0 O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Dermatitis B-OSE_Labeled_AE
/ O
Rash B-OSE_Labeled_AE
25 O
0 O
14 O
0 O
Table O
4 O
Laboratory O
Abnormalities O
in O
Patients O
with O
gBRCA-Mutated O
Ovarian O
Cancer O
in O
the O
Randomized O
Trial O
Laboratory O
parameter1 O
Lynparza O
N=53 O
Placebo O
N=43 O
Grades O
1-4 O
% O
Grades O
3-4 O
% O
Grades O
1-4 O
% O
Grades O
3-4 O
% O
Decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
85 O
8 O
58 O
2 O
Decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
absolute I-OSE_Labeled_AE
neutrophil I-OSE_Labeled_AE
count I-OSE_Labeled_AE
32 O
8 O
23 O
0 O
Decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
platelets I-OSE_Labeled_AE
26 O
6 O
19 O
0 O
Mean B-OSE_Labeled_AE
corpuscular I-OSE_Labeled_AE
volume I-OSE_Labeled_AE
elevation I-OSE_Labeled_AE
85 O
- O
44 O
- O
Increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
Patients O
were O
allowed O
to O
enter O
clinical O
studies O
with O
laboratory O
values O
of O
CTCAE O
Grade O
1 O
. O

26 O
0 O
5 O
0 O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Myelodysplastic O
syndrome/Acute O
Myeloid O
Leukemia O
: O
( O
MDS/AML O
) O
occurred O
in O
patients O
exposed O
to O
Lynparza O
, O
and O
some O
cases O
were O
fatal O
. O

Monitor O
patients O
for O
hematological O
toxicity O
at O
baseline O
and O
monthly O
thereafter O
. O

Discontinue O
if O
MDS/AML O
is O
confirmed O
. O

( O
5.1 O
) O
* O
Pneumonitis O
: O
occurred O
in O
patients O
exposed O
to O
Lynparza O
, O
and O
some O
cases O
were O
fatal O
. O

Interrupt O
treatment O
if O
pneumonitis O
is O
suspected O
. O

Discontinue O
if O
pneumonitis O
is O
confirmed O
. O

( O
5.2 O
) O
* O
Embryo-Fetal O
toxicity O
: O
Lynparza O
can O
cause O
fetal O
harm O
. O

Advise O
females O
of O
reproductive O
potential O
of O
the O
potential O
risk O
to O
a O
fetus O
and O
to O
avoid O
pregnancy O
. O

( O
5.3 O
, O
8.1 O
) O
5.1 O
Myelodysplastic O
syndrome/Acute O
Myeloid O
Leukemia O
Myelodysplastic B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
/ O
Acute B-OSE_Labeled_AE
Myeloid I-OSE_Labeled_AE
Leukemia I-OSE_Labeled_AE
( O
MDS/AML O
) O
have O
been O
confirmed O
in O
6 O
out O
of O
298 O
( O
2 O
% O
) O
patients O
enrolled O
in O
a O
single O
arm O
trial O
of O
Lynparza O
monotherapy O
, O
in O
patients O
with O
deleterious O
or O
suspected O
deleterious O
germline O
BRCA B-Not_AE_Candidate
- I-Not_AE_Candidate
mutated I-Not_AE_Candidate
( I-Not_AE_Candidate
gBRCA I-Not_AE_Candidate
m I-Not_AE_Candidate
) I-Not_AE_Candidate
advanced I-Not_AE_Candidate
cancers I-Not_AE_Candidate
. O

In O
a O
randomized O
placebo O
controlled O
trial O
, O
MDS B-OSE_Labeled_AE
/ O
AML B-OSE_Labeled_AE
occurred O
in O
3 O
out O
of O
136 O
( O
2 O
% O
) O
patients O
with O
advanced O
ovarian B-Not_AE_Candidate
cancer I-Not_AE_Candidate
treated O
with O
Lynparza O
. O

Overall O
, O
MDS B-OSE_Labeled_AE
/ O
AML B-OSE_Labeled_AE
were O
reported O
in O
22 O
of O
2,618 O
( O
< O
1 O
% O
) O
patients O
treated O
with O
Lynparza O
. O

The O
majority O
of O
MDS B-OSE_Labeled_AE
/ O
AML B-OSE_Labeled_AE
cases O
( O
17 O
of O
22 O
cases O
) O
were O
fatal B-NonOSE_AE
, O
and O
the O
duration O
of O
therapy O
with O
Lynparza O
in O
patients O
who O
developed O
secondary O
MDS B-OSE_Labeled_AE
/cancer-therapy O
related O
AML B-OSE_Labeled_AE
varied O
from O
< O
6 O
months O
to O
> O
2 O
years O
. O

All O
patients O
had O
previous O
chemotherapy O
with O
platinum O
agents O
and/or O
other O
DNA O
damaging O
agents O
. O

Monitor O
complete O
blood O
count O
testing O
at O
baseline O
and O
monthly O
thereafter O
. O

Do O
not O
start O
Lynparza O
until O
patients O
have O
recovered O
from O
hematological B-NonOSE_AE
toxicity I-NonOSE_AE
caused O
by O
previous O
chemotherapy O
( O
< O
=CTCAE O
Grade O
1 O
) O
. O

For O
prolonged O
hematological B-NonOSE_AE
toxicities I-NonOSE_AE
, O
interrupt O
Lynparza O
and O
monitor O
blood O
counts O
weekly O
until O
recovery O
. O

If O
the O
levels O
have O
not O
recovered O
to O
CTCAE O
Grade O
1 O
or O
less O
after O
4 O
weeks O
, O
refer O
the O
patient O
to O
a O
hematologist O
for O
further O
investigations O
, O
including O
bone O
marrow O
analysis O
and O
blood O
sample O
for O
cytogenetics O
. O

If O
MDS B-NonOSE_AE
/ O
AML B-NonOSE_AE
is O
confirmed O
, O
discontinue O
Lynparza O
. O

5.2 O
Pneumonitis O
Pneumonitis B-OSE_Labeled_AE
, O
including O
fatal B-NonOSE_AE
cases O
, O
occurred O
in O
< O
1 O
% O
of O
patients O
treated O
with O
Lynparza O
. O

If O
patients O
present O
with O
new O
or O
worsening B-NonOSE_AE
respiratory I-NonOSE_AE
symptoms I-NonOSE_AE
such O
as O
dyspnea B-NonOSE_AE
, O
fever B-NonOSE_AE
, O
cough B-NonOSE_AE
, O
wheezing B-NonOSE_AE
, O
or O
a O
radiological O
abnormality O
occurs O
, O
interrupt O
treatment O
with O
Lynparza O
and O
initiate O
prompt O
investigation O
. O

If O
pneumonitis B-NonOSE_AE
is O
confirmed O
, O
discontinue O
Lynparza O
. O

5.3 O
Embryo B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Fetal I-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
Lynparza O
can O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
when O
administered O
to O
a O
pregnant B-Not_AE_Candidate
woman O
based O
on O
its O
mechanism O
of O
action O
and O
findings O
in O
animals O
. O

Olaparib O
was O
teratogenic B-NonOSE_AE
and O
caused O
embryo B-NonOSE_AE
- I-NonOSE_AE
fetal I-NonOSE_AE
toxicity I-NonOSE_AE
in O
rats O
at O
exposures O
below O
those O
in O
patients O
receiving O
the O
recommended O
human O
dose O
of O
400 O
mg O
twice O
daily O
. O

If O
the O
patient O
becomes O
pregnant B-NonOSE_AE
while O
taking O
this O
drug O
, O
apprise O
the O
patient O
of O
the O
potential O
hazard B-OSE_Labeled_AE
to I-OSE_Labeled_AE
a I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.1 O
) O
] O
. O

Advise O
females O
of O
reproductive O
potential O
to O
avoid O
becoming O
pregnant B-NonOSE_AE
while O
taking O
Lynparza O
. O

If O
contraceptive O
methods O
are O
being O
considered O
, O
use O
effective O
contraception O
during O
treatment O
and O
for O
at O
least O
one O
month O
after O
receiving O
the O
last O
dose O
of O
Lynparza O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.6 O
) O
] O
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
serious O
adverse O
reactions O
are O
discussed O
elsewhere O
in O
labeling O
: O
* O
Cardiovascular B-OSE_Labeled_AE
Disorders I-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
, O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Malignant B-OSE_Labeled_AE
Neoplasms I-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
, O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
> O
= O
5 O
percent O
) O
are O
: O
abdominal O
pain O
, O
asthenia O
, O
pain O
, O
back O
pain O
, O
headache O
, O
flatulence O
, O
nausea O
, O
depression O
, O
insomnia O
, O
breast O
pain O
, O
endometrial O
hyperplasia O
, O
leucorrhea O
, O
vaginal O
hemorrhage O
, O
and O
vaginitis O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Pfizer O
Inc O
. O
at O
1-800-438-1985 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
6.1 O
Clinical O
Study O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

During O
the O
first O
year O
of O
a O
2-year O
clinical O
trial O
with O
2,333 O
postmenopausal B-Not_AE_Candidate
women O
with O
a O
uterus O
between O
40 O
and O
65 O
years O
of O
age O
( O
88 O
percent O
Caucasian O
) O
, O
1,012 O
women O
were O
treated O
with O
conjugated O
estrogens O
, O
and O
332 O
were O
treated O
with O
placebo O
. O

Table O
1 O
summarizes O
treatment-related O
adverse O
reactions O
that O
occurred O
at O
a O
rate O
of O
> O
= O
1 O
percent O
in O
any O
treatment O
group O
. O

Table O
1 O
: O
TREATMENT O
RELATED O
ADVERSE O
REACTIONS O
AT O
A O
FREQUENCY O
> O
= O
1 O
PERCENT O
PREMARIN0.625 O
mg O
( O
n=348 O
) O
PREMARIN0.45 O
mg O
( O
n=338 O
) O
PREMARIN0.3 O
mg O
( O
n=326 O
) O
Placebo O
( O
n=332 O
) O
Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
whole I-NonOSE_AE
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
38 O
( O
11 O
) O
28 O
( O
8 O
) O
30 O
( O
9 O
) O
21 O
( O
6 O
) O
Asthenia B-OSE_Labeled_AE
16 O
( O
5 O
) O
8 O
( O
2 O
) O
14 O
( O
4 O
) O
3 O
( O
1 O
) O
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
18 O
( O
5 O
) O
11 O
( O
3 O
) O
13 O
( O
4 O
) O
4 O
( O
1 O
) O
Chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
2 O
( O
1 O
) O
3 O
( O
1 O
) O
4 O
( O
1 O
) O
2 O
( O
1 O
) O
Generalized B-NonOSE_AE
edema I-NonOSE_AE
7 O
( O
2 O
) O
6 O
( O
2 O
) O
4 O
( O
1 O
) O
8 O
( O
2 O
) O
Headache B-OSE_Labeled_AE
45 O
( O
13 O
) O
47 O
( O
14 O
) O
44 O
( O
13 O
) O
46 O
( O
14 O
) O
Moniliasis B-OSE_Labeled_AE
5 O
( O
1 O
) O
4 O
( O
1 O
) O
4 O
( O
1 O
) O
1 O
( O
0 O
) O
Pain B-OSE_Labeled_AE
17 O
( O
5 O
) O
10 O
( O
3 O
) O
12 O
( O
4 O
) O
14 O
( O
4 O
) O
Pelvic B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
10 O
( O
3 O
) O
9 O
( O
3 O
) O
8 O
( O
2 O
) O
4 O
( O
1 O
) O
Cardiovascular B-NonOSE_AE
system I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
4 O
( O
1 O
) O
4 O
( O
1 O
) O
7 O
( O
2 O
) O
5 O
( O
2 O
) O
Migraine B-OSE_Labeled_AE
7 O
( O
2 O
) O
1 O
( O
0 O
) O
0 O
3 O
( O
1 O
) O
Palpitation B-NonOSE_AE
3 O
( O
1 O
) O
3 O
( O
1 O
) O
3 O
( O
1 O
) O
4 O
( O
1 O
) O
Vasodilatation B-NonOSE_AE
2 O
( O
1 O
) O
2 O
( O
1 O
) O
3 O
( O
1 O
) O
5 O
( O
2 O
) O
Digestive B-NonOSE_AE
system I-NonOSE_AE
Constipation B-OSE_Labeled_AE
7 O
( O
2 O
) O
6 O
( O
2 O
) O
4 O
( O
1 O
) O
3 O
( O
1 O
) O
Diarrhea B-NonOSE_AE
4 O
( O
1 O
) O
5 O
( O
1 O
) O
5 O
( O
2 O
) O
8 O
( O
2 O
) O
Dyspepsia B-NonOSE_AE
7 O
( O
2 O
) O
5 O
( O
1 O
) O
6 O
( O
2 O
) O
14 O
( O
4 O
) O
Eructation B-OSE_Labeled_AE
1 O
( O
0 O
) O
1 O
( O
0 O
) O
4 O
( O
1 O
) O
1 O
( O
0 O
) O
Flatulence B-OSE_Labeled_AE
22 O
( O
6 O
) O
18 O
( O
5 O
) O
13 O
( O
4 O
) O
8 O
( O
2 O
) O
Increased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
4 O
( O
1 O
) O
1 O
( O
0 O
) O
1 O
( O
0 O
) O
2 O
( O
1 O
) O
Nausea B-NonOSE_AE
16 O
( O
5 O
) O
10 O
( O
3 O
) O
15 O
( O
5 O
) O
16 O
( O
5 O
) O
Metabolic B-NonOSE_AE
and I-NonOSE_AE
nutritional I-NonOSE_AE
Hyperlipidemia B-OSE_Labeled_AE
2 O
( O
1 O
) O
4 O
( O
1 O
) O
3 O
( O
1 O
) O
2 O
( O
1 O
) O
Peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
5 O
( O
1 O
) O
2 O
( O
1 O
) O
4 O
( O
1 O
) O
3 O
( O
1 O
) O
Weight B-NonOSE_AE
gain I-NonOSE_AE
11 O
( O
3 O
) O
10 O
( O
3 O
) O
8 O
( O
2 O
) O
14 O
( O
4 O
) O
Musculoskeletal B-NonOSE_AE
system I-NonOSE_AE
Arthralgia B-OSE_Labeled_AE
6 O
( O
2 O
) O
3 O
( O
1 O
) O
2 O
( O
1 O
) O
5 O
( O
2 O
) O
Leg B-OSE_Labeled_AE
cramps I-OSE_Labeled_AE
10 O
( O
3 O
) O
5 O
( O
1 O
) O
9 O
( O
3 O
) O
4 O
( O
1 O
) O
Myalgia B-OSE_Labeled_AE
2 O
( O
1 O
) O
1 O
( O
0 O
) O
4 O
( O
1 O
) O
1 O
( O
0 O
) O
Nervous B-NonOSE_AE
system I-NonOSE_AE
Anxiety B-OSE_Labeled_AE
6 O
( O
2 O
) O
4 O
( O
1 O
) O
2 O
( O
1 O
) O
4 O
( O
1 O
) O
Depression B-NonOSE_AE
17 O
( O
5 O
) O
15 O
( O
4 O
) O
10 O
( O
3 O
) O
17 O
( O
5 O
) O
Dizziness B-OSE_Labeled_AE
9 O
( O
3 O
) O
7 O
( O
2 O
) O
4 O
( O
1 O
) O
5 O
( O
2 O
) O
Emotional B-NonOSE_AE
lability I-NonOSE_AE
3 O
( O
1 O
) O
4 O
( O
1 O
) O
5 O
( O
2 O
) O
8 O
( O
2 O
) O
Hypertonia B-OSE_Labeled_AE
1 O
( O
0 O
) O
1 O
( O
0 O
) O
5 O
( O
2 O
) O
3 O
( O
1 O
) O
Insomnia B-OSE_Labeled_AE
16 O
( O
5 O
) O
10 O
( O
3 O
) O
13 O
( O
4 O
) O
14 O
( O
4 O
) O
Nervousness B-OSE_Labeled_AE
9 O
( O
3 O
) O
12 O
( O
4 O
) O
2 O
( O
1 O
) O
6 O
( O
2 O
) O
Skin B-NonOSE_AE
and I-NonOSE_AE
appendages I-NonOSE_AE
Acne B-OSE_Labeled_AE
3 O
( O
1 O
) O
1 O
( O
0 O
) O
8 O
( O
2 O
) O
3 O
( O
1 O
) O
Alopecia B-OSE_Labeled_AE
6 O
( O
2 O
) O
6 O
( O
2 O
) O
5 O
( O
2 O
) O
2 O
( O
1 O
) O
Hirsutism B-OSE_Labeled_AE
4 O
( O
1 O
) O
2 O
( O
1 O
) O
1 O
( O
0 O
) O
0 O
Pruritus B-OSE_Labeled_AE
11 O
( O
3 O
) O
11 O
( O
3 O
) O
10 O
( O
3 O
) O
3 O
( O
1 O
) O
Rash B-OSE_Labeled_AE
6 O
( O
2 O
) O
3 O
( O
1 O
) O
1 O
( O
0 O
) O
2 O
( O
1 O
) O
Skin B-OSE_Labeled_AE
discoloration I-OSE_Labeled_AE
4 O
( O
1 O
) O
2 O
( O
1 O
) O
0 O
1 O
( O
0 O
) O
Sweating B-NonOSE_AE
4 O
( O
1 O
) O
1 O
( O
0 O
) O
3 O
( O
1 O
) O
4 O
( O
1 O
) O
Urogenital B-NonOSE_AE
system I-NonOSE_AE
Breast B-NonOSE_AE
disorder I-NonOSE_AE
6 O
( O
2 O
) O
3 O
( O
1 O
) O
3 O
( O
1 O
) O
6 O
( O
2 O
) O
Breast B-OSE_Labeled_AE
enlargement I-OSE_Labeled_AE
3 O
( O
1 O
) O
4 O
( O
1 O
) O
7 O
( O
2 O
) O
3 O
( O
1 O
) O
Breast B-NonOSE_AE
neoplasm I-NonOSE_AE
4 O
( O
1 O
) O
4 O
( O
1 O
) O
7 O
( O
2 O
) O
7 O
( O
2 O
) O
Breast B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
37 O
( O
11 O
) O
39 O
( O
12 O
) O
24 O
( O
7 O
) O
26 O
( O
8 O
) O
Cervix B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
8 O
( O
2 O
) O
4 O
( O
1 O
) O
5 O
( O
2 O
) O
0 O
Dysmenorrhea B-OSE_Labeled_AE
12 O
( O
3 O
) O
10 O
( O
3 O
) O
4 O
( O
1 O
) O
2 O
( O
1 O
) O
Endometrial B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
4 O
( O
1 O
) O
2 O
( O
1 O
) O
2 O
( O
1 O
) O
0 O
Endometrial B-OSE_Labeled_AE
hyperplasia I-OSE_Labeled_AE
16 O
( O
5 O
) O
8 O
( O
2 O
) O
1 O
( O
0 O
) O
0 O
Leukorrhea B-OSE_Labeled_AE
17 O
( O
5 O
) O
17 O
( O
5 O
) O
12 O
( O
4 O
) O
6 O
( O
2 O
) O
Metrorrhagia B-OSE_Labeled_AE
11 O
( O
3 O
) O
4 O
( O
1 O
) O
3 O
( O
1 O
) O
1 O
( O
0 O
) O
Urinary B-NonOSE_AE
tract I-NonOSE_AE
infection I-NonOSE_AE
1 O
( O
0 O
) O
2 O
( O
1 O
) O
1 O
( O
0 O
) O
4 O
( O
1 O
) O
Uterine B-OSE_Labeled_AE
fibroids I-OSE_Labeled_AE
enlarged I-OSE_Labeled_AE
6 O
( O
2 O
) O
1 O
( O
0 O
) O
2 O
( O
1 O
) O
2 O
( O
1 O
) O
Uterine B-OSE_Labeled_AE
spasm I-OSE_Labeled_AE
11 O
( O
3 O
) O
5 O
( O
1 O
) O
3 O
( O
1 O
) O
2 O
( O
1 O
) O
Vaginal B-NonOSE_AE
dryness I-NonOSE_AE
1 O
( O
0 O
) O
2 O
( O
1 O
) O
1 O
( O
0 O
) O
6 O
( O
2 O
) O
Vaginal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
46 O
( O
13 O
) O
13 O
( O
4 O
) O
6 O
( O
2 O
) O
0 O
Vaginal B-OSE_Labeled_AE
moniliasis I-OSE_Labeled_AE
14 O
( O
4 O
) O
10 O
( O
3 O
) O
12 O
( O
4 O
) O
5 O
( O
2 O
) O
Vaginitis B-OSE_Labeled_AE
18 O
( O
5 O
) O
7 O
( O
2 O
) O
9 O
( O
3 O
) O
1 O
( O
0 O
) O
6.2 O
Postmarketing O
Experience O
The O
following O
additional O
adverse O
reactions O
have O
been O
identified O
during O
post-approval O
use O
of O
PREMARIN O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
possible O
always O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Genitourinary B-NonOSE_AE
system I-NonOSE_AE
Abnormal B-OSE_Labeled_AE
uterine I-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
; O
dysmenorrheal B-OSE_Labeled_AE
or O
pelvic O
pain I-OSE_Labeled_AE
, O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
size I-OSE_Labeled_AE
of I-OSE_Labeled_AE
uterine I-OSE_Labeled_AE
leiomyomata I-OSE_Labeled_AE
, O
vaginitis B-OSE_Labeled_AE
, O
including O
vaginal B-OSE_Labeled_AE
candidiasis I-OSE_Labeled_AE
, O
change B-OSE_Labeled_AE
in I-OSE_Labeled_AE
cervical I-OSE_Labeled_AE
secretion I-OSE_Labeled_AE
, O
ovarian B-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
, O
endometrial B-OSE_Labeled_AE
hyperplasia I-OSE_Labeled_AE
, O
endometrial B-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
, O
leukorrhea B-OSE_Labeled_AE
. O

Breasts B-OSE_Labeled_AE
Tendern I-OSE_Labeled_AE
ess O
, O
enlargement O
, O
pain O
, O
discharge O
, O
galactorrhea B-OSE_Labeled_AE
, O
fibrocystic B-OSE_Labeled_AE
breast I-OSE_Labeled_AE
changes I-OSE_Labeled_AE
, O
breast B-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
, O
gynecomastia B-OSE_Labeled_AE
in O
males O
. O

Cardiovascular B-NonOSE_AE
Deep B-OSE_Labeled_AE
and O
superficial O
venous I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
, O
thrombophlebitis B-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
, O
stroke B-OSE_Labeled_AE
, O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
. O

Gastrointestinal B-NonOSE_AE
Nausea B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
bloating B-OSE_Labeled_AE
, O
cholestatic B-OSE_Labeled_AE
jaundice I-OSE_Labeled_AE
, O
increased O
incidence O
of O
gallbladder B-OSE_Labeled_AE
disease I-OSE_Labeled_AE
, O
pancreatitis B-OSE_Labeled_AE
, O
enlargement B-OSE_Labeled_AE
of I-OSE_Labeled_AE
hepatic I-OSE_Labeled_AE
hemangiomas I-OSE_Labeled_AE
, O
ischemic B-OSE_Labeled_AE
colitis I-OSE_Labeled_AE
. O

Skin B-NonOSE_AE
Chloasma B-OSE_Labeled_AE
or O
melasma B-OSE_Labeled_AE
that O
may O
persist O
when O
drug O
is O
discontinued O
, O
erythema B-OSE_Labeled_AE
multiforme I-OSE_Labeled_AE
, O
erythema B-OSE_Labeled_AE
nodosum I-OSE_Labeled_AE
, O
loss B-OSE_Labeled_AE
of I-OSE_Labeled_AE
scalp I-OSE_Labeled_AE
hair I-OSE_Labeled_AE
, O
hirsutism B-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
. O

Eyes B-NonOSE_AE
Retinal B-OSE_Labeled_AE
vascular I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
, O
intolerance B-OSE_Labeled_AE
to I-OSE_Labeled_AE
contact I-OSE_Labeled_AE
lenses I-OSE_Labeled_AE
. O

Central B-NonOSE_AE
nervous I-NonOSE_AE
system I-NonOSE_AE
Headache B-OSE_Labeled_AE
, O
migraine B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
mental B-OSE_Labeled_AE
depression I-OSE_Labeled_AE
, O
nervousness B-OSE_Labeled_AE
, O
mood B-OSE_Labeled_AE
disturbances I-OSE_Labeled_AE
, O
irritability B-OSE_Labeled_AE
, O
exacerbation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
epilepsy I-OSE_Labeled_AE
, O
dementia B-OSE_Labeled_AE
, O
possible O
growth B-OSE_Labeled_AE
potentiation I-OSE_Labeled_AE
of I-OSE_Labeled_AE
benign I-OSE_Labeled_AE
meningioma I-OSE_Labeled_AE
. O

Miscellaneous O
Increase B-OSE_Labeled_AE
or O
decrease O
in I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
, O
glucose B-OSE_Labeled_AE
intolerance I-OSE_Labeled_AE
, O
aggravation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
porphyria I-OSE_Labeled_AE
, O
edema B-OSE_Labeled_AE
, O
arthralgias B-OSE_Labeled_AE
, O
leg B-OSE_Labeled_AE
cramps I-OSE_Labeled_AE
, O
changes B-OSE_Labeled_AE
in I-OSE_Labeled_AE
libido I-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
exacerbation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
asthma I-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
triglycerides I-OSE_Labeled_AE
, O
hypersensitivity B-OSE_Labeled_AE
. O

BOXED O
WARNING O
: O
WARNING O
: O
ENDOMETRIAL O
CANCER O
, O
CARDIOVASCULAR O
DISORDERS O
, O
BREAST O
CANCER O
AND O
PROBABLE O
DEMENTIA O
WARNING O
: O
ENDOMETRIAL O
CANCER O
, O
CARDIOVASCULAR O
DISORDERS O
, O
BREAST O
CANCER O
AND O
PROBABLE O
DEMENTIA O
EXCERPT O
: O
WARNING O
: O
ENDOMETRIAL O
CANCER O
, O
CARDIOVASCULAR O
DISORDERS O
, O
BREAST O
CANCER O
AND O
PROBABLE O
DEMENTIA O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

Estrogen-Alone O
Therapy O
* O
There O
is O
an O
increased O
risk O
of O
endometrial O
cancer O
in O
a O
woman O
with O
a O
uterus O
who O
uses O
unopposed O
estrogens O
( O
5.2 O
) O
* O
Estrogen-alone O
therapy O
should O
not O
be O
used O
for O
the O
prevention O
of O
cardiovascular O
disease O
or O
dementia O
( O
5.1 O
, O
5.3 O
) O
* O
Women O
's O
Health O
Initiative O
( O
WHI O
) O
estrogen-alone O
substudy O
reported O
increased O
risks O
of O
stroke O
and O
deep O
vein O
thrombosis O
( O
DVT O
) O
( O
5.1 O
) O
* O
The O
WHI O
Memory O
Study O
( O
WHIMS O
) O
estrogen-alone O
ancillary O
study O
of O
WHI O
reported O
an O
increased O
risk O
of O
probable O
dementia O
in O
postmenopausal O
women O
65 O
years O
of O
age O
and O
older O
( O
5.3 O
) O
Estrogen O
Plus O
Progestin O
Therapy O
* O
Estrogen O
plus O
progestin O
therapy O
should O
not O
be O
used O
for O
the O
prevention O
of O
cardiovascular O
disease O
or O
dementia O
( O
5.1 O
, O
5.3 O
) O
* O
The O
WHI O
estrogen O
plus O
progestin O
substudy O
reported O
increased O
risks O
of O
stroke O
, O
DVT O
, O
pulmonary O
embolism O
( O
PE O
) O
, O
and O
myocardial O
infarction O
( O
MI O
) O
( O
5.1 O
) O
* O
The O
WHI O
estrogen O
plus O
progestin O
substudy O
reported O
increased O
risks O
of O
invasive O
breast O
cancer O
( O
5.2 O
) O
* O
The O
WHIMS O
estrogen O
plus O
progestin O
ancillary O
study O
of O
WHI O
reported O
an O
increased O
risk O
of O
probable O
dementia O
in O
postmenopausal O
women O
65 O
years O
of O
age O
and O
older O
( O
5.3 O
) O
Estrogen-Alone O
Therapy O
Endometrial O
Cancer O
There O
is O
an O
increased O
risk O
of O
endometrial B-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
in O
a O
woman O
with O
a O
uterus O
who O
uses O
unopposed O
estrogens O
. O

Adding O
a O
progestin O
to O
estrogen O
therapy O
has O
been O
shown O
to O
reduce O
the O
risk O
of O
endometrial B-NonOSE_AE
hyperplasia I-NonOSE_AE
, O
which O
may O
be O
a O
precursor O
to O
endometrial B-NonOSE_AE
cancer I-NonOSE_AE
. O

Adequate O
diagnostic O
measures O
, O
including O
directed O
or O
random O
endometrial O
sampling O
when O
indicated O
, O
should O
be O
undertaken O
to O
rule O
out O
malignancy B-Not_AE_Candidate
in O
postmenopausal B-Not_AE_Candidate
women O
with O
undiagnosed O
persistent O
or O
recurring O
abnormal B-Not_AE_Candidate
genital I-Not_AE_Candidate
bleeding I-Not_AE_Candidate
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

Cardiovascular O
Disorders O
and O
Probable O
Dementia O
Estrogen-alone O
therapy O
should O
not O
be O
used O
for O
the O
prevention O
of O
cardiovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
or O
dementia B-Not_AE_Candidate
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
, O
5.3 O
) O
, O
and O
Clinical O
Studies O
( O
14.5 O
, O
14.6 O
) O
] O
. O

The O
Women O
's O
Health O
Initiative O
( O
WHI O
) O
estrogen-alone O
substudy O
reported O
increased O
risks O
of O
stroke B-OSE_Labeled_AE
and O
deep B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
( I-OSE_Labeled_AE
DVT I-OSE_Labeled_AE
) O
in O
postmenopausal B-Not_AE_Candidate
women O
( O
50 O
to O
79 O
years O
of O
age O
) O
during O
7.1 O
years O
of O
treatment O
with O
daily O
oral O
conjugated O
estrogens O
( O
CE O
) O
[ O
0.625 O
mg O
] O
-alone O
, O
relative O
to O
placebo O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
, O
and O
Clinical O
Studies O
( O
14.5 O
) O
] O
. O

The O
WHI O
Memory O
Study O
( O
WHIMS O
) O
estrogen-alone O
ancillary O
study O
of O
WHI O
reported O
an O
increased O
risk O
of O
developing O
probable O
dementia B-OSE_Labeled_AE
in O
postmenopausal B-Not_AE_Candidate
women O
65 O
years O
of O
age O
or O
older O
during O
5.2 O
years O
of O
treatment O
with O
daily O
CE O
( O
0.625 O
mg O
) O
-alone O
, O
relative O
to O
placebo O
. O

It O
is O
unknown O
whether O
this O
finding O
applies O
to O
younger O
postmenopausal B-Not_AE_Candidate
women O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
, O
Use O
in O
Specific O
Populations O
( O
8.5 O
) O
, O
and O
Clinical O
Studies O
( O
14.6 O
) O
] O
. O

In O
the O
absence O
of O
comparable O
data O
, O
these O
risks O
should O
be O
assumed O
to O
be O
similar O
for O
other O
doses O
of O
CE O
and O
other O
dosage O
forms O
of O
estrogens O
. O

Estrogens O
with O
or O
without O
progestins O
should O
be O
prescribed O
at O
the O
lowest O
effective O
doses O
and O
for O
the O
shortest O
duration O
consistent O
with O
treatment O
goals O
and O
risks O
for O
the O
individual O
woman O
. O

Estrogen O
Plus O
Progestin O
Therapy O
Cardiovascular O
Disorders O
and O
Probable O
Dementia O
Estrogen O
plus O
progestin O
therapy O
should O
not O
be O
used O
for O
the O
prevention O
of O
cardiovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
or O
dementia B-Not_AE_Candidate
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
, O
5.3 O
) O
, O
and O
Clinical O
Studies O
( O
14.5 O
, O
14.6 O
) O
] O
. O

The O
WHI O
estrogen O
plus O
progestin O
substudy O
reported O
increased O
risks O
of O
DVT B-NonOSE_AE
, O
pulmonary B-NonOSE_AE
embolism I-NonOSE_AE
( I-NonOSE_AE
PE I-NonOSE_AE
) O
, O
stroke B-NonOSE_AE
and O
myocardial B-NonOSE_AE
infarction I-NonOSE_AE
( I-NonOSE_AE
MI I-NonOSE_AE
) O
in O
postmenopausal B-Not_AE_Candidate
women O
( O
50 O
to O
79 O
years O
of O
age O
) O
during O
5.6 O
years O
of O
treatment O
with O
daily O
oral O
CE O
( O
0.625 O
mg O
) O
combined O
with O
medroxyprogesterone O
acetate O
( O
MPA O
) O
[ O
2.5 O
mg O
] O
, O
relative O
to O
placebo O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
, O
and O
Clinical O
Studies O
( O
14.5 O
) O
] O
. O

The O
WHIMS O
estrogen O
plus O
progestin O
ancillary O
study O
of O
the O
WHI O
, O
reported O
an O
increased O
risk O
of O
developing O
probable O
dementia B-NonOSE_AE
in O
postmenopausal B-Not_AE_Candidate
women O
65 O
years O
of O
age O
or O
older O
during O
4 O
years O
of O
treatment O
with O
daily O
CE O
( O
0.625 O
mg O
) O
combined O
with O
MPA O
( O
2.5 O
mg O
) O
, O
relative O
to O
placebo O
. O

It O
is O
unknown O
whether O
this O
finding O
applies O
to O
younger O
postmenopausal B-Not_AE_Candidate
women O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
, O
Use O
in O
Specific O
Populations O
( O
8.5 O
) O
, O
and O
Clinical O
Studies O
( O
14.6 O
) O
] O
. O

Breast O
Cancer O
The O
WHI O
estrogen O
plus O
progestin O
substudy O
also O
demonstrated O
an O
increased O
risk O
of O
invasive O
breast B-NonOSE_AE
cancer I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
, O
and O
Clinical O
Studies O
( O
14.5 O
) O
] O
. O

In O
the O
absence O
of O
comparable O
data O
, O
these O
risks O
should O
be O
assumed O
to O
be O
similar O
for O
other O
doses O
of O
CE O
and O
MPA O
, O
and O
other O
combinations O
and O
dosage O
forms O
of O
estrogens O
and O
progestins O
. O

Estrogens O
with O
or O
without O
progestins O
should O
be O
prescribed O
at O
the O
lowest O
effective O
doses O
and O
for O
the O
shortest O
duration O
consistent O
with O
treatment O
goals O
and O
risks O
for O
the O
individual O
woman O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Estrogens O
increase O
the O
risk O
of O
gallbladder O
disease O
( O
5.4 O
) O
* O
Discontinue O
estrogen O
if O
severe O
hypercalcemia O
, O
loss O
of O
vision O
, O
severe O
hypertriglyceridemia O
or O
cholestatic O
jaundice O
occurs O
( O
5.5 O
, O
5.6 O
, O
5.11 O
, O
5.12 O
) O
* O
Monitor O
thyroid O
function O
in O
women O
on O
thyroid O
replacement O
therapy O
( O
5.13 O
, O
5.18 O
) O
5.1 O
Cardiovascular B-OSE_Labeled_AE
Disorders I-OSE_Labeled_AE
An O
increased O
risk O
of O
stroke B-OSE_Labeled_AE
and O
DVT B-OSE_Labeled_AE
has O
been O
reported O
with O
estrogen-alone O
therapy O
. O

An O
increased O
risk O
of O
PE B-NonOSE_AE
, O
DVT B-NonOSE_AE
, O
stroke B-NonOSE_AE
and O
MI B-NonOSE_AE
has O
been O
reported O
with O
estrogen O
plus O
progestin O
therapy O
. O

Should O
any O
of O
these O
events O
occur O
or O
be O
suspected O
, O
estrogen O
with O
or O
without O
progestin O
therapy O
should O
be O
discontinued O
immediately O
. O

Risk O
factors O
for O
arterial B-Not_AE_Candidate
vascular I-Not_AE_Candidate
disease I-Not_AE_Candidate
( O
for O
example O
, O
hypertension B-Not_AE_Candidate
, O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
, O
tobacco B-Not_AE_Candidate
use I-Not_AE_Candidate
, O
hypercholesterolemia B-Not_AE_Candidate
, O
and O
obesity B-Not_AE_Candidate
) O
and/or O
venous B-Not_AE_Candidate
thromboembolism I-Not_AE_Candidate
( I-Not_AE_Candidate
VTE I-Not_AE_Candidate
) O
( O
for O
example O
, O
personal O
or O
family O
history O
of O
VTE B-Not_AE_Candidate
, O
obesity B-Not_AE_Candidate
, O
and O
systemic B-Not_AE_Candidate
lupus I-Not_AE_Candidate
erythematosus I-Not_AE_Candidate
) O
should O
be O
managed O
appropriately O
. O

Stroke O
In O
the O
WHI O
estrogen-alone O
substudy O
, O
a O
statistically O
significant O
increased O
risk O
of O
stroke B-OSE_Labeled_AE
was O
reported O
in O
women O
50 O
to O
79 O
years O
of O
age O
receiving O
daily O
CE O
( O
0.625 O
mg O
) O
-alone O
compared O
to O
women O
in O
the O
same O
age O
group O
receiving O
placebo O
( O
45 O
versus O
33 O
per O
10,000 O
women-years O
) O
. O

The O
increase O
in O
risk O
was O
demonstrated O
in O
year O
1 O
and O
persisted O
[ O
see O
Clinical O
Studies O
( O
14.5 O
) O
] O
. O

Should O
a O
stroke B-NonOSE_AE
occur O
or O
be O
suspected O
, O
estrogen-alone O
therapy O
should O
be O
discontinued O
immediately O
. O

Subgroup O
analyses O
of O
women O
50 O
to O
59 O
years O
of O
age O
suggest O
no O
increased O
risk O
of O
stroke B-NonOSE_AE
for O
those O
women O
receiving O
CE O
( O
0.625 O
mg O
) O
-alone O
versus O
those O
receiving O
placebo O
( O
18 O
versus O
21 O
per O
10,000 O
women-years O
) O
. O

1 O
In O
the O
WHI O
estrogen O
plus O
progestin O
substudy O
, O
a O
statistically O
significant O
increased O
risk O
of O
stroke B-NonOSE_AE
was O
reported O
in O
women O
50 O
to O
79 O
years O
of O
age O
receiving O
daily O
CE O
( O
0.625 O
mg O
) O
plus O
MPA O
( O
2.5 O
mg O
) O
compared O
to O
women O
in O
the O
same O
age O
group O
receiving O
placebo O
( O
33 O
versus O
25 O
per O
10,000 O
women-years O
) O
[ O
see O
Clinical O
Studies O
( O
14.5 O
) O
] O
. O

The O
increase O
in O
risk O
was O
demonstrated O
after O
the O
first O
year O
and O
persisted O
. O

1 O
Should O
a O
stroke B-NonOSE_AE
occur O
or O
be O
suspected O
, O
estrogen O
plus O
progestin O
therapy O
should O
be O
discontinued O
immediately O
. O

Coronary O
Heart O
Disease O
In O
the O
WHI O
estrogen-alone O
substudy O
, O
no O
overall O
effect O
on O
coronary B-NonOSE_AE
heart I-NonOSE_AE
disease I-NonOSE_AE
( I-NonOSE_AE
CHD I-NonOSE_AE
) O
events O
( O
defined O
as O
nonfatal O
MI B-NonOSE_AE
, O
silent B-NonOSE_AE
MI I-NonOSE_AE
, O
or O
CHD B-NonOSE_AE
death I-NonOSE_AE
) O
was O
reported O
in O
women O
receiving O
estrogen-alone O
compared O
to O
placebo O
2 O
[ O
see O
Clinical O
Studies O
( O
14.5 O
) O
] O
. O

Subgroup O
analyses O
of O
women O
50 O
to O
59 O
years O
of O
age O
suggest O
a O
statistically O
non-significant O
reduction O
in O
CHD B-NonOSE_AE
events O
( O
CE O
[ O
0.625 O
mg O
] O
-alone O
compared O
to O
placebo O
) O
in O
women O
with O
less O
than O
10 O
years O
since O
menopause B-Not_AE_Candidate
( O
8 O
versus O
16 O
per O
10,000 O
women-years O
) O
. O

1 O
In O
the O
WHI O
estrogen O
plus O
progestin O
substudy O
, O
there O
was O
a O
statistically O
non-significant O
increased O
risk O
of O
CHD B-NonOSE_AE
events O
reported O
in O
women O
receiving O
daily O
CE O
( O
0.625 O
mg O
) O
plus O
MPA O
( O
2.5 O
mg O
) O
compared O
to O
women O
receiving O
placebo O
( O
41 O
versus O
34 O
per O
10,000 O
women-years O
) O
. O

1 O
An O
increase O
in O
relative O
risk O
was O
demonstrated O
in O
year O
1 O
, O
and O
a O
trend O
toward O
decreasing O
relative O
risk O
was O
reported O
in O
years O
2 O
through O
5 O
[ O
see O
Clinical O
Studies O
( O
14.5 O
) O
] O
. O

In O
postmenopausal B-Not_AE_Candidate
women O
with O
documented O
heart B-Not_AE_Candidate
disease I-Not_AE_Candidate
( O
n O
= O
2,763 O
, O
average O
66.7 O
years O
of O
age O
) O
, O
in O
a O
controlled O
clinical O
trial O
of O
secondary O
prevention O
of O
cardiovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
( O
Heart O
and O
Estrogen/Progestin O
Replacement O
Study O
; O
HERS O
) O
, O
treatment O
with O
daily O
CE O
( O
0.625 O
mg O
) O
plus O
MPA O
( O
2.5 O
mg O
) O
demonstrated O
no O
cardiovascular O
benefit O
. O

During O
an O
average O
follow-up O
of O
4.1 O
years O
, O
treatment O
with O
CE O
plus O
MPA O
did O
not O
reduce O
the O
overall O
rate O
of O
CHD B-NonOSE_AE
events O
in O
postmenopausal B-Not_AE_Candidate
women O
with O
established O
CHD B-Not_AE_Candidate
. O

There O
were O
more O
CHD B-NonOSE_AE
events O
in O
the O
CE O
plus O
MPA-treated O
group O
than O
in O
the O
placebo O
group O
in O
year O
1 O
, O
but O
not O
during O
the O
subsequent O
years O
. O

Two O
thousand O
, O
three O
hundred O
and O
twenty-one O
( O
2,321 O
) O
women O
from O
the O
original O
HERS O
trial O
agreed O
to O
participate O
in O
an O
open O
label O
extension O
of O
HERS O
, O
HERS O
II O
. O

Average O
follow-up O
in O
HERS O
II O
was O
an O
additional O
2.7 O
years O
, O
for O
a O
total O
of O
6.8 O
years O
overall O
. O

Rates O
of O
CHD B-NonOSE_AE
events I-NonOSE_AE
were O
comparable O
among O
women O
in O
the O
CE O
( O
0.625 O
mg O
) O
plus O
MPA O
( O
2.5 O
mg O
) O
group O
and O
the O
placebo O
group O
in O
HERS O
, O
HERS O
II O
, O
and O
overall O
. O

Venous O
Thromboembolism O
( O
VTE O
) O
In O
the O
WHI O
estrogen-alone O
substudy O
, O
the O
risk O
of O
VTE B-OSE_Labeled_AE
( O
DVT B-OSE_Labeled_AE
and O
PE B-OSE_Labeled_AE
) O
, O
was O
increased O
for O
women O
receiving O
daily O
CE O
( O
0.625 O
mg O
) O
-alone O
compared O
to O
placebo O
( O
30 O
versus O
22 O
per O
10,000 O
women-years O
) O
, O
although O
only O
the O
increased O
risk O
of O
DVT B-OSE_Labeled_AE
reached O
statistical O
significance O
( O
23 O
versus O
15 O
per O
10,000 O
women-years O
) O
. O

The O
increase O
in O
VTE B-OSE_Labeled_AE
risk O
was O
demonstrated O
during O
the O
first O
2 O
years O
3 O
[ O
see O
Clinical O
Studies O
( O
14.5 O
) O
] O
. O

Should O
a O
VTE B-NonOSE_AE
occur O
or O
be O
suspected O
, O
estrogen-alone O
therapy O
should O
be O
discontinued O
immediately O
. O

In O
the O
WHI O
estrogen O
plus O
progestin O
substudy O
, O
a O
statistically O
significant O
2-fold O
greater O
rate O
of O
VTE B-NonOSE_AE
was O
reported O
in O
women O
receiving O
daily O
CE O
( O
0.625 O
mg O
) O
plus O
MPA O
( O
2.5 O
mg O
) O
compared O
to O
women O
receiving O
placebo O
( O
35 O
versus O
17 O
per O
10,000 O
women-years O
) O
. O

Statistically O
significant O
increases O
in O
risk O
for O
both O
DVT B-NonOSE_AE
( O
26 O
versus O
13 O
per O
10,000 O
women-years O
) O
and O
PE B-NonOSE_AE
( O
18 O
versus O
8 O
per O
10,000 O
women-years O
) O
were O
also O
demonstrated O
. O

The O
increase O
in O
VTE B-NonOSE_AE
risk O
was O
demonstrated O
during O
the O
first O
year O
and O
persisted O
4 O
[ O
see O
Clinical O
Studies O
( O
14.5 O
) O
] O
. O

Should O
a O
VTE B-NonOSE_AE
occur O
or O
be O
suspected O
, O
estrogen O
plus O
progestin O
therapy O
should O
be O
discontinued O
immediately O
. O

If O
feasible O
, O
estrogens O
should O
be O
discontinued O
at O
least O
4 O
to O
6 O
weeks O
before O
surgery O
of O
the O
type O
associated O
with O
an O
increased O
risk O
of O
thromboembolism B-NonOSE_AE
, O
or O
during O
periods O
of O
prolonged O
immobilization O
. O

5.2 O
Malignant B-OSE_Labeled_AE
Neoplasms I-OSE_Labeled_AE
Endometrial O
Cancer O
An O
increased O
risk O
of O
endometrial B-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
has O
been O
reported O
with O
the O
use O
of O
unopposed O
estrogen O
therapy O
in O
a O
woman O
with O
a O
uterus O
. O

The O
reported O
endometrial B-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
risk O
among O
unopposed O
estrogen O
users O
is O
about O
2 O
to O
12 O
times O
greater O
than O
in O
non-users O
, O
and O
appears O
dependent O
on O
duration O
of O
treatment O
and O
on O
estrogen O
dose O
. O

Most O
studies O
show O
no O
significant O
increased O
risk O
associated O
with O
use O
of O
estrogens O
for O
less O
than O
1 O
year O
. O

The O
greatest O
risk O
appears O
associated O
with O
prolonged O
use O
, O
with O
increased O
risks O
of O
15- O
to O
24-fold O
for O
5 O
to O
10 O
years O
or O
more O
, O
and O
this O
risk O
has O
been O
shown O
to O
persist O
for O
at O
least O
8 O
to O
15 O
years O
after O
estrogen O
therapy O
is O
discontinued O
. O

Clinical O
surveillance O
of O
all O
women O
using O
estrogen-alone O
or O
estrogen O
plus O
progestin O
therapy O
is O
important O
. O

Adequate O
diagnostic O
measures O
, O
including O
directed O
or O
random O
endometrial O
sampling O
when O
indicated O
, O
should O
be O
undertaken O
to O
rule O
out O
malignancy B-NonOSE_AE
in O
postmenopausal B-Not_AE_Candidate
women O
with O
undiagnosed O
persistent O
or O
recurring O
abnormal O
genital B-Not_AE_Candidate
bleeding I-Not_AE_Candidate
. O

There O
is O
no O
evidence O
that O
the O
use O
of O
natural O
estrogens O
results O
in O
a O
different O
endometrial O
risk O
profile O
than O
synthetic O
estrogens O
of O
equivalent O
estrogen O
dose O
. O

Adding O
a O
progestin O
to O
postmenopausal B-NonOSE_AE
estrogen O
therapy O
has O
been O
shown O
to O
reduce O
the O
risk O
of O
endometrial B-NonOSE_AE
hyperplasia I-NonOSE_AE
, O
which O
may O
be O
a O
precursor O
to O
endometrial B-NonOSE_AE
cancer I-NonOSE_AE
. O

Breast O
Cancer O
The O
most O
important O
randomized O
clinical O
trial O
providing O
information O
about O
breast B-NonOSE_AE
cancer I-NonOSE_AE
in O
estrogen-alone O
users O
is O
the O
WHI O
substudy O
of O
daily O
CE O
( O
0.625 O
mg O
) O
-alone O
. O

In O
the O
WHI O
estrogen-alone O
substudy O
, O
after O
an O
average O
follow-up O
of O
7.1 O
years O
, O
daily O
CE O
( O
0.625 O
mg O
) O
-alone O
was O
not O
associated O
with O
an O
increased O
risk O
of O
invasive B-NonOSE_AE
breast I-NonOSE_AE
cancer I-NonOSE_AE
[ O
relative O
risk O
( O
RR O
) O
0.80 O
] O
5 O
[ O
see O
Clinical O
Studies O
( O
14.5 O
) O
] O
. O

The O
most O
important O
randomized O
clinical O
trial O
providing O
information O
about O
breast B-NonOSE_AE
cancer I-NonOSE_AE
in O
estrogen O
plus O
progestin O
users O
is O
the O
WHI O
substudy O
of O
daily O
CE O
( O
0.625 O
mg O
) O
plus O
MPA O
( O
2.5 O
mg O
) O
. O

After O
a O
mean O
follow-up O
of O
5.6 O
years O
, O
the O
estrogen O
plus O
progestin O
substudy O
reported O
an O
increased O
risk O
of O
invasive B-NonOSE_AE
breast I-NonOSE_AE
cancer I-NonOSE_AE
in O
women O
who O
took O
daily O
CE O
plus O
MPA O
. O

In O
this O
substudy O
, O
prior O
use O
of O
estrogen-alone O
or O
estrogen O
plus O
progestin O
therapy O
was O
reported O
by O
26 O
percent O
of O
the O
women O
. O

The O
relative O
risk O
of O
invasive B-NonOSE_AE
breast I-NonOSE_AE
cancer I-NonOSE_AE
was O
1.24 O
, O
and O
the O
absolute O
risk O
was O
41 O
versus O
33 O
cases O
per O
10,000 O
women-years O
, O
for O
CE O
plus O
MPA O
compared O
with O
placebo O
. O

6 O
Among O
women O
who O
reported O
prior O
use O
of O
hormone O
therapy O
, O
the O
relative O
risk O
of O
invasive B-NonOSE_AE
breast I-NonOSE_AE
cancer I-NonOSE_AE
was O
1.86 O
, O
and O
the O
absolute O
risk O
was O
46 O
versus O
25 O
cases O
per O
10,000 O
women-years O
for O
CE O
plus O
MPA O
compared O
with O
placebo O
. O

Among O
women O
who O
reported O
no O
prior O
use O
of O
hormone O
therapy O
, O
the O
relative O
risk O
of O
invasive B-NonOSE_AE
breast I-NonOSE_AE
cancer I-NonOSE_AE
was O
1.09 O
, O
and O
the O
absolute O
risk O
was O
40 O
versus O
36 O
cases O
per O
10,000 O
women-years O
for O
CE O
plus O
MPA O
compared O
with O
placebo O
. O

In O
the O
same O
substudy O
, O
invasive B-NonOSE_AE
breast I-NonOSE_AE
cancers I-NonOSE_AE
were O
larger O
, O
were O
more O
likely O
to O
be O
node O
positive O
, O
and O
were O
diagnosed O
at O
a O
more O
advanced O
stage O
in O
the O
CE O
( O
0.625 O
mg O
) O
plus O
MPA O
( O
2.5 O
mg O
) O
group O
compared O
with O
the O
placebo O
group O
. O

Metastatic O
disease O
was O
rare O
, O
with O
no O
apparent O
difference O
between O
the O
two O
groups O
. O

Other O
prognostic O
factors O
, O
such O
as O
histologic O
subtype O
, O
grade O
and O
hormone O
receptor O
status O
did O
not O
differ O
between O
the O
groups O
[ O
see O
Clinical O
Studies O
( O
14.5 O
) O
] O
. O

Consistent O
with O
the O
WHI O
clinical O
trial O
, O
observational O
studies O
have O
also O
reported O
an O
increased O
risk O
of O
breast B-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
for O
estrogen O
plus O
progestin O
therapy O
, O
and O
a O
smaller O
increased O
risk O
for O
estrogen-alone O
therapy O
, O
after O
several O
years O
of O
use O
. O

The O
risk O
increased O
with O
duration O
of O
use O
, O
and O
appeared O
to O
return O
to O
baseline O
over O
about O
5 O
years O
after O
stopping O
treatment O
( O
only O
the O
observational O
studies O
have O
substantial O
data O
on O
risk O
after O
stopping O
) O
. O

Observational O
studies O
also O
suggest O
that O
the O
risk O
of O
breast B-NonOSE_AE
cancer I-NonOSE_AE
was O
greater O
, O
and O
became O
apparent O
earlier O
, O
with O
estrogen O
plus O
progestin O
therapy O
as O
compared O
to O
estrogen-alone O
therapy O
. O

However O
, O
these O
studies O
have O
not O
found O
significant O
variation O
in O
the O
risk O
of O
breast B-NonOSE_AE
cancer I-NonOSE_AE
among O
different O
estrogen O
plus O
progestin O
combinations O
, O
doses O
, O
or O
routes O
of O
administration O
. O

The O
use O
of O
estrogen-alone O
and O
estrogen O
plus O
progestin O
has O
been O
reported O
to O
result O
in O
an O
increase O
in O
abnormal B-OSE_Labeled_AE
mammograms I-OSE_Labeled_AE
, O
requiring O
further O
evaluation O
. O

All O
women O
should O
receive O
yearly O
breast O
examinations O
by O
a O
healthcare O
provider O
and O
perform O
monthly O
breast O
self-examinations O
. O

In O
addition O
, O
mammography O
examinations O
should O
be O
scheduled O
based O
on O
patient O
age O
, O
risk O
factors O
, O
and O
prior O
mammogram O
results O
. O

Ovarian O
Cancer O
The O
WHI O
estrogen O
plus O
progestin O
substudy O
reported O
a O
statistically O
non-significant O
increased O
risk O
of O
ovarian B-NonOSE_AE
cancer I-NonOSE_AE
. O

After O
an O
average O
follow-up O
of O
5.6 O
years O
, O
the O
relative O
risk O
for O
ovarian B-NonOSE_AE
cancer I-NonOSE_AE
for O
CE O
plus O
MPA O
versus O
placebo O
was O
1.58 O
( O
95 O
percent O
CI O
0.77-3.24 O
) O
. O

The O
absolute O
risk O
for O
CE O
plus O
MPA O
versus O
placebo O
was O
4 O
versus O
3 O
cases O
per O
10,000 O
women-years O
. O

7 O
A O
meta-analysis O
of O
17 O
prospective O
and O
35 O
retrospective O
epidemiology O
studies O
found O
that O
women O
who O
used O
hormonal O
therapy O
for O
menopausal B-Not_AE_Candidate
symptoms I-Not_AE_Candidate
had O
an O
increased O
risk O
for O
ovarian B-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
. O

The O
primary O
analysis O
, O
using O
case-control O
comparisons O
, O
included O
12,110 O
cancer B-NonOSE_AE
cases O
from O
the O
17 O
prospective O
studies O
. O

The O
relative O
risks O
associated O
with O
current O
use O
of O
hormonal O
therapy O
was O
1.41 O
( O
95 O
% O
confidence O
interval O
[ O
CI O
] O
1.32 O
to O
1.50 O
) O
; O
there O
was O
no O
difference O
in O
the O
risk O
estimates O
by O
duration O
of O
the O
exposure O
( O
less O
than O
5 O
years O
[ O
median O
of O
3 O
years O
] O
vs O
. O
greater O
than O
5 O
years O
[ O
median O
of O
10 O
years O
] O
of O
use O
before O
the O
cancer B-NonOSE_AE
diagnosis O
) O
. O

The O
relative O
risk O
associated O
with O
combined O
current O
and O
recent O
use O
( O
discontinued O
use O
within O
5 O
years O
before O
cancer B-NonOSE_AE
diagnosis O
) O
was O
1.37 O
( O
95 O
% O
CI O
1.27-1.48 O
) O
, O
and O
the O
elevated O
risk O
was O
significant O
for O
both O
estrogen-alone O
and O
estrogen O
plus O
progestin O
products O
. O

The O
exact O
duration O
of O
hormone O
therapy O
use O
associated O
with O
an O
increased O
risk O
of O
ovarian B-NonOSE_AE
cancer I-NonOSE_AE
, O
however O
, O
is O
unknown O
. O

5.3 O
Probable O
Dementia O
In O
the O
WHIMS O
estrogen-alone O
ancillary O
study O
of O
WHI O
, O
a O
population O
of O
2,947 O
hysterectomized O
women O
65 O
to O
79 O
years O
of O
age O
was O
randomized O
to O
daily O
CE O
( O
0.625 O
mg O
) O
-alone O
or O
placebo O
. O

After O
an O
average O
follow-up O
of O
5.2 O
years O
, O
28 O
women O
in O
the O
estrogen-alone O
group O
and O
19 O
women O
in O
the O
placebo O
group O
were O
diagnosed O
with O
probable O
dementia B-OSE_Labeled_AE
. O

The O
relative O
risk O
of O
probable O
dementia B-OSE_Labeled_AE
for O
CE-alone O
versus O
placebo O
was O
1.49 O
( O
95 O
percent O
CI O
0.83-2.66 O
) O
. O

The O
absolute O
risk O
of O
probable O
dementia B-OSE_Labeled_AE
for O
CE-alone O
versus O
placebo O
was O
37 O
versus O
25 O
cases O
per O
10,000 O
women-years O
8 O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.5 O
) O
, O
and O
Clinical O
Studies O
( O
14.6 O
) O
] O
. O

In O
the O
WHIMS O
estrogen O
plus O
progestin O
ancillary O
study O
of O
WHI O
, O
a O
population O
of O
4,532 O
postmenopausal B-Not_AE_Candidate
women O
65 O
to O
79 O
years O
of O
age O
was O
randomized O
to O
daily O
CE O
( O
0.625 O
mg O
) O
plus O
MPA O
( O
2.5 O
mg O
) O
or O
placebo O
. O

After O
an O
average O
follow-up O
of O
4 O
years O
, O
40 O
women O
in O
the O
CE O
plus O
MPA O
group O
and O
21 O
women O
in O
the O
placebo O
group O
were O
diagnosed O
with O
probable O
dementia B-NonOSE_AE
. O

The O
relative O
risk O
of O
probable O
dementia B-NonOSE_AE
for O
CE O
plus O
MPA O
versus O
placebo O
was O
2.05 O
( O
95 O
percent O
CI O
1.21-3.48 O
) O
. O

The O
absolute O
risk O
of O
probable O
dementia B-NonOSE_AE
for O
CE O
plus O
MPA O
versus O
placebo O
was O
45 O
versus O
22 O
cases O
per O
10,000 O
women-years O
8 O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.5 O
) O
, O
and O
Clinical O
Studies O
( O
14.6 O
) O
] O
. O

When O
data O
from O
the O
two O
populations O
in O
the O
WHIMS O
estrogen-alone O
and O
estrogen O
plus O
progestin O
ancillary O
studies O
were O
pooled O
as O
planned O
in O
the O
WHIMS O
protocol O
, O
the O
reported O
overall O
relative O
risk O
for O
probable O
dementia B-OSE_Labeled_AE
was O
1.76 O
( O
95 O
percent O
CI O
1.19-2.60 O
) O
. O

Since O
both O
ancillary O
studies O
were O
conducted O
in O
women O
65 O
to O
79 O
years O
of O
age O
, O
it O
is O
unknown O
whether O
these O
findings O
apply O
to O
younger O
postmenopausal B-Not_AE_Candidate
women O
8 O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.5 O
) O
, O
and O
Clinical O
Studies O
( O
14.6 O
) O
] O
. O

5.4 O
Gallbladder O
Disease O
A O
2- O
to O
4-fold O
increase O
in O
the O
risk O
of O
gallbladder B-OSE_Labeled_AE
disease I-OSE_Labeled_AE
requiring O
surgery O
in O
postmenopausal B-Not_AE_Candidate
women O
receiving O
estrogens O
has O
been O
reported O
. O

5.5 O
Hypercalcemia O
Estrogen O
administration O
may O
lead O
to O
severe O
hypercalcemia B-OSE_Labeled_AE
in O
patients O
with O
breast B-Not_AE_Candidate
cancer I-Not_AE_Candidate
and O
bone B-Not_AE_Candidate
metastases I-Not_AE_Candidate
. O

If O
hypercalcemia B-NonOSE_AE
occurs O
, O
use O
of O
the O
drug O
should O
be O
stopped O
and O
appropriate O
measures O
taken O
to O
reduce B-NonOSE_AE
the I-NonOSE_AE
serum I-NonOSE_AE
calcium I-NonOSE_AE
level I-NonOSE_AE
. O

5.6 O
Visual B-OSE_Labeled_AE
Abnormalities I-OSE_Labeled_AE
Retinal B-OSE_Labeled_AE
vascular I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
has O
been O
reported O
in O
patients O
receiving O
estrogens O
. O

Discontinue O
medication O
pending O
examination O
if O
there O
is O
sudden O
partial B-NonOSE_AE
or O
complete O
loss I-NonOSE_AE
of I-NonOSE_AE
vision I-NonOSE_AE
, O
or O
a O
sudden O
onset O
of O
proptosis B-NonOSE_AE
, O
diplopia B-NonOSE_AE
, O
or O
migraine B-NonOSE_AE
. O

If O
examination O
reveals O
papilledema B-NonOSE_AE
or O
retinal B-NonOSE_AE
vascular I-NonOSE_AE
lesions I-NonOSE_AE
, O
estrogens O
should O
be O
permanently O
discontinued O
. O

5.7 O
Anaphylactic O
Reaction O
and O
Angioedema O
Cases O
of O
anaphylaxis B-OSE_Labeled_AE
, O
which O
developed O
within O
minutes O
to O
hours O
after O
taking O
PREMARIN O
and O
require O
emergency O
medical O
management O
, O
have O
been O
reported O
in O
the O
postmarketing O
setting O
. O

Skin B-OSE_Labeled_AE
( O
hives O
, O
pruritis O
, O
sw O
ollen B-OSE_Labeled_AE
l O
ips B-OSE_Labeled_AE
- I-OSE_Labeled_AE
tong I-OSE_Labeled_AE
ue O
- B-OSE_Labeled_AE
face I-OSE_Labeled_AE
) I-OSE_Labeled_AE
and I-OSE_Labeled_AE
e I-OSE_Labeled_AE
ither O
respiratory O
tract O
( O
respiratory B-OSE_Labeled_AE
compr I-OSE_Labeled_AE
omise O
) O
or O
gastrointestinal O
tract O
( O
abdominal O
pain O
, O
vomiting O
) O
involveme B-OSE_Labeled_AE
n I-OSE_Labeled_AE
t I-OSE_Labeled_AE
  I-OSE_Labeled_AE
I-O I-OSE_Labeled_AE
S I-OSE_Labeled_AE
E I-OSE_Labeled_AE
_ O
Labele O
d B-OSE_Labeled_AE
  I-OSE_Labeled_AE
I I-OSE_Labeled_AE
- I-OSE_Labeled_AE
OSE I-OSE_Labeled_AE
_ I-OSE_Labeled_AE
Labeled I-OSE_Labeled_AE
_ I-OSE_Labeled_AE
AE I-OSE_Labeled_AE
_ I-OSE_Labeled_AE
  I-OSE_Labeled_AE
I-OSE_Labeled_AE O
AE I-OSE_L
abeled I-OSE_Labeled_AE
_ I-O
SE B-OSE_Labeled_AE
_ I-OSE_Labeled_AE
Labeled I-OSE_Labeled_AE
_ I-OSE_Labeled_AE
AE I-OSE_Labeled_AE
A O
E B-OSE_Labeled_AE
  I-OSE_Labeled_AE
I I-OSE_Labeled_AE
- I-OSE_Labeled_AE
OSE I-OSE_Labeled_AE
_ I-OSE_Labeled_AE
Labeled_AE O
has O
been O
noted O
. O

Angioedema B-OSE_Labeled_AE
involving O
the O
tongue O
, O
larynx O
, O
face O
, O
hands O
, O
and O
feet O
requiring O
medical O
intervention O
has O
occurred O
postmarketing O
in O
patients O
taking O
PREMARIN O
. O

If O
angioedema B-NonOSE_AE
involves O
the O
tongue O
, O
glottis O
, O
or O
larynx O
, O
airway B-NonOSE_AE
obstruction I-NonOSE_AE
may O
occur O
. O

Patients O
who O
develop O
an O
anaphylactic B-NonOSE_AE
reaction I-NonOSE_AE
with O
or O
without O
angioedema B-NonOSE_AE
after O
treatment O
with O
PREMARIN O
should O
not O
receive O
PREMARIN O
again O
. O

5.8 O
Addition O
of O
a O
Progestin O
When O
a O
Woman O
Has O
Not O
Had O
a O
Hysterectomy O
Studies O
of O
the O
addition O
of O
a O
progestin O
for O
10 O
or O
more O
days O
of O
a O
cycle O
of O
estrogen O
administration O
or O
daily O
with O
estrogen O
in O
a O
continuous O
regimen O
, O
have O
reported O
a O
lowered O
incidence O
of O
endometrial B-NonOSE_AE
hyperplasia I-NonOSE_AE
than O
would O
be O
induced O
by O
estrogen O
treatment O
alone O
. O

Endometrial B-NonOSE_AE
hyperplasia I-NonOSE_AE
may O
be O
a O
precursor O
to O
endometrial B-NonOSE_AE
cancer I-NonOSE_AE
. O

There O
are O
, O
however O
, O
possible O
risks O
that O
may O
be O
associated O
with O
the O
use O
of O
progestins O
with O
estrogens O
compared O
to O
estrogen-alone O
regimens O
. O

These O
include O
an O
increased O
risk O
of O
breast B-NonOSE_AE
cancer I-NonOSE_AE
. O

5.9 O
Elevated O
Blood O
Pressure O
In O
a O
small O
number O
of O
case O
reports O
, O
substantial O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
have O
been O
attributed O
to O
idiosyncratic O
reactions O
to O
estrogens O
. O

In O
a O
large O
, O
randomized O
, O
placebo-controlled O
clinical O
trial O
, O
a O
generalized O
effect O
of O
estrogen O
therapy O
on O
blood O
pressure O
was O
not O
seen O
. O

5.10 O
Hypertriglyceridemia O
In O
women O
with O
pre-existing O
hypertriglyceridemia B-Not_AE_Candidate
, O
estrogen O
therapy O
may O
be O
associated O
with O
elevations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
plasma I-OSE_Labeled_AE
triglycerides I-OSE_Labeled_AE
leading O
to O
pancreatitis B-NonOSE_AE
. O

Consider O
discontinuation O
of O
treatment O
if O
pancreatitis B-NonOSE_AE
occurs O
. O

5.11 O
Hepatic O
Impairment O
and/or O
Past O
History O
of O
Cholestatic O
Jaundice O
Estrogens O
may O
be O
poorly O
metabolized O
in O
patients O
with O
impaired B-Not_AE_Candidate
liver I-Not_AE_Candidate
function I-Not_AE_Candidate
. O

For O
women O
with O
a O
history O
of O
cholestatic B-Not_AE_Candidate
jaundice I-Not_AE_Candidate
associated O
with O
past O
estrogen O
use O
or O
with O
pregnancy B-Not_AE_Candidate
, O
caution O
should O
be O
exercised O
, O
and O
in O
the O
case O
of O
recurrence O
, O
medication O
should O
be O
discontinued O
. O

5.12 O
Hypothyroidism O
Estrogen O
administration O
leads O
to O
increased B-OSE_Labeled_AE
thyroid I-OSE_Labeled_AE
- I-OSE_Labeled_AE
binding I-OSE_Labeled_AE
globulin I-OSE_Labeled_AE
( I-OSE_Labeled_AE
TBG I-OSE_Labeled_AE
) I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
. O

Women O
with O
normal O
thyroid O
function O
can O
compensate O
for O
the O
increased B-NonOSE_AE
TBG I-NonOSE_AE
by O
making O
more O
thyroid O
hormone O
, O
thus O
maintaining O
free O
T4and O
T3serum O
concentrations O
in O
the O
normal O
range O
. O

Women O
dependent O
on O
thyroid O
hormone O
replacement O
therapy O
who O
are O
also O
receiving O
estrogens O
may O
require O
increased O
doses O
of O
their O
thyroid O
replacement O
therapy O
. O

These O
women O
should O
have O
their O
thyroid O
function O
monitored O
in O
order O
to O
maintain O
their O
free O
thyroid O
hormone O
levels O
in O
an O
acceptable O
range O
. O

5.13 O
Fluid O
Retention O
Estrogens O
may O
cause O
some O
degree O
of O
fluid B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
. O

Women O
with O
conditions O
that O
might O
be O
influenced O
by O
this O
factor O
, O
such O
as O
cardiac B-Not_AE_Candidate
or O
renal O
dysfunction I-Not_AE_Candidate
, O
warrant O
careful O
observation O
when O
estrogen O
alone O
is O
prescribed O
. O

5.14 O
Hypocalcemia O
Estrogen O
therapy O
should O
be O
used O
with O
caution O
in O
individuals O
with O
hypoparathyroidism B-Not_AE_Candidate
as O
estrogen-induced O
hypocalcemia B-OSE_Labeled_AE
may O
occur O
. O

5.15 O
Hereditary O
Angioedema O
Exogenous O
estrogens O
may O
exacerbate B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
of I-OSE_Labeled_AE
angioedema I-OSE_Labeled_AE
in O
women O
with O
hereditary B-Not_AE_Candidate
angioedema I-Not_AE_Candidate
. O

5.16 O
Exacerbation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
Endometriosis I-OSE_Labeled_AE
A O
few O
cases O
of O
malignant B-OSE_Labeled_AE
transformation I-OSE_Labeled_AE
of I-OSE_Labeled_AE
residual I-OSE_Labeled_AE
endometrial I-OSE_Labeled_AE
implants I-OSE_Labeled_AE
have O
been O
reported O
in O
women O
treated O
post-hysterectomy O
with O
estrogen-alone O
therapy O
. O

For O
women O
known O
to O
have O
residual O
endometriosis B-Not_AE_Candidate
post-hysterectomy O
, O
the O
addition O
of O
progestin O
should O
be O
considered O
. O

5.17 O
Exacerbation O
of O
Other O
Conditions O
Estrogen O
therapy O
may O
cause O
an O
exacerbation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
asthma I-OSE_Labeled_AE
, O
diabetes O
mellitus O
, O
epilepsy O
, O
migraine O
, O
porphyria O
, O
systemic O
lupus O
erythematosus O
, O
and O
hepatic O
hemangiomas O
and O
should O
be O
used O
with O
caution O
in O
women O
with O
these O
conditions O
. O

5.18 O
Laboratory O
Tests O
Serum O
follicle O
stimulating O
hormone O
( O
FSH O
) O
and O
estradiol O
levels O
have O
not O
been O
shown O
to O
be O
useful O
in O
the O
management O
of O
moderate O
to O
severe O
vasomotor B-Not_AE_Candidate
symptoms I-Not_AE_Candidate
and O
moderate O
to O
severe O
symptoms O
of O
vulvar B-Not_AE_Candidate
and O
vaginal O
atrophy I-Not_AE_Candidate
. O

Laboratory O
parameters O
may O
be O
useful O
in O
guiding O
dosage O
for O
the O
treatment O
of O
hypoestrogenism B-Not_AE_Candidate
due O
to O
hypogonadism B-Not_AE_Candidate
, O
castration O
and O
primary B-Not_AE_Candidate
ovarian I-Not_AE_Candidate
failure I-Not_AE_Candidate
. O

5.19 O
Drug-Laboratory O
Test O
Interactions O
Accelerated B-OSE_Labeled_AE
prothrombin O
time O
, O
partial O
thromboplastin O
time O
, O
and O
platelet I-OSE_Labeled_AE
aggregation I-OSE_Labeled_AE
time I-OSE_Labeled_AE
; O
increased B-OSE_Labeled_AE
platelet I-OSE_Labeled_AE
count I-OSE_Labeled_AE
; O
increased B-OSE_Labeled_AE
factors O
II O
, O
VII O
antigen O
, O
VIII O
antigen O
, O
VIII O
coagulant O
activity O
, O
IX O
, O
X O
, O
XII O
, O
VII-X O
complex O
, O
II-VII-X O
complex O
, O
and O
beta I-OSE_Labeled_AE
- I-OSE_Labeled_AE
thromboglobulin I-OSE_Labeled_AE
; O
decreased B-OSE_Labeled_AE
levels I-OSE_Labeled_AE
of I-OSE_Labeled_AE
antifactor O
Xa O
and O
antithrombin I-OSE_Labeled_AE
III I-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
antithrombin I-OSE_Labeled_AE
III I-OSE_Labeled_AE
activity I-OSE_Labeled_AE
; O
increased B-OSE_Labeled_AE
levels O
of O
fibrinogen I-OSE_Labeled_AE
and O
fibrinogen O
activity I-OSE_Labeled_AE
; O
increased B-OSE_Labeled_AE
plasminogen I-OSE_Labeled_AE
antigen O
and O
activity I-OSE_Labeled_AE
. O

Increased B-OSE_Labeled_AE
thyroid I-OSE_Labeled_AE
- I-OSE_Labeled_AE
binding I-OSE_Labeled_AE
globulin I-OSE_Labeled_AE
( I-OSE_Labeled_AE
TBG I-OSE_Labeled_AE
) I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
leading O
to O
increased B-NonOSE_AE
circulating I-NonOSE_AE
total I-NonOSE_AE
thyroid I-NonOSE_AE
hormone I-NonOSE_AE
levels I-NonOSE_AE
as O
measured O
by O
protein-bound O
iodine O
( O
PBI O
) O
, O
T4levels O
( O
by O
column O
or O
by O
radioimmunoassay O
) O
or O
T3levels O
by O
radioimmunoassay O
. O

T B-OSE_Labeled_AE
3 I-OSE_Labeled_AE
resin I-OSE_Labeled_AE
uptake I-OSE_Labeled_AE
is I-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
reflecting O
the O
elevated B-NonOSE_AE
TBG I-NonOSE_AE
. O

Free O
T4and O
free O
T3concentrations O
are O
unaltered O
. O

Women O
on O
thyroid O
replacement O
therapy O
may O
require O
higher O
doses O
of O
thyroid O
hormone O
. O

Other O
binding O
proteins O
may O
be O
elevated B-OSE_Labeled_AE
in O
serum O
, O
for O
example O
, O
corticosteroid I-OSE_Labeled_AE
binding I-OSE_Labeled_AE
globulin I-OSE_Labeled_AE
( I-OSE_Labeled_AE
CBG I-OSE_Labeled_AE
) O
, O
sex O
hormone-binding O
globulin O
( O
SHBG O
) O
, O
leading O
to O
increased B-NonOSE_AE
total I-NonOSE_AE
circulating I-NonOSE_AE
corticosteroids I-NonOSE_AE
and I-NonOSE_AE
sex I-NonOSE_AE
steroids I-NonOSE_AE
, O
respectively O
. O

Free O
hormone O
concentrations O
, O
such O
as O
testosterone B-OSE_Labeled_AE
and O
estradiol O
, O
may O
be O
decreased I-OSE_Labeled_AE
. O

Other O
plasma O
proteins O
may O
be O
increased B-OSE_Labeled_AE
( O
angiotensinogen/renin O
substrate O
, O
alpha-1-antitrypsin O
, O
ceruloplasmin I-OSE_Labeled_AE
) O
. O

Increased B-OSE_Labeled_AE
plasma I-OSE_Labeled_AE
high I-OSE_Labeled_AE
- I-OSE_Labeled_AE
density I-OSE_Labeled_AE
lipoprotein I-OSE_Labeled_AE
( I-OSE_Labeled_AE
HDL I-OSE_Labeled_AE
) O
and O
HDL2cholesterol O
subfraction O
concentrations O
, O
reduced B-OSE_Labeled_AE
low I-OSE_Labeled_AE
- I-OSE_Labeled_AE
density I-OSE_Labeled_AE
lipoprotein I-OSE_Labeled_AE
( I-OSE_Labeled_AE
LDL I-OSE_Labeled_AE
) I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
concentrations I-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
triglyceride I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
. O

Impaired B-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
tolerance I-OSE_Labeled_AE
. O

ADVERSE O
REACTIONS O
Associated O
with O
Discontinuation O
of O
Treatment O
Approximately O
16 O
% O
of O
the O
453 O
patients O
who O
received O
REMERON O
( O
mirtazapine O
) O
Tablets O
in O
US O
6-week O
controlled O
clinical O
trials O
discontinued O
treatment O
due O
to O
an O
adverse O
experience O
, O
compared O
to O
7 O
% O
of O
the O
361 O
placebo-treated O
patients O
in O
those O
studies O
. O

The O
most O
common O
events O
( O
> O
=1 O
% O
) O
associated O
with O
discontinuation O
and O
considered O
to O
be O
drug O
related O
( O
i.e. O
, O
those O
events O
associated O
with O
dropout O
at O
a O
rate O
at O
least O
twice O
that O
of O
placebo O
) O
are O
included O
in O
Table O
2 O
. O

Table O
2 O
: O
Common O
Adverse O
Events O
Associated O
With O
Discontinuation O
of O
Treatment O
in O
6-Week O
US O
REMERON O
Trials O
Adverse O
Event O
Percentage O
of O
Patients O
Discontinuing O
With O
Adverse O
Event O
REMERON O
( O
n=453 O
) O
Placebo O
( O
n=361 O
) O
Somnolence B-OSE_Labeled_AE
10.4 O
% O
2.2 O
% O
Nausea B-OSE_Labeled_AE
1.5 O
% O
0 O
% O
Commonly O
Observed O
Adverse O
Events O
in O
US O
Controlled O
Clinical O
Trials O
The O
most O
commonly O
observed O
adverse O
events O
associated O
with O
the O
use O
of O
REMERON O
( O
mirtazapine O
) O
Tablets O
( O
incidence O
of O
5 O
% O
or O
greater O
) O
and O
not O
observed O
at O
an O
equivalent O
incidence O
among O
placebo-treated O
patients O
( O
REMERON O
incidence O
at O
least O
twice O
that O
for O
placebo O
) O
are O
listed O
in O
Table O
3 O
. O

Table O
3 O
: O
Common O
Treatment-Emergent O
Adverse O
Events O
Associated O
With O
the O
Use O
of O
REMERON O
in O
6-Week O
US O
Trials O
Adverse O
Event O
Percentage O
of O
Patients O
Reporting O
Adverse O
Event O
REMERON O
( O
n=453 O
) O
Placebo O
( O
n=361 O
) O
Somnolence B-OSE_Labeled_AE
54 O
% O
18 O
% O
Increased B-OSE_Labeled_AE
Appetite I-OSE_Labeled_AE
17 O
% O
2 O
% O
Weight B-OSE_Labeled_AE
Gain I-OSE_Labeled_AE
12 O
% O
2 O
% O
Dizziness B-OSE_Labeled_AE
7 O
% O
3 O
% O
Adverse O
Events O
Occurring O
at O
an O
Incidence O
of O
1 O
% O
or O
More O
Among O
REMERON-Treated O
Patients O
Table O
4 O
enumerates O
adverse O
events O
that O
occurred O
at O
an O
incidence O
of O
1 O
% O
or O
more O
, O
and O
were O
more O
frequent O
than O
in O
the O
placebo O
group O
, O
among O
REMERON O
( O
mirtazapine O
) O
Tablets-treated O
patients O
who O
participated O
in O
short-term O
US O
placebo-controlled O
trials O
in O
which O
patients O
were O
dosed O
in O
a O
range O
of O
5 O
to O
60 O
mg/day O
. O

This O
table O
shows O
the O
percentage O
of O
patients O
in O
each O
group O
who O
had O
at O
least O
1 O
episode O
of O
an O
event O
at O
some O
time O
during O
their O
treatment O
. O

Reported O
adverse O
events O
were O
classified O
using O
a O
standard O
COSTART-based O
dictionary O
terminology O
. O

The O
prescriber O
should O
be O
aware O
that O
these O
figures O
can O
not O
be O
used O
to O
predict O
the O
incidence O
of O
side O
effects O
in O
the O
course O
of O
usual O
medical O
practice O
where O
patient O
characteristics O
and O
other O
factors O
differ O
from O
those O
which O
prevailed O
in O
the O
clinical O
trials O
. O

Similarly O
, O
the O
cited O
frequencies O
can O
not O
be O
compared O
with O
figures O
obtained O
from O
other O
investigations O
involving O
different O
treatments O
, O
uses O
, O
and O
investigators O
. O

The O
cited O
figures O
, O
however O
, O
do O
provide O
the O
prescribing O
physician O
with O
some O
basis O
for O
estimating O
the O
relative O
contribution O
of O
drug O
and O
nondrug O
factors O
to O
the O
side-effect O
incidence O
rate O
in O
the O
population O
studied O
. O

Table O
4 O
: O
Incidence O
of O
Adverse O
Clinical O
ExperiencesEvents O
reported O
by O
at O
least O
1 O
% O
of O
patients O
treated O
with O
REMERON O
are O
included O
, O
except O
the O
following O
events O
, O
which O
had O
an O
incidence O
on O
placebo O
greater O
than O
or O
equal O
to O
REMERON O
: O
headache B-NonOSE_AE
, O
infection B-NonOSE_AE
, O
pain B-NonOSE_AE
, O
chest B-NonOSE_AE
pain I-NonOSE_AE
, O
palpitation B-NonOSE_AE
, O
tachycardia B-NonOSE_AE
, O
postural B-NonOSE_AE
hypotension I-NonOSE_AE
, O
nausea B-NonOSE_AE
, O
dyspepsia B-NonOSE_AE
, O
diarrhea B-NonOSE_AE
, O
flatulence B-NonOSE_AE
, O
insomnia B-NonOSE_AE
, O
nervousness B-NonOSE_AE
, O
libido B-NonOSE_AE
decreased I-NonOSE_AE
, O
hypertonia B-NonOSE_AE
, O
pharyngitis B-NonOSE_AE
, O
rhinitis B-NonOSE_AE
, O
sweating B-NonOSE_AE
, O
amblyopia B-NonOSE_AE
, O
tinnitus B-NonOSE_AE
, O
taste B-NonOSE_AE
perversion I-NonOSE_AE
. O

( O
> O
=1 O
% O
) O
in O
Short-Term O
US O
Controlled O
Studies O
Body O
System O
Adverse O
Clinical O
Experience O
REMERON O
( O
n=453 O
) O
Placebo O
( O
n=361 O
) O
Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
Asthenia B-OSE_Labeled_AE
8 O
% O
5 O
% O
Flu B-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
5 O
% O
3 O
% O
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
2 O
% O
1 O
% O
Digestive B-NonOSE_AE
System I-NonOSE_AE
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
25 O
% O
15 O
% O
Increased B-OSE_Labeled_AE
Appetite I-OSE_Labeled_AE
17 O
% O
2 O
% O
Constipation B-OSE_Labeled_AE
13 O
% O
7 O
% O
Metabolic B-NonOSE_AE
and I-NonOSE_AE
Nutritional I-NonOSE_AE
Disorders I-NonOSE_AE
Weight B-OSE_Labeled_AE
Gain I-OSE_Labeled_AE
12 O
% O
2 O
% O
Peripheral B-OSE_Labeled_AE
Edema I-OSE_Labeled_AE
2 O
% O
1 O
% O
Edema B-OSE_Labeled_AE
1 O
% O
0 O
% O
Musculoskeletal B-NonOSE_AE
System I-NonOSE_AE
Myalgia B-OSE_Labeled_AE
2 O
% O
1 O
% O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Somnolence B-OSE_Labeled_AE
54 O
% O
18 O
% O
Dizziness B-OSE_Labeled_AE
7 O
% O
3 O
% O
Abnormal B-OSE_Labeled_AE
Dreams I-OSE_Labeled_AE
4 O
% O
1 O
% O
Thinking B-OSE_Labeled_AE
Abnormal I-OSE_Labeled_AE
3 O
% O
1 O
% O
Tremor B-OSE_Labeled_AE
2 O
% O
1 O
% O
Confusion B-OSE_Labeled_AE
2 O
% O
0 O
% O
Respiratory B-NonOSE_AE
System I-NonOSE_AE
Dyspnea B-OSE_Labeled_AE
1 O
% O
0 O
% O
Urogenital B-NonOSE_AE
System I-NonOSE_AE
Urinary B-OSE_Labeled_AE
Frequency I-OSE_Labeled_AE
2 O
% O
1 O
% O
ECG B-OSE_Labeled_AE
Changes I-OSE_Labeled_AE
The O
electrocardiograms O
for O
338 O
patients O
who O
received O
REMERON O
( O
mirtazapine O
) O
Tablets O
and O
261 O
patients O
who O
received O
placebo O
in O
6-week O
, O
placebo-controlled O
trials O
were O
analyzed O
. O

Prolongation B-NonOSE_AE
in I-NonOSE_AE
QTc I-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
5 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
msec I-NonOSE_AE
was O
not O
observed O
among O
mirtazapine-treated O
patients O
; O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
QTc I-OSE_Labeled_AE
was O
+1.6 O
msec O
for O
mirtazapine O
and O
-3.1 O
msec O
for O
placebo O
. O

Mirtazapine O
was O
associated O
with O
a O
mean O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
heart I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
of O
3.4 O
bpm O
, O
compared O
to O
0.8 O
bpm O
for O
placebo O
. O

The O
clinical O
significance O
of O
these O
changes O
is O
unknown O
. O

The O
effect O
of O
REMERON O
( O
mirtazapine O
) O
on O
QTc O
interval O
was O
assessed O
in O
a O
clinical O
randomized O
trial O
with O
placebo O
and O
positive O
( O
moxifloxacin O
) O
controls O
involving O
54 O
healthy O
volunteers O
using O
exposure O
response O
analysis O
. O

This O
trial O
showed O
a O
positive O
relationship O
between O
mirtazapine O
concentrations O
and O
prolongation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
QTc I-OSE_Labeled_AE
interval I-OSE_Labeled_AE
. O

However O
, O
the O
degree O
of O
QT B-NonOSE_AE
prolongation I-NonOSE_AE
observed O
with O
both O
45 O
mg O
( O
therapeutic O
) O
and O
75 O
mg O
( O
supratherapeutic O
) O
doses O
of O
mirtazapine O
was O
not O
at O
a O
level O
generally O
considered O
to O
be O
clinically O
meaningful O
. O

Other O
Adverse O
Events O
Observed O
During O
the O
Premarketing O
Evaluation O
of O
REMERON O
During O
its O
premarketing O
assessment O
, O
multiple O
doses O
of O
REMERON O
( O
mirtazapine O
) O
Tablets O
were O
administered O
to O
2796 O
patients O
in O
clinical O
studies O
. O

The O
conditions O
and O
duration O
of O
exposure O
to O
mirtazapine O
varied O
greatly O
, O
and O
included O
( O
in O
overlapping O
categories O
) O
open O
and O
double-blind O
studies O
, O
uncontrolled O
and O
controlled O
studies O
, O
inpatient O
and O
outpatient O
studies O
, O
fixed-dose O
and O
titration O
studies O
. O

Untoward O
events O
associated O
with O
this O
exposure O
were O
recorded O
by O
clinical O
investigators O
using O
terminology O
of O
their O
own O
choosing O
. O

Consequently O
, O
it O
is O
not O
possible O
to O
provide O
a O
meaningful O
estimate O
of O
the O
proportion O
of O
individuals O
experiencing O
adverse O
events O
without O
first O
grouping O
similar O
types O
of O
untoward O
events O
into O
a O
smaller O
number O
of O
standardized O
event O
categories O
. O

In O
the O
tabulations O
that O
follow O
, O
reported O
adverse O
events O
were O
classified O
using O
a O
standard O
COSTART-based O
dictionary O
terminology O
. O

The O
frequencies O
presented O
, O
therefore O
, O
represent O
the O
proportion O
of O
the O
2796 O
patients O
exposed O
to O
multiple O
doses O
of O
REMERON O
who O
experienced O
an O
event O
of O
the O
type O
cited O
on O
at O
least O
1 O
occasion O
while O
receiving O
REMERON O
. O

All O
reported O
events O
are O
included O
except O
those O
already O
listed O
in O
Table O
4 O
, O
those O
adverse O
experiences O
subsumed O
under O
COSTART O
terms O
that O
are O
either O
overly O
general O
or O
excessively O
specific O
so O
as O
to O
be O
uninformative O
, O
and O
those O
events O
for O
which O
a O
drug O
cause O
was O
very O
remote O
. O

It O
is O
important O
to O
emphasize O
that O
, O
although O
the O
events O
reported O
occurred O
during O
treatment O
with O
REMERON O
, O
they O
were O
not O
necessarily O
caused O
by O
it O
. O

Events O
are O
further O
categorized O
by O
body O
system O
and O
listed O
in O
order O
of O
decreasing O
frequency O
according O
to O
the O
following O
definitions O
: O
frequent O
adverse O
events O
are O
those O
occurring O
on O
1 O
or O
more O
occasions O
in O
at O
least O
1/100 O
patients O
; O
infrequent O
adverse O
events O
are O
those O
occurring O
in O
1/100 O
to O
1/1000 O
patients O
; O
rare O
events O
are O
those O
occurring O
in O
fewer O
than O
1/1000 O
patients O
. O

Only O
those O
events O
not O
already O
listed O
in O
Table O
4 O
appear O
in O
this O
listing O
. O

Events O
of O
major O
clinical O
importance O
are O
also O
described O
in O
the O
WARNINGS O
and O
PRECAUTIONS O
sections O
. O

Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
: O
frequent O
: O
malaise B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
acute I-OSE_Labeled_AE
; O
infrequent O
: O
chills B-OSE_Labeled_AE
, O
fever B-OSE_Labeled_AE
, O
face B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
ulcer B-OSE_Labeled_AE
, O
photosensitivity B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
neck B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
neck B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
abdomen B-OSE_Labeled_AE
enlarged I-OSE_Labeled_AE
; O
rare O
: O
cellulitis B-OSE_Labeled_AE
, O
chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
substernal I-OSE_Labeled_AE
. O

Cardiovascular B-NonOSE_AE
System I-NonOSE_AE
: O
frequent O
: O
hypertension B-OSE_Labeled_AE
, O
vasodilatation B-OSE_Labeled_AE
; O
infrequent O
: O
angina B-OSE_Labeled_AE
pectoris I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
, O
bradycardia B-OSE_Labeled_AE
, O
ventricular B-OSE_Labeled_AE
extrasystoles I-OSE_Labeled_AE
, O
syncope B-OSE_Labeled_AE
, O
migraine B-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
; O
rare O
: O
atrial B-OSE_Labeled_AE
arrhythmia I-OSE_Labeled_AE
, O
bigeminy B-OSE_Labeled_AE
, O
vascular B-OSE_Labeled_AE
headache I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
embolus I-OSE_Labeled_AE
, O
cerebral B-OSE_Labeled_AE
ischemia I-OSE_Labeled_AE
, O
cardiomegaly B-OSE_Labeled_AE
, O
phlebitis B-OSE_Labeled_AE
, O
left B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
. O

Digestive B-NonOSE_AE
System I-NonOSE_AE
: O
frequent O
: O
vomiting B-OSE_Labeled_AE
, O
anorexia B-OSE_Labeled_AE
; O
infrequent O
: O
eructation B-OSE_Labeled_AE
, O
glossitis B-OSE_Labeled_AE
, O
cholecystitis B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
and O
vomiting B-OSE_Labeled_AE
, O
gum B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
stomatitis B-OSE_Labeled_AE
, O
colitis B-OSE_Labeled_AE
, O
liver B-OSE_Labeled_AE
function I-OSE_Labeled_AE
tests I-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
; O
rare O
: O
tongue B-OSE_Labeled_AE
discoloration I-OSE_Labeled_AE
, O
ulcerative B-OSE_Labeled_AE
stomatitis I-OSE_Labeled_AE
, O
salivary B-OSE_Labeled_AE
gland I-OSE_Labeled_AE
enlargement I-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
salivation I-OSE_Labeled_AE
, O
intestinal B-OSE_Labeled_AE
obstruction I-OSE_Labeled_AE
, O
pancreatitis B-OSE_Labeled_AE
, O
aphthous B-OSE_Labeled_AE
stomatitis I-OSE_Labeled_AE
, O
cirrhosis B-OSE_Labeled_AE
of O
liver O
, O
gastritis B-OSE_Labeled_AE
, O
gastroenteritis B-OSE_Labeled_AE
, O
oral B-OSE_Labeled_AE
moniliasis I-OSE_Labeled_AE
, O
tongue B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
. O

Endocrine B-NonOSE_AE
System I-NonOSE_AE
: O
rare O
: O
goiter B-OSE_Labeled_AE
, O
hypothyroidism B-OSE_Labeled_AE
. O

Hemic B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
System I-NonOSE_AE
: O
rare O
: O
lymphadenopathy B-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
petechia B-OSE_Labeled_AE
, O
anemia B-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
, O
lymphocytosis B-OSE_Labeled_AE
, O
pancytopenia B-OSE_Labeled_AE
. O

Metabolic B-NonOSE_AE
and I-NonOSE_AE
Nutritional I-NonOSE_AE
Disorders I-NonOSE_AE
: O
frequent O
: O
thirst B-OSE_Labeled_AE
; O
infrequent O
: O
dehydration B-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
; O
rare O
: O
gout B-OSE_Labeled_AE
, O
SGOT B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
healing B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
acid B-OSE_Labeled_AE
phosphatase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
SGPT B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
diabetes B-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
, O
hyponatremia B-OSE_Labeled_AE
. O

Musculoskeletal B-NonOSE_AE
System I-NonOSE_AE
: O
frequent O
: O
myasthenia B-OSE_Labeled_AE
, O
arthralgia B-OSE_Labeled_AE
; O
infrequent O
: O
arthritis B-OSE_Labeled_AE
, O
tenosynovitis B-OSE_Labeled_AE
; O
rare O
: O
pathologic B-OSE_Labeled_AE
fracture I-OSE_Labeled_AE
, O
osteoporosis B-OSE_Labeled_AE
fracture I-OSE_Labeled_AE
, O
bone B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
myositis B-OSE_Labeled_AE
, O
tendon B-OSE_Labeled_AE
rupture I-OSE_Labeled_AE
, O
arthrosis B-OSE_Labeled_AE
, O
bursitis B-OSE_Labeled_AE
. O

Nervous B-NonOSE_AE
System I-NonOSE_AE
: O
frequent O
: O
hypesthesia B-OSE_Labeled_AE
, O
apathy B-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
, O
hypokinesia B-OSE_Labeled_AE
, O
vertigo B-OSE_Labeled_AE
, O
twitching B-OSE_Labeled_AE
, O
agitation B-OSE_Labeled_AE
, O
anxiety B-OSE_Labeled_AE
, O
amnesia B-OSE_Labeled_AE
, O
hyperkinesia B-OSE_Labeled_AE
, O
paresthesia B-OSE_Labeled_AE
; O
infrequent O
: O
ataxia B-OSE_Labeled_AE
, O
delirium B-OSE_Labeled_AE
, O
delusions B-OSE_Labeled_AE
, O
depersonalization B-OSE_Labeled_AE
, O
dyskinesia B-OSE_Labeled_AE
, O
extrapyramidal B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
libido B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
coordination B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
dysarthria B-OSE_Labeled_AE
, O
hallucinations B-OSE_Labeled_AE
, O
manic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
neurosis B-OSE_Labeled_AE
, O
dystonia B-OSE_Labeled_AE
, O
hostility B-OSE_Labeled_AE
, O
reflexes B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
emotional B-OSE_Labeled_AE
lability I-OSE_Labeled_AE
, O
euphoria B-OSE_Labeled_AE
, O
paranoid B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
; O
rare O
: O
aphasia B-OSE_Labeled_AE
, O
nystagmus B-OSE_Labeled_AE
, O
akathisia B-OSE_Labeled_AE
( O
psychomotor B-OSE_Labeled_AE
restlessness I-OSE_Labeled_AE
) O
, O
stupor B-OSE_Labeled_AE
, O
dementia B-OSE_Labeled_AE
, O
diplopia B-OSE_Labeled_AE
, O
drug B-OSE_Labeled_AE
dependence I-OSE_Labeled_AE
, O
paralysis B-OSE_Labeled_AE
, O
grand B-OSE_Labeled_AE
mal I-OSE_Labeled_AE
convulsion I-OSE_Labeled_AE
, O
hypotonia B-OSE_Labeled_AE
, O
myoclonus B-OSE_Labeled_AE
, O
psychotic B-OSE_Labeled_AE
depression I-OSE_Labeled_AE
, O
withdrawal B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
serotonin B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
. O

Respiratory B-NonOSE_AE
System I-NonOSE_AE
: O
frequent O
: O
cough B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
sinusitis B-OSE_Labeled_AE
; O
infrequent O
: O
epistaxis B-OSE_Labeled_AE
, O
bronchitis B-OSE_Labeled_AE
, O
asthma B-OSE_Labeled_AE
, O
pneumonia B-OSE_Labeled_AE
; O
rare O
: O
asphyxia B-OSE_Labeled_AE
, O
laryngitis B-OSE_Labeled_AE
, O
pneumothorax B-OSE_Labeled_AE
, O
hiccup B-OSE_Labeled_AE
. O

Skin B-NonOSE_AE
and I-NonOSE_AE
Appendages I-NonOSE_AE
: O
frequent O
: O
pruritus B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
; O
infrequent O
: O
acne B-OSE_Labeled_AE
, O
exfoliative B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
, O
herpes B-OSE_Labeled_AE
simplex I-OSE_Labeled_AE
, O
alopecia B-OSE_Labeled_AE
; O
rare O
: O
urticaria B-OSE_Labeled_AE
, O
herpes B-OSE_Labeled_AE
zoster I-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
hypertrophy I-OSE_Labeled_AE
, O
seborrhea B-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
ulcer I-OSE_Labeled_AE
. O

Special B-NonOSE_AE
Senses I-NonOSE_AE
: O
infrequent O
: O
eye B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
abnormality B-OSE_Labeled_AE
of I-OSE_Labeled_AE
accommodation I-OSE_Labeled_AE
, O
conjunctivitis B-OSE_Labeled_AE
, O
deafness B-OSE_Labeled_AE
, O
keratoconjunctivitis B-OSE_Labeled_AE
, O
lacrimation B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
angle B-OSE_Labeled_AE
- I-OSE_Labeled_AE
closure I-OSE_Labeled_AE
glaucoma I-OSE_Labeled_AE
, O
hyperacusis B-OSE_Labeled_AE
, O
ear B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
; O
rare O
: O
blepharitis B-OSE_Labeled_AE
, O
partial B-OSE_Labeled_AE
transitory I-OSE_Labeled_AE
deafness I-OSE_Labeled_AE
, O
otitis B-OSE_Labeled_AE
media I-OSE_Labeled_AE
, O
taste B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
, O
parosmia B-OSE_Labeled_AE
. O

Urogenital B-NonOSE_AE
System I-NonOSE_AE
: O
frequent O
: O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
; O
infrequent O
: O
kidney B-OSE_Labeled_AE
calculus I-OSE_Labeled_AE
, O
cystitis B-OSE_Labeled_AE
, O
dysuria B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
incontinence I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
, O
vaginitis B-OSE_Labeled_AE
, O
hematuria B-OSE_Labeled_AE
, O
breast B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
amenorrhea B-OSE_Labeled_AE
, O
dysmenorrhea B-OSE_Labeled_AE
, O
leukorrhea B-OSE_Labeled_AE
, O
impotence B-OSE_Labeled_AE
; O
rare O
: O
polyuria B-OSE_Labeled_AE
, O
urethritis B-OSE_Labeled_AE
, O
metrorrhagia B-OSE_Labeled_AE
, O
menorrhagia B-OSE_Labeled_AE
, O
abnormal B-OSE_Labeled_AE
ejaculation I-OSE_Labeled_AE
, O
breast B-OSE_Labeled_AE
engorgement I-OSE_Labeled_AE
, O
breast B-OSE_Labeled_AE
enlargement I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
urgency I-OSE_Labeled_AE
. O

Other O
Adverse O
Events O
Observed O
During O
Postmarketing O
Evaluation O
of O
REMERON O
Adverse O
events O
reported O
since O
market O
introduction O
, O
which O
were O
temporally O
( O
but O
not O
necessarily O
causally O
) O
related O
to O
mirtazapine O
therapy O
, O
include O
cases O
of O
the O
ventricular B-OSE_Labeled_AE
arrhythmia I-OSE_Labeled_AE
Torsades B-OSE_Labeled_AE
de I-OSE_Labeled_AE
Pointes I-OSE_Labeled_AE
. O

In O
the O
majority O
of O
these O
cases O
, O
however O
, O
concomitant O
drugs O
were O
implicated O
. O

Cases O
of O
severe O
skin B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
including O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
bullous B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
erythema B-OSE_Labeled_AE
multiforme I-OSE_Labeled_AE
and O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
have O
also O
been O
reported O
. O

Increased B-OSE_Labeled_AE
creatine I-OSE_Labeled_AE
kinase I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
and O
rhabdomyolysis B-OSE_Labeled_AE
have O
also O
been O
reported O
. O

BOXED O
WARNING O
: O
Suicidality O
and O
Antidepressant O
Drugs O
Antidepressants O
increased O
the O
risk O
compared O
to O
placebo O
of O
suicidal B-OSE_Labeled_AE
thinking O
and O
behavior I-OSE_Labeled_AE
( O
suicidality B-OSE_Labeled_AE
) O
in O
children O
, O
adolescents O
, O
and O
young O
adults O
in O
short-term O
studies O
of O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
MDD I-Not_AE_Candidate
) O
and O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
. O

Anyone O
considering O
the O
use O
of O
REMERON O
( O
r O
) O
( O
mirtazapine O
) O
Tablets O
or O
any O
other O
antidepressant O
in O
a O
child O
, O
adolescent O
, O
or O
young O
adult O
must O
balance O
this O
risk O
with O
the O
clinical O
need O
. O

Short-term O
studies O
did O
not O
show O
an O
increase O
in O
the O
risk O
of O
suicidality B-NonOSE_AE
with O
antidepressants O
compared O
to O
placebo O
in O
adults O
beyond O
age O
24 O
; O
there O
was O
a O
reduction O
in O
risk O
with O
antidepressants O
compared O
to O
placebo O
in O
adults O
aged O
65 O
and O
older O
. O

Depression B-Not_AE_Candidate
and O
certain O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
are O
themselves O
associated O
with O
increases O
in O
the O
risk O
of O
suicide B-NonOSE_AE
. O

Patients O
of O
all O
ages O
who O
are O
started O
on O
antidepressant O
therapy O
should O
be O
monitored O
appropriately O
and O
observed O
closely O
for O
clinical O
worsening O
, O
suicidality B-NonOSE_AE
, O
or O
unusual O
changes B-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
. O

Families O
and O
caregivers O
should O
be O
advised O
of O
the O
need O
for O
close O
observation O
and O
communication O
with O
the O
prescriber O
. O

REMERON O
is O
not O
approved O
for O
use O
in O
pediatric O
patients O
. O

( O
See O
WARNINGS O
: O
Clinical O
Worsening O
and O
Suicide B-NonOSE_AE
Risk O
, O
PRECAUTIONS O
: O
Information O
for O
Patients O
, O
and O
PRECAUTIONS O
: O
Pediatric O
Use O
) O

PRECAUTIONS O
General O
Discontinuation O
Symptoms O
There O
have O
been O
reports O
of O
adverse B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
upon I-OSE_Labeled_AE
the I-OSE_Labeled_AE
discontinuation I-OSE_Labeled_AE
of I-OSE_Labeled_AE
REMERON I-OSE_Labeled_AE
( O
mirtazapine O
) O
Tablets O
( O
particularly O
when O
abrupt O
) O
, O
including O
but O
not O
limited O
to O
the O
following O
: O
dizziness B-NonOSE_AE
, O
abnormal B-NonOSE_AE
dreams I-NonOSE_AE
, O
sensory B-NonOSE_AE
disturbances I-NonOSE_AE
( O
including O
paresthesia B-NonOSE_AE
and O
electric B-NonOSE_AE
shock I-NonOSE_AE
sensations I-NonOSE_AE
) O
, O
agitation B-NonOSE_AE
, O
anxiety B-NonOSE_AE
, O
fatigue B-NonOSE_AE
, O
confusion B-NonOSE_AE
, O
headache B-NonOSE_AE
, O
tremor B-NonOSE_AE
, O
nausea B-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
and O
sweating B-NonOSE_AE
, O
or O
other O
symptoms O
which O
may O
be O
of O
clinical O
significance O
. O

The O
majority O
of O
the O
reported O
cases O
are O
mild O
and O
self-limiting O
. O

Even O
though O
these O
have O
been O
reported O
as O
adverse O
reactions O
, O
it O
should O
be O
realized O
that O
these O
symptoms O
may O
be O
related O
to O
underlying O
disease O
. O

Patients O
currently O
taking O
REMERON O
should O
NOT O
discontinue O
treatment O
abruptly O
, O
due O
to O
risk O
of O
discontinuation B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
. O

At O
the O
time O
that O
a O
medical O
decision O
is O
made O
to O
discontinue O
treatment O
with O
REMERON O
, O
a O
gradual O
reduction O
in O
the O
dose O
, O
rather O
than O
an O
abrupt O
cessation O
, O
is O
recommended O
. O

Akathisia/Psychomotor O
Restlessness O
The O
use O
of O
antidepressants O
has O
been O
associated O
with O
the O
development O
of O
akathisia B-OSE_Labeled_AE
, O
characterized O
by O
a O
subjectively B-OSE_Labeled_AE
unpleasant I-OSE_Labeled_AE
or I-OSE_Labeled_AE
distressing I-OSE_Labeled_AE
restlessness I-OSE_Labeled_AE
and I-OSE_Labeled_AE
need I-OSE_Labeled_AE
to I-OSE_Labeled_AE
move I-OSE_Labeled_AE
, O
often O
accompanied O
by O
an O
inability B-OSE_Labeled_AE
to I-OSE_Labeled_AE
sit I-OSE_Labeled_AE
or I-OSE_Labeled_AE
stand I-OSE_Labeled_AE
still I-OSE_Labeled_AE
. O

This O
is O
most O
likely O
to O
occur O
within O
the O
first O
few O
weeks O
of O
treatment O
. O

In O
patients O
who O
develop O
these O
symptoms O
, O
increasing O
the O
dose O
may O
be O
detrimental O
. O

Hyponatremia O
Hyponatremia B-OSE_Labeled_AE
has O
been O
reported O
very O
rarely O
with O
the O
use O
of O
mirtazapine O
. O

Caution O
should O
be O
exercised O
in O
patients O
at O
risk O
, O
such O
as O
elderly O
patients O
or O
patients O
concomitantly O
treated O
with O
medications O
known O
to O
cause O
hyponatremia B-NonOSE_AE
. O

Somnolence O
In O
US O
controlled O
studies O
, O
somnolence B-OSE_Labeled_AE
was O
reported O
in O
54 O
% O
of O
patients O
treated O
with O
REMERON O
( O
mirtazapine O
) O
Tablets O
, O
compared O
to O
18 O
% O
for O
placebo O
and O
60 O
% O
for O
amitriptyline O
. O

In O
these O
studies O
, O
somnolence B-OSE_Labeled_AE
resulted O
in O
discontinuation O
for O
10.4 O
% O
of O
REMERON-treated O
patients O
, O
compared O
to O
2.2 O
% O
for O
placebo O
. O

It O
is O
unclear O
whether O
or O
not O
tolerance O
develops O
to O
the O
somnolent O
effects O
of O
REMERON O
. O

Because O
of O
the O
potentially O
significant O
effects O
of O
REMERON O
on O
impairment B-NonOSE_AE
of I-NonOSE_AE
performance I-NonOSE_AE
, O
patients O
should O
be O
cautioned O
about O
engaging O
in O
activities O
requiring O
alertness O
until O
they O
have O
been O
able O
to O
assess O
the O
drug O
's O
effect O
on O
their O
own O
psychomotor O
performance O
( O
see O
PRECAUTIONS O
: O
Information O
for O
Patients O
) O
. O

Dizziness O
In O
US O
controlled O
studies O
, O
dizziness B-OSE_Labeled_AE
was O
reported O
in O
7 O
% O
of O
patients O
treated O
with O
REMERON O
, O
compared O
to O
3 O
% O
for O
placebo O
and O
14 O
% O
for O
amitriptyline O
. O

It O
is O
unclear O
whether O
or O
not O
tolerance O
develops O
to O
the O
dizziness B-NonOSE_AE
observed O
in O
association O
with O
the O
use O
of O
REMERON O
. O

Increased O
Appetite/Weight O
Gain O
In O
US O
controlled O
studies O
, O
appetite B-OSE_Labeled_AE
increase I-OSE_Labeled_AE
was O
reported O
in O
17 O
% O
of O
patients O
treated O
with O
REMERON O
, O
compared O
to O
2 O
% O
for O
placebo O
and O
6 O
% O
for O
amitriptyline O
. O

In O
these O
same O
trials O
, O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
of I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
7 I-OSE_Labeled_AE
% I-OSE_Labeled_AE
of I-OSE_Labeled_AE
body I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
was O
reported O
in O
7.5 O
% O
of O
patients O
treated O
with O
mirtazapine O
, O
compared O
to O
0 O
% O
for O
placebo O
and O
5.9 O
% O
for O
amitriptyline O
. O

In O
a O
pool O
of O
premarketing O
US O
studies O
, O
including O
many O
patients O
for O
long-term O
, O
open-label O
treatment O
, O
8 O
% O
of O
patients O
receiving O
REMERON O
discontinued O
for O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
. O

In O
an O
8-week-long O
pediatric O
clinical O
trial O
of O
doses O
between O
15 O
to O
45 O
mg/day O
, O
49 O
% O
of O
REMERON-treated O
patients O
had O
a O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
of O
at O
least O
7 O
% O
, O
compared O
to O
5.7 O
% O
of O
placebo-treated O
patients O
( O
see O
PRECAUTIONS O
: O
Pediatric O
Use O
) O
. O

Cholesterol/Triglycerides O
In O
US O
controlled O
studies O
, O
nonfasting O
cholesterol B-OSE_Labeled_AE
increases I-OSE_Labeled_AE
to O
> O
=20 O
% O
above O
the O
upper O
limits O
of O
normal O
were O
observed O
in O
15 O
% O
of O
patients O
treated O
with O
REMERON O
, O
compared O
to O
7 O
% O
for O
placebo O
and O
8 O
% O
for O
amitriptyline O
. O

In O
these O
same O
studies O
, O
nonfasting O
triglyceride B-OSE_Labeled_AE
increases I-OSE_Labeled_AE
to O
> O
=500 O
mg/dL O
were O
observed O
in O
6 O
% O
of O
patients O
treated O
with O
mirtazapine O
, O
compared O
to O
3 O
% O
for O
placebo O
and O
3 O
% O
for O
amitriptyline O
. O

Transaminase B-OSE_Labeled_AE
Elevations I-OSE_Labeled_AE
Clinically O
significant O
ALT B-OSE_Labeled_AE
( I-OSE_Labeled_AE
SGPT I-OSE_Labeled_AE
) I-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
( O
> O
=3 O
times O
the O
upper O
limit O
of O
the O
normal O
range O
) O
were O
observed O
in O
2.0 O
% O
( O
8/424 O
) O
of O
patients O
exposed O
to O
REMERON O
in O
a O
pool O
of O
short-term O
US O
controlled O
trials O
, O
compared O
to O
0.3 O
% O
( O
1/328 O
) O
of O
placebo O
patients O
and O
2.0 O
% O
( O
3/181 O
) O
of O
amitriptyline O
patients O
. O

Most O
of O
these O
patients O
with O
ALT B-NonOSE_AE
increases I-NonOSE_AE
did O
not O
develop O
signs O
or O
symptoms O
associated O
with O
compromised B-NonOSE_AE
liver I-NonOSE_AE
function I-NonOSE_AE
. O

While O
some O
patients O
were O
discontinued O
for O
the O
ALT B-OSE_Labeled_AE
increases I-OSE_Labeled_AE
, O
in O
other O
cases O
, O
the O
enzyme O
levels O
returned O
to O
normal O
despite O
continued O
REMERON O
treatment O
. O

REMERON O
should O
be O
used O
with O
caution O
in O
patients O
with O
impaired B-Not_AE_Candidate
hepatic I-Not_AE_Candidate
function I-Not_AE_Candidate
( O
see O
CLINICAL O
PHARMACOLOGY O
and O
DOSAGE O
AND O
ADMINISTRATION O
) O
. O

Activation O
of O
Mania/Hypomania O
Mania B-OSE_Labeled_AE
/ O
hypomania B-OSE_Labeled_AE
occurred O
in O
approximately O
0.2 O
% O
( O
3/1299 O
patients O
) O
of O
REMERON-treated O
patients O
in O
US O
studies O
. O

Although O
the O
incidence O
of O
mania B-OSE_Labeled_AE
/ O
hypomania B-OSE_Labeled_AE
was O
very O
low O
during O
treatment O
with O
mirtazapine O
, O
it O
should O
be O
used O
carefully O
in O
patients O
with O
a O
history O
of O
mania B-Not_AE_Candidate
/ O
hypomania B-Not_AE_Candidate
. O

Seizure O
In O
premarketing O
clinical O
trials O
, O
only O
1 O
seizure B-OSE_Labeled_AE
was O
reported O
among O
the O
2796 O
US O
and O
non-US O
patients O
treated O
with O
REMERON O
. O

However O
, O
no O
controlled O
studies O
have O
been O
carried O
out O
in O
patients O
with O
a O
history O
of O
seizures B-Not_AE_Candidate
. O

Therefore O
, O
care O
should O
be O
exercised O
when O
mirtazapine O
is O
used O
in O
these O
patients O
. O

Use O
in O
Patients O
with O
Concomitant O
Illness O
Clinical O
experience O
with O
REMERON O
in O
patients O
with O
concomitant O
systemic O
illness O
is O
limited O
. O

Accordingly O
, O
care O
is O
advisable O
in O
prescribing O
mirtazapine O
for O
patients O
with O
diseases O
or O
conditions O
that O
affect O
metabolism O
or O
hemodynamic O
responses O
. O

REMERON O
has O
not O
been O
systematically O
evaluated O
or O
used O
to O
any O
appreciable O
extent O
in O
patients O
with O
a O
recent O
history O
of O
myocardial B-Not_AE_Candidate
infarction I-Not_AE_Candidate
or O
other O
significant O
heart B-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

REMERON O
was O
associated O
with O
significant O
orthostatic B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
in O
early O
clinical O
pharmacology O
trials O
with O
normal O
volunteers O
. O

Orthostatic B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
was O
infrequently O
observed O
in O
clinical O
trials O
with O
depressed B-Not_AE_Candidate
patients O
. O

REMERON O
should O
be O
used O
with O
caution O
in O
patients O
with O
known O
cardiovascular B-Not_AE_Candidate
or O
cerebrovascular O
disease I-Not_AE_Candidate
that O
could O
be O
exacerbated O
by O
hypotension B-NonOSE_AE
( O
history O
of O
myocardial B-Not_AE_Candidate
infarction I-Not_AE_Candidate
, O
angina B-Not_AE_Candidate
, O
or O
ischemic B-Not_AE_Candidate
stroke I-Not_AE_Candidate
) O
and O
conditions O
that O
would O
predispose O
patients O
to O
hypotension B-NonOSE_AE
( O
dehydration B-Not_AE_Candidate
, O
hypovolemia B-Not_AE_Candidate
, O
and O
treatment O
with O
antihypertensive O
medication O
) O
. O

Mirtazapine O
clearance O
is O
decreased O
in O
patients O
with O
moderate O
[ O
glomerular B-Not_AE_Candidate
filtration I-Not_AE_Candidate
rate I-Not_AE_Candidate
( I-Not_AE_Candidate
GFR I-Not_AE_Candidate
) I-Not_AE_Candidate
= I-Not_AE_Candidate
1 I-Not_AE_Candidate
1 I-Not_AE_Candidate
- I-Not_AE_Candidate
3 I-Not_AE_Candidate
9 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
/ I-Not_AE_Candidate
1 I-Not_AE_Candidate
. I-Not_AE_Candidate
7 I-Not_AE_Candidate
3 I-Not_AE_Candidate
m I-Not_AE_Candidate
2 I-Not_AE_Candidate
] O
and O
severe O
[ O
GFR B-Not_AE_Candidate
< I-Not_AE_Candidate
1 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
/ I-Not_AE_Candidate
1 I-Not_AE_Candidate
. I-Not_AE_Candidate
7 I-Not_AE_Candidate
3 I-Not_AE_Candidate
m I-Not_AE_Candidate
2 I-Not_AE_Candidate
] O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
, O
and O
also O
in O
patients O
with O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
. O

Caution O
is O
indicated O
in O
administering O
REMERON O
to O
such O
patients O
( O
see O
CLINICAL O
PHARMACOLOGY O
and O
DOSAGE O
AND O
ADMINISTRATION O
) O
. O

Information O
for O
Patients O
Prescribers O
or O
other O
health O
professionals O
should O
inform O
patients O
, O
their O
families O
, O
and O
their O
caregivers O
about O
the O
benefits O
and O
risks O
associated O
with O
treatment O
with O
REMERON O
( O
mirtazapine O
) O
Tablets O
and O
should O
counsel O
them O
in O
its O
appropriate O
use O
. O

A O
patient O
Medication O
Guide O
about O
`` O
Antidepressant O
Medicines O
, O
Depression B-NonOSE_AE
and O
other O
Serious O
Mental B-NonOSE_AE
Illnesses I-NonOSE_AE
, O
and O
Suicidal B-NonOSE_AE
Thoughts O
or O
Actions I-NonOSE_AE
`` O
is O
available O
for O
REMERON O
. O

The O
prescriber O
or O
health O
professional O
should O
instruct O
patients O
, O
their O
families O
, O
and O
their O
caregivers O
to O
read O
the O
Medication O
Guide O
and O
should O
assist O
them O
in O
understanding O
its O
contents O
. O

Patients O
should O
be O
given O
the O
opportunity O
to O
discuss O
the O
contents O
of O
the O
Medication O
Guide O
and O
to O
obtain O
answers O
to O
any O
questions O
they O
may O
have O
. O

The O
complete O
text O
of O
the O
Medication O
Guide O
is O
reprinted O
at O
the O
end O
of O
this O
document O
. O

Patients O
should O
be O
advised O
of O
the O
following O
issues O
and O
asked O
to O
alert O
their O
prescriber O
if O
these O
occur O
while O
taking O
REMERON O
. O

Clinical O
Worsening O
and O
Suicide O
Risk O
Patients O
, O
their O
families O
, O
and O
their O
caregivers O
should O
be O
encouraged O
to O
be O
alert O
to O
the O
emergence O
of O
anxiety B-NonOSE_AE
, O
agitation B-NonOSE_AE
, O
panic B-NonOSE_AE
attacks I-NonOSE_AE
, O
insomnia B-NonOSE_AE
, O
irritability B-NonOSE_AE
, O
hostility B-NonOSE_AE
, O
aggressiveness B-NonOSE_AE
, O
impulsivity B-NonOSE_AE
, O
akathisia B-NonOSE_AE
( O
psychomotor B-NonOSE_AE
restlessness I-NonOSE_AE
) O
, O
hypomania B-NonOSE_AE
, O
mania B-NonOSE_AE
, O
other O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
worsening B-NonOSE_AE
of I-NonOSE_AE
depression I-NonOSE_AE
, O
and O
suicidal B-NonOSE_AE
ideation I-NonOSE_AE
, O
especially O
early O
during O
antidepressant O
treatment O
and O
when O
the O
dose O
is O
adjusted O
up O
or O
down O
. O

Families O
and O
caregivers O
of O
patients O
should O
be O
advised O
to O
look O
for O
the O
emergence O
of O
such O
symptoms O
on O
a O
day-to-day O
basis O
, O
since O
changes O
may O
be O
abrupt O
. O

Such O
symptoms O
should O
be O
reported O
to O
the O
patient O
's O
prescriber O
or O
health O
professional O
, O
especially O
if O
they O
are O
severe O
, O
abrupt O
in O
onset O
, O
or O
were O
not O
part O
of O
the O
patient O
's O
presenting O
symptoms O
. O

Symptoms O
such O
as O
these O
may O
be O
associated O
with O
an O
increased O
risk O
for O
suicidal B-NonOSE_AE
thinking O
and O
behavior I-NonOSE_AE
and O
indicate O
a O
need O
for O
very O
close O
monitoring O
and O
possibly O
changes O
in O
the O
medication O
. O

Agranulocytosis O
Patients O
who O
are O
to O
receive O
REMERON O
should O
be O
warned O
about O
the O
risk O
of O
developing O
agranulocytosis B-NonOSE_AE
. O

Patients O
should O
be O
advised O
to O
contact O
their O
physician O
if O
they O
experience O
any O
indication O
of O
infection B-NonOSE_AE
such O
as O
fever B-NonOSE_AE
, O
chills B-NonOSE_AE
, O
sore B-NonOSE_AE
throat I-NonOSE_AE
, O
mucous B-NonOSE_AE
membrane I-NonOSE_AE
ulceration I-NonOSE_AE
, O
or O
other O
possible O
signs O
of O
infection B-NonOSE_AE
. O

Particular O
attention O
should O
be O
paid O
to O
any O
flu-like O
complaints O
or O
other O
symptoms O
that O
might O
suggest O
infection B-NonOSE_AE
. O

Interference O
with O
Cognitive O
and O
Motor O
Performance O
REMERON O
may O
impair B-NonOSE_AE
judgment I-NonOSE_AE
, O
thinking O
, O
and O
particularly O
, O
motor O
skills O
, O
because O
of O
its O
prominent O
sedative B-NonOSE_AE
effect I-NonOSE_AE
. O

The O
drowsiness B-NonOSE_AE
associated O
with O
mirtazapine O
use O
may O
impair B-NonOSE_AE
a I-NonOSE_AE
patient I-NonOSE_AE
' I-NonOSE_AE
s I-NonOSE_AE
ability I-NonOSE_AE
to I-NonOSE_AE
drive I-NonOSE_AE
, O
use O
machines O
, O
or O
perform O
tasks O
that O
require O
alertness O
. O

Thus O
, O
patients O
should O
be O
cautioned O
about O
engaging O
in O
hazardous O
activities O
until O
they O
are O
reasonably O
certain O
that O
REMERON O
therapy O
does O
not O
adversely B-NonOSE_AE
affect I-NonOSE_AE
their I-NonOSE_AE
ability I-NonOSE_AE
to I-NonOSE_AE
engage I-NonOSE_AE
in I-NonOSE_AE
such I-NonOSE_AE
activities I-NonOSE_AE
. O

Completing O
Course O
of O
Therapy O
While O
patients O
may O
notice O
improvement O
with O
REMERON O
therapy O
in O
1 O
to O
4 O
weeks O
, O
they O
should O
be O
advised O
to O
continue O
therapy O
as O
directed O
. O

Concomitant O
Medication O
Patients O
should O
be O
advised O
to O
inform O
their O
physician O
if O
they O
are O
taking O
, O
or O
intend O
to O
take O
, O
any O
prescription O
or O
over-the-counter O
drugs O
, O
since O
there O
is O
a O
potential O
for O
REMERON O
to O
interact O
with O
other O
drugs O
. O

Patients O
should O
be O
made O
aware O
of O
a O
potential O
increased O
risk O
for O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
if O
concomitant O
use O
of O
REMERON O
with O
other O
serotonergic O
drugs O
, O
including O
triptans O
, O
tricyclic O
antidepressants O
, O
fentanyl O
, O
lithium O
, O
tramadol O
, O
buspirone O
, O
tryptophan O
, O
and O
St O
. O
John O
's O
wort O
, O
is O
clinically O
warranted O
, O
particularly O
during O
treatment O
initiation O
and O
dose O
increases O
. O

Alcohol O
The O
impairment B-NonOSE_AE
of I-NonOSE_AE
cognitive O
and O
motor I-NonOSE_AE
skills I-NonOSE_AE
produced O
by O
REMERON O
has O
been O
shown O
to O
be O
additive O
with O
those O
produced O
by O
alcohol O
. O

Accordingly O
, O
patients O
should O
be O
advised O
to O
avoid O
alcohol O
while O
taking O
mirtazapine O
. O

Pregnancy O
Patients O
should O
be O
advised O
to O
notify O
their O
physician O
if O
they O
become O
pregnant B-NonOSE_AE
or O
intend O
to O
become O
pregnant B-NonOSE_AE
during O
REMERON O
therapy O
. O

Nursing O
Patients O
should O
be O
advised O
to O
notify O
their O
physician O
if O
they O
are O
breastfeeding O
an O
infant O
. O

Laboratory O
Tests O
There O
are O
no O
routine O
laboratory O
tests O
recommended O
. O

Drug O
Interactions O
As O
with O
other O
drugs O
, O
the O
potential O
for O
interaction O
by O
a O
variety O
of O
mechanisms O
( O
e.g. O
, O
pharmacodynamic O
, O
pharmacokinetic O
inhibition O
or O
enhancement O
, O
etc O
. O
) O

is O
a O
possibility O
( O
see O
CLINICAL O
PHARMACOLOGY O
) O
. O

Monoamine O
Oxidase O
Inhibitors O
( O
See O
CONTRAINDICATIONS O
, O
WARNINGS O
, O
and O
DOSAGE O
AND O
ADMINISTRATION O
. O
) O

Serotonergic O
Drugs O
( O
See O
CONTRAINDICATIONS O
and O
WARNINGS O
. O
) O

Drugs O
Affecting O
Hepatic O
Metabolism O
The O
metabolism O
and O
pharmacokinetics O
of O
REMERON O
( O
mirtazapine O
) O
Tablets O
may O
be O
affected O
by O
the O
induction O
or O
inhibition O
of O
drug-metabolizing O
enzymes O
. O

Drugs O
that O
are O
Metabolized O
by O
and/or O
Inhibit O
Cytochrome O
P450 O
Enzymes O
CYP O
Enzyme O
Inducers O
( O
these O
studies O
used O
both O
drugs O
at O
steady O
state O
) O
Phenytoin O
In O
healthy O
male O
patients O
( O
n=18 O
) O
, O
phenytoin O
( O
200 O
mg O
daily O
) O
increased O
mirtazapine O
( O
30 O
mg O
daily O
) O
clearance O
about O
2-fold O
, O
resulting O
in O
a O
decrease O
in O
average O
plasma O
mirtazapine O
concentrations O
of O
45 O
% O
. O

Mirtazapine O
did O
not O
significantly O
affect O
the O
pharmacokinetics O
of O
phenytoin O
. O

Carbamazepine O
In O
healthy O
male O
patients O
( O
n=24 O
) O
, O
carbamazepine O
( O
400 O
mg O
b.i.d O
. O
) O

increased O
mirtazapine O
( O
15 O
mg O
b.i.d O
. O
) O

clearance O
about O
2-fold O
, O
resulting O
in O
a O
decrease O
in O
average O
plasma O
mirtazapine O
concentrations O
of O
60 O
% O
. O

When O
phenytoin O
, O
carbamazepine O
, O
or O
another O
inducer O
of O
hepatic O
metabolism O
( O
such O
as O
rifampicin O
) O
is O
added O
to O
mirtazapine O
therapy O
, O
the O
mirtazapine O
dose O
may O
have O
to O
be O
increased O
. O

If O
treatment O
with O
such O
a O
medicinal O
product O
is O
discontinued O
, O
it O
may O
be O
necessary O
to O
reduce O
the O
mirtazapine O
dose O
. O

CYP O
Enzyme O
Inhibitors O
Cimetidine O
In O
healthy O
male O
patients O
( O
n=12 O
) O
, O
when O
cimetidine O
, O
a O
weak O
inhibitor O
of O
CYP1A2 O
, O
CYP2D6 O
, O
and O
CYP3A4 O
, O
given O
at O
800 O
mg O
b.i.d O
. O

at O
steady O
state O
was O
coadministered O
with O
mirtazapine O
( O
30 O
mg O
daily O
) O
at O
steady O
state O
, O
the O
Area O
Under O
the O
Curve O
( O
AUC O
) O
of O
mirtazapine O
increased O
more O
than O
50 O
% O
. O

Mirtazapine O
did O
not O
cause O
relevant O
changes O
in O
the O
pharmacokinetics O
of O
cimetidine O
. O

The O
mirtazapine O
dose O
may O
have O
to O
be O
decreased O
when O
concomitant O
treatment O
with O
cimetidine O
is O
started O
, O
or O
increased O
when O
cimetidine O
treatment O
is O
discontinued O
. O

Ketoconazole O
In O
healthy O
, O
male O
, O
Caucasian O
patients O
( O
n=24 O
) O
, O
coadministration O
of O
the O
potent O
CYP3A4 O
inhibitor O
ketoconazole O
( O
200 O
mg O
b.i.d O
. O

for O
6.5 O
days O
) O
increased O
the O
peak O
plasma O
levels O
and O
the O
AUC O
of O
a O
single O
30-mg O
dose O
of O
mirtazapine O
by O
approximately O
40 O
% O
and O
50 O
% O
, O
respectively O
. O

Caution O
should O
be O
exercised O
when O
coadministering O
mirtazapine O
with O
potent O
CYP3A4 O
inhibitors O
, O
HIV O
protease O
inhibitors O
, O
azole O
antifungals O
, O
erythromycin O
, O
or O
nefazodone O
. O

Paroxetine O
In O
an O
in O
vivo O
interaction O
study O
in O
healthy O
, O
CYP2D6 O
extensive O
metabolizer O
patients O
( O
n=24 O
) O
, O
mirtazapine O
( O
30 O
mg/day O
) O
, O
at O
steady O
state O
, O
did O
not O
cause O
relevant O
changes O
in O
the O
pharmacokinetics O
of O
steady O
state O
paroxetine O
( O
40 O
mg/day O
) O
, O
a O
CYP2D6 O
inhibitor O
. O

Other O
Drug-Drug O
Interactions O
Amitriptyline O
In O
healthy O
, O
CYP2D6 O
extensive O
metabolizer O
patients O
( O
n=32 O
) O
, O
amitriptyline O
( O
75 O
mg O
daily O
) O
, O
at O
steady O
state O
, O
did O
not O
cause O
relevant O
changes O
in O
the O
pharmacokinetics O
of O
steady O
state O
mirtazapine O
( O
30 O
mg O
daily O
) O
; O
mirtazapine O
also O
did O
not O
cause O
relevant O
changes O
to O
the O
pharmacokinetics O
of O
amitriptyline O
. O

Warfarin O
In O
healthy O
male O
subjects O
( O
n=16 O
) O
, O
mirtazapine O
( O
30 O
mg O
daily O
) O
, O
at O
steady O
state O
, O
caused O
a O
small O
( O
0.2 O
) O
but O
statistically O
significant O
increase B-NonOSE_AE
in I-NonOSE_AE
the I-NonOSE_AE
International I-NonOSE_AE
Normalized I-NonOSE_AE
Ratio I-NonOSE_AE
( I-NonOSE_AE
INR I-NonOSE_AE
) O
in O
subjects O
treated O
with O
warfarin O
. O

As O
at O
a O
higher O
dose O
of O
mirtazapine O
, O
a O
more O
pronounced O
effect O
can O
not O
be O
excluded O
, O
it O
is O
advisable O
to O
monitor O
the O
INR O
in O
case O
of O
concomitant O
treatment O
of O
warfarin O
with O
mirtazapine O
. O

Lithium O
No O
relevant O
clinical O
effects O
or O
significant O
changes O
in O
pharmacokinetics O
have O
been O
observed O
in O
healthy O
male O
subjects O
on O
concurrent O
treatment O
with O
subtherapeutic O
levels O
of O
lithium O
( O
600 O
mg/day O
for O
10 O
days O
) O
at O
steady O
state O
and O
a O
single O
30-mg O
dose O
of O
mirtazapine O
. O

The O
effects O
of O
higher O
doses O
of O
lithium O
on O
the O
pharmacokinetics O
of O
mirtazapine O
are O
unknown O
. O

Risperidone O
In O
an O
in O
vivo O
, O
nonrandomized O
, O
interaction O
study O
, O
subjects O
( O
n=6 O
) O
in O
need O
of O
treatment O
with O
an O
antipsychotic O
and O
antidepressant O
drug O
, O
showed O
that O
mirtazapine O
( O
30 O
mg O
daily O
) O
at O
steady O
state O
did O
not O
influence O
the O
pharmacokinetics O
of O
risperidone O
( O
up O
to O
3 O
mg O
b.i.d O
. O
) O
. O

Alcohol O
Concomitant O
administration O
of O
alcohol O
( O
equivalent O
to O
60 O
g O
) O
had O
a O
minimal O
effect O
on O
plasma O
levels O
of O
mirtazapine O
( O
15 O
mg O
) O
in O
6 O
healthy O
male O
subjects O
. O

However O
, O
the O
impairment B-NonOSE_AE
of I-NonOSE_AE
cognitive I-NonOSE_AE
and O
motor O
skills I-NonOSE_AE
produced O
by O
REMERON O
were O
shown O
to O
be O
additive O
with O
those O
produced O
by O
alcohol O
. O

Accordingly O
, O
patients O
should O
be O
advised O
to O
avoid O
alcohol O
while O
taking O
REMERON O
. O

Diazepam O
Concomitant O
administration O
of O
diazepam O
( O
15 O
mg O
) O
had O
a O
minimal O
effect O
on O
plasma O
levels O
of O
mirtazapine O
( O
15 O
mg O
) O
in O
12 O
healthy O
subjects O
. O

However O
, O
the O
impairment B-NonOSE_AE
of I-NonOSE_AE
motor I-NonOSE_AE
skills I-NonOSE_AE
produced O
by O
REMERON O
has O
been O
shown O
to O
be O
additive O
with O
those O
caused O
by O
diazepam O
. O

Accordingly O
, O
patients O
should O
be O
advised O
to O
avoid O
diazepam O
and O
other O
similar O
drugs O
while O
taking O
REMERON O
. O

QTc-Prolonging O
Drugs O
The O
risk O
of O
QT B-NonOSE_AE
prolongation I-NonOSE_AE
and/or O
ventricular B-NonOSE_AE
arrhythmias I-NonOSE_AE
( O
e.g. O
, O
Torsades B-NonOSE_AE
de I-NonOSE_AE
Pointes I-NonOSE_AE
) O
may O
be O
increased O
with O
concomitant O
use O
of O
medicines O
which O
prolong B-NonOSE_AE
the I-NonOSE_AE
QTc I-NonOSE_AE
interval I-NonOSE_AE
( O
e.g. O
, O
some O
antipsychotics O
and O
antibiotics O
) O
and O
in O
case O
of O
mirtazapine O
overdose O
( O
see O
ADVERSE O
REACTIONS O
and O
OVERDOSE O
sections O
) O
. O

Carcinogenesis O
, O
Mutagenesis O
, O
Impairment O
of O
Fertility O
Carcinogenesis O
Carcinogenicity B-NonOSE_AE
studies O
were O
conducted O
with O
mirtazapine O
given O
in O
the O
diet O
at O
doses O
of O
2 O
, O
20 O
, O
and O
200 O
mg/kg/day O
to O
mice O
and O
2 O
, O
20 O
, O
and O
60 O
mg/kg/day O
to O
rats O
. O

The O
highest O
doses O
used O
are O
approximately O
20 O
and O
12 O
times O
the O
maximum O
recommended O
human O
dose O
( O
MRHD O
) O
of O
45 O
mg/day O
on O
an O
mg/m O
2 O
basis O
in O
mice O
and O
rats O
, O
respectively O
. O

There O
was O
an O
increased O
incidence O
of O
hepatocellular B-NonOSE_AE
adenoma O
and O
carcinoma I-NonOSE_AE
in O
male O
mice O
at O
the O
high O
dose O
. O

In O
rats O
, O
there O
was O
an O
increase O
in O
hepatocellular B-NonOSE_AE
adenoma I-NonOSE_AE
in O
females O
at O
the O
mid O
and O
high O
doses O
and O
in O
hepatocellular B-NonOSE_AE
tumors I-NonOSE_AE
and O
thyroid B-NonOSE_AE
follicular I-NonOSE_AE
adenoma/cystadenoma O
and O
carcinoma I-NonOSE_AE
in O
males O
at O
the O
high O
dose O
. O

The O
data O
suggest O
that O
the O
above O
effects O
could O
possibly O
be O
mediated O
by O
non-genotoxic O
mechanisms O
, O
the O
relevance O
of O
which O
to O
humans O
is O
not O
known O
. O

The O
doses O
used O
in O
the O
mouse O
study O
may O
not O
have O
been O
high O
enough O
to O
fully O
characterize O
the O
carcinogenic B-NonOSE_AE
potential O
of O
REMERON O
( O
mirtazapine O
) O
Tablets O
. O

Mutagenesis O
Mirtazapine O
was O
not O
mutagenic B-NonOSE_AE
or O
clastogenic B-NonOSE_AE
and O
did O
not O
induce O
general O
DNA O
damage O
as O
determined O
in O
several O
genotoxicity B-NonOSE_AE
tests O
: O
Ames O
test O
, O
in O
vitro O
gene O
mutation O
assay O
in O
Chinese O
hamster O
V O
79 O
cells O
, O
in O
vitro O
sister O
chromatid O
exchange O
assay O
in O
cultured O
rabbit O
lymphocytes O
, O
in O
vivo O
bone O
marrow O
micronucleus O
test O
in O
rats O
, O
and O
unscheduled O
DNA O
synthesis O
assay O
in O
HeLa O
cells O
. O

Impairment B-NonOSE_AE
of I-NonOSE_AE
Fertility I-NonOSE_AE
In O
a O
fertility O
study O
in O
rats O
, O
mirtazapine O
was O
given O
at O
doses O
up O
to O
100 O
mg/kg O
[ O
20 O
times O
the O
maximum O
recommended O
human O
dose O
( O
MRHD O
) O
on O
an O
mg/m O
2 O
basis O
] O
. O

Mating O
and O
conception O
were O
not O
affected O
by O
the O
drug O
, O
but O
estrous O
cycling O
was O
disrupted O
at O
doses O
that O
were O
3 O
or O
more O
times O
the O
MRHD O
, O
and O
pre B-NonOSE_AE
- I-NonOSE_AE
implantation I-NonOSE_AE
losses I-NonOSE_AE
occurred O
at O
20 O
times O
the O
MRHD O
. O

Pregnancy O
Teratogenic O
Effects O
Pregnancy O
Category O
C O
Reproduction O
studies O
in O
pregnant B-NonOSE_AE
rats O
and O
rabbits O
at O
doses O
up O
to O
100 O
mg/kg O
and O
40 O
mg/kg O
, O
respectively O
[ O
20 O
and O
17 O
times O
the O
maximum O
recommended O
human O
dose O
( O
MRHD O
) O
on O
an O
mg/m O
2 O
basis O
, O
respectively O
] O
, O
have O
revealed O
no O
evidence O
of O
teratogenic B-NonOSE_AE
effects I-NonOSE_AE
. O

However O
, O
in O
rats O
, O
there O
was O
an O
increase O
in O
postimplantation B-NonOSE_AE
losses I-NonOSE_AE
in O
dams O
treated O
with O
mirtazapine O
. O

There O
was O
an O
increase O
in O
pup B-NonOSE_AE
deaths I-NonOSE_AE
during O
the O
first O
3 O
days O
of O
lactation O
and O
a O
decrease B-NonOSE_AE
in I-NonOSE_AE
pup I-NonOSE_AE
birth I-NonOSE_AE
weights I-NonOSE_AE
. O

The O
cause O
of O
these O
deaths B-NonOSE_AE
is O
not O
known O
. O

The O
effects O
occurred O
at O
doses O
that O
were O
20 O
times O
the O
MRHD O
, O
but O
not O
at O
3 O
times O
the O
MRHD O
, O
on O
an O
mg/m O
2 O
basis O
. O

There O
are O
no O
adequate O
and O
well-controlled O
studies O
in O
pregnant B-Not_AE_Candidate
women O
. O

Because O
animal O
reproduction O
studies O
are O
not O
always O
predictive O
of O
human O
response O
, O
this O
drug O
should O
be O
used O
during O
pregnancy B-Not_AE_Candidate
only O
if O
clearly O
needed O
. O

Nursing O
Mothers O
Because O
some O
REMERON O
may O
be O
excreted O
into O
breast O
milk O
, O
caution O
should O
be O
exercised O
when O
REMERON O
( O
mirtazapine O
) O
Tablets O
are O
administered O
to O
nursing O
women O
. O

Pediatric O
Use O
Safety O
and O
effectiveness O
in O
the O
pediatric O
population O
have O
not O
been O
established O
( O
see O
BOXED O
WARNING O
and O
WARNINGS O
: O
Clinical O
Worsening O
and O
Suicide O
Risk O
) O
. O

Two O
placebo-controlled O
trials O
in O
258 O
pediatric O
patients O
with O
MDD B-Not_AE_Candidate
have O
been O
conducted O
with O
REMERON O
( O
mirtazapine O
) O
Tablets O
, O
and O
the O
data O
were O
not O
sufficient O
to O
support O
a O
claim O
for O
use O
in O
pediatric O
patients O
. O

Anyone O
considering O
the O
use O
of O
REMERON O
in O
a O
child O
or O
adolescent O
must O
balance O
the O
potential O
risks O
with O
the O
clinical O
need O
. O

In O
an O
8-week-long O
pediatric O
clinical O
trial O
of O
doses O
between O
15 O
to O
45 O
mg/day O
, O
49 O
% O
of O
REMERON-treated O
patients O
had O
a O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
of O
at O
least O
7 O
% O
, O
compared O
to O
5.7 O
% O
of O
placebo-treated O
patients O
. O

The O
mean O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
was O
4 O
kg O
( O
2 O
kg O
SD O
) O
for O
REMERON-treated O
patients O
versus O
1 O
kg O
( O
2 O
kg O
SD O
) O
for O
placebo-treated O
patients O
( O
see O
PRECAUTIONS O
: O
Increased B-NonOSE_AE
Appetite I-NonOSE_AE
/ O
Weight B-NonOSE_AE
Gain I-NonOSE_AE
) O
. O

Geriatric O
Use O
Approximately O
190 O
elderly O
individuals O
( O
> O
=65 O
years O
of O
age O
) O
participated O
in O
clinical O
studies O
with O
REMERON O
( O
mirtazapine O
) O
Tablets O
. O

This O
drug O
is O
known O
to O
be O
substantially O
excreted O
by O
the O
kidney O
( O
75 O
% O
) O
, O
and O
the O
risk O
of O
decreased O
clearance O
of O
this O
drug O
is O
greater O
in O
patients O
with O
impaired B-Not_AE_Candidate
renal I-Not_AE_Candidate
function I-Not_AE_Candidate
. O

Because O
elderly O
patients O
are O
more O
likely O
to O
have O
decreased B-Not_AE_Candidate
renal I-Not_AE_Candidate
function I-Not_AE_Candidate
, O
care O
should O
be O
taken O
in O
dose O
selection O
. O

Sedating O
drugs O
may O
cause O
confusion B-NonOSE_AE
and O
over B-NonOSE_AE
- I-NonOSE_AE
sedation I-NonOSE_AE
in O
the O
elderly O
. O

No O
unusual O
adverse O
age-related O
phenomena O
were O
identified O
in O
this O
group O
. O

Pharmacokinetic O
studies O
revealed O
a O
decreased O
clearance O
in O
the O
elderly O
. O

Caution O
is O
indicated O
in O
administering O
REMERON O
to O
elderly O
patients O
( O
see O
CLINICAL O
PHARMACOLOGY O
and O
DOSAGE O
AND O
ADMINISTRATION O
) O
. O

WARNINGS O
Clinical O
Worsening O
and O
Suicide O
Risk O
Patients O
with O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
MDD I-Not_AE_Candidate
) O
, O
both O
adult O
and O
pediatric O
, O
may O
experience O
worsening B-NonOSE_AE
of I-NonOSE_AE
their I-NonOSE_AE
depression I-NonOSE_AE
and/or O
the O
emergence O
of O
suicidal B-NonOSE_AE
ideation O
and O
behavior I-NonOSE_AE
( O
suicidality B-NonOSE_AE
) O
or O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
whether O
or O
not O
they O
are O
taking O
antidepressant O
medications O
, O
and O
this O
risk O
may O
persist O
until O
significant O
remission O
occurs O
. O

Suicide B-NonOSE_AE
is I-NonOSE_AE
a O
known O
risk O
of O
depression B-Not_AE_Candidate
and O
certain O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
, O
and O
these O
disorders O
themselves O
are O
the O
strongest O
predictors O
of O
suicide B-NonOSE_AE
. O

There O
has O
been O
a O
long-standing O
concern O
, O
however O
, O
that O
antidepressants O
may O
have O
a O
role O
in O
inducing O
worsening B-OSE_Labeled_AE
of I-OSE_Labeled_AE
depression I-OSE_Labeled_AE
and O
the O
emergence O
of O
suicidality B-OSE_Labeled_AE
in O
certain O
patients O
during O
the O
early O
phases O
of O
treatment O
. O

Pooled O
analyses O
of O
short-term O
placebo-controlled O
trials O
of O
antidepressant O
drugs O
( O
SSRIs O
and O
others O
) O
showed O
that O
these O
drugs O
increase O
the O
risk O
of O
suicidal B-OSE_Labeled_AE
thinking O
and O
behavior I-OSE_Labeled_AE
( O
suicidality B-OSE_Labeled_AE
) O
in O
children O
, O
adolescents O
, O
and O
young O
adults O
( O
ages O
18-24 O
) O
with O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
MDD I-Not_AE_Candidate
) O
and O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
. O

Short-term O
studies O
did O
not O
show O
an O
increase O
in O
the O
risk O
of O
suicidality B-NonOSE_AE
with O
antidepressants O
compared O
to O
placebo O
in O
adults O
beyond O
age O
24 O
; O
there O
was O
a O
reduction O
in O
risk O
with O
antidepressants O
compared O
to O
placebo O
in O
adults O
aged O
65 O
and O
older O
. O

The O
pooled O
analyses O
of O
placebo-controlled O
trials O
in O
children O
and O
adolescents O
with O
MDD B-Not_AE_Candidate
, O
obsessive B-Not_AE_Candidate
compulsive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
OCD I-Not_AE_Candidate
) O
, O
or O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
included O
a O
total O
of O
24 O
short-term O
trials O
of O
9 O
antidepressant O
drugs O
in O
over O
4400 O
patients O
. O

The O
pooled O
analyses O
of O
placebo-controlled O
trials O
in O
adults O
with O
MDD B-Not_AE_Candidate
or O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
included O
a O
total O
of O
295 O
short-term O
trials O
( O
median O
duration O
of O
2 O
months O
) O
of O
11 O
antidepressant O
drugs O
in O
over O
77,000 O
patients O
. O

There O
was O
considerable O
variation O
in O
risk O
of O
suicidality B-OSE_Labeled_AE
among O
drugs O
, O
but O
a O
tendency O
toward O
an O
increase I-OSE_Labeled_AE
in O
the O
younger O
patients O
for O
almost O
all O
drugs O
studied O
. O

There O
were O
differences O
in O
absolute O
risk O
of O
suicidality B-NonOSE_AE
across O
different O
indications O
, O
with O
the O
highest O
incidence O
in O
MDD B-Not_AE_Candidate
. O

The O
risk O
differences O
( O
drug O
vs O
. O
placebo O
) O
, O
however O
, O
were O
relatively O
stable O
within O
age O
strata O
and O
across O
indications O
. O

These O
risk O
differences O
( O
drug-placebo O
difference O
in O
the O
number O
of O
cases O
of O
suicidality B-NonOSE_AE
per O
1000 O
patients O
treated O
) O
are O
provided O
in O
Table O
1 O
. O

Table O
1 O
Age O
Range O
Drug-Placebo O
Difference O
in O
Number O
of O
Cases O
of O
Suicidality B-OSE_Labeled_AE
per O
1000 O
Patients O
Treated O
Increases O
Compared O
to O
Placebo O
< O
18 O
14 O
additional O
cases O
18-24 O
5 O
additional O
cases O
Decreases O
Compared O
to O
Placebo O
25-64 O
1 O
fewer O
case O
> O
=65 O
6 O
fewer O
cases O
No O
suicides B-NonOSE_AE
occurred O
in O
any O
of O
the O
pediatric O
trials O
. O

There O
were O
suicides B-NonOSE_AE
in O
the O
adult O
trials O
, O
but O
the O
number O
was O
not O
sufficient O
to O
reach O
any O
conclusion O
about O
drug O
effect O
on O
suicide B-NonOSE_AE
. O

It O
is O
unknown O
whether O
the O
suicidality B-NonOSE_AE
risk O
extends O
to O
longer-term O
use O
, O
i.e. O
, O
beyond O
several O
months O
. O

However O
, O
there O
is O
substantial O
evidence O
from O
placebo-controlled O
maintenance O
trials O
in O
adults O
with O
depression B-Not_AE_Candidate
that O
the O
use O
of O
antidepressants O
can O
delay O
the O
recurrence O
of O
depression B-NonOSE_AE
. O

All O
patients O
being O
treated O
with O
antidepressants O
for O
any O
indication O
should O
be O
monitored O
appropriately O
and O
observed O
closely O
for O
clinical O
worsening O
, O
suicidality B-NonOSE_AE
, O
and O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
especially O
during O
the O
initial O
few O
months O
of O
a O
course O
of O
drug O
therapy O
, O
or O
at O
times O
of O
dose O
changes O
, O
either O
increases O
or O
decreases O
. O

The O
following O
symptoms O
, O
anxiety B-OSE_Labeled_AE
, O
agitation B-OSE_Labeled_AE
, O
panic B-OSE_Labeled_AE
attacks I-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
irritability B-OSE_Labeled_AE
, O
hostility B-OSE_Labeled_AE
, O
aggressiveness B-OSE_Labeled_AE
, O
impulsivity B-OSE_Labeled_AE
, O
akathisia B-OSE_Labeled_AE
( O
psychomotor B-OSE_Labeled_AE
restlessness I-OSE_Labeled_AE
) O
, O
hypomania B-OSE_Labeled_AE
, O
and O
mania B-OSE_Labeled_AE
, O
have O
been O
reported O
in O
adult O
and O
pediatric O
patients O
being O
treated O
with O
antidepressants O
for O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
as O
well O
as O
for O
other O
indications O
, O
both O
psychiatric B-Not_AE_Candidate
and O
nonpsychiatric O
. O

Although O
a O
causal O
link O
between O
the O
emergence O
of O
such O
symptoms O
and O
either O
the O
worsening B-NonOSE_AE
of I-NonOSE_AE
depression I-NonOSE_AE
and/or O
the O
emergence O
of O
suicidal B-NonOSE_AE
impulses I-NonOSE_AE
has O
not O
been O
established O
, O
there O
is O
concern O
that O
such O
symptoms O
may O
represent O
precursors O
to O
emerging O
suicidality B-NonOSE_AE
. O

Consideration O
should O
be O
given O
to O
changing O
the O
therapeutic O
regimen O
, O
including O
possibly O
discontinuing O
the O
medication O
, O
in O
patients O
whose O
depression B-Not_AE_Candidate
is O
persistently O
worse O
, O
or O
who O
are O
experiencing O
emergent O
suicidality B-NonOSE_AE
or O
symptoms O
that O
might O
be O
precursors O
to O
worsening B-NonOSE_AE
depression I-NonOSE_AE
or O
suicidality B-NonOSE_AE
, O
especially O
if O
these O
symptoms O
are O
severe O
, O
abrupt O
in O
onset O
, O
or O
were O
not O
part O
of O
the O
patient O
's O
presenting O
symptoms O
. O

Families O
and O
caregivers O
of O
patients O
being O
treated O
with O
antidepressants O
for O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
or O
other O
indications O
, O
both O
psychiatric O
and O
nonpsychiatric O
, O
should O
be O
alerted O
about O
the O
need O
to O
monitor O
patients O
for O
the O
emergence O
of O
agitation B-NonOSE_AE
, O
irritability B-NonOSE_AE
, O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
and O
the O
other O
symptoms O
described O
above O
, O
as O
well O
as O
the O
emergence O
of O
suicidality B-NonOSE_AE
, O
and O
to O
report O
such O
symptoms O
immediately O
to O
health O
care O
providers O
. O

Such O
monitoring O
should O
include O
daily O
observation O
by O
families O
and O
caregivers O
. O

Prescriptions O
for O
REMERON O
( O
mirtazapine O
) O
Tablets O
should O
be O
written O
for O
the O
smallest O
quantity O
of O
tablets O
consistent O
with O
good O
patient O
management O
, O
in O
order O
to O
reduce O
the O
risk O
of O
overdose B-NonOSE_AE
. O

Screening O
Patients O
for O
Bipolar O
Disorder O
A O
major B-NonOSE_AE
depressive I-NonOSE_AE
episode I-NonOSE_AE
may O
be O
the O
initial O
presentation O
of O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

It O
is O
generally O
believed O
( O
though O
not O
established O
in O
controlled O
trials O
) O
that O
treating O
such O
an O
episode O
with O
an O
antidepressant O
alone O
may O
increase O
the O
likelihood O
of O
precipitation B-NonOSE_AE
of I-NonOSE_AE
a I-NonOSE_AE
mixed I-NonOSE_AE
/ I-NonOSE_AE
manic I-NonOSE_AE
episode I-NonOSE_AE
in O
patients O
at O
risk O
for O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

Whether O
any O
of O
the O
symptoms O
described O
above O
represent O
such O
a O
conversion O
is O
unknown O
. O

However O
, O
prior O
to O
initiating O
treatment O
with O
an O
antidepressant O
, O
patients O
with O
depressive B-Not_AE_Candidate
symptoms I-Not_AE_Candidate
should O
be O
adequately O
screened O
to O
determine O
if O
they O
are O
at O
risk O
for O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
; O
such O
screening O
should O
include O
a O
detailed O
psychiatric B-Not_AE_Candidate
history O
, O
including O
a O
family B-Not_AE_Candidate
history I-Not_AE_Candidate
of I-Not_AE_Candidate
suicide I-Not_AE_Candidate
, O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
and O
depression B-Not_AE_Candidate
. O

It O
should O
be O
noted O
that O
REMERON O
( O
mirtazapine O
) O
Tablets O
are O
not O
approved O
for O
use O
in O
treating O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
. O

Agranulocytosis O
In O
premarketing O
clinical O
trials O
, O
2 O
( O
1 O
with O
Sjogren B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
Syndrome I-Not_AE_Candidate
) O
out O
of O
2796 O
patients O
treated O
with O
REMERON O
( O
mirtazapine O
) O
Tablets O
developed O
agranulocytosis B-OSE_Labeled_AE
[ O
absolute B-OSE_Labeled_AE
neutrophil I-OSE_Labeled_AE
count I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ANC I-OSE_Labeled_AE
) I-OSE_Labeled_AE
< I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
mm I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
with O
associated O
signs O
and O
symptoms O
, O
e.g. O
, O
fever B-NonOSE_AE
, O
infection B-NonOSE_AE
, O
etc O
. O
] O

and O
a O
third O
patient O
developed O
severe O
neutropenia B-OSE_Labeled_AE
( O
ANC B-OSE_Labeled_AE
< I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
mm I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
without O
any O
associated O
symptoms O
) O
. O

For O
these O
3 O
patients O
, O
onset O
of O
severe O
neutropenia B-OSE_Labeled_AE
was O
detected O
on O
days O
61 O
, O
9 O
, O
and O
14 O
of O
treatment O
, O
respectively O
. O

All O
3 O
patients O
recovered O
after O
REMERON O
was O
stopped O
. O

These O
3 O
cases O
yield O
a O
crude O
incidence O
of O
severe O
neutropenia B-OSE_Labeled_AE
( O
with O
or O
without O
associated O
infection O
) O
of O
approximately O
1.1 O
per O
thousand O
patients O
exposed O
, O
with O
a O
very O
wide O
95 O
% O
confidence O
interval O
, O
i.e. O
, O
2.2 O
cases O
per O
10,000 O
to O
3.1 O
cases O
per O
1000 O
. O

If O
a O
patient O
develops O
a O
sore B-NonOSE_AE
throat I-NonOSE_AE
, O
fever B-NonOSE_AE
, O
stomatitis B-NonOSE_AE
, O
or O
other O
signs O
of O
infection B-NonOSE_AE
, O
along O
with O
a O
low B-NonOSE_AE
WBC I-NonOSE_AE
count I-NonOSE_AE
, O
treatment O
with O
REMERON O
should O
be O
discontinued O
and O
the O
patient O
should O
be O
closely O
monitored O
. O

Serotonin O
Syndrome O
The O
development O
of O
a O
potentially O
life-threatening O
serotonin B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
has O
been O
reported O
with O
SNRIs O
and O
SSRIs O
, O
including O
REMERON O
, O
alone O
but O
particularly O
with O
concomitant O
use O
of O
other O
serotonergic O
drugs O
( O
including O
triptans O
, O
tricyclic O
antidepressants O
, O
fentanyl O
, O
lithium O
, O
tramadol O
, O
tryptophan O
, O
buspirone O
, O
and O
St O
. O
John O
's O
wort O
) O
, O
and O
with O
drugs O
that O
impair O
metabolism O
of O
serotonin O
( O
in O
particular O
, O
MAOIs O
, O
both O
those O
intended O
to O
treat O
psychiatric O
disorders O
and O
also O
others O
, O
such O
as O
linezolid O
and O
intravenous O
methylene O
blue O
) O
. O

Serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
symptoms O
may O
include O
mental B-NonOSE_AE
status I-NonOSE_AE
changes I-NonOSE_AE
( O
e.g. O
, O
agitation B-NonOSE_AE
, O
hallucinations B-NonOSE_AE
, O
delirium B-NonOSE_AE
, O
and O
coma B-NonOSE_AE
) O
, O
autonomic B-NonOSE_AE
instability I-NonOSE_AE
( O
e.g. O
, O
tachycardia B-NonOSE_AE
, O
labile B-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
, O
dizziness B-NonOSE_AE
, O
diaphoresis B-NonOSE_AE
, O
flushing B-NonOSE_AE
, O
hyperthermia B-NonOSE_AE
) O
, O
neuromuscular B-NonOSE_AE
symptoms I-NonOSE_AE
( O
e.g. O
, O
tremor B-NonOSE_AE
, O
rigidity B-NonOSE_AE
, O
myoclonus B-NonOSE_AE
, O
hyperreflexia B-NonOSE_AE
, O
incoordination B-NonOSE_AE
) O
, O
seizures B-NonOSE_AE
, O
and/or O
gastrointestinal B-NonOSE_AE
symptoms I-NonOSE_AE
( O
e.g. O
, O
nausea B-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
diarrhea B-NonOSE_AE
) O
. O

Patients O
should O
be O
monitored O
for O
the O
emergence O
of O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
. O

The O
concomitant O
use O
of O
REMERON O
with O
MAOIs O
intended O
to O
treat O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
is O
contraindicated O
. O

REMERON O
should O
also O
not O
be O
started O
in O
a O
patient O
who O
is O
being O
treated O
with O
MAOIs O
such O
as O
linezolid O
or O
intravenous O
methylene O
blue O
. O

All O
reports O
with O
methylene O
blue O
that O
provided O
information O
on O
the O
route O
of O
administration O
involved O
intravenous O
administration O
in O
the O
dose O
range O
of O
1 O
mg/kg O
to O
8 O
mg/kg O
. O

No O
reports O
involved O
the O
administration O
of O
methylene O
blue O
by O
other O
routes O
( O
such O
as O
oral O
tablets O
or O
local O
tissue O
injection O
) O
or O
at O
lower O
doses O
. O

There O
may O
be O
circumstances O
when O
it O
is O
necessary O
to O
initiate O
treatment O
with O
an O
MAOI O
such O
as O
linezolid O
or O
intravenous O
methylene O
blue O
in O
a O
patient O
taking O
REMERON O
. O

REMERON O
should O
be O
discontinued O
before O
initiating O
treatment O
with O
the O
MAOI O
( O
see O
CONTRAINDICATIONS O
and O
DOSAGE O
AND O
ADMINISTRATION O
) O
. O

If O
concomitant O
use O
of O
REMERON O
with O
other O
serotonergic O
drugs O
, O
including O
triptans O
, O
tricyclic O
antidepressants O
, O
fentanyl O
, O
lithium O
, O
tramadol O
, O
buspirone O
, O
tryptophan O
, O
and O
St O
. O
John O
's O
wort O
, O
is O
clinically O
warranted O
, O
be O
aware O
of O
a O
potential O
increased O
risk O
for O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
, O
particularly O
during O
treatment O
initiation O
and O
dose O
increases O
. O

Treatment O
with O
REMERON O
and O
any O
concomitant O
serotonergic O
agents O
should O
be O
discontinued O
immediately O
if O
the O
above O
events O
occur O
and O
supportive O
symptomatic O
treatment O
should O
be O
initiated O
. O

Angle-Closure O
Glaucoma O
The O
pupillary B-OSE_Labeled_AE
dilation I-OSE_Labeled_AE
that O
occurs O
following O
use O
of O
many O
antidepressant O
drugs O
including O
REMERON O
may O
trigger O
an O
angle B-OSE_Labeled_AE
- I-OSE_Labeled_AE
closure I-OSE_Labeled_AE
attack I-OSE_Labeled_AE
in O
a O
patient O
with O
anatomically B-Not_AE_Candidate
narrow I-Not_AE_Candidate
angles I-Not_AE_Candidate
who O
does O
not O
have O
a O
patent O
iridectomy O
. O

QT O
Prolongation O
and O
Torsades O
de O
Pointes O
The O
effect B-NonOSE_AE
of O
REMER O
ON I-NonOSE_AE
( O
mirtazapine O
) O
on O
QTc I-NonOSE_AE
interval I-NonOSE_AE
was O
assessed O
in O
a O
clinical O
randomized O
trial O
with O
placebo O
and O
positive O
( O
moxifloxacin O
) O
controls O
involving O
54 O
healthy O
volunteers O
using O
exposure O
response O
analysis O
. O

This O
trial O
showed O
a O
positive O
relationship O
between O
mirtazapine O
concentrations O
and O
prolongation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
QTc I-OSE_Labeled_AE
interval I-OSE_Labeled_AE
. O

However O
, O
the O
degree O
of O
QT B-NonOSE_AE
prolongation I-NonOSE_AE
observed O
with O
both O
45 O
mg O
( O
therapeutic O
) O
and O
75 O
mg O
( O
supratherapeutic O
) O
doses O
of O
mirtazapine O
was O
not O
at O
a O
level O
generally O
considered O
to O
be O
clinically O
meaningful O
. O

During O
the O
postmarketing O
use O
of O
mirtazapine O
, O
cases O
of O
QT B-OSE_Labeled_AE
prolongation I-OSE_Labeled_AE
, O
Torsades B-OSE_Labeled_AE
de I-OSE_Labeled_AE
Pointes I-OSE_Labeled_AE
, O
ventricular B-OSE_Labeled_AE
tachycardia I-OSE_Labeled_AE
, O
and O
sudden B-OSE_Labeled_AE
death I-OSE_Labeled_AE
, O
have O
been O
reported O
( O
see O
ADVERSE O
REACTIONS O
) O
. O

The O
majority O
of O
reports O
occurred O
in O
association O
with O
overdose B-NonOSE_AE
or O
in O
patients O
with O
other O
risk O
factors O
for O
QT B-NonOSE_AE
prolongation I-NonOSE_AE
, O
including O
concomitant O
use O
of O
QTc B-NonOSE_AE
- I-NonOSE_AE
prolonging I-NonOSE_AE
medicines O
( O
see O
PRECAUTIONS O
, O
Drug O
Interactions O
and O
OVERDOSE O
sections O
) O
. O

Caution O
should O
be O
exercised O
when O
REMERON O
is O
prescribed O
in O
patients O
with O
known O
cardiovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
or O
family O
history O
of O
QT B-Not_AE_Candidate
prolongation I-Not_AE_Candidate
, O
and O
in O
concomitant O
use O
with O
other O
medicinal O
products O
thought O
to O
prolong B-NonOSE_AE
the I-NonOSE_AE
QTc I-NonOSE_AE
interval I-NonOSE_AE
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
serious O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
the O
labeling O
: O
* O
Infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Mucocutaneous B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Hepatitis B-OSE_Labeled_AE
B I-OSE_Labeled_AE
reactivation I-OSE_Labeled_AE
with O
fulminant B-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Progressive B-OSE_Labeled_AE
multifocal I-OSE_Labeled_AE
leukoencephalopathy I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Tumor B-OSE_Labeled_AE
lysis I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Infections B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Cardiac B-OSE_Labeled_AE
arrhythmias I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Renal B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
* O
Bowel B-OSE_Labeled_AE
obstruction O
and O
perforation I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
The O
most O
common O
adverse O
reactions O
of O
Rituxan O
( O
incidence O
> O
= O
25 O
% O
) O
observed O
in O
clinical O
trials O
of O
patients O
with O
NHL B-Not_AE_Candidate
were O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
fever B-OSE_Labeled_AE
, O
lymphopenia B-OSE_Labeled_AE
, O
chills B-OSE_Labeled_AE
, O
infection B-OSE_Labeled_AE
, O
and O
asthenia B-OSE_Labeled_AE
. O

The O
most O
common O
adverse O
reactions O
of O
Rituxan O
( O
incidence O
> O
= O
25 O
% O
) O
observed O
in O
clinical O
trials O
of O
patients O
with O
CLL B-Not_AE_Candidate
were O
: O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
and O
neutropenia B-OSE_Labeled_AE
. O

EXCERPT O
: O
Most O
common O
adverse O
reactions O
in O
clinical O
trials O
were O
: O
* O
NHL O
( O
> O
= O
25 O
% O
) O
: O
infusion O
reactions O
, O
fever O
, O
lymphopenia O
, O
chills O
, O
infection O
and O
asthenia O
( O
6.1 O
) O
. O

* O
CLL O
( O
> O
= O
25 O
% O
) O
: O
infusion O
reactions O
and O
neutropenia O
( O
6.1 O
) O
. O

* O
RA O
( O
> O
= O
10 O
% O
) O
: O
upper O
respiratory O
tract O
infection O
, O
nasopharyngitis O
, O
urinary O
tract O
infection O
, O
and O
bronchitis O
( O
other O
important O
adverse O
reactions O
include O
infusion O
reactions O
, O
serious O
infections O
, O
and O
cardiovascular O
events O
) O
( O
6.2 O
) O
. O

* O
GPA O
and O
MPA O
( O
> O
=15 O
% O
) O
: O
infections O
, O
nausea O
, O
diarrhea O
, O
headache O
, O
muscle O
spasms O
, O
anemia O
, O
peripheral O
edema O
( O
other O
important O
adverse O
reactions O
include O
infusion O
reactions O
) O
( O
6.3 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Genentech O
at O
1-888-835-2555 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
in O
Lymphoid O
Malignancies O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

The O
data O
described O
below O
reflect O
exposure O
to O
Rituxan O
in O
2783 O
patients O
, O
with O
exposures O
ranging O
from O
a O
single O
infusion O
up O
to O
2 O
years O
. O

Rituxan O
was O
studied O
in O
both O
single-arm O
and O
controlled O
trials O
( O
n=356 O
and O
n=2427 O
) O
. O

The O
population O
included O
1180 O
patients O
with O
low O
grade O
or O
follicular B-Not_AE_Candidate
lymphoma I-Not_AE_Candidate
, O
927 O
patients O
with O
DLBCL B-Not_AE_Candidate
, O
and O
676 O
patients O
with O
CLL B-Not_AE_Candidate
. O

Most O
NHL B-Not_AE_Candidate
patients O
received O
Rituxan O
as O
an O
infusion O
of O
375 O
mg/m O
2 O
per O
infusion O
, O
given O
as O
a O
single O
agent O
weekly O
for O
up O
to O
8 O
doses O
, O
in O
combination O
with O
chemotherapy O
for O
up O
to O
8 O
doses O
, O
or O
following O
chemotherapy O
for O
up O
to O
16 O
doses O
. O

CLL B-Not_AE_Candidate
patients O
received O
Rituxan O
375 O
mg/m O
2 O
as O
an O
initial O
infusion O
followed O
by O
500 O
mg/m O
2 O
for O
up O
to O
5 O
doses O
, O
in O
combination O
with O
fludarabine O
and O
cyclophosphamide O
. O

Seventy-one O
percent O
of O
CLL B-Not_AE_Candidate
patients O
received O
6 O
cycles O
and O
90 O
% O
received O
at O
least O
3 O
cycles O
of O
Rituxan-based O
therapy O
. O

Infusion O
Reactions O
In O
the O
majority O
of O
patients O
with O
NHL B-Not_AE_Candidate
, O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
consisting O
of O
fever B-NonOSE_AE
, O
chills B-NonOSE_AE
/ O
rigors B-NonOSE_AE
, O
nausea B-NonOSE_AE
, O
pruritus B-NonOSE_AE
, O
angioedema B-NonOSE_AE
, O
hypotension B-NonOSE_AE
, O
headache B-NonOSE_AE
, O
bronchospasm B-NonOSE_AE
, O
urticaria B-NonOSE_AE
, O
rash B-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
myalgia B-NonOSE_AE
, O
dizziness B-NonOSE_AE
, O
or O
hypertension B-NonOSE_AE
occurred O
during O
the O
first O
Rituxan O
infusion O
. O

Infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
typically O
occurred O
within O
30 O
to O
120 O
minutes O
of O
beginning O
the O
first O
infusion O
and O
resolved O
with O
slowing O
or O
interruption O
of O
the O
Rituxan O
infusion O
and O
with O
supportive O
care O
( O
diphenhydramine O
, O
acetaminophen O
, O
and O
intravenous O
saline O
) O
. O

The O
incidence O
of O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
was O
highest O
during O
the O
first O
infusion O
( O
77 O
% O
) O
and O
decreased O
with O
each O
subsequent O
infusion O
. O

[ O
See O
Boxed O
Warning O
, O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

In O
patients O
with O
previously O
untreated O
follicular O
NHL B-Not_AE_Candidate
or O
previously O
untreated O
DLBCL B-Not_AE_Candidate
, O
who O
did O
not O
experience O
a O
Grade O
3 O
or O
4 O
infusion B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
reaction I-NonOSE_AE
in O
Cycle O
1 O
and O
received O
a O
90-minute O
infusion O
of O
Rituxan O
at O
Cycle O
2 O
, O
the O
incidence O
of O
Grade O
3-4 O
infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
on O
the O
day O
of O
, O
or O
day O
after O
the O
infusion O
was O
1.1 O
% O
( O
95 O
% O
CI O
[ O
0.3 O
% O
, O
2.8 O
% O
] O
) O
. O

For O
Cycles O
2-8 O
, O
the O
incidence O
of O
Grade O
3-4 O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
on O
the O
day O
of O
or O
day O
after O
the O
90-minute O
infusion O
, O
was O
2.8 O
% O
( O
95 O
% O
CI O
[ O
1.3 O
% O
, O
5.0 O
% O
] O
) O
. O

[ O
See O
Warnings O
and O
Precautions O
( O
5.1 O
) O
, O
Clinical O
Studies O
( O
14.4 O
) O
] O
. O

Infections O
Serious O
infections B-OSE_Labeled_AE
( O
NCI O
CTCAE O
Grade O
3 O
or O
4 O
) O
, O
including O
sepsis B-OSE_Labeled_AE
, O
occurred O
in O
less O
than O
5 O
% O
of O
patients O
with O
NHL B-Not_AE_Candidate
in O
the O
single-arm O
studies O
. O

The O
overall O
incidence O
of O
infections B-OSE_Labeled_AE
was O
31 O
% O
( O
bacterial I-OSE_Labeled_AE
19 O
% O
, O
viral O
10 O
% O
, O
unknown O
6 O
% O
, O
and O
fungal O
1 O
% O
) O
. O

[ O
See O
Warnings O
and O
Precautions O
( O
5.4 O
) O
, O
( O
5.5 O
) O
, O
( O
5.6 O
) O
] O
. O

In O
randomized O
, O
controlled O
studies O
where O
Rituxan O
was O
administered O
following O
chemotherapy O
for O
the O
treatment O
of O
follicular O
or O
low-grade O
NHL B-Not_AE_Candidate
, O
the O
rate O
of O
infection B-OSE_Labeled_AE
was O
higher O
among O
patients O
who O
received O
Rituxan O
. O

In O
diffuse B-Not_AE_Candidate
large I-Not_AE_Candidate
B I-Not_AE_Candidate
- I-Not_AE_Candidate
cell I-Not_AE_Candidate
lymphoma I-Not_AE_Candidate
patients O
, O
viral B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
occurred O
more O
frequently O
in O
those O
who O
received O
Rituxan O
. O

Cytopenias O
and O
hypogammaglobulinemia O
In O
patients O
with O
NHL B-Not_AE_Candidate
receiving O
rituximab O
monotherapy O
, O
NCI-CTC O
Grade O
3 O
and O
4 O
cytopenias B-OSE_Labeled_AE
were O
reported O
in O
48 O
% O
of O
patients O
. O

These O
included O
lymphopenia B-OSE_Labeled_AE
( O
40 O
% O
) O
, O
neutropenia B-OSE_Labeled_AE
( O
6 O
% O
) O
, O
leukopenia B-OSE_Labeled_AE
( O
4 O
% O
) O
, O
anemia B-OSE_Labeled_AE
( O
3 O
% O
) O
, O
and O
thrombocytopenia B-OSE_Labeled_AE
( O
2 O
% O
) O
. O

The O
median O
duration O
of O
lymphopenia B-OSE_Labeled_AE
was O
14 O
days O
( O
range O
, O
1-588 O
days O
) O
and O
of O
neutropenia B-OSE_Labeled_AE
was O
13 O
days O
( O
range O
, O
2-116 O
days O
) O
. O

A O
single O
occurrence O
of O
transient O
aplastic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
( O
pure B-OSE_Labeled_AE
red I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
aplasia I-OSE_Labeled_AE
) O
and O
two O
occurrences O
of O
hemolytic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
following O
Rituxan O
therapy O
occurred O
during O
the O
single-arm O
studies O
. O

In O
studies O
of O
monotherapy O
, O
Rituxan-induced O
B B-NonOSE_AE
- I-NonOSE_AE
cell I-NonOSE_AE
depletion I-NonOSE_AE
occurred O
in O
70 O
% O
to O
80 O
% O
of O
patients O
with O
NHL B-Not_AE_Candidate
. O

Decreased B-OSE_Labeled_AE
IgM O
and O
IgG I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
occurred O
in O
14 O
% O
of O
these O
patients O
. O

In O
CLL B-Not_AE_Candidate
trials O
, O
the O
frequency O
of O
prolonged O
neutropenia B-OSE_Labeled_AE
and O
late-onset O
neutropenia B-OSE_Labeled_AE
was O
higher O
in O
patients O
treated O
with O
R-FC O
compared O
to O
patients O
treated O
with O
FC O
. O

Prolonged O
neutropenia B-NonOSE_AE
is O
defined O
as O
Grade O
3-4 O
neutropenia B-NonOSE_AE
that O
has O
not O
resolved O
between O
24 O
and O
42 O
days O
after O
the O
last O
dose O
of O
study O
treatment O
. O

Late-onset O
neutropenia B-NonOSE_AE
is O
defined O
as O
Grade O
3-4 O
neutropenia B-NonOSE_AE
starting O
at O
least O
42 O
days O
after O
the O
last O
treatment O
dose O
. O

In O
patients O
with O
previously O
untreated O
CLL B-Not_AE_Candidate
, O
the O
frequency O
of O
prolonged O
neutropenia B-OSE_Labeled_AE
was O
8.5 O
% O
for O
patients O
who O
received O
R-FC O
( O
n=402 O
) O
and O
5.8 O
% O
for O
patients O
who O
received O
FC O
( O
n=398 O
) O
. O

In O
patients O
who O
did O
not O
have O
prolonged O
neutropenia B-NonOSE_AE
, O
the O
frequency O
of O
late-onset O
neutropenia B-OSE_Labeled_AE
was O
14.8 O
% O
of O
209 O
patients O
who O
received O
R-FC O
and O
4.3 O
% O
of O
230 O
patients O
who O
received O
FC O
. O

For O
patients O
with O
previously O
treated O
CLL B-Not_AE_Candidate
, O
the O
frequency O
of O
prolonged O
neutropenia B-OSE_Labeled_AE
was O
24.8 O
% O
for O
patients O
who O
received O
R-FC O
( O
n=274 O
) O
and O
19.1 O
% O
for O
patients O
who O
received O
FC O
( O
n=274 O
) O
. O

In O
patients O
who O
did O
not O
have O
prolonged O
neutropenia B-NonOSE_AE
, O
the O
frequency O
of O
late-onset O
neutropenia B-OSE_Labeled_AE
was O
38.7 O
% O
in O
160 O
patients O
who O
received O
R-FC O
and O
13.6 O
% O
of O
147 O
patients O
who O
received O
FC O
. O

Relapsed O
or O
Refractory O
, O
Low-Grade O
NHL O
Adverse O
reactions O
in O
Table O
1 O
occurred O
in O
356 O
patients O
with O
relapsed O
or O
refractory O
, O
low-grade O
or O
follicular O
, O
CD20-positive O
, O
B-cell O
NHL B-Not_AE_Candidate
treated O
in O
single-arm O
studies O
of O
Rituxan O
administered O
as O
a O
single O
agent O
[ O
See O
Clinical O
Studies O
( O
14.1 O
) O
] O
. O

Most O
patients O
received O
Rituxan O
375 O
mg/m O
2 O
weekly O
for O
4 O
doses O
. O

Table O
1 O
Incidence O
of O
Adverse O
Reactions O
in O
> O
= O
5 O
% O
of O
Patients O
with O
Relapsed O
or O
Refractory O
, O
Low-Grade O
or O
Follicular O
NHL O
, O
Receiving O
Single-agent O
Rituxan O
( O
N=356 O
) O
Adverse O
reactions O
observed O
up O
to O
12 O
months O
following O
Rituxan. O
, O
Adverse O
reactions O
graded O
for O
severity O
by O
NCI-CTC O
criteria O
. O

All O
Grades O
( O
% O
) O
Grade O
3 O
and O
4 O
( O
% O
) O
Any O
Adverse O
Reactions O
99 O
57 O
Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
86 O
10 O
Fever B-OSE_Labeled_AE
53 O
1 O
Chills B-OSE_Labeled_AE
33 O
3 O
Infection B-OSE_Labeled_AE
31 O
4 O
Asthenia B-OSE_Labeled_AE
26 O
1 O
Headache B-OSE_Labeled_AE
19 O
1 O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
14 O
1 O
Pain B-OSE_Labeled_AE
12 O
1 O
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
10 O
1 O
Throat B-OSE_Labeled_AE
Irritation I-OSE_Labeled_AE
9 O
0 O
Flushing B-OSE_Labeled_AE
5 O
0 O
Heme B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
System I-NonOSE_AE
67 O
48 O
Lymphopenia B-OSE_Labeled_AE
48 O
40 O
Leukopenia B-OSE_Labeled_AE
14 O
4 O
Neutropenia B-OSE_Labeled_AE
14 O
6 O
Thrombocytopenia B-OSE_Labeled_AE
12 O
2 O
Anemia B-OSE_Labeled_AE
8 O
3 O
Skin B-NonOSE_AE
and I-NonOSE_AE
Appendages I-NonOSE_AE
44 O
2 O
Night B-OSE_Labeled_AE
Sweats I-OSE_Labeled_AE
15 O
1 O
Rash B-OSE_Labeled_AE
15 O
1 O
Pruritus B-OSE_Labeled_AE
14 O
1 O
Urticaria B-OSE_Labeled_AE
8 O
1 O
Respiratory B-NonOSE_AE
System I-NonOSE_AE
38 O
4 O
Increased B-OSE_Labeled_AE
Cough I-OSE_Labeled_AE
13 O
1 O
Rhinitis B-OSE_Labeled_AE
12 O
1 O
Bronchospasm B-OSE_Labeled_AE
8 O
1 O
Dyspnea B-OSE_Labeled_AE
7 O
1 O
Sinusitis B-OSE_Labeled_AE
6 O
0 O
Metabolic B-NonOSE_AE
and I-NonOSE_AE
Nutritional I-NonOSE_AE
Disorders I-NonOSE_AE
38 O
3 O
Angioedema B-OSE_Labeled_AE
11 O
1 O
Hyperglycemia B-OSE_Labeled_AE
9 O
1 O
Peripheral B-OSE_Labeled_AE
Edema I-OSE_Labeled_AE
8 O
0 O
LDH B-OSE_Labeled_AE
Increase I-OSE_Labeled_AE
7 O
0 O
Digestive B-NonOSE_AE
System I-NonOSE_AE
37 O
2 O
Nausea B-OSE_Labeled_AE
23 O
1 O
Diarrhea B-OSE_Labeled_AE
10 O
1 O
Vomiting B-OSE_Labeled_AE
10 O
1 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
32 O
1 O
Dizziness B-OSE_Labeled_AE
10 O
1 O
Anxiety B-OSE_Labeled_AE
5 O
1 O
Musculoskeletal B-NonOSE_AE
System I-NonOSE_AE
26 O
3 O
Myalgia B-OSE_Labeled_AE
10 O
1 O
Arthralgia B-OSE_Labeled_AE
10 O
1 O
Cardiovascular B-NonOSE_AE
System I-NonOSE_AE
25 O
3 O
Hypotension B-OSE_Labeled_AE
10 O
1 O
Hypertension B-OSE_Labeled_AE
6 O
1 O
In O
these O
single-arm O
Rituxan O
studies O
, O
bronchiolitis B-OSE_Labeled_AE
obliterans I-OSE_Labeled_AE
occurred O
during O
and O
up O
to O
6 O
months O
after O
Rituxan O
infusion O
. O

Previously O
Untreated O
, O
Low-Grade O
or O
Follicular O
, O
NHL O
In O
Study O
4 O
, O
patients O
in O
the O
R-CVP O
arm O
experienced O
a O
higher O
incidence O
of O
infusional B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
and O
neutropenia B-OSE_Labeled_AE
compared O
to O
patients O
in O
the O
CVP O
arm O
. O

The O
following O
adverse O
reactions O
occurred O
more O
frequently O
( O
> O
= O
5 O
% O
) O
in O
patients O
receiving O
R-CVP O
compared O
to O
CVP O
alone O
: O
rash B-OSE_Labeled_AE
( O
17 O
% O
vs O
. O
5 O
% O
) O
, O
cough B-OSE_Labeled_AE
( O
15 O
% O
vs O
. O
6 O
% O
) O
, O
flushing B-OSE_Labeled_AE
( O
14 O
% O
vs O
. O
3 O
% O
) O
, O
rigors B-OSE_Labeled_AE
( O
10 O
% O
vs O
. O
2 O
% O
) O
, O
pruritus B-OSE_Labeled_AE
( O
10 O
% O
vs O
. O
1 O
% O
) O
, O
neutropenia B-OSE_Labeled_AE
( O
8 O
% O
vs O
. O
3 O
% O
) O
, O
and O
chest B-OSE_Labeled_AE
tightness I-OSE_Labeled_AE
( O
7 O
% O
vs O
. O
1 O
% O
) O
. O

[ O
See O
Clinical O
Studies O
( O
14.2 O
) O
] O
. O

In O
Study O
5 O
, O
detailed O
safety O
data O
collection O
was O
limited O
to O
serious O
adverse O
reactions O
, O
Grade O
> O
= O
2 O
infections B-NonOSE_AE
, O
and O
Grade O
> O
= O
3 O
adverse O
reactions O
. O

In O
patients O
receiving O
Rituxan O
as O
single-agent O
maintenance O
therapy O
following O
Rituxan O
plus O
chemotherapy O
, O
infections B-OSE_Labeled_AE
were O
reported O
more O
frequently O
compared O
to O
the O
observation O
arm O
( O
37 O
% O
vs O
. O
22 O
% O
) O
. O

Grade O
3-4 O
adverse O
reactions O
occurring O
at O
a O
higher O
incidence O
( O
> O
= O
2 O
% O
) O
in O
the O
Rituxan O
group O
were O
infections B-OSE_Labeled_AE
( O
4 O
% O
vs O
. O
1 O
% O
) O
and O
neutropenia B-OSE_Labeled_AE
( O
4 O
% O
vs O
. O
< O
1 O
% O
) O
. O

In O
Study O
6 O
, O
the O
following O
adverse O
reactions O
were O
reported O
more O
frequently O
( O
> O
= O
5 O
% O
) O
in O
patients O
receiving O
Rituxan O
following O
CVP O
compared O
to O
patients O
who O
received O
no O
further O
therapy O
: O
fatigue B-OSE_Labeled_AE
( O
39 O
% O
vs O
. O
14 O
% O
) O
, O
anemia B-OSE_Labeled_AE
( O
35 O
% O
vs O
. O
20 O
% O
) O
, O
peripheral B-OSE_Labeled_AE
sensory I-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
( O
30 O
% O
vs O
. O
18 O
% O
) O
, O
infections B-OSE_Labeled_AE
( O
19 O
% O
vs O
. O
9 O
% O
) O
, O
pulmonary B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
( O
18 O
% O
vs O
. O
10 O
% O
) O
, O
hepato B-OSE_Labeled_AE
- I-OSE_Labeled_AE
biliary I-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
( O
17 O
% O
vs O
. O
7 O
% O
) O
, O
rash B-OSE_Labeled_AE
and/or O
pruritus B-OSE_Labeled_AE
( O
17 O
% O
vs O
. O
5 O
% O
) O
, O
arthralgia B-OSE_Labeled_AE
( O
12 O
% O
vs O
. O
3 O
% O
) O
, O
and O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
( O
11 O
% O
vs O
. O
4 O
% O
) O
. O

Neutropenia B-OSE_Labeled_AE
was O
the O
only O
Grade O
3 O
or O
4 O
adverse O
reaction O
that O
occurred O
more O
frequently O
( O
> O
= O
2 O
% O
) O
in O
the O
Rituxan O
arm O
compared O
with O
those O
who O
received O
no O
further O
therapy O
( O
4 O
% O
vs O
. O
1 O
% O
) O
. O

[ O
See O
Clinical O
Studies O
( O
14.3 O
) O
] O
. O

DLBCL O
In O
Studies O
7 O
and O
8 O
, O
[ O
see O
Clinical O
Studies O
( O
14.3 O
) O
] O
, O
the O
following O
adverse O
reactions O
, O
regardless O
of O
severity O
, O
were O
reported O
more O
frequently O
( O
> O
= O
5 O
% O
) O
in O
patients O
age O
> O
= O
60 O
years O
receiving O
R-CHOP O
as O
compared O
to O
CHOP O
alone O
: O
pyrexia B-OSE_Labeled_AE
( O
56 O
% O
vs O
. O
46 O
% O
) O
, O
lung B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
( O
31 O
% O
vs O
. O
24 O
% O
) O
, O
cardiac B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
( O
29 O
% O
vs O
. O
21 O
% O
) O
, O
and O
chills B-OSE_Labeled_AE
( O
13 O
% O
vs O
. O
4 O
% O
) O
. O

Detailed O
safety O
data O
collection O
in O
these O
studies O
was O
primarily O
limited O
to O
Grade O
3 O
and O
4 O
adverse O
reactions O
and O
serious O
adverse O
reactions O
. O

In O
Study O
8 O
, O
a O
review O
of O
cardiac B-NonOSE_AE
toxicity I-NonOSE_AE
determined O
that O
supraventricular B-OSE_Labeled_AE
arrhythmias I-OSE_Labeled_AE
or O
tachycardia B-OSE_Labeled_AE
accounted O
for O
most O
of O
the O
difference O
in O
cardiac B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
( O
4.5 O
% O
for O
R-CHOP O
vs O
. O
1.0 O
% O
for O
CHOP O
) O
. O

The O
following O
Grade O
3 O
or O
4 O
adverse O
reactions O
occurred O
more O
frequently O
among O
patients O
in O
the O
R-CHOP O
arm O
compared O
with O
those O
in O
the O
CHOP O
arm O
: O
thrombocytopenia B-OSE_Labeled_AE
( O
9 O
% O
vs O
. O
7 O
% O
) O
and O
lung B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
( O
6 O
% O
vs O
. O
3 O
% O
) O
. O

Other O
Grade O
3 O
or O
4 O
adverse O
reactions O
occurring O
more O
frequently O
among O
patients O
receiving O
R-CHOP O
were O
viral B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
Study O
8 O
) O
, O
neutropenia B-OSE_Labeled_AE
( O
Studies O
8 O
and O
9 O
) O
, O
and O
anemia B-OSE_Labeled_AE
( O
Study O
9 O
) O
. O

CLL O
The O
data O
below O
reflect O
exposure O
to O
Rituxan O
in O
combination O
with O
fludarabine O
and O
cyclophosphamide O
in O
676 O
patients O
with O
CLL B-Not_AE_Candidate
in O
Study O
11 O
or O
Study O
12 O
[ O
See O
Clinical O
Studies O
( O
14.5 O
) O
] O
. O

The O
age O
range O
was O
30-83 O
years O
and O
71 O
% O
were O
men O
. O

Detailed O
safety O
data O
collection O
in O
Study O
11 O
was O
limited O
to O
Grade O
3 O
and O
4 O
adverse O
reactions O
and O
serious O
adverse O
reactions O
. O

Infusion B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
were O
defined O
by O
any O
of O
the O
following O
adverse O
events O
occurring O
during O
or O
within O
24 O
hours O
of O
the O
start O
of O
infusion O
: O
nausea B-NonOSE_AE
, O
pyrexia B-NonOSE_AE
, O
chills B-NonOSE_AE
, O
hypotension B-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
and O
dyspnea B-NonOSE_AE
. O

In O
Study O
11 O
, O
the O
following O
Grade O
3 O
and O
4 O
adverse O
reactions O
occurred O
more O
frequently O
in O
R-FC-treated O
patients O
compared O
to O
FC-treated O
patients O
: O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
9 O
% O
in O
R-FC O
arm O
) O
, O
neutropenia B-OSE_Labeled_AE
( O
30 O
% O
vs O
. O
19 O
% O
) O
, O
febrile B-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
( O
9 O
% O
vs O
. O
6 O
% O
) O
, O
leukopenia B-OSE_Labeled_AE
( O
23 O
% O
vs O
. O
12 O
% O
) O
, O
and O
pancytopenia B-OSE_Labeled_AE
( O
3 O
% O
vs O
. O
1 O
% O
) O
. O

In O
Study O
12 O
, O
the O
following O
Grade O
3 O
or O
4 O
adverse O
reactions O
occurred O
more O
frequently O
in O
R-FC-treated O
patients O
compared O
to O
FC-treated O
patients O
: O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
7 O
% O
in O
R-FC O
arm O
) O
, O
neutropenia B-OSE_Labeled_AE
( O
49 O
% O
vs O
. O
44 O
% O
) O
, O
febrile B-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
( O
15 O
% O
vs O
. O
12 O
% O
) O
, O
thrombocytopenia B-OSE_Labeled_AE
( O
11 O
% O
vs O
. O
9 O
% O
) O
, O
hypotension B-OSE_Labeled_AE
( O
2 O
% O
vs O
. O
0 O
% O
) O
, O
and O
hepatitis B-OSE_Labeled_AE
B I-OSE_Labeled_AE
( O
2 O
% O
vs O
. O
< O
1 O
% O
) O
. O

Fifty-nine O
percent O
of O
R-FC-treated O
patients O
experienced O
an O
infusion B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
of O
any O
severity O
. O

6.2 O
Clinical O
Trials O
Experience O
in O
Rheumatoid O
Arthritis O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

The O
data O
presented O
below O
reflect O
the O
experience O
in O
2578 O
RA B-Not_AE_Candidate
patients O
treated O
with O
Rituxan O
in O
controlled O
and O
long-term O
studies O
with O
a O
total O
exposure O
of O
5014 O
patient-years O
. O

Among O
all O
exposed O
patients O
, O
adverse O
reactions O
reported O
in O
greater O
than O
10 O
% O
of O
patients O
include O
infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
nasopharyngitis B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
and O
bronchitis B-OSE_Labeled_AE
. O

In O
placebo-controlled O
studies O
, O
patients O
received O
2 O
* O
500 O
mg O
or O
2 O
* O
1000 O
mg O
intravenous O
infusions O
of O
Rituxan O
or O
placebo O
, O
in O
combination O
with O
methotrexate O
, O
during O
a O
24-week O
period O
. O

From O
these O
studies O
, O
938 O
patients O
treated O
with O
Rituxan O
( O
2 O
* O
1000 O
mg O
) O
or O
placebo O
have O
been O
pooled O
( O
see O
Table O
2 O
) O
. O

Adverse O
reactions O
reported O
in O
> O
= O
5 O
% O
of O
patients O
were O
hypertension B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
arthralgia B-OSE_Labeled_AE
, O
pyrexia B-OSE_Labeled_AE
and O
pruritus B-OSE_Labeled_AE
( O
see O
Table O
2 O
) O
. O

The O
rates O
and O
types O
of O
adverse O
reactions O
in O
patients O
who O
received O
Rituxan O
2 O
* O
500 O
mg O
were O
similar O
to O
those O
observed O
in O
patients O
who O
received O
Rituxan O
2 O
* O
1000 O
mg O
. O
Table O
2These O
data O
are O
based O
on O
938 O
patients O
treated O
in O
Phase O
2 O
and O
3 O
studies O
of O
Rituxan O
( O
2 O
* O
1000 O
mg O
) O
or O
placebo O
administered O
in O
combination O
with O
methotrexate O
. O

Incidence O
of O
All O
Adverse O
ReactionsCoded O
using O
MedDRA O
. O

Occurring O
in O
> O
= O
2 O
% O
and O
at O
Least O
1 O
% O
Greater O
than O
Placebo O
Among O
Rheumatoid O
Arthritis O
Patients O
in O
Clinical O
Studies O
Up O
to O
Week O
24 O
( O
Pooled O
) O
Preferred O
Term O
Placebo O
+ O
MTXN=398n O
( O
% O
) O
Rituxan O
+ O
MTXN=540n O
( O
% O
) O
Hypertension B-OSE_Labeled_AE
21 O
( O
5 O
) O
43 O
( O
8 O
) O
Nausea B-OSE_Labeled_AE
19 O
( O
5 O
) O
41 O
( O
8 O
) O
Upper B-OSE_Labeled_AE
Respiratory I-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
23 O
( O
6 O
) O
37 O
( O
7 O
) O
Arthralgia B-OSE_Labeled_AE
14 O
( O
4 O
) O
31 O
( O
6 O
) O
Pyrexia B-OSE_Labeled_AE
8 O
( O
2 O
) O
27 O
( O
5 O
) O
Pruritus B-OSE_Labeled_AE
5 O
( O
1 O
) O
26 O
( O
5 O
) O
Chills B-OSE_Labeled_AE
9 O
( O
2 O
) O
16 O
( O
3 O
) O
Dyspepsia B-OSE_Labeled_AE
3 O
( O
< O
1 O
) O
16 O
( O
3 O
) O
Rhinitis B-OSE_Labeled_AE
6 O
( O
2 O
) O
14 O
( O
3 O
) O
Paresthesia B-OSE_Labeled_AE
3 O
( O
< O
1 O
) O
12 O
( O
2 O
) O
Urticaria B-OSE_Labeled_AE
3 O
( O
< O
1 O
) O
12 O
( O
2 O
) O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
Upper I-OSE_Labeled_AE
4 O
( O
1 O
) O
11 O
( O
2 O
) O
Throat B-OSE_Labeled_AE
Irritation I-OSE_Labeled_AE
0 O
( O
0 O
) O
11 O
( O
2 O
) O
Anxiety B-OSE_Labeled_AE
5 O
( O
1 O
) O
9 O
( O
2 O
) O
Migraine B-OSE_Labeled_AE
2 O
( O
< O
1 O
) O
9 O
( O
2 O
) O
Asthenia B-OSE_Labeled_AE
1 O
( O
< O
1 O
) O
9 O
( O
2 O
) O
Infusion O
Reactions O
In O
the O
Rituxan O
RA B-Not_AE_Candidate
pooled O
placebo-controlled O
studies O
, O
32 O
% O
of O
Rituxan-treated O
patients O
experienced O
an O
adverse O
reaction O
during O
or O
within O
24 O
hours O
following O
their O
first O
infusion O
, O
compared O
to O
23 O
% O
of O
placebo-treated O
patients O
receiving O
their O
first O
infusion O
. O

The O
incidence O
of O
adverse O
reactions O
during O
the O
24-hour O
period O
following O
the O
second O
infusion O
, O
Rituxan O
or O
placebo O
, O
decreased O
to O
11 O
% O
and O
13 O
% O
, O
respectively O
. O

Acute O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
manifested O
by O
fever B-NonOSE_AE
, O
chills B-NonOSE_AE
, O
rigors B-NonOSE_AE
, O
pruritus B-NonOSE_AE
, O
urticaria B-NonOSE_AE
/ O
rash B-NonOSE_AE
, O
angioedema B-NonOSE_AE
, O
sneezing B-NonOSE_AE
, O
throat B-NonOSE_AE
irritation I-NonOSE_AE
, O
cough B-NonOSE_AE
, O
and/or O
bronchospasm B-NonOSE_AE
, O
with O
or O
without O
associated O
hypotension B-NonOSE_AE
or O
hypertension B-NonOSE_AE
) O
were O
experienced O
by O
27 O
% O
of O
Rituxan-treated O
patients O
following O
their O
first O
infusion O
, O
compared O
to O
19 O
% O
of O
placebo-treated O
patients O
receiving O
their O
first O
placebo O
infusion O
. O

The O
incidence O
of O
these O
acute O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
following O
the O
second O
infusion O
of O
Rituxan O
or O
placebo O
decreased O
to O
9 O
% O
and O
11 O
% O
, O
respectively O
. O

Serious O
acute O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
were O
experienced O
by O
< O
1 O
% O
of O
patients O
in O
either O
treatment O
group O
. O

Acute O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
required O
dose O
modification O
( O
stopping O
, O
slowing O
, O
or O
interruption O
of O
the O
infusion O
) O
in O
10 O
% O
and O
2 O
% O
of O
patients O
receiving O
rituximab O
or O
placebo O
, O
respectively O
, O
after O
the O
first O
course O
. O

The O
proportion O
of O
patients O
experiencing O
acute O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
decreased O
with O
subsequent O
courses O
of O
Rituxan O
. O

The O
administration O
of O
intravenous O
glucocorticoids O
prior O
to O
Rituxan O
infusions O
reduced O
the O
incidence O
and O
severity O
of O
such O
reactions O
, O
however O
, O
there O
was O
no O
clear O
benefit O
from O
the O
administration O
of O
oral O
glucocorticoids O
for O
the O
prevention O
of O
acute O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
. O

Patients O
in O
clinical O
studies O
also O
received O
antihistamines O
and O
acetaminophen O
prior O
to O
Rituxan O
infusions O
. O

Infections O
In O
the O
pooled O
, O
placebo-controlled O
studies O
, O
39 O
% O
of O
patients O
in O
the O
Rituxan O
group O
experienced O
an O
infection B-OSE_Labeled_AE
of O
any O
type O
compared O
to O
34 O
% O
of O
patients O
in O
the O
placebo O
group O
. O

The O
most O
common O
infections B-OSE_Labeled_AE
were O
nasopharyngitis B-OSE_Labeled_AE
, O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
bronchitis B-OSE_Labeled_AE
, O
and O
sinusitis B-OSE_Labeled_AE
. O

The O
incidence O
of O
serious O
infections B-OSE_Labeled_AE
was O
2 O
% O
in O
the O
Rituxan-treated O
patients O
and O
1 O
% O
in O
the O
placebo O
group O
. O

In O
the O
experience O
with O
Rituxan O
in O
2578 O
RA B-Not_AE_Candidate
patients O
, O
the O
rate O
of O
serious O
infections B-OSE_Labeled_AE
was O
4.31 O
per O
100 O
patient O
years O
. O

The O
most O
common O
serious O
infections B-OSE_Labeled_AE
( O
> O
= O
0.5 O
% O
) O
were O
pneumonia B-OSE_Labeled_AE
or O
lower B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
cellulitis B-OSE_Labeled_AE
and O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
. O

Fatal B-NonOSE_AE
serious O
infections B-OSE_Labeled_AE
included O
pneumonia B-OSE_Labeled_AE
, O
sepsis B-OSE_Labeled_AE
and O
colitis B-OSE_Labeled_AE
. O

Rates O
of O
serious O
infection B-NonOSE_AE
remained O
stable O
in O
patients O
receiving O
subsequent O
courses O
. O

In O
185 O
Rituxan-treated O
RA B-Not_AE_Candidate
patients O
with O
active O
disease O
, O
subsequent O
treatment O
with O
a O
biologic O
DMARD O
, O
the O
majority O
of O
which O
were O
TNF O
antagonists O
, O
did O
not O
appear O
to O
increase O
the O
rate O
of O
serious O
infection B-NonOSE_AE
. O

Thirteen O
serious O
infections B-OSE_Labeled_AE
were O
observed O
in O
186.1 O
patient O
years O
( O
6.99 O
per O
100 O
patient O
years O
) O
prior O
to O
exposure O
and O
10 O
were O
observed O
in O
182.3 O
patient O
years O
( O
5.49 O
per O
100 O
patient O
years O
) O
after O
exposure O
. O

Cardiac O
Adverse O
Reactions O
In O
the O
pooled O
, O
placebo-controlled O
studies O
, O
the O
proportion O
of O
patients O
with O
serious O
cardiovascular B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
was O
1.7 O
% O
and O
1.3 O
% O
in O
the O
Rituxan O
and O
placebo O
treatment O
groups O
, O
respectively O
. O

Three O
cardiovascular O
deaths B-NonOSE_AE
occurred O
during O
the O
double-blind O
period O
of O
the O
RA B-Not_AE_Candidate
studies O
including O
all O
rituximab O
regimens O
( O
3/769 O
= O
0.4 O
% O
) O
as O
compared O
to O
none O
in O
the O
placebo O
treatment O
group O
( O
0/389 O
) O
. O

In O
the O
experience O
with O
Rituxan O
in O
2578 O
RA B-Not_AE_Candidate
patients O
, O
the O
rate O
of O
serious O
cardiac B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
was O
1.93 O
per O
100 O
patient O
years O
. O

The O
rate O
of O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
( I-OSE_Labeled_AE
MI I-OSE_Labeled_AE
) O
was O
0.56 O
per O
100 O
patient O
years O
( O
28 O
events O
in O
26 O
patients O
) O
, O
which O
is O
consistent O
with O
MI B-NonOSE_AE
rates O
in O
the O
general O
RA B-Not_AE_Candidate
population O
. O

These O
rates O
did O
not O
increase O
over O
three O
courses O
of O
Rituxan O
. O

Since O
patients O
with O
RA B-Not_AE_Candidate
are O
at O
increased O
risk O
for O
cardiovascular B-NonOSE_AE
events I-NonOSE_AE
compared O
with O
the O
general O
population O
, O
patients O
with O
RA B-Not_AE_Candidate
should O
be O
monitored O
throughout O
the O
infusion O
and O
Rituxan O
should O
be O
discontinued O
in O
the O
event O
of O
a O
serious O
or O
life-threatening O
cardiac B-NonOSE_AE
event I-NonOSE_AE
. O

Hypophosphatemia O
and O
hyperuricemia O
In O
the O
pooled O
, O
placebo-controlled O
studies O
, O
newly-occurring O
hypophosphatemia B-OSE_Labeled_AE
( O
< O
2.0 O
mg/dl O
) O
was O
observed O
in O
12 O
% O
( O
67/540 O
) O
of O
patients O
on O
Rituxan O
versus O
10 O
% O
( O
39/398 O
) O
of O
patients O
on O
placebo O
. O

Hypophosphatemia B-OSE_Labeled_AE
was O
more O
common O
in O
patients O
who O
received O
corticosteroids O
. O

Newly-occurring O
hyperuricemia B-OSE_Labeled_AE
( O
> O
10 O
mg/dl O
) O
was O
observed O
in O
1.5 O
% O
( O
8/540 O
) O
of O
patients O
on O
Rituxan O
versus O
0.3 O
% O
( O
1/398 O
) O
of O
patients O
on O
placebo O
. O

In O
the O
experience O
with O
Rituxan O
in O
RA B-Not_AE_Candidate
patients O
, O
newly-occurring O
hypophosphatemia B-OSE_Labeled_AE
was O
observed O
in O
21 O
% O
( O
528/2570 O
) O
of O
patients O
and O
newly-occurring O
hyperuricemia B-OSE_Labeled_AE
was O
observed O
in O
2 O
% O
( O
56/2570 O
) O
of O
patients O
. O

The O
majority O
of O
the O
observed O
hypophosphatemia B-OSE_Labeled_AE
occurred O
at O
the O
time O
of O
the O
infusions O
and O
was O
transient O
. O

Retreatment O
in O
Patients O
with O
RA O
In O
the O
experience O
with O
Rituxan O
in O
RA B-Not_AE_Candidate
patients O
, O
2578 O
patients O
have O
been O
exposed O
to O
Rituxan O
and O
have O
received O
up O
to O
10 O
courses O
of O
Rituxan O
in O
RA B-Not_AE_Candidate
clinical O
trials O
, O
with O
1890 O
, O
1043 O
, O
and O
425 O
patients O
having O
received O
at O
least O
two O
, O
three O
, O
and O
four O
courses O
, O
respectively O
. O

Most O
of O
the O
patients O
who O
received O
additional O
courses O
did O
so O
24 O
weeks O
or O
more O
after O
the O
previous O
course O
and O
none O
were O
retreated O
sooner O
than O
16 O
weeks O
. O

The O
rates O
and O
types O
of O
adverse O
reactions O
reported O
for O
subsequent O
courses O
of O
Rituxan O
were O
similar O
to O
rates O
and O
types O
seen O
for O
a O
single O
course O
of O
Rituxan O
. O

In O
RA O
Study O
2 O
, O
where O
all O
patients O
initially O
received O
Rituxan O
, O
the O
safety O
profile O
of O
patients O
who O
were O
retreated O
with O
Rituxan O
was O
similar O
to O
those O
who O
were O
retreated O
with O
placebo O
[ O
See O
Clinical O
Studies O
( O
14.6 O
) O
, O
and O
Dosage O
and O
Administration O
( O
2.5 O
) O
] O
. O

6.3 O
Clinical O
Trials O
Experience O
in O
Granulomatosis O
with O
Polyangiitis O
( O
GPA O
) O
( O
Wegener O
's O
Granulomatosis O
) O
and O
Microscopic O
Polyangiitis O
( O
MPA O
) O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

The O
data O
presented O
below O
reflect O
the O
experience O
in O
197 O
patients O
with O
GPA B-Not_AE_Candidate
and O
MPA B-Not_AE_Candidate
treated O
with O
Rituxan O
or O
cyclophosphamide O
in O
a O
single O
controlled O
study O
, O
which O
was O
conducted O
in O
two O
phases O
: O
a O
6 O
month O
randomized O
, O
double-blind O
, O
double-dummy O
, O
active-controlled O
remission O
induction O
phase O
and O
an O
additional O
12 O
month O
remission O
maintenance O
phase O
. O

In O
the O
6-month O
remission O
induction O
phase O
, O
197 O
patients O
with O
GPA B-Not_AE_Candidate
and O
MPA B-Not_AE_Candidate
were O
randomized O
to O
either O
Rituxan O
375 O
mg/ O
m O
2 O
once O
weekly O
for O
4 O
weeks O
plus O
glucocorticoids O
, O
or O
oral O
cyclophosphamide O
2 O
mg/kg O
daily O
( O
adjusted O
for O
renal O
function O
, O
white O
blood O
cell O
count O
, O
and O
other O
factors O
) O
plus O
glucocorticoids O
to O
induce O
remission O
. O

Once O
remission O
was O
achieved O
or O
at O
the O
end O
of O
the O
6 O
month O
remission O
induction O
period O
, O
the O
cyclophosphamide O
group O
received O
azathioprine O
to O
maintain O
remission O
. O

The O
Rituxan O
group O
did O
not O
receive O
additional O
therapy O
to O
maintain O
remission O
. O

The O
primary O
analysis O
was O
at O
the O
end O
of O
the O
6 O
month O
remission O
induction O
period O
and O
the O
safety O
results O
for O
this O
period O
are O
described O
below O
. O

Adverse O
reactions O
presented O
below O
in O
Table O
3 O
were O
adverse O
events O
which O
occurred O
at O
a O
rate O
of O
greater O
than O
or O
equal O
to O
10 O
% O
in O
the O
Rituxan O
group O
. O

This O
table O
reflects O
experience O
in O
99 O
GPA O
and O
MPA B-Not_AE_Candidate
patients O
treated O
with O
Rituxan O
, O
with O
a O
total O
of O
47.6 O
patient-years O
of O
observation O
and O
98 O
GPA B-Not_AE_Candidate
and O
MPA B-Not_AE_Candidate
patients O
treated O
with O
cyclophosphamide O
, O
with O
a O
total O
of O
47.0 O
patient-years O
of O
observation O
. O

Infection B-OSE_Labeled_AE
was O
the O
most O
common O
category O
of O
adverse O
events O
reported O
( O
47-62 O
% O
) O
and O
is O
discussed O
below O
. O

Table O
3 O
Incidence O
of O
All O
Adverse O
Reactions O
Occurring O
in O
> O
= O
10 O
% O
of O
Rituxan-treated O
GPA O
and O
MPA O
Patients O
in O
the O
Clinical O
Study O
Up O
to O
Month O
6The O
study O
design O
allowed O
for O
crossover O
or O
treatment O
by O
best O
medical O
judgment O
, O
and O
13 O
patients O
in O
each O
treatment O
group O
received O
a O
second O
therapy O
during O
the O
6 O
month O
study O
period O
. O

Preferred O
Term O
RituxanN=99n O
( O
% O
) O
CyclophosphamideN=98n O
( O
% O
) O
Nausea B-OSE_Labeled_AE
18 O
( O
18 O
% O
) O
20 O
( O
20 O
% O
) O
Diarrhea B-OSE_Labeled_AE
17 O
( O
17 O
% O
) O
12 O
( O
12 O
% O
) O
Headache B-OSE_Labeled_AE
17 O
( O
17 O
% O
) O
19 O
( O
19 O
% O
) O
Muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
17 O
( O
17 O
% O
) O
15 O
( O
15 O
% O
) O
Anemia B-OSE_Labeled_AE
16 O
( O
16 O
% O
) O
20 O
( O
20 O
% O
) O
Peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
16 O
( O
16 O
% O
) O
6 O
( O
6 O
% O
) O
Insomnia B-OSE_Labeled_AE
14 O
( O
14 O
% O
) O
12 O
( O
12 O
% O
) O
Arthralgia B-OSE_Labeled_AE
13 O
( O
13 O
% O
) O
9 O
( O
9 O
% O
) O
Cough B-OSE_Labeled_AE
13 O
( O
13 O
% O
) O
11 O
( O
11 O
% O
) O
Fatigue B-OSE_Labeled_AE
13 O
( O
13 O
% O
) O
21 O
( O
21 O
% O
) O
Increased B-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
13 O
( O
13 O
% O
) O
15 O
( O
15 O
% O
) O
Hypertension B-OSE_Labeled_AE
12 O
( O
12 O
% O
) O
5 O
( O
5 O
% O
) O
Epistaxis B-OSE_Labeled_AE
11 O
( O
11 O
% O
) O
6 O
( O
6 O
% O
) O
Dyspnea B-OSE_Labeled_AE
10 O
( O
10 O
% O
) O
11 O
( O
11 O
% O
) O
Leukopenia B-OSE_Labeled_AE
10 O
( O
10 O
% O
) O
26 O
( O
27 O
% O
) O
Rash B-OSE_Labeled_AE
10 O
( O
10 O
% O
) O
17 O
( O
17 O
% O
) O
Infusion O
Reactions O
Infusion B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
reactions I-NonOSE_AE
in O
the O
active-controlled O
, O
double-blind O
study O
were O
defined O
as O
any O
adverse O
event O
occurring O
within O
24 O
hours O
of O
an O
infusion O
and O
considered O
to O
be O
infusion-related O
by O
investigators O
. O

Among O
the O
99 O
patients O
treated O
with O
Rituxan O
, O
12 O
% O
experienced O
at O
least O
one O
infusion B-OSE_Labeled_AE
related I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
compared O
with O
11 O
% O
of O
the O
98 O
patients O
in O
the O
cyclophosphamide O
group O
. O

Infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
included O
cytokine B-OSE_Labeled_AE
release I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
flushing B-OSE_Labeled_AE
, O
throat B-OSE_Labeled_AE
irritation I-OSE_Labeled_AE
, O
and O
tremor B-OSE_Labeled_AE
. O

In O
the O
Rituxan O
group O
, O
the O
proportion O
of O
patients O
experiencing O
an O
infusion B-OSE_Labeled_AE
related I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
was O
12 O
% O
, O
5 O
% O
, O
4 O
% O
, O
and O
1 O
% O
following O
the O
first O
, O
second O
, O
third O
, O
and O
fourth O
infusions O
, O
respectively O
. O

Patients O
were O
pre-medicated O
with O
antihistamine O
and O
acetaminophen O
before O
each O
Rituxan O
infusion O
and O
were O
on O
background O
oral O
corticosteroids O
which O
may O
have O
mitigated O
or O
masked O
an O
infusion B-NonOSE_AE
reaction I-NonOSE_AE
; O
however O
, O
there O
is O
insufficient O
evidence O
to O
determine O
whether O
premedication O
diminishes O
the O
frequency O
or O
severity O
of O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
. O

Infections O
In O
the O
active-controlled O
, O
double-blind O
study O
, O
62 O
% O
( O
61/99 O
) O
of O
patients O
in O
the O
Rituxan O
group O
experienced O
an O
infection B-OSE_Labeled_AE
of O
any O
type O
compared O
to O
47 O
% O
( O
46/98 O
) O
patients O
in O
the O
cyclophosphamide O
group O
by O
Month O
6 O
. O

The O
most O
common O
infections B-OSE_Labeled_AE
in O
the O
Rituxan O
group O
were O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
and O
herpes B-OSE_Labeled_AE
zoster I-OSE_Labeled_AE
. O

The O
incidence O
of O
serious O
infections B-OSE_Labeled_AE
was O
11 O
% O
in O
the O
Rituxan-treated O
patients O
and O
10 O
% O
in O
the O
cyclophosphamide O
treated O
patients O
, O
with O
rates O
of O
approximately O
25 O
and O
28 O
per O
100 O
patient-years O
, O
respectively O
. O

The O
most O
common O
serious O
infection O
was O
pneumonia B-OSE_Labeled_AE
. O

Hypogammaglobulinemia O
Hypogammaglobulinemia B-OSE_Labeled_AE
( O
IgA B-OSE_Labeled_AE
, O
IgG O
or O
IgM O
below I-OSE_Labeled_AE
the I-OSE_Labeled_AE
lower I-OSE_Labeled_AE
limit I-OSE_Labeled_AE
of I-OSE_Labeled_AE
normal I-OSE_Labeled_AE
) O
has O
been O
observed O
in O
patients O
with O
GPA B-Not_AE_Candidate
and O
MPA B-Not_AE_Candidate
treated O
with O
Rituxan O
. O

At O
6 O
months O
, O
in O
the O
Rituxan O
group O
, O
27 O
% O
, O
58 O
% O
and O
51 O
% O
of O
patients O
with O
normal O
immunoglobulin O
levels O
at O
baseline O
, O
had O
low B-OSE_Labeled_AE
IgA I-OSE_Labeled_AE
, O
IgG O
and O
IgM O
levels O
, O
respectively O
compared O
to O
25 O
% O
, O
50 O
% O
and O
46 O
% O
in O
the O
cyclophosphamide O
group O
. O

Retreatment O
in O
Patients O
with O
GPA O
and O
MPA O
In O
the O
active-controlled O
, O
double-blind O
study O
, O
subsequent O
courses O
of O
Rituxan O
were O
allowed O
for O
patients O
experiencing O
a O
relapse O
of O
disease O
. O

The O
limited O
data O
preclude O
any O
conclusions O
regarding O
the O
safety O
of O
subsequent O
courses O
of O
Rituxan O
with O
GPA B-Not_AE_Candidate
and O
MPA B-Not_AE_Candidate
[ O
See O
Dosage O
and O
Administration O
( O
2.6 O
) O
, O
and O
Warnings O
and O
Precautions O
( O
5.14 O
) O
] O
. O

6.4 O
Immunogenicity O
As O
with O
all O
therapeutic O
proteins O
, O
there O
is O
a O
potential O
for O
immunogenicity B-OSE_Labeled_AE
. O

The O
observed O
incidence O
of O
antibody B-NonOSE_AE
( O
including O
neutralizing O
a O
ntibody B-NonOSE_AE
) I-NonOSE_AE
positivity I-NonOSE_AE
  I-NonOSE_AE
I-NonOSE_AE O
in O
an O
assay O
is O
highly O
dependent O
on O
several O
factors O
including O
assay O
sensitivity O
and O
specificity O
, O
assay O
methodology O
, O
sample O
handling O
, O
timing O
of O
sample O
collection O
, O
concomitant O
medications O
, O
and O
underlying O
disease O
. O

For O
these O
reasons O
, O
comparison O
of O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
Rituxan I-NonOSE_AE
with O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
other I-NonOSE_AE
products I-NonOSE_AE
may O
be O
misleading O
. O

Using O
an O
ELISA O
assay O
, O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
human I-OSE_Labeled_AE
anti I-OSE_Labeled_AE
- I-OSE_Labeled_AE
chimeric I-OSE_Labeled_AE
antibody I-OSE_Labeled_AE
( I-OSE_Labeled_AE
HACA I-OSE_Labeled_AE
) O
was O
detected O
in O
4 O
of O
356 O
( O
1.1 O
% O
) O
patients O
with O
low-grade O
or O
follicular O
NHL B-Not_AE_Candidate
receiving O
single-agent O
Rituxan O
. O

Three O
of O
the O
four O
patients O
had O
an O
objective O
clinical O
response O
. O

A O
total O
of O
273/2578 O
( O
11 O
% O
) O
patients O
with O
RA B-Not_AE_Candidate
tested O
positive B-OSE_Labeled_AE
for I-OSE_Labeled_AE
HACA I-OSE_Labeled_AE
at O
any O
time O
after O
receiving O
Rituxan O
. O

HACA B-NonOSE_AE
positivity O
was O
not O
associated O
with O
increased O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
or O
other O
adverse O
reactions O
. O

Upon O
further O
treatment O
, O
the O
proportions O
of O
patients O
with O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
were O
similar O
between O
HACA B-NonOSE_AE
positive I-NonOSE_AE
and O
negative O
patients O
, O
and O
most O
reactions O
were O
mild O
to O
moderate O
. O

Four O
HACA B-OSE_Labeled_AE
positive I-OSE_Labeled_AE
patients O
had O
serious O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
and O
the O
temporal O
relationship O
between O
HACA B-NonOSE_AE
positivity I-NonOSE_AE
and O
infusion B-NonOSE_AE
reaction I-NonOSE_AE
was O
variable O
. O

A O
total O
of O
23/99 O
( O
23 O
% O
) O
Rituxan-treated O
patients O
with O
GPA B-Not_AE_Candidate
and O
MPA B-Not_AE_Candidate
tested O
positive B-OSE_Labeled_AE
for I-OSE_Labeled_AE
HACA I-OSE_Labeled_AE
by O
18 O
months O
. O

The O
clinical O
relevance O
of O
HACA B-NonOSE_AE
formation I-NonOSE_AE
in O
Rituxan-treated O
patients O
is O
unclear O
. O

6.5 O
Postmarketing O
Experience O
Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Decisions O
to O
include O
these O
reactions O
in O
labeling O
are O
typically O
based O
on O
one O
or O
more O
of O
the O
following O
factors O
: O
( O
1 O
) O
seriousness O
of O
the O
reaction O
, O
( O
2 O
) O
frequency O
of O
reporting O
, O
or O
( O
3 O
) O
strength O
of O
causal O
connection O
to O
Rituxan O
. O

* O
Hematologic B-NonOSE_AE
: O
prolonged O
pancytopenia B-OSE_Labeled_AE
, O
marrow B-OSE_Labeled_AE
hypoplasia I-OSE_Labeled_AE
, O
Grade O
3-4 O
prolonged O
or O
late-onset O
neutropenia B-OSE_Labeled_AE
, O
hyperviscosity B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
in I-OSE_Labeled_AE
Waldenstrom I-OSE_Labeled_AE
' I-OSE_Labeled_AE
s I-OSE_Labeled_AE
macroglobulinemia I-OSE_Labeled_AE
, O
prolonged O
hypogammaglobulinemia B-OSE_Labeled_AE
[ O
See O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
. O

* O
Cardiac B-NonOSE_AE
: O
fatal B-NonOSE_AE
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
. O

* O
Immune B-NonOSE_AE
/ I-NonOSE_AE
Autoimmune I-NonOSE_AE
Events I-NonOSE_AE
: O
uveitis B-OSE_Labeled_AE
, O
optic B-OSE_Labeled_AE
neuritis I-OSE_Labeled_AE
, O
systemic B-OSE_Labeled_AE
vasculitis I-OSE_Labeled_AE
, O
pleuritis B-OSE_Labeled_AE
, O
lupus B-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
serum B-OSE_Labeled_AE
sickness I-OSE_Labeled_AE
, O
polyarticular B-OSE_Labeled_AE
arthritis I-OSE_Labeled_AE
, O
and O
vasculitis B-OSE_Labeled_AE
with O
rash B-OSE_Labeled_AE
. O

* O
Infection B-NonOSE_AE
: O
viral B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
including O
progressive B-OSE_Labeled_AE
multifocal I-OSE_Labeled_AE
leukoencephalopathy I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PML I-OSE_Labeled_AE
) O
, O
increase O
in O
fatal B-NonOSE_AE
infections B-OSE_Labeled_AE
in O
HIV B-Not_AE_Candidate
- I-Not_AE_Candidate
associated I-Not_AE_Candidate
lymphoma I-Not_AE_Candidate
, O
and O
a O
reported O
increased O
incidence O
of O
Grade O
3 O
and O
4 O
infections B-OSE_Labeled_AE
[ O
See O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
. O

* O
Neoplasia B-NonOSE_AE
: O
disease B-OSE_Labeled_AE
progression I-OSE_Labeled_AE
of I-OSE_Labeled_AE
Kaposi I-OSE_Labeled_AE
' I-OSE_Labeled_AE
s I-OSE_Labeled_AE
sarcoma I-OSE_Labeled_AE
. O

* O
Skin B-NonOSE_AE
: O
severe O
mucocutaneous B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

* O
Gastrointestinal B-NonOSE_AE
: O
bowel B-OSE_Labeled_AE
obstruction I-OSE_Labeled_AE
and O
perforation O
. O

* O
Pulmonary B-NonOSE_AE
: O
fatal B-NonOSE_AE
bronchiolitis B-OSE_Labeled_AE
obliterans I-OSE_Labeled_AE
and O
fatal B-NonOSE_AE
interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
. O

* O
Nervous B-NonOSE_AE
system I-NonOSE_AE
: O
Posterior B-OSE_Labeled_AE
Reversible I-OSE_Labeled_AE
Encephalopathy I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PRES I-OSE_Labeled_AE
) O
/ O
Reversible B-OSE_Labeled_AE
Posterior I-OSE_Labeled_AE
Leukoencephalopathy I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
RPLS I-OSE_Labeled_AE
) O
. O

BOXED O
WARNING O
: O
WARNING O
: O
FATAL O
INFUSION O
REACTIONS O
, O
SEVERE O
MUCOCUTANEOUS O
REACTIONS O
, O
HEPATITIS O
B O
VIRUS O
REACTIVATION O
and O
PROGRESSIVE O
MULTIFOCAL O
LEUKOENCEPHALOPATHY O
WARNING O
: O
FATAL O
INFUSION O
REACTIONS O
, O
SEVERE O
MUCOCUTANEOUS O
REACTIONS O
, O
HEPATITIS O
B O
VIRUS O
REACTIVATION O
and O
PROGRESSIVE O
MULTIFOCAL O
LEUKOENCEPHALOPATHY O
Infusion O
Reactions O
Rituxan O
administration O
can O
result O
in O
serious O
, O
including O
fatal B-NonOSE_AE
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

Deaths B-NonOSE_AE
within O
24 O
hours O
of O
Rituxan O
infusion O
have O
occurred O
. O

Approximately O
80 O
% O
of O
fatal B-NonOSE_AE
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
occurred O
in O
association O
with O
the O
first O
infusion O
. O

Monitor O
patients O
closely O
. O

Discontinue O
Rituxan O
infusion O
for O
severe O
reactions O
and O
provide O
medical O
treatment O
for O
Grade O
3 O
or O
4 O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
, O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Severe O
Mucocutaneous O
Reactions O
Severe O
, O
including O
fatal B-NonOSE_AE
, O
mucocutaneous B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
can O
occur O
in O
patients O
receiving O
Rituxan O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
, O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

Hepatitis O
B O
Virus O
( O
HBV O
) O
Reactivation O
HBV B-OSE_Labeled_AE
reactivation I-OSE_Labeled_AE
can O
occur O
in O
patients O
treated O
with O
Rituxan O
, O
in O
some O
cases O
resulting O
in O
fulminant O
hepatitis B-NonOSE_AE
, O
hepatic B-NonOSE_AE
failure I-NonOSE_AE
, O
and O
death B-NonOSE_AE
. O

Screen O
all O
patients O
for O
HBV B-Not_AE_Candidate
infection I-Not_AE_Candidate
before O
treatment O
initiation O
, O
and O
monitor O
patients O
during O
and O
after O
treatment O
with O
Rituxan O
. O

Discontinue O
Rituxan O
and O
concomitant O
medications O
in O
the O
event O
of O
HBV B-NonOSE_AE
reactivation I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
, O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

Progressive B-OSE_Labeled_AE
Multifocal I-OSE_Labeled_AE
Leukoencephalopathy I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PML I-OSE_Labeled_AE
) O
, O
including O
fatal B-NonOSE_AE
PML B-OSE_Labeled_AE
, O
can O
occur O
in O
patients O
receiving O
Rituxan O
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
, O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

EXCERPT O
: O
WARNING O
: O
FATAL O
INFUSION O
REACTIONS O
, O
SEVERE O
MUCOCUTANEOUS O
REACTIONS O
, O
HEPATITIS O
B O
VIRUS O
REACTIVATION O
and O
PROGRESSIVE O
MULTIFOCAL O
LEUKOENCEPHALOPATHY O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
Fatal O
infusion O
reactions O
within O
24 O
hours O
of O
Rituxan O
infusion O
; O
approximately O
80 O
% O
of O
fatal O
reactions O
occurred O
with O
first O
infusion O
. O

Monitor O
patients O
and O
discontinue O
Rituxan O
infusion O
for O
severe O
reactions O
( O
5.1 O
) O
. O

* O
Severe O
mucocutaneous O
reactions O
, O
some O
with O
fatal O
outcomes O
( O
5.2 O
) O
. O

* O
Hepatitis O
B O
virus O
( O
HBV O
) O
reactivation O
, O
in O
some O
cases O
resulting O
in O
fulminant O
hepatitis O
, O
hepatic O
failure O
, O
and O
death O
( O
5.3 O
) O
. O

* O
Progressive O
multifocal O
leukoencephalopathy O
( O
PML O
) O
resulting O
in O
death O
( O
5.4 O
) O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Tumor O
lysis O
syndrome O
: O
Administer O
aggressive O
intravenous O
hydration O
, O
anti-hyperuricemic O
agents O
, O
monitor O
renal O
function O
( O
5.5 O
) O
. O

* O
Infections O
: O
Withhold O
Rituxan O
and O
institute O
appropriate O
anti-infective O
therapy O
( O
5.6 O
) O
. O

* O
Cardiac O
arrhythmias O
and O
angina O
: O
Discontinue O
infusions O
in O
case O
of O
serious O
or O
life-threatening O
events O
( O
5.7 O
) O
. O

* O
Bowel O
obstruction O
and O
perforation O
: O
Consider O
and O
evaluate O
for O
abdominal O
pain O
, O
vomiting O
, O
or O
related O
symptoms O
( O
5.9 O
) O
. O

* O
Live O
virus O
vaccines O
: O
Do O
not O
administer O
live O
virus O
vaccines O
prior O
to O
or O
during O
Rituxan O
( O
5.10 O
) O
. O

* O
Cytopenias O
: O
Monitor O
blood O
counts O
at O
regular O
intervals O
( O
5.11 O
, O
6.1 O
) O
. O

5.1 O
Infusion O
Reactions O
Rituxan O
can O
cause O
severe O
, O
including O
fatal B-NonOSE_AE
, O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

Severe O
reactions O
typically O
occurred O
during O
the O
first O
infusion O
with O
time O
to O
onset O
of O
30-120 O
minutes O
. O

Rituxan B-OSE_Labeled_AE
- I-OSE_Labeled_AE
induced I-OSE_Labeled_AE
infusion I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
and O
sequelae O
include O
urticaria B-NonOSE_AE
, O
hypotension B-NonOSE_AE
, O
angioedema B-NonOSE_AE
, O
hypoxia B-NonOSE_AE
, O
bronchospasm B-NonOSE_AE
, O
pulmonary B-NonOSE_AE
infiltrates I-NonOSE_AE
, O
acute B-NonOSE_AE
respiratory I-NonOSE_AE
distress I-NonOSE_AE
syndrome I-NonOSE_AE
, O
myocardial B-NonOSE_AE
infarction I-NonOSE_AE
, O
ventricular B-NonOSE_AE
fibrillation I-NonOSE_AE
, O
cardiogenic B-NonOSE_AE
shock I-NonOSE_AE
, O
anaphylactoid B-NonOSE_AE
events I-NonOSE_AE
, O
or O
death B-NonOSE_AE
. O

Premedicate O
patients O
with O
an O
antihistamine O
and O
acetaminophen O
prior O
to O
dosing O
. O

For O
RA B-Not_AE_Candidate
patients O
, O
methylprednisolone O
100 O
mg O
intravenously O
or O
its O
equivalent O
is O
recommended O
30 O
minutes O
prior O
to O
each O
infusion O
. O

Institute O
medical O
management O
( O
e.g O
. O

glucocorticoids O
, O
epinephrine O
, O
bronchodilators O
, O
or O
oxygen O
) O
for O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
as O
needed O
. O

Depending O
on O
the O
severity O
of O
the O
infusion B-NonOSE_AE
reaction I-NonOSE_AE
and O
the O
required O
interventions O
, O
temporarily O
or O
permanently O
discontinue O
Rituxan O
. O

Resume O
infusion O
at O
a O
minimum O
50 O
% O
reduction O
in O
rate O
after O
symptoms O
have O
resolved O
. O

Closely O
monitor O
the O
following O
patients O
: O
those O
with O
pre-existing O
cardiac B-Not_AE_Candidate
or O
pulmonary O
conditions I-Not_AE_Candidate
, O
those O
who O
experienced O
prior O
cardiopulmonary B-Not_AE_Candidate
adverse I-Not_AE_Candidate
reactions I-Not_AE_Candidate
, O
and O
those O
with O
high B-Not_AE_Candidate
numbers I-Not_AE_Candidate
of I-Not_AE_Candidate
circulating I-Not_AE_Candidate
malignant I-Not_AE_Candidate
cells I-Not_AE_Candidate
( I-Not_AE_Candidate
> I-Not_AE_Candidate
= I-Not_AE_Candidate
2 I-Not_AE_Candidate
5 I-Not_AE_Candidate
, I-Not_AE_Candidate
0 I-Not_AE_Candidate
0 I-Not_AE_Candidate
0 I-Not_AE_Candidate
/ I-Not_AE_Candidate
mm I-Not_AE_Candidate
3 I-Not_AE_Candidate
) O
. O

[ O
See O
Boxed O
Warning O
, O
Warnings O
and O
Precautions O
( O
5.7 O
) O
, O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.2 O
Severe O
Mucocutaneous O
Reactions O
Mucocutaneous B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
some O
with O
fatal B-NonOSE_AE
outcome O
, O
can O
occur O
in O
patients O
treated O
with O
Rituxan O
. O

These O
reactions O
include O
paraneoplastic B-OSE_Labeled_AE
pemphigus I-OSE_Labeled_AE
, O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
lichenoid B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
vesiculobullous B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
and O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
. O

The O
onset O
of O
these O
reactions O
has O
been O
variable O
and O
includes O
reports O
with O
onset O
on O
the O
first O
day O
of O
Rituxan O
exposure O
. O

Discontinue O
Rituxan O
in O
patients O
who O
experience O
a O
severe O
mucocutaneous B-NonOSE_AE
reaction I-NonOSE_AE
. O

The O
safety O
of O
readministration O
of O
Rituxan O
to O
patients O
with O
severe O
mucocutaneous B-NonOSE_AE
reactions I-NonOSE_AE
has O
not O
been O
determined O
. O

[ O
See O
Boxed O
Warning O
, O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

5.3 O
Hepatitis O
B O
Virus O
Reactivation O
Hepatitis B-OSE_Labeled_AE
B I-OSE_Labeled_AE
virus I-OSE_Labeled_AE
( I-OSE_Labeled_AE
HBV I-OSE_Labeled_AE
) I-OSE_Labeled_AE
reactivation I-OSE_Labeled_AE
, O
in O
some O
cases O
resulting O
in O
fulminant O
hepatitis B-NonOSE_AE
, O
hepatic B-NonOSE_AE
failure I-NonOSE_AE
and O
death B-NonOSE_AE
, O
can O
occur O
in O
patients O
treated O
with O
drugs O
classified O
as O
CD B-NonOSE_AE
2 I-NonOSE_AE
0 I-NonOSE_AE
- I-NonOSE_AE
directed I-NonOSE_AE
cytolytic I-NonOSE_AE
antibodies I-NonOSE_AE
, O
including O
Rituxan O
. O

Cases O
have O
been O
reported O
in O
patients O
who O
are O
hepatitis B-Not_AE_Candidate
B I-Not_AE_Candidate
surface I-Not_AE_Candidate
antigen I-Not_AE_Candidate
( I-Not_AE_Candidate
HBsAg I-Not_AE_Candidate
) I-Not_AE_Candidate
positive I-Not_AE_Candidate
and O
also O
in O
patients O
who O
are O
HBsAg B-Not_AE_Candidate
negative I-Not_AE_Candidate
but O
are O
hepatitis B-Not_AE_Candidate
B I-Not_AE_Candidate
core I-Not_AE_Candidate
antibody I-Not_AE_Candidate
( I-Not_AE_Candidate
anti I-Not_AE_Candidate
- I-Not_AE_Candidate
HBc I-Not_AE_Candidate
) I-Not_AE_Candidate
positive I-Not_AE_Candidate
. O

Reactivation O
also O
has O
occurred O
in O
patients O
who O
appear O
to O
have O
resolved O
hepatitis B-Not_AE_Candidate
B I-Not_AE_Candidate
infection I-Not_AE_Candidate
( I-Not_AE_Candidate
i I-Not_AE_Candidate
. I-Not_AE_Candidate
e I-Not_AE_Candidate
. I-Not_AE_Candidate
, I-Not_AE_Candidate
HBsAg I-Not_AE_Candidate
negative I-Not_AE_Candidate
, O
anti B-Not_AE_Candidate
- I-Not_AE_Candidate
HBc I-Not_AE_Candidate
positive I-Not_AE_Candidate
and O
hepatitis B-Not_AE_Candidate
B I-Not_AE_Candidate
surface I-Not_AE_Candidate
antibody I-Not_AE_Candidate
[ I-Not_AE_Candidate
anti I-Not_AE_Candidate
- I-Not_AE_Candidate
HBs I-Not_AE_Candidate
] I-Not_AE_Candidate
positive I-Not_AE_Candidate
) O
. O

HBV B-NonOSE_AE
reactivation I-NonOSE_AE
is O
defined O
as O
an O
abrupt O
increase B-NonOSE_AE
in I-NonOSE_AE
HBV I-NonOSE_AE
replication I-NonOSE_AE
manifesting O
as O
a O
rapid O
increase B-NonOSE_AE
in I-NonOSE_AE
serum I-NonOSE_AE
HBV I-NonOSE_AE
DNA I-NonOSE_AE
level I-NonOSE_AE
or O
detection B-NonOSE_AE
of I-NonOSE_AE
HBsAg I-NonOSE_AE
in O
a O
person O
who O
was O
previously O
HBsAg B-Not_AE_Candidate
negative I-Not_AE_Candidate
and O
anti B-Not_AE_Candidate
- I-Not_AE_Candidate
HBc I-Not_AE_Candidate
positive I-Not_AE_Candidate
. O

Reactivation B-NonOSE_AE
of I-NonOSE_AE
HBV I-NonOSE_AE
replication I-NonOSE_AE
is O
often O
followed O
by O
hepatitis B-NonOSE_AE
, O
i.e. O
, O
increase B-NonOSE_AE
in I-NonOSE_AE
transaminase I-NonOSE_AE
levels I-NonOSE_AE
. O

In O
severe O
cases O
increase B-NonOSE_AE
in I-NonOSE_AE
bilirubin I-NonOSE_AE
levels I-NonOSE_AE
, O
liver B-NonOSE_AE
failure I-NonOSE_AE
, O
and O
death B-NonOSE_AE
can O
occur O
. O

Screen O
all O
patients O
for O
HBV B-Not_AE_Candidate
infection I-Not_AE_Candidate
by O
measuring O
HBsAg O
and O
anti-HBc O
before O
initiating O
treatment O
with O
Rituxan O
. O

For O
patients O
who O
show O
evidence O
of O
prior O
hepatitis B-Not_AE_Candidate
B I-Not_AE_Candidate
infection I-Not_AE_Candidate
( O
HBsAg B-Not_AE_Candidate
positive I-Not_AE_Candidate
[ O
regardless O
of O
antibody B-NonOSE_AE
status O
] O
or O
HBsAg B-Not_AE_Candidate
negative I-Not_AE_Candidate
but O
anti B-Not_AE_Candidate
- I-Not_AE_Candidate
HBc I-Not_AE_Candidate
positive I-Not_AE_Candidate
) O
, O
consult O
with O
physicians O
with O
expertise O
in O
managing O
hepatitis B-NonOSE_AE
B I-NonOSE_AE
regarding O
monitoring O
and O
consideration O
for O
HBV B-NonOSE_AE
antiviral O
therapy O
before O
and/or O
during O
Rituxan O
treatment O
. O

Monitor O
patients O
with O
evidence O
of O
current O
or O
prior O
HBV B-Not_AE_Candidate
infection I-Not_AE_Candidate
for O
clinical O
and O
laboratory O
signs O
of O
hepatitis B-NonOSE_AE
or O
HBV B-NonOSE_AE
reactivation I-NonOSE_AE
during O
and O
for O
several O
months O
following O
Rituxan O
therapy O
. O

HBV B-OSE_Labeled_AE
reactivation I-OSE_Labeled_AE
has O
been O
reported O
up O
to O
24 O
months O
following O
completion O
of O
Rituxan O
therapy O
. O

In O
patients O
who O
develop O
reactivation B-NonOSE_AE
of I-NonOSE_AE
HBV I-NonOSE_AE
while O
on O
Rituxan O
, O
immediately O
discontinue O
Rituxan O
and O
any O
concomitant O
chemotherapy O
, O
and O
institute O
appropriate O
treatment O
. O

Insufficient O
data O
exist O
regarding O
the O
safety O
of O
resuming O
Rituxan O
in O
patients O
who O
develop O
HBV B-NonOSE_AE
reactivation I-NonOSE_AE
. O

Resumption O
of O
Rituxan O
in O
patients O
whose O
HBV B-NonOSE_AE
reactivation I-NonOSE_AE
resolves O
should O
be O
discussed O
with O
physicians O
with O
expertise O
in O
managing O
hepatitis O
B O
. O

[ O
See O
Boxed O
Warning O
, O
Adverse O
Reactions O
( O
6 O
) O
] O
5.4 O
Progressive B-OSE_Labeled_AE
Multifocal I-OSE_Labeled_AE
Leukoencephalopathy I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PML I-OSE_Labeled_AE
) O
JC B-OSE_Labeled_AE
virus I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
resulting O
in O
PML B-OSE_Labeled_AE
and O
death B-NonOSE_AE
can O
occur O
in O
Rituxan-treated O
patients O
with O
hematologic B-Not_AE_Candidate
malignancies I-Not_AE_Candidate
or O
with O
autoimmune B-Not_AE_Candidate
diseases I-Not_AE_Candidate
. O

The O
majority O
of O
patients O
with O
hematologic B-Not_AE_Candidate
malignancies I-Not_AE_Candidate
diagnosed O
with O
PML B-OSE_Labeled_AE
received O
Rituxan O
in O
combination O
with O
chemotherapy O
or O
as O
part O
of O
a O
hematopoietic O
stem O
cell O
transplant O
. O

The O
patients O
with O
autoimmune B-Not_AE_Candidate
diseases I-Not_AE_Candidate
had O
prior O
or O
concurrent O
immunosuppressive O
therapy O
. O

Most O
cases O
of O
PML B-OSE_Labeled_AE
were O
diagnosed O
within O
12 O
months O
of O
their O
last O
infusion O
of O
Rituxan O
. O

Consider O
the O
diagnosis O
of O
PML B-NonOSE_AE
in O
any O
patient O
presenting O
with O
new-onset O
neurologic O
manifestations O
. O

Evaluation O
of O
PML B-NonOSE_AE
includes O
, O
but O
is O
not O
limited O
to O
, O
consultation O
with O
a O
neurologist O
, O
brain O
MRI O
, O
and O
lumbar O
puncture O
. O

Discontinue O
Rituxan O
and O
consider O
discontinuation O
or O
reduction O
of O
any O
concomitant O
chemotherapy O
or O
immunosuppressive O
therapy O
in O
patients O
who O
develop O
PML B-NonOSE_AE
. O

[ O
See O
Boxed O
Warning O
, O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

5.5 O
Tumor B-OSE_Labeled_AE
Lysis I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
TLS I-OSE_Labeled_AE
) O
Acute B-NonOSE_AE
renal I-NonOSE_AE
failure I-NonOSE_AE
, O
hyperkalemia B-NonOSE_AE
, O
hypocalcemia B-NonOSE_AE
, O
hyperuricemia B-NonOSE_AE
, O
or O
hyperphosphatemia B-NonOSE_AE
from O
tumor B-OSE_Labeled_AE
lysis I-OSE_Labeled_AE
, O
some O
fatal B-NonOSE_AE
, O
can O
occur O
within O
12-24 O
hours O
after O
the O
first O
infusion O
of O
Rituxan O
in O
patients O
with O
NHL B-Not_AE_Candidate
. O

A O
high B-Not_AE_Candidate
number I-Not_AE_Candidate
of I-Not_AE_Candidate
circulating I-Not_AE_Candidate
malignant I-Not_AE_Candidate
cells I-Not_AE_Candidate
( I-Not_AE_Candidate
> I-Not_AE_Candidate
= I-Not_AE_Candidate
2 I-Not_AE_Candidate
5 I-Not_AE_Candidate
, I-Not_AE_Candidate
0 I-Not_AE_Candidate
0 I-Not_AE_Candidate
0 I-Not_AE_Candidate
/ I-Not_AE_Candidate
mm I-Not_AE_Candidate
3 I-Not_AE_Candidate
) O
or O
high O
tumor B-Not_AE_Candidate
burden O
, O
confers O
a O
greater O
risk O
of O
TLS B-NonOSE_AE
. O

Administer O
aggressive O
intravenous O
hydration O
and O
anti-hyperuricemic O
therapy O
in O
patients O
at O
high O
risk O
for O
TLS B-NonOSE_AE
. O

Correct O
electrolyte B-Not_AE_Candidate
abnormalities I-Not_AE_Candidate
, O
monitor O
renal O
function O
and O
fluid O
balance O
, O
and O
administer O
supportive O
care O
, O
including O
dialysis O
as O
indicated O
. O

[ O
See O
Warnings O
and O
Precautions O
( O
5.8 O
) O
, O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

5.6 O
Infections O
Serious O
, O
including O
fatal B-NonOSE_AE
, O
bacterial B-OSE_Labeled_AE
, O
fungal O
, O
and O
new O
or O
reactivated O
viral O
infections I-OSE_Labeled_AE
can O
occur O
during O
and O
following O
the O
completion O
of O
Rituxan-based O
therapy O
. O

Infections B-OSE_Labeled_AE
have O
been O
reported O
in O
some O
patients O
with O
prolonged O
hypogammaglobulinemia B-NonOSE_AE
( O
defined O
as O
hypogammaglobulinemia B-NonOSE_AE
> O
11 O
months O
after O
rituximab O
exposure O
) O
. O

New O
or O
reactivated O
viral B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
included O
cytomegalovirus B-OSE_Labeled_AE
, O
herpes B-OSE_Labeled_AE
simplex I-OSE_Labeled_AE
virus I-OSE_Labeled_AE
, O
parvovirus B-OSE_Labeled_AE
B I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
9 I-OSE_Labeled_AE
, O
varicella B-OSE_Labeled_AE
zoster I-OSE_Labeled_AE
virus I-OSE_Labeled_AE
, O
West B-OSE_Labeled_AE
Nile I-OSE_Labeled_AE
virus I-OSE_Labeled_AE
, O
and O
hepatitis B-OSE_Labeled_AE
B I-OSE_Labeled_AE
and O
C O
. O
Discontinue O
Rituxan O
for O
serious O
infections B-NonOSE_AE
and O
institute O
appropriate O
anti-infective O
therapy O
. O

[ O
See O
Adverse O
Reactions O
( O
6 O
, O
6.1 O
) O
] O
. O

5.7 O
Cardiovascular B-OSE_Labeled_AE
Discontinue O
infusions O
for O
serious O
or O
life-threatening O
cardiac B-NonOSE_AE
arrhythmias I-NonOSE_AE
. O

Perform O
cardiac O
monitoring O
during O
and O
after O
all O
infusions O
of O
Rituxan O
for O
patients O
who O
develop O
clinically O
significant O
arrhythmias B-NonOSE_AE
, O
or O
who O
have O
a O
history O
of O
arrhythmia B-Not_AE_Candidate
or O
angina B-Not_AE_Candidate
. O

[ O
See O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

5.8 O
Renal O
Severe O
, O
including O
fatal B-NonOSE_AE
, O
renal B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
can O
occur O
after O
Rituxan O
administration O
in O
patients O
with O
NHL B-Not_AE_Candidate
. O

Renal B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
has O
occurred O
in O
patients O
who O
experience O
tumor B-NonOSE_AE
lysis I-NonOSE_AE
syndrome I-NonOSE_AE
and O
in O
patients O
with O
NHL B-Not_AE_Candidate
administered O
concomitant O
cisplatin O
therapy O
during O
clinical O
trials O
. O

The O
combination O
of O
cisplatin O
and O
Rituxan O
is O
not O
an O
approved O
treatment O
regimen O
. O

Monitor O
closely O
for O
signs O
of O
renal B-NonOSE_AE
failure I-NonOSE_AE
and O
discontinue O
Rituxan O
in O
patients O
with O
a O
rising B-NonOSE_AE
serum I-NonOSE_AE
creatinine I-NonOSE_AE
or O
oliguria B-NonOSE_AE
. O

[ O
See O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
. O

5.9 O
Bowel O
Obstruction O
and O
Perforation O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
bowel B-OSE_Labeled_AE
obstruction I-OSE_Labeled_AE
and O
perforation O
, O
in O
some O
cases O
leading O
to O
death B-NonOSE_AE
, O
can O
occur O
in O
patients O
receiving O
Rituxan O
in O
combination O
with O
chemotherapy O
. O

In O
postmarketing O
reports O
, O
the O
mean O
time O
to O
documented O
gastrointestinal B-NonOSE_AE
perforation O
was O
6 O
( O
range O
1-77 O
) O
days O
in O
patients O
with O
NHL O
. O

Evaluate O
if B-Not_AE_Candidate
symptoms O
of O
obstruction I-NonOSE_AE
such O
as O
abdominal B-NonOSE_AE
pain I-NonOSE_AE
or O
repeated O
vomiting B-NonOSE_AE
occur O
. O

[ O
See O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

5.10 O
Immunization O
The O
safety O
of O
immunization O
with O
live O
viral O
vaccines O
following O
Rituxan O
therapy O
has O
not O
been O
studied O
and O
vaccination O
with O
live O
virus O
vaccines O
is O
not O
recommended O
. O

For O
RA B-Not_AE_Candidate
patients O
, O
physicians O
should O
follow O
current O
immunization O
guidelines O
and O
administer O
non-live O
vaccines O
at O
least O
4 O
weeks O
prior O
to O
a O
course O
of O
Rituxan O
. O

The O
effect O
of O
Rituxan O
on O
immune O
responses O
was O
assessed O
in O
a O
randomized O
, O
controlled O
study O
in O
patients O
with O
RA B-Not_AE_Candidate
treated O
with O
Rituxan O
and O
methotrexate O
( O
MTX O
) O
compared O
to O
patients O
treated O
with O
MTX O
alone O
. O

A O
response O
to O
pneumococcal O
vaccination O
( O
a O
T-cell O
independent O
antigen O
) O
as O
measured O
by O
an O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
antibody I-OSE_Labeled_AE
titers I-OSE_Labeled_AE
to I-OSE_Labeled_AE
at I-OSE_Labeled_AE
least I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
of I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
serotypes I-OSE_Labeled_AE
was I-OSE_Labeled_AE
lower I-OSE_Labeled_AE
in O
patients O
treated O
with O
Rituxan O
plus O
MTX O
as O
compared O
to O
patients O
treated O
with O
MTX O
alone O
( O
19 O
% O
vs O
. O
61 O
% O
) O
. O

A O
lower B-OSE_Labeled_AE
proportion I-OSE_Labeled_AE
of I-OSE_Labeled_AE
patients I-OSE_Labeled_AE
in I-OSE_Labeled_AE
the I-OSE_Labeled_AE
Rituxan I-OSE_Labeled_AE
plus I-OSE_Labeled_AE
MTX I-OSE_Labeled_AE
group I-OSE_Labeled_AE
developed I-OSE_Labeled_AE
detectable I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
of I-OSE_Labeled_AE
anti I-OSE_Labeled_AE
- I-OSE_Labeled_AE
keyhole I-OSE_Labeled_AE
limpet I-OSE_Labeled_AE
hemocyanin I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
( I-OSE_Labeled_AE
a I-OSE_Labeled_AE
novel I-OSE_Labeled_AE
protein I-OSE_Labeled_AE
antigen I-OSE_Labeled_AE
) I-OSE_Labeled_AE
after I-OSE_Labeled_AE
vaccination I-OSE_Labeled_AE
compared O
to O
patients O
on O
MTX O
alone O
( O
47 O
% O
vs O
. O
93 O
% O
) O
. O

A O
positive O
response O
to O
tetanus O
toxoid O
vaccine O
( O
a O
T-cell O
dependent O
antigen O
with O
existing O
immunity O
) O
was O
similar O
in O
patients O
treated O
with O
Rituxan O
plus O
MTX O
compared O
to O
patients O
on O
MTX O
alone O
( O
39 O
% O
vs O
. O
42 O
% O
) O
. O

The O
proportion O
of O
patients O
maintaining O
a O
positive B-NonOSE_AE
Candida I-NonOSE_AE
skin I-NonOSE_AE
test I-NonOSE_AE
( O
to O
evaluate O
delayed O
type O
hypersensitivity B-NonOSE_AE
) O
was O
also O
similar O
( O
77 O
% O
of O
patients O
on O
Rituxan O
plus O
MTX O
vs O
. O
70 O
% O
of O
patients O
on O
MTX O
alone O
) O
. O

Most O
patients O
in O
the O
Rituxan-treated O
group O
had O
B B-NonOSE_AE
- I-NonOSE_AE
cell I-NonOSE_AE
counts I-NonOSE_AE
below I-NonOSE_AE
the I-NonOSE_AE
lower I-NonOSE_AE
limit I-NonOSE_AE
of I-NonOSE_AE
normal I-NonOSE_AE
at O
the O
time O
of O
immunization O
. O

The O
clinical O
implications O
of O
these O
findings O
are O
not O
known O
. O

5.11 O
Laboratory O
Monitoring O
In O
patients O
with O
lymphoid B-Not_AE_Candidate
malignancies I-Not_AE_Candidate
, O
during O
treatment O
with O
Rituxan O
monotherapy O
, O
obtain O
complete O
blood O
counts O
( O
CBC O
) O
and O
platelet O
counts O
prior O
to O
each O
Rituxan O
course O
. O

During O
treatment O
with O
Rituxan O
and O
chemotherapy O
, O
obtain O
CBC O
and O
platelet O
counts O
at O
weekly O
to O
monthly O
intervals O
and O
more O
frequently O
in O
patients O
who O
develop O
cytopenias B-NonOSE_AE
[ O
See O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

In O
patients O
with O
RA B-Not_AE_Candidate
, O
GPA B-Not_AE_Candidate
or O
MPA B-Not_AE_Candidate
, O
obtain O
CBC O
and O
platelet O
counts O
at O
two O
to O
four O
month O
intervals O
during O
Rituxan O
therapy O
. O

The O
duration O
of O
cytopenias B-NonOSE_AE
caused O
by O
Rituxan O
can O
extend O
months O
beyond O
the O
treatment O
period O
. O

5.12 O
Concomitant O
Use O
with O
Biologic O
Agents O
and O
DMARDS O
other O
than O
Methotrexate O
in O
RA O
, O
GPA O
and O
MPA O
Limited O
data O
are O
available O
on O
the O
safety O
of O
the O
use O
of O
biologic O
agents O
or O
DMARDs O
other O
than O
methotrexate O
in O
RA B-Not_AE_Candidate
patients O
exhibiting O
peripheral O
B B-NonOSE_AE
- I-NonOSE_AE
cell I-NonOSE_AE
depletion I-NonOSE_AE
following O
treatment O
with O
rituximab O
. O

Observe O
patients O
closely O
for O
signs O
of O
infection B-NonOSE_AE
if O
biologic O
agents O
and/or O
DMARDs O
are O
used O
concomitantly O
. O

Use O
of O
concomitant O
immunosuppressants O
other O
than O
corticosteroids O
has O
not O
been O
studied O
in O
GPA B-Not_AE_Candidate
or O
MPA B-Not_AE_Candidate
patients O
exhibiting O
peripheral O
B B-NonOSE_AE
- I-NonOSE_AE
cell I-NonOSE_AE
depletion I-NonOSE_AE
following O
treatment O
with O
Rituxan O
. O

5.13 O
Use O
in O
RA O
Patients O
Who O
Have O
Not O
Had O
Prior O
Inadequate O
Response O
to O
Tumor O
Necrosis O
Factor O
( O
TNF O
) O
Antagonists O
While O
the O
efficacy O
of O
Rituxan O
was O
supported O
in O
four O
controlled O
trials O
in O
patients O
with O
RA B-Not_AE_Candidate
with O
prior O
inadequate O
responses O
to O
non-biologic O
DMARDs O
, O
and O
in O
a O
controlled O
trial O
in O
MTX-naive O
patients O
, O
a O
favorable O
risk-benefit O
relationship O
has O
not O
been O
established O
in O
these O
populations O
. O

The O
use O
of O
Rituxan O
in O
patients O
with O
RA B-Not_AE_Candidate
who O
have O
not O
had O
prior O
inadequate O
response O
to O
one O
or O
more O
TNF O
antagonists O
is O
not O
recommended O
[ O
See O
Clinical O
Studies O
( O
14.6 O
) O
] O
. O

5.14 O
Retreatment O
in O
Patients O
with O
Granulomatosis O
with O
Polyangiitis O
( O
GPA O
) O
( O
Wegener O
's O
Granulomatosis O
) O
and O
Microscopic O
Polyangiitis O
( O
MPA O
) O
Limited O
data O
are O
available O
on O
the O
safety O
and O
efficacy O
of O
subsequent O
courses O
of O
Rituxan O
in O
patients O
with O
GPA B-Not_AE_Candidate
and O
MPA B-Not_AE_Candidate
. O

The O
safety O
and O
efficacy O
of O
retreatment O
with O
Rituxan O
have O
not O
been O
established O
[ O
See O
Dosage O
and O
Administration O
( O
2.6 O
) O
, O
Adverse O
Reactions O
( O
6.3 O
) O
, O
and O
Clinical O
Studies O
( O
14.7 O
) O
] O
. O

6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
incidence O
> O
5 O
% O
) O
are O
upper O
respiratory O
tract O
infection O
, O
nasopharyngitis O
, O
injection O
site O
reactions O
( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Janssen O
Biotech O
, O
Inc O
. O
at O
1-800-JANSSEN O
( O
1-800-526-7736 O
) O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

The O
safety O
data O
described O
below O
are O
based O
on O
5 O
pooled O
, O
randomized O
, O
double-blind O
, O
controlled O
Phase O
3 O
trials O
in O
patients O
with O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
, O
and O
AS B-Not_AE_Candidate
( O
Trials O
RA-1 O
, O
RA-2 O
, O
RA-3 O
, O
PsA B-Not_AE_Candidate
, O
and O
AS B-Not_AE_Candidate
) O
[ O
see O
Clinical O
Studies O
( O
14.1 O
, O
14.2 O
, O
and O
14.3 O
) O
] O
. O

These O
5 O
trials O
included O
639 O
control-treated O
patients O
and O
1659 O
SIMPONI-treated O
patients O
including O
1089 O
with O
RA B-Not_AE_Candidate
, O
292 O
with O
PsA B-Not_AE_Candidate
, O
and O
278 O
with O
AS B-Not_AE_Candidate
. O

The O
safety O
data O
in O
1233 O
SIMPONI-treated O
patients O
with O
ulcerative B-Not_AE_Candidate
colitis I-Not_AE_Candidate
from O
3 O
pooled O
, O
randomized O
, O
double-blind O
, O
controlled O
Phase O
2/3 O
trials O
are O
also O
described O
below O
( O
Trials O
UC-1 O
, O
UC-2 O
, O
and O
UC-3 O
) O
[ O
see O
Clinical O
Studies O
( O
14.4 O
) O
] O
. O

The O
proportion O
of O
patients O
who O
discontinued O
treatment O
due O
to O
adverse O
reactions O
in O
the O
controlled O
Phase O
3 O
trials O
through O
Week O
16 O
in O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
and O
AS B-Not_AE_Candidate
was O
2 O
% O
for O
SIMPONI-treated O
patients O
and O
3 O
% O
for O
placebo-treated O
patients O
. O

The O
most O
common O
adverse O
reactions O
leading O
to O
discontinuation O
of O
SIMPONI O
in O
the O
controlled O
Phase O
3 O
trials O
in O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
and O
AS B-Not_AE_Candidate
through O
Week O
16 O
were O
sepsis B-OSE_Labeled_AE
( O
0.2 O
% O
) O
, O
alanine B-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
( O
0.2 O
% O
) O
, O
and O
aspartate B-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
( O
0.2 O
% O
) O
. O

The O
most O
common O
adverse O
drug O
reactions O
leading O
to O
discontinuation O
through O
Week O
60 O
of O
the O
UC B-Not_AE_Candidate
trials O
in O
patients O
who O
received O
SIMPONI O
induction O
and O
100 O
mg O
during O
maintenance O
compared O
with O
patients O
who O
received O
SIMPONI O
induction O
and O
placebo O
during O
maintenance O
were O
tuberculosis B-OSE_Labeled_AE
( O
0.3 O
% O
vs O
0.6 O
% O
) O
and O
anemia B-OSE_Labeled_AE
( O
0.3 O
% O
vs O
0 O
% O
) O
, O
respectively O
. O

The O
most O
serious O
adverse O
reactions O
were O
: O
* O
Serious O
Infections B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Malignancies B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
and O
nasopharyngitis B-OSE_Labeled_AE
were O
the O
most O
common O
adverse O
reactions O
reported O
in O
the O
combined O
Phase O
3 O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
and O
AS B-Not_AE_Candidate
trials O
through O
Week O
16 O
, O
occurring O
in O
7 O
% O
and O
6 O
% O
of O
SIMPONI-treated O
patients O
as O
compared O
with O
6 O
% O
and O
5 O
% O
of O
control-treated O
patients O
, O
respectively O
. O

Infections O
In O
controlled O
Phase O
3 O
trials O
through O
Week O
16 O
in O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
, O
and O
AS B-Not_AE_Candidate
, O
infections B-OSE_Labeled_AE
were O
observed O
in O
28 O
% O
of O
SIMPONI-treated O
patients O
compared O
to O
25 O
% O
of O
control-treated O
patients O
. O

For O
serious O
infections B-OSE_Labeled_AE
, O
see O
the O
Warnings O
and O
Precautions O
section O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

In O
the O
controlled O
Phase O
2/3 O
trial O
of O
SIMPONI O
induction O
through O
Week O
6 O
in O
UC B-Not_AE_Candidate
, O
the O
rates O
of O
infections B-OSE_Labeled_AE
were O
similar O
in O
SIMPONI O
200/100 O
mg-treated O
patients O
and O
placebo-treated O
patients O
, O
or O
approximately O
12 O
% O
. O

Through O
Week O
60 O
, O
the O
incidence O
per O
patient O
year O
of O
infections B-OSE_Labeled_AE
was O
similar O
in O
patients O
who O
received O
SIMPONI O
induction O
and O
100 O
mg O
during O
maintenance O
compared O
with O
patients O
who O
received O
SIMPONI O
induction O
and O
placebo O
during O
the O
maintenance O
portion O
of O
the O
UC B-Not_AE_Candidate
trial O
. O

Demyelinating B-OSE_Labeled_AE
Disorders I-OSE_Labeled_AE
In O
the O
controlled O
Phase O
2/3 O
trial O
of O
SIMPONI O
induction O
through O
Week O
6 O
, O
no O
cases O
of O
demyelination B-NonOSE_AE
were O
observed O
in O
SIMPONI O
200/100 O
mg-treated O
patients O
or O
placebo-treated O
patients O
. O

Through O
Week O
60 O
, O
there O
were O
no O
cases O
of O
demyelination B-NonOSE_AE
in O
the O
SIMPONI O
100-mg O
group O
during O
maintenance O
. O

One O
case O
of O
CNS B-OSE_Labeled_AE
demyelination I-OSE_Labeled_AE
was O
observed O
in O
the O
placebo O
maintenance O
group O
in O
a O
patient O
who O
received O
SIMPONI O
400/200 O
mg O
during O
induction O
. O

Liver B-OSE_Labeled_AE
Enzyme I-OSE_Labeled_AE
Elevations I-OSE_Labeled_AE
There O
have O
been O
reports O
of O
severe O
hepatic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
including O
acute B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
in O
patients O
receiving O
TNF O
blockers O
. O

In O
controlled O
Phase O
3 O
trials O
of O
SIMPONI O
in O
patients O
with O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
, O
and O
AS B-Not_AE_Candidate
through O
Week O
16 O
, O
ALT B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
> O
= O
5 O
* O
ULN O
occurred O
in O
0.2 O
% O
of O
control-treated O
patients O
and O
0.7 O
% O
of O
SIMPONI-treated O
patients O
and O
ALT B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
> O
= O
3 O
* O
ULN O
occurred O
in O
2 O
% O
of O
control-treated O
patients O
and O
2 O
% O
of O
SIMPONI-treated O
patients O
. O

Since O
many O
of O
the O
patients O
in O
the O
Phase O
3 O
trials O
for O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
, O
and O
AS B-Not_AE_Candidate
were O
also O
taking O
medications O
that O
cause O
liver B-NonOSE_AE
enzyme I-NonOSE_AE
elevations I-NonOSE_AE
( O
e.g. O
, O
NSAIDs O
, O
MTX O
) O
, O
the O
relationship O
between O
SIMPONI O
and O
liver B-NonOSE_AE
enzyme I-NonOSE_AE
elevation I-NonOSE_AE
is O
not O
clear O
. O

In O
Phase O
2/3 O
UC B-Not_AE_Candidate
trials O
, O
the O
incidence O
of O
ALT B-NonOSE_AE
elevations I-NonOSE_AE
> O
= O
5 O
* O
ULN O
was O
similar O
in O
SIMPONI-treated O
patients O
and O
placebo-treated O
patients O
, O
or O
approximately O
1 O
% O
, O
with O
an O
average O
duration O
of O
follow-up O
of O
46 O
weeks O
and O
18 O
weeks O
, O
respectively O
. O

ALT B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
> O
= O
3 O
* O
ULN O
occurred O
in O
2.0 O
% O
of O
SIMPONI-treated O
patients O
compared O
with O
1.5 O
% O
of O
placebo-treated O
patients O
with O
an O
average O
duration O
of O
follow-up O
of O
46 O
weeks O
and O
18 O
weeks O
, O
respectively O
. O

Autoimmune O
Disorders O
and O
Autoantibodies O
In O
the O
controlled O
Phase O
3 O
trials O
in O
patients O
with O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
, O
and O
AS B-Not_AE_Candidate
through O
Week O
14 O
, O
there O
was O
no O
association O
of O
SIMPONI O
treatment O
and O
the O
development O
of O
newly O
positive B-NonOSE_AE
anti I-NonOSE_AE
- I-NonOSE_AE
dsDNA I-NonOSE_AE
antibodies I-NonOSE_AE
. O

In O
Phase O
3 O
trials O
in O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
, O
and O
AS B-Not_AE_Candidate
through O
1 O
year O
of O
follow-up O
, O
4.0 O
% O
of O
SIMPONI-treated O
patients O
and O
2.6 O
% O
of O
control O
patients O
were O
newly O
antinuclear B-OSE_Labeled_AE
antibody I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ANA I-OSE_Labeled_AE
) I-OSE_Labeled_AE
- I-OSE_Labeled_AE
positive I-OSE_Labeled_AE
( O
at O
titers O
of O
1:160 O
or O
greater O
) O
. O

The O
frequency O
of O
anti B-NonOSE_AE
- I-NonOSE_AE
dsDNA I-NonOSE_AE
antibodies I-NonOSE_AE
at O
1 O
year O
of O
follow-up O
was O
uncommon O
in O
patients O
who O
were O
anti B-Not_AE_Candidate
- I-Not_AE_Candidate
dsDNA I-Not_AE_Candidate
negative I-Not_AE_Candidate
at O
baseline O
. O

Through O
Week O
60 O
of O
the O
UC B-Not_AE_Candidate
trials O
, O
3.5 O
% O
of O
patients O
who O
received O
SIMPONI O
induction O
and O
100 O
mg O
during O
maintenance O
were O
newly O
ANA B-OSE_Labeled_AE
- I-OSE_Labeled_AE
positive I-OSE_Labeled_AE
( O
at O
titers O
of O
1:160 O
or O
greater O
) O
compared O
with O
3.5 O
% O
of O
patients O
who O
received O
SIMPONI O
induction O
and O
placebo O
during O
the O
maintenance O
portion O
of O
the O
UC B-Not_AE_Candidate
trial O
. O

The O
frequency O
of O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
dsDNA I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
at O
1 O
year O
of O
follow-up O
in O
patients O
who O
were O
anti B-Not_AE_Candidate
- I-Not_AE_Candidate
dsDNA I-Not_AE_Candidate
negative I-Not_AE_Candidate
at O
baseline O
was O
0.5 O
% O
in O
patients O
receiving O
SIMPONI O
induction O
and O
100 O
mg O
during O
maintenance O
compared O
with O
0 O
% O
in O
patients O
who O
received O
SIMPONI O
induction O
and O
placebo O
during O
maintenance O
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
. O

Injection O
Site O
Reactions O
In O
controlled O
Phase O
3 O
trials O
through O
Week O
16 O
in O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
and O
AS B-Not_AE_Candidate
, O
6 O
% O
of O
SIMPONI-treated O
patients O
had O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
compared O
with O
2 O
% O
of O
control-treated O
patients O
. O

The O
majority O
of O
the O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
were O
mild O
and O
the O
most O
frequent O
manifestation O
was O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
erythema I-OSE_Labeled_AE
. O

In O
the O
controlled O
Phase O
2/3 O
trial O
through O
Week O
6 O
in O
UC B-Not_AE_Candidate
, O
3.4 O
% O
of O
SIMPONI-treated O
patients O
had O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
compared O
with O
1.5 O
% O
in O
control-treated O
patients O
. O

The O
majority O
of O
the O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
were O
mild O
and O
moderate O
and O
the O
most O
frequent O
manifestation O
was O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
erythema I-OSE_Labeled_AE
. O

In O
controlled O
Phase O
2 O
and O
3 O
trials O
in O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
, O
AS B-Not_AE_Candidate
, O
and O
Phase O
2/3 O
UC B-Not_AE_Candidate
trials O
, O
no O
patients O
treated O
with O
SIMPONI O
developed O
anaphylactic B-NonOSE_AE
reactions I-NonOSE_AE
. O

Immunogenicity O
Antibodies B-OSE_Labeled_AE
to I-OSE_Labeled_AE
SIMPONI I-OSE_Labeled_AE
were O
detected O
in O
57 O
( O
4 O
% O
) O
of O
SIMPONI-treated O
patients O
across O
the O
Phase O
3 O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
, O
and O
AS B-Not_AE_Candidate
trials O
through O
Week O
24 O
. O

Similar O
rates O
were O
observed O
in O
each O
of O
the O
3 O
indications O
. O

Patients O
who O
received O
SIMPONI O
with O
concomitant O
MTX O
had O
a O
lower O
proportion O
of O
antibodies B-OSE_Labeled_AE
to I-OSE_Labeled_AE
SIMPONI I-OSE_Labeled_AE
than O
patients O
who O
received O
SIMPONI O
without O
MTX O
( O
approximately O
2 O
% O
vs O
. O
7 O
% O
, O
respectively O
) O
. O

The O
presence O
of O
serum O
concentrations O
of O
golimumab O
can O
interfere O
with O
the O
detection O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
SIMPONI I-NonOSE_AE
leading O
to O
inconclusive O
results O
. O

In O
UC B-Not_AE_Candidate
trials O
, O
34 O
( O
3 O
% O
) O
, O
341 O
( O
28 O
% O
) O
and O
823 O
( O
69 O
% O
) O
of O
SIMPONI-treated O
subjects O
were O
positive B-OSE_Labeled_AE
, I-OSE_Labeled_AE
negative I-OSE_Labeled_AE
and I-OSE_Labeled_AE
inconclusive I-OSE_Labeled_AE
for I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
to I-OSE_Labeled_AE
SIMPONI I-OSE_Labeled_AE
, O
respectively O
. O

Treatment O
with O
concomitant O
immunomodulators O
( O
AZA O
, O
6-MP O
and O
MTX O
) O
resulted O
in O
a O
lower O
proportion O
of O
patients O
with O
antibodies B-OSE_Labeled_AE
to I-OSE_Labeled_AE
SIMPONI I-OSE_Labeled_AE
than O
patients O
receiving O
SIMPONI O
without O
immunomodulators O
( O
2 O
% O
vs O
. O
4 O
% O
, O
respectively O
) O
. O

Of O
the O
patients O
with O
a O
positive B-OSE_Labeled_AE
antibody I-OSE_Labeled_AE
response I-OSE_Labeled_AE
to I-OSE_Labeled_AE
SIMPONI I-OSE_Labeled_AE
in O
the O
Phase O
2 O
and O
3 O
trials O
, O
most O
were O
determined O
to O
have O
neutralizing B-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
to I-OSE_Labeled_AE
golimumab I-OSE_Labeled_AE
as O
measured O
by O
a O
cell-based O
functional O
assay O
. O

The O
small O
number O
of O
patients O
positive B-OSE_Labeled_AE
for I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
to I-OSE_Labeled_AE
SIMPONI I-OSE_Labeled_AE
limits O
the O
ability O
to O
draw O
definitive O
conclusions O
regarding O
the O
relationship O
between O
antibodies B-NonOSE_AE
to I-NonOSE_AE
golimumab I-NonOSE_AE
and O
clinical O
efficacy O
or O
safety O
measures O
. O

The O
data O
above O
reflect O
the O
percentage O
of O
patients O
whose O
test O
results O
were O
considered O
positive B-NonOSE_AE
for I-NonOSE_AE
antibodies I-NonOSE_AE
to I-NonOSE_AE
SIMPONI I-NonOSE_AE
in O
an O
ELISA O
assay O
, O
and O
are O
highly O
dependent O
on O
the O
sensitivity O
and O
specificity O
of O
the O
assay O
. O

Additionally O
, O
the O
observed O
incidence O
of O
antibody B-NonOSE_AE
positivity I-NonOSE_AE
in O
an O
assay O
may O
be O
influenced O
by O
several O
factors O
including O
sample O
handling O
, O
timing O
of O
sample O
collection O
, O
concomitant O
medications O
, O
and O
underlying O
disease O
. O

For O
these O
reasons O
, O
comparison O
of O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
SIMPONI I-NonOSE_AE
with O
the O
incidence O
of O
antibodies B-NonOSE_AE
to O
other O
products O
or O
results O
from O
different O
assays O
may O
be O
misleading O
. O

Other O
Adverse O
Reactions O
Table O
1 O
summarizes O
the O
adverse O
drug O
reactions O
that O
occurred O
at O
a O
rate O
of O
at O
least O
1 O
% O
in O
the O
SIMPONI O
+/- O
DMARD O
group O
and O
with O
a O
higher O
incidence O
than O
in O
the O
placebo O
+/- O
DMARD O
group O
during O
the O
controlled O
period O
of O
the O
5 O
pooled O
Phase O
3 O
trials O
through O
Week O
16 O
in O
patients O
with O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
, O
and O
AS B-Not_AE_Candidate
. O

Table O
1 O
: O
Adverse O
Drug O
Reactions O
Reported O
by O
> O
= O
1 O
% O
of O
SIMPONI-Treated O
Patients O
and O
With O
a O
Higher O
Incidence O
Than O
Placebo-Treated O
Patients O
in O
the O
Phase O
3 O
Trials O
of O
RA O
, O
PsA O
, O
and O
AS O
through O
Week O
16Patients O
may O
have O
taken O
concomitant O
MTX O
, O
sulfasalazine O
, O
hydroxychloroquine O
, O
low O
dose O
corticosteroids O
( O
< O
= O
10 O
mg O
of O
prednisone/day O
or O
equivalent O
) O
, O
and/or O
NSAIDs O
during O
the O
trials O
) O
. O

SIMPONI O
+/- O
DMARDs O
Placebo O
+/- O
DMARDs O
Patients O
treated O
1659 O
639 O
Adverse O
Reaction O
Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
nasopharyngitis B-OSE_Labeled_AE
, O
pharyngitis B-OSE_Labeled_AE
, O
laryngitis B-OSE_Labeled_AE
, O
and O
rhinitis B-OSE_Labeled_AE
) O
16 O
% O
13 O
% O
Viral B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
( O
such O
as O
influenza O
and O
herpes O
) O
5 O
% O
3 O
% O
Bronchitis B-OSE_Labeled_AE
2 O
% O
1 O
% O
Superficial B-OSE_Labeled_AE
fungal I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
2 O
% O
1 O
% O
Sinusitis B-OSE_Labeled_AE
2 O
% O
1 O
% O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
( O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
erythema I-OSE_Labeled_AE
, O
urticaria O
, O
induration O
, O
pain O
, O
bruising O
, O
pruritus O
, O
irritation O
, O
paresthesia O
) O
6 O
% O
2 O
% O
Investigations B-NonOSE_AE
Alanine B-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
4 O
% O
3 O
% O
Aspartate B-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
3 O
% O
2 O
% O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
3 O
% O
2 O
% O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Dizziness B-OSE_Labeled_AE
2 O
% O
1 O
% O
Paresthesia B-OSE_Labeled_AE
2 O
% O
1 O
% O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Constipation B-OSE_Labeled_AE
1 O
% O
< O
1 O
% O
Less O
Common O
Clinical O
Trial O
Adverse O
Drug O
Reactions O
Adverse O
drug O
reactions O
that O
occurred O
< O
1 O
% O
in O
SIMPONI-treated O
patients O
during O
the O
SIMPONI O
clinical O
trials O
that O
do O
not O
appear O
in O
the O
Warnings O
and O
Precautions O
section O
included O
the O
following O
events O
listed O
by O
system O
organ O
class O
: O
Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
: O
Septic B-OSE_Labeled_AE
shock I-OSE_Labeled_AE
, O
atypical B-OSE_Labeled_AE
mycobacterial I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
pyelonephritis B-OSE_Labeled_AE
, O
arthritis B-OSE_Labeled_AE
bacterial I-OSE_Labeled_AE
, O
bursitis B-OSE_Labeled_AE
infective I-OSE_Labeled_AE
Neoplasms B-NonOSE_AE
benign I-NonOSE_AE
, I-NonOSE_AE
malignant I-NonOSE_AE
and I-NonOSE_AE
unspecified I-NonOSE_AE
: O
Leukemia B-OSE_Labeled_AE
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
Psoriasis B-OSE_Labeled_AE
( O
new O
onset O
or O
worsening O
, O
palmar/plantar O
and O
pustular O
) O
, O
vasculitis B-OSE_Labeled_AE
( I-OSE_Labeled_AE
cutaneous I-OSE_Labeled_AE
) O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
: O
Vasculitis B-OSE_Labeled_AE
( I-OSE_Labeled_AE
systemic I-OSE_Labeled_AE
) O
Other O
Clinical O
Trial O
Adverse O
Drug O
Reactions O
in O
Ulcerative O
Colitis O
Clinical O
Trials O
In O
the O
Phase O
2/3 O
trials O
in O
UC B-Not_AE_Candidate
evaluating O
1233 O
SIMPONI-treated O
patients O
, O
no O
new O
adverse O
drug O
reactions O
were O
identified O
and O
the O
frequency O
of O
adverse O
drug O
reactions O
was O
similar O
to O
the O
safety O
profile O
observed O
in O
patients O
with O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
and O
AS B-Not_AE_Candidate
. O

6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
post-approval O
use O
of O
golimumab O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
SIMPONI O
exposure O
. O

Immune B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
Serious O
systemic B-OSE_Labeled_AE
hypersensitivity I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
including O
anaphylactic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.11 O
) O
] O
, O
sarcoidosis B-OSE_Labeled_AE
Neoplasms B-NonOSE_AE
benign I-NonOSE_AE
, I-NonOSE_AE
malignant I-NonOSE_AE
and I-NonOSE_AE
unspecified I-NonOSE_AE
: O
Melanoma B-OSE_Labeled_AE
, O
Merkel B-OSE_Labeled_AE
cell I-OSE_Labeled_AE
carcinoma I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
: O
Interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
Skin B-OSE_Labeled_AE
exfoliation I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
bullous B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE

BOXED O
WARNING O
: O
WARNING O
: O
SERIOUS O
INFECTIONS O
AND O
MALIGNANCY O
WARNING O
: O
SERIOUS O
INFECTIONS O
AND O
MALIGNANCY O
EXCERPT O
: O
WARNING O
: O
SERIOUS O
INFECTIONS O
AND O
MALIGNANCY O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
Serious O
infections O
leading O
to O
hospitalization O
or O
death O
including O
tuberculosis O
( O
TB O
) O
, O
bacterial O
sepsis O
, O
invasive O
fungal O
( O
such O
as O
histoplasmosis O
) O
, O
and O
other O
opportunistic O
infections O
have O
occurred O
in O
patients O
receiving O
SIMPONI O
( O
5.1 O
) O
* O
Discontinue O
SIMPONI O
if O
a O
patient O
develops O
a O
serious O
infection O
or O
sepsis O
( O
5.1 O
) O
* O
Perform O
test O
for O
latent O
TB O
; O
if O
positive O
, O
start O
treatment O
for O
TB O
prior O
to O
starting O
SIMPONI O
( O
5.1 O
) O
* O
Monitor O
all O
patients O
for O
active O
TB O
during O
treatment O
, O
even O
if O
initial O
latent O
TB O
test O
is O
negative O
( O
5.1 O
) O
* O
Lymphoma O
and O
other O
malignancies O
, O
some O
fatal O
, O
have O
been O
reported O
in O
children O
and O
adolescent O
patients O
treated O
with O
TNF O
blockers O
, O
of O
which O
SIMPONI O
is O
a O
member O
( O
5.2 O
) O
SERIOUS O
INFECTIONS O
Patients O
treated O
with O
SIMPONI O
( O
r O
) O
are O
at O
increased O
risk O
for O
developing O
serious O
infections B-OSE_Labeled_AE
that O
may O
lead O
to O
hospitalization O
or O
death B-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

Most O
patients O
who O
developed O
these O
infections B-NonOSE_AE
were O
taking O
concomitant O
immunosuppressants B-NonOSE_AE
such O
as O
methotrexate O
or O
corticosteroids O
. O

Discontinue O
SIMPONI O
if O
a O
patient O
develops O
a O
serious O
infection B-NonOSE_AE
. O

Reported O
infections B-OSE_Labeled_AE
with O
TNF O
blockers O
, O
of O
which O
SIMPONI O
is O
a O
member O
, O
include O
: O
* O
Active B-OSE_Labeled_AE
tuberculosis I-OSE_Labeled_AE
, O
including O
reactivation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
latent I-OSE_Labeled_AE
tuberculosis I-OSE_Labeled_AE
. O

Patients O
with O
tuberculosis B-OSE_Labeled_AE
have O
frequently O
presented O
with I-OSE_Labeled_AE
disseminated O
or O
extrapulmonary I-OSE_
Labeled B-OSE_Labeled_AE
_ I-OSE_Labeled_AE
AE I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
. O

Test O
patients O
for O
latent B-NonOSE_AE
tuberculosis I-NonOSE_AE
before O
SIMPONI O
use O
and O
during O
therapy O
. O

Initiate O
treatment O
for O
latent B-Not_AE_Candidate
TB I-Not_AE_Candidate
prior O
to O
SIMPONI O
use O
. O

* O
Invasive B-OSE_Labeled_AE
fungal I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
including O
histoplasmosis B-OSE_Labeled_AE
, O
coccidioidomycosis B-OSE_Labeled_AE
, O
candidiasis B-OSE_Labeled_AE
, O
aspergillosis B-OSE_Labeled_AE
, O
blastomycosis B-OSE_Labeled_AE
, O
and O
pneumocystosis B-OSE_Labeled_AE
. O

Patients O
with O
histoplasmosis B-OSE_Labeled_AE
or O
other O
invasive B-OSE_Labeled_AE
fungal I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
may O
present O
with O
disseminated O
, O
rather O
than O
localized O
, O
disease O
. O

Antigen B-NonOSE_AE
and O
antibody O
testing I-NonOSE_AE
for I-NonOSE_AE
histoplasmosis I-NonOSE_AE
may I-NonOSE_AE
be I-NonOSE_AE
negative I-NonOSE_AE
in O
some O
patients O
with O
active O
infection B-NonOSE_AE
. O

Consider O
empiric O
antifungal O
therapy O
in O
patients O
at O
risk O
for O
invasive B-NonOSE_AE
fungal I-NonOSE_AE
infections I-NonOSE_AE
who O
develop O
severe O
systemic B-NonOSE_AE
illness I-NonOSE_AE
. O

* O
Bacterial B-OSE_Labeled_AE
, O
viral O
, O
and O
other O
infections I-OSE_Labeled_AE
due I-OSE_Labeled_AE
to I-OSE_Labeled_AE
opportunistic I-OSE_Labeled_AE
pathogens I-OSE_Labeled_AE
, O
including O
Legionella B-OSE_Labeled_AE
and O
Listeria B-OSE_Labeled_AE
. O

Consider O
the O
risks O
and O
benefits O
of O
treatment O
with O
SIMPONI O
prior O
to O
initiating O
therapy O
in O
patients O
with O
chronic O
or O
recurrent O
infection B-NonOSE_AE
. O

Monitor O
patients O
closely O
for O
the O
development O
of O
signs O
and O
symptoms O
of O
infection B-NonOSE_AE
during O
and O
after O
treatment O
with O
SIMPONI O
, O
including O
the O
possible O
development O
of O
tuberculosis B-NonOSE_AE
in O
patients O
who O
tested B-Not_AE_Candidate
negative I-Not_AE_Candidate
for O
latent O
tuberculosis I-Not_AE_Candidate
infection I-Not_AE_Candidate
prior O
to O
initiating O
therapy O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

MALIGNANCY O
Lymphoma B-OSE_Labeled_AE
and O
other O
malignancies B-OSE_Labeled_AE
, O
some O
fatal B-NonOSE_AE
, O
have O
been O
reported O
in O
children O
and O
adolescent O
patients O
treated O
with O
TNF O
blockers O
, O
of O
which O
SIMPONI O
is O
a O
member O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Serious O
Infections O
: O
Do O
not O
start O
SIMPONI O
during O
an O
active O
infection O
. O

If O
an O
infection O
develops O
, O
monitor O
carefully O
, O
and O
stop O
SIMPONI O
if O
infection O
becomes O
serious O
( O
5.1 O
) O
* O
Invasive O
Fungal O
Infections O
: O
For O
patients O
who O
develop O
a O
systemic O
illness O
on O
SIMPONI O
, O
consider O
empiric O
antifungal O
therapy O
for O
those O
who O
reside O
in O
or O
travel O
to O
regions O
where O
mycoses O
are O
endemic O
( O
5.1 O
) O
* O
Hepatitis O
B O
Reactivation O
: O
Monitor O
HBV O
carriers O
during O
and O
several O
months O
after O
therapy O
. O

If O
reactivation O
occurs O
, O
stop O
SIMPONI O
and O
begin O
antiviral O
therapy O
( O
5.1 O
) O
* O
Malignancies O
: O
Incidence O
of O
lymphoma O
was O
greater O
than O
in O
the O
general O
U.S O
. O
population O
. O

Cases O
of O
other O
malignancies O
have O
been O
observed O
among O
patients O
receiving O
TNF O
blockers O
( O
5.2 O
) O
* O
Congestive O
Heart O
Failure O
: O
Worsening O
, O
or O
new O
onset O
, O
may O
occur O
. O

Stop O
SIMPONI O
if O
new O
or O
worsening O
symptoms O
occur O
( O
5.3 O
) O
* O
Demyelinating O
Disorders O
: O
Exacerbation O
or O
new O
onset O
may O
occur O
( O
5.4 O
) O
* O
Lupus-like O
Syndrome O
: O
Discontinue O
SIMPONI O
if O
symptoms O
develop O
( O
5.5 O
) O
* O
Hypersensitivity O
Reactions O
: O
Serious O
systemic O
hypersensitivity O
reactions O
including O
anaphylaxis O
may O
occur O
( O
5.11 O
) O
5.1 O
Serious O
Infections O
Patients O
treated O
with O
SIMPONI O
are O
at O
increased O
risk O
for O
developing O
serious O
infections B-OSE_Labeled_AE
involving O
various O
organ O
systems O
and O
sites O
that O
may O
lead O
to O
hospitalization O
or O
death B-NonOSE_AE
. O

Opportunistic B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
due I-OSE_Labeled_AE
to I-OSE_Labeled_AE
bacterial I-OSE_Labeled_AE
, O
mycobacterial O
, O
invasive O
fungal O
, O
viral O
, O
or O
parasitic O
organisms I-OSE_Labeled_AE
including O
aspergillosis B-OSE_Labeled_AE
, O
blastomycosis B-OSE_Labeled_AE
, O
candidiasis B-OSE_Labeled_AE
, O
coccidioidomycosis B-OSE_Labeled_AE
, O
histoplasmosis B-OSE_Labeled_AE
, O
legionellosis B-OSE_Labeled_AE
, O
listeriosis B-OSE_Labeled_AE
, O
pneumocystosis B-OSE_Labeled_AE
, O
and O
tuberculosis B-OSE_Labeled_AE
have O
been O
reported O
with O
TNF O
blockers O
. O

Patients O
have O
frequently O
presented O
with O
disseminated O
rather O
than O
localized O
disease O
. O

The O
concomitant O
use O
of O
a O
TNF O
blocker O
and O
abatacept O
or O
anakinra O
was O
associated O
with O
a O
higher O
risk O
of O
serious O
infections B-NonOSE_AE
; O
therefore O
, O
the O
concomitant O
use O
of O
SIMPONI O
and O
these O
biologic O
products O
is O
not O
recommended O
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
, O
5.7 O
) O
and O
Drug O
Interactions O
( O
7.2 O
) O
] O
. O

Treatment O
with O
SIMPONI O
should O
not O
be O
initiated O
in O
patients O
with O
an O
active B-Not_AE_Candidate
infection I-Not_AE_Candidate
, O
including O
clinically O
important O
localized B-Not_AE_Candidate
infections I-Not_AE_Candidate
. O

Patients O
greater O
than O
65 O
years O
of O
age O
, O
patients O
with O
co-morbid O
conditions O
and/or O
patients O
taking O
concomitant O
immunosuppressants B-NonOSE_AE
such O
as O
corticosteroids O
or O
methotrexate O
may O
be O
at O
greater O
risk O
of O
infection B-NonOSE_AE
. O

Consider O
the O
risks O
and O
benefits O
of O
treatment O
prior O
to O
initiating O
SIMPONI O
in O
patients O
: O
* O
with O
chronic O
or O
recurrent O
infection B-Not_AE_Candidate
; O
* O
who O
have O
been O
exposed B-Not_AE_Candidate
to I-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
; O
* O
with O
a O
history O
of O
an O
opportunistic B-Not_AE_Candidate
infection I-Not_AE_Candidate
; O
* O
who O
have O
resided O
or O
traveled O
in O
areas O
of O
endemic O
tuberculosis B-NonOSE_AE
or O
endemic O
mycoses B-NonOSE_AE
, O
such O
as O
histoplasmosis B-NonOSE_AE
, O
coccidioidomycosis B-NonOSE_AE
, O
or O
blastomycosis B-NonOSE_AE
; O
or O
* O
with O
underlying O
conditions O
that O
may O
predispose B-Not_AE_Candidate
them I-Not_AE_Candidate
to I-Not_AE_Candidate
infection I-Not_AE_Candidate
. O

Monitoring O
Closely O
monitor O
patients O
for O
the O
development O
of O
signs O
and O
symptoms O
of O
infection B-NonOSE_AE
during O
and O
after O
treatment O
with O
SIMPONI O
. O

Discontinue O
SIMPONI O
if O
a O
patient O
develops O
a O
serious O
infection B-NonOSE_AE
, O
an O
opportunistic B-NonOSE_AE
infection I-NonOSE_AE
, O
or O
sepsis B-NonOSE_AE
. O

For O
a O
patient O
who O
develops O
a O
new O
infection B-NonOSE_AE
during O
treatment O
with O
SIMPONI O
, O
perform O
a O
prompt O
and O
complete O
diagnostic O
workup O
appropriate O
for O
an O
immunocompromised B-NonOSE_AE
patient O
, O
initiate O
appropriate O
antimicrobial O
therapy O
, O
and O
closely O
monitor O
them O
. O

Serious O
Infection O
in O
Clinical O
Trials O
In O
controlled O
Phase O
3 O
trials O
through O
Week O
16 O
in O
patients O
with O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
, O
and O
AS B-Not_AE_Candidate
, O
serious O
infections B-OSE_Labeled_AE
were O
observed O
in O
1.4 O
% O
of O
SIMPONI-treated O
patients O
and O
1.3 O
% O
of O
control-treated O
patients O
. O

In O
the O
controlled O
Phase O
3 O
trials O
through O
Week O
16 O
in O
patients O
with O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
, O
and O
AS B-Not_AE_Candidate
, O
the O
incidence O
of O
serious O
infections B-OSE_Labeled_AE
per O
100 O
patient-years O
of O
follow-up O
was O
5.7 O
( O
95 O
% O
CI O
: O
3.8 O
, O
8.2 O
) O
for O
the O
SIMPONI O
group O
and O
4.2 O
( O
95 O
% O
CI O
: O
1.8 O
, O
8.2 O
) O
for O
the O
placebo O
group O
. O

In O
the O
controlled O
Phase O
2/3 O
trial O
through O
Week O
6 O
of O
SIMPONI O
induction O
in O
UC B-Not_AE_Candidate
, O
the O
incidence O
of O
serious O
infections B-OSE_Labeled_AE
in O
SIMPONI O
200/100 O
mg-treated O
patients O
was O
similar O
to O
the O
incidence O
of O
serious O
infections B-OSE_Labeled_AE
in O
placebo-treated O
patients O
. O

Through O
Week O
60 O
, O
the O
incidence O
of O
serious O
infections B-OSE_Labeled_AE
was O
similar O
in O
patients O
who O
received O
SIMPONI O
induction O
and O
100 O
mg O
during O
maintenance O
compared O
with O
patients O
who O
received O
SIMPONI O
induction O
and O
placebo O
during O
the O
maintenance O
portion O
of O
the O
UC B-Not_AE_Candidate
trial O
. O

Serious O
infections B-OSE_Labeled_AE
observed O
in O
SIMPONI-treated O
patients O
included O
sepsis B-OSE_Labeled_AE
, O
pneumonia B-OSE_Labeled_AE
, O
cellulitis B-OSE_Labeled_AE
, O
abscess B-OSE_Labeled_AE
, O
tuberculosis B-OSE_Labeled_AE
, O
invasive B-OSE_Labeled_AE
fungal I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
and O
hepatitis B-OSE_Labeled_AE
B I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
. O

Tuberculosis O
Cases O
of O
reactivation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
tuberculosis I-OSE_Labeled_AE
or O
new O
tuberculosis B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
have O
been O
observed O
in O
patients O
receiving O
TNF O
blockers O
, O
including O
patients O
who O
have O
previously O
received O
treatment O
for O
latent B-Not_AE_Candidate
or O
active O
tuberculosis I-Not_AE_Candidate
. O

Evaluate O
patients O
for O
tuberculosis B-NonOSE_AE
risk O
factors O
and O
test O
for O
latent B-NonOSE_AE
infection I-NonOSE_AE
prior O
to O
initiating O
SIMPONI O
and O
periodically O
during O
therapy O
. O

Treatment O
of O
latent B-NonOSE_AE
tuberculosis I-NonOSE_AE
infection I-NonOSE_AE
prior O
to O
therapy O
with O
TNF O
blockers O
has O
been O
shown O
to O
reduce O
the O
risk O
of O
tuberculosis B-NonOSE_AE
reactivation I-NonOSE_AE
during O
therapy O
. O

Prior O
to O
initiating O
SIMPONI O
, O
assess O
if O
treatment O
for O
latent B-NonOSE_AE
tuberculosis I-NonOSE_AE
is O
needed O
; O
an O
induration O
of O
5 O
mm O
or O
greater O
is O
a O
positive B-NonOSE_AE
tuberculin I-NonOSE_AE
skin I-NonOSE_AE
test I-NonOSE_AE
, O
even O
for O
patients O
previously O
vaccinated O
with O
Bacille B-NonOSE_AE
Calmette I-NonOSE_AE
- I-NonOSE_AE
Guerin I-NonOSE_AE
( I-NonOSE_AE
BCG I-NonOSE_AE
) O
. O

Consider O
anti B-NonOSE_AE
- I-NonOSE_AE
tuberculosis I-NonOSE_AE
therapy O
prior O
to O
initiation O
of O
SIMPONI O
in O
patients O
with O
a O
past O
history O
of O
latent B-Not_AE_Candidate
or O
active O
tuberculosis I-Not_AE_Candidate
in O
whom O
an O
adequate O
course O
of O
treatment O
can O
not O
be O
confirmed O
, O
and O
for O
patients O
with O
a O
negative B-Not_AE_Candidate
test I-Not_AE_Candidate
for I-Not_AE_Candidate
latent I-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
but O
having O
risk O
factors O
for O
tuberculosis B-Not_AE_Candidate
infection I-Not_AE_Candidate
. O

Consultation O
with O
a O
physician O
with O
expertise O
in O
the O
treatment O
of O
tuberculosis B-NonOSE_AE
is O
recommended O
to O
aid O
in O
the O
decision O
whether O
initiating O
anti B-NonOSE_AE
- I-NonOSE_AE
tuberculosis I-NonOSE_AE
therapy O
is O
appropriate O
for O
an O
individual O
patient O
. O

Cases O
of O
active B-OSE_Labeled_AE
tuberculosis I-OSE_Labeled_AE
have O
occurred O
in O
patients O
treated O
with O
SIMPONI O
during O
and O
after O
treatment O
for O
latent B-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
. O

Monitor O
patients O
for O
the O
development O
of O
signs O
and O
symptoms O
of O
tuberculosis B-NonOSE_AE
including O
patients O
who O
tested O
negative B-NonOSE_AE
for I-NonOSE_AE
latent I-NonOSE_AE
tuberculosis I-NonOSE_AE
infection I-NonOSE_AE
prior O
to O
initiating O
therapy O
, O
patients O
who O
are O
on O
treatment O
for O
latent B-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
, O
or O
patients O
who O
were O
previously O
treated O
for O
tuberculosis B-Not_AE_Candidate
infection I-Not_AE_Candidate
. O

Consider O
tuberculosis B-NonOSE_AE
in O
the O
differential O
diagnosis O
in O
patients O
who O
develop O
a O
new O
infection B-NonOSE_AE
during O
SIMPONI O
treatment O
, O
especially O
in O
patients O
who O
have O
previously O
or O
recently O
traveled O
to O
countries O
with O
a O
high O
prevalence O
of O
tuberculosis B-NonOSE_AE
, O
or O
who O
have O
had O
close O
contact O
with O
a O
person O
with O
active B-NonOSE_AE
tuberculosis I-NonOSE_AE
. O

In O
the O
controlled O
and O
uncontrolled O
portions O
of O
the O
Phase O
2 O
RA B-Not_AE_Candidate
and O
Phase O
3 O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
, O
and O
AS B-Not_AE_Candidate
trials O
, O
the O
incidence O
of O
active B-OSE_Labeled_AE
TB I-OSE_Labeled_AE
was O
0.23 O
and O
0 O
per O
100 O
patient-years O
in O
2347 O
SIMPONI-treated O
patients O
and O
674 O
placebo-treated O
patients O
, O
respectively O
. O

Cases O
of O
TB B-OSE_Labeled_AE
included O
pulmonary B-OSE_Labeled_AE
and O
extrapulmonary O
TB I-OSE_Labeled_AE
. O

The O
overwhelming O
majority O
of O
the O
TB B-NonOSE_AE
cases O
occurred O
in O
countries O
with O
a O
high O
incidence O
rate O
of O
TB B-NonOSE_AE
. O

In O
the O
controlled O
Phase O
2/3 O
trial O
of O
SIMPONI O
induction O
through O
Week O
6 O
in O
UC B-Not_AE_Candidate
, O
no O
cases O
of O
TB B-NonOSE_AE
were O
observed O
in O
SIMPONI O
200/100 O
mg-treated O
patients O
or O
in O
placebo-treated O
patients O
. O

Through O
Week O
60 O
, O
the O
incidence O
per O
100 O
patient-years O
of O
TB B-OSE_Labeled_AE
in O
patients O
who O
received O
SIMPONI O
induction O
and O
100 O
mg O
during O
the O
maintenance O
portion O
of O
the O
UC B-Not_AE_Candidate
trial O
was O
0.52 O
( O
95 O
% O
CI O
: O
0.11 O
, O
1.53 O
) O
. O

One O
case O
of O
TB B-OSE_Labeled_AE
was O
observed O
in O
the O
placebo O
maintenance O
group O
in O
a O
patient O
who O
received O
SIMPONI O
intravenous O
( O
IV O
) O
induction O
. O

Invasive B-OSE_Labeled_AE
Fungal I-OSE_Labeled_AE
Infections I-OSE_Labeled_AE
If O
patients O
develop O
a O
serious O
systemic B-NonOSE_AE
illness I-NonOSE_AE
and O
they O
reside O
or O
travel O
in O
regions O
where O
mycoses B-NonOSE_AE
are O
endemic O
, O
consider O
invasive B-NonOSE_AE
fungal I-NonOSE_AE
infection I-NonOSE_AE
in O
the O
differential O
diagnosis O
. O

Consider O
appropriate O
empiric O
antifungal O
therapy O
, O
and O
take O
into O
account O
both O
the O
risk O
for O
severe O
fungal B-NonOSE_AE
infection I-NonOSE_AE
and O
the O
risks O
of O
antifungal O
therapy O
while O
a O
diagnostic O
workup O
is O
being O
performed O
. O

Antigen B-NonOSE_AE
and O
antibody O
testing I-NonOSE_AE
for I-NonOSE_AE
histoplasmosis I-NonOSE_AE
may I-NonOSE_AE
be I-NonOSE_AE
negative I-NonOSE_AE
in O
some O
patients O
with O
active B-NonOSE_AE
infection I-NonOSE_AE
. O

To O
aid O
in O
the O
management O
of O
such O
patients O
, O
consider O
consultation O
with O
a O
physician O
with O
expertise O
in O
the O
diagnosis O
and O
treatment O
of O
invasive B-NonOSE_AE
fungal I-NonOSE_AE
infections I-NonOSE_AE
. O

Hepatitis O
B O
Virus O
Reactivation O
The O
use O
of O
TNF O
blockers O
including O
SIMPONI O
has O
been O
associated O
with O
reactivation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
B I-OSE_Labeled_AE
virus I-OSE_Labeled_AE
( I-OSE_Labeled_AE
HBV I-OSE_Labeled_AE
) O
in O
patients O
who O
are O
chronic B-Not_AE_Candidate
hepatitis I-Not_AE_Candidate
B I-Not_AE_Candidate
carriers I-Not_AE_Candidate
( I-Not_AE_Candidate
i I-Not_AE_Candidate
. I-Not_AE_Candidate
e I-Not_AE_Candidate
. I-Not_AE_Candidate
, I-Not_AE_Candidate
surface I-Not_AE_Candidate
antigen I-Not_AE_Candidate
positive I-Not_AE_Candidate
) O
. O

In O
some O
instances O
, O
HBV B-NonOSE_AE
reactivation I-NonOSE_AE
occurring O
in O
conjunction O
with O
TNF O
blocker O
therapy O
has O
been O
fatal B-NonOSE_AE
. O

The O
majority O
of O
these O
reports O
have O
occurred O
in O
patients O
who O
received O
concomitant O
immunosuppressants B-NonOSE_AE
. O

All O
patients O
should O
be O
tested O
for O
HBV B-NonOSE_AE
infection I-NonOSE_AE
before O
initiating O
TNF-blocker O
therapy O
. O

For O
patients O
who O
test O
positive B-NonOSE_AE
for I-NonOSE_AE
hepatitis I-NonOSE_AE
B I-NonOSE_AE
surface I-NonOSE_AE
antigen I-NonOSE_AE
, O
consultation O
with O
a O
physician O
with O
expertise O
in O
the O
treatment O
of O
hepatitis B-NonOSE_AE
B I-NonOSE_AE
is O
recommended O
before O
initiating O
TNF-blocker O
therapy O
. O

The O
risks O
and O
benefits O
of O
treatment O
should O
be O
considered O
prior O
to O
prescribing O
TNF O
blockers O
, O
including O
SIMPONI O
, O
to O
patients O
who O
are O
carriers B-Not_AE_Candidate
of I-Not_AE_Candidate
HBV I-Not_AE_Candidate
. O

Adequate O
data O
are O
not O
available O
on O
whether O
antiviral O
therapy O
can O
reduce O
the O
risk O
of O
HBV B-NonOSE_AE
reactivation I-NonOSE_AE
in O
HBV B-Not_AE_Candidate
carriers I-Not_AE_Candidate
who O
are O
treated O
with O
TNF O
blockers O
. O

Patients O
who O
are O
carriers B-Not_AE_Candidate
of I-Not_AE_Candidate
HBV I-Not_AE_Candidate
and O
require O
treatment O
with O
TNF O
blockers O
should O
be O
closely O
monitored O
for O
clinical O
and O
laboratory O
signs O
of O
active O
HBV B-NonOSE_AE
infection I-NonOSE_AE
throughout O
therapy O
and O
for O
several O
months O
following O
termination O
of O
therapy O
. O

In O
patients O
who O
develop O
HBV B-NonOSE_AE
reactivation I-NonOSE_AE
, O
TNF O
blockers O
should O
be O
stopped O
and O
antiviral O
therapy O
with O
appropriate O
supportive O
treatment O
should O
be O
initiated O
. O

The O
safety O
of O
resuming O
TNF O
blockers O
after O
HBV B-NonOSE_AE
reactivation I-NonOSE_AE
has O
been O
controlled O
is O
not O
known O
. O

Therefore O
, O
prescribers O
should O
exercise O
caution O
when O
considering O
resumption O
of O
TNF O
blockers O
in O
this O
situation O
and O
monitor O
patients O
closely O
. O

5.2 O
Malignancies O
Malignancies B-OSE_Labeled_AE
, O
some O
fatal B-NonOSE_AE
, O
have O
been O
reported O
among O
children O
, O
adolescents O
, O
and O
young O
adults O
who O
received O
treatment O
with O
TNF-blocking O
agents O
( O
initiation O
of O
therapy O
< O
= O
18 O
years O
of O
age O
) O
, O
of O
which O
SIMPONI O
is O
a O
member O
. O

Approximately O
half O
the O
cases O
were O
lymphomas B-OSE_Labeled_AE
, O
including O
Hodgkin B-OSE_Labeled_AE
' I-OSE_Labeled_AE
s I-OSE_Labeled_AE
and O
non-Hodgkin O
's O
lymphoma I-OSE_Labeled_AE
. O

The O
other O
cases O
represented O
a O
variety O
of O
malignancies B-OSE_Labeled_AE
, O
including O
rare O
malignancies B-OSE_Labeled_AE
that O
are O
usually O
associated O
with O
immunosuppression B-NonOSE_AE
, O
and O
malignancies B-OSE_Labeled_AE
that O
are O
not O
usually O
observed O
in O
children O
and O
adolescents O
. O

The O
malignancies B-OSE_Labeled_AE
occurred O
after O
a O
median O
of O
30 O
months O
( O
range O
1 O
to O
84 O
months O
) O
after O
the O
first O
dose O
of O
TNF-blocker O
therapy O
. O

Most O
of O
the O
patients O
were O
receiving O
concomitant O
immunosuppressants B-NonOSE_AE
. O

These O
cases O
were O
reported O
postmarketing O
and O
are O
derived O
from O
a O
variety O
of O
sources O
, O
including O
registries O
and O
spontaneous O
postmarketing O
reports O
. O

The O
risks O
and O
benefits O
of O
TNF-blocker O
treatment O
, O
including O
SIMPONI O
, O
should O
be O
considered O
prior O
to O
initiating O
therapy O
in O
patients O
with O
a O
known O
malignancy B-Not_AE_Candidate
other O
than O
a O
successfully O
treated O
nonmelanoma B-Not_AE_Candidate
skin I-Not_AE_Candidate
cancer I-Not_AE_Candidate
( I-Not_AE_Candidate
NMSC I-Not_AE_Candidate
) O
or O
when O
considering O
continuing O
a O
TNF-blocker O
in O
patients O
who O
develop O
a O
malignancy B-NonOSE_AE
. O

In O
the O
controlled O
portions O
of O
clinical O
trials O
of O
TNF O
blockers O
, O
including O
SIMPONI O
, O
more O
cases O
of O
lymphoma B-OSE_Labeled_AE
have O
been O
observed O
among O
patients O
receiving O
anti-TNF O
treatment O
compared O
with O
patients O
in O
the O
control O
groups O
. O

During O
the O
controlled O
portions O
of O
the O
Phase O
2 O
trials O
in O
RA B-Not_AE_Candidate
, O
and O
the O
Phase O
3 O
trials O
in O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
and O
AS B-Not_AE_Candidate
, O
the O
incidence O
of O
lymphoma B-OSE_Labeled_AE
per O
100 O
patient-years O
of O
follow-up O
was O
0.21 O
( O
95 O
% O
CI O
: O
0.03 O
, O
0.77 O
) O
in O
the O
combined O
SIMPONI O
group O
compared O
with O
an O
incidence O
of O
0 O
( O
95 O
% O
CI O
: O
0 O
, O
0.96 O
) O
in O
the O
placebo O
group O
. O

In O
the O
controlled O
and O
uncontrolled O
portions O
of O
these O
clinical O
trials O
in O
2347 O
SIMPONI-treated O
patients O
with O
a O
median O
follow-up O
of O
1.4 O
years O
, O
the O
incidence O
of O
lymphoma B-OSE_Labeled_AE
was O
3.8-fold O
higher O
than O
expected O
in O
the O
general O
U.S O
. O
population O
according O
to O
the O
SEER O
database O
( O
adjusted O
for O
age O
, O
gender O
, O
and O
race O
) O
. O

1 O
Through O
Week O
60 O
of O
the O
UC B-Not_AE_Candidate
trials O
, O
there O
were O
no O
cases O
of O
lymphoma B-NonOSE_AE
with O
SIMPONI O
. O

Patients O
with O
RA B-Not_AE_Candidate
and O
other O
chronic B-Not_AE_Candidate
inflammatory I-Not_AE_Candidate
diseases I-Not_AE_Candidate
, O
particularly O
patients O
with O
highly O
active O
disease O
and/or O
chronic O
exposure O
to O
immunosuppressant B-NonOSE_AE
therapies I-NonOSE_AE
, O
may O
be O
at O
higher O
risk O
( O
up O
to O
several O
fold O
) O
than O
the O
general O
population O
for O
the O
development O
of O
lymphoma B-NonOSE_AE
, O
even O
in O
the O
absence O
of O
TNF-blocking O
therapy O
. O

Cases O
of O
acute B-OSE_Labeled_AE
and O
chronic O
leukemia I-OSE_Labeled_AE
have O
been O
reported O
with O
TNF-blocker O
use O
, O
including O
SIMPONI O
, O
in O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
and O
other O
indications O
. O

Even O
in O
the O
absence O
of O
TNF-blocker O
therapy O
, O
patients O
with O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
may O
be O
at O
a O
higher O
risk O
( O
approximately O
2-fold O
) O
than O
the O
general O
population O
for O
the O
development O
of O
leukemia B-NonOSE_AE
. O

Rare O
postmarketing O
cases O
of O
hepatosplenic B-OSE_Labeled_AE
T I-OSE_Labeled_AE
- I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
lymphoma I-OSE_Labeled_AE
( I-OSE_Labeled_AE
HSTCL I-OSE_Labeled_AE
) O
have O
been O
reported O
in O
patients O
treated O
with O
TNF-blocking O
agents O
. O

This O
rare O
type O
of O
T B-NonOSE_AE
- I-NonOSE_AE
cell I-NonOSE_AE
lymphoma I-NonOSE_AE
has O
a O
very O
aggressive O
disease O
course O
and O
is O
usually O
fatal B-NonOSE_AE
. O

Nearly O
all O
of O
the O
reported O
TNF O
blocker O
associated O
cases O
have O
occurred O
in O
patients O
with O
Crohn B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
disease I-Not_AE_Candidate
or O
ulcerative B-Not_AE_Candidate
colitis I-Not_AE_Candidate
. O

The O
majority O
were O
in O
adolescent O
and O
young O
adult O
males O
. O

Almost O
all O
these O
patients O
had O
received O
treatment O
with O
azathioprine O
( O
AZA O
) O
or O
6-mercaptopurine O
( O
6-MP O
) O
concomitantly O
with O
a O
TNF O
blocker O
at O
or O
prior O
to O
diagnosis O
. O

The O
potential O
risk O
with O
the O
combination O
of O
AZA O
or O
6-MP O
and O
SIMPONI O
should O
be O
carefully O
considered O
. O

A O
risk O
for O
the O
development O
for O
hepatosplenic B-NonOSE_AE
T I-NonOSE_AE
- I-NonOSE_AE
cell I-NonOSE_AE
lymphoma I-NonOSE_AE
in O
patients O
treated O
with O
TNF O
blockers O
can O
not O
be O
excluded O
. O

During O
the O
controlled O
portions O
of O
the O
Phase O
2 O
trial O
in O
RA B-Not_AE_Candidate
, O
and O
the O
Phase O
3 O
trials O
in O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
and O
AS B-Not_AE_Candidate
, O
the O
incidence O
of O
malignancies B-NonOSE_AE
other O
than O
lymphoma B-NonOSE_AE
per O
100 O
patient-years O
of O
follow-up O
was O
not O
elevated O
in O
the O
combined O
SIMPONI O
group O
compared O
with O
the O
placebo O
group O
. O

In O
the O
controlled O
and O
uncontrolled O
portions O
of O
these O
trials O
, O
the O
incidence O
of O
malignancies B-NonOSE_AE
, O
other O
than O
lymphoma B-NonOSE_AE
, O
in O
SIMPONI-treated O
patients O
was O
similar O
to O
that O
expected O
in O
the O
general O
U.S O
. O
population O
according O
to O
the O
SEER O
database O
( O
adjusted O
for O
age O
, O
gender O
, O
and O
race O
) O
. O

1 O
In O
the O
6-week O
placebo-controlled O
portions O
of O
the O
SIMPONI O
Phase O
2/3 O
clinical O
trials O
in O
UC B-Not_AE_Candidate
, O
the O
incidence O
of O
non B-NonOSE_AE
- I-NonOSE_AE
lymphoma I-NonOSE_AE
malignancies I-NonOSE_AE
( O
excluding O
nonmelanoma B-NonOSE_AE
skin I-NonOSE_AE
cancer I-NonOSE_AE
) O
was O
similar O
between O
the O
SIMPONI O
and O
the O
placebo O
group O
. O

Through O
Week O
60 O
, O
the O
incidence O
of O
non B-NonOSE_AE
- I-NonOSE_AE
lymphoma I-NonOSE_AE
malignancies I-NonOSE_AE
( O
excluding O
nonmelanoma B-NonOSE_AE
skin I-NonOSE_AE
cancer I-NonOSE_AE
) O
was O
similar O
to O
the O
general O
U.S O
. O
population O
according O
to O
the O
SEER O
database O
( O
adjusted O
for O
age O
, O
gender O
, O
and O
race O
) O
. O

1 O
Short O
follow-up O
periods O
, O
such O
as O
those O
of O
one O
year O
or O
less O
in O
the O
studies O
above O
, O
may O
not O
adequately O
reflect O
the O
true O
incidence O
of O
malignancies B-NonOSE_AE
. O

It O
is O
not O
known O
if O
SIMPONI O
treatment O
influences O
the O
risk O
for O
developing O
dysplasia B-NonOSE_AE
or O
colon B-NonOSE_AE
cancer I-NonOSE_AE
. O

All O
patients O
with O
ulcerative B-Not_AE_Candidate
colitis I-Not_AE_Candidate
who O
are O
at O
increased O
risk O
for O
dysplasia B-NonOSE_AE
or O
colon B-NonOSE_AE
carcinoma I-NonOSE_AE
( O
for O
example O
, O
patients O
with O
long-standing O
ulcerative B-Not_AE_Candidate
colitis I-Not_AE_Candidate
or O
primary B-Not_AE_Candidate
sclerosing I-Not_AE_Candidate
cholangitis I-Not_AE_Candidate
) O
, O
or O
who O
had O
a O
prior O
history O
of O
dysplasia B-Not_AE_Candidate
or O
colon B-Not_AE_Candidate
carcinoma I-Not_AE_Candidate
should O
be O
screened O
for O
dysplasia B-NonOSE_AE
at O
regular O
intervals O
before O
therapy O
and O
throughout O
their O
disease O
course O
. O

This O
evaluation O
should O
include O
colonoscopy O
and O
biopsies O
per O
local O
recommendations O
. O

In O
patients O
with O
newly O
diagnosed O
dysplasia B-NonOSE_AE
treated O
with O
SIMPONI O
, O
the O
risks O
and O
benefits O
to O
the O
individual O
patient O
must O
be O
carefully O
reviewed O
and O
consideration O
should O
be O
given O
to O
whether O
therapy O
should O
be O
continued O
. O

Melanoma B-OSE_Labeled_AE
and O
Merkel B-OSE_Labeled_AE
cell I-OSE_Labeled_AE
carcinoma I-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
treated O
with O
TNF-blocking O
agents O
, O
including O
SIMPONI O
. O

Periodic O
skin O
examination O
is O
recommended O
for O
all O
patients O
, O
particularly O
those O
with O
risk O
factors O
for O
skin B-NonOSE_AE
cancer I-NonOSE_AE
. O

In O
controlled O
trials O
of O
other O
TNF O
blockers O
in O
patients O
at O
higher O
risk O
for O
malignancies B-NonOSE_AE
( O
e.g. O
, O
patients O
with O
chronic B-Not_AE_Candidate
obstructive I-Not_AE_Candidate
pulmonary I-Not_AE_Candidate
disease I-Not_AE_Candidate
[ I-Not_AE_Candidate
COPD I-Not_AE_Candidate
] O
, O
patients O
with O
Wegener B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
granulomatosis I-Not_AE_Candidate
treated O
with O
concomitant O
cyclophosphamide O
) O
a O
greater O
portion O
of O
malignancies B-NonOSE_AE
occurred O
in O
the O
TNF-blocker O
group O
compared O
to O
the O
controlled O
group O
. O

In O
an O
exploratory O
1-year O
clinical O
trial O
evaluating O
the O
use O
of O
50 O
mg O
, O
100 O
mg O
, O
and O
200 O
mg O
of O
SIMPONI O
in O
309 O
patients O
with O
severe O
persistent O
asthma B-Not_AE_Candidate
, O
6 O
patients O
developed O
malignancies B-OSE_Labeled_AE
other O
than O
NMSC B-NonOSE_AE
in O
the O
SIMPONI O
groups O
compared O
to O
none O
in O
the O
control O
group O
. O

Three O
of O
the O
6 O
patients O
were O
in O
the O
200-mg O
SIMPONI O
group O
. O

5.3 O
Congestive O
Heart O
Failure O
Cases O
of O
worsening B-OSE_Labeled_AE
congestive I-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
( I-OSE_Labeled_AE
CHF I-OSE_Labeled_AE
) O
and O
new O
onset O
CHF B-OSE_Labeled_AE
have O
been O
reported O
with O
TNF O
blockers O
, O
including O
SIMPONI O
. O

Some O
cases O
had O
a O
fatal B-NonOSE_AE
outcome O
. O

In O
several O
exploratory O
trials O
of O
other O
TNF O
blockers O
in O
the O
treatment O
of O
CHF B-NonOSE_AE
, O
there O
were O
greater O
proportions O
of O
TNF-blocker-treated O
patients O
who O
had O
CHF B-NonOSE_AE
exacerbations I-NonOSE_AE
requiring O
hospitalization O
or O
increased O
mortality B-NonOSE_AE
. O

SIMPONI O
has O
not O
been O
studied O
in O
patients O
with O
a O
history O
of O
CHF B-Not_AE_Candidate
and O
SIMPONI O
should O
be O
used O
with O
caution O
in O
patients O
with O
CHF B-Not_AE_Candidate
. O

If O
a O
decision O
is O
made O
to O
administer O
SIMPONI O
to O
patients O
with O
CHF B-Not_AE_Candidate
, O
these O
patients O
should O
be O
closely O
monitored O
during O
therapy O
, O
and O
SIMPONI O
should O
be O
discontinued O
if O
new O
or O
worsening O
symptoms O
of O
CHF B-NonOSE_AE
appear O
. O

5.4 O
Demyelinating O
Disorders O
Use O
of O
TNF O
blockers O
, O
of O
which O
SIMPONI O
is O
a O
member O
, O
has O
been O
associated O
with O
rare O
cases O
of O
new O
onset O
or O
exacerbation O
of O
central B-OSE_Labeled_AE
nervous I-OSE_Labeled_AE
system I-OSE_Labeled_AE
( I-OSE_Labeled_AE
CNS I-OSE_Labeled_AE
) I-OSE_Labeled_AE
demyelinating I-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
, O
including O
multiple B-OSE_Labeled_AE
sclerosis I-OSE_Labeled_AE
( I-OSE_Labeled_AE
MS I-OSE_Labeled_AE
) O
and O
peripheral B-OSE_Labeled_AE
demyelinating I-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
, O
including O
Guillain B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Barre I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
. O

Cases O
of O
central B-OSE_Labeled_AE
demyelination I-OSE_Labeled_AE
, O
MS B-OSE_Labeled_AE
, O
optic B-OSE_Labeled_AE
neuritis I-OSE_Labeled_AE
, O
and O
peripheral B-OSE_Labeled_AE
demyelinating I-OSE_Labeled_AE
polyneuropathy I-OSE_Labeled_AE
have O
rarely O
been O
reported O
in O
patients O
treated O
with O
SIMPONI O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Prescribers O
should O
exercise O
caution O
in O
considering O
the O
use O
of O
TNF O
blockers O
, O
including O
SIMPONI O
, O
in O
patients O
with O
central B-Not_AE_Candidate
or O
peripheral O
nervous I-Not_AE_Candidate
system I-Not_AE_Candidate
demyelinating I-Not_AE_Candidate
disorders I-Not_AE_Candidate
. O

Discontinuation O
of O
SIMPONI O
should O
be O
considered O
if O
these O
disorders O
develop O
. O

5.5 O
Autoimmunity B-OSE_Labeled_AE
Treatment O
with O
TNF O
blockers O
, O
including O
SIMPONI O
, O
may O
result O
in O
the O
formation O
of O
antinuclear B-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ANA I-OSE_Labeled_AE
) O
and O
, O
rarely O
, O
in O
the O
development O
of O
a O
lupus B-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

If O
a O
patient O
develops O
symptoms O
suggestive O
of O
a O
lupus B-NonOSE_AE
- I-NonOSE_AE
like I-NonOSE_AE
syndrome I-NonOSE_AE
following O
treatment O
with O
SIMPONI O
, O
treatment O
should O
be O
discontinued O
. O

5.6 O
Use O
with O
Abatacept O
In O
controlled O
trials O
, O
the O
concurrent O
administration O
of O
another O
TNF O
blocker O
and O
abatacept O
was O
associated O
with O
a O
greater O
proportion O
of O
serious O
infections B-NonOSE_AE
than O
the O
use O
of O
a O
TNF O
blocker O
alone O
; O
and O
the O
combination O
therapy O
, O
compared O
to O
the O
use O
of O
a O
TNF O
blocker O
alone O
, O
has O
not O
demonstrated O
improved O
clinical O
benefit O
in O
the O
treatment O
of O
RA B-Not_AE_Candidate
. O

Therefore O
, O
the O
combination O
of O
TNF O
blockers O
, O
including O
SIMPONI O
, O
and O
abatacept O
is O
not O
recommended O
[ O
see O
Drug O
Interactions O
( O
7.2 O
) O
] O
. O

5.7 O
Use O
with O
Anakinra O
Concurrent O
administration O
of O
anakinra O
( O
an O
interleukin-1 O
antagonist O
) O
and O
another O
TNF O
blocker O
was O
associated O
with O
a O
greater O
portion O
of O
serious O
infections B-NonOSE_AE
and O
neutropenia B-NonOSE_AE
and O
no O
additional O
benefits O
compared O
with O
the O
TNF-blocker O
alone O
. O

Therefore O
, O
the O
combination O
of O
anakinra O
with O
TNF O
blockers O
, O
including O
SIMPONI O
, O
is O
not O
recommended O
[ O
see O
Drug O
Interactions O
( O
7.2 O
) O
] O
. O

5.8 O
Switching O
Between O
Biological O
Disease-Modifying O
Antirheumatic O
Drugs O
Care O
should O
be O
taken O
when O
switching O
from O
one O
biological O
product O
to O
another O
biological O
product O
since O
overlapping O
biological O
activity O
may O
further O
increase O
the O
risk O
of O
infection B-NonOSE_AE
. O

5.9 O
Hematologic B-OSE_Labeled_AE
Cytopenias I-OSE_Labeled_AE
There O
have O
been O
postmarketing O
reports O
of O
pancytopenia B-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
aplastic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
, O
and O
thrombocytopenia B-OSE_Labeled_AE
in O
patients O
receiving O
TNF O
blockers O
. O

In O
clinical O
trials O
, O
cases O
of O
pancytopenia B-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
and O
thrombocytopenia B-OSE_Labeled_AE
have O
also O
occurred O
in O
SIMPONI-treated O
patients O
. O

Caution O
should O
be O
exercised O
when O
using O
TNF O
blockers O
, O
including O
SIMPONI O
, O
in O
patients O
who O
have O
or O
have O
had O
significant O
cytopenias B-Not_AE_Candidate
. O

5.10 O
Vaccinations/Therapeutic O
Infectious O
Agents O
Live O
Vaccines O
Patients O
treated O
with O
SIMPONI O
may O
receive O
vaccinations O
, O
except O
for O
live O
vaccines O
. O

In O
patients O
receiving O
anti-TNF O
therapy O
, O
limited O
data O
are O
available O
on O
the O
response O
to O
live O
vaccination O
, O
or O
on O
the O
secondary O
transmission O
of O
infection B-NonOSE_AE
by O
live O
vaccines O
. O

Use O
of O
live O
vaccines O
could O
result O
in O
clinical O
infections B-NonOSE_AE
, O
including O
disseminated B-NonOSE_AE
infections I-NonOSE_AE
. O

Therapeutic O
Infectious O
Agents O
Other O
uses O
of O
therapeutic B-NonOSE_AE
infectious I-NonOSE_AE
agents I-NonOSE_AE
such O
as O
live O
attenuated O
bacteria O
( O
e.g. O
, O
BCG O
bladder O
instillation O
for O
the O
treatment O
of O
cancer B-NonOSE_AE
) O
could O
result O
in O
clinical O
infections B-NonOSE_AE
, O
including O
disseminated B-NonOSE_AE
infections I-NonOSE_AE
. O

It O
is O
recommended O
that O
therapeutic O
infectious B-NonOSE_AE
agents O
not O
be O
given O
concurrently O
with O
SIMPONI O
. O

Non-live O
Vaccines O
In O
the O
Phase O
3 O
PsA B-Not_AE_Candidate
trial O
, O
after O
pneumococcal B-NonOSE_AE
vaccination I-NonOSE_AE
, O
a O
similar O
proportion O
of O
SIMPONI-treated O
and O
placebo-treated O
patients O
were O
able O
to O
mount B-NonOSE_AE
an I-NonOSE_AE
adequate I-NonOSE_AE
immune I-NonOSE_AE
response I-NonOSE_AE
of O
at O
least O
a O
2-fold O
increase B-NonOSE_AE
in I-NonOSE_AE
antibody I-NonOSE_AE
titers I-NonOSE_AE
to I-NonOSE_AE
pneumococcal I-NonOSE_AE
polysaccharide I-NonOSE_AE
vaccine I-NonOSE_AE
. O

In O
both O
SIMPONI-treated O
and O
placebo-treated O
patients O
, O
the O
proportions O
of O
patients O
with O
response O
to O
pneumococcal B-NonOSE_AE
vaccine I-NonOSE_AE
were O
lower O
among O
patients O
receiving O
MTX O
compared O
with O
patients O
not O
receiving O
MTX O
. O

The O
data O
suggest O
that O
SIMPONI O
does O
not O
suppress B-NonOSE_AE
the I-NonOSE_AE
humoral I-NonOSE_AE
immune I-NonOSE_AE
response I-NonOSE_AE
to O
the O
pneumococcal B-NonOSE_AE
vaccine I-NonOSE_AE
. O

5.11 O
Hypersensitivity O
Reactions O
In O
postmarketing O
experience O
, O
serious O
systemic O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
including O
anaphylactic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
) O
have O
been O
reported O
following O
SIMPONI O
administration O
. O

Some O
of O
these O
reactions O
occurred O
after O
the O
first O
administration O
of O
SIMPONI O
. O

If O
an O
anaphylactic B-NonOSE_AE
or O
other O
serious O
allergic O
reaction I-NonOSE_AE
occurs O
, O
administration O
of O
SIMPONI O
should O
be O
discontinued O
immediately O
and O
appropriate O
therapy O
instituted O
. O

6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
incidence O
> O
=5 O
% O
and O
greater O
than O
placebo O
listed O
in O
descending O
order O
of O
frequency O
) O
: O
upper O
respiratory O
infection O
, O
fever O
, O
headache O
, O
pharyngitis O
, O
cough O
, O
abdominal O
pain O
, O
diarrhea O
, O
otitis O
media O
, O
influenza O
, O
rhinorrhea O
, O
sinusitis O
, O
otitis O
( O
6.1 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Merck O
Sharp O
& O
Dohme O
Corp. O
, O
a O
subsidiary O
of O
Merck O
& O
Co. O
, O
Inc. O
, O
at O
1-877-888-4231 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

In O
the O
following O
description O
of O
clinical O
trials O
experience O
, O
adverse O
reactions O
are O
listed O
regardless O
of O
causality O
assessment O
. O

The O
most O
common O
adverse O
reactions O
( O
incidence O
> O
=5 O
% O
and O
greater O
than O
placebo O
; O
listed O
in O
descending O
order O
of O
frequency O
) O
in O
controlled O
clinical O
trials O
were O
: O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
fever B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
pharyngitis B-OSE_Labeled_AE
, O
cough B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
otitis B-OSE_Labeled_AE
media I-OSE_Labeled_AE
, O
influenza B-OSE_Labeled_AE
, O
rhinorrhea B-OSE_Labeled_AE
, O
sinusitis B-OSE_Labeled_AE
, O
otitis B-OSE_Labeled_AE
. O

Adults O
and O
Adolescents O
15 O
Years O
of O
Age O
and O
Older O
with O
Asthma O
SINGULAIR O
has O
been O
evaluated O
for O
safety O
in O
approximately O
2950 O
adult O
and O
adolescent O
patients O
15 O
years O
of O
age O
and O
older O
in O
clinical O
trials O
. O

In O
placebo-controlled O
clinical O
trials O
, O
the O
following O
adverse O
experiences O
reported O
with O
SINGULAIR O
occurred O
in O
greater O
than O
or O
equal O
to O
1 O
% O
of O
patients O
and O
at O
an O
incidence O
greater O
than O
that O
in O
patients O
treated O
with O
placebo O
: O
Table O
1 O
: O
Adverse O
Experiences O
Occurring O
in O
> O
=1 O
% O
of O
Patients O
with O
an O
Incidence O
Greater O
than O
that O
in O
Patients O
Treated O
with O
Placebo O
SINGULAIR O
10 O
mg/day O
( O
% O
) O
( O
n=1955 O
) O
Placebo O
( O
% O
) O
( O
n=1180 O
) O
Body B-NonOSE_AE
As I-NonOSE_AE
A I-NonOSE_AE
Whole I-NonOSE_AE
Pain B-OSE_Labeled_AE
, O
abdominal I-OSE_Labeled_AE
Asthenia B-OSE_Labeled_AE
/ O
fatigue B-OSE_Labeled_AE
Fever B-OSE_Labeled_AE
Trauma B-OSE_Labeled_AE
2.91.81.51.0 O
2.51.20.90.8 O
Digestive B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Dyspepsia B-OSE_Labeled_AE
Pain B-OSE_Labeled_AE
, O
dental I-OSE_Labeled_AE
Gastroenteritis B-OSE_Labeled_AE
, O
infectious I-OSE_Labeled_AE
2.11.71.5 O
1.11.00.5 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
/ I-NonOSE_AE
Psychiatric I-NonOSE_AE
Headache B-OSE_Labeled_AE
Dizziness B-OSE_Labeled_AE
18.41.9 O
18.11.4 O
Respiratory B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Influenza B-OSE_Labeled_AE
Cough B-OSE_Labeled_AE
Congestion B-OSE_Labeled_AE
, O
nasal I-OSE_Labeled_AE
4.22.71.6 O
3.92.41.3 O
Skin B-NonOSE_AE
/ I-NonOSE_AE
Skin I-NonOSE_AE
Appendages I-NonOSE_AE
Disorder I-NonOSE_AE
Rash B-OSE_Labeled_AE
1.6 O
1.2 O
Laboratory B-NonOSE_AE
Adverse I-NonOSE_AE
Experiences I-NonOSE_AE
[ O
note O
: O
Number O
of O
patients O
tested O
( O
SINGULAIR O
and O
placebo O
, O
respectively O
) O
: O
ALT O
and O
AST O
, O
1935 O
, O
1170 O
; O
pyuria B-OSE_Labeled_AE
, O
1924 O
, O
1159 O
. O
] O

ALT B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
AST B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
Pyuria B-OSE_Labeled_AE
2.11.61.0 O
2.01.20.9 O
The O
frequency O
of O
less O
common O
adverse O
events O
was O
comparable O
between O
SINGULAIR O
and O
placebo O
. O

The O
safety O
profile O
of O
SINGULAIR O
, O
when O
administered O
as O
a O
single O
dose O
for O
prevention O
of O
EIB B-Not_AE_Candidate
in O
adult O
and O
adolescent O
patients O
15 O
years O
of O
age O
and O
older O
, O
was O
consistent O
with O
the O
safety O
profile O
previously O
described O
for O
SINGULAIR O
. O

Cumulatively O
, O
569 O
patients O
were O
treated O
with O
SINGULAIR O
for O
at O
least O
6 O
months O
, O
480 O
for O
one O
year O
, O
and O
49 O
for O
two O
years O
in O
clinical O
trials O
. O

With O
prolonged O
treatment O
, O
the O
adverse O
experience O
profile O
did O
not O
significantly O
change O
. O

Pediatric O
Patients O
6 O
to O
14 O
Years O
of O
Age O
with O
Asthma O
SINGULAIR O
has O
been O
evaluated O
for O
safety O
in O
476 O
pediatric O
patients O
6 O
to O
14 O
years O
of O
age O
. O

Cumulatively O
, O
289 O
pediatric O
patients O
were O
treated O
with O
SINGULAIR O
for O
at O
least O
6 O
months O
, O
and O
241 O
for O
one O
year O
or O
longer O
in O
clinical O
trials O
. O

The O
safety O
profile O
of O
SINGULAIR O
in O
the O
8-week O
, O
double-blind O
, O
pediatric O
efficacy O
trial O
was O
generally O
similar O
to O
the O
adult O
safety O
profile O
. O

In O
pediatric O
patients O
6 O
to O
14 O
years O
of O
age O
receiving O
SINGULAIR O
, O
the O
following O
events O
occurred O
with O
a O
frequency O
> O
=2 O
% O
and O
more O
frequently O
than O
in O
pediatric O
patients O
who O
received O
placebo O
: O
pharyngitis B-OSE_Labeled_AE
, O
influenza B-OSE_Labeled_AE
, O
fever B-OSE_Labeled_AE
, O
sinusitis B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
dyspepsia B-OSE_Labeled_AE
, O
otitis B-OSE_Labeled_AE
, O
viral B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
and O
laryngitis B-OSE_Labeled_AE
. O

The O
frequency O
of O
less O
common O
adverse O
events O
was O
comparable O
between O
SINGULAIR O
and O
placebo O
. O

With O
prolonged O
treatment O
, O
the O
adverse O
experience O
profile O
did O
not O
significantly O
change O
. O

The O
safety O
profile O
of O
SINGULAIR O
, O
when O
administered O
as O
a O
single O
dose O
for O
prevention O
of O
EIB B-Not_AE_Candidate
in O
pediatric O
patients O
6 O
years O
of O
age O
and O
older O
, O
was O
consistent O
with O
the O
safety O
profile O
previously O
described O
for O
SINGULAIR O
. O

In O
studies O
evaluating O
growth O
rate O
, O
the O
safety O
profile O
in O
these O
pediatric O
patients O
was O
consistent O
with O
the O
safety O
profile O
previously O
described O
for O
SINGULAIR O
. O

In O
a O
56-week O
, O
double-blind O
study O
evaluating O
growth O
rate O
in O
pediatric O
patients O
6 O
to O
8 O
years O
of O
age O
receiving O
SINGULAIR O
, O
the O
following O
events O
not O
previously O
observed O
with O
the O
use O
of O
SINGULAIR O
in O
this O
age O
group O
occurred O
with O
a O
frequency O
> O
=2 O
% O
and O
more O
frequently O
than O
in O
pediatric O
patients O
who O
received O
placebo O
: O
headache B-OSE_Labeled_AE
, O
rhinitis B-OSE_Labeled_AE
( I-OSE_Labeled_AE
infective I-OSE_Labeled_AE
) O
, O
varicella B-OSE_Labeled_AE
, O
gastroenteritis B-OSE_Labeled_AE
, O
atopic B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
acute B-OSE_Labeled_AE
bronchitis I-OSE_Labeled_AE
, O
tooth B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
and O
myopia B-OSE_Labeled_AE
. O

Pediatric O
Patients O
2 O
to O
5 O
Years O
of O
Age O
with O
Asthma O
SINGULAIR O
has O
been O
evaluated O
for O
safety O
in O
573 O
pediatric O
patients O
2 O
to O
5 O
years O
of O
age O
in O
single- O
and O
multiple-dose O
studies O
. O

Cumulatively O
, O
426 O
pediatric O
patients O
2 O
to O
5 O
years O
of O
age O
were O
treated O
with O
SINGULAIR O
for O
at O
least O
3 O
months O
, O
230 O
for O
6 O
months O
or O
longer O
, O
and O
63 O
patients O
for O
one O
year O
or O
longer O
in O
clinical O
trials O
. O

In O
pediatric O
patients O
2 O
to O
5 O
years O
of O
age O
receiving O
SINGULAIR O
, O
the O
following O
events O
occurred O
with O
a O
frequency O
> O
=2 O
% O
and O
more O
frequently O
than O
in O
pediatric O
patients O
who O
received O
placebo O
: O
fever B-OSE_Labeled_AE
, O
cough B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
rhinorrhea B-OSE_Labeled_AE
, O
sinusitis B-OSE_Labeled_AE
, O
otitis B-OSE_Labeled_AE
, O
influenza B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
ear B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
gastroenteritis B-OSE_Labeled_AE
, O
eczema B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
varicella B-OSE_Labeled_AE
, O
pneumonia B-OSE_Labeled_AE
, O
dermatitis B-OSE_Labeled_AE
, O
and O
conjunctivitis B-OSE_Labeled_AE
. O

Pediatric O
Patients O
6 O
to O
23 O
Months O
of O
Age O
with O
Asthma O
Safety O
and O
effectiveness O
in O
pediatric O
patients O
younger O
than O
12 O
months O
of O
age O
with O
asthma B-Not_AE_Candidate
have O
not O
been O
established O
. O

SINGULAIR O
has O
been O
evaluated O
for O
safety O
in O
175 O
pediatric O
patients O
6 O
to O
23 O
months O
of O
age O
. O

The O
safety O
profile O
of O
SINGULAIR O
in O
a O
6-week O
, O
double-blind O
, O
placebo-controlled O
clinical O
study O
was O
generally O
similar O
to O
the O
safety O
profile O
in O
adults O
and O
pediatric O
patients O
2 O
to O
14 O
years O
of O
age O
. O

In O
pediatric O
patients O
6 O
to O
23 O
months O
of O
age O
receiving O
SINGULAIR O
, O
the O
following O
events O
occurred O
with O
a O
frequency O
> O
=2 O
% O
and O
more O
frequently O
than O
in O
pediatric O
patients O
who O
received O
placebo O
: O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
wheezing B-OSE_Labeled_AE
; O
otitis B-OSE_Labeled_AE
media I-OSE_Labeled_AE
; O
pharyngitis B-OSE_Labeled_AE
, O
tonsillitis B-OSE_Labeled_AE
, O
cough B-OSE_Labeled_AE
; O
and O
rhinitis B-OSE_Labeled_AE
. O

The O
frequency O
of O
less O
common O
adverse O
events O
was O
comparable O
between O
SINGULAIR O
and O
placebo O
. O

Adults O
and O
Adolescents O
15 O
Years O
of O
Age O
and O
Older O
with O
Seasonal O
Allergic O
Rhinitis O
SINGULAIR O
has O
been O
evaluated O
for O
safety O
in O
2199 O
adult O
and O
adolescent O
patients O
15 O
years O
of O
age O
and O
older O
in O
clinical O
trials O
. O

SINGULAIR O
administered O
once O
daily O
in O
the O
morning O
or O
in O
the O
evening O
had O
a O
safety O
profile O
similar O
to O
that O
of O
placebo O
. O

In O
placebo-controlled O
clinical O
trials O
, O
the O
following O
event O
was O
reported O
with O
SINGULAIR O
with O
a O
frequency O
> O
=1 O
% O
and O
at O
an O
incidence O
greater O
than O
placebo O
: O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
1.9 O
% O
of O
patients O
receiving O
SINGULAIR O
vs O
. O
1.5 O
% O
of O
patients O
receiving O
placebo O
. O

In O
a O
4-week O
, O
placebo-controlled O
clinical O
study O
, O
the O
safety O
profile O
was O
consistent O
with O
that O
observed O
in O
2-week O
studies O
. O

The O
incidence O
of O
somnolence B-NonOSE_AE
was O
similar O
to O
that O
of O
placebo O
in O
all O
studies O
. O

Pediatric O
Patients O
2 O
to O
14 O
Years O
of O
Age O
with O
Seasonal O
Allergic O
Rhinitis O
SINGULAIR O
has O
been O
evaluated O
in O
280 O
pediatric O
patients O
2 O
to O
14 O
years O
of O
age O
in O
a O
2-week O
, O
multicenter O
, O
double-blind O
, O
placebo-controlled O
, O
parallel-group O
safety O
study O
. O

SINGULAIR O
administered O
once O
daily O
in O
the O
evening O
had O
a O
safety O
profile O
similar O
to O
that O
of O
placebo O
. O

In O
this O
study O
, O
the O
following O
events O
occurred O
with O
a O
frequency O
> O
=2 O
% O
and O
at O
an O
incidence O
greater O
than O
placebo O
: O
headache B-OSE_Labeled_AE
, O
otitis B-OSE_Labeled_AE
media I-OSE_Labeled_AE
, O
pharyngitis B-OSE_Labeled_AE
, O
and O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
. O

Adults O
and O
Adolescents O
15 O
Years O
of O
Age O
and O
Older O
with O
Perennial O
Allergic O
Rhinitis O
SINGULAIR O
has O
been O
evaluated O
for O
safety O
in O
3357 O
adult O
and O
adolescent O
patients O
15 O
years O
of O
age O
and O
older O
with O
perennial B-Not_AE_Candidate
allergic I-Not_AE_Candidate
rhinitis I-Not_AE_Candidate
of O
whom O
1632 O
received O
SINGULAIR O
in O
two O
, O
6-week O
, O
clinical O
studies O
. O

SINGULAIR O
administered O
once O
daily O
had O
a O
safety O
profile O
consistent O
with O
that O
observed O
in O
patients O
with O
seasonal B-Not_AE_Candidate
allergic I-Not_AE_Candidate
rhinitis I-Not_AE_Candidate
and O
similar O
to O
that O
of O
placebo O
. O

In O
these O
two O
studies O
, O
the O
following O
events O
were O
reported O
with O
SINGULAIR O
with O
a O
frequency O
> O
=1 O
% O
and O
at O
an O
incidence O
greater O
than O
placebo O
: O
sinusitis B-OSE_Labeled_AE
, O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
sinus B-OSE_Labeled_AE
headache I-OSE_Labeled_AE
, O
cough B-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
and O
increased B-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
. O

The O
incidence O
of O
somnolence B-NonOSE_AE
was O
similar O
to O
that O
of O
placebo O
. O

Pediatric O
Patients O
6 O
Months O
to O
14 O
Years O
of O
Age O
with O
Perennial O
Allergic O
Rhinitis O
The O
safety O
in O
patients O
2 O
to O
14 O
years O
of O
age O
with O
perennial B-Not_AE_Candidate
allergic I-Not_AE_Candidate
rhinitis I-Not_AE_Candidate
is O
supported O
by O
the O
safety O
in O
patients O
2 O
to O
14 O
years O
of O
age O
with O
seasonal B-Not_AE_Candidate
allergic I-Not_AE_Candidate
rhinitis I-Not_AE_Candidate
. O

The O
safety O
in O
patients O
6 O
to O
23 O
months O
of O
age O
is O
supported O
by O
data O
from O
pharmacokinetic O
and O
safety O
and O
efficacy O
studies O
in O
asthma B-Not_AE_Candidate
in O
this O
pediatric O
population O
and O
from O
adult O
pharmacokinetic O
studies O
. O

6.2 O
Post-Marketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
post-approval O
use O
of O
SINGULAIR O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
increased B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
tendency I-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
. O

Immune B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
including O
anaphylaxis B-OSE_Labeled_AE
, O
hepatic B-OSE_Labeled_AE
eosinophilic I-OSE_Labeled_AE
infiltration I-OSE_Labeled_AE
. O

Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
: O
agitation B-OSE_Labeled_AE
including O
aggressive B-OSE_Labeled_AE
behavior I-OSE_Labeled_AE
or O
hostility B-OSE_Labeled_AE
, O
anxiousness B-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
, O
disorientation B-OSE_Labeled_AE
, O
disturbance B-OSE_Labeled_AE
in I-OSE_Labeled_AE
attention I-OSE_Labeled_AE
, O
dream B-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
, O
hallucinations B-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
irritability B-OSE_Labeled_AE
, O
memory B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
, O
restlessness B-OSE_Labeled_AE
, O
somnambulism B-OSE_Labeled_AE
, O
suicidal B-OSE_Labeled_AE
thinking O
and O
behavior I-OSE_Labeled_AE
( O
including O
suicide B-OSE_Labeled_AE
) O
, O
tic B-OSE_Labeled_AE
, O
and O
tremor B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
. O

Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
drowsiness B-OSE_Labeled_AE
, O
paraesthesia B-OSE_Labeled_AE
/ O
hypoesthesia B-OSE_Labeled_AE
, O
seizures B-OSE_Labeled_AE
. O

Cardiac B-NonOSE_AE
disorders I-NonOSE_AE
: O
palpitations B-OSE_Labeled_AE
. O

Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
: O
epistaxis B-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
eosinophilia I-OSE_Labeled_AE
. O

Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
: O
diarrhea B-OSE_Labeled_AE
, O
dyspepsia B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
pancreatitis B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
. O

Hepatobiliary B-NonOSE_AE
disorders I-NonOSE_AE
: O
Cases O
of O
cholestatic B-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
, O
hepatocellular B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
- I-OSE_Labeled_AE
injury I-OSE_Labeled_AE
, O
and O
mixed B-OSE_Labeled_AE
- I-OSE_Labeled_AE
pattern I-OSE_Labeled_AE
liver I-OSE_Labeled_AE
injury I-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
treated O
with O
SINGULAIR O
. O

Most O
of O
these O
occurred O
in O
combination O
with O
other O
confounding O
factors O
, O
such O
as O
use O
of O
other O
medications O
, O
or O
when O
SINGULAIR O
was O
administered O
to O
patients O
who O
had O
underlying O
potential O
for O
liver B-Not_AE_Candidate
disease I-Not_AE_Candidate
such O
as O
alcohol O
use O
or O
other O
forms O
of O
hepatitis B-Not_AE_Candidate
. O

Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
angioedema B-OSE_Labeled_AE
, O
bruising B-OSE_Labeled_AE
, O
erythema B-OSE_Labeled_AE
multiforme I-OSE_Labeled_AE
, O
erythema B-OSE_Labeled_AE
nodosum I-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
/ O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
. O

Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
arthralgia B-OSE_Labeled_AE
, O
myalgia B-OSE_Labeled_AE
including O
muscle B-OSE_Labeled_AE
cramps I-OSE_Labeled_AE
. O

Renal B-NonOSE_AE
and I-NonOSE_AE
urinary I-NonOSE_AE
disorders I-NonOSE_AE
: O
enuresis B-OSE_Labeled_AE
in O
children O
. O

General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
: O
edema B-OSE_Labeled_AE
. O

Patients O
with O
asthma B-Not_AE_Candidate
on O
therapy O
with O
SINGULAIR O
may O
present O
with O
systemic B-OSE_Labeled_AE
eosinophilia I-OSE_Labeled_AE
, O
sometimes O
presenting O
with O
clinical O
features O
of O
vasculitis B-OSE_Labeled_AE
consistent O
with O
Churg B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Strauss I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
a O
condition O
which O
is O
often O
treated O
with O
systemic O
corticosteroid O
therapy O
. O

These O
events O
have O
been O
sometimes O
associated O
with O
the O
reduction O
of O
oral O
corticosteroid O
therapy O
. O

Physicians O
should O
be O
alert O
to O
eosinophilia B-NonOSE_AE
, O
vasculitic B-NonOSE_AE
rash I-NonOSE_AE
, O
worsening B-NonOSE_AE
pulmonary I-NonOSE_AE
symptoms I-NonOSE_AE
, O
cardiac B-NonOSE_AE
complications I-NonOSE_AE
, O
and/or O
neuropathy B-NonOSE_AE
presenting O
in O
their O
patients O
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
. O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Do O
not O
prescribe O
SINGULAIR O
to O
treat O
an O
acute O
asthma O
attack O
( O
5.1 O
) O
. O

* O
Advise O
patients O
to O
have O
appropriate O
rescue O
medication O
available O
( O
5.1 O
) O
. O

* O
Inhaled O
corticosteroid O
may O
be O
reduced O
gradually O
. O

Do O
not O
abruptly O
substitute O
SINGULAIR O
for O
inhaled O
or O
oral O
corticosteroids O
( O
5.2 O
) O
. O

* O
Patients O
with O
known O
aspirin O
sensitivity O
should O
continue O
to O
avoid O
aspirin O
or O
non-steroidal O
anti-inflammatory O
agents O
while O
taking O
SINGULAIR O
( O
5.3 O
) O
. O

* O
Neuropsychiatric O
events O
have O
been O
reported O
with O
SINGULAIR O
. O

Instruct O
patients O
to O
be O
alert O
for O
neuropsychiatric O
events O
. O

Evaluate O
the O
risks O
and O
benefits O
of O
continuing O
treatment O
with O
SINGULAIR O
if O
such O
events O
occur O
( O
5.4 O
and O
6.2 O
) O
. O

* O
Systemic O
eosinophilia O
, O
sometimes O
presenting O
with O
clinical O
features O
of O
vasculitis O
consistent O
with O
Churg-Strauss O
syndrome O
, O
has O
been O
reported O
. O

These O
events O
have O
been O
sometimes O
associated O
with O
the O
reduction O
of O
oral O
corticosteroid O
therapy O
( O
5.5 O
and O
6.2 O
) O
. O

* O
Inform O
patients O
with O
phenylketonuria O
that O
the O
4-mg O
and O
5-mg O
chewable O
tablets O
contain O
phenylalanine O
( O
5.6 O
) O
. O

5.1 O
Acute O
Asthma O
SINGULAIR O
is O
not O
indicated O
for O
use O
in O
the O
reversal O
of O
bronchospasm B-Not_AE_Candidate
in O
acute B-Not_AE_Candidate
asthma I-Not_AE_Candidate
attacks I-Not_AE_Candidate
, O
including O
status B-Not_AE_Candidate
asthmaticus I-Not_AE_Candidate
. O

Patients O
should O
be O
advised O
to O
have O
appropriate O
rescue O
medication O
available O
. O

Therapy O
with O
SINGULAIR O
can O
be O
continued O
during O
acute B-Not_AE_Candidate
exacerbations I-Not_AE_Candidate
of I-Not_AE_Candidate
asthma I-Not_AE_Candidate
. O

Patients O
who O
have O
exacerbations B-Not_AE_Candidate
of I-Not_AE_Candidate
asthma I-Not_AE_Candidate
after I-Not_AE_Candidate
exercise I-Not_AE_Candidate
should O
have O
available O
for O
rescue O
a O
short-acting O
inhaled O
beta-agonist O
. O

5.2 O
Concomitant O
Corticosteroid O
Use O
While O
the O
dose O
of O
inhaled O
corticosteroid O
may O
be O
reduced O
gradually O
under O
medical O
supervision O
, O
SINGULAIR O
should O
not O
be O
abruptly O
substituted O
for O
inhaled O
or O
oral O
corticosteroids O
. O

5.3 O
Aspirin O
Sensitivity O
Patients O
with O
known O
aspirin B-Not_AE_Candidate
sensitivity I-Not_AE_Candidate
should O
continue O
avoidance O
of O
aspirin O
or O
non-steroidal O
anti-inflammatory O
agents O
while O
taking O
SINGULAIR O
. O

Although O
SINGULAIR O
is O
effective O
in O
improving O
airway O
function O
in O
asthmatics B-Not_AE_Candidate
with O
documented O
aspirin B-Not_AE_Candidate
sensitivity I-Not_AE_Candidate
, O
it O
has O
not O
been O
shown O
to O
truncate O
bronchoconstrictor B-Not_AE_Candidate
response I-Not_AE_Candidate
to I-Not_AE_Candidate
aspirin I-Not_AE_Candidate
and O
other O
non-steroidal O
anti-inflammatory O
drugs O
in O
aspirin B-Not_AE_Candidate
- I-Not_AE_Candidate
sensitive I-Not_AE_Candidate
asthmatic B-Not_AE_Candidate
patients O
[ O
see O
Clinical O
Studies O
( O
14.1 O
) O
] O
. O

5.4 O
Neuropsychiatric O
Events O
Neuropsychiatric B-OSE_Labeled_AE
events I-OSE_Labeled_AE
have O
been O
reported O
in O
adult O
, O
adolescent O
, O
and O
pediatric O
patients O
taking O
SINGULAIR O
. O

Post-marketing O
reports O
with O
SINGULAIR O
use O
include O
agitation B-OSE_Labeled_AE
, O
aggressive B-OSE_Labeled_AE
behavior I-OSE_Labeled_AE
or O
hostility B-OSE_Labeled_AE
, O
anxiousness B-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
, O
disorientation B-OSE_Labeled_AE
, O
disturbance B-OSE_Labeled_AE
in I-OSE_Labeled_AE
attention I-OSE_Labeled_AE
, O
dream B-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
, O
hallucinations B-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
irritability B-OSE_Labeled_AE
, O
memory B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
, O
restlessness B-OSE_Labeled_AE
, O
somnambulism B-OSE_Labeled_AE
, O
suicidal B-OSE_Labeled_AE
thinking I-OSE_Labeled_AE
and O
behavior I-OSE_Labeled_AE
( O
including O
suicide B-OSE_Labeled_AE
) O
, O
tic B-OSE_Labeled_AE
, O
and O
tremor B-OSE_Labeled_AE
. O

The O
clinical O
details O
of O
some O
post-marketing O
reports O
involving O
SINGULAIR O
appear O
consistent O
with O
a O
drug-induced O
effect O
. O

Patients O
and O
prescribers O
should O
be O
alert O
for O
neuropsychiatric B-NonOSE_AE
events I-NonOSE_AE
. O

Patients O
should O
be O
instructed O
to O
notify O
their O
prescriber O
if O
these O
changes O
occur O
. O

Prescribers O
should O
carefully O
evaluate O
the O
risks O
and O
benefits O
of O
continuing O
treatment O
with O
SINGULAIR O
if O
such O
events O
occur O
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

5.5 O
Eosinophilic O
Conditions O
Patients O
with O
asthma B-Not_AE_Candidate
on O
therapy O
with O
SINGULAIR O
may O
present O
with O
systemic B-OSE_Labeled_AE
eosinophilia I-OSE_Labeled_AE
, O
sometimes O
presenting O
with O
clinical O
features O
of O
vasculitis B-OSE_Labeled_AE
consistent O
with O
Churg B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Strauss I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
a O
condition O
which O
is O
often O
treated O
with O
systemic O
corticosteroid O
therapy O
. O

These O
events O
have O
been O
sometimes O
associated O
with O
the O
reduction O
of O
oral O
corticosteroid O
therapy O
. O

Physicians O
should O
be O
alert O
to O
eosinophilia B-NonOSE_AE
, O
vasculitic B-NonOSE_AE
rash I-NonOSE_AE
, O
worsening B-NonOSE_AE
pulmonary I-NonOSE_AE
symptoms I-NonOSE_AE
, O
cardiac B-NonOSE_AE
complications I-NonOSE_AE
, O
and/or O
neuropathy B-NonOSE_AE
presenting O
in O
their O
patients O
. O

A O
causal O
association O
between O
SINGULAIR O
and O
these O
underlying O
conditions O
has O
not O
been O
established O
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

5.6 O
Phenylketonuria O
Phenylketonuric B-Not_AE_Candidate
patients O
should O
be O
informed O
that O
the O
4-mg O
and O
5-mg O
chewable O
tablets O
contain O
phenylalanine O
( O
a O
component O
of O
aspartame O
) O
, O
0.674 O
and O
0.842 O
mg O
per O
4-mg O
and O
5-mg O
chewable O
tablet O
, O
respectively O
. O

6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
* O
Adverse O
reactions O
reported O
in O
> O
=5 O
% O
of O
patients O
treated O
with O
TRADJENTA O
and O
more O
commonly O
than O
in O
patients O
treated O
with O
placebo O
included O
nasopharyngitis O
( O
6.1 O
) O
* O
Hypoglycemia O
was O
more O
commonly O
reported O
in O
patients O
treated O
with O
the O
combination O
of O
TRADJENTA O
and O
sulfonylurea O
compared O
with O
those O
treated O
with O
the O
combination O
of O
placebo O
and O
sulfonylurea O
( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Boehringer O
Ingelheim O
Pharmaceuticals O
, O
Inc O
. O
at O
1-800-542-6257 O
or O
1-800-459-9906 O
TTY O
, O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

The O
safety O
evaluation O
of O
TRADJENTA O
5 O
mg O
once O
daily O
in O
patients O
with O
type B-Not_AE_Candidate
2 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
is O
based O
on O
14 O
placebo-controlled O
trials O
, O
1 O
active-controlled O
study O
, O
and O
one O
study O
in O
patients O
with O
severe O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
. O

In O
the O
14 O
placebo-controlled O
studies O
, O
a O
total O
of O
3625 O
patients O
were O
randomized O
and O
treated O
with O
TRADJENTA O
5 O
mg O
daily O
and O
2176 O
with O
placebo O
. O

The O
mean O
exposure O
in O
patients O
treated O
with O
TRADJENTA O
across O
studies O
was O
29.6 O
weeks O
. O

The O
maximum O
follow-up O
was O
78 O
weeks O
. O

TRADJENTA O
5 O
mg O
once O
daily O
was O
studied O
as O
monotherapy O
in O
three O
placebo-controlled O
trials O
of O
18 O
and O
24 O
weeks O
' O
duration O
and O
in O
five O
additional O
placebo-controlled O
studies O
lasting O
< O
=18 O
weeks O
. O

The O
use O
of O
TRADJENTA O
in O
combination O
with O
other O
antihyperglycemic O
agents O
was O
studied O
in O
six O
placebo-controlled O
trials O
: O
two O
with O
metformin O
( O
12 O
and O
24 O
weeks O
' O
treatment O
duration O
) O
; O
one O
with O
a O
sulfonylurea O
( O
18 O
weeks O
' O
treatment O
duration O
) O
; O
one O
with O
metformin O
and O
sulfonylurea O
( O
24 O
weeks O
' O
treatment O
duration O
) O
; O
one O
with O
pioglitazone O
( O
24 O
weeks O
' O
treatment O
duration O
) O
; O
and O
one O
with O
insulin O
( O
primary O
endpoint O
at O
24 O
weeks O
) O
. O

In O
a O
pooled O
dataset O
of O
14 O
placebo-controlled O
clinical O
trials O
, O
adverse O
reactions O
that O
occurred O
in O
> O
=2 O
% O
of O
patients O
receiving O
TRADJENTA O
( O
n O
= O
3625 O
) O
and O
more O
commonly O
than O
in O
patients O
given O
placebo O
( O
n O
= O
2176 O
) O
, O
are O
shown O
in O
Table O
1 O
. O

The O
overall O
incidence O
of O
adverse O
events O
with O
TRADJENTA O
were O
similar O
to O
placebo O
. O

Table O
1 O
Adverse O
Reactions O
Reported O
in O
> O
=2 O
% O
of O
Patients O
Treated O
with O
TRADJENTA O
and O
Greater O
than O
Placebo O
in O
Placebo-Controlled O
Clinical O
Studies O
of O
TRADJENTA O
Monotherapy O
or O
Combination O
Therapy O
Number O
( O
% O
) O
of O
Patients O
TRADJENTA O
5 O
mgn O
= O
3625 O
Placebon O
= O
2176 O
Nasopharyngitis B-OSE_Labeled_AE
254 O
( O
7.0 O
) O
132 O
( O
6.1 O
) O
Diarrhea B-OSE_Labeled_AE
119 O
( O
3.3 O
) O
65 O
( O
3.0 O
) O
Cough B-OSE_Labeled_AE
76 O
( O
2.1 O
) O
30 O
( O
1.4 O
) O
Rates O
for O
other O
adverse O
reactions O
for O
TRADJENTA O
5 O
mg O
vs O
placebo O
when O
TRADJENTA O
was O
used O
in O
combination O
with O
specific O
anti-diabetic O
agents O
were O
: O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
3.1 O
% O
vs O
0 O
% O
) O
and O
hypertriglyceridemia B-OSE_Labeled_AE
( O
2.4 O
% O
vs O
0 O
% O
) O
when O
TRADJENTA O
was O
used O
as O
add-on O
to O
sulfonylurea O
; O
hyperlipidemia B-OSE_Labeled_AE
( O
2.7 O
% O
vs O
0.8 O
% O
) O
and O
weight B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
( O
2.3 O
% O
vs O
0.8 O
% O
) O
when O
TRADJENTA O
was O
used O
as O
add-on O
to O
pioglitazone O
; O
and O
constipation B-OSE_Labeled_AE
( O
2.1 O
% O
vs O
1 O
% O
) O
when O
TRADJENTA O
was O
used O
as O
add-on O
to O
basal O
insulin O
therapy O
. O

Following O
104 O
weeks O
' O
treatment O
in O
a O
controlled O
study O
comparing O
TRADJENTA O
with O
glimepiride O
in O
which O
all O
patients O
were O
also O
receiving O
metformin O
, O
adverse O
reactions O
reported O
in O
> O
=5 O
% O
of O
patients O
treated O
with O
TRADJENTA O
( O
n O
= O
776 O
) O
and O
more O
frequently O
than O
in O
patients O
treated O
with O
a O
sulfonylurea O
( O
n O
= O
775 O
) O
were O
back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
9.1 O
% O
vs O
8.4 O
% O
) O
, O
arthralgia B-OSE_Labeled_AE
( O
8.1 O
% O
vs O
6.1 O
% O
) O
, O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
8.0 O
% O
vs O
7.6 O
% O
) O
, O
headache B-OSE_Labeled_AE
( O
6.4 O
% O
vs O
5.2 O
% O
) O
, O
cough B-OSE_Labeled_AE
( O
6.1 O
% O
vs O
4.9 O
% O
) O
, O
and O
pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
( O
5.3 O
% O
vs O
3.9 O
% O
) O
. O

Other O
adverse O
reactions O
reported O
in O
clinical O
studies O
with O
treatment O
of O
TRADJENTA O
were O
hypersensitivity B-OSE_Labeled_AE
( O
e.g. O
, O
urticaria B-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
, O
localized B-OSE_Labeled_AE
skin O
exfoliation I-OSE_Labeled_AE
, O
or O
bronchial B-OSE_Labeled_AE
hyperreactivity I-OSE_Labeled_AE
) O
, O
and O
myalgia B-OSE_Labeled_AE
. O

In O
the O
clinical O
trial O
program O
, O
pancreatitis B-OSE_Labeled_AE
was O
reported O
in O
15.2 O
cases O
per O
10,000 O
patient O
year O
exposure O
while O
being O
treated O
with O
TRADJENTA O
compared O
with O
3.7 O
cases O
per O
10,000 O
patient O
year O
exposure O
while O
being O
treated O
with O
comparator O
( O
placebo O
and O
active O
comparator O
, O
sulfonylurea O
) O
. O

Three O
additional O
cases O
of O
pancreatitis B-OSE_Labeled_AE
were O
reported O
following O
the O
last O
administered O
dose O
of O
linagliptin O
. O

Hypoglycemia O
In O
the O
placebo-controlled O
studies O
, O
199 O
( O
6.6 O
% O
) O
of O
the O
total O
2994 O
patients O
treated O
with O
TRADJENTA O
5 O
mg O
reported O
hypoglycemia B-OSE_Labeled_AE
compared O
to O
56 O
patients O
( O
3.6 O
% O
) O
of O
1546 O
placebo-treated O
patients O
. O

The O
incidence O
of O
hypoglycemia B-NonOSE_AE
was O
similar O
to O
placebo O
when O
TRADJENTA O
was O
administered O
as O
monotherapy O
or O
in O
combination O
with O
metformin O
, O
or O
with O
pioglitazone O
. O

When O
TRADJENTA O
was O
administered O
in O
combination O
with O
metformin O
and O
a O
sulfonylurea O
, O
181 O
of O
792 O
( O
22.9 O
% O
) O
patients O
reported O
hypoglycemia B-OSE_Labeled_AE
compared O
with O
39 O
of O
263 O
( O
14.8 O
% O
) O
patients O
administered O
placebo O
in O
combination O
with O
metformin O
and O
a O
sulfonylurea O
. O

Adverse O
reactions O
of O
hypoglycemia B-NonOSE_AE
were O
based O
on O
all O
reports O
of O
hypoglycemia B-NonOSE_AE
. O

A O
concurrent O
glucose O
measurement O
was O
not O
required O
or O
was O
normal O
in O
some O
patients O
. O

Therefore O
, O
it O
is O
not O
possible O
to O
conclusively O
determine O
that O
all O
these O
reports O
reflect O
true O
hypoglycemia B-NonOSE_AE
. O

In O
the O
study O
of O
patients O
receiving O
TRADJENTA O
as O
add-on O
therapy O
to O
a O
stable O
dose O
of O
insulin O
for O
up O
to O
52 O
weeks O
( O
n=1261 O
) O
, O
no O
significant O
difference O
in O
the O
incidence O
of O
investigator O
reported O
hypoglycemia B-NonOSE_AE
, O
defined O
as O
all O
symptomatic O
or O
asymptomatic O
episodes O
with O
a O
self-measured O
blood B-NonOSE_AE
glucose I-NonOSE_AE
< I-NonOSE_AE
= I-NonOSE_AE
7 I-NonOSE_AE
0 I-NonOSE_AE
mg I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
, O
was O
noted O
between O
the O
TRADJENTA- O
( O
31.4 O
% O
) O
and O
placebo- O
( O
32.9 O
% O
) O
treated O
groups O
. O

During O
the O
same O
time O
period O
, O
severe O
hypoglycemic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
, O
defined O
as O
requiring O
the O
assistance O
of O
another O
person O
to O
actively O
administer O
carbohydrate O
, O
glucagon O
or O
other O
resuscitative O
actions O
, O
were O
reported O
in O
11 O
( O
1.7 O
% O
) O
of O
TRADJENTA O
treated O
patients O
and O
7 O
( O
1.1 O
% O
) O
of O
placebo O
treated O
patients O
. O

Events O
that O
were O
considered O
life-threatening O
or O
required O
hospitalization O
were O
reported O
in O
3 O
( O
0.5 O
% O
) O
patients O
on O
TRADJENTA O
and O
1 O
( O
0.2 O
% O
) O
on O
placebo O
. O

Use O
in O
Renal B-NonOSE_AE
Impairment I-NonOSE_AE
TRADJENTA O
was O
compared O
to O
placebo O
as O
add-on O
to O
pre-existing O
antidiabetic O
therapy O
over O
52 O
weeks O
in O
133 O
patients O
with O
severe O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
( O
estimated O
GFR B-Not_AE_Candidate
< I-Not_AE_Candidate
3 I-Not_AE_Candidate
0 I-Not_AE_Candidate
mL I-Not_AE_Candidate
/ I-Not_AE_Candidate
min I-Not_AE_Candidate
) O
. O

For O
the O
initial O
12 O
weeks O
of O
the O
study O
, O
background O
antidiabetic O
therapy O
was O
kept O
stable O
and O
included O
insulin O
, O
sulfonylurea O
, O
glinides O
, O
and O
pioglitazone O
. O

For O
the O
remainder O
of O
the O
trial O
, O
dose O
adjustments O
in O
antidiabetic O
background O
therapy O
were O
allowed O
. O

In O
general O
, O
the O
incidence O
of O
adverse O
events O
including O
severe O
hypoglycemia B-OSE_Labeled_AE
was O
similar O
to O
those O
reported O
in O
other O
TRADJENTA O
trials O
. O

The O
observed O
incidence O
of O
hypoglycemia B-OSE_Labeled_AE
was O
higher O
( O
TRADJENTA O
, O
63 O
% O
compared O
to O
placebo O
, O
49 O
% O
) O
due O
to O
an O
increase O
in O
asymptomatic O
hypoglycemic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
especially O
during O
the O
first O
12 O
weeks O
when O
background O
glycemic O
therapies O
were O
kept O
stable O
. O

Ten O
TRADJENTA-treated O
patients O
( O
15 O
% O
) O
and O
11 O
placebo-treated O
patients O
( O
17 O
% O
) O
reported O
at O
least O
one O
episode O
of O
confirmed O
symptomatic O
hypoglycemia B-NonOSE_AE
( O
accompanying O
finger O
stick O
glucose O
< O
=54 O
mg/dL O
) O
. O

During O
the O
same O
time O
period O
, O
severe O
hypoglycemic B-NonOSE_AE
events I-NonOSE_AE
, O
defined O
as O
an O
event O
requiring O
the O
assistance O
of O
another O
person O
to O
actively O
administer O
carbohydrate O
, O
glucagon O
or O
other O
resuscitative O
actions O
, O
were O
reported O
in O
3 O
( O
4.4 O
% O
) O
TRADJENTA-treated O
patients O
and O
3 O
( O
4.6 O
% O
) O
placebo-treated O
patients O
. O

Events O
that O
were O
considered O
life-threatening O
or O
required O
hospitalization O
were O
reported O
in O
2 O
( O
2.9 O
% O
) O
patients O
on O
TRADJENTA O
and O
1 O
( O
1.5 O
% O
) O
patient O
on O
placebo O
. O

Renal O
function O
as O
measured O
by O
mean O
eGFR O
and O
creatinine O
clearance O
did O
not O
change O
over O
52 O
weeks O
' O
treatment O
compared O
to O
placebo O
. O

Laboratory O
Tests O
Changes O
in O
laboratory O
findings O
were O
similar O
in O
patients O
treated O
with O
TRADJENTA O
5 O
mg O
compared O
to O
patients O
treated O
with O
placebo O
. O

Changes B-NonOSE_AE
in I-NonOSE_AE
laboratory I-NonOSE_AE
values I-NonOSE_AE
that O
occurred O
more O
frequently O
in O
the O
TRADJENTA O
group O
and O
> O
1 O
% O
more O
than O
in O
the O
placebo O
group O
were O
increases B-OSE_Labeled_AE
in O
uric I-OSE_Labeled_AE
acid I-OSE_Labeled_AE
( O
1.3 O
% O
in O
the O
placebo O
group O
, O
2.7 O
% O
in O
the O
TRADJENTA O
group O
) O
. O

No O
clinically O
meaningful O
changes O
in O
vital O
signs O
were O
observed O
in O
patients O
treated O
with O
TRADJENTA O
. O

6.2 O
Postmarketing O
Experience O
Additional O
adverse O
reactions O
have O
been O
identified O
during O
postapproval O
use O
of O
TRADJENTA O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
generally O
not O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

* O
Acute B-OSE_Labeled_AE
pancreatitis I-OSE_Labeled_AE
, O
including O
fatal B-NonOSE_AE
pancreatitis B-OSE_Labeled_AE
[ O
see O
Indications O
and O
Usage O
( O
1.2 O
) O
and O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
including O
anaphylaxis B-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
, O
and O
exfoliative B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
conditions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Severe O
and O
disabling O
arthralgia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Rash B-OSE_Labeled_AE
* O
Mouth B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
, O
stomatitis B-OSE_Labeled_AE

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
There O
have O
been O
postmarketing O
reports O
of O
acute O
pancreatitis O
, O
including O
fatal O
pancreatitis O
. O

If O
pancreatitis O
is O
suspected O
, O
promptly O
discontinue O
TRADJENTA O
. O

( O
5.1 O
) O
* O
When O
used O
with O
an O
insulin O
secretagogue O
( O
e.g. O
, O
sulfonylurea O
) O
or O
insulin O
, O
consider O
lowering O
the O
dose O
of O
the O
insulin O
secretagogue O
or O
insulin O
to O
reduce O
the O
risk O
of O
hypoglycemia O
( O
5.2 O
) O
* O
There O
have O
been O
postmarketing O
reports O
of O
serious O
hypersensitivity O
reactions O
in O
patients O
treated O
with O
TRADJENTA O
including O
anaphylaxis O
, O
angioedema O
, O
and O
exfoliative O
skin O
conditions O
. O

In O
such O
cases O
, O
promptly O
discontinue O
TRADJENTA O
, O
assess O
for O
other O
potential O
causes O
, O
institute O
appropriate O
monitoring O
and O
treatment O
, O
and O
initiate O
alternative O
treatment O
for O
diabetes O
. O

( O
5.3 O
) O
* O
Severe O
and O
disabling O
arthralgia O
has O
been O
reported O
in O
patients O
taking O
DPP-4 O
inhibitors O
. O

Consider O
as O
a O
possible O
cause O
for O
severe O
joint O
pain O
and O
discontinue O
drug O
if O
appropriate O
. O

( O
5.4 O
) O
* O
There O
have O
been O
no O
clinical O
studies O
establishing O
conclusive O
evidence O
of O
macrovascular O
risk O
reduction O
with O
TRADJENTA O
or O
any O
other O
antidiabetic O
drug O
( O
5.5 O
) O
5.1 O
Pancreatitis O
There O
have O
been O
postmarketing O
reports O
of O
acute B-OSE_Labeled_AE
pancreatitis I-OSE_Labeled_AE
, O
including O
fatal B-NonOSE_AE
pancreatitis B-OSE_Labeled_AE
, O
in O
patients O
taking O
TRADJENTA O
. O

Take O
careful O
notice O
of O
potential O
signs O
and O
symptoms O
of O
pancreatitis B-NonOSE_AE
. O

If O
pancreatitis B-NonOSE_AE
is O
suspected O
, O
promptly O
discontinue O
TRADJENTA O
and O
initiate O
appropriate O
management O
. O

It O
is O
unknown O
whether O
patients O
with O
a O
history O
of O
pancreatitis B-Not_AE_Candidate
are O
at O
increased O
risk O
for O
the O
development O
of O
pancreatitis B-NonOSE_AE
while O
using O
TRADJENTA O
. O

5.2 O
Use O
with O
Medications O
Known O
to O
Cause O
Hypoglycemia O
Insulin O
secretagogues O
and O
insulin O
are O
known O
to O
cause O
hypoglycemia B-NonOSE_AE
. O

The O
use O
of O
TRADJENTA O
in O
combination O
with O
an O
insulin O
secretagogue O
( O
e.g. O
, O
sulfonylurea O
) O
was O
associated O
with O
a O
higher O
rate O
of O
hypoglycemia B-NonOSE_AE
compared O
with O
placebo O
in O
a O
clinical O
trial O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

The O
use O
of O
TRADJENTA O
in O
combination O
with O
insulin O
in O
subjects O
with O
severe O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
was O
associated O
with O
a O
higher O
rate O
of O
hypoglycemia B-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Therefore O
, O
a O
lower O
dose O
of O
the O
insulin O
secretagogue O
or O
insulin O
may O
be O
required O
to O
reduce O
the O
risk O
of O
hypoglycemia B-NonOSE_AE
when O
used O
in O
combination O
with O
TRADJENTA O
. O

5.3 O
Hypersensitivity O
Reactions O
There O
have O
been O
postmarketing O
reports O
of O
serious O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
in O
patients O
treated O
with O
TRADJENTA O
. O

These O
reactions O
include O
anaphylaxis B-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
, O
and O
exfoliative B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
conditions I-OSE_Labeled_AE
. O

Onset O
of O
these O
reactions O
occurred O
within O
the O
first O
3 O
months O
after O
initiation O
of O
treatment O
with O
TRADJENTA O
, O
with O
some O
reports O
occurring O
after O
the O
first O
dose O
. O

If O
a O
serious O
hypersensitivity B-NonOSE_AE
reaction I-NonOSE_AE
is O
suspected O
, O
discontinue O
TRADJENTA O
, O
assess O
for O
other O
potential O
causes O
for O
the O
event O
, O
and O
institute O
alternative O
treatment O
for O
diabetes B-Not_AE_Candidate
. O

Angioedema B-NonOSE_AE
has O
also O
been O
reported O
with O
other O
dipeptidyl O
peptidase-4 O
( O
DPP-4 O
) O
inhibitors O
. O

Use O
caution O
in O
a O
patient O
with O
a O
history O
of O
angioedema B-Not_AE_Candidate
to O
another O
DPP-4 O
inhibitor O
because O
it O
is O
unknown O
whether O
such O
patients O
will O
be O
predisposed O
to O
angioedema B-NonOSE_AE
with O
TRADJENTA O
. O

5.4 O
Severe O
and O
Disabling O
Arthralgia O
There O
have O
been O
postmarketing O
reports O
of O
severe O
and O
disabling O
arthralgia B-OSE_Labeled_AE
in O
patients O
taking O
DPP-4 O
inhibitors O
. O

The O
time O
to O
onset O
of O
symptoms O
following O
initiation O
of O
drug O
therapy O
varied O
from O
one O
day O
to O
years O
. O

Patients O
experienced O
relief O
of O
symptoms O
upon O
discontinuation O
of O
the O
medication O
. O

A O
subset O
of O
patients O
experienced O
a O
recurrence O
of O
symptoms O
when O
restarting O
the O
same O
drug O
or O
a O
different O
DPP-4 O
inhibitor O
. O

Consider O
DPP-4 O
inhibitors O
as O
a O
possible O
cause O
for O
severe O
joint B-NonOSE_AE
pain I-NonOSE_AE
and O
discontinue O
drug O
if O
appropriate O
. O

5.5 O
Macrovascular O
Outcomes O
There O
have O
been O
no O
clinical O
studies O
establishing O
conclusive O
evidence O
of O
macrovascular B-NonOSE_AE
risk I-NonOSE_AE
reduction O
with O
TRADJENTA O
tablets O
or O
any O
other O
antidiabetic O
drug O
. O

ADVERSE O
REACTIONS O
Side O
effects O
most O
commonly O
reported O
were O
drowsiness B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
weakness I-OSE_Labeled_AE
, O
and O
ataxia B-OSE_Labeled_AE
. O

The O
following O
have O
also O
been O
reported O
: O
Central O
Nervous O
System O
: O
confusion B-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
, O
dysarthria B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
slurred B-OSE_Labeled_AE
speech I-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
vertigo B-OSE_Labeled_AE
Gastrointestinal O
System O
: O
constipation B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
gastrointestinal B-OSE_Labeled_AE
disturbances I-OSE_Labeled_AE
Special O
Senses O
: O
blurred B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
, O
diplopia B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
Cardiovascular O
System O
: O
hypotension B-OSE_Labeled_AE
Psychiatric O
and O
Paradoxical O
Reactions O
: O
stimulation B-OSE_Labeled_AE
, O
restlessness B-OSE_Labeled_AE
, O
acute B-OSE_Labeled_AE
hyperexcited I-OSE_Labeled_AE
states I-OSE_Labeled_AE
, O
anxiety B-OSE_Labeled_AE
, O
agitation B-OSE_Labeled_AE
, O
aggressiveness B-OSE_Labeled_AE
, O
irritability B-OSE_Labeled_AE
, O
rage B-OSE_Labeled_AE
, O
hallucinations B-OSE_Labeled_AE
, O
psychoses B-OSE_Labeled_AE
, O
delusions B-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
muscle I-OSE_Labeled_AE
spasticity I-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
sleep B-OSE_Labeled_AE
disturbances I-OSE_Labeled_AE
, O
and O
nightmares B-OSE_Labeled_AE
. O

Inappropriate B-OSE_Labeled_AE
behavior I-OSE_Labeled_AE
and O
other O
adverse B-OSE_Labeled_AE
behavioral I-OSE_Labeled_AE
effects I-OSE_Labeled_AE
have O
been O
reported O
when O
using O
benzodiazepines O
. O

Should O
these O
occur O
, O
use O
of O
the O
drug O
should O
be O
discontinued O
. O

They O
are O
more O
likely O
to O
occur O
in O
children O
and O
in O
the O
elderly O
. O

Urogenital O
System O
: O
incontinence B-OSE_Labeled_AE
, O
changes B-OSE_Labeled_AE
in I-OSE_Labeled_AE
libido I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
Skin O
and O
Appendages O
: O
skin B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
Laboratories O
: O
elevated B-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
and O
alkaline O
phosphatase O
Other O
: O
changes B-OSE_Labeled_AE
in I-OSE_Labeled_AE
salivation I-OSE_Labeled_AE
, O
including O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
hypersalivation B-OSE_Labeled_AE
Antegrade B-OSE_Labeled_AE
amnesia I-OSE_Labeled_AE
may O
occur O
using O
therapeutic O
dosages O
, O
the O
risk O
increasing O
at O
higher O
dosages O
. O

Amnestic B-OSE_Labeled_AE
effects I-OSE_Labeled_AE
may O
be O
associated O
with O
inappropriate B-OSE_Labeled_AE
behavior I-OSE_Labeled_AE
. O

Minor O
changes B-OSE_Labeled_AE
in I-OSE_Labeled_AE
EEG I-OSE_Labeled_AE
patterns O
, O
usually O
low-voltage O
fast O
activity O
, O
have O
been O
observed O
in O
patients O
during O
and O
after O
Valium O
therapy O
and O
are O
of O
no O
known O
significance O
. O

Because O
of O
isolated O
reports O
of O
neutropenia B-OSE_Labeled_AE
and O
jaundice B-OSE_Labeled_AE
, O
periodic O
blood O
counts O
and O
liver O
function O
tests O
are O
advisable O
during O
long-term O
therapy O
. O

Postmarketing O
Experience O
Injury O
, O
Poisoning O
and O
Procedural O
Complications O
There O
have O
been O
reports O
of O
falls B-OSE_Labeled_AE
and O
fractures B-OSE_Labeled_AE
in O
benzodiazepine O
users O
. O

The O
risk O
is O
increased O
in O
those O
taking O
concomitant O
sedatives O
( O
including O
alcohol O
) O
, O
and O
in O
the O
elderly O
. O

BOXED O
WARNING O
: O
WARNING O
: O
RISKS O
FROM O
CONCOMITANT O
USE O
WITH O
OPIOIDS O
WARNING O
: O
RISKS O
FROM O
CONCOMITANT O
USE O
WITH O
OPIOIDS O
Concomitant O
use O
of O
benzodiazepines O
and O
opioids O
may O
result O
in O
profound O
sedation B-NonOSE_AE
, O
respiratory B-NonOSE_AE
depression I-NonOSE_AE
, O
coma B-NonOSE_AE
, O
and O
death B-NonOSE_AE
( O
see O
Drug O
Interactions O
) O
. O

* O
Reserve O
concomitant O
prescribing O
of O
these O
drugs O
for O
use O
in O
patients O
for O
whom O
alternative O
treatment O
options O
are O
inadequate O
. O

* O
Limit O
dosages O
and O
durations O
to O
the O
minimum O
required O
. O

* O
Follow O
patients O
for O
signs O
and O
symptoms O
of O
respiratory B-NonOSE_AE
depression I-NonOSE_AE
and O
sedation B-NonOSE_AE
. O

PRECAUTIONS O
General O
If O
Valium O
is O
to O
be O
combined O
with O
other O
psychotropic O
agents O
or O
anticonvulsant O
drugs O
, O
careful O
consideration O
should O
be O
given O
to O
the O
pharmacology O
of O
the O
agents O
to O
be O
employed O
- O
particularly O
with O
known O
compounds O
that O
may O
potentiate O
the O
action O
of O
diazepam O
, O
such O
as O
phenothiazines O
, O
narcotics O
, O
barbiturates O
, O
MAO O
inhibitors O
and O
other O
antidepressants O
( O
see O
Drug O
Interactions O
) O
. O

The O
usual O
precautions O
are O
indicated O
for O
severely O
depressed B-Not_AE_Candidate
patients O
or O
those O
in O
whom O
there O
is O
any O
evidence O
of O
latent O
depression B-Not_AE_Candidate
or O
anxiety B-Not_AE_Candidate
associated O
with I-Not_AE_Candidate
depression I-Not_AE_Candidate
, O
particularly O
the O
recognition O
that O
suicidal B-Not_AE_Candidate
tendencies I-Not_AE_Candidate
may O
be O
present O
and O
protective O
measures O
may O
be O
necessary O
. O

Psychiatric B-OSE_Labeled_AE
and O
paradoxical O
reactions I-OSE_Labeled_AE
are O
known O
to O
occur O
when O
using O
benzodiazepines O
( O
see O
ADVERSE O
REACTIONS O
) O
. O

Should O
this O
occur O
, O
use O
of O
the O
drug O
should O
be O
discontinued O
. O

These O
reactions O
are O
more O
likely O
to O
occur O
in O
children O
and O
the O
elderly O
. O

A O
lower O
dose O
is O
recommended O
for O
patients O
with O
chronic B-Not_AE_Candidate
respiratory I-Not_AE_Candidate
insufficiency I-Not_AE_Candidate
, O
due O
to O
the O
risk O
of O
respiratory B-NonOSE_AE
depression I-NonOSE_AE
. O

Benzodiazepines O
should O
be O
used O
with O
extreme O
caution O
in O
patients O
with O
a O
history O
of O
alcohol B-Not_AE_Candidate
or O
drug O
abuse I-Not_AE_Candidate
( O
see O
DRUG O
ABUSE O
AND O
DEPENDENCE O
) O
. O

In O
debilitated B-Not_AE_Candidate
patients O
, O
it O
is O
recommended O
that O
the O
dosage O
be O
limited O
to O
the O
smallest O
effective O
amount O
to O
preclude O
the O
development O
of O
ataxia B-NonOSE_AE
or O
oversedation B-NonOSE_AE
( O
2 O
mg O
to O
2.5 O
mg O
once O
or O
twice O
daily O
, O
initially O
, O
to O
be O
increased O
gradually O
as O
needed O
and O
tolerated O
) O
. O

Some O
loss B-OSE_Labeled_AE
of I-OSE_Labeled_AE
response I-OSE_Labeled_AE
to I-OSE_Labeled_AE
the I-OSE_Labeled_AE
effects I-OSE_Labeled_AE
of O
benzodiazepines O
may O
develop O
after O
repeated O
use O
of O
Valium O
for O
a O
prolonged O
time O
. O

Information O
For O
Patients O
To O
assure O
the O
safe O
and O
effective O
use O
of O
benzodiazepines O
, O
patients O
should O
be O
informed O
that O
, O
since O
benzodiazepines O
may O
produce O
psychological O
and O
physical O
dependence O
, O
it O
is O
advisable O
that O
they O
consult O
with O
their O
physician O
before O
either O
increasing O
the O
dose O
or O
abruptly O
discontinuing O
this O
drug O
. O

The O
risk O
of O
dependence O
increases O
with O
duration O
of O
treatment O
; O
it O
is O
also O
greater O
in O
patients O
with O
a O
history O
of O
alcohol O
or O
drug O
abuse O
. O

Patients O
should O
be O
advised O
against O
the O
simultaneous O
ingestion O
of O
alcohol O
and O
other O
CNS-depressant O
drugs O
during O
Valium O
therapy O
. O

As O
is O
true O
of O
most O
CNS-acting O
drugs O
, O
patients O
receiving O
Valium O
should O
be O
cautioned O
against O
engaging O
in O
hazardous O
occupations O
requiring O
complete O
mental O
alertness O
, O
such O
as O
operating O
machinery O
or O
driving O
a O
motor O
vehicle O
. O

Drug O
Interactions O
Opioids O
The O
concomitant O
use O
of O
benzodiazepines O
and O
opioids O
increases O
the O
risk O
of O
respiratory B-NonOSE_AE
depression I-NonOSE_AE
because O
of O
actions O
at O
different O
receptor O
sites O
in O
the O
CNS O
that O
control O
respiration O
. O

Benzodiazepines O
interact O
at O
GABAAsites O
and O
opioids O
interact O
primarily O
at O
mu O
receptors O
. O

When O
benzodiazepines O
and O
opioids O
are O
combined O
, O
the O
potential O
for O
benzodiazepines O
to O
significantly O
worsen O
opioid-related O
respiratory B-NonOSE_AE
depression I-NonOSE_AE
exists O
. O

Limit O
dosage O
and O
duration O
of O
concomitant O
use O
of O
benzodiazepines O
and O
opioids O
, O
and O
monitor O
patients O
closely O
for O
respiratory B-NonOSE_AE
depression I-NonOSE_AE
and O
sedation B-NonOSE_AE
. O

Centrally O
Acting O
Agents O
If O
Valium O
is O
to O
be O
combined O
with O
other O
centrally O
acting O
agents O
careful O
consideration O
should O
be O
given O
to O
the O
pharmacology O
of O
the O
agents O
employed O
particularly O
with O
compounds O
that O
may O
potentiate O
or O
be O
potentiated O
by O
the O
action O
of O
Valium O
, O
such O
as O
phenothiazines O
, O
antipsychotics O
, O
anxiolytics/sedatives O
, O
hypnotics O
, O
anticonvulsants O
, O
narcotic O
analgesics O
, O
anesthetics O
, O
sedative O
antihistamines O
, O
narcotics O
, O
barbiturates O
, O
MAO O
inhibitors O
and O
other O
antidepressants O
. O

Alcohol O
Concomitant O
use O
with O
alcohol O
is O
not O
recommended O
due O
to O
enhancement B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
sedative I-NonOSE_AE
effect I-NonOSE_AE
. O

Antacids O
Diazepam O
peak O
concentrations O
are O
30 O
% O
lower O
when O
antacids O
are O
administered O
concurrently O
. O

However O
, O
there O
is O
no O
effect O
on O
the O
extent O
of O
absorption O
. O

The O
lower O
peak O
concentrations O
appear O
due O
to O
a O
slower O
rate O
of O
absorption O
, O
with O
the O
time O
required O
to O
achieve O
peak O
concentrations O
on O
average O
20 O
- O
25 O
minutes O
greater O
in O
the O
presence O
of O
antacids O
. O

However O
, O
this O
difference O
was O
not O
statistically O
significant O
. O

Compounds O
Which O
Inhibit O
Certain O
Hepatic O
Enzymes O
There O
is O
a O
potentially O
relevant O
interaction O
between O
diazepam O
and O
compounds O
which O
inhibit O
certain O
hepatic O
enzymes O
( O
particularly O
cytochrome O
P450 O
3A O
and O
2C19 O
) O
. O

Data O
indicate O
that O
these O
compounds O
influence O
the O
pharmacokinetics O
of O
diazepam O
and O
may O
lead O
to O
increased O
and O
prolonged O
sedation B-NonOSE_AE
. O

At O
present O
, O
this O
reaction O
is O
known O
to O
occur O
with O
cimetidine O
, O
ketoconazole O
, O
fluvoxamine O
, O
fluoxetine O
, O
and O
omeprazole O
. O

Phenytoin O
There O
have O
also O
been O
reports O
that O
the O
metabolic O
elimination O
of O
phenytoin O
is O
decreased O
by O
diazepam O
. O

Carcinogenesis O
, O
Mutagenesis O
, O
Impairment O
of O
Fertility O
In O
studies O
in O
which O
mice O
and O
rats O
were O
administered O
diazepam O
in O
the O
diet O
at O
a O
dose O
of O
75 O
mg/kg/day O
( O
approximately O
6 O
and O
12 O
times O
, O
respectively O
, O
the O
maximum O
recommended O
human O
dose O
[ O
MRHD=1 O
mg/kg/day O
] O
on O
a O
mg/m O
2 O
basis O
) O
for O
80 O
and O
104 O
weeks O
, O
respectively O
, O
an O
increased O
incidence O
of O
liver B-NonOSE_AE
tumors I-NonOSE_AE
was O
observed O
in O
males O
of O
both O
species O
. O

The O
data O
currently O
available O
are O
inadequate O
to O
determine O
the O
mutagenic B-NonOSE_AE
potential O
of O
diazepam O
. O

Reproduction O
studies O
in O
rats O
showed O
decreases B-NonOSE_AE
in I-NonOSE_AE
the I-NonOSE_AE
number I-NonOSE_AE
of I-NonOSE_AE
pregnancies I-NonOSE_AE
and O
in O
the O
number O
of O
surviving O
offspring O
following O
administration O
of O
an O
oral O
dose O
of O
100 O
mg/kg/day O
( O
approximately O
16 O
times O
the O
MRHD O
on O
a O
mg/m O
2 O
basis O
) O
prior O
to O
and O
during O
mating O
and O
throughout O
gestation O
and O
lactation O
. O

No O
adverse O
effects O
on O
fertility B-NonOSE_AE
or O
offspring B-NonOSE_AE
viability I-NonOSE_AE
were O
noted O
at O
a O
dose O
of O
80 O
mg/kg/day O
( O
approximately O
13 O
times O
the O
MRHD O
on O
a O
mg/m O
2 O
basis O
) O
. O

Pregnancy O
Category O
D O
( O
see O
WARNINGS O
: O
Pregnancy B-NonOSE_AE
) O
. O

Pediatric O
Use O
Safety O
and O
effectiveness O
in O
pediatric O
patients O
below O
the O
age O
of O
6 O
months O
have O
not O
been O
established O
. O

Geriatric O
Use O
In O
elderly O
patients O
, O
it O
is O
recommended O
that O
the O
dosage O
be O
limited O
to O
the O
smallest O
effective O
amount O
to O
preclude O
the O
development O
of O
ataxia B-NonOSE_AE
or O
oversedation B-NonOSE_AE
( O
2 O
mg O
to O
2.5 O
mg O
once O
or O
twice O
daily O
, O
initially O
to O
be O
increased O
gradually O
as O
needed O
and O
tolerated O
) O
. O

Extensive O
accumulation O
of O
diazepam O
and O
its O
major O
metabolite O
, O
desmethyldiazepam O
, O
has O
been O
noted O
following O
chronic O
administration O
of O
diazepam O
in O
healthy O
elderly O
male O
subjects O
. O

Metabolites O
of O
this O
drug O
are O
known O
to O
be O
substantially O
excreted O
by O
the O
kidney O
, O
and O
the O
risk O
of O
toxic B-NonOSE_AE
reactions I-NonOSE_AE
may O
be O
greater O
in O
patients O
with O
impaired B-Not_AE_Candidate
renal I-Not_AE_Candidate
function I-Not_AE_Candidate
. O

Because O
elderly O
patients O
are O
more O
likely O
to O
have O
decreased B-Not_AE_Candidate
renal I-Not_AE_Candidate
function I-Not_AE_Candidate
, O
care O
should O
be O
taken O
in O
dose O
selection O
, O
and O
it O
may O
be O
useful O
to O
monitor O
renal O
function O
. O

Hepatic O
Insufficiency O
Decreases O
in O
clearance O
and O
protein O
binding O
, O
and O
increases O
in O
volume O
of O
distribution O
and O
half-life O
have O
been O
reported O
in O
patients O
with O
cirrhosis B-Not_AE_Candidate
. O

In O
such O
patients O
, O
a O
2- O
to O
5- O
fold O
increase O
in O
mean O
half-life O
has O
been O
reported O
. O

Delayed O
elimination O
has O
also O
been O
reported O
for O
the O
active O
metabolite O
desmethyldiazepam O
. O

Benzodiazepines O
are O
commonly O
implicated O
in O
hepatic B-OSE_Labeled_AE
encephalopathy I-OSE_Labeled_AE
. O

Increases O
in O
half-life O
have O
also O
been O
reported O
in O
hepatic B-Not_AE_Candidate
fibrosis I-Not_AE_Candidate
and O
in O
both O
acute B-Not_AE_Candidate
and O
chronic O
hepatitis I-Not_AE_Candidate
( O
see O
CLINICAL O
PHARMACOLOGY O
: O
Pharmacokinetics O
in O
Special O
Populations O
: O
Hepatic O
Insufficiency O
) O
. O

WARNINGS O
Concomitant O
use O
of O
benzodiazepiones O
, O
including O
Valium O
, O
and O
opioids O
may O
result O
in O
profound O
sedation B-NonOSE_AE
, O
respiratory B-NonOSE_AE
depression I-NonOSE_AE
, O
coma B-NonOSE_AE
, O
and O
death B-NonOSE_AE
. O

Because O
of O
these O
risks O
, O
reserve O
concomitant O
prescribing O
of O
these O
drugs O
for O
use O
in O
patients O
for O
whom O
alternative O
treatment O
options O
are O
inadequate O
. O

Observational O
studies O
have O
demonstrated O
that O
concomitant O
use O
of O
opioid O
analgesics O
and O
benzodiazepines O
increases O
the O
risk O
of O
drug-related O
mortality B-NonOSE_AE
compared O
to O
use O
of O
opioids O
alone O
. O

If O
a O
decision O
is O
made O
to O
prescribe O
Valium O
concomitantly O
with O
opioids O
, O
prescribe O
the O
lowest O
effective O
dosages O
and O
minimum O
durations O
of O
concomitant O
use O
, O
and O
follow O
patients O
closely O
for O
signs O
and O
symptoms O
of O
respiratory B-NonOSE_AE
depression I-NonOSE_AE
and O
sedation B-NonOSE_AE
. O

In O
patients O
already O
receiving O
an O
opioid O
analgesic O
, O
prescribe O
a O
lower O
initial O
dose O
of O
Valium O
than O
indicated O
in O
the O
absence O
of O
an O
opioid O
and O
titrate O
based O
on O
clinical O
response O
. O

If O
an O
opioid O
is O
initiated O
in O
a O
patient O
already O
taking O
Valium O
, O
prescribe O
a O
lower O
initial O
dose O
of O
the O
opioid O
and O
titrate O
based O
upon O
clinical O
response O
. O

Advise O
both O
patients O
and O
caregivers O
about O
the O
risks O
of O
respiratory B-NonOSE_AE
depression I-NonOSE_AE
and O
sedation B-NonOSE_AE
when O
Valium O
is O
used O
with O
opioids O
. O

Advise O
patients O
not O
to O
drive O
or O
operate O
heavy O
machinery O
until O
the O
effects O
of O
concomitant O
use O
with O
the O
opioid O
have O
been O
determined O
( O
see O
Drug O
Interactions O
) O
. O

Valium O
is O
not O
recommended O
in O
the O
treatment O
of O
psychotic B-Not_AE_Candidate
patients O
and O
should O
not O
be O
employed O
instead O
of O
appropriate O
treatment O
. O

Since O
Valium O
has O
a O
central B-OSE_Labeled_AE
nervous I-OSE_Labeled_AE
system I-OSE_Labeled_AE
depressant I-OSE_Labeled_AE
effect I-OSE_Labeled_AE
, O
patients O
should O
be O
advised O
against O
the O
simultaneous O
ingestion O
of O
alcohol O
and O
other O
CNS-depressant O
drugs O
during O
Valium O
therapy O
. O

As O
with O
other O
agents O
that O
have O
anticonvulsant O
activity O
, O
when O
Valium O
is O
used O
as O
an O
adjunct O
in O
treating O
convulsive B-Not_AE_Candidate
disorders I-Not_AE_Candidate
, O
the O
possibility O
of O
an O
increase O
in O
the O
frequency O
and/or O
severity O
of O
grand B-Not_AE_Candidate
mal I-Not_AE_Candidate
seizures I-Not_AE_Candidate
may O
require O
an O
increase O
in O
the O
dosage O
of O
standard O
anticonvulsant O
medication O
. O

Abrupt O
withdrawal O
of O
Valium O
in O
such O
cases O
may O
also O
be O
associated O
with O
a O
temporary O
increase O
in O
the O
frequency O
and/or O
severity O
of O
seizures B-NonOSE_AE
. O

Pregnancy O
An O
increased O
risk O
of O
congenital B-OSE_Labeled_AE
malformation I-OSE_Labeled_AE
s O
and O
other O
developmental B-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
associated O
with O
the O
use O
of O
benzodiazepine O
drugs O
during O
pregnancy B-Not_AE_Candidate
has O
been O
suggested O
. O

There O
may O
also O
be O
non B-OSE_Labeled_AE
- I-OSE_Labeled_AE
teratogenic I-OSE_Labeled_AE
risks I-OSE_Labeled_AE
associated O
with O
the O
use O
of O
benzodiazepines O
during O
pregnancy B-Not_AE_Candidate
. O

There O
have O
been O
reports O
of O
neonatal B-OSE_Labeled_AE
flaccidity I-OSE_Labeled_AE
, O
respiratory O
and O
feeding O
difficulties O
, O
and O
hypothermia O
in O
children O
born O
to O
mothers O
who O
have O
been O
receiving O
benzodiazepines O
late O
in O
pregnancy B-Not_AE_Candidate
. O

In O
addition O
, O
children O
born O
to O
mothers O
receiving O
benzodiazepines O
on O
a O
regular O
basis O
late O
in O
pregnancy B-Not_AE_Candidate
may O
be O
at O
some O
risk O
of O
experiencing O
withdrawal B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
during O
the O
postnatal I-OSE_Labeled_AE
period O
. O

Diazepam O
has O
been O
shown O
to O
be O
teratogenic B-NonOSE_AE
in O
mice O
and O
hamsters O
when O
given O
orally O
at O
daily O
doses O
of O
100 O
mg/kg O
or O
greater O
( O
approximately O
eight O
times O
the O
maximum O
recommended O
human O
dose O
[ O
MRHD=1 O
mg/kg/day O
] O
or O
greater O
on O
a O
mg/m O
2 O
basis O
) O
. O

Cleft B-NonOSE_AE
palate I-NonOSE_AE
and O
encephalopathy B-NonOSE_AE
are O
the O
most O
common O
and O
consistently O
reported O
malformations B-NonOSE_AE
produced O
in O
these O
species O
by O
administration O
of O
high O
, O
maternally O
toxic O
doses O
of O
diazepam O
during O
organogenesis O
. O

Rodent O
studies O
have O
indicated O
that O
prenatal O
exposure O
to O
diazepam O
doses O
similar O
to O
those O
used O
clinically O
can O
produce O
long-term O
changes B-NonOSE_AE
in I-NonOSE_AE
cellular I-NonOSE_AE
immune I-NonOSE_AE
responses I-NonOSE_AE
, O
brain O
neurochemistry O
, O
and O
behavior O
. O

In O
general O
, O
the O
use O
of O
diazepam O
in O
women O
of O
childbearing O
potential O
, O
and O
more O
specifically O
during O
known O
pregnancy B-Not_AE_Candidate
, O
should O
be O
considered O
only O
when O
the O
clinical O
situation O
warrants O
the O
risk B-OSE_Labeled_AE
to I-OSE_Labeled_AE
the I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
. O

The O
possibility O
that O
a O
woman O
of O
childbearing O
potential O
may O
be O
pregnant B-NonOSE_AE
at O
the O
time O
of O
institution O
of O
therapy O
should O
be O
considered O
. O

If O
this O
drug O
is O
used O
during O
pregnancy B-Not_AE_Candidate
, O
or O
if O
the O
patient O
becomes O
pregnant B-NonOSE_AE
while O
taking O
this O
drug O
, O
the O
patient O
should O
be O
apprised O
of O
the O
potential O
hazard B-OSE_Labeled_AE
to I-OSE_Labeled_AE
the I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
. O

Patients O
should O
also O
be O
advised O
that O
if O
they O
become O
pregnant B-NonOSE_AE
during O
therapy O
or O
intend O
to O
become O
pregnant B-NonOSE_AE
they O
should O
communicate O
with O
their O
physician O
about O
the O
desirability O
of O
discontinuing O
the O
drug O
. O

Labor O
and O
Delivery O
Special O
care O
must O
be O
taken O
when O
Valium O
is O
used O
during O
labor O
and O
delivery O
, O
as O
high O
single O
doses O
may O
produce O
irregularities B-OSE_Labeled_AE
in I-OSE_Labeled_AE
the I-OSE_Labeled_AE
fetal I-OSE_Labeled_AE
heart I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
and O
hypotonia B-OSE_Labeled_AE
, O
poor O
sucking O
, O
hypothermia O
, O
and O
moderate O
respiratory O
depression O
in O
the O
neonates I-OSE_Labeled_AE
. O

With O
newborn O
infants O
it O
must O
be O
remembered O
that O
the O
enzyme O
system O
involved O
in O
the O
breakdown O
of O
the O
drug O
is O
not O
yet O
fully O
developed O
( O
especially O
in O
premature B-Not_AE_Candidate
infants I-Not_AE_Candidate
) O
. O

Nursing O
Mothers O
Diazepam O
passes O
into O
breast O
milk O
. O

Breastfeeding O
is O
therefore O
not O
recommended O
in O
patients O
receiving O
Valium O
. O

6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
the O
labeling O
: O
* O
Known O
hypersensitivity B-OSE_Labeled_AE
to O
amphetamine O
products O
or O
other O
ingredients O
of O
VYVANSE O
[ O
see O
Contraindications O
( O
4 O
) O
] O
* O
Hypertensive B-NonOSE_AE
Crisis I-NonOSE_AE
When O
Used O
Concomitantly O
with O
Monoamine O
Oxidase O
Inhibitors O
[ O
see O
Contraindications O
( O
4 O
) O
and O
Drug O
Interactions O
( O
7.1 O
) O
] O
* O
Drug B-OSE_Labeled_AE
Dependence I-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
, O
Warnings O
and O
Precautions O
( O
5.1 O
) O
, O
and O
Drug O
Abuse O
and O
Dependence O
( O
9.2 O
, O
9.3 O
) O
] O
* O
Serious O
Cardiovascular B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Blood B-OSE_Labeled_AE
Pressure I-OSE_Labeled_AE
and O
Heart O
Rate O
Increases I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Psychiatric B-OSE_Labeled_AE
Adverse I-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Suppression B-OSE_Labeled_AE
of I-OSE_Labeled_AE
Growth I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Peripheral B-OSE_Labeled_AE
Vasculopathy I-OSE_Labeled_AE
, O
including O
Raynaud B-OSE_Labeled_AE
' I-OSE_Labeled_AE
s I-OSE_Labeled_AE
phenomenon I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Serotonin B-NonOSE_AE
Syndrome I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
incidence O
> O
=5 O
% O
and O
at O
a O
rate O
at O
least O
twice O
placebo O
) O
in O
children O
, O
adolescents O
, O
and/or O
adults O
with O
ADHD O
were O
anorexia O
, O
anxiety O
, O
decreased O
appetite O
, O
decreased O
weight O
, O
diarrhea O
, O
dizziness O
, O
dry O
mouth O
, O
irritability O
, O
insomnia O
, O
nausea O
, O
upper O
abdominal O
pain O
, O
and O
vomiting O
( O
6.1 O
) O
Most O
common O
adverse O
reactions O
( O
incidence O
> O
= O
5 O
% O
and O
at O
a O
rate O
at O
least O
twice O
placebo O
) O
in O
adults O
with O
BED O
were O
dry O
mouth O
, O
insomnia O
, O
decreased O
appetite O
, O
increased O
heart O
rate O
, O
constipation O
, O
feeling O
jittery O
, O
and O
anxiety O
( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Shire O
US O
Inc O
. O
at O
1-800-828-2088 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
6.1 O
Clinical O
Trial O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Attention B-Not_AE_Candidate
Deficit I-Not_AE_Candidate
Hyperactivity I-Not_AE_Candidate
Disorder I-Not_AE_Candidate
The O
safety O
data O
in O
this O
section O
is O
based O
on O
data O
from O
the O
4-week O
parallel-group O
controlled O
clinical O
studies O
of O
VYVANSE O
in O
pediatric O
and O
adult O
patients O
with O
ADHD B-Not_AE_Candidate
[ O
see O
Clinical O
Studies O
( O
14.1 O
) O
] O
. O

Adverse O
Reactions O
Associated O
with O
Discontinuation O
of O
Treatment O
in O
ADHD O
Clinical O
Trials O
In O
the O
controlled O
trial O
in O
patients O
ages O
6 O
to O
12 O
years O
( O
Study O
1 O
) O
, O
8 O
% O
( O
18/218 O
) O
of O
VYVANSE-treated O
patients O
discontinued O
due O
to O
adverse O
reactions O
compared O
to O
0 O
% O
( O
0/72 O
) O
of O
placebo-treated O
patients O
. O

The O
most O
frequently O
reported O
adverse O
reactions O
( O
1 O
% O
or O
more O
and O
twice O
rate O
of O
placebo O
) O
were O
ECG B-OSE_Labeled_AE
voltage I-OSE_Labeled_AE
criteria I-OSE_Labeled_AE
for I-OSE_Labeled_AE
ventricular I-OSE_Labeled_AE
hypertrophy I-OSE_Labeled_AE
, O
tic B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
psychomotor B-OSE_Labeled_AE
hyperactivity I-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
and O
rash B-OSE_Labeled_AE
[ O
2 O
instances O
for O
each O
adverse O
reaction O
, O
i.e. O
, O
2/218 O
( O
1 O
% O
) O
] O
. O

Less O
frequently O
reported O
adverse O
reactions O
( O
less O
than O
1 O
% O
or O
less O
than O
twice O
rate O
of O
placebo O
) O
included O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
somnolence B-OSE_Labeled_AE
, O
logorrhea B-OSE_Labeled_AE
, O
chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
anger B-OSE_Labeled_AE
and O
hypertension B-OSE_Labeled_AE
. O

In O
the O
controlled O
trial O
in O
patients O
ages O
13 O
to O
17 O
years O
( O
Study O
4 O
) O
, O
3 O
% O
( O
7/233 O
) O
of O
VYVANSE-treated O
patients O
discontinued O
due O
to O
adverse O
reactions O
compared O
to O
1 O
% O
( O
1/77 O
) O
of O
placebo-treated O
patients O
. O

The O
most O
frequently O
reported O
adverse O
reactions O
( O
1 O
% O
or O
more O
and O
twice O
rate O
of O
placebo O
) O
were O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
( O
2/233 O
; O
1 O
% O
) O
and O
insomnia B-OSE_Labeled_AE
( O
2/233 O
; O
1 O
% O
) O
. O

Less O
frequently O
reported O
adverse O
reactions O
( O
less O
than O
1 O
% O
or O
less O
than O
twice O
rate O
of O
placebo O
) O
included O
irritability B-OSE_Labeled_AE
, O
dermatillomania B-OSE_Labeled_AE
, O
mood B-OSE_Labeled_AE
swings I-OSE_Labeled_AE
, O
and O
dyspnea B-OSE_Labeled_AE
. O

In O
the O
controlled O
adult O
trial O
( O
Study O
7 O
) O
, O
6 O
% O
( O
21/358 O
) O
of O
VYVANSE-treated O
patients O
discontinued O
due O
to O
adverse O
reactions O
compared O
to O
2 O
% O
( O
1/62 O
) O
of O
placebo-treated O
patients O
. O

The O
most O
frequently O
reported O
adverse O
reactions O
( O
1 O
% O
or O
more O
and O
twice O
rate O
of O
placebo O
) O
were O
insomnia B-OSE_Labeled_AE
( O
8/358 O
; O
2 O
% O
) O
, O
tachycardia B-OSE_Labeled_AE
( O
3/358 O
; O
1 O
% O
) O
, O
irritability B-OSE_Labeled_AE
( O
2/358 O
; O
1 O
% O
) O
, O
hypertension B-OSE_Labeled_AE
( O
4/358 O
; O
1 O
% O
) O
, O
headache B-OSE_Labeled_AE
( O
2/358 O
; O
1 O
% O
) O
, O
anxiety B-OSE_Labeled_AE
( O
2/358 O
; O
1 O
% O
) O
, O
and O
dyspnea B-OSE_Labeled_AE
( O
3/358 O
; O
1 O
% O
) O
. O

Less O
frequently O
reported O
adverse O
reactions O
( O
less O
than O
1 O
% O
or O
less O
than O
twice O
rate O
of O
placebo O
) O
included O
palpitations B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
agitation B-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
, O
paranoia B-OSE_Labeled_AE
and O
restlessness B-OSE_Labeled_AE
. O

Adverse O
Reactions O
Occurring O
at O
an O
Incidence O
of O
> O
=5 O
% O
or O
More O
Among O
VYVANSE O
Treated O
Patients O
with O
ADHD O
in O
Clinical O
Trials O
The O
most O
common O
adverse O
reactions O
( O
incidence O
> O
=5 O
% O
and O
at O
a O
rate O
at O
least O
twice O
placebo O
) O
reported O
in O
children O
, O
adolescents O
, O
and/or O
adults O
were O
anorexia B-OSE_Labeled_AE
, O
anxiety B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
weight I-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
irritability B-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
upper B-OSE_Labeled_AE
abdominal I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
and O
vomiting B-OSE_Labeled_AE
. O

Adverse O
Reactions O
Occurring O
at O
an O
Incidence O
of O
2 O
% O
or O
More O
Among O
VYVANSE O
Treated O
Patients O
with O
ADHD O
in O
Clinical O
Trials O
Adverse O
reactions O
reported O
in O
the O
controlled O
trials O
in O
pediatric O
patients O
ages O
6 O
to O
12 O
years O
( O
Study O
1 O
) O
, O
adolescent O
patients O
ages O
13 O
to O
17 O
years O
( O
Study O
4 O
) O
, O
and O
adult O
patients O
( O
Study O
7 O
) O
treated O
with O
VYVANSE O
or O
placebo O
are O
presented O
in O
Tables O
1 O
, O
2 O
, O
and O
3 O
below O
. O

Table O
1 O
Adverse O
Reactions O
Reported O
by O
2 O
% O
or O
More O
of O
Children O
( O
Ages O
6 O
to O
12 O
Years O
) O
with O
ADHD O
Taking O
VYVANSE O
and O
at O
least O
Twice O
the O
Incidence O
in O
Patients O
Taking O
Placebo O
in O
a O
4-Week O
Clinical O
Trial O
( O
Study O
1 O
) O
VYVANSE O
( O
n=218 O
) O
Placebo O
( O
n=72 O
) O
Decreased B-OSE_Labeled_AE
Appetite I-OSE_Labeled_AE
39 O
% O
4 O
% O
Insomnia B-OSE_Labeled_AE
22 O
% O
3 O
% O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
Upper I-OSE_Labeled_AE
12 O
% O
6 O
% O
Irritability B-OSE_Labeled_AE
10 O
% O
0 O
% O
Vomiting B-OSE_Labeled_AE
9 O
% O
4 O
% O
Weight B-OSE_Labeled_AE
Decreased I-OSE_Labeled_AE
9 O
% O
1 O
% O
Nausea B-OSE_Labeled_AE
6 O
% O
3 O
% O
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
5 O
% O
0 O
% O
Dizziness B-OSE_Labeled_AE
5 O
% O
0 O
% O
Affect B-OSE_Labeled_AE
lability I-OSE_Labeled_AE
3 O
% O
0 O
% O
Rash B-OSE_Labeled_AE
3 O
% O
0 O
% O
Pyrexia B-OSE_Labeled_AE
2 O
% O
1 O
% O
Somnolence B-OSE_Labeled_AE
2 O
% O
1 O
% O
Tic B-OSE_Labeled_AE
2 O
% O
0 O
% O
Anorexia B-OSE_Labeled_AE
2 O
% O
0 O
% O
Table O
2 O
Adverse O
Reactions O
Reported O
by O
2 O
% O
or O
More O
of O
Adolescent O
( O
Ages O
13 O
to O
17 O
Years O
) O
Patients O
with O
ADHD O
Taking O
VYVANSE O
and O
at O
least O
Twice O
the O
Incidence O
in O
Patients O
Taking O
Placebo O
in O
a O
4-Week O
Clinical O
Trial O
( O
Study O
4 O
) O
VYVANSE O
( O
n=233 O
) O
Placebo O
( O
n=77 O
) O
Decreased B-OSE_Labeled_AE
Appetite I-OSE_Labeled_AE
34 O
% O
3 O
% O
Insomnia B-OSE_Labeled_AE
13 O
% O
4 O
% O
Weight B-OSE_Labeled_AE
Decreased I-OSE_Labeled_AE
9 O
% O
0 O
% O
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
4 O
% O
1 O
% O
Palpitations B-OSE_Labeled_AE
2 O
% O
1 O
% O
Anorexia B-OSE_Labeled_AE
2 O
% O
0 O
% O
Tremor B-OSE_Labeled_AE
2 O
% O
0 O
% O
Table O
3 O
Adverse O
Reactions O
Reported O
by O
2 O
% O
or O
More O
of O
Adult O
Patients O
with O
ADHD O
Taking O
VYVANSE O
and O
at O
least O
Twice O
the O
Incidence O
in O
Patients O
Taking O
Placebo O
in O
a O
4-Week O
Clinical O
Trial O
( O
Study O
7 O
) O
VYVANSE O
( O
n=358 O
) O
Placebo O
( O
n=62 O
) O
Decreased B-OSE_Labeled_AE
Appetite I-OSE_Labeled_AE
27 O
% O
2 O
% O
Insomnia B-OSE_Labeled_AE
27 O
% O
8 O
% O
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
26 O
% O
3 O
% O
Diarrhea B-OSE_Labeled_AE
7 O
% O
0 O
% O
Nausea B-OSE_Labeled_AE
7 O
% O
0 O
% O
Anxiety B-OSE_Labeled_AE
6 O
% O
0 O
% O
Anorexia B-OSE_Labeled_AE
5 O
% O
0 O
% O
Feeling B-OSE_Labeled_AE
Jittery I-OSE_Labeled_AE
4 O
% O
0 O
% O
Agitation B-OSE_Labeled_AE
3 O
% O
0 O
% O
Increased B-OSE_Labeled_AE
Blood I-OSE_Labeled_AE
Pressure I-OSE_Labeled_AE
3 O
% O
0 O
% O
Hyperhidrosis B-OSE_Labeled_AE
3 O
% O
0 O
% O
Restlessness B-OSE_Labeled_AE
3 O
% O
0 O
% O
Decreased B-OSE_Labeled_AE
Weight I-OSE_Labeled_AE
3 O
% O
0 O
% O
Dyspnea B-OSE_Labeled_AE
2 O
% O
0 O
% O
Increased B-OSE_Labeled_AE
Heart I-OSE_Labeled_AE
Rate I-OSE_Labeled_AE
2 O
% O
0 O
% O
Tremor B-OSE_Labeled_AE
2 O
% O
0 O
% O
Palpitations B-OSE_Labeled_AE
2 O
% O
0 O
% O
In O
addition O
, O
in O
the O
adult O
population O
erectile B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
was O
observed O
in O
2.6 O
% O
of O
males O
on O
VYVANSE O
and O
0 O
% O
on O
placebo O
; O
decreased B-OSE_Labeled_AE
libido I-OSE_Labeled_AE
was O
observed O
in O
1.4 O
% O
of O
subjects O
on O
VYVANSE O
and O
0 O
% O
on O
placebo O
. O

Weight O
Loss O
and O
Slowing O
Growth O
Rate O
in O
Pediatric O
Patients O
with O
ADHD O
In O
a O
controlled O
trial O
of O
VYVANSE O
in O
children O
ages O
6 O
to O
12 O
years O
( O
Study O
1 O
) O
, O
mean O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
from O
baseline O
after O
4 O
weeks O
of O
therapy O
was O
-0.9 O
, O
-1.9 O
, O
and O
-2.5 O
pounds O
, O
respectively O
, O
for O
patients O
receiving O
30 O
mg O
, O
50 O
mg O
, O
and O
70 O
mg O
of O
VYVANSE O
, O
compared O
to O
a O
1 O
pound O
weight B-NonOSE_AE
gain I-NonOSE_AE
for O
patients O
receiving O
placebo O
. O

Higher O
doses O
were O
associated O
with O
greater O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
with O
4 O
weeks O
of O
treatment O
. O

Careful O
follow-up O
for O
weight O
in O
children O
ages O
6 O
to O
12 O
years O
who O
received O
VYVANSE O
over O
12 O
months O
suggests O
that O
consistently O
medicated O
children O
( O
i.e O
. O

treatment O
for O
7 O
days O
per O
week O
throughout O
the O
year O
) O
have O
a O
slowing B-OSE_Labeled_AE
in I-OSE_Labeled_AE
growth I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
, O
measured O
by O
body O
weight O
as O
demonstrated O
by O
an O
age- O
and O
sex-normalized O
mean O
change O
from O
baseline O
in O
percentile O
, O
of O
-13.4 O
over O
1 O
year O
( O
average O
percentiles O
at O
baseline O
and O
12 O
months O
were O
60.9 O
and O
47.2 O
, O
respectively O
) O
. O

In O
a O
4-week O
controlled O
trial O
of O
VYVANSE O
in O
adolescents O
ages O
13 O
to O
17 O
years O
, O
mean O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
from O
baseline O
to O
endpoint O
was O
-2.7 O
, O
-4.3 O
, O
and O
-4.8 O
lbs. O
, O
respectively O
, O
for O
patients O
receiving O
30 O
mg O
, O
50 O
mg O
, O
and O
70 O
mg O
of O
VYVANSE O
, O
compared O
to O
a O
2.0 O
pound O
weight B-NonOSE_AE
gain I-NonOSE_AE
for O
patients O
receiving O
placebo O
. O

Careful O
follow-up O
of O
weight O
and O
height O
in O
children O
ages O
7 O
to O
10 O
years O
who O
were O
randomized O
to O
either O
methylphenidate O
or O
non-medication O
treatment O
groups O
over O
14 O
months O
, O
as O
well O
as O
in O
naturalistic O
subgroups O
of O
newly O
methylphenidate-treated O
and O
non-medication O
treated O
children O
over O
36 O
months O
( O
to O
the O
ages O
of O
10 O
to O
13 O
years O
) O
, O
suggests O
that O
consistently O
medicated O
children O
( O
i.e O
. O

treatment O
for O
7 O
days O
per O
week O
throughout O
the O
year O
) O
have O
a O
temporary O
slowing B-OSE_Labeled_AE
in I-OSE_Labeled_AE
growth I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
( O
on O
average O
, O
a O
total O
of O
about O
2 B-OSE_Labeled_AE
cm I-OSE_Labeled_AE
less I-OSE_Labeled_AE
growth I-OSE_Labeled_AE
in I-OSE_Labeled_AE
height I-OSE_Labeled_AE
and O
2 B-OSE_Labeled_AE
. I-OSE_Labeled_AE
7 I-OSE_Labeled_AE
kg I-OSE_Labeled_AE
less I-OSE_Labeled_AE
growth I-OSE_Labeled_AE
in I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
over O
3 O
years O
) O
, O
without O
evidence O
of O
growth O
rebound O
during O
this O
period O
of O
development O
. O

In O
a O
controlled O
trial O
of O
amphetamine O
( O
d- O
to O
l-enantiomer O
ratio O
of O
3:1 O
) O
in O
adolescents O
, O
mean O
weight B-OSE_Labeled_AE
change I-OSE_Labeled_AE
from O
baseline O
within O
the O
initial O
4 O
weeks O
of O
therapy O
was O
-1.1 O
pounds O
and O
-2.8 O
pounds O
, O
respectively O
, O
for O
patients O
receiving O
10 O
mg O
and O
20 O
mg O
of O
amphetamine O
. O

Higher O
doses O
were O
associated O
with O
greater O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
within O
the O
initial O
4 O
weeks O
of O
treatment O
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
. O

Weight O
Loss O
in O
Adults O
with O
ADHD O
In O
the O
controlled O
adult O
trial O
( O
Study O
7 O
) O
, O
mean O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
after O
4 O
weeks O
of O
therapy O
was O
2.8 O
pounds O
, O
3.1 O
pounds O
, O
and O
4.3 O
pounds O
, O
for O
patients O
receiving O
final O
doses O
of O
30 O
mg O
, O
50 O
mg O
, O
and O
70 O
mg O
of O
VYVANSE O
, O
respectively O
, O
compared O
to O
a O
mean O
weight B-NonOSE_AE
gain I-NonOSE_AE
of O
0.5 O
pounds O
for O
patients O
receiving O
placebo O
. O

Binge B-Not_AE_Candidate
Eating I-Not_AE_Candidate
Disorder I-Not_AE_Candidate
The O
safety O
data O
in O
this O
section O
is O
based O
on O
data O
from O
two O
12 O
week O
parallel O
group O
, O
flexible-dose O
, O
placebo-controlled O
studies O
in O
adults O
with O
BED B-Not_AE_Candidate
[ O
see O
Clinical O
Studies O
14.2 O
] O
. O

Patients O
with O
cardiovascular O
risk O
factors O
other O
than O
obesity B-Not_AE_Candidate
and O
smoking O
were O
excluded O
. O

Adverse O
Reactions O
Associated O
with O
Discontinuation O
of O
Treatment O
in O
BED O
Clinical O
Trials O
In O
controlled O
trials O
of O
patients O
ages O
18 O
to O
55 O
years O
, O
5.1 O
% O
( O
19/373 O
) O
of O
VYVANSE-treated O
patients O
discontinued O
due O
to O
adverse O
reactions O
compared O
to O
2.4 O
% O
( O
9/372 O
) O
of O
placebo-treated O
patients O
. O

No O
single O
adverse O
reaction O
led O
to O
discontinuation O
in O
1 O
% O
or O
more O
of O
VYVANSE-treated O
patients O
. O

Less O
commonly O
reported O
adverse O
reactions O
( O
less O
than O
1 O
% O
or O
less O
than O
twice O
rate O
of O
placebo O
) O
included O
increased B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
irritability B-OSE_Labeled_AE
, O
feeling B-OSE_Labeled_AE
jittery I-OSE_Labeled_AE
and O
anxiety B-OSE_Labeled_AE
. O

The O
most O
common O
adverse O
reactions O
( O
incidence O
> O
=5 O
% O
and O
at O
a O
rate O
at O
least O
twice O
placebo O
) O
reported O
in O
adults O
were O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
feeling B-OSE_Labeled_AE
jittery I-OSE_Labeled_AE
, O
and O
anxiety B-OSE_Labeled_AE
. O

Adverse O
reactions O
reported O
in O
the O
pooled O
controlled O
trials O
in O
adult O
patients O
( O
Study O
11 O
and O
12 O
) O
treated O
with O
VYVANSE O
or O
placebo O
are O
presented O
in O
Table O
4 O
below O
. O

Table O
4 O
Adverse O
Reactions O
Reported O
by O
2 O
% O
or O
More O
of O
Adult O
Patients O
with O
BED O
Taking O
VYVANSE O
and O
at O
least O
Twice O
the O
Incidence O
in O
Patients O
Taking O
Placebo O
in O
12-Week O
Clinical O
Trials O
( O
Study O
11 O
and O
12 O
) O
VYVANSE O
( O
N=373 O
) O
Placebo O
( O
N=372 O
) O
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
36 O
% O
7 O
% O
Insomnia B-OSE_Labeled_AE
[ O
note O
: O
Includes O
all O
preferred O
terms O
containing O
the O
word O
" B-OSE_Labeled_AE
insomnia I-OSE_Labeled_AE
. O
'' O
] O

20 O
% O
8 O
% O
Decreased B-OSE_Labeled_AE
Appetite I-OSE_Labeled_AE
8 O
% O
2 O
% O
Increased B-OSE_Labeled_AE
Heart I-OSE_Labeled_AE
Rate I-OSE_Labeled_AE
[ O
note O
: O
Includes O
the O
preferred O
terms O
`` O
heart B-OSE_Labeled_AE
rate I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
`` O
and O
`` O
tachycardia B-OSE_Labeled_AE
. O
'' O
] O

7 O
% O
1 O
% O
Feeling B-OSE_Labeled_AE
Jittery I-OSE_Labeled_AE
6 O
% O
1 O
% O
Constipation B-OSE_Labeled_AE
6 O
% O
1 O
% O
Anxiety B-OSE_Labeled_AE
5 O
% O
1 O
% O
Diarrhea B-OSE_Labeled_AE
4 O
% O
2 O
% O
Decreased B-OSE_Labeled_AE
Weight I-OSE_Labeled_AE
4 O
% O
0 O
% O
Hyperhidrosis B-OSE_Labeled_AE
4 O
% O
0 O
% O
Vomiting B-OSE_Labeled_AE
2 O
% O
1 O
% O
Gastroenteritis B-OSE_Labeled_AE
2 O
% O
1 O
% O
Paresthesia B-OSE_Labeled_AE
2 O
% O
1 O
% O
Pruritis B-OSE_Labeled_AE
2 O
% O
1 O
% O
Upper B-OSE_Labeled_AE
Abdominal I-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
2 O
% O
0 O
% O
Energy B-OSE_Labeled_AE
Increased I-OSE_Labeled_AE
2 O
% O
0 O
% O
Urinary B-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
2 O
% O
0 O
% O
Nightmare B-OSE_Labeled_AE
2 O
% O
0 O
% O
Restlessness B-OSE_Labeled_AE
2 O
% O
0 O
% O
Oropharyngeal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
2 O
% O
0 O
% O
6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
post O
approval O
use O
of O
VYVANSE O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

These O
events O
are O
as O
follows O
: O
cardiomyopathy B-OSE_Labeled_AE
, O
mydriasis B-OSE_Labeled_AE
, O
diplopia B-OSE_Labeled_AE
, O
difficulties B-OSE_Labeled_AE
with I-OSE_Labeled_AE
visual I-OSE_Labeled_AE
accommodation I-OSE_Labeled_AE
, O
blurred B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
, O
eosinophilic B-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
, O
anaphylactic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
hypersensitivity B-OSE_Labeled_AE
, O
dyskinesia B-OSE_Labeled_AE
, O
dysgeusia B-OSE_Labeled_AE
, O
tics B-OSE_Labeled_AE
, O
bruxism B-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
, O
dermatillomania B-OSE_Labeled_AE
, O
alopecia B-OSE_Labeled_AE
, O
aggression B-OSE_Labeled_AE
, O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
, O
chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
seizures B-OSE_Labeled_AE
, O
libido B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
, O
frequent B-OSE_Labeled_AE
or O
prolonged O
erections I-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
and O
rhabdomyolysis B-OSE_Labeled_AE
. O

BOXED O
WARNING O
: O
WARNING O
: O
ABUSE O
AND O
DEPENDENCE O
WARNING O
: O
ABUSE O
AND O
DEPENDENCE O
CNS O
stimulants O
( O
amphetamines O
and O
methylphenidate-containing O
products O
) O
, O
including O
VYVANSE O
, O
have O
a O
high O
potential O
for O
abuse B-OSE_Labeled_AE
and O
dependence B-OSE_Labeled_AE
. O

Assess O
the O
risk O
of O
abuse B-NonOSE_AE
prior O
to O
prescribing O
and O
monitor O
for O
signs O
of O
abuse B-NonOSE_AE
and O
dependence B-NonOSE_AE
while O
on O
therapy O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
, O
5.2 O
) O
, O
and O
Drug B-NonOSE_AE
Abuse I-NonOSE_AE
and O
Dependence B-NonOSE_AE
( O
9.2 O
, O
9.3 O
) O
] O
. O

EXCERPT O
: O
WARNING O
: O
ABUSE O
AND O
DEPENDENCE O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
CNS O
stimulants O
( O
amphetamines O
and O
methylphenidate-containing O
products O
) O
, O
including O
VYVANSE O
, O
have O
a O
high O
potential O
for O
abuse O
and O
dependence O
( O
5.1 O
, O
9.2 O
, O
9.3 O
) O
* O
Assess O
the O
risk O
of O
abuse O
prior O
to O
prescribing O
and O
monitor O
for O
signs O
of O
abuse O
and O
dependence O
while O
on O
therapy O
( O
5.1 O
, O
9.2 O
) O

5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Serious O
Cardiovascular O
Reactions O
: O
Sudden O
death O
has O
been O
reported O
in O
association O
with O
CNS O
stimulant O
treatment O
at O
recommended O
doses O
in O
pediatric O
patients O
with O
structural O
cardiac O
abnormalities O
or O
other O
serious O
heart O
problems O
. O

In O
adults O
, O
sudden O
death O
, O
stroke O
, O
and O
myocardial O
infarction O
have O
been O
reported O
. O

Avoid O
use O
in O
patients O
with O
known O
structural O
cardiac O
abnormalities O
, O
cardiomyopathy O
, O
serious O
heart O
arrhythmia O
, O
or O
coronary O
artery O
disease O
( O
5.2 O
) O
* O
Blood O
Pressure O
and O
Heart O
Rate O
Increases O
: O
Monitor O
blood O
pressure O
and O
pulse O
. O

Consider O
benefits O
and O
risks O
before O
use O
in O
patients O
for O
whom O
blood O
pressure O
increases O
may O
be O
problematic O
( O
5.3 O
) O
* O
Psychiatric O
Adverse O
Reactions O
: O
May O
cause O
psychotic O
or O
manic O
symptoms O
in O
patients O
with O
no O
prior O
history O
, O
or O
exacerbation O
of O
symptoms O
in O
patients O
with O
pre-existing O
psychosis O
. O

Evaluate O
for O
bipolar O
disorder O
prior O
to O
stimulant O
use O
( O
5.4 O
) O
* O
Suppression O
of O
Growth O
: O
Monitor O
height O
and O
weight O
in O
pediatric O
patients O
during O
treatment O
( O
5.5 O
) O
* O
Peripheral O
Vasculopathy O
, O
including O
Raynaud O
's O
phenomenon O
: O
Stimulants O
are O
associated O
with O
peripheral O
vasculopathy O
, O
including O
Raynaud O
's O
phenomenon O
. O

Careful O
observation O
for O
digital O
changes O
is O
necessary O
during O
treatment O
with O
stimulants O
( O
5.6 O
) O
* O
Serotonin O
Syndrome O
: O
Increased O
risk O
when O
co-administered O
with O
serotonergic O
agents O
( O
e.g. O
, O
SSRIs O
, O
SNRIs O
, O
triptans O
) O
, O
but O
also O
during O
overdosage O
situations O
. O

If O
it O
occurs O
, O
discontinue O
VYVANSE O
and O
initiate O
supportive O
treatment O
( O
4 O
, O
5.7 O
, O
10 O
) O
. O

5.1 O
Potential O
for O
Abuse O
and O
Dependence O
CNS O
stimulants O
( O
amphetamines O
and O
methylphenidate-containing O
products O
) O
, O
including O
VYVANSE O
, O
have O
a O
high O
potential O
for O
abuse B-OSE_Labeled_AE
and O
dependence B-OSE_Labeled_AE
. O

Assess O
the O
risk O
of O
abuse B-NonOSE_AE
prior O
to O
prescribing O
, O
and O
monitor O
for O
signs O
of O
abuse B-NonOSE_AE
and O
dependence B-NonOSE_AE
while O
on O
therapy O
[ O
see O
Drug B-NonOSE_AE
Abuse I-NonOSE_AE
and O
Dependence B-NonOSE_AE
( O
9.2 O
, O
9.3 O
) O
] O
. O

5.2 O
Serious O
Cardiovascular B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
Sudden B-OSE_Labeled_AE
death I-OSE_Labeled_AE
, O
stroke B-OSE_Labeled_AE
and O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
have O
been O
reported O
in O
adults O
with O
CNS O
stimulant O
treatment O
at O
recommended O
doses O
. O

Sudden B-OSE_Labeled_AE
death I-OSE_Labeled_AE
has O
been O
reported O
in O
children O
and O
adolescents O
with O
structural B-Not_AE_Candidate
cardiac I-Not_AE_Candidate
abnormalities I-Not_AE_Candidate
and O
other O
serious O
heart B-Not_AE_Candidate
problems I-Not_AE_Candidate
taking O
CNS O
stimulants O
at O
recommended O
doses O
for O
ADHD B-Not_AE_Candidate
. O

Avoid O
use O
in O
patients O
with O
known O
structural B-Not_AE_Candidate
cardiac I-Not_AE_Candidate
abnormalities I-Not_AE_Candidate
, O
cardiomyopathy B-Not_AE_Candidate
, O
serious O
heart B-Not_AE_Candidate
arrhythmia I-Not_AE_Candidate
, O
coronary B-Not_AE_Candidate
artery I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
and O
other O
serious O
heart B-Not_AE_Candidate
problems I-Not_AE_Candidate
. O

Further O
evaluate O
patients O
who O
develop O
exertional B-NonOSE_AE
chest I-NonOSE_AE
pain I-NonOSE_AE
, O
unexplained B-NonOSE_AE
syncope I-NonOSE_AE
, O
or O
arrhythmias B-NonOSE_AE
during O
VYVANSE O
treatment O
. O

5.3 O
Blood O
Pressure O
and O
Heart O
Rate O
Increases O
CNS O
stimulants O
cause O
an O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
( O
mean O
increase O
about O
2-4 O
mm O
Hg O
) O
and O
heart O
rate O
( O
mean O
increase O
about O
3-6 O
bpm O
) O
. O

Monitor O
all O
patients O
for O
potential O
tachycardia B-NonOSE_AE
and O
hypertension B-NonOSE_AE
. O

5.4 O
Psychiatric B-OSE_Labeled_AE
Adverse I-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
Exacerbation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
Pre I-OSE_Labeled_AE
- I-OSE_Labeled_AE
existing I-OSE_Labeled_AE
Psychosis I-OSE_Labeled_AE
CNS O
stimulants O
may O
exacerbate B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
of I-OSE_Labeled_AE
behavior I-OSE_Labeled_AE
disturbance I-OSE_Labeled_AE
and O
thought O
disorder O
in O
patients O
with O
a O
pre-existing O
psychotic B-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

Induction O
of O
a O
Manic O
Episode O
in O
Patients O
with O
Bipolar O
Disorder O
CNS O
stimulants O
may O
induce O
a O
mixed B-OSE_Labeled_AE
/manic O
episode I-OSE_Labeled_AE
in I-OSE_Labeled_AE
patients I-OSE_Labeled_AE
with I-OSE_Labeled_AE
bipolar I-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
. O

Prior O
to O
initiating O
treatment O
, O
screen O
patients O
for O
risk O
factors O
for O
developing O
a O
manic B-NonOSE_AE
episode I-NonOSE_AE
( O
e.g. O
, O
comorbid O
or O
history O
of O
depressive B-Not_AE_Candidate
symptoms I-Not_AE_Candidate
or O
a O
family O
history O
of O
suicide B-Not_AE_Candidate
, O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
and O
depression B-Not_AE_Candidate
) O
. O

New O
Psychotic O
or O
Manic O
Symptoms O
CNS O
stimulants O
, O
at O
recommended O
doses O
, O
may O
cause O
psychotic B-OSE_Labeled_AE
or O
manic O
symptoms I-OSE_Labeled_AE
, O
e.g O
. O

hallucinations B-OSE_Labeled_AE
, O
delusional B-OSE_Labeled_AE
thinking I-OSE_Labeled_AE
, O
or O
mania B-OSE_Labeled_AE
in O
children O
and O
adolescents O
without O
a O
prior O
history O
of O
psychotic B-Not_AE_Candidate
illness I-Not_AE_Candidate
or O
mania B-Not_AE_Candidate
. O

If O
such O
symptoms O
occur O
, O
consider O
discontinuing O
VYVANSE O
. O

In O
a O
pooled O
analysis O
of O
multiple O
short-term O
, O
placebo-controlled O
studies O
of O
CNS O
stimulants O
, O
psychotic B-OSE_Labeled_AE
or O
manic O
symptoms I-OSE_Labeled_AE
occurred O
in O
0.1 O
% O
of O
CNS O
stimulant-treated O
patients O
compared O
to O
0 O
% O
in O
placebo-treated O
patients O
. O

5.5 O
Suppression B-OSE_Labeled_AE
of I-OSE_Labeled_AE
Growth I-OSE_Labeled_AE
CNS O
stimulants O
have O
been O
associated O
with O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
and O
slowing B-OSE_Labeled_AE
of I-OSE_Labeled_AE
growth I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
in O
pediatric O
patients O
. O

Closely O
monitor O
growth O
( O
weight O
and O
height O
) O
in O
pediatric O
patients O
treated O
with O
CNS O
stimulants O
, O
including O
VYVANSE O
. O

In O
a O
4-week O
, O
placebo-controlled O
trial O
of O
VYVANSE O
in O
patients O
ages O
6 O
to O
12 O
years O
old O
with O
ADHD B-Not_AE_Candidate
, O
there O
was O
a O
dose-related O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
in O
the O
VYVANSE O
groups O
compared O
to O
weight B-NonOSE_AE
gain I-NonOSE_AE
in O
the O
placebo O
group O
. O

Additionally O
, O
in O
studies O
of O
another O
stimulant O
, O
there O
was O
slowing B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
increase I-NonOSE_AE
in I-NonOSE_AE
height I-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.6 O
Peripheral O
Vasculopathy O
, O
including O
Raynaud O
's O
Phenomenon O
Stimulants O
, O
including O
VYVANSE O
, O
are O
associated O
with O
peripheral B-OSE_Labeled_AE
vasculopathy I-OSE_Labeled_AE
, O
including O
Raynaud B-OSE_Labeled_AE
' I-OSE_Labeled_AE
s I-OSE_Labeled_AE
phenomenon I-OSE_Labeled_AE
. O

Signs O
and O
symptoms O
are O
usually O
intermittent O
and O
mild O
; O
however O
, O
very O
rare O
sequelae O
include O
digital B-NonOSE_AE
ulceration I-NonOSE_AE
and/or O
soft B-NonOSE_AE
tissue I-NonOSE_AE
breakdown I-NonOSE_AE
. O

Effects O
of O
peripheral B-OSE_Labeled_AE
vasculopathy I-OSE_Labeled_AE
, O
including O
Raynaud B-OSE_Labeled_AE
' I-OSE_Labeled_AE
s I-OSE_Labeled_AE
phenomenon I-OSE_Labeled_AE
, O
were O
observed O
in O
post-marketing O
reports O
at O
different O
times O
and O
at O
therapeutic O
doses O
in O
all O
age O
groups O
throughout O
the O
course O
of O
treatment O
. O

Signs O
and O
symptoms O
generally O
improve O
after O
reduction O
in O
dose O
or O
discontinuation O
of O
drug O
. O

Careful O
observation O
for O
digital B-NonOSE_AE
changes I-NonOSE_AE
is O
necessary O
during O
treatment O
with O
stimulants O
. O

Further O
clinical O
evaluation O
( O
e.g. O
, O
rheumatology O
referral O
) O
may O
be O
appropriate O
for O
certain O
patients O
. O

5.7 O
Serotonin O
Syndrome O
Serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
, O
a O
potentially O
life-threatening O
reaction O
, O
may O
occur O
when O
amphetamines O
are O
used O
in O
combination O
with O
other O
drugs O
that O
affect O
the O
serotonergic O
neurotransmitter O
systems O
such O
as O
monoamine O
oxidase O
inhibitors O
( O
MAOIs O
) O
, O
selective O
serotonin O
reuptake O
inhibitors O
( O
SSRIs O
) O
, O
serotonin O
norepinephrine O
reuptake O
inhibitors O
( O
SNRIs O
) O
, O
triptans O
, O
tricyclic O
antidepressants O
, O
fentanyl O
, O
lithium O
, O
tramadol O
, O
tryptophan O
, O
buspirone O
, O
and O
St O
. O
John O
's O
Wort O
[ O
see O
Drug O
Interactions O
( O
7.1 O
) O
] O
. O

Amphetamines O
and O
amphetamine O
derivatives O
are O
known O
to O
be O
metabolized O
, O
to O
some O
degree O
, O
by O
cytochrome O
P450 O
2D6 O
( O
CYP2D6 O
) O
and O
display O
minor O
inhibition O
of O
CYP2D6 O
metabolism O
[ O
see O
Clinical O
Pharmacology O
12.3 O
] O
. O

The O
potential O
for O
a O
pharmacokinetic O
interaction O
exists O
with O
the O
co-administration O
of O
CYP2D6 O
inhibitors O
which O
may O
increase O
the O
risk O
with O
increased O
exposure O
to O
the O
active O
metabolite O
of O
VYVANSE O
( O
dextroamphetamine O
) O
. O

In O
these O
situations O
, O
consider O
an O
alternative O
non-serotonergic O
drug O
or O
an O
alternative O
drug O
that O
does O
not O
inhibit O
CYP2D6 O
[ O
see O
Drug O
Interactions O
( O
7.1 O
) O
] O
. O

Serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
symptoms O
may O
include O
mental B-NonOSE_AE
status I-NonOSE_AE
changes I-NonOSE_AE
( O
e.g. O
, O
agitation B-NonOSE_AE
, O
hallucinations B-NonOSE_AE
, O
delirium B-NonOSE_AE
, O
and O
coma B-NonOSE_AE
) O
, O
autonomic B-NonOSE_AE
instability I-NonOSE_AE
( O
e.g. O
, O
tachycardia B-NonOSE_AE
, O
labile B-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
, O
dizziness B-NonOSE_AE
, O
diaphoresis B-NonOSE_AE
, O
flushing B-NonOSE_AE
, O
hyperthermia B-NonOSE_AE
) O
, O
neuromuscular B-NonOSE_AE
symptoms I-NonOSE_AE
( O
e.g. O
, O
tremor B-NonOSE_AE
, O
rigidity B-NonOSE_AE
, O
myoclonus B-NonOSE_AE
, O
hyperreflexia B-NonOSE_AE
, O
incoordination B-NonOSE_AE
) O
, O
seizures B-NonOSE_AE
, O
and/or O
gastrointestinal B-NonOSE_AE
symptoms I-NonOSE_AE
( O
e.g. O
, O
nausea B-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
diarrhea B-NonOSE_AE
) O
. O

Concomitant O
use O
of O
VYVANSE O
with O
MAOI O
drugs O
is O
contraindicated O
[ O
see O
Contraindications O
( O
4 O
) O
] O
. O

Discontinue O
treatment O
with O
VYVANSE O
and O
any O
concomitant O
serotonergic O
agents O
immediately O
if O
symptoms O
of O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
occur O
, O
and O
initiate O
supportive O
symptomatic O
treatment O
. O

Concomitant O
use O
of O
VYVANSE O
with O
other O
serotonergic O
drugs O
or O
CYP2D6 O
inhibitors O
should O
be O
used O
only O
if O
the O
potential O
benefit O
justifies O
the O
potential O
risk O
. O

If O
clinically O
warranted O
, O
consider O
initiating O
VYVANSE O
with O
lower O
doses O
, O
monitoring O
patients O
for O
the O
emergence O
of O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
during O
drug O
initiation O
or O
titration O
, O
and O
informing O
patients O
of O
the O
increased O
risk O
for O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
. O

